0000885725-24-000017.txt : 20240220 0000885725-24-000017.hdr.sgml : 20240220 20240220162327 ACCESSION NUMBER: 0000885725-24-000017 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 96 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240220 DATE AS OF CHANGE: 20240220 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 24653727 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 10-K 1 bsx-20231231.htm 10-K bsx-20231231
00008857252023FYfalseP3YP7YP2YP5YP1Yhttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#AccountsPayableCurrenthttp://fasb.org/us-gaap/2023#AccountsPayableCurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent42143642100008857252023-01-012023-12-310000885725us-gaap:CommonStockMember2023-01-012023-12-310000885725bsx:SeniorNotedue2027Member2023-01-012023-12-3100008857252023-06-30iso4217:USDiso4217:USDxbrli:shares00008857252024-01-31xbrli:shares00008857252022-01-012022-12-3100008857252021-01-012021-12-3100008857252023-12-3100008857252022-12-310000885725us-gaap:PreferredStockMember2022-12-310000885725us-gaap:PreferredStockMember2021-12-310000885725us-gaap:PreferredStockMember2020-12-310000885725us-gaap:PreferredStockMember2023-01-012023-12-310000885725us-gaap:PreferredStockMember2022-01-012022-12-310000885725us-gaap:PreferredStockMember2021-01-012021-12-310000885725us-gaap:PreferredStockMember2023-12-310000885725us-gaap:CommonStockMember2022-12-310000885725us-gaap:CommonStockMember2021-12-310000885725us-gaap:CommonStockMember2020-12-310000885725us-gaap:CommonStockMember2023-01-012023-12-310000885725us-gaap:CommonStockMember2022-01-012022-12-310000885725us-gaap:CommonStockMember2021-01-012021-12-3100008857252021-12-310000885725us-gaap:CommonStockMember2023-12-310000885725us-gaap:TreasuryStockCommonMember2022-12-310000885725us-gaap:TreasuryStockCommonMember2021-12-310000885725us-gaap:TreasuryStockCommonMember2020-12-310000885725us-gaap:TreasuryStockCommonMember2023-01-012023-12-310000885725us-gaap:TreasuryStockCommonMember2022-01-012022-12-310000885725us-gaap:TreasuryStockCommonMember2021-01-012021-12-310000885725us-gaap:TreasuryStockCommonMember2023-12-310000885725us-gaap:AdditionalPaidInCapitalMember2022-12-310000885725us-gaap:AdditionalPaidInCapitalMember2021-12-310000885725us-gaap:AdditionalPaidInCapitalMember2020-12-310000885725us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310000885725us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310000885725us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310000885725us-gaap:AdditionalPaidInCapitalMember2023-12-310000885725us-gaap:RetainedEarningsMember2022-12-310000885725us-gaap:RetainedEarningsMember2021-12-310000885725us-gaap:RetainedEarningsMember2020-12-310000885725us-gaap:RetainedEarningsMember2023-01-012023-12-310000885725us-gaap:RetainedEarningsMember2022-01-012022-12-310000885725us-gaap:RetainedEarningsMember2021-01-012021-12-310000885725us-gaap:RetainedEarningsMember2023-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000885725us-gaap:NoncontrollingInterestMember2022-12-310000885725us-gaap:NoncontrollingInterestMember2021-12-310000885725us-gaap:NoncontrollingInterestMember2020-12-310000885725us-gaap:NoncontrollingInterestMember2023-01-012023-12-310000885725us-gaap:NoncontrollingInterestMember2022-01-012022-12-310000885725us-gaap:NoncontrollingInterestMember2021-01-012021-12-310000885725us-gaap:NoncontrollingInterestMember2023-12-3100008857252020-12-310000885725us-gaap:BuildingMember2023-12-310000885725bsx:EquipmentFurnitureFixturesMembersrt:MinimumMember2023-12-310000885725srt:MaximumMemberbsx:EquipmentFurnitureFixturesMember2023-12-310000885725bsx:PatentsAndLicensesMembersrt:MinimumMember2023-12-310000885725srt:MaximumMemberbsx:PatentsAndLicensesMember2023-12-310000885725bsx:TechnologyRelatedAndCustomerRelationshipsMembersrt:MinimumMember2023-12-310000885725bsx:TechnologyRelatedAndCustomerRelationshipsMembersrt:MaximumMember2023-12-310000885725srt:MinimumMemberus-gaap:SoftwareDevelopmentMember2023-12-310000885725srt:MaximumMemberus-gaap:SoftwareDevelopmentMember2023-12-310000885725bsx:AxonicsMemberus-gaap:SubsequentEventMember2024-01-08xbrli:pure0000885725bsx:AxonicsMemberus-gaap:SubsequentEventMember2024-01-082024-01-080000885725bsx:AcotecMember2023-02-200000885725bsx:AcotecMember2023-02-202023-02-20iso4217:HKD0000885725bsx:ApolloMember2023-04-040000885725bsx:ApolloMember2023-04-042023-04-040000885725bsx:RelievantMedsystemsMember2023-11-170000885725bsx:RelievantMedsystemsMember2023-11-172023-11-170000885725bsx:AcotecMember2023-01-012023-12-310000885725bsx:ApolloMember2023-01-012023-12-310000885725bsx:RelievantMedsystemsMember2023-01-012023-12-310000885725bsx:AcotecMember2023-12-310000885725bsx:ApolloMember2023-12-310000885725bsx:RelievantMedsystemsMember2023-12-310000885725bsx:AcotecMember2023-02-200000885725bsx:AcotecMemberus-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310000885725bsx:AcotecMemberus-gaap:TechnologyBasedIntangibleAssetsMember2023-01-012023-12-310000885725bsx:AcotecMembersrt:WeightedAverageMemberus-gaap:TechnologyBasedIntangibleAssetsMember2023-01-012023-12-310000885725us-gaap:CustomerRelationshipsMemberbsx:AcotecMember2023-12-310000885725us-gaap:CustomerRelationshipsMemberbsx:AcotecMember2023-01-012023-12-310000885725us-gaap:CustomerRelationshipsMemberbsx:AcotecMembersrt:WeightedAverageMember2023-01-012023-12-310000885725bsx:AcotecMemberus-gaap:OtherIntangibleAssetsMember2023-12-310000885725bsx:AcotecMemberus-gaap:OtherIntangibleAssetsMember2023-01-012023-12-310000885725bsx:AcotecMemberus-gaap:OtherIntangibleAssetsMembersrt:WeightedAverageMember2023-01-012023-12-310000885725bsx:ApolloMemberus-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310000885725bsx:ApolloMemberus-gaap:TechnologyBasedIntangibleAssetsMember2023-01-012023-12-310000885725bsx:ApolloMembersrt:WeightedAverageMemberus-gaap:TechnologyBasedIntangibleAssetsMember2023-01-012023-12-310000885725us-gaap:CustomerRelationshipsMemberbsx:ApolloMember2023-12-310000885725us-gaap:CustomerRelationshipsMemberbsx:ApolloMember2023-01-012023-12-310000885725us-gaap:CustomerRelationshipsMemberbsx:ApolloMembersrt:WeightedAverageMember2023-01-012023-12-310000885725bsx:RelievantMedsystemsMemberus-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310000885725bsx:RelievantMedsystemsMemberus-gaap:TechnologyBasedIntangibleAssetsMember2023-01-012023-12-310000885725bsx:RelievantMedsystemsMembersrt:WeightedAverageMemberus-gaap:TechnologyBasedIntangibleAssetsMember2023-01-012023-12-310000885725us-gaap:CustomerRelationshipsMemberbsx:RelievantMedsystemsMember2023-12-310000885725us-gaap:CustomerRelationshipsMemberbsx:RelievantMedsystemsMember2023-01-012023-12-310000885725us-gaap:CustomerRelationshipsMemberbsx:RelievantMedsystemsMembersrt:WeightedAverageMember2023-01-012023-12-310000885725bsx:BaylisMedicalMember2023-01-012023-12-310000885725bsx:BaylisMedicalMember2023-12-310000885725bsx:BaylisMedicalMemberus-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310000885725bsx:BaylisMedicalMemberus-gaap:TechnologyBasedIntangibleAssetsMember2023-01-012023-12-310000885725bsx:BaylisMedicalMembersrt:WeightedAverageMemberus-gaap:TechnologyBasedIntangibleAssetsMember2023-01-012023-12-310000885725us-gaap:OtherIntangibleAssetsMemberbsx:BaylisMedicalMember2023-12-310000885725us-gaap:OtherIntangibleAssetsMemberbsx:BaylisMedicalMember2023-01-012023-12-310000885725us-gaap:OtherIntangibleAssetsMemberbsx:BaylisMedicalMembersrt:WeightedAverageMember2023-01-012023-12-310000885725bsx:RevenueBasedPaymentsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-12-310000885725bsx:RevenueBasedPaymentsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MinimumMember2023-01-012023-12-310000885725srt:MaximumMemberbsx:RevenueBasedPaymentsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-01-012023-12-310000885725bsx:RevenueBasedPaymentsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:WeightedAverageMember2023-01-012023-12-310000885725bsx:RevenueBasedPaymentsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MinimumMember2023-12-310000885725srt:MaximumMemberbsx:RevenueBasedPaymentsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-12-310000885725bsx:RevenueBasedPaymentsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:WeightedAverageMember2023-12-310000885725us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310000885725us-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310000885725us-gaap:PatentsMember2023-12-310000885725us-gaap:PatentsMember2022-12-310000885725us-gaap:OtherIntangibleAssetsMember2023-12-310000885725us-gaap:OtherIntangibleAssetsMember2022-12-310000885725us-gaap:InProcessResearchAndDevelopmentMember2023-12-310000885725us-gaap:InProcessResearchAndDevelopmentMember2022-12-310000885725us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310000885725us-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310000885725bsx:MedsurgMember2021-12-310000885725bsx:CardiovascularMember2021-12-310000885725bsx:MedsurgMember2022-01-012022-12-310000885725bsx:CardiovascularMember2022-01-012022-12-310000885725bsx:MedsurgMember2022-12-310000885725bsx:CardiovascularMember2022-12-310000885725bsx:MedsurgMember2023-01-012023-12-310000885725bsx:CardiovascularMember2023-01-012023-12-310000885725bsx:MedsurgMember2023-12-310000885725bsx:CardiovascularMember2023-12-310000885725bsx:November2019AggregateOfferingMember2021-12-31iso4217:EUR0000885725bsx:December2027NotesMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2022-12-310000885725us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-12-310000885725us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-12-310000885725us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberbsx:ForeignCurrencyDenominatedInDebtMember2023-12-310000885725us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberbsx:ForeignCurrencyDenominatedInDebtMember2022-12-310000885725us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2023-12-310000885725us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-12-31bsx:units0000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2023-01-012023-12-310000885725us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMember2023-01-012023-12-310000885725us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberbsx:ForeignCurrencyDenominatedInDebtMemberus-gaap:InterestExpenseMember2023-01-012023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateContractMemberus-gaap:InterestExpenseMember2023-01-012023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2022-01-012022-12-310000885725us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMember2022-01-012022-12-310000885725us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberbsx:ForeignCurrencyDenominatedInDebtMemberus-gaap:InterestExpenseMember2022-01-012022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateContractMemberus-gaap:InterestExpenseMember2022-01-012022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2021-01-012021-12-310000885725us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMember2021-01-012021-12-310000885725us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberbsx:ForeignCurrencyDenominatedInDebtMemberus-gaap:InterestExpenseMember2021-01-012021-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateContractMemberus-gaap:InterestExpenseMember2021-01-012021-12-310000885725us-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2023-12-310000885725us-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMember2023-12-310000885725us-gaap:CashFlowHedgingMemberus-gaap:InterestRateContractMemberus-gaap:InterestExpenseMember2023-12-310000885725us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2023-01-012023-12-310000885725us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2022-01-012022-12-310000885725us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2021-01-012021-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000885725us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2023-12-310000885725us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2022-12-310000885725us-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-12-310000885725us-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentLiabilitiesMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2022-12-310000885725us-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2023-12-310000885725us-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2022-12-310000885725us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-310000885725us-gaap:FairValueMeasurementsRecurringMember2023-12-310000885725us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310000885725us-gaap:FairValueMeasurementsRecurringMember2022-12-310000885725us-gaap:FairValueInputsLevel3Member2023-12-310000885725bsx:LicensingArrangementAssetsMember2023-01-012023-12-310000885725bsx:LicensingArrangementAssetsMembersrt:WeightedAverageMember2023-01-012023-12-310000885725bsx:LicensingArrangementLiabilitiesMembersrt:MinimumMember2023-01-012023-12-310000885725srt:MaximumMemberbsx:LicensingArrangementLiabilitiesMember2023-01-012023-12-310000885725bsx:LicensingArrangementLiabilitiesMembersrt:WeightedAverageMember2023-01-012023-12-310000885725bsx:LicensingArrangementAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000885725bsx:LicensingArrangementAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-12-310000885725bsx:LicensingArrangementAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310000885725bsx:LicensingArrangementAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-01-012023-12-310000885725bsx:LicensingArrangementAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-310000885725bsx:LicensingArrangementLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000885725bsx:LicensingArrangementLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-12-310000885725bsx:LicensingArrangementLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310000885725bsx:LicensingArrangementLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-01-012023-12-310000885725bsx:LicensingArrangementLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-310000885725bsx:October2023NotesMember2023-12-310000885725bsx:October2023NotesMember2022-12-310000885725bsx:March2024NotesMember2023-12-310000885725bsx:March2024NotesMember2022-12-310000885725bsx:June2025NotesMember2023-12-310000885725bsx:June2025NotesMember2022-12-310000885725bsx:March2026NotesMember2023-12-310000885725bsx:March2026NotesMember2022-12-310000885725bsx:December2027NotesMember2022-12-310000885725bsx:March2028SeniorNotesMember2023-12-310000885725bsx:March2028SeniorNotesMember2022-12-310000885725bsx:March2028NotesMember2023-12-310000885725bsx:March2028NotesMember2022-12-310000885725bsx:March2029NotesMember2023-12-310000885725bsx:March2029NotesMember2022-12-310000885725bsx:June2030NotesMember2023-12-310000885725bsx:June2030NotesMember2022-12-310000885725bsx:March2031NotesMember2023-12-310000885725bsx:March2031NotesMember2022-12-310000885725bsx:March2034NotesMember2023-12-310000885725bsx:March2034NotesMember2022-12-310000885725bsx:November2035NotesMember2023-12-310000885725bsx:November2035NotesMember2022-12-310000885725bsx:March2039NotesMember2023-12-310000885725bsx:March2039NotesMember2022-12-310000885725bsx:January2040NotesMember2023-12-310000885725bsx:January2040NotesMember2022-12-310000885725bsx:March2049NotesMember2023-12-310000885725bsx:March2049NotesMember2022-12-310000885725us-gaap:SeniorNotesMember2023-12-310000885725us-gaap:SeniorNotesMember2022-12-310000885725us-gaap:CapitalLeaseObligationsMember2023-12-310000885725us-gaap:CapitalLeaseObligationsMember2022-12-310000885725us-gaap:RevolvingCreditFacilityMember2021-05-100000885725bsx:RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember2023-12-310000885725bsx:ActualCovenantMember2023-12-310000885725bsx:RequirementAsOfMarch312021Member2023-12-310000885725bsx:RequirementFourQuartersFollowingMaterialAcquisitionMember2023-12-310000885725bsx:RequirementfifthquarterfollowingqualifiedacquisitionMember2023-12-310000885725bsx:RequirementSixthQuarterFollowingQualifiedAcquisitionMember2023-12-310000885725bsx:RequirementSeventhQuarterFollowingQualifiedAcquisitionMember2023-12-310000885725bsx:RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember2023-12-310000885725bsx:TheOfferingAggregatePrincipalAmountMember2023-12-310000885725bsx:March2025NotesMember2023-12-31utr:Rate0000885725bsx:TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember2023-12-3100008857252022-01-012022-03-310000885725bsx:EuroDenominatedFactoringArrangementsMember2023-12-310000885725bsx:EuroDenominatedFactoringArrangementsMember2023-01-012023-12-310000885725bsx:EuroDenominatedFactoringArrangementsMember2022-12-310000885725bsx:EuroDenominatedFactoringArrangementsMember2022-01-012022-12-310000885725bsx:YenDenominatedFactoringArrangementsMember2023-12-310000885725bsx:YenDenominatedFactoringArrangementsMember2023-01-012023-12-310000885725bsx:YenDenominatedFactoringArrangementsMember2022-12-310000885725bsx:YenDenominatedFactoringArrangementsMember2022-01-012022-12-310000885725bsx:RenminbiDenominatedFactoringArrangementsMember2023-12-310000885725bsx:RenminbiDenominatedFactoringArrangementsMember2023-01-012023-12-310000885725bsx:RenminbiDenominatedFactoringArrangementsMember2022-12-310000885725bsx:RenminbiDenominatedFactoringArrangementsMember2022-01-012022-12-310000885725srt:MinimumMember2023-12-310000885725srt:MaximumMember2023-12-310000885725srt:MaximumMember2023-01-012023-12-310000885725us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310000885725us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2022-12-310000885725bsx:DeferredTaxAssetsMember2023-12-310000885725bsx:DeferredTaxAssetsMember2022-12-310000885725bsx:DeferredTaxLiabilitiesMember2023-12-310000885725bsx:DeferredTaxLiabilitiesMember2022-12-3100008857252023-01-312023-01-31bsx:Unit0000885725bsx:A550MCPSSeriesAMember2020-05-270000885725bsx:A550MCPSSeriesAMember2020-05-272020-05-270000885725srt:MinimumMemberbsx:A550MCPSSeriesAMember2023-01-012023-12-3100008857252023-06-012023-06-010000885725bsx:A550MCPSSeriesAMember2023-01-012023-12-3100008857252020-12-140000885725bsx:A2011LtipPlanMember2020-10-010000885725us-gaap:CostOfSalesMember2023-01-012023-12-310000885725us-gaap:CostOfSalesMember2022-01-012022-12-310000885725us-gaap:CostOfSalesMember2021-01-012021-12-310000885725us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-12-310000885725us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310000885725us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-310000885725us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-12-310000885725us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310000885725us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310000885725srt:MinimumMember2023-01-012023-12-310000885725srt:MinimumMember2022-01-012022-12-310000885725srt:MaximumMember2022-01-012022-12-310000885725srt:MinimumMember2021-01-012021-12-310000885725srt:MaximumMember2021-01-012021-12-3100008857252021-02-1700008857252020-02-1800008857252019-02-210000885725us-gaap:EmployeeStockOptionMember2023-01-012023-12-310000885725us-gaap:EmployeeStockOptionMember2022-01-012022-12-310000885725us-gaap:EmployeeStockOptionMember2021-01-012021-12-310000885725bsx:A550MCPSSeriesAMember2023-01-012023-12-310000885725bsx:A550MCPSSeriesAMember2022-01-012022-12-310000885725bsx:A550MCPSSeriesAMember2021-01-012021-12-31bsx:reportablesegments0000885725us-gaap:OperatingSegmentsMemberbsx:MedsurgMember2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:MedsurgMember2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:MedsurgMember2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:CardiovascularMember2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:CardiovascularMember2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:CardiovascularMember2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMember2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMember2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMember2021-01-012021-12-310000885725bsx:OtherMember2023-01-012023-12-310000885725bsx:OtherMember2022-01-012022-12-310000885725bsx:OtherMember2021-01-012021-12-310000885725us-gaap:CorporateNonSegmentMember2023-01-012023-12-310000885725us-gaap:CorporateNonSegmentMember2022-01-012022-12-310000885725us-gaap:CorporateNonSegmentMember2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:MedsurgMember2023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:MedsurgMember2022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:CardiovascularMember2023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:CardiovascularMember2022-12-310000885725us-gaap:OperatingSegmentsMember2023-12-310000885725us-gaap:OperatingSegmentsMember2022-12-310000885725us-gaap:CorporateNonSegmentMember2023-12-310000885725us-gaap:CorporateNonSegmentMember2022-12-310000885725country:US2023-12-310000885725country:US2022-12-310000885725country:IE2023-12-310000885725country:IE2022-12-310000885725country:CR2023-12-310000885725country:CR2022-12-310000885725bsx:OtherCountriesMember2023-12-310000885725bsx:OtherCountriesMember2022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalEndoscopyEndoReportingUnitMembercountry:US2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalEndoscopyEndoReportingUnitMemberus-gaap:NonUsMember2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalEndoscopyEndoReportingUnitMember2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalEndoscopyEndoReportingUnitMembercountry:US2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalEndoscopyEndoReportingUnitMemberus-gaap:NonUsMember2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalEndoscopyEndoReportingUnitMember2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalEndoscopyEndoReportingUnitMembercountry:US2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalEndoscopyEndoReportingUnitMemberus-gaap:NonUsMember2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalEndoscopyEndoReportingUnitMember2021-01-012021-12-310000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMemberus-gaap:OperatingSegmentsMembercountry:US2023-01-012023-12-310000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalUrologyandPelvicHealthReportingUnitMember2023-01-012023-12-310000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMemberus-gaap:OperatingSegmentsMembercountry:US2022-01-012022-12-310000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalUrologyandPelvicHealthReportingUnitMember2022-01-012022-12-310000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-12-310000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalUrologyandPelvicHealthReportingUnitMember2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalNeuromodulationNmReportingUnitMembercountry:US2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbsx:GlobalNeuromodulationNmReportingUnitMember2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalNeuromodulationNmReportingUnitMember2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalNeuromodulationNmReportingUnitMembercountry:US2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbsx:GlobalNeuromodulationNmReportingUnitMember2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalNeuromodulationNmReportingUnitMember2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalNeuromodulationNmReportingUnitMembercountry:US2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbsx:GlobalNeuromodulationNmReportingUnitMember2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalNeuromodulationNmReportingUnitMember2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:MedsurgMembercountry:US2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbsx:MedsurgMember2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:MedsurgMembercountry:US2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbsx:MedsurgMember2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:MedsurgMembercountry:US2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbsx:MedsurgMember2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:InterventionalCardiologyTherapiesMembercountry:US2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:InterventionalCardiologyTherapiesMemberus-gaap:NonUsMember2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:InterventionalCardiologyTherapiesMember2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:InterventionalCardiologyTherapiesMembercountry:US2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:InterventionalCardiologyTherapiesMemberus-gaap:NonUsMember2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:InterventionalCardiologyTherapiesMember2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:InterventionalCardiologyTherapiesMembercountry:US2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:InterventionalCardiologyTherapiesMemberus-gaap:NonUsMember2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:InterventionalCardiologyTherapiesMember2021-01-012021-12-310000885725bsx:WatchmanMemberus-gaap:OperatingSegmentsMembercountry:US2023-01-012023-12-310000885725bsx:WatchmanMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:WatchmanMember2023-01-012023-12-310000885725bsx:WatchmanMemberus-gaap:OperatingSegmentsMembercountry:US2022-01-012022-12-310000885725bsx:WatchmanMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:WatchmanMember2022-01-012022-12-310000885725bsx:WatchmanMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-12-310000885725bsx:WatchmanMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:WatchmanMember2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:CardiacRhythmManagementMembercountry:US2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:CardiacRhythmManagementMemberus-gaap:NonUsMember2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:CardiacRhythmManagementMember2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:CardiacRhythmManagementMembercountry:US2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:CardiacRhythmManagementMemberus-gaap:NonUsMember2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:CardiacRhythmManagementMember2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:CardiacRhythmManagementMembercountry:US2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:CardiacRhythmManagementMemberus-gaap:NonUsMember2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:CardiacRhythmManagementMember2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:ElectrophysiologyEPMembercountry:US2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbsx:ElectrophysiologyEPMember2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:ElectrophysiologyEPMember2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:ElectrophysiologyEPMembercountry:US2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbsx:ElectrophysiologyEPMember2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:ElectrophysiologyEPMember2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:ElectrophysiologyEPMembercountry:US2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbsx:ElectrophysiologyEPMember2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:ElectrophysiologyEPMember2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalCardiologyReportingUnitMembercountry:US2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalCardiologyReportingUnitMemberus-gaap:NonUsMember2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalCardiologyReportingUnitMember2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalCardiologyReportingUnitMembercountry:US2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalCardiologyReportingUnitMemberus-gaap:NonUsMember2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalCardiologyReportingUnitMember2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalCardiologyReportingUnitMembercountry:US2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalCardiologyReportingUnitMemberus-gaap:NonUsMember2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:GlobalCardiologyReportingUnitMember2021-01-012021-12-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMemberus-gaap:OperatingSegmentsMembercountry:US2023-01-012023-12-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2023-01-012023-12-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMemberus-gaap:OperatingSegmentsMember2023-01-012023-12-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMemberus-gaap:OperatingSegmentsMembercountry:US2022-01-012022-12-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-01-012022-12-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMemberus-gaap:OperatingSegmentsMember2022-01-012022-12-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-12-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2021-01-012021-12-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMemberus-gaap:OperatingSegmentsMember2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberbsx:CardiovascularMembercountry:US2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbsx:CardiovascularMember2023-01-012023-12-310000885725us-gaap:OperatingSegmentsMemberbsx:CardiovascularMembercountry:US2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbsx:CardiovascularMember2022-01-012022-12-310000885725us-gaap:OperatingSegmentsMemberbsx:CardiovascularMembercountry:US2021-01-012021-12-310000885725us-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberbsx:CardiovascularMember2021-01-012021-12-310000885725bsx:OtherMembercountry:US2023-01-012023-12-310000885725bsx:OtherMemberus-gaap:NonUsMember2023-01-012023-12-310000885725bsx:OtherMembercountry:US2022-01-012022-12-310000885725bsx:OtherMemberus-gaap:NonUsMember2022-01-012022-12-310000885725bsx:OtherMembercountry:US2021-01-012021-12-310000885725bsx:OtherMemberus-gaap:NonUsMember2021-01-012021-12-310000885725country:US2023-01-012023-12-310000885725us-gaap:NonUsMember2023-01-012023-12-310000885725country:US2022-01-012022-12-310000885725us-gaap:NonUsMember2022-01-012022-12-310000885725country:US2021-01-012021-12-310000885725us-gaap:NonUsMember2021-01-012021-12-310000885725bsx:USExcludingOtherNetSalesMember2023-01-012023-12-310000885725bsx:USExcludingOtherNetSalesMember2022-01-012022-12-310000885725bsx:USExcludingOtherNetSalesMember2021-01-012021-12-310000885725us-gaap:EMEAMember2023-01-012023-12-310000885725us-gaap:EMEAMember2022-01-012022-12-310000885725us-gaap:EMEAMember2021-01-012021-12-310000885725srt:AsiaPacificMember2023-01-012023-12-310000885725srt:AsiaPacificMember2022-01-012022-12-310000885725srt:AsiaPacificMember2021-01-012021-12-310000885725bsx:LatinAmericaandCanadaMember2023-01-012023-12-310000885725bsx:LatinAmericaandCanadaMember2022-01-012022-12-310000885725bsx:LatinAmericaandCanadaMember2021-01-012021-12-310000885725bsx:EmergingMarketsMember2023-01-012023-12-310000885725bsx:EmergingMarketsMember2022-01-012022-12-310000885725bsx:EmergingMarketsMember2021-01-012021-12-310000885725us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000885725us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-12-310000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-12-310000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-12-310000885725us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000885725us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310000885725us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-12-310000885725us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-12-310000885725us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-12-310000885725bsx:ExecutiveRetirementPlanMember2023-12-310000885725bsx:InternationalRetirementPlansMember2023-12-310000885725bsx:ExecutiveRetirementPlanMember2022-12-310000885725bsx:InternationalRetirementPlansMember2022-12-310000885725us-gaap:DomesticPlanMember2023-12-310000885725bsx:OtherInternationalPlansMember2023-12-310000885725us-gaap:DomesticPlanMember2022-12-310000885725bsx:OtherInternationalPlansMember2022-12-310000885725bsx:JohnBradleySorensonMember2023-01-012023-12-310000885725bsx:JohnBradleySorensonMember2023-10-012023-12-310000885725bsx:JohnBradleySorensonMemberbsx:JohnBradleySorensonRuleTradingArrangementCommonStockMember2023-12-310000885725bsx:WendyCarruthersMember2023-01-012023-12-310000885725bsx:WendyCarruthersMember2023-10-012023-12-310000885725bsx:WendyCarruthersRuleTradingArrangementCommonStockMemberbsx:WendyCarruthersMember2023-12-310000885725bsx:WendyCarruthersRuleTradingArrangementStockOptionsMemberbsx:WendyCarruthersMember2023-12-310000885725bsx:ArthurButcherMember2023-01-012023-12-310000885725bsx:ArthurButcherMember2023-10-012023-12-310000885725bsx:WendyCarruthersRuleTradingArrangementCommonStockMemberbsx:ArthurButcherMember2023-12-310000885725bsx:ArthurButcherRuleTradingArrangementPSUAndRSUMemberbsx:ArthurButcherMember2023-12-310000885725bsx:ArthurButcherRuleTradingArrangementStockOptionsMemberbsx:ArthurButcherMember2023-12-3100008857252018-01-012018-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934, or
For the fiscal year ended December 31, 2023
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File No. 1-11083
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
Delaware04-2695240
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)

    300 Boston Scientific Way, Marlborough, Massachusetts                    01752-1234
        (Address of Principal Executive Offices)                         (Zip Code)

508 683-4000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par valueBSXNew York Stock Exchange
0.625% Senior Notes due 2027BSX27New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act:
NONE
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes: ☑ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes: ☐ No ☑
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes: ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorted period that the registrant was required to submit such files). Yes: ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer☑Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☑
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes: ☐ No ☑
The aggregate market value of the registrant’s common stock held by non-affiliates was approximately $79.0 billion based on the last reported sale price of $54.09 of the registrant’s common stock on the New York Stock Exchange on June 30, 2023, the last business day of the registrant’s most recently completed second fiscal quarter. (For this computation, the registrant has excluded the market value of all shares of common stock of the registrant reported as beneficially owned by executive officers, and directors of the registrant; such exclusion shall not be deemed to constitute an admission that any such person is an affiliate of the registrant.)
The number of shares outstanding of Common Stock, $0.01 par value per share, as of January 31, 2024 was 1,467,095,627.


Documents Incorporated by Reference
Portions of the registrant’s definitive proxy statement to be filed within 120 days of December 31, 2023 with the Securities and Exchange Commission in connection with its 2024 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K.



TABLE OF CONTENTS
   
 
  
 
  
 
  
 


2

PART I

ITEM 1. BUSINESS

Our Company

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. As a medical technology leader for more than 40 years, we have advanced the practice of less-invasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients’ quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the body. We advance science for life by providing a broad range of high performance solutions to address unmet patient needs and reduce the cost of health care. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries.

Business Strategy

We operate pursuant to five strategic imperatives. We aim to: Strengthen Category Leadership, Expand into High Growth Adjacencies, Drive Global Expansion, Fund the Journey to Fuel Growth and Develop Key Capabilities. We believe that our execution of these strategic imperatives will help us deliver on our mission, drive innovation and increase value for our customers and employees, while strengthening our leadership position in the medical device industry and delivering profitable revenue growth.

We expect to continue to invest in our core businesses and pursue opportunities to diversify and further expand our presence in strategic, high-growth adjacencies and new global markets, including growth within the countries we define as emerging markets. Maintaining and expanding our international presence is an important component of our long-term growth strategy. Through our international presence, we seek to increase net sales and market share, leverage our relationships with leading physicians and their clinical research programs, accelerate the time to bring new products to market and gain access to worldwide technological developments that we can implement across our product lines. Our research and development efforts are focused largely on the development of next-generation and novel technology offerings across multiple programs and all divisions. In the past several years, we have completed numerous acquisitions in support of our growth strategy, both strengthening our core businesses and expanding into high growth adjacent markets. We continue to develop digital tools and technologies that enable us to compete more effectively and deliver first class remote physician education, drive deeper patient engagement and increase digitally-enabled sales force productivity.

We have a firm commitment to corporate social responsibility and living our values as a global business and global corporate citizen. This includes taking actions to combat discrimination and advancing equality and diversity, including through financial support of racial equity initiatives in the communities where we live and work, protecting the environment, investing in our employees' health and well-being, and many other initiatives that we believe ultimately help us create value responsibly. Refer to discussion of Community Outreach below and Corporate Responsibility included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for additional information regarding measures we are undertaking.

Product Offerings

Our core businesses are organized into two reportable segments: MedSurg and Cardiovascular. The following describes our key product offerings and new product innovations by reportable segment and business unit.

MedSurg

Endoscopy

Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with innovative, less invasive technologies. Our product offerings include the following:

•Resolution 360™ Clips and Resolution 360™ ULTRA Clips, hemostatic clipping technology designed to stop and help prevent bleeding during endoscopic procedures,
•WallFlex™ Biliary Stent Systems, used for relieving biliary obstructions by providing bile drainage in both malignant and benign strictures,
3

•AXIOS™ Stents and Electrocautery Enhanced Delivery Systems, the first, and currently only stent systems in the U.S. indicated for endoscopic drainage of pancreatic pseudocysts and used to facilitate endoscopic drainage of the gallbladder for patients with acute cholecystitis,
•SpyGlass™ DS II Direct Visualization Systems and SpyGlass™ Discover Digital Catheters, the first single-use scopes to enable physicians to take a single-stage approach to diagnostic and therapeutic procedures in the pancreaticobiliary system, including treating patients with bile duct stones,
•EXALT™ Model D Single-Use Duodenoscopes for use in endoscopic retrograde cholangiopancreatography (ERCP) procedures, the first U.S. Food and Drug Administration (FDA)-cleared single-use (disposable) duodenoscopes on the market and
•our infection prevention portfolio, designed to minimize the risk of infection transmission and improve operational efficiencies by streamlining manual cleaning or eliminating the need for cleaning and tracking.

In the second quarter of 2023, we completed the acquisition of Apollo Endosurgery, Inc., a public company that has developed and commercialized endoscopic suturing devices including OverStitch™ Endoscopic Suturing Systems and X-Tack™ Endoscopic HeliX Tacking Systems and endobariatric devices including the Apollo ESG™ and Apollo REVISE™ Systems, the first devices authorized by the FDA for endoscopic sleeve gastroplasty and endoscopic bariatric revision procedures, as well as the Orbera™® Intragastric Balloon for endoscopic weight management.

Urology

Our Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction and incontinence. Our product offerings include the following:

•a comprehensive line of stone management products, including ureteral stents, catheters, baskets, guidewires, sheaths and balloons,
•LithoVue™ Single-Use Digital Flexible Ureteroscopes, which deliver detailed high-resolution digital images for high-quality visualization and seamless navigation,
•Lumenis Pulse™ Holmium Laser Systems with MOSES™ Technology, complemented by a full line of laser fibers and accessories used in urology procedures,
•our prosthetic urology portfolio, which includes our AMS 700™ penile implant to treat erectile dysfunction and our AMS 800™ Artificial Urinary Sphincter to treat male urinary incontinence,
•GreenLight XPS™ Laser System, MoXy™ Fiber, and Rezūm™ Systems for treatment of BPH and
•SpaceOAR™ Hydrogel Systems which help reduce side effects that men may experience after receiving radiotherapy to treat prostate cancer, together with our SpaceOAR VUE™ Hydrogel, providing clinicians with enhanced product visualization.

In the first quarter of 2023, we received FDA clearance for and launched our LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System, the first ureteroscope with the ability to monitor intrarenal pressure in real-time during ureteroscopy procedures.

Pending Axonics Acquisition

On January 8, 2024, we announced our entry into a definitive agreement to acquire Axonics, Inc. (Axonics), a publicly traded medical technology company primarily focused on the development and commercialization of devices to treat urinary and bowel dysfunction. The Axonics product portfolio includes the Axonics R20™ and Axonics F15™ Systems used to deliver sacral neuromodulation (SNM) therapy for the treatment of over-active bladder and fecal incontinence. The purchase price is $71.00 in cash per share, or approximately $3.670 billion. The transaction is expected to close in the first half of 2024, subject to customary closing conditions. We plan to fund the acquisition through a mix of cash on hand and new debt. The Axonics business will be integrated into our Urology division.

Neuromodulation

Our Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Our product offerings include the following:

•Precision Montage™ and WaveWriter Alpha™ Spinal Cord Stimulator (SCS) Systems, designed to provide improved pain relief to a wide range of patients who suffer from chronic pain, with proprietary features such as Multiple Independent Current Control, our Illumina 3D™ Proprietary Programming Software and FAST™ Therapy for
4

profound parathesia-free pain relief in minutes, used by physicians to target specific areas of pain and customize stimulation of nerve fibers more precisely,
•our G4™ Generator and consumable portfolio in Radiofrequency Ablation (RFA) for pain management used by physicians to treat patients with chronic pain,
•Superion™ Indirect Decompression Systems, minimally-invasive devices used to improve physical function and reduce pain in patients with moderate lumbar spinal stenosis (LSS),
•our Cognita™ Practice Optimization suite of tools designed to increase awareness, streamline patient management, and sustain long-term outcomes for patients
•Vercise Genus™ Deep Brain Stimulation (DBS) System for the treatment of Parkinson's disease, tremor, and intractable primary and secondary dystonia, a neurological movement disorder characterized by involuntary muscle contractions, utilizing Stimview™ XT, our proprietary DBS visualization software developed in collaboration with Brainlab AG, providing clinicians with real-time, 3D visualization and stimulation of brain anatomy.

In the second quarter of 2023, we received FDA approval for the Vercise™ Neural Navigator 5 Software, which when used with the Vercise Genus™ DBS systems can help provide clinicians with simple and actionable data for efficient programming in the treatment of people living with Parkinson's disease or essential tremor.

In addition, in the fourth quarter of 2023, we completed the acquisition of Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept™ Intraosseous Nerve Ablation System, the only FDA-cleared system to treat vertebrogenic pain, a form of chronic low back pain.

Cardiovascular

Cardiology

Interventional Cardiology Therapies (ICTx)

Our Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions. Our product offerings include the following:

•OptiCross™ Intravascular Ultrasound (IVUS) Imaging Catheters,
•iLab™ Ultrasound Imaging Systems with Polaris Software, designed to enhance the diagnosis and treatment of blocked vessels and other heart disorders, compatible with our full line of imaging catheters,
•AVVIGO™ Guidance Systems and AVVIGO™ Guidance System II, incorporating high-definition IVUS all in a mobile or integrated platform,
•ROTAPRO™ Rotational Atherectomy Systems, designed to treat coronary calcification in lesions by regulating the flow of air to the advancer, controlling burr rotation speed, and also monitoring and displaying burr rotation speed and rotational atherectomy procedural time,
•SYNERGY™, SYNERGY MEGATRON™ and SYNERGY™ XD Everolimus-Eluting Platinum Chromium Coronary Stent Systems, featuring an ultra-thin abluminal (outer) bioabsorbable polymer coating,
•Safari2™ Pre-Shaped Guidewires, intended to facilitate the introduction and placement of interventional devices within the heart,
•WOLVERINE™ Coronary Cutting Balloon™, a cutting balloon angioplasty device with a unique mechanism of action that enables precise vessel preparation across a wide range of resistant lesions,
•AGENT™ Drug-Coated Balloon, which is designed to provide a targeted, therapeutic dose of anti-proliferative paclitaxel to the coronary lesion and minimize downstream particulates,
•ACURATE neo2™ Aortic Valve Systems for use in transcatheter aortic valve replacement (TAVR) procedures and
•SENTINEL™ Cerebral Embolic Protection Systems, used to reduce the risk of stroke in TAVR procedures and is clinically proven to decrease cerebral embolization and its associated neurological effects.

In the third quarter of 2023, we received CE Mark, FDA clearance and Japanese Pharmaceuticals and Medical Devices Agency (PMDA) approval for the AVVIGO™+ Multi-Modality Guidance System, a next-generation technology that provides high-quality IVUS imaging and physiologic assessment of coronary vessels and lesions.
5


Watchman

Our WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Devices are designed to close the left atrial appendage in patients with non-valvular atrial fibrillation who are at risk for ischemic stroke. WATCHMAN™ is the first device to offer a non-pharmacologic alternative to oral anti-coagulants that has been studied in a randomized clinical trial and is the leading device in percutaneous LAAC globally. In the third quarter of 2023, we received FDA approval for the latest-generation WATCHMAN FLX™ Pro LAAC Device, which is designed to improve visualization during device placement, reduce device-related thrombus post-implant and treat a broader range of patient anatomies.

Cardiac Rhythm Management

Our Cardiac Rhythm Management (CRM) business develops and manufactures a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. Our product offerings include the following:

•the RESONATE™ family of implantable cardioverter defibrillators (ICD) and implantable cardiac resynchronization therapy defibrillators (CRT-D), including our proprietary HeartLogic™ Heart Failure (HF) Diagnostic and SmartCRT™ Technology with Multisite pacing in CRT-D,
•EMBLEM™ MRI S-ICD Systems, the world's first commercially available subcutaneous implantable cardiac defibrillators (S-ICD), which provides physicians the ability to treat patients who are at risk for sudden cardiac arrest without touching the heart,
•ACCOLADE™ family of pacemakers and implantable cardiac resynchronization therapy pacemakers (CRT-P),
•ACUITY™ X4 Quadripolar LV Leads, RELIANCE™ family of ICD Leads and our INGEVITY™ Pacing Leads,
•LATITUDE™ Remote Patient Management Systems, which allow for more frequent monitoring and better guided treatment decisions by enabling physicians to monitor implantable system performance remotely,
•LUX-Dx™ Insertable Cardiac Monitor (ICM) systems, long-term diagnostic devices implanted in patients to detect arrhythmias associated with conditions such as atrial fibrillation (AF), cryptogenic stroke and syncope and
•BodyGuardian™ Remote Cardiac Monitoring Systems provide a full range of mobile health solutions and remote monitoring services, ranging from ambulatory cardiac monitors – including short and long-term holter monitors – to cardiac event monitors and mobile cardiac telemetry.

In the third quarter of 2023, we received FDA clearance and launched the next-generation LUX-Dx II/II+™ ICM system for long-term monitoring of arrhythmias. Additionally, our entire transvenous defibrillator portfolio leverages our EnduraLife™ Battery Technology and has magnetic resonance imaging (MRI) conditional labeling when used with our current generation of leads.

Electrophysiology

Our Electrophysiology business develops and manufactures less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart, including a broad portfolio of therapeutic and diagnostic catheters and a variety of equipment used in the Electrophysiology lab. Our product offerings include the following:

•Farapulse™ Pulsed Field Ablation (PFA) System for the treatment of AF,
•POLARx™ Cryoablation Systems for the treatment of AF,
•VersaCross Connect™ Access Solutions for our WATCHMAN FXD Curve™ Sheath, Polarsheath™ and Faradrive™ Steerable Sheath providing safe and efficient access to the left side of the heart,
•Rhythmia™ Mapping Systems, catheter-based, 3-D cardiac mapping and navigation solutions designed to help diagnose and guide treatment of a variety of arrhythmias,
•A portfolio of radiofrequency (RF) cardiac ablation catheters, including our INTELLANAV STABLEPOINT™ catheter, which also includes DIRECTSENSE™ Software for monitoring RF energy during ablations and
•IntellaMap Orion™ Mapping Catheters, for use with our Rhythmia Mapping System to provide high-density, high-resolution maps of the heart.

In the third quarter of 2023, we received FDA approval for the POLARx™ Cryoablation System, which includes the POLARx™ FIT Cryoablation Balloon Catheter, and in the first quarter of 2024, we received FDA approval for the FARAPULSE™ PFA System, both of which are used to treat patients with paroxysmal AF.
6

Peripheral Interventions

Our Peripheral Interventions business develops and manufactures products to diagnose and treat peripheral arterial and venous diseases, as well as products to diagnose, treat and ease various forms of cancer. Our broad peripheral portfolio includes stent systems, balloon catheters, guidewires, atherectomy and thrombectomy systems, embolization devices, radioactive microspheres, radiofrequency and cryotherapy ablation systems, microcatheters and drainage catheters.

Our peripheral arterial product offerings include:

•Eluvia™ Drug Eluting Vascular Stent Systems, innovative stents built on the Innova stent platform, designed to deliver a sustained dosage of paclitaxel during the time when restenosis is most likely to occur, in addition to the Eluvia™ line extension, the longest-length stent available for treatment of patients with peripheral artery disease (PAD) in the superficial femoral artery,
•Mustang™, Coyote™ and Sterling™ PTA Balloon Catheters designed for a wide variety of peripheral angioplasty procedures and
•Ranger™ Drug-Coated Balloons, innovative balloons built on the Sterling balloon platform, featuring a low-dose of paclitaxel.

Our venous disease product offerings include the following:

•AngioJet™ Thrombectomy Systems, used in endovascular procedures to remove blood clots from blocked arteries and veins and our AngioJet Zelante DVT™ Thrombectomy Catheters to treat deep vein thrombosis,
•EKOS™ Ultrasound Assisted Thrombolysis systems used to treat pulmonary embolisms and
•Varithena™ Polidocanol Injectable Foam used to improve the symptoms of superficial venous incompetence and the appearance of visible varicosities.

Our interventional oncology product offerings include the following:

•TheraSphere™ Y-90 radioactive glass microspheres used in the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer,
•Renegade™ HI-FLO™ Fathom™ Microcatheter and Guidewire System and Interlock™ - 35 Fibered IDC™ and 18 Fibered IDC™ Occlusion System for peripheral embolization,
•EMBOLD™ Detachable Coil System, used for arterial and venous embolizations in the peripheral vasculature and
•ICEFX™ and Visual ICE™ Cryoablation Systems for destruction of tissue, using image-guided needles to enable cryoablation visualization for optimal tumor coverage.

In the first quarter of 2023, we acquired a majority stake investment in Acotec Scientific Holdings Limited (Acotec), a publicly traded Chinese manufacturer of drug-coated balloons and other products used in the treatment of vascular and other diseases, complementing our existing Peripheral Interventions portfolio. In addition, in the second quarter of 2023, we received FDA 510(k) clearance for the EMBOLD™ Soft and Packing Coils, which, along with the EMBOLD™ Fibered Coil, complete the EMBOLD™ Detachable Coil System, a peripheral embolization platform for vessel occlusion designed to simplify operator workflow and streamline inventory for hospitals. In the fourth quarter of 2023, we started to introduce our OBSIDIO™ Conformable Embolic for use in the embolization of hypervascular tumors and blood vessels to occlude blood flow for controlling bleeding/hemorrhaging in the peripheral vasculature.

Markets

Competition

We encounter significant competition across our product lines and in each market in which we sell our products and solutions, some from companies that may have greater financial, sales and marketing resources than we do. Our primary competitors include Abbott Laboratories and Medtronic plc, as well as a wide range of medical device companies that sell a single or limited number of competitive products or participate in only a specific market segment. In certain countries, and particularly in China, we also face competition from domestic medical device companies that may benefit from their status as local suppliers. We also face competition from non-medical device companies, which may offer alternative therapies for disease states that could also be treated using our products, or from companies offering technologies that could augment or replace procedures using our products.

7

We believe that our products and solutions compete primarily on their ability to deliver both differentiated clinical and economic outcomes for our customers by enabling physicians to perform diagnostic and therapeutic procedures safely and effectively often in a less-invasive and cost effective manner. We also compete on ease of use, comparative effectiveness, reliability and physician familiarity. In the current environment of managed care, with economically motivated buyers, consolidation among health care providers, increasing prevalence and importance of regional and national tenders, increased competition and declining reimbursement rates, we are also required to compete on the basis of price, value, reliability and efficiency. We recognize that our continued competitive success will depend upon our ability to:

•offer products and solutions that provide differentiated clinical and economic outcomes,
•create or acquire innovative, scientifically advanced technologies,
•apply our technology and solutions cost-effectively and with superior quality across product lines and markets,
•develop or acquire proprietary products and solutions,
•attract and retain qualified personnel,
•obtain patent or other protection for our products,
•obtain required regulatory and reimbursement approvals,
•continually provide quality products and enhance our quality systems and
•supply sufficient inventory at competitive prices to meet customer demand.

Research and Development

Our investment in research and development is critical to driving our future growth. Our investment in research and development supports the following:

•internal research and development programs, regulatory design and clinical science, as well as other programs obtained through our strategic acquisitions and alliances and
•engineering efforts that incorporate customer feedback into continuous improvement efforts for currently marketed and next-generation products.

We have directed our development efforts toward innovative technologies designed to expand current markets or enter adjacent markets. We continue to transform how we conduct research and development by identifying best practices, driving efficiencies and optimizing our cost structure, which we believe will enable increased development activity and faster concept-to-market timelines. Focused, cross-functional teams take a formal approach to new product design and development, helping us to manufacture and offer innovative products consistently and efficiently. Involving cross-functional teams early in the process is the cornerstone of our product development cycle. We believe this collaboration allows our teams to concentrate resources on the most viable and clinically relevant new products and technologies and to maximize cost and time savings as we bring them to market.

In addition to internal development, we work with leading research institutions, universities and clinicians around the world to develop, evaluate and clinically test our products. We continue to expand our collaborations to include research and development teams in our emerging market countries; these teams will focus on both global and local market requirements at a lower cost of development. We believe that these efforts will play a significant role in our future success.

Marketing and Sales

We market our products and solutions to hospitals, clinics, outpatient facilities and medical offices in 140 countries worldwide. In addition, large group purchasing organizations, hospital networks and other buying groups are important to our business and represent a substantial portion of our net sales. Each of our businesses maintains dedicated sales forces and marketing teams focused on physicians who specialize in the diagnosis and treatment of different medical conditions, as well as on key hospital service line administrators.

The majority of our net sales are derived from countries in which we have direct sales organizations. We also have a network of distributors and dealers who offer our products in certain countries and markets. We expect to continue to leverage our infrastructure in markets where commercially appropriate and use third party distributors in those markets where it is not economical or strategic to establish or maintain a direct presence.




8

Resources

Manufacturing and Raw Materials

We are focused on continuously improving our supply chain effectiveness, strengthening our manufacturing processes and increasing operational efficiencies within our organization worldwide. In doing so, we seek to focus our internal resources on the development and commercial launch of new products and the enhancement of existing products. We also drive continuous improvement in product quality through process controls and validations, supplier and distribution controls and training and tools for our operations team. In addition, we remain focused on examining our operations and general business activities to enhance our operational effectiveness by identifying cost-improvement opportunities.

We remain committed to maintaining appropriate investments to ensure supply chain stability. We have an ongoing supplier resiliency program which identifies and mitigates risk and have taken measures to mitigate the impact of challenges within the global supply chain in recent years. We consistently monitor our inventory levels, manufacturing, sterilization and distribution capabilities and partnerships and maintain recovery plans to address potential disruptions. Many components used in the manufacturing of our products are readily fabricated from commonly available raw materials or off-the-shelf items available from multiple supply sources; however, certain items are custom made to meet our specifications.

On an on-going basis, we track supplier status and inventory in risk areas and take action to prevent shortages, monitoring safety stock levels and building up product supplies as warranted, and mitigating risk of technology and material shortages by identifying new vendors.

Predictability in the supply of certain raw materials and components used in the manufacturing of our products has improved but continues to be a risk for certain materials and vendors. While we continue to believe we will have access to the raw materials and components that we need, these supply chain dynamics could result in increased costs to us or an inability to fully meet customer demand for certain of our products.

Proprietary Rights and Patent Litigation

We rely on a combination of patents, trademarks, trade secrets and other forms of intellectual property to protect our proprietary rights. We generally file patent applications in the U.S. and other countries where patent protection for our technology is appropriate and available. We hold patents worldwide that cover various aspects of our technology. In addition, we hold exclusive and non-exclusive licenses to a variety of third-party technologies covered by patents and patent applications. In the aggregate, these intellectual property assets and licenses are of material importance to our business; however, we believe that no single patent, technology, trademark, intellectual property asset or license is material in relation to our business as a whole.

We rely on non-disclosure and non-competition agreements with employees, consultants and other parties to protect, in part, trade secrets and other proprietary technology. There has been substantial litigation regarding patent and other intellectual property rights in the medical device industry, particularly in the areas in which we compete. We continue to defend ourselves against claims and legal actions alleging infringement of the patent rights of others. Additionally, we may find it necessary to initiate litigation to enforce our patent rights, to protect our trade secrets or know-how and to determine the scope and validity of the proprietary rights of others. Accordingly, we may seek to settle some or all of our pending litigation, particularly to manage risk over time. Settlement may include cross licensing of the patents that are the subject of the litigation as well as our other intellectual property and may involve monetary payments to or from third parties.

We maintain insurance policies providing limited coverage against securities claims. We are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. See Note I – Commitments and Contingencies to our 2023 consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for a discussion of intellectual property, product liability and other litigation and proceedings in which we are involved.

9

Regulatory Environment

Medical Device Regulatory Approvals

The medical devices that we manufacture, market and commercialize are subject to regulation by numerous worldwide regulatory bodies, including the FDA and comparable international regulatory agencies. These agencies require manufacturers of medical devices to comply with applicable laws and regulations governing development, testing, manufacturing, labeling, marketing and distribution. Medical devices are also generally subject to varying levels of regulatory control based on risk level of the device.

In the U.S., authorization to distribute a new device can generally be met in one of two ways. The first process requires that a premarket notification (510(k)) be made to the FDA to demonstrate that the device is as safe and effective as, or substantially equivalent to, a legally marketed device (the “predicate” device). Applicants must submit performance data to establish substantial equivalence. In some instances, data from human clinical trials must also be submitted in support of a 510(k) premarket notification. If so, these data must be collected in a manner that conforms to the applicable Investigational Device Exemption (IDE) regulations. The FDA must issue a decision finding substantial equivalence before commercial distribution can occur. Changes to cleared devices that could not significantly affect the safety or effectiveness of the device can generally be made without additional 510(k) premarket notifications; otherwise, a new 510(k) is required.

The second process requires the submission of a premarket approval (PMA) application to the FDA to demonstrate that the device is safe and effective for its intended use. This approval process applies to most Class III devices and generally requires clinical data to support the safety and effectiveness of the device, obtained in adherence with IDE requirements. The FDA will approve the PMA application if it finds that there is a reasonable assurance that the device is safe and effective for its intended purpose and that the proposed manufacturing is in compliance with the Quality System Regulation (QSR). For novel technologies, the FDA may seek input from an advisory panel of medical experts and seek their views on the safety, effectiveness and benefit-risk of the device. The PMA process is generally more detailed, lengthier and more expensive than the 510(k) process.

In the European Union (EU), we are required to comply with the Medical Device Regulation (MDR or EU MDR) which became effective in May 2021, superseding the existing Medical Device and Active Implantable Medical Device Directives. Medical devices which have a valid CE Certificate to the prior Directives (issued before May 2021) can continue to be sold during the applicable transition period or until the CE Certificate expires, whichever comes first, providing there are no significant changes to the design or intended use. The CE Mark, which is required to sell medical devices in the EU is affixed following a Conformity Assessment and either approval from the appointed independent Notified Body or through self-certification by the manufacturer. The selected pathway to CE marking is based on device risk classification. CE marking indicates conformity to the applicable General Safety and Performance Requirements (GSPRs) for the MDR. The MDR changes multiple aspects of the regulatory framework for CE marking, such as increased clinical evidence requirements, changes to labelling, and new requirements, including Unique Device Identification (UDI), and many new post-market reporting obligations. MDR also modifies and increases the compliance requirements for the medical device industry and will continue to require significant investment over the next few years to transition all products. The CE mark continues to be a prerequisite for successful registration in many other global geographies. In addition, other EU countries continue to impose significant local registration requirements despite the implementation of MDR, and the United Kingdom has introduced new requirements following its exit from the EU.

We are also required to comply with the regulations of every other country where we commercialize products before we can launch or maintain new products on the market, including regulations that have been introduced in many countries in the Middle East and Southeast Asia that previously did not have medical device regulations, or had minimal regulations. In Japan, we are required to comply with Japan’s Ministry of Health, Labor and Welfare (MHLW) regulations. In conjunction with the MHLW, the Pharmaceutical and Medical Device Agency is an independent agency that is responsible for reviewing drug and medical device applications and works with the MHLW to assess new product safety, develop comprehensive regulations, and monitor post-market safety.

The FDA and other worldwide regulatory agencies and competent authorities actively monitor compliance to local laws and regulations through review and inspection of design and manufacturing practices, record-keeping, reporting of adverse events, labeling and promotional practices. The FDA can ban certain medical devices, detain or seize adulterated or misbranded medical devices, order recall or market withdrawal of these devices and require notification of health professionals and others with regard to medical devices that present unreasonable risks of substantial harm to the public health. The FDA may also enjoin and restrain a company for certain violations of the Food, Drug and Cosmetic Act and the Safe Medical Devices Act,
10

pertaining to medical devices, or initiate action for criminal prosecution of such violations. Regulatory agencies and authorities in the countries where we do business can halt production in or distribution within their respective country or otherwise take action in accordance with local laws and regulations.

International sales of medical devices manufactured in the U.S. that are not approved by the FDA for use in the U.S., or that are banned or deviate from lawful performance standards, are subject to FDA export requirements. Additionally, exported devices are subject to the regulatory requirements of each country to which the device is exported.

Our quality system is designed to enable us to satisfy various international quality system regulations, including those of the FDA with respect to products sold in the U.S. The International Standards Organization (ISO) established the ISO 13485 quality system standard, which includes requirements for an implemented quality system that applies to component quality, supplier control, product design and manufacturing operations. All of our medical device manufacturing facilities and key distribution sites are certified under the ISO 13485 quality system standard.

Health Care Policies and Reimbursement

Political, economic, technological and regulatory influences around the world continue to subject the health care industry to potential fundamental changes that could substantially affect our results of operations. We maintain a global Government Affairs presence, headquartered in Washington, D.C., to actively monitor and advocate on myriad legislation and policies that may potentially impact us, both on a domestic and an international front. The Government Affairs office works closely with members of Congress and committee staff, the White House and administration offices, state governors, legislatures and regulatory agencies, embassies and global governments on issues affecting our business. The Government Affairs office also advocates for public policy that benefits our employees and the patients we serve and supports the communities in which we live.

Our products are purchased principally by hospitals, physicians and other health care providers around the world that typically bill various third-party payers, including government programs (e.g., Medicare and Medicaid in the U.S.) and private insurance payers, for the items and services provided to their patients. Government and private sector initiatives related to limiting the growth of health care costs (including price regulation), coverage and payment policies, comparative effectiveness reviews of therapies, technology assessments, price transparency and health care delivery and payment structure reforms, are continuing in many countries where we do business. We believe that these changes are causing the marketplace to place increased emphasis on the delivery of treatments that can reduce costs, improve efficiencies and/or increase patient access. Although we believe our products and technologies generate favorable clinical outcomes, value and cost efficiency, while also being less invasive than alternatives, the resources necessary to demonstrate value to our customers, patients, payers and other stakeholders are significant and new therapies may take significantly longer periods of time to gain widespread adoption.

Implementation of cost containment initiatives and health care reforms in significant markets such as the U.S., China, Australia, and other markets may limit the price of, or the level at which reimbursement is provided for, our products or procedures using our products, which in turn may make it less likely that a hospital or physician will select our products to treat patients.

Environmental Regulation and Management

We are subject to various environmental laws, directives and regulations both in the U.S. and abroad. Our operations involve the use of substances regulated under environmental laws, primarily in manufacturing and sterilization processes. We are focused on continuous improvement in environmental metrics with a goal of reducing pollution, minimizing depletion of natural resources and reducing our overall environmental footprint. Specifically, we are working to optimize energy and resource usage, ultimately reducing greenhouse gas emissions and waste. Refer to Corporate Responsibility included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for further discussion.

Human Capital

At Boston Scientific, our work is guided by core values that define our culture and empower our employees, including Caring, Diversity, Global Collaboration, High Performance, Meaningful Innovation and Winning Spirit. As of December 31, 2023, we had approximately 48,000 employees, of which approximately 58 percent were outside the U.S. We believe the collective talent of our employees and our shared corporate culture, values and behaviors give us a competitive advantage.
11

Attracting, developing and retaining talented employees are key parts of our strategy and are critical to our success. We strive to do this by fostering a diverse, equitable and inclusive workplace, providing competitive pay and benefits and flexible work conditions, offering ongoing employee growth and development opportunities and cultivating a culture that prioritizes employee health, safety and well-being.

Diversity, Equity and Inclusion (DE&I)

We do our best work to advance health care when we have a diverse range of perspectives and experience on our team. Innovation thrives in a culture of engagement, inclusion and equity. The society in which we live and the customers and patients we serve are diverse and our employees at all levels of the organization must reflect this diversity. In recent years, we have made steady progress to increase the overall representation of employees who identify as women and as Black/African American, Asian, Hispanic/Latino, American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander, and two or more races (together, multicultural talent). As of December 31, 2023, women represented 36 percent of our Board of Directors, and 49 percent of our employees. In addition, 38 percent of employees in the U.S. and Puerto Rico identified as multicultural.

We continue to focus on improving workforce diversity through intentional actions to drive meaningful change. We listen to our employees and use that feedback to complement and expand our existing DE&I programs to emphasize initiatives aimed at developing our pipeline of talent and fostering a psychologically safe and inclusive workplace for all. Additionally, our Executive Committee and our Board of Directors have oversight of our policies and strategies related to diversity and inclusion, employee engagement, talent recruitment and development, pay equity and company culture.

In addition, our ten Employee Resource Groups (ERGs) are at the heart of our DE&I strategy. ERGs are voluntary, company-sponsored employee groups that foster and celebrate our diverse workforce and inclusive work environment. They provide forums for us to learn from one another, celebrate our uniqueness and develop inclusive leadership skills. We support each ERG by designating global and local executive sponsors and providing financial resources. Our ERG chapters around the world collaborate across the business at all levels and are powerful voices for change in the company.

Additionally, our approach to supplier selection involves building DE&I throughout the Boston Scientific supplier network. We are committed to the increased and sustained support of diverse businesses that share our dedication to improving the quality of patient care. We have taken steps to further expand the number of Black-owned enterprises that provide supply chain services for our business in the U.S., and also support small and diverse vendors by shortening our standard payment terms.

Compensation and Benefits

We offer competitive, performance-based compensation programs, recognizing that employee well-being, safety, culture, engagement and recognition are all critical to a healthy work environment and productive workforce. We offer programs that acknowledge, respect and support an individual’s life and work choices. Our holistic programs are guided by overall workforce health, focusing on physical, financial and emotional well-being as well as a healthy work environment. We believe that investing in employee well-being leads to improved performance for the individual and the organization.

As part of our broader rewards portfolio, we offer competitive pay and benefits that are flexible and affordable to meet the individual needs of our employees. In addition to cash-based salaries, our rewards portfolio includes cash bonus programs, sales incentives, stock awards, recognition awards, health insurance, paid time off and family leave, retirement savings plans, childcare and Employee Assistance Programs that encourage overall well-being, including help with finances, inclusive family planning and support, elder/child care, legal support and mental health resources. Since 2021, our annual bonus plan has included performance measures for certain environmental, social and governance (ESG) goals. For additional information on our annual bonus plan, refer to our Proxy Statement for the 2023 Annual Meeting of Shareholders.

Equal pay for equal work is rooted in our values and foundational to fostering an inclusive environment. Pay equity is an important part of our long-standing global compensation planning practices. Sustaining pay equity requires constant measurement and attention, so we regularly conduct comprehensive audits, internal and external analyses and company-wide benchmarking of salaries to identify and eliminate disparities. In addition, we periodically contract with an independent, third party to assess pay equity across all positions. Our most recent pay equity study, completed in 2023, reported no statistically significant pay disparity for more than 99 percent of our employees across gender globally and for multicultural talent in the U.S. and Puerto Rico. We continue to educate and train our people, update policies and expand benefits to decrease bias, increase gender and racial representation within our organization, and foster a culture where all employees feel valued and included.

12

Employee Health and Safety

We take a global approach to prioritizing and monitoring employee health and safety and we strive to foster a safety-oriented culture in all of our offices and facilities. We set health and safety goals which measure the number of injuries per 100 employees for the global organization. Our Employee Health & Safety Global and Regional Councils review performance monthly to discuss trends and risks, as well as opportunities for improvement. We have obtained ISO 45001:2018 Occupational Health and Safety Management System at 14 of our key global locations. This is a globally recognized standard for employee Occupational Health and Safety, established by the International Standards Organization, which provides a voluntary framework to identify key occupational health and safety aspects associated with our business helping to deliver continuous improvement. We have established a company-wide safety goal of 0.25 or fewer injuries per 100 employees by 2030, cutting our year-over-year incident rate by approximately 50 percent from a base year of 2019. As of December 31, 2023, we have achieved a safety level of 0.32 per 100 employees.

Employee Growth and Development

Developing our people professionally is one of the most important things we do. We have robust succession planning to ensure our future leaders are ready to assume roles as they become available. At every level of the company, employees have access to training and tools they can use to advance their skills and expertise and create greater possibilities for their careers. We offer professional and technical courses, including on-the-job training, skills-based learning, mentoring opportunities and leadership development programs for all employees.

Employee Engagement

We seek ongoing feedback from our employees to better understand what we are doing well and, conversely, how we can improve their experience. In addition to encouraging ongoing communication and feedback between employees and their managers, we conduct periodic employee engagement surveys to ensure all employees have an opportunity to share their insights and we take appropriate action in response.

Community Outreach

We are united by a goal to make a difference in the lives of the over 37 million patients we serve annually. The Boston Scientific Caring value guides us in the work we do each day including how we invest in the well-being of communities. We work to advance possibilities in our three focus areas of health, STEM education and community. Our efforts evolve frequently as do the pressing needs of our communities. In 2023, we focused on providing aid to those impacted by natural and humanitarian disasters and addressing the basic needs of underserved populations in communities where we live and work. In 2023, we provided approximately $2 million in aid to 9 countries impacted by disasters through Boston Scientific and Boston Scientific Foundation funding.

Our global community programs empowered employees to participate in and influence the way we care for local communities through volunteerism and personal donations. Many employees chose to support their communities and causes they are passionate about through the use of the Employee Matching Gifts program. Through employee contributions and the Boston Scientific match, a total of nearly $2 million was donated in 2023.

We have also collaborated with non-profit community organizations to decrease health disparities and reduce the risk for chronic disease for the underserved by increasing access to health care and screenings. Our global and U.S. Signature Health Grant programs support education and development for health care workers in vulnerable communities worldwide. To help offset a World Health Organization projected shortfall of 10 million health care workers by 2030, we collaborate with organizations training medical staff to conduct critical disease screenings. In 2023, we provided approximately $1 million in these grants to organizations working in the U.S., Colombia, Peru and India. We also continue our long-term Close the Gap initiative, which focuses on raising awareness and empowering health care providers to reach more patients of color, fight longstanding inequities, and address barriers to care. Through Close the Gap, hospitals and health systems are provided with zip code level data that highlight the disease prevalence and disparities occurring in their communities. The information, along with our health equity resources, allows health care administrators and providers to focus on improving care to underserved populations within their communities.

We are also passionate about inspiring young learners to see themselves in a Science, Technology, Engineering and Math (STEM) role in the future. Employees on our global STEM teams work with underrepresented K-12 students to share their passion for STEM by providing interactive product demos, development programs, and hands-on activities for young learners in their communities. In 2023, more than 110,000 students were reached through our STEM activities and events.
13


Seasonality

Our net sales are influenced by many factors, including product launches, acquisitions, regulatory and reimbursement approvals, patient, physician and employee holiday schedules and other macro-economic conditions. While our consolidated net sales do not reflect any significant degree of seasonality, customer purchases of our medical devices have historically been lower in the first and third quarters of the year.

Available Information

Copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act), are available free of charge on our website (www.bostonscientific.com) as soon as reasonably practicable after we electronically file the material with or furnish it to the U.S. Securities and Exchange Commission (SEC). Additionally, the SEC maintains an internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Printed copies of these posted materials are also available free of charge to stockholders who request them in writing from Investor Relations, 300 Boston Scientific Way, Marlborough, MA 01752-1234. Information on our website or linked to our website is not incorporated by reference into this Annual Report on Form 10-K.

Safe Harbor for Forward-Looking Statements

Certain statements that we may make from time to time, including statements contained in this Annual Report on Form 10-K and information incorporated by reference herein, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend,” “aim,” "goal," "target," "continue," "hope," "may" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.

The forward-looking statements in this Annual Report on Form 10-K are based on certain risks and uncertainties, including the risk factors described in Item 1A under the heading “Risk Factors” and the specific risk factors discussed herein and in connection with forward-looking statements throughout this Annual Report on Form 10-K, which could cause actual results to vary materially from the expectations and projections expressed or implied by our forward-looking statements. These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this Annual Report on Form 10-K. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations, future U.S. and global political, competitive, reimbursement and regulatory conditions; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions and the market acceptance of those products; market competition for our products; expected pricing environment; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our restructuring program; the execution and effect of our business strategy, including our cost-savings and growth initiatives; our ability to achieve environmental, social and governance goals and commitments; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A. Risk Factors contained within this Annual Report on Form 10-K filed with the SEC, which we may update in Part II, Item 1A. Risk Factors in subsequent Quarterly Reports on Form 10-Q that we will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this Annual Report on Form 10-K.

14

The following are some of the important risk factors that could cause our actual results to differ materially from our expectations in any forward-looking statements. For further discussion of these and other risk factors, see Item 1A. Risk Factors.

Our Business

•Labor shortages and the impact of inflation on the cost of raw materials and direct labor,

•Risks associated with challenging or uncertain domestic and international economic conditions, including those related to interest rates, inflation, supply chain disruptions and constraints, adverse developments and volatility in the banking industry, currency devaluations or economies entering into periods of recession,

•The impact of disruptions in the supply of the materials and components used in manufacturing our products or the sterilization of our products,

•The impact of any future pandemics or other public health crises on worldwide economies, financial markets, manufacturing and distribution systems, including disruption in the manufacture or supply of certain components, materials or products, and business operations,

•The impact of natural disasters, climate change or other catastrophic events on our ability to manufacture, distribute and sell our products,

•The impact of competitive offerings, value-based procurement practices, government-imposed payback provisions and changes in reimbursement practices and policies on average selling prices for our products,

•The ongoing impact on our business of physician alignment to hospitals, governmental investigations and audits of hospitals and other market and economic conditions on the overall number of procedures performed,

•The performance of, and physician and patient confidence in, our products and technologies or those of our competitors,

•The impact and outcome of ongoing and future clinical trials and market studies undertaken by us, our competitors or other third parties or perceived product performance of our or our competitors' products,
 
•Variations in clinical results, reliability or product performance of our and our competitors' products,

•Our ability to acquire or develop, launch and supply new or next-generation products and technologies worldwide and in line with our commercialization strategies in a timely and successful manner and with respect to our recent acquisitions,

•The effect of consolidation and competition in the markets in which we do business or plan to do business,

•Our ability to achieve our projected level or mix of product sales, as some of our products are more profitable than others,

•Our ability to attract and retain talent, including key personnel associated with acquisitions, and to maintain our corporate culture,

•The impact of enhanced requirements to obtain and maintain regulatory approval in the U.S. and around the world, including EU MDR and the associated timing and cost of product approval,
 
•The impact of increased pressure on the availability and rate of third-party reimbursement for our products and procedures in the U.S. and around the world, including with respect to the timing and costs of creating and expanding markets for new products and technologies,

•The issuance of new or revised accounting standards by the Financial Accounting Standards Board or the Securities and Exchange Commission, and

•The impact of potential goodwill and intangible asset impairment charges on our results of operations.
15

Regulatory Compliance, Litigation and Data Protection

•The impact of health care policy changes and legislative or regulatory efforts in the U.S., the EU and around the world to modify product approval or reimbursement processes, including a trend toward demonstrating clinical outcomes, comparative effectiveness and cost efficiency, as well as the impact of other health care reform legislation,

•Risks associated with our regulatory compliance and quality systems and activities in the U.S., the EU and around the world, including meeting regulatory standards applicable to manufacturing and quality processes,

•The effect of global legal, regulatory or market responses to climate change and sustainability matters, including increased compliance burdens and costs to meet regulatory obligations,

•Our ability to minimize or avoid future field actions or FDA warning letters relating to our products and processes and the ongoing inherent risk of potential physician advisories related to our or our competitors' products,

•The impact of increased scrutiny of and heightened global regulatory enforcement facing the medical device industry arising from political and regulatory changes, economic pressures or otherwise, including under U.S. Anti-Kickback Statute, U.S. False Claims Act and similar laws in other jurisdictions, U.S. Foreign Corrupt Practices Act (FCPA) and similar laws in other jurisdictions, and U.S. and foreign export control, trade embargo and customs laws,

•Costs and risks associated with current and future asserted litigation,

•The effect of our litigation and risk management practices, including self-insurance and compliance activities on our loss contingencies, legal provisions and cash flows,
 
•The impact of, diversion of management attention as a result of, and costs to cooperate with, litigate and/or resolve governmental investigations and our class action, product liability, contract and other legal proceedings,

•The possibility of failure to protect our intellectual property rights and the outcome of patent litigation,

•Our ability to secure our information systems that support our business operations and protect our data integrity and products from a cyber-attack or other breach that may have a material adverse effect on our business, reputation or results of operations including increased risks as an indirect result of the ongoing Russia/ Ukraine war and Israel/Hamas war, and

•The potential impact to internal control over financial reporting relating to potential restrictions to access to consigned inventory at customer locations for our inventory count procedures.

Innovation and Certain Growth Initiatives

•The timing, size and nature of our strategic growth initiatives and market opportunities, including with respect to our internal research and development platforms and externally available research and development platforms and technologies and the ultimate cost and success of those initiatives and opportunities,

•Our ability to complete planned clinical trials successfully, obtain regulatory approvals and launch new and next generation products in a timely manner consistent with cost estimates, including the successful completion of projects from in-process research and development,

•Our ability to identify and prioritize our internal research and development project portfolio and our external investment portfolio on profitable net sales growth opportunities as well as to maintain the estimated timing and costs of such projects and expected revenue levels for the resulting products and technologies,

•Our ability to develop, manufacture and market new products and technologies successfully and in a timely manner and the ability of our competitors and other third parties to develop products or technologies that render our products or technologies noncompetitive or obsolete,

•Our ability to execute appropriate decisions to discontinue, write-down or reduce the funding of any of our research and development projects, including projects from in-process research and development from our acquisitions, in our growth adjacencies or otherwise,
16


•Our dependence on acquisitions, alliances or investments to introduce new products or technologies and to enter new or adjacent growth markets and our ability to fund them or to fund contingent payments with respect to those acquisitions, alliances and investments, and

•The potential failure to successfully integrate, collaborate or realize the expected benefits, including cost synergies, from strategic acquisitions, alliances and investments we have consummated or may consummate in the future.

International Markets

•Our dependency on international net sales to achieve growth, and our ability to maintain or expand our worldwide market positions in the various markets in which we compete or seek to compete, including through investments in China and other Emerging Market countries,

•The timing and collectability of customer payments, as well as our ability to continue factoring customer receivables where we have factoring arrangements, or to enter new factoring arrangements with favorable terms,

•The impact on pricing due to national and regional tenders, including value-based procurement practices and government-imposed payback provisions,

•Geopolitical and economic conditions, including civil unrest, terrorist activity, governmental changes, restrictions on the ability to transfer capital across borders, tariffs and other protectionist measures,

•The impact of the Russia/Ukraine war, Israel/Hamas war and tension between China/Taiwan, and related, downstream effects thereof, including disruptions to operations or the impact of sanctions on U.S. manufacturers doing business in these regions,

•Protection of our intellectual property,

•Our ability to comply with established and developing U.S. and foreign legal and regulatory requirements, including FCPA, EU MDR and similar laws in other jurisdictions,

•Our ability to comply with U.S. and foreign export control, trade embargo and customs laws,

•The impact of significant developments or uncertainties stemming from changes in the U.S. government following the 2024 presidential and congressional elections, including changes in U.S. trade policies, tariffs and the reaction of other countries thereto, particularly China, and

•The potential effect of foreign currency fluctuations and interest rate fluctuations on our net sales, operating expenses and resulting profit margins.

Liquidity

•Our ability to generate sufficient cash flow to fund operations, capital expenditures, global expansion initiatives, any litigation settlements and judgments, share repurchases and strategic investments and acquisitions as well as maintaining our investment grade ratings and managing our debt levels and financial covenant compliance,

•Our ability to access the public and private capital markets when desired and to issue debt or equity securities on terms reasonably acceptable to us,

•The unfavorable resolution of open tax matters, exposure to additional tax liabilities and the impact of changes in U.S. and international tax laws,

•The unfavorable resolution of open litigation matters, exposure to additional loss contingencies and legal provisions,

•The impact of examinations and assessments by domestic and international taxing authorities on our tax provisions, financial condition or results of operations,

•The possibility of counterparty default on our derivative financial instruments, and
17


•Our ability to collect outstanding and future receivables and/or sell receivables under our factoring programs.

Cost Reduction and Optimization Initiatives

•Risks associated with changes made or expected to be made to our organizational and operational structure, pursuant to our restructuring plans as well as any further restructuring or optimization plans we may undertake in the future and our ability to recognize benefits and cost reductions from such programs and

•Business disruption and employee distraction as we execute our global compliance program, restructuring and optimization plans and any divestitures of assets or businesses and implement our other strategic and cost reduction initiatives.
18

ITEM 1A. RISK FACTORS
In addition to the other information contained in this Annual Report on Form 10-K and the exhibits hereto, the following risk factors should be considered carefully in evaluating our business. Our business, financial condition, cash flows or results of operations could be materially adversely affected by any of these risks. This section contains forward-looking statements. You should refer to the explanation of the qualifications and limitations on forward-looking statements set forth at the end of Item 1. Business of this Annual Report on Form 10-K. The considerations and risks that follow are organized within relevant headings but may be relevant to other headings as well. Additional risks not presently known to us or that we currently deem immaterial may also adversely affect our business, financial condition, cash flows or results of operations.
Economic and Market Risks

Challenging domestic and international economic conditions could adversely affect our business, financial condition, cash flows and results of operations.

The global macroeconomic environment has experienced challenging conditions and uncertainty, which could adversely impact our business, financial condition, cash flows and results of operations. Uncertainty around inflationary pressures, interest rates and monetary policy could potentially cause new, or exacerbate existing, economic challenges that we may face. These conditions could worsen, or others could arise, if the U.S. and global economies were to enter recessionary periods, triggered or exacerbated by monetary policy designed to curb inflation. If there were a general economic downturn, we may experience decreased customer spending or demand for our products and services, and our customers’ ability to pay for our products on a timely basis, or at all, may be impacted. The same economic conditions could also adversely affect our third-party vendors, including those that we utilize in our supply-chain and manufacturing operations, which may lead to a reduction or interruption in the supply of materials and components used in manufacturing our products or increase the price of such materials or components, as well as the distributors and dealers who offer our products in certain countries and markets. Inflationary pressure may also increase certain operational costs, including due to wage increases, or increases in the cost of materials or components. These adverse economic conditions or events could adversely affect our business, results of operations or financial condition.

Further, uncertainty about global economic conditions, including those resulting from credit and sovereign debt issues, has caused and may continue to cause disruption in the financial markets, including diminished liquidity and credit availability. These conditions may adversely affect our suppliers, leading them to experience financial difficulties or be unable to borrow money to fund their operations, which could cause disruptions in our ability to produce our products. Our customers may experience financial difficulties or be unable to borrow money to fund their operations, which may adversely impact their ability or decision to purchase our products, particularly capital equipment, or to pay for our products that they purchase on a timely basis, if at all. In addition, we have accounts receivable factoring programs in certain European and Asian countries. Deterioration of the global economy or increase in sovereign debt issues may impact our ability to transfer receivables to third parties in certain of those countries. Third parties, such as banks, offering factoring programs in these countries are looking to reduce their exposure levels to government owned or supported debt. This could result in terminations of, or changes to the costs or credit limits of our existing factoring programs. Such terminations or changes could have a negative impact on our cash flow and days sales outstanding. Uncertain or challenging economic conditions could also lead to greater fluctuations in foreign currency exchange rates, which could adversely impact our results of operations and financial performance.

In addition, global pandemics or other public health crises, such as the COVID-19 pandemic, could adversely impact our business, financial condition or results of operations, and those of our customers and suppliers, and any such future pandemics or public health crises could include disruptions in global economic activity, global supply chains and labor markets, operational challenges such as site shutdowns, workplace disruptions or limited provider capacity to perform procedures using our products, volatile financial market dynamics and significant volatility in price and availability of goods and services.

There can be no assurance that there will not be further uncertainty, disruptions or deterioration in the global economy. Accordingly, we cannot predict to what extent global economic conditions, including negative or uncertain economic conditions, sovereign debt issues and increased focus on health care systems and costs in the U.S. and abroad, may impact negatively our average selling prices, net sales and profit margins, operations, procedural volumes and reimbursement rates from third party payers. In addition, economic and financial market conditions and other factors beyond our control may adversely affect our ability to borrow money in the credit markets, access the capital markets and obtain financing for mergers and acquisitions (M&A) or other general purposes.
We face intense competition and may not be able to keep pace with the rapid technological changes in the medical devices industry, which could have an adverse effect on our business, financial condition or results of operations.
19

The medical device markets in which we participate are highly competitive. We encounter significant competition across our product lines and in each market in which our products are sold from various medical device companies. Some of our competitors may have greater financial and marketing resources than we do, including as a result of consolidation among companies in our industry. Our primary competitors include Abbott Laboratories and Medtronic plc, as well as a wide range of medical device companies that sell a single or limited number of competitive products or which participate in only a specific market segment or segments. We also face competition from non-medical device companies, including pharmaceutical companies, biotech companies and providers of various diagnostic tests, which may offer alternative therapies or diagnostics for disease states also amenable to treatment or diagnosis using our products. New competitors may emerge in the future, potentially including companies introducing new sales or distribution models to our industry or leveraging genomic robotic, navigation, and/or other automation technologies. Digital technologies, including artificial intelligence (AI) and machine learning capabilities, have and may continue to increase in their applicability and importance to various aspects of our business, operating and competitive environments, R&D pipeline and product portfolio. We believe we will need to develop new and enhanced digital capabilities and competences in order to remain competitive.
In addition, the medical device markets in which we participate are characterized by extensive research and development and rapid technological change. Developments by other companies of products and/or services, processes or technologies may make our products or proposed products obsolete or less competitive and may negatively impact our net sales. It is necessary for us to devote continued efforts and financial resources to the development or acquisition of scientifically advanced technologies and products. In addition, we will need to apply our technologies cost-effectively across product lines and markets, obtain patent and other protection for our technologies and products, obtain required regulatory and reimbursement approvals and successfully manufacture and market our products consistent with our quality standards. If we fail to develop or acquire new products or enhance existing products, such failure could have a material adverse effect on our business, financial condition or results of operations. In addition, a delay in the timing of the launch of next-generation products and the overall performance of, and continued physician confidence in, those products may result in declines in our market share and have an adverse impact on our business, financial condition or results of operations.
We may experience declines in market size, average selling prices for our products, medical procedure volumes and our share of the markets in which we compete, which may materially adversely affect our results of operations and financial condition.
We continue to experience pressures across many of our businesses due to competitive activity, increased market power of our customers as the health care industry consolidates, national and regional government tenders, economic pressures experienced by our customers, staffing shortages within health care facilities that have and may continue to negatively impact demand for our products, public perception of our products, and the impact of managed care organizations and other third-party payers. These and other factors may adversely impact market sizes, as well as our share of the markets in which we compete, the average selling prices for our products or medical procedure volumes. There can be no assurance that the size of the markets in which we compete will increase, that we will be able to hold or gain market share or compete effectively on the basis of price or that the number of procedures in which our products are used will increase. Decreases in market sizes or our market share and declines in average selling prices or procedural volumes could materially adversely affect our results of operations or financial condition.

Continued consolidation in the health care industry or additional governmental controls exerted over pricing and access in key markets could lead to increased demands for price concessions or limit or eliminate our ability to sell to certain of our significant market segments, which could have an adverse effect on our business, financial condition or results of operations.
Numerous initiatives and reforms by legislators, regulators and third-party payers to curb the rising cost of health care, and to increase access to care, have catalyzed a consolidation of aggregate purchasing power within the markets in which we sell our products. Additionally, a growing number of countries have instituted or are contemplating introducing regional or national tender processes driven primarily by price. In some cases, such processes may favor local companies to multinational companies like us. In other instances, multinationals may be subject to a separate tender bidding process in which they compete only with each other and not with domestic companies. Further, in certain markets, the regulatory process through which new medical devices are approved may be faster and/or less burdensome for domestic companies compared to multinationals. As the health care industry consolidates, competition to provide products and services is expected to continue to intensify, resulting in pricing pressures, decreased average selling prices and the exclusion of certain suppliers from important market segments. We expect that market demand, government regulation, third-party coverage and reimbursement policies, government contracting requirements and societal pressures will continue to change the worldwide health care industry, resulting in further business consolidations and alliances among our customers, which may increase competition, exert further downward pressure on the prices of our products and services and may adversely impact our business, financial condition or results of operations.
20


Health care cost containment pressures, government payment and delivery system reforms, changes in private payer policies, and marketplace consolidations could decrease the demand for our products, the prices which customers are willing to pay for those products and/or the number of procedures performed using our devices, which could have an adverse effect on our business, financial condition or results of operations.

Our products are purchased principally by hospitals, physicians and other health care providers around the world that typically bill various third-party payers, including government programs, authorities or agencies (e.g., Medicare and Medicaid in the U.S.) and private health plans, for the health care supplies and services provided to their patients. Governments and payers may institute changes in health care delivery or payment systems that may reduce funding for services or encourage greater scrutiny of health care costs. The ability of customers to obtain appropriate reimbursement for their products and services is critical to the success of medical technology companies because it affects which products customers purchase and the prices they are willing to pay. Reimbursement and funding vary by country and can significantly impact the acceptance of new products and technologies and the use of established products and technologies. We may find limited demand for otherwise promising new products unless reimbursement approval is obtained from private and governmental third-party payers. Further legislative or administrative reforms to the reimbursement systems in the U.S., Japan, China, or other countries in a manner that significantly reduce or eliminate reimbursement for procedures using our medical devices, including price regulation, site of service requirements, competitive bidding and tendering, coverage and payment policies, comparative effectiveness of therapies, heightened clinical data requirements, technology assessments and managed-care arrangements, could have a material adverse effect on our business, financial condition or results of operations.
Geopolitical Risks
We are subject to a number of market, business, financial, legal and regulatory risks and uncertainties with respect to our international operations that could have a material impact on our business, financial condition or results of operations.
International net sales accounted for 41 percent of our global net sales in 2023. An important part of our strategy is to continue pursuing growth opportunities in net sales and market share outside of the U.S. by expanding global presence, including in Emerging Markets. Our international operations are subject to a number of market, business and financial risks and uncertainties, including those related to our use of channel partners, go-to-market strategies, geopolitical and economic instability, foreign currency exchange and interest rate fluctuations, competitive product offerings, local changes in health care financing and payment systems and health care delivery systems, local product preferences and requirements, including preferences for local manufacturers, workforce instability, weaker intellectual property protection in certain countries than exists in the U.S. and longer accounts receivable cycles. Such risks and uncertainties may adversely impact our ability to implement our growth strategy in these markets and, as a result, our sales growth, market share and operating profits from our international operations may be adversely affected.
Our international operations are subject to established and developing legal and regulatory requirements for medical devices in each country in which our products are marketed and sold. Most foreign countries have medical device regulations. Further, most countries outside of the U.S. require product approvals be renewed or re-certified on a regular basis in order to continue to be marketed and sold there. In addition, several countries that previously did not have regulatory requirements for medical devices have established such requirements in recent years and other countries have expanded, or plan to expand, existing regulations, including requiring local clinical data in addition to global clinical data. These factors have caused or may cause us to experience more uncertainty, risk, expense and delay in obtaining approvals and commercializing products in certain jurisdictions, which could adversely impact our net sales, market share and operating profits from our international operations.
Further, international markets are affected by economic pressure to contain health care costs, which can lead to more rigorous evidence requirements and lower reimbursement rates for either our products directly or procedures in which our products are used. Governments and payers may also institute changes in health care delivery systems that may reduce funding for services, seek payback from market participants, or encourage greater scrutiny of health care costs. In addition, certain international markets may also be affected by foreign government efforts to reference reimbursement rates in other countries. All of these types of changes may ultimately reduce selling prices of our products and/or reduce the number of procedures in which our products are used, which may adversely impact our net sales, market share and operating profits from our international operations.
In addition, our international operations are subject to other established and developing U.S. and foreign legal and regulatory requirements, including FCPA and/or similar laws in other countries and U.S. and foreign import and export controls and licensing requirements, trade protection and embargo measures and customs laws. Global businesses, including those in the medical device industry, are facing increasing scrutiny of, and heightened enforcement efforts with respect to, their international operations. Any alleged or actual failure to comply with legal and regulatory requirements may subject us to
21

government scrutiny, civil and/or criminal proceedings, sanctions and other liabilities, which may have a material adverse effect on our international operations, financial condition, results of operations and/or liquidity.

The US-China relationship will continue to shape the geopolitical stage. Legislation aimed at boosting competitiveness of U.S. businesses may have unintended effects on our business. We may also face greater competition in China, among other countries, from domestic medical device companies that may benefit from their status as local manufacturers and suppliers. Ultimately, tariffs, restrictions or other protectionist measures, and any countermeasures thereto, as well as prolonged uncertainty, could have adverse effects on our ability to source and manufacture products in a timely and cost effective manner, thereby adversely affecting our business.

Lastly, geopolitical developments related to various global conflicts are sources of uncertainty and may cause disruptions to global or regional markets, supply chains or operations in the regions. Sanctions and export restrictions are expected to continue to proliferate, leading to greater uncertainty in emerging and growth markets. Notably the Russia/Ukraine war has created barriers to doing business in Russia and in parts of Eastern Europe, the tension between China/Taiwan has created geopolitical shifts in Asia, and the Israel/Hamas war has disrupted operations of companies doing business in the Middle East. Any significant changes in the political, economic, financial, competitive, legal and regulatory or reimbursement conditions where we conduct, or plan to expand, our international operations may have a material impact on our business, financial condition or results of operations.
Credit and Financial Risks
If we are unable to manage our debt levels, maintain investment grade credit ratings at the three ratings agencies, or if we experience a disruption in our cash flows, it could have an adverse effect on our cost of borrowing, financial condition or results of operations.
As part of our strategy to maximize stockholder value, we use financial leverage to manage our cost of capital. Our outstanding debt balance was $9.102 billion as of December 31, 2023. Although we currently have investment grade ratings at Moody's Investor Service, Standard & Poor's Rating Service and Fitch Ratings, our inability to maintain investment grade credit ratings could increase our cost of borrowing funds in the future and reduce our access to liquidity. Uncertain or negative economic conditions could also increase our cost of borrowing in the future or reduce our access to liquidity. Delays in our product development and new product launches could result in disruption in our cash flow or our ability to continue to effectively manage our debt levels, which could have an adverse effect on our cost of borrowing, financial condition or results of operations. In addition, our credit agreements contain a financial covenant that requires us to maintain a minimum specified leverage ratio and place other limits on our business. If we are unable to satisfy this covenant, we may be required to obtain waivers from our lenders and no assurance can be made that our lenders would grant such waivers on favorable terms or at all and we could be required to repay any borrowings on demand.
We may record future goodwill impairment charges related to one or more of our global reporting units or other intangible asset impairment charges, which could materially adversely impact our results of operations.

We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist. We assess goodwill for impairment at the reporting unit level. We also test our indefinite-lived intangible assets at least annually, or more frequently if impairment indicators are present, and we review intangible assets subject to amortization quarterly for impairment. In evaluating the potential for impairment, we make assumptions regarding estimated revenue projections, growth rates, cash flows and discount rates.
On a quarterly basis, we monitor the key drivers of fair value to detect events or other changes that would warrant an interim impairment test of our goodwill and other intangible assets. Relatively small declines in the future performance and cash flows of a reporting unit or asset group, changes in our reporting units or in the structure of our business as a result of future reorganizations, acquisitions or divestitures of assets or businesses, or small changes in other key assumptions, may result in the recognition of significant asset impairment charges, which could have a material adverse impact on our results of operations.
Business and Operational Risks
Failure to integrate acquired businesses into our operations successfully could adversely affect our business, financial condition and operating results.
As part of our strategy to realign our business portfolio, we have completed multiple acquisitions in recent years and may pursue additional acquisitions in the future. Our integration of acquired businesses requires significant efforts, including
22

corporate restructuring and the coordination of information technologies, research and development, sales and marketing, operations, regulatory, supply chain, manufacturing, quality systems and finance. These efforts result in additional expenses and involve significant management time. Some of the factors that could affect the success of our acquisitions include, among others, the effectiveness of our due diligence process, our ability to execute our business plan for the acquired companies, the strength of the acquired technology, results of clinical trials, regulatory approvals and reimbursement levels of the acquired products and related procedures, the continued performance of critical transition services, our ability to adequately fund acquired in-process research and development projects and retain key employees and our ability to achieve synergies with our acquired companies, such as increasing sales of our products, achieving cost savings and effectively combining technologies to develop new products. Foreign acquisitions involve unique risks, including those related to integration of operations across different geographies, cultures and languages, currency risks and risks associated with the economic, political, legal and regulatory environment in specific countries. In addition, we have and may in the future acquire less than full ownership interests in other businesses, which involve unique challenges for effective collaboration. Further, other parties that hold remaining ownership interests in such businesses may at any time have economic or business goals that are inconsistent with our goals or the goals of such businesses. Our failure to manage these challenges successfully and coordinate the growth of such businesses or other investments could have an adverse impact on our business and our future growth. In addition, we cannot be certain that the businesses we acquire or invest in will become profitable or remain so, and if our acquisitions or investments are not successful, we may record related asset impairment charges in the future or experience other negative consequences on our operating results.
We may not be successful in our strategy relating to future strategic acquisitions of, investments in, or alliances with, other companies and businesses.

Our strategic acquisitions, investments and alliances are intended to further expand our ability to offer customers effective, high quality medical devices. We face competition for acquisitions from other health care and non-health care acquirers, financial sponsors, and from the market for initial public offerings (IPOs). Some of our competitors in the medical device sector may have access to substantially greater amounts of cash than we do that could be deployed into M&A or strategic investments if they so choose. The market for IPOs may also reduce the opportunities available to us for M&A and/or cause us to need to pay higher prices. If we are unsuccessful in our acquisitions, investments and alliances, it may adversely impact our ability to grow our business. Any potential future acquisitions we consummate may be dilutive to our earnings and may require additional debt or equity financing, depending on their size or nature. The success of our strategy relating to future acquisitions, investments or alliances will depend on a number of factors, including our ability to:

•identify suitable opportunities for acquisition, investment or alliance, if at all,
•manage acquisition, investment or alliance opportunities within our capital capacity and prioritize those investments to execute on our strategy,
•manage our due diligence process to uncover potential issues with targets,
•finance any future acquisition, investment or alliance on terms acceptable to us, if at all,
•complete acquisitions, investments or alliances in a timely manner on terms that are satisfactory to us, if at all,
•successfully integrate and operate acquired businesses and collaborate with non-wholly owned businesses,
•successfully identify and retain key target employees,
•comply with applicable laws and regulations, including foreign laws and regulations, and
•protect intellectual property and prevail in litigation related to newly acquired technologies. 

We may not realize the expected benefits from our restructuring and optimization initiatives, our long-term cost savings programs may result in an increase in short-term expenses and our efforts may lead to unintended consequences.

We monitor the dynamics of the economy, the health care industry and the markets in which we compete, and assess opportunities for improved operational effectiveness and efficiency and to better align expenses with revenues, while preserving our ability to make investments in research and development projects, capital and our people, which we believe is important to our long-term success. As a result of these assessments, we have undertaken prior restructuring and optimization initiatives to enhance our growth potential and position us for long-term success. On February 22, 2023, our Board of Directors approved, and we committed to, a new global restructuring program (the 2023 Restructuring Plan) intended to support our efforts to expand operating performance and meet evolving global market demands and conditions by ensuring that we are structured and resourced to support our strategic imperatives and deliver sustainable value. The 2023 Restructuring Plan further builds on our Global Supply Chain Optimization strategy, which is intended to simplify our manufacturing and distribution network by transferring certain production lines among facilities and expanding operational efficiencies and resiliency across production, sterilization, and distribution. Key activities under the 2023 Restructuring Plan will also include optimizing certain functional capabilities to better support business growth and achieve cost synergies. These activities were initiated during the first quarter of 2023, and are expected to be substantially completed by the end of 2025. The 2023 Restructuring Plan is expected to result in
23

total pre-tax charges of approximately $450 million to $550 million and reduce gross annual pre-tax expenses by approximately $225 million to $275 million as program benefits are realized. We expect a substantial portion of the savings to be reinvested in strategic growth initiatives. While we expect limited role reductions as a result of these restructuring activities, we anticipate that our overall employee base will remain relatively unchanged upon completion of the 2023 Restructuring Plan as new jobs are created in areas of growth and resources are deployed to support an expanding portfolio and growing global market needs. These measures could yield unintended consequences, such as distraction of our management and employees, reduced employee productivity, business disruption, and inability to attract or retain key personnel, which could negatively affect our business, sales, financial condition and results of operations. Moreover, our restructuring and optimization initiatives result in charges and expenses which impact our operating results. We cannot guarantee that the activities under our restructuring plans or other optimization initiatives will result in the desired efficiencies and estimated cost savings.
Our future growth is dependent upon the development of new products and enhancement of existing products, which requires significant research and development, clinical trials and regulatory approvals, all of which may be very expensive and time-consuming and may not result in commercially viable products.
In order to develop new products and enhance existing products, we focus our research and development programs largely on the development of next-generation and novel technology offerings across multiple programs and businesses. The development of new products and enhancement of existing products requires significant investment in research and development, clinical trials and regulatory approvals. The results of our product development efforts may be affected by a number of factors, including our ability to anticipate customer needs, innovate and develop new products, complete clinical trials, obtain regulatory approvals and reimbursement in the U.S. and abroad, manufacture products in a cost-effective manner, obtain appropriate intellectual property protection for our products and gain and maintain market approval of our products. There can be no assurance that any products now in development or that we may seek to develop in the future will achieve technological feasibility, obtain regulatory approval or gain market acceptance. If we are unable to develop and launch new products and enhanced products, our ability to maintain or expand our market position in the markets in which we participate may be materially adversely impacted. Further, we are continuing to investigate and have completed several acquisitions that involve opportunities to further expand our presence in and diversify into, priority growth areas by accessing new products and technologies. There can be no assurance that our investments will be successful or that we will be able to access new products and technologies on terms favorable to us, or that these products and technologies will achieve commercial feasibility, obtain regulatory approval or gain market acceptance. A delay in the development or approval of new products and technologies or our decision to reduce or terminate our investments may adversely impact the contribution of these technologies to our future growth.
Additionally, certain products or groups of products, in particular new products or enhancements of existing products, may have a disproportionate impact on our business, financial condition and results of operations. Failure to meet growth projections, poor clinical outcomes, increasing regulatory requirements, launch delays and inability to effectively scale manufacturing and achieve targeted margins with respect to any of these products or groups of products in particular may materially adversely impact on our business, financial condition and results of operations.
Interruption of our supply chain or manufacturing operations, including resulting from natural disasters, public health crises and other catastrophic events or other events outside of our control, could adversely affect our results of operations and financial condition.
Our products are designed and manufactured in technology centers around the world, either by us or third parties. In most cases, the manufacturing of any specific product is concentrated in one or a few locations. Factors such as a failure to follow specific internal protocols and procedures, equipment malfunction, environmental factors or damage to one or more of our facilities could adversely affect our ability to manufacture our products. In the event of an interruption in manufacturing, we may be unable to quickly move to alternate means of producing affected products or to meet customer demand. In the event of a significant interruption, for example, as a result of a failure to follow regulatory protocols and procedures, we may experience lengthy delays in resuming production of affected products due primarily to needs for regulatory approvals. As a result, we may experience loss of market share, which we may be unable to recapture and harm to our reputation, which could adversely affect our results of operations and financial condition.
24

Disruptions in the supply of the materials and components used in manufacturing our products by third-party vendors or the sterilization of our products could adversely affect our results of operations and financial condition.
We purchase the majority of the materials and components used in manufacturing our products from third-party vendors. Certain of these materials and components are purchased from single sources due to quality considerations, expertise, costs or constraints resulting from regulatory requirements. In certain cases, we may not be able to establish additional or replacement vendors for such materials or components in a timely or cost effective manner, largely as a result of FDA regulations that require validation of materials and components prior to their use in our products and the complex nature of our and many of our vendors' manufacturing processes. Further, uncertain or negative economic conditions, including as a result of inflationary pressures, interest rates or impacts from pandemics, could negatively affect our third-party vendors, which could lead to a reduction or interruption in the supply of materials and components used in manufacturing our products or increase the price of such materials or components. A reduction or interruption in the supply of materials and components used in manufacturing our products, an inability to timely develop and validate alternative sources if required or a significant increase in the price of such materials or components could adversely affect our results of operations and financial condition.

In addition, many of our products require sterilization prior to sale and we utilize a mix of internal resources and contract sterilizers to perform this service. To the extent we or our contract sterilizers are unable to sterilize our products, whether due to capacity, availability of materials for sterilization, regulatory or other constraints, including federal and state regulations on the use of ethylene oxide, we may be unable to transition to alternative internal or external resources or methods in a timely or cost effective manner or at all, which could have a material impact on our results of operations and financial condition. Additionally, U.S. and international governments have or are considering adopting regulations on the use of per- and polyfluoroalkyl substances (PFAS), and primary manufacturers of PFAS materials have announced that they are discontinuing the supply of such materials. These changes could have an adverse impact on our ability to manufacture or supply certain products in a timely or cost effective manner or at all. Other environmental laws may have similar impacts on us or our suppliers, or result in liability to us.

If we are unable to attract or retain key talent, it could have an adverse effect on our business, financial condition and results of operations.

In our industry, there is substantial competition for key personnel in the regions in which we operate and we may face increased competition for such employees. Our business depends to a significant extent on the continued service of senior management and other key personnel, the development of additional management personnel and the hiring of new qualified employees. There can be no assurance that we will be successful in retaining and developing existing personnel or recruiting new personnel. The loss of one or more key employees, our ability to attract or develop additional qualified employees or any delay in hiring key personnel could have material adverse effects on our business, financial condition or results of operations. A shortage of skilled labor could also require higher wages that would increase labor costs. Our ability to attract and retain key talent at all levels of our organization has been and could continue to be challenged by these conditions, and inability to attract and retain talent could result in material adverse impacts to our business and results of operations.

Legal and Regulatory Risk Factors

Health care policy changes may have a material adverse effect on our business, financial condition, results of operations and cash flows.

Political, economic and policy influences are leading the health care industry to make substantial structural and financial changes that will continue affecting our results of operations. Government and private sector initiatives aimed at limiting the growth of health care costs (including price regulation), coverage and payment policies, comparative effectiveness of therapies, technology assessments, increasing price transparency and reforming health care delivery and payment structures, are continuing in many countries where we do business. We believe that these changes are causing the marketplace to place increased emphasis on the delivery of treatments that can reduce costs, improve efficiencies and/or increase patient access. Although we believe our products and technologies generate favorable clinical outcomes, value and cost efficiency, while also being less invasive than alternatives, the resources and evidence necessary to demonstrate value to our customers, patients, payers and other stakeholders may be significant, and it may take a significant period of time to gain widespread adoption. Moreover, there can be no assurance that our strategies will succeed for every product.

We cannot predict the specific health care programs and regulations that will be ultimately implemented by various regional and national governments. However, any changes that lower reimbursements for either our products and/or procedures using our products reduce medical procedure volumes and/or increase cost containment pressures on us or others in the health care sector could adversely affect our business and results of operations.
25


We are subject to extensive and dynamic medical device regulation, which may impede or hinder the approval or sale of our products and, in some cases, may ultimately result in an inability to obtain approval of certain products or may result in the recall or seizure of previously approved products.
Our products, marketing, sales and development activities and manufacturing processes are subject to extensive and rigorous regulation by the FDA pursuant to the Federal Food, Drug and Cosmetic Act (FDC Act), by comparable agencies in foreign countries and by other regulatory agencies and governing bodies. Under the FDC Act, medical devices must receive FDA clearance or approval or an exemption from such clearance or approval before they can be commercially marketed in the U.S. In the EU, we are required to comply with the new MDR effective May 2021 which supersedes the Medical Device Directives. Medical devices which have a valid CE Certificate to the current Directives (issued before May 2021) can continue to be sold until the earlier of May 2024 or when the CE Certificate expires, providing there are no significant changes to the design or intended use. In 2023, updates to the legislative text of the EU MDR were adopted by the European Parliament and the Council of the European Union, including an extension of the transitional period to 2027 for certain high risk class devices and 2028 for lower risk class medical devices which have a valid CE Certificate to the prior Directives (issued before May 2021). The CE Mark is applied following approval from an independent notified body or declaration of conformity. The process of obtaining marketing approval or clearance from the FDA or by comparable agencies in foreign countries for new products, or with respect to enhancements or modifications to existing products, could:

•take a significant period of time,
•require the expenditure of substantial resources,
•involve rigorous pre-clinical and clinical testing, as well as increased post-market surveillance,
•require changes to products, and
•result in limitations on the indicated uses of products.
 
In addition, exported devices are subject to the regulatory requirements of each country to which the device is exported. Some countries do not have medical device regulations, but in most countries, medical devices are regulated. Frequently, regulatory approval may first be obtained in a foreign country prior to application in the U.S. due to differing regulatory requirements; however, other countries, such as China for example, require approval in the country of origin or legal manufacturer first. Most countries outside of the U.S. require that product approvals be renewed or recertified on a regular basis, generally every four to five years. The renewal or recertification process requires that we evaluate any device changes and any new regulations or standards relevant to the device and conduct appropriate testing to document continued compliance. Where renewal or recertification applications are required, they may need to be renewed and/or approved in order to continue selling our products in those countries. There can be no assurance that we will receive the required approvals for new products or modifications to existing products on a timely basis or that any approval will not be subsequently withdrawn or conditioned upon extensive post-market study requirements.

Our global regulatory environment is becoming increasingly stringent and unpredictable, which could increase the time, cost and complexity of obtaining regulatory approvals, as well as the clinical and regulatory costs of supporting those approvals. Several countries that did not previously have regulatory requirements for medical devices have established such requirements in recent years and other countries have expanded on existing regulations. Certain regulators are exhibiting less flexibility and are requiring local preclinical and clinical data in addition to global data. While harmonization of global regulations has been pursued, requirements continue to differ significantly among countries. We expect this global regulatory environment will continue to evolve, which could impact our ability, or increase the time and cost, to obtain future approvals for our products.
The FDA and other worldwide regulatory agencies actively monitor compliance with local laws and regulations through review and inspection of design and manufacturing practices, recordkeeping, reporting of adverse events, labeling and promotional practices. The FDA can ban certain medical devices, detain or seize adulterated or misbranded medical devices, order repair, replacement or refund of these devices and require notification of health professionals and others with regard to medical devices that present unreasonable risks of substantial harm to the public health. The FDA can take action against a company that promotes "off-label" uses. The FDA may also enjoin and restrain a company for certain violations of the FDC Act and other amending laws pertaining to medical devices, or initiate action for criminal prosecution of such violations. Any adverse regulatory action, depending on its magnitude, may restrict a company from effectively marketing and selling its products, may limit a company's ability to obtain future premarket clearances or approvals and could result in a substantial modification to our business practices and operations. International sales of medical devices manufactured in the U.S. that are not approved by the FDA for use in the U.S., or that are banned or deviate from lawful performance standards, are subject to FDA export requirements.
26

Regulations regarding the development, manufacture and sale of medical devices are evolving and subject to future change. We cannot predict what impact, if any, those changes might have on our business. Failure to comply with regulatory requirements could have a material adverse effect on our business, financial condition and results of operations. Later discovery of previously unknown problems with a product or manufacturer could result in fines, delays or suspensions of regulatory clearances or approvals, seizures or recalls of products, physician advisories or other field actions, operating restrictions and/or criminal prosecution. We may also initiate field actions as a result of a failure to strictly comply with our internal quality policies. The failure to receive product approval clearance on a timely basis, suspensions of regulatory clearances, seizures or recalls of products, physician advisories or other field actions, or the withdrawal of product approval by the FDA or by comparable agencies in foreign countries could have a material adverse effect on our business, financial condition or results of operations.
Our products are continually subject to clinical trials and other analyses conducted by us, our competitors or other third parties, the results of which may be unexpected, or perceived as unfavorable by the market, and could have a material adverse effect on our business, financial condition or results of operations.
As a part of the regulatory process of obtaining marketing clearance for new products and new indications for existing products, we conduct and participate in numerous clinical trials with a variety of study designs, patient populations and trial endpoints. Unexpected or inconsistent clinical data from existing or future clinical trials or other analyses conducted by us, by our competitors or by third parties, including acquired businesses prior to acquisition by us, or the FDA's or the market's perception of this clinical data, may adversely impact our ability to obtain product approvals, our position in, and share of, the markets in which we participate and our business, financial condition, results of operations or future prospects.
The medical device industry and its customers continue to face scrutiny and regulation by governmental authorities and are often the subject of numerous investigations, often involving marketing and other business practices or product quality issues including device recalls or advisories. These investigations could result in the commencement of civil and criminal proceedings; imposition of substantial fines, penalties and administrative remedies, including corporate integrity agreements, stipulated judgments or exclusion; diversion of our employees' and management's attention; imposition of administrative costs and have an adverse effect on our financial condition, results of operations and liquidity; and may lead to greater governmental regulation in the future.
The medical devices we design, develop, manufacture and market are subject to rigorous regulation by the FDA and numerous other federal, state and foreign governmental authorities. These authorities continue to closely scrutinize our industry. We have received and in the future may receive, subpoenas and other requests for information from Congress and state and federal governmental agencies, including, among others, the U.S. Department of Justice (DOJ), the Office of Inspector General of the Department of Health and Human Services (HHS) and the Department of Defense, as well as from foreign governments and agencies. The requests and/or subpoenas we have received relate primarily to financial arrangements with health care providers, regulatory compliance and sale and/or product promotional practices. We have cooperated with these subpoenas and other requests for information and expect to continue to do so in the future. We cannot predict when a matter will be resolved, the outcome of the matter or its impact on us and cooperation may involve significant costs, including document production costs. An adverse outcome in any matter could include the commencement of an investigation, civil and criminal proceedings, substantial fines, penalties and administrative remedies, including exclusion from government reimbursement programs, entry into Corporate Integrity Agreements (CIAs) with governmental agencies and amendments to any existing CIAs. In addition, resolution of any matter could involve the imposition of additional and costly compliance obligations. Cooperation with requests and investigations from external agencies result in employee resource costs and diversion of employee focus. If any requests or investigations continue over a long period of time, they could divert the attention of management from the day-to-day operations of our business and impose significant additional administrative burdens on us. These potential consequences, as well as any adverse outcome from these requests or investigations, could have a material adverse effect on our financial condition, results of operations and liquidity.
In addition, certain foreign governments, state governments (including that of Massachusetts, where we are headquartered) and the U.S. federal government have enacted legislation aimed at increasing transparency of our interactions with health care providers. As an example, compliance with the U.S. Physician Payment Sunshine Act requires us by law to disclose payments and other transfers of value to all U.S. physicians and U.S. teaching hospitals at the U.S. federal level made after August 1, 2013. Failure to comply with these legal and regulatory requirements could impact our business. In addition, we have and may continue to devote substantial additional time and financial resources to further develop and implement enhanced structure, policies, systems and processes to comply with enhanced legal and regulatory requirements, which may also impact our business.
We anticipate that governmental authorities will continue to scrutinize our industry closely and that additional regulation may increase compliance and legal cost and exposure to litigation and have additional adverse effects on our operations.
27

Changes in tax laws, unfavorable resolution of tax contingencies, or exposure to additional income tax liabilities could have a material impact on our financial condition, results of operations and/or liquidity.
We are subject to income taxes as well as non-income based taxes and tariffs, in the U.S. and numerous foreign jurisdictions. We are subject to ongoing tax audits in various jurisdictions. Tax authorities may disagree with certain positions we have taken and assess additional taxes. We regularly assess the likely outcomes of these audits to determine the appropriateness of our tax provision, and we have established contingency reserves for material, known tax exposures. However, the calculation of such tax exposures involves the application of complex tax laws and regulations in many jurisdictions, as well as interpretations as to the legality under European Union state aid rules of tax advantages granted in certain jurisdictions. Therefore, there can be no assurance that we will accurately predict the outcomes of these disputes or other tax audits or that issues raised by tax authorities will be resolved at a financial cost that does not exceed our related reserves and the actual outcomes of these disputes and other tax audits could have a material impact on our results of operations or financial condition.

Changes in tax laws and regulations, or their interpretation and application, in the jurisdictions where we are subject to tax could materially impact our effective tax rate. The U.S. enacted the Tax Cuts and Jobs Act (TCJA) on December 22, 2017 and the Inflation Reduction Act on August 16, 2022. We expect the U.S. Treasury to issue future notices and regulations regarding the application and interpretation of these laws which could have a significant impact on our future results of operations as could interpretations made by the Company in the absence of regulatory guidance and judicial interpretations.

The Group of Twenty (G20), the Organization for Economic Co-operation and Development (OECD), the European Commission (EC) and individual taxing jurisdictions where we and our affiliates do business have recently focused on issues related to the taxation of multinational corporations. The OECD/G20 Inclusive Framework (IF) on base erosion and profit shifting (BEPS) includes actions intended to equip governments with domestic and international rules and instruments to address tax avoidance, ensuring that profits are taxed where economic activities generating the profits are performed and where value is created. The actions include a two-pillar solution to address the tax challenges of the digitalized economy. Pillar One focuses on how profits are allocated between taxing jurisdictions and Pillar Two creates a 15% global minimum tax. As of December 31, 2023, many countries where we do business, including 17 in the European Union, the United Kingdom, South Korea and Japan have already implemented the Pillar Two global minimum tax into their national laws. Other countries are considering enacting laws consistent with the Pillar Two rules but have yet to pass legislation, while still others have yet to announce their intentions to adopt. Additionally, the OECD has continued to issue new guidance on the Pillar Two framework throughout 2023. While we continue to monitor legislative adoption by country of the Pillar Two rules, as well as for additional guidance from the OECD, there is significant uncertainty that exists regarding the interpretation of the detailed Pillar Two rules, whether such rules will be implemented consistently across taxing jurisdictions, how such rules interact with existing national tax laws and whether such rules are consistent with existing tax treaty obligations. Accordingly, the final adoption, implementation, and interpretation of Pillar Two across all jurisdictions where we do business could have a material adverse impact on our financial condition, results of operations and cash flows.

The tax laws in the U.S. and other countries in which we and our affiliates do business could change on a prospective or retroactive basis and any such changes could have a material adverse effect on our business. Furthermore, changes in customs laws and regulations in the U.S. and various foreign jurisdictions could have a material impact on our results of operations or financial condition.

Our operations in Puerto Rico, Costa Rica and Malaysia presently benefit from various tax incentives and grants. Unless these incentives and grants are extended, they will expire between 2027 and 2034. If we are unable to renew, extend, or obtain new incentive and grants, the expiration of the existing incentives and grants could have a material impact on our financial results in future periods.

We may not effectively be able to protect our intellectual property, systems, software-based products or other sensitive data, which could have a material adverse effect on our business, financial condition or results of operations.

The medical device market in which we participate is largely technology driven. Physician customers have historically moved quickly to new products and new technologies. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. However, intellectual property litigation is inherently complex and unpredictable and appellate courts can overturn lower court decisions. Furthermore, as our business increasingly relies on technology systems and infrastructure, our intellectual property, other proprietary technology and other sensitive data are potentially vulnerable to loss, damage or misappropriation. Finally, our ability to protect novel business models is uncertain.

Competing parties in our industry frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the
28

same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These forces frequently drive settlement not only of individual cases, but also of a series of pending and potentially related and unrelated cases. In addition, although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.

A number of third parties have asserted that our current and former product offerings infringe patents owned or licensed by them. We have similarly asserted that products sold by our competitors infringe patents owned or licensed by us. Adverse outcomes in one or more of the proceedings against us could limit our ability to sell certain products in certain jurisdictions, or reduce our operating margin on the sale of these products and could have a material adverse effect on our financial condition, results of operations or liquidity.

Patents and other proprietary rights are and will continue to be essential to our business, and our ability to compete effectively with other companies will be dependent upon the proprietary nature of our technologies. We rely upon trade secrets, know-how, continuing technological innovations, strategic alliances, and licensing opportunities to develop, maintain and strengthen our competitive position. We pursue a policy of generally obtaining patent protection in both the U.S. and abroad for patentable subject matter in our proprietary devices and attempt to review third-party patents and patent applications to the extent publicly available in order to develop an effective patent strategy, avoid infringement of third-party patents, identify licensing opportunities and monitor the patent claims of others. We own numerous U.S. and foreign patents and have numerous patent applications pending. We also are party to license agreements pursuant to which patent rights have been obtained or granted in consideration for cash, cross-licensing rights or royalty payments. No assurance can be made that any pending or future patent applications will result in the issuance of patents, that any current or future patents issued to, or licensed by, us will not be challenged or circumvented by our competitors, or that our patents will not be found invalid. In addition, we may have to take legal action in the future to protect our patents, trade secrets or know-how or to assert them against claimed infringement by others. Any legal action of that type could be costly and time consuming and no assurances can be made that any lawsuit will be successful. We are generally involved as both a plaintiff and a defendant in a number of patent infringement and other intellectual property-related actions. The invalidation of key patents or proprietary rights that we own, or an unsuccessful outcome in lawsuits to protect our intellectual property, could have a material adverse effect on our business, financial condition or results of operations.

In addition, the laws of certain countries in which we market and plan on manufacturing some of our products in the near future, do not protect our intellectual property rights to the same extent as the laws of the U.S. If we are unable to protect our intellectual property in these countries, it could have a material adverse effect on our business, financial condition or results of operations.

Furthermore, our intellectual property, other proprietary technology and other sensitive data are potentially vulnerable to loss, damage or misappropriation from system malfunction, computer viruses and unauthorized access to our data or misappropriation or misuse thereof by those with permitted access and other events. While we have invested to protect our intellectual property, products and other data and continue to work diligently in this area, there can be no assurance that our precautionary measures will prevent breakdowns, breaches, cyber-attacks or other events. Such events could have a material adverse effect on our reputation, business, financial condition or results of operations.
Pending and future intellectual property litigation could be costly and disruptive to us.
We operate in an industry that is susceptible to significant intellectual property litigation and, in recent years, it has been common for companies in the medical device field to aggressively challenge the patent rights of other companies. We are currently the subject of various patent litigation proceedings and other proceedings described in more detail under Note I – Commitments and Contingencies to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K. Intellectual property litigation is expensive, complex and lengthy and its outcome is difficult to predict. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial condition, results of operation or liquidity. Pending or future patent litigation may result in significant royalty or other payments or injunctions that can prevent the sale of products and may significantly divert the attention of our technical and management personnel. In the event that our right to market any of our products is successfully challenged, we may be required to obtain a license on terms which may not be favorable to us, if at all. If we fail to obtain a required license or are unable to design around a patent, our business, financial condition or results of operations could be materially adversely affected.

29

Pending and future product liability claims and other litigation, including private securities litigation, stockholder derivative suits and contract litigation, may adversely affect our financial condition and results of operations or liquidity.

The design, manufacturing and marketing of medical devices of the types that we produce entail an inherent risk of product liability claims. Many of the medical devices that we manufacture and market are designed to be implanted in the human body for long periods of time or indefinitely. A number of factors could result in an unsafe condition or injury to, or death of, a patient with respect to these or other products that we manufacture or sell, including physician technique and experience in performing the surgical procedure, component failures, manufacturing flaws, design defects, off-label use or inadequate disclosure of product-related risks or product-related information. These factors could result in product liability claims, a recall of one or more of our products or a safety alert relating to one or more of our products. Product liability claims may be brought by individuals or by groups seeking to represent a class.

We are currently the subject of product liability litigation proceedings and other proceedings described in more detail under Note I – Commitments and Contingencies to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K. The outcome of litigation, particularly class action lawsuits, is difficult to assess or quantify. Plaintiffs in these types of lawsuits often seek recovery of very large or indeterminate amounts, including not only actual damages, but also punitive damages. The magnitude of the potential losses relating to these lawsuits may remain unknown for substantial periods of time. In addition, the cost to defend against any future litigation may be significant. Product liability claims, securities and commercial litigation and other litigation in the future, regardless of the outcome, could have a material adverse effect on our financial condition, results of operations or liquidity. Additionally, we maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The fact that we do not maintain third-party insurance coverage for all categories of losses increases our exposure to unanticipated claims and adverse decisions and these losses could have a material adverse effect on our financial condition, results of operations or liquidity.
Any failure to meet regulatory quality standards applicable to our manufacturing and quality processes could have an adverse effect on our business, financial condition and results of operations.

As a medical device manufacturer, we are required to register our establishments and list our devices with the FDA and are subject to periodic inspection by the FDA for compliance with its Quality System Regulation requirements, which require manufacturers of medical devices to adhere to certain regulations, including testing, quality control and documentation procedures. In addition, the Federal Medical Device Reporting regulations require us to provide information to the FDA whenever there is evidence that reasonably suggests that a device may have caused or contributed to a death or serious injury or, if a malfunction were to occur, could cause or contribute to a death or serious injury. Compliance with applicable regulatory requirements is subject to continual review and is monitored rigorously through periodic inspections by the FDA which may result in observations on Form 483 and in some cases warning letters that require corrective action. In the European Community, we are required to maintain certain International Standards Organization (ISO) certifications in order to sell our products and must undergo periodic inspections by notified bodies to obtain and maintain these certifications. Many other countries in which we do business have similar requirements and other foreign governments or agencies may subject us to periodic inspections. If we, or our manufacturers, fail to adhere to quality system regulations or ISO requirements, this could delay production of our products and lead to fines, difficulties in obtaining regulatory clearances, recalls, enforcement actions, including injunctive relief or consent decrees, or other consequences, which could, in turn, have a material adverse effect on our financial condition or results of operations.

Other Risk Factors

We rely on the proper function, availability and security of information technology systems to operate our business and a cyber-attack or other breach of these systems could have a material adverse effect on our business, financial condition or results of operations.

We rely on information technology (IT) and operational technology (OT) systems, including technology from third party vendors, to manufacture and ship our products, as well as to process, transmit and store electronic information in our day-to-day operations. Similar to other large multi-national companies, the size and complexity of our IT systems makes them vulnerable to a cyber-attack, malicious intrusion, breakdown, destruction, loss of data privacy, or other significant disruption. Various other factors may also cause system failures or security breaches, including power outages, natural disasters, inadequate or ineffective backups, issues with upgrading or creating new systems or platforms, vulnerabilities in third-party software or services, errors by our staff or third-party service providers, or breaches in the security of these technologies. Malicious actors may attempt to trick staff to disclose information to gain access to our systems and/or data. International conflicts, including but
30

not limited to the Russia/Ukraine war, the Israel/Hamas war and tension between China/Taiwan, have also heightened cybersecurity risks on a global basis. If our incident response, disaster recovery, and business continuity plans fail, such failure could result in adverse impacts to our business operations and our financial results.

Our information systems require an ongoing commitment of significant resources to maintain, protect and enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving systems and regulatory standards, the increasing need to protect patient and customer information and changing customer patterns. In addition, third parties have and may continue to attempt to hack into our products to obtain data relating to patients, or alter the intended functionality of our medical devices, or disrupt performance of our products, or access our proprietary information and the technology from third party vendors that we rely upon may have defects or vulnerabilities which, in turn, create vulnerabilities or disruptions in our system. Cyber-attacks continue to evolve in complexity and scope, and inherently may be difficult to detect. This includes emerging technologies such as generative AI which may be used by malicious actors to create more targeted phishing narratives or otherwise strengthen social engineering capabilities, which may increase our threat landscape. We have seen, and could continue to see, software and supply-chain vulnerabilities and malware, which could affect our systems and the systems of our third-party vendors and business partners. Some of our IT and OT systems contain legacy third-party software components for which we depend on a layered security approach to protect against exploitation, and such layered security approach may not be effective. Any failure by us to maintain or protect our IT or OT systems, products and data integrity, including from cyber-attacks, intrusions or other breaches, could result in outages or unauthorized access to patient data and personally identifiable information, theft of intellectual property or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations, or, in the worst case, could result in harm to patients. In addition, such attackers may make demands for ransom, which could result in financial loss, or, if we determine not to pay such ransom, other harm, loss, or misappropriation of our data and assets. Such failure, or demonstration of vulnerability to such failure, may also result in additional regulatory scrutiny. We also grow our company through acquisitions and may face risks associated with defects and vulnerabilities in their acquired systems as we work to integrate the acquisitions into our IT system.

In the U.S., federal and state privacy and security laws require certain parts of our operations to protect the confidentiality of personal information, including patient medical records and other health information, and to comply with other requirements with respect to personal data. In Europe, the Data Protection Directive requires us to manage individually identifiable information in the EU, and the General Data Protection Regulation (GDPR) may impose fines of up to four percent of our global revenue. Internationally, some countries have also passed laws that require individually identifiable data on their citizens to be maintained on local servers and that may restrict transfer or processing of that data. Our product systems also require adherence to evolving regulatory standards and customer patterns and requirements worldwide. We strive to meet the expectations of applicable regulations, however, there is no guarantee that we will avoid enforcement actions by governmental bodies or civil actions based on this growing body of regulations. Enforcement actions could be costly and interrupt regular operations of our business, including related to market approvals of products and technologies. Any of these events, in turn, may cause us to lose existing customers, have difficulty preventing, detecting and controlling fraud, have disputes with customers, physicians and other health care professionals, be subject to legal claims and liability, have regulatory sanctions or penalties imposed, have increases in operating expenses, incur expenses or lose revenues as a result of a data privacy breach or theft of intellectual property, or suffer other adverse consequences, any of which could have a material adverse effect on our business, financial condition or results of operations.

Our business and operations are subject to risks related to climate change.
The effects of global climate change present risks to our business. Natural disasters, extreme weather and other conditions caused by or related to climate change could adversely impact our supply chain, including manufacturing and distribution networks, the availability and cost of raw materials and components, energy supply, transportation, or other inputs necessary for the operation of our business. Climate change and natural disasters could also result in physical damage to our facilities as well as those of our suppliers, customers, and other business partners, which could cause disruption in our business and operations or increase costs to operate our business. Additionally, increased environmental regulation, including to address climate change, may result in increases in our costs to operate our business or restrict certain aspects of our activities. The extent and severity of climate change impacts are unknown, and therefore, the scope of potential impact on our business may be difficult to predict and it may be difficult to adequately prepare.

Our business could be negatively impacted by corporate social responsibility and sustainability matters.
In recent years, there has been an increased focus from certain investors, customers, employees, regulators and other stakeholders globally concerning corporate social responsibility and sustainability matters. From time to time, we announce certain initiatives, including goals, regarding our focus areas, which include environmental matters, including carbon emissions
31

and renewable energy goals, responsible sourcing, social investments and diversity, equity and inclusion. We may fail, or be perceived to fail, in our achievement of such initiatives or goals, or we could fail in accurately reporting our progress on such initiatives and goals. Such failures could be due to changes in our business. Moreover, the standards by which corporate social responsibility and sustainability efforts and related matters are measured are developing and evolving, and certain areas are subject to assumptions that could change over time. In addition, we could be criticized for the scope of such initiatives or goals or perceived as not acting responsibly in connection with these matters. Any such matters, or related corporate social responsibility and sustainability matters, could have a material adverse impact on our future results of operations, financial condition and cash flows.
32

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 1C. CYBERSECURITY
We rely on information technology (IT) and operational technology (OT) systems, including technology from third party vendors, to manufacture and ship our products, as well as to process, transmit and store electronic information in our day-to-day operations. We have established a security program and processes to assess, identify and manage cybersecurity risks related to our IT and OT systems, as well as our products. Our global cybersecurity organization is led by our chief information security officer (CISO), who reports directly to our chief information officer (CIO) and under the organization of our chief information and digital officer (CIDO). Our current CISO has extensive information technology experience, including in security architecture, software development and engineering, as well as leading security operations and incident response, offensive and defensive cyber projects in increasing roles of responsibility. He also previously held Certified Information Systems Security Professional (CISSP) and GIAC Certified Forensics Analyst certifications. Our current CIDO has extensive experience overseeing information technology and security programs, including roles of increasing leadership within our Information and Digital organizations over the last ten years, and prior to that in increasing roles of responsibility managing information systems, including over 18 years at General Electric. Our current CIDO holds CISSP and other IT certifications.

Our enterprise cybersecurity program is designed to monitor and continually enhance our enterprise security posture, with the goal of preventing cybersecurity incidents to the extent feasible, including assessments to better understand our readiness for cybersecurity threats and the resilience of our critical business functions, with the goal of avoiding or reducing the impact if such an event were to occur. We have implemented cybersecurity policies mapped to industry and government standards and frameworks, such as U.S. National Institute of Standards and Technology (NIST) and International Standard of Organization (ISO). Our cybersecurity strategy and maturity is aligned to the NIST-Cybersecurity Framework (NIST CSF). This framework provides us a structured approach to managing our cybersecurity risk through its five core functions: Identification of digital assets, their risks, and business context; Protection, by implementing safeguards such as firewalls, network segmentation, and email security; Detection: through monitoring for anomalies and potential threats on the network, endpoints and data; Response, by having up to date incident response plans and skilled teams in place, including utilizing a crisis committee to respond in the event of a cybersecurity incident; and Recovery, achieved through ensuring data and system backups as well as testing our disaster recovery procedures. We also regularly review our cybersecurity policies and require annual cybersecurity training for our employees. Our product cybersecurity focus begins with our design protocols and is supported by quality testing, provider education, and packaging and distribution standards. We use penetration testing to simulate cyberattacks and better understand our exploitable weaknesses, and we monitor threat intelligence feeds, including avenues for product users to report vulnerabilities directly to us, and use scanning tools to detect and assess vulnerabilities that could affect our products. In addition, we conduct product, enterprise and vendor/third party risk assessments, vulnerability assessments and analyses to gain insights into potential vulnerabilities and their impact on critical functions, and leverage their outcomes to prioritize our security investments and balance our resource allocation.

We use third party security providers for specialized areas such as incident response, penetration testing, and on-demand cybersecurity services, including staff augmentation and consulting. We also leverage a managed security service provider to augment our cybersecurity organization and to provide additional monitoring and response capabilities.

We engage and rely upon third parties to provide services and/or goods, represent and or otherwise act on our behalf. Prior to engaging or conducting any business with or on our behalf, such parties undergo a due diligence review, and a third party security risk assessment is conducted to validate they are legally permitted and qualified to maintain appropriate safeguards to protect our information assets in connection with the services they intend to provide.

Assessing, identifying, and managing cybersecurity related risks are integrated into our enterprise risk management (ERM) program. Cybersecurity related risks are included in the risk universe that the ERM function evaluates to assess top risks to the Company on an annual basis. Risks are discussed with appropriate members of management, who manage risk coverage, monitoring and reporting in the relevant risk function, including our cybersecurity program, and incorporate those activities as part of developing our strategic plan. The ERM program’s annual risk assessment is presented annually to our Board of Directors and the Risk Committee of the Board.

Our Board of Directors oversees an enterprise-wide approach to risk management, including cybersecurity risks. While the Board has the ultimate responsibility for risk oversight, each committee of the Board also oversees risk to the extent it relates to the committee’s responsibilities and provides reports to the Board in its respective area of responsibility. The Risk Committee
33

of our Board also focuses on an enterprise-wide approach to risk management, and has primary oversight responsibility for areas of quality and nonfinancial compliance issues, including cybersecurity risks. The Risk Committee receives periodic updates from the CISO and CIDO on our cyber risks and threats, assessments of our cybersecurity program and the evolving threat landscape. Our Board of Directors also receives annual updates on such cybersecurity matters, or more frequently as appropriate under the procedures described below. Our Board and Risk Committee also receive cybersecurity risk assessments as part of the annual ERM program presentation described above.

We have established controls and procedures to escalate enterprise level issues, including cybersecurity matters, to the appropriate management levels within our organization and our Board of Directors, or members or committees thereof, as appropriate. Under our framework, cybersecurity issues, including those involving vulnerabilities introduced by our use of third-party software, are analyzed by subject matter experts, including a crisis committee as needed in accordance with our incident response plans, for potential financial, operational, and reputational risks, based on, among other factors, the nature of the matter and breadth of impact. Matters determined to present potential material impacts to our financial results, operations, and/or reputation are immediately reported by management to the Board of Directors, or individual members or committees thereof, as appropriate, in accordance with our established escalation framework. In addition, we have established procedures to help ensure that members of management responsible for overseeing the effectiveness of disclosure controls are informed in a timely manner of known cybersecurity risks and incidents that may materially impact our operations and that timely public disclosure is made, as appropriate.

Based on the information available as of the date of this Annual Report on Form 10-K, we are not aware of any risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. Despite our security measures, however, there can be no assurance that we, or the third parties with which we interact, will not experience a cybersecurity incident in the future that may materially affect us. For additional information, see Item 1A. “Risk Factors” for a discussion of cybersecurity risks that we face.

ITEM 2. PROPERTIES
Our world headquarters is located in the U.S, in Marlborough, Massachusetts, with principal regional headquarters located in Singapore and Voisins-le-Bretonneux, France. As of December 31, 2023, we maintained 15 principal manufacturing facilities, including eight in the U.S. and Puerto Rico, three in Ireland, two in Costa Rica, one in Malaysia, one in Brazil, as well as a Global Headquarters in the U.S. and various distribution and technology centers around the world. Many of these facilities produce and manufacture products for more than one of our divisions, and also perform research activities. Our products are distributed worldwide from primary customer fulfillment centers in Massachusetts, the Netherlands, Malaysia and Japan. The following is a summary of our facilities as of December 31, 2023 (in approximate square feet):
Owned(1)
Leased(2)
Total
U.S.4,264,041 1,904,898 6,168,939 
International2,928,410 2,088,089 5,016,499 
 7,192,451 3,992,987 11,185,438 
(1) Includes our principal manufacturing facilities in Minnesota, Ireland, Puerto Rico and Coyol, Costa Rica, our manufacturing facility in Malaysia, our primary customer fulfillment centers in Massachusetts, the Netherlands, Malaysia and Japan, as well as our global headquarters located in Marlborough, Massachusetts.
(2) Includes our principal manufacturing facilities in California, Indiana, Brazil and Heredia, Costa Rica, as well as our regional headquarters located in Singapore and Voisins-le-Bretonneux, France.

ITEM 3. LEGAL PROCEEDINGS
See Note I – Commitments and Contingencies to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of Part II of this Annual Report on Form 10-K, which is incorporated herein by reference.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

34

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

The principal market on which our common stock is traded is the New York Stock Exchange (NYSE) under the symbol “BSX.”
Holders of Record
As of January 31, 2024, there were 5,432 holders of record of our common stock.
Dividends
We did not pay a cash dividend in 2023, 2022 or 2021 on our common stock and currently we do not intend to pay cash dividends on our common stock. We may consider declaring and paying a cash dividend in the future; however, there can be no assurance that we will do so.
Securities Authorized for Issuance under Equity Compensation Plans
Please see Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters under Part III of this Annual Report on Form 10-K for information on where to find information required by Item 201(d) of Regulation S-K.
Purchases of Equity Securities by the Issuer and Affiliated Purchases
On December 14, 2020, our Board of Directors approved, and we announced, a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock (2020 Share Repurchase Program). We made no share repurchases in 2023 or 2022 and, as of December 31, 2023, had the full $1.000 billion remaining available under the 2020 Share Repurchase Program. Refer to Note J – Stockholders' Equity to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional information.
There were no purchases of equity securities by the issuer or affiliated purchases in the fourth quarter of 2023, required to be reported here.

35

Stock Performance Graph
The graph below compares the five-year total return to stockholders on our common stock with the return of the Standard & Poor’s (S&P) 500 Stock Index and the S&P Health Care Equipment Index. The graph assumes $100 was invested in our common stock and in each of the named indices on December 31, 2018 and that any dividends were reinvested.
5 Yr Cumulative Total Return Graph.jpg
Note: The stock price performance shown on the graph above is not indicative of future price performance. This graph shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing.
36

ITEM 6. RESERVED
37

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis provides information management believes to be relevant to understanding the financial condition and results of operations of Boston Scientific Corporation and its subsidiaries for the years ended December 31, 2023 and 2022. For a full understanding of our financial condition and results of operations, this discussion should be read in conjunction with our consolidated financial statements and accompanying notes included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K.
For additional information on our financial condition and results of operations for the year ended December 31, 2021, refer to Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our previously filed Annual Report on Form 10-K.
Executive Summary
Financial Highlights and Trends

In 2023, our net sales were $14.240 billion, compared to $12.682 billion in 2022. This increase of $1.558 billion, or 12.3 percent, included operational1 net sales growth of 13.1 percent and the negative impact of 80 basis points from foreign currency fluctuations. Operational net sales growth included organic2 net sales growth of 12.3 percent in 2023 and the positive impact of 80 basis points driven by our majority stake investment in Acotec Scientific Holdings Limited (Acotec) and the acquisitions of Apollo Endosurgery, Inc. (Apollo) and Relievant Medsystems, Inc. (Relievant) during the first, second and fourth quarters of 2023, respectively, as well as the divestiture of our pathology business during the second quarter of 2023 and our acquisition of Baylis Medical Company Inc. (Baylis Medical) during the first quarter of 2022, for which there is less than a full period of comparable net sales. The increase in our net sales was primarily driven by recent acquisitions as well as the strength and diversity of our product portfolio coupled with growth in the underlying markets in which we compete and strong commercial execution. Refer to the Business and Market Overview section for further discussion of our net sales by business.

Our reported net income attributable to Boston Scientific common stockholders in 2023 was $1.570 billion, or $1.07 per diluted share. Our reported results for 2023 included certain charges and/or credits which are excluded by management for purposes of assessing operating performance, totaling $1.429 billion (after-tax), or $0.98 per diluted share. Excluding these items, adjusted net income attributable to Boston Scientific common stockholders3 for 2023 was $2.999 billion, or $2.05 per diluted share.

Our reported net income attributable to Boston Scientific common stockholders in 2022 was $642 million, or $0.45 per diluted share. Our reported results for 2022 included certain charges and/or credits which are excluded by management for purposes of assessing operating performance, totaling $1.816 billion (after-tax), or $1.26 per diluted share. Excluding these items, adjusted net income attributable to Boston Scientific common stockholders3 for 2022 was $2.459 billion, or $1.71 per diluted share.















1 Operational net sales growth excludes the impact of foreign currency fluctuations.
2 Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for
which there are less than a full period of comparable net sales.
3 Adjusted measures, including operational and organic net sales growth and adjusted net income attributable to Boston Scientific common stockholders, exclude certain items required by generally accepted accounting principles in the United States (GAAP), are not prepared in accordance with GAAP and should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP measure. Refer to Additional Information for a discussion of management’s use of these non-GAAP financial measures.
38

The following is a reconciliation of our results of operations prepared in accordance with GAAP to those adjusted results considered by management. Refer to Results of Operations and Additional Information for a discussion of each reconciling item:
Year Ended December 31, 2023
(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Preferred Stock Dividends
Net Income (Loss) Attributable to Boston Scientific Common Stockholders(4)
Impact per Share(5)
Reported$1,985 $393 $1,592 $(23)$1,570 $1.07 
Non-GAAP adjustments:
Amortization expense828 (115)713 — 709 0.48 
Goodwill and other intangible asset impairment charges58 (4)54 — 54 0.04 
Acquisition/divestiture-related net charges (credits)373 (21)352 — 352 0.24 
Restructuring and restructuring-related net charges (credits)185 (29)156 — 156 0.11 
Litigation-related net charges (credits)(111)23 (88)— (88)(0.06)
Investment portfolio net losses (gains) and impairments21 3 24 — 24 0.02 
European Union (EU) Medical device regulation (MDR) implementation costs69 (10)59 — 59 0.04 
Deferred tax expenses (benefits)— 155 155 — 155 0.11 
Discrete tax items— 8 8 — 8 0.01 
Adjusted$3,407 $382 $3,025 $(23)$2,999 $2.05 

 Year Ended December 31, 2022
(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Preferred Stock DividendsNet Income (Loss) Attributable to Boston Scientific Common Stockholders
Impact per Share(5)
Reported$1,141 $443 $698 $(55)$642 $0.45 
Non-GAAP adjustments:
Amortization expense803 (109)694 — 694 0.48 
Goodwill and other intangible asset impairment charges132 (29)102 — 102 0.07 
Acquisition/divestiture-related net charges (credits)285 53 338 — 338 0.24 
Restructuring and restructuring-related net charges (credits)110 (14)96 — 96 0.07 
Litigation-related net charges (credits)173 (40)133 — 133 0.09 
Investment portfolio net losses (gains) and impairments(30)2 (28)— (28)(0.02)
EU MDR implementation costs71 (10)62 — 62 0.04 
Debt extinguishment net charges194 (45)149 — 149 0.10 
Deferred tax expenses (benefits)— 140 140 — 140 0.10 
Discrete tax items— 129 129 — 129 0.09 
Adjusted$2,880 $366 $2,514 $(55)$2,459 $1.71 

4 Excludes $4 million of amortization expense attributable to noncontrolling interests in 2023.
5 For 2023 and 2022, the effect of assuming the conversion of our 5.50% Mandatory Convertible Preferred Stock, Series A (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of Net income (loss) per common share — diluted (EPS). Accordingly, GAAP Net income (loss) and Adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our consolidated statements of operations, for purposes of calculating GAAP Net income (loss) attributable to Boston Scientific common stockholders. On June 1, 2023, all outstanding shares of our MCPS automatically converted into shares of common stock.

39

Business and Market Overview

In the first quarter of 2022, we reorganized our operational structure and have aggregated our core businesses, each of which generate revenues from the sale of medical devices into two reportable segments: MedSurg and Cardiovascular. Within the Cardiovascular segment, the Cardiology division represents the combined former Rhythm Management and Interventional Cardiology divisions. We have revised prior periods to conform to the current year presentation. The following section describes our results of operations by reportable segment and business. For additional information on our businesses and product offerings, refer to Item 1. Business of this Annual Report on Form 10-K.

MedSurg

Endoscopy

Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with innovative, less invasive technologies. Net sales of Endoscopy products of $2.482 billion represented 17 percent of our consolidated net sales in 2023. Endoscopy net sales increased $261 million, or 11.7 percent, in 2023 compared to 2022. This increase included operational net sales growth of 12.3 percent and the negative impact of 60 basis points from foreign currency fluctuations. Operational net sales growth included organic net sales growth of 11.1 percent in 2023, and the positive impact of 120 basis points from our acquisition of Apollo and the divestiture of our pathology business in the second quarter of 2023.

Organic net sales growth was primarily driven by our biliary franchise led by our AXIOS™ Stent and Delivery System, and our hemostasis and single use imaging franchises.

Urology

Our Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction and incontinence. Net sales of Urology products of $1.964 billion represented 14 percent of our consolidated net sales in 2023. Urology net sales increased $191 million, or 10.8 percent, in 2023 compared to 2022. This increase included operational net sales growth of 11.1 percent and the negative impact of 40 basis points from foreign currency fluctuations.

Operational net sales growth was primarily driven by our stone management franchise, led by our LithoVue™ Single-Use Digital Flexible Ureteroscope System, and our prosthetic urology franchise.

Neuromodulation

Our Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Net sales of Neuromodulation products of $976 million represented seven percent of our consolidated net sales in 2023. Neuromodulation net sales increased $59 million, or 6.4 percent, in 2023 compared to 2022. This increase included operational net sales growth of 6.7 percent and the negative impact of 30 basis points from foreign currency fluctuations. Operational net sales growth included organic net sales growth of 5.3 percent in 2023, and the positive impact of 130 basis points from our acquisition of Relievant in the fourth quarter of 2023.

Organic net sales growth was primarily driven by growth within our deep brain stimulation (DBS) franchise led by our Vercise Genus™ DBS System.












40

Cardiovascular

Cardiology

Our Cardiology business develops and manufactures devices and medical technologies for diagnosing and treating a variety of diseases and abnormalities of the heart. Net sales of Cardiology products of $6.709 billion represented 47 percent of our consolidated net sales in 2023. Cardiology net sales increased $776 million, or 13.1 percent in 2023 compared to 2022. This increase included operational net sales growth of 14.0 percent and the negative impact of 90 basis points from foreign currency fluctuations. Operational net sales growth included organic net sales growth of 13.6 percent in 2023 and the positive impact of 50 basis points from our acquisition of Baylis Medical in the first quarter of 2022.

Organic net sales growth was primarily driven by strong demand and continued market expansion of Left Atrial Appendage Closure (LAAC) procedures with our WATCHMAN FLX™ LAAC Device, as well as growth of our electrophysiology business, led by our Farapulse™ Ablation System, our POLARx™ technologies and our access solutions portfolio, and our percutaneous coronary intervention guidance franchises.

Peripheral Interventions

Our Peripheral Interventions business develops and manufactures products to diagnose and treat peripheral arterial and venous diseases, as well as products to diagnose, treat and ease various forms of cancer. Net sales of Peripheral Interventions products of $2.110 billion represented 15 percent of our consolidated net sales in 2023. Peripheral Interventions net sales increased $211 million, or 11.1 percent in 2023 compared to 2022. This increase included operational net sales growth of 12.6 percent and the negative impact of 140 basis points from foreign currency fluctuations. Operational net sales growth included organic net sales growth of 10.9 percent, and the positive impact of 160 basis points from our majority stake investment in Acotec which we acquired in the first quarter of 2023.

Organic net sales growth was primarily driven by our interventional oncology franchise led by our Therasphere™ Y-90 Radioactive Glass Microspheres and EMBOLD™ Fibered Coil, as well as our drug-eluting portfolio within our vascular franchise led by our Eluvia™ Drug-Eluting Stent System and Ranger™ Drug Coated Balloon.

Emerging Markets

As part of our strategic imperative to drive global expansion, we are seeking to grow net sales and market share by expanding our global presence, including in Emerging Markets. Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. We have revised prior year amounts to conform to the current year's presentation.

Our Emerging Markets' net sales represented 16 percent of our consolidated net sales in both 2023 and 2022. In 2023, our Emerging Markets net sales grew 17.3 percent on a reported basis including operational net sales growth of 21.9 percent and the negative impact of 450 basis points from foreign currency fluctuations, compared to 2022. Operational growth was primarily driven by growth in China, fueled by the breadth of our portfolio and focus on innovation and strong commercial execution.

Economic Environment
Our business has been impacted by global supply chain disruptions which improved in 2023 compared to 2022, however challenges still exist. In particular, we have experienced, and may continue to experience, increases in cost and limited availability of certain raw materials, components, and other inputs necessary to manufacture and distribute our products due to constraints and inflation within the global supply chain, as well as increases in wage costs and the cost and time to distribute our products. Uncertainty around inflationary pressures, interest rates, monetary policy and changes in tax laws could potentially cause new, or exacerbate existing, economic challenges that we may face, including the impact of foreign currency fluctuations on our results of operations, or result in an economic downtown or recession, which could negatively impact our business operations and results. Existing and future potential geopolitical dynamics, including matters related to the Russia/Ukraine war, Israel/Hamas war, as well as the tension between China/Taiwan, may create economic, supply chain, energy, and other challenges, including disruptions to business operations, which impact, and may in the future negatively impact our business. In particular, international conflicts could create instability, have and may further result in sanctions, tariffs, and other measures that restrict international trade and may negatively affect our business operations and results.
41

Results of Operations

Net Sales

The following table provides our net sales by reportable segment and business, and the relative change in growth on a reported basis:
Year Ended December 31,2023 versus 20222022 versus 2021
(in millions)202320222021
Endoscopy$2,482 $2,221 $2,141 11.7%3.7%
Urology1,964 1,773 1,583 10.8%12.0%
Neuromodulation976 917 909 6.4%0.9%
MedSurg5,422 4,911 4,633 10.4%6.0%
Cardiology6,709 5,932 5,422 13.1%9.4%
Peripheral Interventions2,110 1,899 1,820 11.1%4.4%
Cardiovascular8,819 7,831 7,242 12.6%8.1%
14,240 12,742 11,875 11.8%7.3%
Other(6)
— (60)13 (100.0)%(+100.0)%
Net Sales$14,240 $12,682 $11,888 12.3%6.7%

(6) In 2022, amounts reflect sales reserves established for Italian government payback provisions, not allocated to reportable segments, which are being disputed in the Italian court system. In 2021, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business.

Refer to Executive Summary for further discussion of our net sales and a comparison of our 2023 and 2022 net sales.

In 2022, we generated net sales of $12.682 billion compared to $11.888 billion in 2021. This increase of $794 million, or 6.7 percent, included operational growth of 11.1% and the negative impact of 440 basis points from foreign currency fluctuations. Operational net sales growth included organic net sales growth of 8.7 percent in 2022 and the positive impact of 240 basis points associated with our acquisitions of Preventice Solutions Inc. (Preventice), Farapulse, Inc. (Farapulse), the global surgical business of Lumenis LTD. (Lumenis) and Baylis Medical, for which there was less than a full prior period of comparable net sales. The increase in our 2022 net sales was primarily driven by acquisitions as well as the strength and diversity of our product portfolio coupled with growth in the underlying markets in which we compete and strong commercial execution.

42

Gross Profit
Our gross profit was $9.896 billion in 2023 and $8.727 billion in 2022. As a percentage of net sales, our gross profit increased to 69.5 percent in 2023 compared to 68.8 percent in 2022. The following is a reconciliation of our gross profit margins and a description of the drivers of the change from period to period:
Gross Profit Margin
Year Ended December 31, 202168.8%
Manufacturing and supply costs(0.6)%
Sales pricing, volume and mix(0.2)%
Net impact of foreign currency fluctuations1.3%
All other, including other period expense(0.5)%
Year Ended December 31, 202268.8%
Manufacturing and supply costs1.7%
Sales pricing, volume and mix1.9%
Net impact of foreign currency fluctuations(2.2)%
All other, including other period expense(0.7)%
Year Ended December 31, 202369.5%

The primary factors contributing to the increase in our gross profit margin for 2023 compared to 2022 were increased sales of higher margin products, as well as improvements in manufacturing, raw material and component, and freight costs. These impacts were partially offset by the unfavorable impact of foreign currency and period expenses.

Our gross profit margin for 2022 was flat compared to 2021. Global supply chain disruption drove increased manufacturing and supply costs, including inflation on costs of certain raw materials and components, direct labor and freight, as well as inefficiencies in our manufacturing plants due to constraints in material availability. The negative impact on our gross profit margin due to global supply chain disruption was offset by foreign currency fluctuations that drove gains on our foreign currency hedging contracts.

EU MDR Implementation Costs

The EU MDR replaced the existing European Medical Devices Directive (MDD) and Active Implantable Medical Device Directive (AIMDD) regulatory frameworks, and manufacturers of medical devices were required to comply with EU MDR beginning in May 2021 for new products and by May 2024 for medical devices which have a valid CE Certificate to the prior Directives (issued before May 2021). In 2023, updates to the legislative text of the EU MDR were adopted by the European Parliament and the Council of the European Union, including an extension of the transitional period to 2027 for certain high risk class devices and 2028 for lower risk class medical devices which have a valid CE Certificate to the prior Directives (issued before May 2021).

We began our EU MDR implementation efforts in late 2019 and have incurred cumulative expenses of $340 million through December 31, 2023, which are primarily being recorded within Cost of product sold. We expect to incur total expenses of approximately $450 million to $500 million over the transition period.

Operating Expenses
The following table provides a summary of our key operating expenses:
Year Ended December 31,
 202320222021
(in millions)$% of Net Sales$% of Net Sales$% of Net Sales
Selling, general and administrative expenses$5,190 36.4 %$4,520 35.6 %$4,359 36.7 %
Research and development expenses1,414 9.9 %1,323 10.4 %1,204 10.1 %


43

Selling, General and Administrative (SG&A) Expenses

In 2023, our SG&A expenses increased $670 million, or 15 percent compared to 2022 and were 80 basis points higher as a percentage of net sales. The increase in SG&A expenses was due primarily to higher selling costs driven by higher global net sales, as well as costs to support recent and upcoming product launches, including the Farapulse™ Pulsed Field Ablation System, and was also due to comparatively higher acquisition-related and restructuring-related expenses.

In 2022, our SG&A expenses increased $161 million, or 4 percent compared to 2021 and were 100 basis points lower as a percentage of net sales. The increase in SG&A expenses was primarily due to higher selling costs driven by higher global net sales.

Research and Development (R&D) Expenses

We remain committed to advancing medical technologies and investing in meaningful research and development projects across our businesses. In 2023, our R&D expenses increased $91 million, or 7 percent compared to 2022, and were 50 basis points lower as a percentage of net sales. R&D expenses increased as a result of investments across our businesses in order to maintain a pipeline of new products that we believe will contribute to profitable sales growth.

In 2022, our R&D expenses increased $119 million, or 10 percent compared to 2021, and were 30 basis points higher as a percentage of sales, as a result of targeted investments across our business.

Other Operating Expenses
The following provides a summary of certain of our other operating expenses, which are excluded by management for purposes of evaluating operating performance; refer to Additional Information for a further description.

Amortization Expense

We recorded Amortization expense of $828 million in 2023 and $803 million in 2022 related to intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents. In 2023, Amortization expense increased $25 million, or 3 percent, as compared to 2022. In 2022, Amortization expense increased $62 million, or 8 percent, as compared to 2021. The increase in both periods was driven by the addition of amortizable intangible assets associated with recent acquisitions.

Intangible Asset Impairment Charges

We recorded Intangible asset impairment charges of $58 million in 2023 and $132 million in 2022. The impairment charges recorded in 2023 were primarily associated with the cancellation of an in-process research and development (IPR&D) program due to the incremental time and cost to complete the program and bring the technology to market. The impairment charges recorded in 2022 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of Vertiflex, Inc., which is now part of our Neuromodulation business, resulting from lower revenue projections due to reimbursement challenges. Refer to Critical Accounting Estimates for a discussion of key assumptions used in our intangible asset impairment testing and future events that could have a negative impact on the recoverability of our intangible assets.

Contingent Consideration Net Expense (Benefit)

To recognize changes in the fair value of our contingent consideration liability, we recorded net charges of $58 million in 2023 and net charges of $35 million in 2022. The net charges recorded in 2023 and 2022 related primarily to an increase in expected revenue-based payments as a result of over-achievement of net sales performance, primarily related to our acquisition of Farapulse. In both periods, this increase was partially offset by a reduction in the contingent consideration liability for certain acquisitions for which we reduced the probability of achievement of associated regulatory and commercialization-based milestones upon which payment is conditioned. In addition, we made payments of $76 million and $371 million associated with prior acquisitions during 2023 and 2022, respectively, following the achievement of revenue and/or regulatory milestones. Refer to Note B – Acquisitions and Strategic Investments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional details related to our contingent consideration arrangements.


44

Restructuring and Restructuring-related Net Charges

On November 15, 2018, our Board of Directors approved, and we committed to, a global restructuring program (the 2019 Restructuring Plan), which was initiated in 2019 and substantially completed in 2022. The 2019 Restructuring Plan resulted in total pre-tax charges of $461 million and approximately $404 million in cash outlays.

On February 22, 2023, our Board of Directors approved, and we committed to, a new global restructuring program (the 2023 Restructuring Plan). For additional information, refer to "2023 Restructuring Plan" under the heading Liquidity and Capital Resources below.

Pursuant to the 2023 Restructuring Plan, we recorded restructuring charges in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 420, Exit or Disposal Cost Obligations of $69 million in 2023. The restructuring reserve balance as of December 31, 2023 was $41 million. In addition, we recorded restructuring-related charges of $115 million in 2023 primarily within Cost of products sold, SG&A Expenses and R&D Expenses. In 2022, we recorded restructuring charges of $24 million and restructuring-related charges of $86 million, and the restructuring reserve balance as of December 31, 2022 was $10 million, all associated with our 2019 Restructuring Plan.

Litigation-related Net Charges (Credits)

We recorded litigation-related net credits of $111 million in 2023 and litigation-related net charges of $173 million in 2022. In 2023, litigation-related net credits primarily related to the settlement of offensive patent litigation. In 2022, litigation-related net charges primarily related to litigation associated with our transvaginal surgical mesh products.

We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation, and therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with the financial covenant required by our credit agreements. Refer to Note I – Commitments and Contingencies to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional discussion of our material legal proceedings.

Interest Expense
The following table provides a summary of our Interest expense and average borrowing rate:
(in millions)Year Ended December 31,
202320222021
Interest expense$(265)$(470)$(341)
Weighted average borrowing rate2.8 %5.0 %3.6 %
Interest expense and our average borrowing rate decreased in 2023, compared to the prior year, primarily due to $194 million of charges associated with the early extinguishment of $3.275 billion of certain of our senior notes, including payment of tender premiums and the acceleration of unamortized debt issuance costs, as well as the issuance of euro-denominated bonds, which carry lower interest rates, during the first quarter of 2022. As of December 31, 2023 and 2022, the weighted average borrowing rate associated with our outstanding senior notes was 2.6 percent. Refer to Liquidity and Capital Resources, as well as Note D – Hedging Activities and Fair Value Measurements and Note E – Contractual Obligations and Commitments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for information regarding our debt obligations.
45

Other, net
The following are the components of Other, net:
 Year Ended December 31,
(in millions)202320222021
Interest income$22 $10 $4 
Net foreign currency gain (loss)(41)(31)(27)
Net gains (losses) on investments(1)
(59)(1)250 
Other income (expense), net(14)(16)(9)
 $(93)$(38)$218 
(1)    Net gains (losses) on investments include investment portfolio net gains and losses and impairments as well as the impact of
recording our share of the earnings or losses of equity method investees.

Tax Rate
The following table provides a summary of our reported tax rate:
Year Ended December 31,
 202320222021
Reported tax rate19.8 %38.9 %3.3 %
Impact of certain receipts/charges(1)
(0.2)%(19.1)%13.0 %
19.6 %19.8 %16.3 %
(1)    These receipts/charges are taxed at different rates than our effective tax rate.

The change in our reported tax rate for 2023 compared to 2022, relates primarily to the impact of certain receipts and charges that are taxed at different rates than our effective tax rate. These include litigation-related net credits, integration-related costs, debt extinguishment net charges, as well as certain discrete tax items primarily related to unrecognized tax benefits and provision-to-return adjustments.

In 2023, we received notification from the IRS that the examination of our 2017 and 2018 tax years was resolved. Due to the resolution of these tax years, we recorded a net tax benefit of $44 million to release the reserves related to these years. We paid tax of $16 million to the IRS reflecting the net balance of amounts due for the tax period including an increase to past transition tax installment payments for periods prior to 2023 and interest. The subsequent transition tax payments in 2024 and 2025 will be increased to reflect the final audit settlement.

On August 16, 2022, the Inflation Reduction Act of 2022 (Inflation Reduction Act) was enacted into law by the U.S. government and includes a new corporate alternative minimum tax (CAMT) of 15 percent on the adjusted financial statement income (AFSI) of corporations with average AFSI exceeding $1.0 billion over a three-year period. Additionally, the Inflation Reduction Act imposes a 1 percent excise tax on the fair market value of net corporate stock repurchases. These provisions became effective beginning on January 1, 2023. It is possible that in certain circumstances CAMT could result in an additional tax liability in a particular year due to temporary differences between book and taxable income. Based on our evaluation, we currently do not anticipate the Inflation Reduction Act will have a material impact on our financial position, results of operations, or cash flows.

See Note H – Income Taxes to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional details on our tax rate.
46

Liquidity and Capital Resources

Based on our current business plan, we believe our existing balance of Cash and cash equivalents, future cash generated from operations, access to capital markets and existing credit facilities will be sufficient to fund our operations, invest in our infrastructure, pay our legal-related liabilities, pay taxes due, service and repay our existing debt and fund possible acquisitions for the next 12 months and for the foreseeable future. Please refer to Contractual Obligations and Commitments below for additional details on our future payment obligations and commitments.

As of December 31, 2023, we had $865 million of unrestricted Cash and cash equivalents on hand, including approximately $123 million held by Acotec, a less than wholly owned entity in which we acquired a majority stake in the first quarter of 2023. The balance is comprised of $454 million invested in money market funds and time deposits and $411 million in interest bearing and non-interest-bearing bank accounts. We invest excess cash on hand in short-term financial instruments that earn at market interest rates while mitigating principal risk through instrument and counterparty diversification, as well as what we believe to be prudent instrument selection. We limit our direct exposure to securities in any one industry or issuer.

In 2021, we entered into our $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks initially scheduled to mature on May 10, 2026, with one-year extension options, subject to certain conditions. On March 1, 2023, we entered into an amendment of the 2021 Revolving Credit Facility, which provided for an extension of the scheduled maturity date to May 10, 2027 and replaced the London Interbank Offered Rate (LIBOR) with the Secured Overnight Financing Rate (SOFR) as the Eurocurrency Rate for Dollars, including applicable credit spread adjustments and relevant SOFR benchmark provisions, as well as modification to the calculation of consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), described under Financial Covenant below. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. There were no amounts outstanding under the 2021 Revolving Credit Facility or our commercial paper program as of December 31, 2023, resulting in an additional $2.750 billion of available liquidity.

For additional details related to our debt obligations, including our financial covenant requirement, refer to Note E – Contractual Obligations and Commitments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K.

On January 8, 2024, we announced our entry into a definitive agreement to acquire Axonics, Inc. (Axonics), a publicly traded medical technology company primarily focused on the development and commercialization of devices to treat urinary and bowel dysfunction. The purchase price is $71.00 in cash per share, or approximately $3.670 billion. The transaction is expected to close in the first half of 2024, subject to customary closing conditions. We plan to fund the acquisition through a mix of cash on hand and new debt.
The following provides a summary and description of our net cash inflows (outflows):
Year Ended December 31,
(in millions)202320222021
Cash provided by (used for) operating activities$2,503 $1,526 $1,870 
Cash provided by (used for) investing activities(2,574)(2,011)(1,597)
Cash provided by (used for) financing activities5 (548)(95)
Operating Activities
In 2023, cash provided by (used for) operating activities increased $977 million as compared to 2022, primarily due to comparatively higher net sales and operating income, lower non-recurring tax payments compared to prior year, as well as timing of employee related accruals and prepaid expenses. This increase was partially offset by the use of cash associated with an increase in inventory purchases as a result of higher sales and ensuring continuity of supply to meet procedural volume demand. In 2022, cash provided by (used for) operating activities decreased $344 million compared to 2021. This decrease was primarily due to changes in working capital, including higher levels of inventory and accounts receivable.
47

Investing Activities
In 2023, cash provided by (used for) investing activities included net cash payments of $1.811 billion for the acquisitions of Apollo, Relievant and a majority stake investment in Acotec, as well as purchases of property, plant and equipment and internal use software of $711 million, in order to meet capacity needs. For more information on our acquisitions, refer to Note B – Acquisitions and Strategic Investments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K. In 2022, cash provided by (used for) investing activities primarily included net cash payments of $1.542 billion for the acquisitions of Baylis Medical and Obsidio Inc, as well as Purchases of property, plant and equipment and internal use software of $588 million partially offset by Proceeds from settlements of hedge contracts of $56 million and Proceeds from royalty rights of $70 million.
Financing Activities
In 2023, cash provided by (used for) financing activities included proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans of $182 million partially offset by cash used to net share settle employee equity awards of $56 million, payments for royalty rights of $50 million and payments of contingent consideration previously established in purchase accounting of $39 million. In 2022, we completed a public offering (the Offering) of €3.000 billion in aggregate principal amount of euro-dominated senior notes. The Offering resulted in cash proceeds of $3.270 billion, net of investor discounts and issuance costs. We used the net proceeds from the Offering to fund the tender offer and early redemption of combined aggregate principal amount of $3.275 billion of certain of our outstanding senior notes, as well as to pay accrued interest, tender premiums, fees and expenses. For more information, refer to Note E – Contractual Obligations and Commitments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K. Additionally, cash provided by (used for) financing activities in 2022 included payments of contingent consideration previously established in purchase accounting of $335 million.
Our liquidity plans are subject to a number of risks and uncertainties, including those described in Item 1A. Risk Factors of this Annual Report on Form 10-K, some of which are outside our control. Macroeconomic conditions, adverse tax and litigation matter outcomes and other risks and uncertainties could limit our ability to successfully execute our business plans and adversely affect our liquidity plans.

Financial Covenant

As of December 31, 2023, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility.

The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times for the remaining term. The agreement provides for higher leverage ratios, at our election, for the period following a qualified acquisition, for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. It steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have not elected to increase the maximum permitted leverage ratio for qualified acquisitions to date, due to our funding of these acquisitions using cash on hand or commercial paper. We believe that we have the ability to comply with the financial covenant for the next 12 months.

The financial covenant requirement, as amended on March 1, 2023, provides for an exclusion from the calculation of consolidated EBITDA, as defined by the credit agreement, through maturity, of certain charges and expenses. The credit agreement amendment reset the starting date for purposes of calculating such permitted exclusions in each case from March 31, 2021 to December 31, 2022. Permitted exclusions include any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of December 31, 2023, we had $317 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreement, are excluded from the calculation of consolidated EBITDA, as defined by the agreement, provided that the sum of any excluded net cash litigation payments do not exceed $1.000 billion plus all accrued legal liabilities as of December 31, 2022. As of December 31, 2023, we had $1.484 billion of the litigation exclusion remaining.


48

Debt

The following table presents the current and long-term portions of our total debt:
 As of
(in millions)December 31, 2023December 31, 2022
Current debt obligations$531 $20 
Long-term debt8,571 $8,915 
Total debt$9,102 $8,935 

The following table presents the portions of our total debt that are comprised of fixed and variable rate debt instruments, which are presented on an amortized cost basis:
 As of
(in millions)December 31, 2023December 31, 2022
Fixed-rate debt instruments$9,070 $8,910 
Variable rate debt instruments32 25 
Total debt$9,102 $8,935 

As of December 31, 2023, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility described above. For additional details related to our debt obligations, including our financial covenant requirements, refer to Note E – Contractual Obligations and Commitments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K.

Equity

On June 1, 2023, in accordance with the terms of our MCPS, all outstanding shares of MCPS automatically converted into shares of common stock. No action by the holders of the MCPS was required in connection with the mandatory conversion. The conversion rate for each share of MCPS was 2.3834 shares of common stock. Cash was paid in lieu of fractional shares in accordance with the terms of the MCPS. An aggregate of approximately 24 million shares of common stock, including shares of common stock issued to holders of MCPS that elected to convert prior to the Mandatory Conversion Date, were issued upon conversion of the MCPS. Following the mandatory conversion of the MCPS, there were no outstanding shares of MCPS, resulting in the retirement of the annualized approximately $55 million cash dividend payment on the MCPS.

In 2023, we received $182 million in proceeds from stock issuances related to our stock option and employee stock purchase plans, compared to $136 million in 2022. Proceeds from the exercise of employee stock options and employee stock purchases vary from period to period based upon, among other factors, fluctuations in the trading price of our common stock and in the exercise and stock purchase patterns of our employees. Stock-based compensation expense related to our stock ownership plans was $233 million in 2023 and $220 million in 2022. Stock-based compensation expense varies from period to period based upon, among other factors, the timing, number and fair value of awards granted during the period, forfeiture levels related to unvested awards and employee contributions to our employee stock purchase plan, as well as the retirement eligibility of stock award recipients.

On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. We did not repurchase any shares of our common stock in 2023 or 2022, and had the full amount available under the authorization as of December 31, 2023. There were approximately 263 million shares in treasury as of December 31, 2023 and 2022.

49

Contractual Obligations and Commitments
(in millions)20242025202620272028ThereafterTotal
Debt obligations(1)
$504 $1,605 $255 $995 $1,173 $4,604 $9,136 
Interest payments(2)
232 219 201 195 181 1,411 2,438 
Lease obligations89 78 65 49 41 217 539 
Purchase obligations(2)
951 283 155 45 31 150 1,615 
Legal reserves(3)
206 — — — — — 206 
One-time transition tax117 147 — — — — 264 
$2,100 $2,332 $676 $1,284 $1,426 $6,382 $14,198 

(1) Debt obligations are comprised of our senior notes outstanding as of December 31, 2023. This does not include unamortized debt issuance
discounts, deferred financing costs and gains on fair value hedges or finance lease obligations. Refer to Note E – Contractual Obligations and Commitments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional information.
(2) In accordance with U.S. GAAP, these obligations relate primarily to expenses associated with future periods and, with the exception of accrued interest, are not reflected in our consolidated balance sheet as of December 31, 2023. Interest payments included above are calculated based on rates and required fees applicable to our outstanding debt obligations as of December 31, 2023 described in Note E – Contractual Obligations and Commitments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K.
(3) Timing of payment for our long-term liability for legal matters that are probable and estimable as of December 31, 2023 is uncertain and as such it is excluded from the table above. Refer to Note I – Commitments and Contingencies to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for more information.

The amounts in the table above with respect to purchase obligations relate primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business. The table above does not include:

•Any future obligations to make payments of contingent consideration pursuant to certain of our acquisition agreements, due to the exact amount and timing of payments being uncertain. Refer to Note B – Acquisitions and Strategic Investments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for more information,

•Unrecognized tax benefits, accrued interest and penalties and other related items because the timing of their future cash settlement is uncertain. Refer to Note H – Income Taxes to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for more information,

•Acquired IPR&D projects that require future funding to complete. We estimate that the total remaining cost to complete acquired IPR&D projects is between $75 million and $85 million. Net cash inflows from the projects currently in development are expected to continue through 2043, following the respective launches of these technologies in the U.S. and Europe. Certain of our acquisitions also involve the potential payment of contingent consideration, but the timing and amounts are uncertain. See Note B – Acquisitions and Strategic Investments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for more information,

•Two leases we have entered into as of December 31, 2023 for additional office, warehouse and lab space which have not yet commenced. These facilities are currently under construction. We do not control the building during construction and are thus not deemed to be the owner during construction. Total estimated undiscounted future lease payments are approximately $500 million, which includes a buyout option exercisable once construction is complete which we are reasonably certain to exercise with respect to one of the leases. These leases will commence at the end of 2024 and second half of 2025 with noncancellable lease terms ranging from 20 to 25 years, and

•The definitive agreement, entered into on January 8, 2024, to acquire 100 percent of the fully diluted equity of Axonics, Inc. for approximately $3.670 billion, which is expected to close during the first half of 2024, subject to customary closing conditions. We plan to fund the acquisition through a mix of cash on hand and new debt.




50

2023 Restructuring Plan

On February 22, 2023, our Board of Directors approved, and we committed to, a new global restructuring program (the 2023 Restructuring Plan).

The 2023 Restructuring Plan will advance our Global Supply Chain Optimization strategy, which is intended to simplify our manufacturing and distribution network by transferring certain production lines among facilities and drive operational efficiencies and resiliency. Key activities under the 2023 Restructuring Plan will also include optimizing certain functional capabilities to achieve cost synergies and better support business growth. These activities were initiated in the first quarter of 2023 and are expected to be substantially complete by the end of 2025.

While we expect limited role reductions as a result of these restructuring activities, we anticipate that our overall employee base will remain relatively unchanged upon completion of the 2023 Restructuring Plan as new jobs are created in areas of growth and resources are deployed to support an expanding portfolio and growing global market needs.

The implementation of the 2023 Restructuring Plan is estimated to result in total pre-tax charges of approximately $450 million to $550 million, of which approximately $350 million to $450 million is expected to result in cash outlays, and reduce gross annual pre-tax expenses by approximately $225 million to $275 million as program benefits are realized. We expect a substantial portion of the savings to be reinvested in strategic growth initiatives. The following table provides a summary of our estimates of total pre-tax charges associated with the 2023 Restructuring Plan by major type of cost:

Type of Cost (in millions)
Total Estimated Amount Expected to be Incurred
Restructuring charges:
Termination benefits(1)
$60-$80
Other(2)
20-40
Restructuring-related expenses:
Transfer costs(3)
300-330
Other(4)
70-100
 $450-$550

(1) Plans detailing specific employee impacts will be developed for each affected region and business, working with employee representative bodies where required under local laws.
(2) Consists primarily of consulting fees and costs associated with contractual cancellations.
(3) Represents costs to transfer product and manufacturing lines between geographically dispersed facilities.
(4) Comprised of other costs directly related to the restructuring program, including program management, accelerated depreciation and fixed asset write-offs.
Legal Matters

For a discussion of our material legal proceedings, see Note I – Commitments and Contingencies to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K.

Critical Accounting Policies and Estimates
Our financial results are affected by the selection and application of accounting policies and methods. We have adopted accounting policies to prepare our consolidated financial statements in conformity with U.S. GAAP.
To prepare our consolidated financial statements in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, including our contingent liabilities, as of the date of our financial statements and the reported amounts of our revenues and expenses during the reporting periods. Our actual results may differ from these estimates. We consider estimates to be critical (i) if we are required to make assumptions about material matters that are uncertain at the time of estimation or (ii) if materially different estimates could have been made or it is reasonably likely that the accounting estimate will change from period to period. The following are areas considered to be critical and require management’s judgment: Revenue Recognition, Inventory Provisions, Valuation of Intangible Assets and Contingent Consideration Liabilities, Goodwill Valuation, Legal and Product Liability Accruals and Income Taxes.
51

See Note A – Significant Accounting Policies to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional information related to our accounting policies and our consideration of these critical accounting areas.
Revenue Recognition

Deferred Revenue

We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.

Our contract liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiology business, for which revenue is recognized over the average service period based on device and patient longevity. Our contract liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor system, also within our Cardiology business, for which revenue is recognized over the average service period based on device longevity and usage. The use of alternative assumptions could impact the period over which revenue is recognized.

Variable Consideration

We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.

We also offer sales rebates and discounts to certain customers and record these as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered.

Post-Implant Services

We provide non-contractual services to customers to ensure the safe and effective use of certain implanted devices. We forward accrue the costs to provide these services at the time the devices are sold by estimating the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost. Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.
Inventory Provisions
We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory.
52

Valuation of Intangible Assets and Contingent Consideration Liabilities
We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&D, on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. Further, for those arrangements that involve potential future contingent consideration, we record on the date of acquisition a liability equal to the fair value of the estimated additional consideration we may be obligated to pay in the future. We re-measure this liability each reporting period and record changes in the fair value through a separate line item within our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows, discount rates, useful life or probability of achieving clinical, regulatory or revenue-based milestones could result in different purchase price allocations and recognized amortization expense and contingent consideration expense or benefit in current and future periods.
We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or adjustment to the remaining useful life. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. If the carrying value of the intangible asset is determined not recoverable, we will write the carrying value down to fair value in the period the impairment is identified. We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset using a risk-adjusted discount rate. The use of alternative assumptions, including estimated cash flows, discount rates and alternative estimated remaining useful lives could result in different calculations of impairment.
In addition, we test our indefinite-lived intangible assets at least annually for impairment and reassess their classification as indefinite-lived assets, or more frequently if indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value. If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to fair value. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows and discount rates could result in different fair value estimates.
Goodwill Valuation

We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances, utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350, Intangibles - Goodwill and Other, in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.

We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2023 annual impairment assessment, we identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components into a single Rhythm Management reporting unit.

In performing annual impairment assessments, when a quantitative test is performed, we typically use the income approach, specifically the Discounted Cash Flow method, to derive the fair value of each of our reporting units in preparing our goodwill impairment assessments. We historically selected this method as being the most meaningful in preparing our goodwill assessments because we believe the income approach most appropriately measures the fair value of our income producing assets. We have considered using the market approach and cost approach but concluded they are not appropriate in valuing our reporting units given the lack of relevant market comparisons available for application of the market approach and the inability to replicate the value of the specific technology-based assets within our reporting units for application of the cost approach.

In applying the income approach, we make assumptions about the amount and timing of future expected cash flows, terminal value growth rates and appropriate discount rates. The amount and timing of future cash flows within our Discounted Cash Flow analysis is based on our most recent operational budgets, long range strategic plans and other estimates. The terminal
53

value growth rate reflects our best estimates for stable, perpetual growth of our reporting units. We use estimates of market-participant risk-adjusted weighted average cost of capital as a basis for determining the discount rates to apply to our reporting units’ future expected cash flows.

Although we use consistent methodologies in developing the assumptions and estimates underlying the fair value calculations used in our impairment tests, these estimates are uncertain by nature and can vary from actual results. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows and discount rates could result in different fair value estimates.

Future events that could have a negative impact on the levels of excess fair value over carrying value of our reporting units include, but are not limited to, the following:

•decreases in estimated market sizes or market growth rates due to greater-than-expected declines in procedural volumes, inclusive of those resulting from macroeconomic conditions, including inflationary pricing pressures and reductions in reimbursement levels,

•declines in our market share and penetration assumptions due to increased competition, an inability to develop or launch new and next-generation products and technology features in line with our commercialization strategies and market and/or regulatory conditions that may cause significant launch delays or product actions,

•decreases in our forecasted profitability due to an inability to implement successfully and achieve timely and sustainable cost improvement measures consistent with our expectations,

•negative developments in intellectual property litigation that may impact our ability to market certain products or increase our costs to sell certain products,

•the level of success of ongoing and future research and development efforts, including those related to acquisitions and increases in the research and development costs necessary to obtain regulatory approvals and launch new products,

•the level of success in managing the growth of acquired companies, achieving sustained profitability consistent with our expectations, establishing government and third-party payer reimbursement, supplying the market and increases in the costs and time necessary to integrate acquired businesses into our operations successfully,

•changes in our reporting units or in the structure of our business as a result of future reorganizations, acquisitions or divestitures of assets or businesses and

•increases in our market-participant risk-adjusted weighted average cost of capital and increases in our market-participant tax rate and/or changes in tax laws or macroeconomic conditions.

Negative changes in one or more of these factors, among others, could result in future impairment charges.

Legal and Product Liability Accruals

We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities litigation and product liability suits. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. Litigation and product liability matters are inherently uncertain, and the outcomes of individual matters are difficult to predict and quantify. As such, significant judgment is required in determining our legal and product liability accruals. Our estimates related to our legal and product liability accruals may change as additional information becomes available to us, including information related to the nature or existence of claims against us, trial court or appellate proceedings, and mediation, arbitration or settlement proceedings.

54

Income Taxes

We establish reserves when we believe that certain positions are likely to be challenged despite our belief that our tax return positions are fully supportable. The calculation of our tax liabilities involves significant judgment based on individual facts, circumstances and information available in addition to applying complex tax regulations in various jurisdictions across our global operations. Under U.S. GAAP, in order to recognize an uncertain tax benefit, the taxpayer must determine it is more likely than not the position will be sustained, and the measurement of the benefit is calculated as the largest amount that is more than 50 percent likely to be realized upon resolution of the benefit. Although we believe that we have adequately provided for liabilities resulting from tax assessments by taxing authorities, positions taken by these tax authorities could have a material impact on our effective tax rate, results of operations, financial position and/or cash flows.

As part of the Tax Cut and Jobs Act (TCJA), we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and report it as a part of continuing operations.

New Accounting Pronouncements
Refer to Note P – New Accounting Pronouncements to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional information on standards implemented during 2023 and standards to be implemented in future periods.
Additional Information

Corporate Responsibility

Our sustainable ESG practices underpin all aspects of our global business. Our approach is aligned with the United Nations Sustainable Development Goals and our material topics and practices are informed by a broad range of internal and external stakeholders – locally, nationally and globally. Our employees around the world work with suppliers and other organizations that share our commitment to these practices that help address issues related to health inequity, economic disparity, climate change and environmental protection. Our global ESG vision and strategy is led by our ESG Executive Steering Committee and our vice president of ESG, who provides regular updates to the Board of Directors. Our ESG team works closely with subject matter experts and key advisors from across the business to implement our ESG practices and determine how we measure and share progress. These efforts are supported by our cross-functional teams, our Environmental Health and Safety teams and policies, our Global Council for Inclusion, as well as our local, regional and national employee and community engagement programs.

We are also making measurable progress toward shaping a better future for our planet by proactively addressing energy consumption, carbon emissions and waste management. We have set a goal of carbon neutrality for scope 1 and scope 2 carbon emissions in our manufacturing and key distribution sites by 2030. Our Global Real Estate, Facilities, Environment, Health & Safety function is responsible for rigorously measuring, assessing and reporting progress toward these goals globally. We are focused on a “C3” strategy: Cutting energy use, Converting to renewable energy sources and Compensating with carbon offset projects where needed. Our Global Headquarters and U.S. distribution center in Massachusetts, and our manufacturing plants in Dorado, Puerto Rico, Coyol and Heredia, Costa Rica, Penang, Malaysia, Cork, Ireland and our European distribution center in the Netherlands all utilize solar energy from on-site installations. Our goal is to fully source or generate electricity from renewable sources by the end of 2024, and by the end of 2027, our goal is that 90 percent of all energy used across our manufacturing and key distribution sites will be from renewable sources, representing an important milestone toward our 2030 carbon neutrality goal.

As of December 31, 2023, we have obtained 13 ISO 50001:2018 and 16 14001:2015 certifications across our Global Headquarters, manufacturing and key distribution sites. These are globally recognized standards for Energy and Environmental Management Systems, established by the International Standards Organization, which provides a voluntary framework to identify key energy and environmental aspects associated with our business. Using these management systems and the specific attributes of our certified locations, we continue to improve our energy and environmental performance. We also have 16 Leadership in Energy and Environmental Design (LEED) certified buildings on campuses in the U.S., Latin America, Europe and Asia. LEED is an internationally recognized certification program that seeks to ensure the mindful development, construction and maintenance of buildings in a way that benefits occupants and the environment by reducing waste and conserving resources.

55

Stock Trading Policy

Our directors and executive officers are subject to our Stock Trading Policy, which is designed to facilitate compliance with insider trading laws and governs transactions in our common stock and related derivative securities. Our policy designates certain regular periods, dictated by release of financial results, in which trading is restricted for individuals in information-sensitive positions, including directors and executive officers. In addition, additional periods of trading restriction may be imposed as determined by the President and Chief Executive Officer, General Counsel, or Chief Financial Officer in light of material pending developments. Further, during permitted windows, certain individuals in information-sensitive positions are required to seek pre-clearance for trades from the General Counsel, who assesses whether there are any important pending developments which need to be made public before the individual may participate in the market.

Periodically, certain of our executive officers adopt written stock trading plans in accordance with Rule 10b5-1 under the Exchange Act and our own Stock Trading Policy. A Rule 10b5-1 trading plan is a written document that pre-establishes the amount, prices and dates (or formulas for determining the amounts, prices and dates) of future purchases or sales of our stock, including shares issued upon exercise of stock options or vesting of restricted stock units. These plans are entered into at a time when the person is not in possession of material non-public information about the Company. In addition to any plans described in Part II, Item 9B of this Annual Report on Form 10-K, we disclose details regarding individual Rule 10b5-1 trading plans on the Investor Relations section of our website.
Use of Non-GAAP Financial Measures

To supplement our consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) attributable to common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with U.S. GAAP and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

To calculate adjusted net income (loss), adjusted net income (loss) attributable to common stockholders and adjusted net income (loss) per share we exclude certain charges (credits) from GAAP net income and GAAP net income attributable to common stockholders, which include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), EU MDR implementation costs, debt extinguishment net charges, deferred tax expenses (benefits) and certain discrete tax items. Amounts are presented after-tax using our effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB ASC Topic 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate."

The GAAP financial measure most directly comparable to adjusted net income (loss), adjusted net income (loss) attributable to common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) attributable to common stockholders and GAAP net income (loss) per common share - assuming dilution, respectively.

To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. To calculate organic net sales growth rates, we also remove the impact of acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales reported on a GAAP basis.

Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the Executive Summary of this Annual Report on Form 10-K.

Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments’ measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.
56


We believe that presenting adjusted net income (loss), adjusted net income (loss) attributable to common stockholders adjusted net income (loss) per share, operational and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results “through the eyes” of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

The following is an explanation of each of the adjustments that management excluded as part of these non-GAAP financial measures as well as reasons for excluding each of these individual items. In each case, management has excluded the item for purposes of calculating the relevant non-GAAP financial measure to facilitate an evaluation of our current operating performance and a comparison to our past operating performance:

Adjusted Net Income (loss), Adjusted Net Income (loss) Attributable to Common Stockholders and Adjusted Net Income (loss) per Share

•Amortization expense - We record intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents at historical cost and amortize them over their estimated useful lives. Amortization expense is excluded from management's assessment of operating performance due to its non-cash nature and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance,

•Goodwill and other intangible asset impairment charges - These amounts represent write-downs of certain goodwill and/or other intangible asset balances. We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment and test our goodwill and other indefinite-lived intangible assets at least annually for impairment. If we determine the carrying value of the amortizable intangible asset is not recoverable, goodwill of a reporting unit is impaired or it is more likely than not that the indefinite-lived asset is impaired, we will write the carrying value down to fair value in the period identified. Impairment charges are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance,

•Acquisition/divestiture-related net charges (credits) - These adjustments may consist of (a) contingent consideration fair value adjustments; (b) gains on previously held investments; (c) due diligence, deal fees and other fees and costs related to our acquisition and divestiture transactions; (d) inventory step-up amortization and accelerated compensation expense; (e) integration and exit costs; and (f) separation costs and gains or losses primarily associated with the sale of a business or portion of a business. The contingent consideration fair value adjustments represent accounting adjustments to state contingent consideration liabilities at their estimated fair value. These adjustments can be highly variable depending on the assessed likelihood and amount of future contingent consideration. Gains on previously held investments, due diligence, deal fees and other fees and costs, inventory step-up amortization, accelerated compensation expense, and other expenses and gains or losses associated with divestitures or acquisitions can be highly variable and not representative of ongoing operations. Integration, separation and exit costs, include contract cancellations, severance and other compensation-related charges and costs, project management fees and costs, and other direct costs associated with the integration of our acquisitions or separation of our divested businesses. These integration, separation and exit activities take place over a defined timeframe and have distinct project timelines, are incremental to activities and costs that arise in the ordinary course of our business and are not considered part of our core, ongoing operations. These acquisition/divestiture-related net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance,

•Restructuring and restructuring-related net charges (credits) - These adjustments primarily represent severance and other compensation-related charges, fixed asset write-offs, contract cancellations, project management fees, facility shut down costs, costs to transfer manufacturing lines between geographically dispersed facilities and other direct costs associated with our restructuring plans. These restructuring plans each consist of distinct initiatives that are fundamentally different from our ongoing, core cost reduction initiatives in terms of, among other things, the frequency with which each action is performed and the required planning, resourcing, cost and timing. Examples of such initiatives include the movement of business activities, facility consolidations and closures and the transfer of product lines between manufacturing facilities, which, due to the highly regulated nature of our industry, requires a significant investment in time and cost to create duplicate manufacturing lines, run product validations and seek regulatory approvals. Restructuring initiatives take place over a defined timeframe and have a distinct project
57

timeline that requires, and begins subsequent to, approval by our Board of Directors. In contrast to our ongoing cost reduction initiatives, restructuring initiatives typically result in duplicative cost and exit costs over the defined timeframe and are not considered part of our core, ongoing operations. These restructuring plans are incremental to the core activities that arise in the ordinary course of our business. Restructuring and restructuring-related net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance,

•Litigation-related net charges (credits) - These adjustments include certain product liability and other litigation-related charges and credits. We record these charges and credits, which we consider to be unusual or infrequent and significant, within the litigation-related charges (credits) line in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within selling, general and administrative expenses. Certain litigation-related net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance,

•EU MDR implementation costs - These adjustments represent certain incremental costs specific to complying with new regulatory requirements in the EU. EU MDR replaced the existing MDD regulatory framework, and manufacturers of medical devices were required to comply with EU MDR beginning in May 2021 for new products and by May 2024 for medical devices which have a valid CE Certificate to the prior Directives (issued before May 2021). In 2023, updates to the legislative text of the EU MDR were adopted by the European Parliament and the Council of the European Union, including an extension of the transitional period to 2027 for certain high risk class devices and 2028 for lower risk class medical devices which have a valid CE Certificate to the prior Directives (issued before May 2021). We expect to incur significant expenditures in connection with the adoption of the EU MDR requirements and we consider the adoption of EU MDR to be a significant change to a regulatory framework, and therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters. As such, certain of these costs are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance,

•Debt extinguishment net charges - These amounts relate to the early extinguishment of certain outstanding principal amounts of our senior notes. Certain debt extinguishment net charges are excluded from management's assessment of operating performance used for making operating decisions and assessing performance,

•Investment portfolio net losses (gains) and impairments - These amounts represent write-downs or fair value remeasurement gains and losses related to our investment portfolio. Each reporting period, we evaluate our investments without a readily determinable fair value to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value and determine if the impairment is other-than-temporary, and recognize an impairment loss. In addition, for those investments accounted for under the measurement alternative method of accounting, we record gains and losses to remeasure the carrying value of the investments to their fair values based on observable market prices or implied market values. Investment impairment charges and fair value remeasurements can be highly variable dependent on external market factors and conditions relative to the underlying investee, which are generally outside of the control of management, as such these amounts are excluded from management's assessment of performance,

•Deferred tax expenses (benefits) - This adjustment relates to a significant non-cash tax benefit arising from an intra-entity asset transfer of intellectual property completed in the fourth quarter of 2019 which resulted in our recording a $4.102 billion net deferred tax asset. The deferred tax benefit associated with the establishment of the net deferred tax asset as well as any deferred tax expense resulting from the reversal of the deferred tax asset are excluded from management's assessment of operating performance used for making operating decisions and assessing performance, and

•Discrete tax items - These items represent adjustments of certain tax positions including those which (a) are related to the tax consequences of non-GAAP charges (credits) on tax benefit limitations in the current period, or (b) are related to the tax consequences of a non-GAAP adjustment item booked in a prior period. These discrete tax items are excluded from management's assessment of operating performance used for making operating decisions and assessing performance.


58

Operational Net Sales

•The impact of foreign currency fluctuations is highly variable and difficult to predict. Accordingly, management excludes the impact of foreign currency fluctuations for purposes of reviewing net sales and growth rates to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

Organic Net Sales

•Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.

59

Management’s Annual Report on Internal Control over Financial Reporting
As the management of Boston Scientific Corporation, we are responsible for establishing and maintaining adequate internal control over financial reporting. We designed our internal control process to provide reasonable assurance to management and the Board of Directors regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
We assessed the effectiveness of our internal control over financial reporting as of December 31, 2023. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control–Integrated Framework (2013 framework). Based on our assessment, we believe that, as of December 31, 2023, our internal control over financial reporting is effective at a reasonable assurance level based on these criteria.

In accordance with the SEC Staff 's interpretive guidance for newly acquired businesses, we are permitted to omit an assessment of an acquired business's internal control over financial reporting from our assessment of internal control for up to one year from the acquisition date. As such, we have excluded our majority stake investment in Acotec Scientific Holdings Limited and our acquisitions of Apollo Endosurgery, Inc. and Relievant Medsystems, Inc., each acquired during 2023, from our annual assessment of internal controls over financial reporting as of December 31, 2023. These businesses represented less than one percent of total assets as of December 31, 2023 and less than one percent of net sales for the year then ended.

Ernst & Young LLP, an independent registered public accounting firm, has issued an audit report on the effectiveness of our internal control over financial reporting. This report, in which they expressed an unqualified opinion, is included below.
 /s/ Michael F. Mahoney /s/ Daniel J. Brennan 
    
 Michael F. Mahoney  Daniel J. Brennan 
 Chief Executive Officer  Executive Vice President and Chief
Financial Officer		 

60


Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of
Boston Scientific Corporation

Opinion on Internal Control Over Financial Reporting

We have audited Boston Scientific Corporation’s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Boston Scientific Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on the COSO criteria.

As indicated in the accompanying Management’s Annual Report on Internal Control over Financial Reporting, management’s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of Acotec Scientific Holdings Limited, Apollo Endosurgery, Inc., and Relievant Medsystems, Inc., which are included in the 2023 consolidated financial statements of the Company and constituted less than 1% of total assets as of December 31, 2023 and approximately 1% of revenues for the year then ended. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of Acotec Scientific Holdings Limited, Apollo Endosurgery, Inc., and Relievant Medsystems, Inc.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2023 consolidated financial statements of the Company and our report dated February 20, 2024 expressed an unqualified opinion thereon.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
61


/s/ Ernst & Young LLP

Boston, Massachusetts
February 20, 2024
62


ITEM 7A.        QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We develop, manufacture and sell medical devices globally and our earnings and cash flows are exposed to market risk from changes in currency exchange rates and interest rates. We address these risks through a risk management program that includes the use of derivative financial instruments. We operate the program pursuant to documented corporate risk management policies. We do not enter derivative transactions for speculative purposes. Gains and losses on derivative financial instruments substantially offset losses and gains on underlying hedged exposures. Furthermore, we manage our exposure to counterparty risk on derivative instruments by entering into contracts with a diversified group of major financial institutions and by actively monitoring outstanding positions.

Our currency risk consists primarily of foreign currency denominated firm commitments, forecasted foreign currency denominated intercompany and third-party transactions and net investments in certain subsidiaries. We use both nonderivative (primarily European manufacturing operations) and derivative instruments to manage our earnings and cash flow exposure to changes in currency exchange rates. We had currency derivative instruments outstanding in the contract amount of $5.899 billion as of December 31, 2023 and $7.324 billion as of December 31, 2022. A ten percent appreciation in the U.S. dollar’s value relative to the hedged currencies would increase the derivative instruments’ fair value by $236 million as of December 31, 2023 compared to $208 million as of December 31, 2022. A ten percent depreciation in the U.S. dollar’s value relative to the hedged currencies would decrease the derivative instruments’ fair value by $288 million as of December 31, 2023 compared to $254 million as of December 31, 2022. Any increase or decrease in the fair value of our currency exchange rate sensitive derivative instruments would be substantially offset by a corresponding decrease or increase in the fair value of the hedged underlying asset, liability or forecasted transaction, resulting in minimal impact on our earnings.

Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We have historically used interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. We had no interest rate derivative instruments outstanding as of December 31, 2023 and December 31, 2022. As of December 31, 2023, $9.136 billion in aggregate principal amount of our outstanding debt obligations were at fixed interest rates, representing approximately 100 percent of our total debt, on an amortized cost basis. As of December 31, 2023, our outstanding debt obligations at fixed interest rates were comprised of senior notes.

See Note D – Hedging Activities and Fair Value Measurements to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for further information regarding our derivative financial instruments.
63


Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of
Boston Scientific Corporation

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Boston Scientific Corporation (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive income (loss), stockholders' equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes and financial statement schedule listed in the Index at Item 15(a) (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 20, 2024 expressed an unqualified opinion thereon.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
64


Description of the Matter
Business Combinations
As disclosed in Note B to the consolidated financial statements, during 2023, the Company completed the acquisition of a majority stake investment in Acotec for a purchase price of $381 million. The Company also completed the acquisitions of Apollo Endosurgery, Inc. for a purchase price of $636 million and Relievant Medsystems, Inc. for a purchase price of $1,067 million, inclusive of a contingent consideration liability with a fair value of $273 million related to future milestone and earn out payments based on future sales performance. The Company determines the fair value of these contingent consideration arrangements, both as part of the initial purchase price allocation, and on an ongoing basis each reporting period until the arrangements are settled. The valuation of contingent consideration represents a Level 3 estimate in the fair value hierarchy due to the significant unobservable inputs used in determining the fair value and the use of management judgment about the assumptions that market participants would use in valuing the liabilities.

Auditing the Company’s accounting for the business combinations was complex due to the significant estimation required by management to determine the fair value of identified intangible assets, which totaled $907 million and principally consisted of developed technology, and the significant estimation required by management to determine the fair value of the contingent consideration liability. A significant emphasis is placed on the appropriateness of the estimates used by management to determine the fair value of acquired intangible assets and the contingent consideration liability due to the sensitivity of the respective fair values to the underlying assumptions. The Company used an income approach to measure the technology-related intangible assets acquired. The significant assumptions used to estimate the fair value of the intangible assets included discount rates and certain assumptions that form the basis of the forecasted results, including revenue growth rates, estimates of technological obsolescence, operating profit margin and market participant synergies. The Company used the income approach to measure the contingent consideration liability assumed. The significant assumptions used to estimate the fair value of the contingent consideration liability included the probability and timing of payment, future sales forecasts, as well as the appropriate discount rate based on the estimated timing of payments. These significant assumptions are forward looking and could be affected by future economic and market conditions.
How We Addressed the Matter in Our Audit
We obtained an understanding, evaluated the design and tested the operating effectiveness of the controls over the Company’s accounting for business combination transactions. For example, we tested controls over the identification and valuation of intangible assets, including the valuation models and underlying assumptions used to develop such estimates. We read the purchase agreements, evaluated the significant assumptions and methods used in developing the fair value estimates, and tested the recognition of (1) the tangible assets acquired and liabilities assumed at fair value; (2) the identifiable intangible assets acquired at fair value; and (3) goodwill measured as a residual.

To test the estimated fair value of the intangible assets acquired, we performed audit procedures that included, among others, evaluating the Company's use of the income approach and testing the significant assumptions used in the model, as described above. To test the estimated fair value of the contingent consideration liability, we performed audit procedures that included, among others, evaluating the methodology used to value the liability, understanding the terms of the arrangements and conditions that must be met for the amounts to become payable, and testing the significant assumptions used in the model, as described above. We evaluated the completeness and accuracy of the underlying data used in the analyses. For example, we compared the significant assumptions to current industry, market and economic trends, to the assumptions used to value similar assets in other acquisitions, to the historical results of the acquired business and to other guideline companies within the same industry. We involved our valuation professionals to assist with our evaluation of the methodology used by the Company and significant assumptions included in the fair value estimates.


/s/ Ernst & Young LLP
We have served as the Company’s auditor since 1992.

Boston, Massachusetts
February 20, 2024
65

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
Year Ended December 31,
(in millions, except per share data)202320222021
Net sales$14,240 $12,682 $11,888 
Cost of products sold4,345 3,956 3,711 
Gross profit9,896 8,727 8,177 
Operating expenses:
Selling, general and administrative expenses5,190 4,520 4,359 
Research and development expenses1,414 1,323 1,204 
Royalty expense46 47 49 
Amortization expense828 803 741 
Intangible asset impairment charges58 132 370 
Contingent consideration net expense (benefit)58 35 (136)
Restructuring net charges (credits)69 24 40 
Litigation-related net charges (credits)(111)173 430 
Loss (gain) on disposal of businesses and assets— 22 (78)
 7,553 7,078 6,978 
Operating income (loss) 2,343 1,649 1,199 
Other income (expense):
Interest expense(265)(470)(341)
Other, net(93)(38)218 
Income (loss) before income taxes1,985 1,141 1,076 
Income tax expense (benefit)393 443 36 
Net income (loss)1,592 698 1,041 
Preferred stock dividends(23)(55)(55)
Net income (loss) attributable to noncontrolling interests(1)— — 
Net income (loss) attributable to Boston Scientific common stockholders$1,570 $642 $985 
Net income (loss) per common share — basic$1.08 $0.45 $0.69 
Net income (loss) per common share — diluted$1.07 $0.45 $0.69 
Weighted-average shares outstanding
Basic1,453.0 1,430.5 1,422.3 
Diluted1,463.5 1,439.7 1,433.8 










See notes to the consolidated financial statements. Amounts may not foot due to rounding.
66

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Year Ended December 31,
(in millions)202320222021
Net income (loss)$1,592 $698 $1,041 
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment(105)(94)(125)
Net change in derivative financial instruments(115)63 170 
Net change in defined benefit pensions and other items(9)37 11 
Other comprehensive income (loss)(230)6 56 
Comprehensive income (loss)$1,362 $704 $1,096 
Comprehensive income (loss) attributable to noncontrolling interests(11)— — 
Comprehensive income attributable to Boston Scientific common stockholders$1,373 $704 $1,096 



















































See notes to the consolidated financial statements. Amounts may not foot due to rounding.
67

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
 As of December 31,
(in millions, except share and per share data)20232022
ASSETS  
Current assets:  
Cash and cash equivalents$865 $928 
Trade accounts receivable, net2,228 1,970 
Inventories2,484 1,867 
Prepaid income taxes315 264 
Other current assets621 731 
Total current assets6,514 5,760 
Property, plant and equipment, net2,859 2,446 
Goodwill14,387 12,920 
Other intangible assets, net6,003 5,902 
Deferred tax assets3,841 3,942 
Other long-term assets1,531 1,500 
TOTAL ASSETS$35,136 $32,469 
LIABILITIES AND STOCKHOLDERS’ EQUITY 
Current liabilities: 
Current debt obligations$531 $20 
Accounts payable942 862 
Accrued expenses2,646 2,160 
Other current liabilities814 761 
Total current liabilities4,933 3,803 
Long-term debt8,571 8,915 
Deferred tax liabilities134 144 
Other long-term liabilities1,967 2,035 
Commitments and contingencies
Stockholders’ equity: 
Preferred stock, $0.01 par value - authorized 50,000,000 shares; 0 shares issued as of December 31, 2023 and 10,062,500 shares issued as of December 31, 2022
— 0 
Common stock, $0.01 par value - authorized 2,000,000,000 shares; 1,729,000,224 shares issued as of December 31, 2023 and 1,696,633,993 shares issued as of December 31, 2022
17 17 
Treasury stock, at cost - 263,289,848 shares as of December 31, 2023 and 2022
(2,251)(2,251)
Additional paid-in capital20,647 20,289 
Retained earnings (Accumulated deficit)819 (750)
Accumulated other comprehensive income (loss), net of tax:49 269 
Total stockholders’ equity19,282 17,573 
Noncontrolling interests248 — 
Total equity19,530 17,573 
TOTAL LIABILITIES AND EQUITY$35,136 $32,469 

See notes to the consolidated financial statements. Amounts may not foot due to rounding.
68

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

Year Ended December 31,
(in millions, except share data)202320222021
Preferred stock shares issued
Beginning10,062,500 10,062,500 10,062,500 
Conversion of mandatory convertible preferred stock to common stock(10,062,500)— — 
Ending— 10,062,500 10,062,500 
Common stock shares issued
Beginning1,696,633,993 1,688,810,052 1,679,911,918 
Impact of stock-based compensation plans8,383,329 7,823,941 8,898,134 
Conversion of mandatory convertible preferred stock to common stock23,982,902 — — 
Ending1,729,000,224 1,696,633,993 1,688,810,052 
Preferred stock
Beginning$0 $0 $0 
Conversion of mandatory convertible preferred stock to common stock(0)— — 
Ending— $0 0 
Common stock
Beginning$17 $17 $17 
Impact of stock-based compensation plans0 0 0 
Conversion of mandatory convertible preferred stock to common stock0 — — 
Ending$17 $17 $17 
Treasury Stock
Beginning$(2,251)$(2,251)$(2,251)
Repurchase of common stock— — — 
Ending$(2,251)$(2,251)$(2,251)
Additional paid-in capital
Beginning$20,289 $19,986 $19,732 
Conversion of mandatory convertible preferred stock to common stock(0)— — 
Impact of stock-based compensation plans359 303 254 
Ending$20,647 $20,289 $19,986 
Retained earnings (Accumulated deficit)
Beginning$(750)$(1,392)$(2,378)
Net income (loss)1,592 698 1,041 
Net (income) loss attributable to noncontrolling interests1 — — 
Preferred stock dividends(23)(55)(55)
Ending$819 $(750)$(1,392)
Accumulated other comprehensive income (loss), net of tax
Beginning$269 $263 $207 
Changes in other comprehensive income (loss), net of tax:
Foreign currency translation adjustment(95)(94)(125)
Derivative financial instruments(115)63 170 
Defined benefit pensions and other items(9)37 11 
Ending$49 $269 $263 
Total stockholders' equity$19,282 $17,573 $16,622 
Noncontrolling interests
Beginning$— $— $— 
Changes to noncontrolling ownership interest259 — — 
Net income (loss) attributable to noncontrolling interests(1)— — 
Changes in other comprehensive income (loss)(10)— — 
Ending$248 $— $— 
Total equity$19,530 $17,573 $16,622 

See notes to the consolidated financial statements. Amounts may not foot due to rounding.
69

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
Year Ended December 31,
(in millions)202320222021
Net income (loss) $1,592 $698 $1,041 
Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities
Loss (gain) on disposal of businesses and assets— 22 (78)
Depreciation and amortization1,196 1,136 1,093 
Deferred and prepaid income taxes(1)(63)(124)
Stock-based compensation expense233 220 194 
Goodwill and other intangible asset impairment charges58 132 370 
Net loss (gain) on investments and notes receivable59 1 (250)
Contingent consideration net expense (benefit)58 35 (136)
Inventory step-up amortization6 32 34 
Debt extinguishment net charges— 194 — 
Other, net73 125 78 
Increase (decrease) in operating assets and liabilities, excluding purchase accounting:
Trade accounts receivable(238)(220)(279)
Inventories(660)(321)(346)
Other assets10 (209)(134)
Accounts payable, accrued expenses and other liabilities118 (255)408 
Cash provided by (used for) operating activities2,503 1,526 1,870 
Purchases of property, plant and equipment and internal use software(711)(588)(554)
Proceeds from sale of property, plant and equipment4 12 14 
Payments for acquisitions of businesses, net of cash acquired(1,811)(1,542)(2,258)
Proceeds from (payments for) investments and acquisitions of certain technologies(89)(24)279 
Proceeds from disposal of certain businesses and assets— 5 826 
Proceeds from royalty rights30 70 82 
Proceeds from settlements of hedge contracts2 56 15 
Cash provided by (used for) investing activities(2,574)(2,011)(1,597)
Payment of contingent consideration previously established in purchase accounting(39)(335)(15)
Payments for royalty rights(50)(75)(85)
Payments on short-term borrowings— (250)— 
Net decrease in commercial paper(4)(1)— 
Payments on long-term borrowings and debt extinguishment costs— (3,184)— 
Proceeds from long-term borrowings, net of debt issuance costs— 3,270 — 
Cash dividends paid on preferred stock(28)(55)(55)
Cash used to net share settle employee equity awards(56)(53)(50)
Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans182 136 110 
Cash provided by (used for) financing activities5 (548)(95)
Effect of foreign exchange rates on cash(4)(9)(6)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents(70)(1,042)173 
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period1,126 2,168 1,995 
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period$1,055 $1,126 $2,168 









See notes to the consolidated financial statements. Amounts may not foot due to rounding.
70

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (SUPPLEMENTAL INFORMATION)
Year Ended December 31,
(in millions)202320222021
Supplemental Information
Cash paid for income taxes, net$512 $662 $302 
Cash paid for interest259 450 338 
Fair value of contingent consideration recorded in purchase accounting273 — 440 
Non-cash impact of transferred royalty rights(30)(70)(82)
(in millions)As of December 31,
Reconciliation to amounts within the consolidated balance sheets:202320222021
Cash and cash equivalents$865 $928 $1,925 
Restricted cash and restricted cash equivalents included in Other current assets
130 149 188 
Restricted cash equivalents included in Other long-term assets
60 48 55 
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period$1,055 $1,126 $2,168 









































See notes to the consolidated financial statements. Amounts may not foot due to rounding.
71

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE A – SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

Our consolidated financial statements include the accounts of Boston Scientific Corporation's wholly owned subsidiaries and entities for which we have a controlling financial interest. All intercompany balances and transactions have been eliminated in consolidation.

When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE). For any VIEs, we perform an analysis to determine whether our variable interests give us a controlling financial interest. The analysis identifies the primary beneficiary of a VIE as the enterprise that has both 1) the power to direct activities of a VIE that most significantly impact the entity’s economic performance and 2) the obligation to absorb losses of the entity or the right to receive benefits from the entity. Based on our assessments under the applicable guidance, we did not have controlling financial interests in any VIEs and, therefore, did not consolidate any VIEs during 2023, 2022 or 2021.

Basis of Presentation

The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and with the instructions to Form 10-K and Regulation S-X.

Amounts reported in millions within this Annual Report on Form 10-K are computed based on the amounts in thousands. As a result, the sum of the components may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded numbers.

Subsequent Events

We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly.

Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note B – Acquisitions and Strategic Investments for further details.

Accounting Estimates

To prepare our consolidated financial statements in accordance with GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our consolidated financial statements and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to Critical Accounting Estimates included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for further discussion.

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents

Cash and Cash Equivalents

We record Cash and cash equivalents in our consolidated balance sheets at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider cash equivalents to be all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash.

72

Restricted Cash

Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in Other current assets within our consolidated balance sheets. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the customer payments collected by us for servicing previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee.

Restricted Cash Equivalents

Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in Other current assets within our consolidated balance sheets. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents included in Other long-term assets within our consolidated balance sheets are related to deferred compensation plans.

Concentrations of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including distributors, hospitals, health care agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral.

We record credit loss reserves to Allowance for credit losses when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach to determine the reserve to record at accounts receivable commencement for certain customers, applying country or region-specific factors. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account.

We write-off amounts determined to be uncollectible against this reserve. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in 2023, 2022 and 2021; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups are important to our business and represent a substantial portion of our net sales.

We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other countries. Further, the ongoing site-of-service trend of shifting procedure volumes in the U.S. toward non-hospital settings, particularly ambulatory surgery centers and office-based labs, continues. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions, as appropriate. We believe our Allowance for credit losses is adequate as of December 31, 2023; however, if significant changes were to occur in the payment practices of government customers, or if there is an increase in bankruptcies among our ambulatory surgery center or office-based customers, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts may increase.
 
73

Revenue Recognition

We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers:

•We have a contract with a customer that creates enforceable rights and obligations,
•Promised products or services are identified,
•The transaction price, or the amount we expect to receive, is determinable and
•We have transferred control of the promised items to the customer.

Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a component of Selling, general and administrative expenses when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.

Deferred Revenue

We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.

Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying consolidated balance sheets. Our contract liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. Our contract liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

Variable Consideration

We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.

We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.

74

Post-Implant Services

We provide non-contractual services to customers, where necessary, to ensure the safe and effective use of certain implanted devices. Because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to Selling, general and administrative expenses within our consolidated statements of operations. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost. Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.

Warranty Obligations

We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our CRM business, which include implantable defibrillator and pacemaker systems. These products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a liability equal to these estimated costs as Cost of products sold at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary.

Inventories

We state inventories at the lower of first-in, first-out cost or net realizable value. We utilize a standard costing system, capitalizing variances between estimated and actual production costs during periods of normal production, and amortize to Cost of products sold over inventory turns. We expense manufacturing variances during periods of abnormal production, or less than 75 percent of manufacturing capacity. We did not record any abnormal production variances during the years ended December 31, 2023, 2022 or 2021.

We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory.

Property, Plant and Equipment

We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of 40 years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a three to seven year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.

Valuation of Business Combinations

We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&D, on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through Selling, general and administrative expenses.

In cases where we acquire a company in which we previously held an equity stake, we attribute a portion of the purchase price to the previously-held equity interest, which is implied based on the total purchase consideration allocable to each of the shareholders, including Boston Scientific, according to priority of equity interests. We record a gain or loss in Other, net equal to the difference between the implied fair value of our prior ownership and the book value immediately prior to the acquisition.

75

Where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through Contingent consideration net expense (benefit) on our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.

Indefinite-lived Intangibles and IPR&D

Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which are foundational to our ongoing operations, as well as IPR&D intangible assets acquired in a business combination. Our IPR&D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&D intangible asset.

We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, Intangibles - Goodwill and Other (FASB ASC Topic 350). If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value.

We use the income approach to determine the fair values of our IPR&D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects’ stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See Note C – Goodwill and Other Intangible Assets for more information related to indefinite-lived intangibles, including IPR&D.

For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date.

Amortization and Impairment of Intangible Assets

We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, two to 20 years; amortizable technology-related and customer relationships, five to 25 years; other intangible assets, various. In addition, we classify internal use software as an intangible asset within our accompanying consolidated balance sheets and amortize over a one to 15 year useful life. Due to the operational nature of these assets, we record the amortization of our internal use software within Cost of products sold; Selling, general and administrative expenses and Research and development expenses, as appropriate within our accompanying consolidated statements of operations, and include in Amortization expense only that associated with intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents.

We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for
76

recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified.

We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See Note C – Goodwill and Other Intangible Assets for more information related to impairments of intangible assets.

For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent.

Goodwill Valuation

We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances, utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350, Intangibles - Goodwill and Other, in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.

We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2023 annual impairment assessment, we identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components into a single Rhythm Management reporting unit.

In performing annual impairment assessments, the qualitative approach is used for testing reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units are tested using the quantitative approach. When a quantitative test is performed, we typically use the income approach, specifically the Discounted Cash Flow method, to derive the fair value of each of our reporting units in preparing our goodwill impairment assessments. We historically selected this method as being the most meaningful in preparing our goodwill assessments because we believe the income approach most appropriately measures the fair value of our income producing assets. We make assumptions about the amount and timing of future expected cash flows, terminal value growth rates and appropriate discount rates. The amount and timing of future cash flows within our Discounted Cash Flow analysis is based on our most recent operational budgets, long range strategic plans and other estimates.

Investments in Publicly Traded and Privately-Held Entities

For publicly-held equity securities for which we do not have the ability to exercise significant influence, we measure at fair value with changes in fair value recognized currently in Other, net within our accompanying consolidated statements of operations. For privately-held equity securities for which we do not have the ability to exercise significant influence, we apply the measurement alternative approach and measure these investments at cost minus impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We account for investments in entities for which we have the ability to exercise significant influence under the equity method if we hold 50 percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with FASB ASC Topic 323, Investments - Equity Method and Joint Ventures. We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing consolidated financial statements. Lastly, we have notes receivable from certain companies that we account for in accordance with FASB ASC Topic 320, Investments - Debt and Equity Securities. Refer to Note B – Acquisitions and Strategic Investments for additional details on our investment balances.

Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an
77

investee’s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. For our investments for which we apply the measurement alternative, if the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. For our equity method investments, if we determine an impairment is other-than-temporary, we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value.

Net gains and losses and impairments associated with our investment portfolio are included within Other, net in our consolidated statements of operations.

Income Taxes

We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial condition and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We recognize interest and penalties related to income taxes as a component of income tax expense. As part of the Tax Cuts and Jobs Act (TCJA), we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and report it as part of continuing operations. See Note H – Income Taxes for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA.

Legal and Product Liability Costs

We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities and product liability litigation. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related charges (credits) in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our consolidated statements of operations. See Note I – Commitments and Contingencies for discussion of our individual material legal proceedings.

Costs Associated with Exit Activities

We record employee termination costs in accordance with FASB ASC Topic 712, Compensation - Nonretirement and Postemployment Benefits, if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with FASB ASC Topic 420, Exit or Disposal Cost Obligations (FASB ASC Topic 420). We record such costs into expense over the employee’s future service period, if any.
78


Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with FASB ASC Topic 420 and are included within Restructuring net charges (credits) in our consolidated statements of operations. We recorded Restructuring net charges (credits) of $69 million in 2023, $24 million in 2022 and $40 million in 2021. The restructuring reserve balance as of December 31, 2023 and 2022 was $41 million and $10 million, respectively. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities are included within Costs of products sold, Selling, general and administrative expenses and Research and development expenses within our consolidated statements of operations. Impairment of right of use lease assets and lease termination costs directly related to our active restructuring initiatives are expensed in accordance with FASB ASC Topic 842, Leases (FASB ASC Topic 842) and included within Costs of products sold or Selling, general and administrative expenses in our consolidated statements of operations.

Translation of Foreign Currency

We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate. We show the net effect of these translation adjustments within our consolidated financial statements as a component of Accumulated other comprehensive income (loss), net of tax. We translate revenues and expenses at the average exchange rates in effect during the year. For any significant foreign subsidiaries located in highly inflationary economies, we re-measure their financial statements as if the functional currency were the U.S. dollar.

Foreign currency transaction gains and losses are included within Other, net in our consolidated statements of operations, net of losses and gains from any related derivative financial instruments.

Financial Instruments

We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815, Derivatives and Hedging (FASB ASC Topic 815), and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our consolidated financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to Note D – Hedging Activities and Fair Value Measurements for more information on our hedging instruments.

Research and Development

We expense research and development (R&D) costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to Indefinite-lived Intangibles and IPR&D above for our policy regarding R&D projects acquired in connection with our business combinations and asset purchases.

NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS

Our consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our consolidated financial statements. Further, transaction costs were immaterial to our consolidated financial statements and were expensed as incurred.

On January 8, 2024, we announced our entry into a definitive agreement to acquire 100 percent of Axonics, Inc. (Axonics), a publicly traded medical technology company primarily focused on the development and commercialization of devices to treat urinary and bowel dysfunction. The purchase price is $71.00 in cash per share, or approximately $3.670 billion. The transaction is expected to close in the first half of 2024, subject to customary closing conditions. The Axonics business will be integrated into our Urology division.

79


2023 Acquisitions

On February 20, 2023, we completed the acquisition of a majority stake investment in Acotec, a publicly traded Chinese manufacturer of drug-coated balloons and other products used in the treatment of vascular and other diseases. We consolidated this majority stake investment in Acotec based on the conclusion we control the entity, and recorded a noncontrolling interest for the portion we do not own. We acquired approximately 65 percent of the outstanding shares of Acotec, for an upfront cash payment of HK$20.00 per share, or $519 million at foreign currency exchange rates at closing. The Acotec portfolio complements our existing Peripheral Interventions portfolio.

On April 4, 2023, we completed our acquisition of 100 percent of the outstanding equity of Apollo Endosurgery, Inc. (Apollo), a public company which offers a portfolio of devices used during endoluminal procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity. The transaction consisted of an upfront cash payment of $636 million, net of cash acquired. The Apollo business is being integrated into our Endoscopy division.

On November 17, 2023, we completed our acquisition of 100 percent of the outstanding equity of Relievant Medsystems, Inc. (Relievant), a privately held medical technology company that developed and commercialized the Intracept® Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain. The transaction consisted of an upfront cash payment of $794 million, net of cash acquired, and additional sales-based milestones over the 3 years following the transaction close. These milestones, certain of which are uncapped, are estimated to have a fair value of $273 million. The Relievant business is being integrated into our Neuromodulation division.

Purchase Price Allocation

We accounted for these transactions as business combinations in accordance with FASB ASC Topic 805, Business Combinations (FASB ASC Topic 805). The preliminary purchase prices were comprised of the amounts presented below:

(in millions)
Acotec(1)
ApolloRelievant
Payment for acquisition, net of cash acquired (2)
$381 $636 $794 
Fair value of contingent consideration— — 273 
$381 $636 $1,067 
(1) Excludes approximately $140 million of cash on hand at the closing of the transaction
(2) Related to Acotec, represents our majority stake investment

We recorded the assets acquired, liabilities assumed and specific to Acotec, the noncontrolling interest, at their respective fair values as of the closing date of the transaction. The preliminary purchase price allocations were comprised of the components presented below, which represent the preliminary determination of the fair value of identifiable assets acquired and liabilities assumed, as well as goodwill. The final determination of the fair value of certain assets and liabilities will be completed within the measurement period in accordance with FASB ASC Topic 805:

(in millions)AcotecApolloRelievant
Goodwill$337 $378 $731 
Amortizable intangible assets334 248 325 
Other assets acquired93 50 24 
Liabilities assumed(48)(33)(15)
Net deferred tax liabilities(76)(5)1 
Fair value of noncontrolling interest(259)— — 
$381 $636 $1,067 

80

The fair value of Acotec's noncontrolling interest was based on the publicly traded market value of the remaining 35 percent of the outstanding shares we did not acquire as of the transaction date and is presented within Stockholders' equity within our accompanying consolidated balance sheets. Goodwill was primarily established for Acotec due to opportunities for collaboration in research and development, manufacturing and commercial strategies, and for Apollo and Relievant, due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies, none of which is deductible for tax purposes.

We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Acotec:
Amortizable intangible assets:
Technology-related$308 1114%
Customer relationships15 1114%
Other intangible assets11 1314%
$334 
Apollo:
Amortizable intangible assets:
Technology-related$222 1112%
Customer relationships26 1112%
$248 
Relievant
Amortizable intangible assets:
Technology-related$287 1212%
Customer relationships38 1212%
$325 

2022 Acquisition

On February 14, 2022, we completed our acquisition of Baylis Medical Company Inc. (Baylis Medical), a privately-held company which developed the radiofrequency (RF) NRG™ and VersaCross™ Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access, which expanded our electrophysiology and structural heart product portfolios. The transaction consisted of an upfront cash payment of $1.463 billion, net of cash acquired, subject to closing adjustments. We are integrating Baylis Medical into our Cardiology division.

Purchase Price Allocation

We accounted for the acquisition of Baylis Medical as a business combination in accordance with FASB ASC Topic 805. The final purchase price was comprised of the amount presented below:

(in millions)
Payment for acquisition, net of cash acquired$1,463 
$1,463 
81


We recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The final purchase price allocation was comprised of the following components:

(in millions)
Goodwill$988 
Amortizable intangible assets657 
Other assets acquired112 
Liabilities assumed(287)
Net deferred tax liabilities(7)
$1,463 

Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies, and was deductible for tax purposes.

We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
Technology-related622 1111%
Other intangible assets36 1111%
$657 

Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes and will carry forward from one product generation to the next. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives.

Contingent Consideration

Changes in the fair value of our contingent consideration liability during 2023 and 2022 associated with current and prior period acquisitions were as follows:
(in millions)
Balance as of December 31, 2021$486 
Contingent consideration net expense (benefit)35 
Contingent consideration payments(371)
Balance as of December 31, 2022$149 
Amount recorded related to current year acquisitions273 
Contingent consideration net expense (benefit)58 
Contingent consideration payments(76)
Balance as of December 31, 2023$404 

82

In 2023, payments were primarily related to our acquisition of Farapulse, Inc. (Farapulse) following the achievement of revenue milestones. In 2022, payments were primarily related to our acquisition of Farapulse and Preventice Solutions, Inc., following the achievement of revenue and/or regulatory milestones. The net expense of $58 million and $35 million recorded in 2023 and 2022, respectively, related primarily to an increase in expected revenue-based payments as a result of over-achievement of net sales performance, primarily related to our acquisition of Farapulse. In both periods, this increase was partially offset by a reduction in the contingent consideration liability for certain acquisitions for which we reduced the probability of achievement of associated regulatory and commercialization-based milestones upon which payment is conditioned.

The maximum amount for certain contingent consideration is not determinable as it is uncapped and based on a percent of certain sales. As of December 31, 2023, the fair value of such uncapped contingent consideration is estimated at $177 million. As of December 31, 2023, the maximum amount that we could be required to pay under our other contingent consideration arrangements (undiscounted) is approximately $398 million.

The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:
Contingent Consideration LiabilityFair Value as of December 31, 2023Valuation TechniqueUnobservable InputRange
Weighted Average(1)
Revenue-based Payments and Milestones$404 millionDiscounted Cash FlowDiscount Rate6 %-12%10%
Probability of Payment90%-100%98%
Projected Year of Payment2024-20272025
(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Projected contingent payment amounts related to our revenue-based payments and milestones are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of December 31, 2023.

Strategic Investments

The aggregate carrying amount of our strategic investments was comprised of the following:
As of December 31,
(in millions)20232022
Equity method investments$219 $188 
Measurement alternative investments(1, 2)
194 219 
$413 $407 
(1) Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying consolidated statements of operations.
(2) Includes publicly-held equity securities and convertible notes measured at fair value with changes in fair value recognized in Other, net within our consolidated statements of operations.

These investments are classified as Other long-term assets within our consolidated balance sheets, in accordance with GAAP and our accounting policies.

In 2023, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $261 million, which represents amortizable intangible assets, IPR&D, goodwill and deferred tax liabilities.

83


NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:
 As of December 31, 2023As of December 31, 2022
(in millions)Gross Carrying AmountAccumulated
Amortization/
Write-offs		Gross Carrying AmountAccumulated
Amortization/
Write-offs
Technology-related$13,207 $(8,101)$12,397 $(7,378)
Patents480 (387)486 (394)
Other intangible assets2,130 (1,500)1,960 (1,400)
Amortizable intangible assets$15,817 $(9,988)$14,843 $(9,173)
Goodwill$24,287 $(9,900)$22,820 $(9,900)
IPR&D54 112 
Technology-related120 120 
Indefinite-lived intangible assets$174 $232 

The increase in our balance of goodwill and amortizable intangible assets is related primarily to our majority stake investment in Acotec completed in the first quarter of 2023 and our acquisitions of Apollo and Relievant completed during the second and fourth quarters of 2023, respectively.

Intangible asset impairment charges were $58 million in 2023, $132 million in 2022 and $370 million in 2021. The impairment charges recorded in 2023 were primarily associated with the cancellation of an IPR&D program due to the incremental time and cost to complete the program and bring the technology to market. The impairment charges recorded in 2022 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of Vertiflex, Inc., which is now part of our Neuromodulation business, resulting from lower revenue projections due to reimbursement challenges.

The following represents a rollforward of our goodwill balance by reportable segment:
(in millions)MedSurgCardiovascularTotal
Balance as of December 31, 2021$4,246 $7,741 $11,988 
Goodwill acquired— 1,030 1,030 
Foreign currency fluctuations and other changes(10)(88)(98)
Balance as of December 31, 2022$4,237 $8,684 $12,920 
Goodwill acquired1,110 337 1,447 
Foreign currency fluctuations and other changes— 20 20 
Balance as of December 31, 2023$5,347 $9,041 $14,387 
In the second quarter of 2023, we performed our annual goodwill impairment test utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350. The qualitative approach was used for testing reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units were tested using the quantitative approach. We determined that the fair value of each reporting unit exceeded its carrying value and concluded that goodwill was not impaired or at risk of impairment.
Refer to Note A – Significant Accounting Policies for further discussion of our goodwill and intangible asset impairment testing.

84

Estimated Amortization expense for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio, consisting of intangible assets acquired in a business combination or asset acquisition, as well as internally developed patents, as of December 31, 2023 is as follows:
Fiscal Year(in millions)
2024$828 
2025757 
2026737 
2027714 
2028690 

These estimates do not include amortization expense associated with future acquisitions that have been announced but not yet completed as of December 31, 2023.

NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS

Derivative Instruments and Hedging Activities

We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.

We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.

Currency Hedging Instruments
Risk Management Strategy
Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities; forecasted intercompany and third-party transactions; and net investments in certain subsidiaries. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates.

The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in euro, Chinese renminbi, Japanese yen, British pound sterling, Australian dollar, Swiss franc and South Korean won. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecasted. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.

Hedge Designations and Relationships

Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the Net change in derivative financial instruments component of Other comprehensive income (loss), net of tax (OCI) within our consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within Cost of products sold in our consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within Accumulated
85

other comprehensive income (loss), net of tax (AOCI) to earnings at that time. The cash flows related to the derivative instruments designated as cash flow hedges are reported as operating activities in our consolidated statements of cash flows.

We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Japanese yen and Taiwan dollar. For these derivative instruments, we elected to use the spot method to assess hedge effectiveness. We also elected to exclude the spot-forward difference, referred to as the excluded component, from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. As such, we defer recognition of foreign currency gains and losses within the Foreign currency translation adjustment (CTA) component of OCI, and we reclassify amortization of the excluded component from AOCI to current period earnings within Interest expense in our consolidated statements of operations.

We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro. As of December 31, 2023 and 2022, we designated as a net investment hedge our €900 million in aggregate principal amount of 0.625% senior notes issued in November 2019 and due in 2027 (2027 Notes). For these nonderivative instruments, we defer recognition of the foreign currency remeasurement gains and losses within the CTA component of OCI. We reclassify these gains and losses to current period earnings within Other, net in our consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary.

We also use forward currency contracts that are not part of designated hedging relationships as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within Other, net in our consolidated statements of operations.

Interest Rate Hedging Instruments
Risk Management Strategy

Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.

Hedge Designations and Relationships

We had no interest rate derivative instruments designated as cash flow hedges outstanding as of December 31, 2023 and December 31, 2022. In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within OCI until the underlying hedged transaction occurs.

We had no interest rate derivative instruments designated as fair value hedges outstanding as of December 31, 2023 and December 31, 2022. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in Interest expense, which generally offset.

The following table presents the contractual amounts of our hedging instruments outstanding:
(in millions)FASB ASC Topic 815 DesignationAs of December 31,
20232022
Forward currency contractsCash flow hedge$2,284 $2,725 
Forward currency contractsNet investment hedge333 365 
Foreign currency-denominated debt(1)
Net investment hedge997 997 
Forward currency contractsNon-designated3,282 4,235 
Total Notional Outstanding$6,896 $8,321 
(1) Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge.

86

The remaining time to maturity as of December 31, 2023 is within 36 months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature between one and two years. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.

The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying consolidated statements of operations. Refer to Note O – Changes in Other Comprehensive Income for the total amounts relating to derivative and nonderivative instruments presented within our consolidated statements of comprehensive income (loss).
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Year Ended December 31, 2023
Forward currency contracts
Cash flow hedges$81 $(18)$63 Cost of products sold$4,345 $(235)$53 $(182)
Net investment hedges(2)
32 (7)25 Interest expense265 (10)2 (8)
Foreign currency-denominated debt
Net investment hedges(3)
(34)8 (27)Other, net93 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense265 3 (1)2 
Year Ended December 31, 2022
Forward currency contracts
Cash flow hedges$276 $(62)$214 Cost of products sold$3,956 $(209)$47 $(162)
Net investment hedges(2)
41 (10)32 Interest expense470 (10)2 (8)
Foreign currency-denominated debt
Net investment hedges(3)
61 (14)47 Other, net38 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense470 16 (4)13 
Year Ended December 31, 2021
Forward currency contracts
Cash flow hedges$268 $(60)$208 Cost of products sold$3,711 $(54)$12 $(42)
Net investment hedges(2)
56 (13)43 Interest expense341 (13)3 (10)
Foreign currency-denominated debt
Net investment hedges(3)
82 (19)64 Other, net(218)— — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense341 5 (1)4 
(1) In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings.
(2) For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.
(3) For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.

87

As of December 31, 2023, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):
Designated Hedging InstrumentFASB ASC Topic 815 DesignationLocation on Consolidated Statements of OperationsAmount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Forward currency contractsCash flow hedgeCost of products sold$152 
Forward currency contractsNet investment hedgeInterest expense9 
Interest rate derivative contractsCash flow hedgeInterest expense(1)

Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
(in millions)Location on Consolidated Statements of OperationsYear Ended December 31,
202320222021
Net gain (loss) on currency hedge contractsOther, net$3 $(53)$(16)
Net gain (loss) on currency transaction exposuresOther, net(44)21 (12)
Net currency exchange gain (loss)$(41)$(31)$(27)


88

Fair Value Measurements

FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures (FASB ASC Topic 820), and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:
(in millions)
Location on Consolidated Balance Sheets(1)
As of December 31,
20232022
Derivative and Nonderivative Assets:   
Designated Hedging Instruments  
Forward currency contractsOther current assets$140 $196 
Forward currency contractsOther long-term assets107 149 
  246 345 
Non-Designated Hedging Instruments   
Forward currency contractsOther current assets20 36 
Total Derivative and Nonderivative Assets $266 $381 
Derivative and Nonderivative Liabilities:   
Designated Hedging Instruments  
Forward currency contractsOther current liabilities$15 $— 
Forward currency contractsOther long-term liabilities9 1 
Foreign currency-denominated debt(2)
Long-term debt988 952 
  1,012 953 
Non-Designated Hedging Instruments   
Forward currency contractsOther current liabilities38 52 
Total Derivative and Nonderivative Liabilities$1,050 $1,005 
(1) We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.
(2) Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.

Recurring Fair Value Measurements
On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
•Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
•Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
•Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
89

Assets and liabilities measured at fair value on a recurring basis consist of the following:
As of
 December 31, 2023December 31, 2022
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets        
Money market funds and time deposits$454 $— $— $454 $673 $— $— $673 
Publicly-held securities18 — — 18 2 — — 2 
Hedging instruments— 266 — 266 — 381 — 381 
Licensing arrangements— — 77 77 — — 127 127 
 $472 $266 $77 $816 $674 $381 $127 $1,182 
Liabilities        
Hedging instruments$— $1,050 $— $1,050 $— $1,005 $— $1,005 
Contingent consideration liability— — 404 404 — — 149 149 
Licensing arrangements— — 90 90 — — 159 159 
 $— $1,050 $494 $1,545 $— $1,005 $308 $1,313 

Our investments in money market funds and time deposits are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents within our accompanying consolidated balance sheets, in accordance with GAAP and our accounting policies. In addition to $454 million invested in money market funds and time deposits as of December 31, 2023 and $673 million as of December 31, 2022, we held $411 million in interest-bearing and non-interest-bearing bank accounts as of December 31, 2023 and $256 million as of December 31, 2022.

Our recurring fair value measurements using Level 3 inputs include those related to our contingent consideration liability. Refer to Note B – Acquisitions and Strategic Investments for a discussion of the changes in the fair value of our contingent consideration liability.

In addition, our recurring fair value measurements using Level 3 inputs related to our licensing arrangements, including the contractual right to receive future royalty payments related to the Zytiga™ Drug. We own the contractual right to receive 50 percent of the future Zytiga Drug royalty payments from the licensee and remit such payments to the inventors associated with the intellectual property. We recognized a financial asset and associated liability for our licensing arrangements at fair value in our consolidated balance sheets using the fair value option in accordance with FASB ASC Topic 825, Financial Instruments. We elected the fair value option to measure the financial asset and associated liability as it provides for consistency and comparability of these financial instruments with others. Royalty payments we receive reduce the fair value of the financial asset and are presented within Proceeds from royalty rights, and payments we remit to inventors reduce the fair value of the financial liability and are presented within Payments for royalty rights within our consolidated statements of cash flows. We sold our right to receive and retain the other 50 percent of the future royalty payments in 2019 for an upfront cash payment, which we accounted for as a secured borrowing in accordance with FASB ASC Topic 860, Transfers and Servicing (FASB ASC Topic 860). Although we sold these rights, we continue to recognize at fair value the future royalty payments as a financial asset and associated liability. Royalty payments associated with the rights we sold no longer impact our cash flows, and we present this activity as Non-cash impact of transferred royalty rights in the supplemental information to our consolidated statements of cash flows. We reduce the fair value of the financial asset and associated liability when such non-cash activity occurs.

We record the fair value of the financial asset and associated liability using a discounted cash flow approach considering the probability-weighted expected future cash flows to be generated by the royalty stream. The fair value of the financial liability also considers the related contractual provisions that govern our payment obligations. Significant increases or decreases in projected cash flows of the royalty stream and the related contractual provisions that govern our payment obligations, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement of the licensing arrangements' financial asset and liability as of December 31, 2023. However, increases or decreases in the financial asset would be offset by increases or decreases in the financial liability, other than for timing of receipt and remittance; as such our earnings are not subject to material gains and losses from the licensing arrangement.

90

The recurring Level 3 fair value measurements of our licensing arrangements recognized in our consolidated balance sheets as of December 31, 2023 include the following significant unobservable inputs:
Licensing ArrangementsFair Value as of December 31, 2023Valuation TechniqueUnobservable InputRange
Weighted Average(1)
Financial Asset$77 millionDiscounted Cash FlowDiscount Rate15%15%
Projected Year of Payment2024-20252024
Financial Liability$90 millionDiscounted Cash FlowDiscount Rate12%-15%13%
Projected Year of Payment2024-20262025
(1) Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Changes in the fair value of our licensing arrangements' financial asset were as follows:
(in millions)
Balance as of December 31, 2021$246 
Proceeds from royalty rights(141)
Fair value adjustment (expense) benefit22 
Balance as of December 31, 2022$127 
Proceeds from royalty rights(61)
Fair value adjustment (expense) benefit11 
Balance as of December 31, 2023$77 

Changes in the fair value of our licensing arrangements' financial liability were as follows:
(in millions)
Balance as of December 31, 2021$281 
Payments for royalty rights(145)
Fair value adjustment expense (benefit)23 
Balance as of December 31, 2022$159 
Payments for royalty rights(80)
Fair value adjustment expense (benefit)12 
Balance as of December 31, 2023$90 

Non-Recurring Fair Value Measurements

We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B – Acquisitions and Strategic Investments for a discussion of our strategic investments and Note C – Goodwill and Other Intangible Assets for a discussion of the fair values of our intangible assets including goodwill.

The fair value of our outstanding debt obligations, excluding finance leases, was $8.735 billion as of December 31, 2023 and $8.203 billion as of December 31, 2022. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to Note E – Contractual Obligations and Commitments for a discussion of our debt obligations.
91

NOTE E – CONTRACTUAL OBLIGATIONS AND COMMITMENTS

Borrowings and Credit Arrangements

We had total debt outstanding of $9.102 billion as of December 31, 2023 and $8.935 billion as of December 31, 2022, with current maturities of $531 million as of December 31, 2023 and $20 million as of December 31, 2022. The debt maturity schedule for our long-term debt obligations is presented below:
Issuance DateMaturity DateAs of December 31,
Coupon Rate(1)
(in millions, except interest rates)20232022
March 2024 NotesFebruary 2019March 2024— 504 3.450%
March 2025 Senior Notes(3)
March 2022March 20251,105 1,067 0.750%
June 2025 Senior NotesMay 2020June 2025500 500 1.900%
March 2026 Senior NotesFebruary 2019March 2026255 255 3.750%
December 2027 Senior Notes(3)
November 2019December 2027995 960 0.625%
March 2028 Senior Notes(3)
March 2022March 2028829 800 1.375%
March 2028 Senior NotesFebruary 2018March 2028344 344 4.000%
March 2029 Senior NotesFebruary 2019March 2029272 272 4.000%
June 2030 Senior NotesMay 2020June 20301,200 1,200 2.650%
March 2031 Senior Notes(3)
March 2022March 2031829 800 1.625%
March 2034 Senior Notes(3)
March 2022March 2034553 534 1.875%
November 2035 Senior Notes(2)
November 2005November 2035350 350 6.500%
March 2039 Senior NotesFebruary 2019March 2039450 450 4.550%
January 2040 Senior NotesDecember 2009January 2040300 300 7.375%
March 2049 Senior NotesFebruary 2019March 2049650 650 4.700%
Unamortized Debt Issuance Discount and Deferred Financing Costs2024 - 2049(65)(76)
Finance Lease ObligationVarious5 5 
Long-term debt $8,571 $8,915 
(1) Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.
(2) Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate of 6.25% if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher.
(3) These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of December 31, 2023 and 2022, respectively.

Contractual maturities of our long-term debt outstanding as of December 31, 2023 are as follows (in millions):

Fiscal Year
20251,605 
2026255 
2027995 
20281,173 
Thereafter4,604 

Revolving Credit Facility

On May 10, 2021, we entered into a $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks, initially scheduled to mature on May 10, 2026, with one-year extension options, subject to certain conditions. On March 1, 2023, we entered into an amendment of the 2021 Revolving Credit Facility credit agreement, which provided for an extension of the scheduled maturity date to May 10, 2027 and replaced the London Interbank Offered Rate (LIBOR) with the Secured Overnight Financing Rate (SOFR) as the Eurocurrency Rate for Dollars, including applicable credit spread adjustments and relevant SOFR benchmark provisions, among other things described under Financial Covenant below. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces
92

borrowing capacity under the 2021 Revolving Credit Facility. We had no amounts outstanding under the 2021 Revolving Credit Facility as of December 31, 2023 or December 31, 2022.

Financial Covenant

As of December 31, 2023, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility.
 Covenant Requirement
as of December 31, 2023		 Actual
as of December 31, 2023
Maximum permitted leverage ratio(1)
3.75 times 2.33 times
(1) Ratio of total debt to deemed consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), as defined by the 2021 Revolving Credit Facility credit agreement, as amended.

The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times for the remaining term. The agreement provides for higher leverage ratios, at our election, for the period following a qualified acquisition, for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. It steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have not elected to increase the maximum permitted leverage ratio for qualified acquisitions to date, due to our funding of these acquisitions using cash on hand or commercial paper.

The financial covenant requirement, as amended on March 1, 2023, provides for an exclusion from the calculation of consolidated EBITDA, as defined by the credit agreement, through maturity, of certain charges and expenses. The credit agreement amendment reset the starting date for purposes of calculating such permitted exclusions in each case from March 31, 2021 to December 31, 2022. Permitted exclusions include any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of December 31, 2023, we had $317 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreement, are excluded from the calculation of consolidated EBITDA, as defined by the agreement, provided that the sum of any excluded net cash litigation payments do not exceed $1.000 billion plus all accrued legal liabilities as of December 31, 2022. As of December 31, 2023, we had $1.484 billion of the litigation exclusion remaining.

Any inability to maintain compliance with this covenant could require us to seek to further renegotiate the terms of our credit arrangements or seek waivers from compliance with this covenant, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all 2021 Revolving Credit Facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our 2021 Revolving Credit Facility may negatively impact the credit ratings assigned to our commercial paper program, which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable.

Commercial Paper

Our commercial paper program is backed by the 2021 Revolving Credit Facility. We did not have any commercial paper outstanding as of December 31, 2023 and 2022.

Senior Notes

We had senior notes outstanding of $9.136 billion as of December 31, 2023 and $8.986 billion as of December 31, 2022. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (see Other Arrangements below).

In March 2022, American Medical Systems Europe B.V. (AMS Europe), an indirect, wholly owned subsidiary of Boston Scientific, completed a registered public offering (the Offering) of €3.000 billion in aggregate principal amount of euro-dominated senior notes comprised of €1.000 billion of 0.750% Senior Notes due 2025, €750 million of 1.375% Senior Notes due 2028, €750 million of 1.625% Senior Notes due 2031 and €500 million of 1.875% Senior Notes due 2034 (collectively, the Eurobonds). Boston Scientific has fully and unconditionally guaranteed all of AMS Europe's obligations under the Eurobonds, and no other subsidiary of Boston Scientific will guarantee these obligations. AMS Europe is a “finance subsidiary” as defined
93

in Rule 13-01(a)(4)(vi) of Regulation S-X. The financial condition, results of operations and cash flows of AMS Europe are consolidated in the financial statements of Boston Scientific. The Offering resulted in cash proceeds of $3.270 billion, net of investor discounts and issuance costs.

We used the net proceeds from the Offering to fund the tender offer and early redemption of combined aggregate principal amount of $3.275 billion of certain of our outstanding senior notes, as well as to pay accrued interest, tender premiums, fees and expenses. We recorded associated debt extinguishment net charges of $194 million during the first quarter of 2022 presented in Interest expense within our consolidated statements of operations.

Other Arrangements

We have accounts receivable factoring programs in certain European countries and with commercial banks in China and Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net in our accompanying consolidated balance sheets, are aggregated by contract denominated currency below (in millions):

As of December 31, 2023As of December 31, 2022
Factoring ArrangementsAmount
De-recognized		Weighted Average Interest RateAmount
De-recognized		Weighted Average Interest Rate
Euro denominated$206 5.1 %$161 2.4 %
Yen denominated214 0.6 %194 0.6 %
Renminbi denominated14 2.9 %13 3.1 %

Other Contractual Obligations and Commitments

We had outstanding letters of credit of $174 million as of December 31, 2023 and $135 million as of December 31, 2022, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of December 31, 2023 and December 31, 2022, we had not recognized a related liability for our outstanding letters of credit in our consolidated balance sheets.

As of December 31, 2023, future minimum purchase obligations, relating primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business, were (in millions):
Fiscal YearUnrecorded Purchase Obligations
2024$951 
2025283 
2026155 
202745 
202831 
Thereafter150 
 $1,615 

We have a supplier financing program offered primarily in the U.S. that enables our suppliers to opt to receive early payment at a nominal discount, while allowing us to lengthen our payment terms and optimize working capital. Our standard payment term in the U.S. is 90 days. All outstanding payables related to the supplier finance program are classified within Accounts Payable within our unaudited consolidated balance sheets and were $152 million as of December 31, 2023 and $129 million as of December 31, 2022.

94

NOTE F – LEASES

We have operating and finance leases for real estate including corporate offices, land, warehouse space, and vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that we are reasonably certain to exercise (short-term leases). We recognize lease expense on a straight-line basis over the lease term for short-term leases that we do not record on our balance sheet. If there is a change in our assessment of the lease term and, as a result, the remaining lease term extends more than 12 months from the end of the previously determined lease term, or we subsequently become reasonably certain that we will exercise an option to purchase the underlying asset, the lease no longer meets the definition of a short-term lease and is accounted for as either an operating or finance lease and recognized on the balance sheet. In accordance with FASB ASC Topic 842, we account for the lease components and the non-lease components as a single lease component, with the exception of our warehouse leases. Our leases have remaining lease terms of less than 1 year to approximately 53 years, some of which may include options to extend the leases for up to 10 years. If we are reasonably certain we will exercise an option to extend the lease, the time period covered by the extension option is included in the lease term.

We determine whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.

Our operating lease right-of-use assets are presented within Other long-term assets and corresponding liabilities are presented within Other current liabilities and Other long-term liabilities on our consolidated balance sheets. Refer to Note E – Contractual Obligations and Commitments for information regarding our finance leases. As of December 31, 2023, we have entered into two leases for additional office, warehouse and lab space which have not yet commenced. These facilities are currently under construction. We do not control the building during construction and are thus not deemed to be the owner during construction. Total estimated undiscounted future lease payments are approximately $500 million, which includes a buyout option exercisable once construction is complete which we are reasonably certain to exercise with respect to one of the leases. These leases will commence at the end of 2024 and second half of 2025 with noncancellable lease terms ranging from 20 to 25 years.

The following table presents supplemental balance sheet information related to our operating leases:
As of December 31,
(in millions)20232022
Assets
Operating lease right-of-use assets in Other long-term assets
$439 $386 
Liabilities
Operating lease liabilities in Other current liabilities
76 61 
Operating lease liabilities in Other long-term liabilities
390 347 

The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:
As of December 31,
20232022
Weighted average remaining lease term9 years10 years
Weighted average discount rate4.5%3.3%
95


Our operating lease cost under FASB ASC Topic 842 was $96 million in 2023, $91 million in 2022 and $90 million in 2021.

The following table presents supplemental cash flow information related to our operating leases:
Year Ended December 31,
(in millions)20232022
Cash paid for amounts included in the measurement of operating lease liabilities
Operating cash flows from operating leases$93 $91 

Right-of-use assets obtained in exchange for operating lease obligations were $123 million and $43 million for the years ended December 31, 2023 and 2022, respectively.

The following table presents the maturities of our operating lease liabilities as of December 31, 2023 (in millions):
Fiscal year
Operating Leases (1)
2024$89 
202578 
202665 
202749 
202841 
Thereafter217 
Total future minimum operating lease payments539 
Less: imputed interest(74)
Present value of operating lease liabilities$466 
(1) Excludes expected lease payments for lease terms that have not yet commenced.
NOTE G – SUPPLEMENTAL BALANCE SHEET INFORMATION

Components of selected captions in our accompanying consolidated balance sheets are as follows:
Trade accounts receivable, net
 As of December 31,
(in millions)20232022
Trade accounts receivable$2,338 $2,079 
Allowance for credit losses(110)(109)
 $2,228 $1,970 

The following is a rollforward of our Allowance for credit losses:
Year Ended December 31,
(in millions)202320222021
Beginning balance$109 $108 $105 
Credit loss expense50 35 28 
Write-offs(48)(35)(25)
Ending balance$110 $109 $108 

96

Inventories
 As of December 31,
(in millions)20232022
Finished goods$1,537 $1,171 
Work-in-process174 147 
Raw materials773 548 
 $2,484 $1,867 

Approximately 22 percent of our finished goods inventory as of December 31, 2023 and approximately 27 percent as of December 31, 2022 was at customer locations pursuant to consignment arrangements or held by sales representatives.

Other current assets
 As of December 31,
(in millions)20232022
Restricted cash and restricted cash equivalents$130 $149 
Derivative assets159 232 
Licensing arrangements47 60 
Other285 290 
 $621 $731 

Property, plant and equipment, net
 As of December 31,
(in millions)20232022
Land$140 $137 
Buildings and improvements1,843 1,695 
Equipment, furniture and fixtures3,503 3,297 
Capital in progress857 598 
 6,343 5,728 
Less: accumulated depreciation3,484 3,282 
 $2,859 $2,446 

Depreciation expense was $367 million in 2023, $333 million in 2022 and $352 million in 2021.

Other long-term assets
 As of December 31,
(in millions)20232022
Restricted cash equivalents$60 $48 
Operating lease right-of-use assets439 386 
Derivative assets107 149 
Investments413 407 
Licensing arrangements30 67 
Indemnification asset176 172 
Other306 271 
 $1,531 $1,500 

97

Accrued expenses
 As of December 31,
(in millions)20232022
Legal reserves$206 $231 
Payroll and related liabilities1,051 830 
Rebates389 352 
Contingent consideration304 74 
Other696 674 
 $2,646 $2,160 

Other current liabilities
 As of December 31,
(in millions)20232022
Deferred revenue$266 $220 
Licensing arrangements49 79 
Taxes payable220 232 
Other278 230 
 $814 $761 

Other long-term liabilities
 As of December 31,
(in millions)20232022
Accrued income taxes$470 $597 
Legal reserves172 212 
Contingent consideration100 75 
Licensing arrangements41 80 
Operating lease liabilities390 347 
Deferred revenue311 289 
Other484 434 
 $1,967 $2,035 

NOTE H – INCOME TAXES

Our Income (loss) before income taxes consisted of the following:
Year Ended December 31,
(in millions)202320222021
Domestic$(394)$(1,119)$(648)
Foreign2,379 2,260 1,724 
$1,985 $1,141 $1,076 

98

The related expense (benefit) for income taxes consisted of the following:
Year Ended December 31,
(in millions)202320222021
Current
Federal$189 $51 $18 
State15 19 33 
Foreign116 381 127 
320 451 178 
Deferred
Federal(82)(92)(256)
State(22)(32)(3)
Foreign176 117 117 
73 (7)(142)
$393 $443 $36 

The reconciliation of income taxes at the federal statutory rate to the actual expense (benefit) for income taxes is as follows:
Year Ended December 31,
202320222021
U.S. federal statutory income tax rate21.0 %21.0 %21.0 %
State income taxes, net of federal benefit0.7 %0.7 %2.5 %
Domestic taxes on foreign earnings6.9 %15.3 %6.8 %
Effect of foreign taxes(15.3)%(3.8)%(14.3)%
Acquisition-related2.2 %4.4 %(8.1)%
Research credit(2.9)%(4.5)%(3.0)%
Valuation allowance7.5 %(1.3)%0.8 %
Compensation-related0.5 %0.6 %(0.6)%
Non-deductible expenses0.4 %0.4 %0.4 %
Uncertain tax positions(0.5)%7.7 %1.2 %
Return to provision(0.1)%(2.1)%(5.7)%
Change in tax rates(0.6)%(0.2)%1.9 %
Other, net— %0.7 %0.4 %
19.8 %38.9 %3.3 %

99

Significant components of our deferred tax assets and liabilities are as follows:
 As of December 31,
 (in millions)
20232022
 Deferred Tax Assets:
 
Inventory costs and related reserves$30 $19 
Tax benefit of net operating losses and credits744 511 
Reserves and accruals305 304 
Restructuring-related charges14 6 
Litigation and product liability reserves88 103 
Investment write-down58 38 
Compensation related154 136 
Federal benefit of uncertain tax positions11 9 
Intangible assets3,394 3,668 
Capitalized R&D232 160 
Property, plant and equipment— 2 
 5,029 4,954 
Less: valuation allowance(1,220)(1,004)
 3,809 3,950 
 Deferred Tax Liabilities:
  
Property, plant and equipment24 — 
Unrealized gains and losses on derivative financial instruments66 117 
Other12 34 
102 151 
 Net Deferred Tax Assets
3,707 3,799 
Prepaid on intercompany profit315 264 
 Net Deferred Tax Assets and Prepaid on Intercompany Profit$4,022 $4,062 

Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit are included in the following locations within our accompanying consolidated balance sheets (in millions):
Location on Consolidated Balance SheetsAs of December 31,
Component20232022
Prepaid on intercompany profitPrepaid income taxes$315 $264 
Non-current deferred tax assetDeferred tax assets3,841 3,942 
Deferred Tax Assets and Prepaid on Intercompany Profit 4,157 4,206 
Non-current deferred tax liabilityDeferred tax liabilities134 144 
Deferred Tax Liabilities 134 144 
Net Deferred Tax Assets and Prepaid on Intercompany Profit$4,022 $4,062 

As of December 31, 2023 and 2022, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $540 million and $464 million, respectively. In addition, we had foreign tax net operating loss carryforwards and tax credits, the tax effect of which was $203 million as of December 31, 2023, and $47 million as of December 31, 2022. These tax attributes expire periodically beginning in 2024.

After consideration of all positive and negative evidence, we believe that it is more likely than not that a portion of our deferred tax assets will not be realized. As a result, we recorded a valuation allowance of $1.220 billion as of December 31, 2023, and $1.004 billion as of December 31, 2022. The increase in the valuation allowance as of December 31, 2023, compared to December 31, 2022, is primarily due to establishing valuation allowances on certain foreign deferred tax assets, mainly a capital loss carryforward in the UK. The income tax impact of the unrealized gain or loss component of other comprehensive income
100

and stockholders' equity was a benefit of $39 million in 2023, a charge of $56 million in 2022 and a charge of $81 million in 2021.

We obtain tax incentives through Free Trade Zone Regime offered in Costa Rica which allows 100 percent exemption from income tax in the first eight years of operations and 50 percent exemption in the following four years. This tax incentive resulted in income tax savings of $212 million in 2023, $162 million in 2022 and $149 million in 2021. The tax incentive for 100 percent exemption from income tax is expected to expire in 2027, with the 50 percent exemption to expire in 2031. The impact on Net income (loss) per common share - diluted was $0.15 for 2023, $0.11 for 2022 and $0.10 for 2021. We also benefit from tax incentives in Puerto Rico through a Grant of Industrial Tax Exemption (Grant) which applies a reduced tax rate to our taxable profits, resulting in income tax savings of $16 million in 2023, $21 million in 2022 and $27 million in 2021. This Grant expires in 2034, with an option to extend for an additional 15 years. The impact on Net income (loss) per common share - diluted was $0.01 in 2023 and $0.02 in the years 2022 and 2021. Additionally, we benefit from tax incentives in Malaysia which allow a full tax exemption on manufacturing of specific medical device products, which will expire in 2029, with an option to renew for an additional five-year term. This incentive has resulted in income tax savings of $20 million in 2023, $17 million in 2022 and $0 in 2021. The impact on Net income (loss) per common share - diluted was $0.01 in the years 2023 and 2022 and de minimis in 2021.

As of December 31, 2023, we had $467 million of gross unrecognized tax benefits, of which a net $395 million, if recognized, would affect our effective tax rate. As of December 31, 2022, we had $492 million of gross unrecognized tax benefits, of which a net $410 million, if recognized, would affect our effective tax rate. As of December 31, 2021, we had $255 million of gross unrecognized tax benefits, of which a net $177 million, if recognized, would affect our effective tax rate. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
 Year Ended December 31,
(in millions)202320222021
Beginning Balance$492 $255 $261 
Additions based on positions related to the current year65 88 8 
Additions based on positions related to prior years67 177 41 
Reductions for tax positions of prior years(114)(20)(36)
Settlements with taxing authorities(14)(1)(2)
Statute of limitation expirations(29)(8)(17)
Ending Balance$467 $492 $255 
We are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. We have concluded all U.S. federal income tax matters through 2018 and substantially all material state and local income tax matters through 2016. We have concluded substantially all foreign income tax matters through 2015.

In 2023, we received notification from the IRS that the examination of our 2017 and 2018 tax years was resolved. Due to the resolution of these tax years, we recorded a net tax benefit of $44 million to release the reserves related to these years. We paid tax of $16 million to the IRS reflecting the net balance of amounts due for the tax period including an increase to past transition tax installment payments for periods prior to 2023 and interest. The subsequent transition tax payments in 2024 and 2025 will be increased to reflect the final audit settlement.

We recognize interest and penalties related to income taxes as a component of income tax expense. We had $70 million accrued for gross interest and penalties as of December 31, 2023, $77 million as of December 31, 2022, and $43 million as of December 31, 2021. Net tax expense related to interest and penalties was immaterial in 2023, 2022 and 2021.

It is reasonably possible that within the next 12 months we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to $24 million.

For the year ended December 31, 2017, we were required under the TCJA to calculate a one-time transition tax based on our total post-1986 foreign subsidiaries' earnings and profits (E&P) that we previously deferred from U.S. income taxes. The amount of transition tax remains unchanged at approximately $937 million for both December 31, 2023 and 2022. We anticipate offsetting this liability against existing tax attributes, reducing the required payment to approximately $586 million, which will be remitted over an eight-year period. We have begun remitting the required installment payments, with a balance remaining of $264 million as of December 31, 2023. In addition, we have provided for U.S. state income taxes of $8 million on all U.S. dollar-denominated E&P accumulated through December 31, 2017, which constitutes the preponderance of our foreign
101

subsidiaries' accumulated E&P through December 31, 2017. We intend to indefinitely reinvest the unremitted foreign earnings of all other subsidiaries as of December 31, 2017, as well as all subsequent earnings generated by all of our foreign subsidiaries. Determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings and additional outside basis difference in these entities is not practicable.

We are subject to a territorial tax system under the TCJA, in which we are required to provide for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have established an accounting policy election to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense.

NOTE I – COMMITMENTS AND CONTINGENCIES

The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.

During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In addition, product liability, securities and commercial claims have been asserted against us and similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity.

In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) within our accompanying consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our accompanying consolidated statements of operations.

Our accrual for legal matters that are probable and estimable was $377 million as of December 31, 2023, and $443 million as of December 31, 2022, and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims related to our transvaginal surgical mesh products. A portion of this accrual is already funded through our qualified settlement fund, which is included in restricted cash and restricted cash equivalents in Other current assets of $130 million as of December 31, 2023, and $149 million as of December 31, 2022. Refer to Note A – Significant Accounting Policies and Note G – Supplemental Balance Sheet Information for additional information.

102

We recorded litigation-related net credits of $111 million in 2023, primarily related to the settlement of offensive patent litigation, and net charges of $173 million in 2022 and $430 million in 2021, primarily related to litigation associated with our transvaginal surgical mesh products, and other legal matters.

We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our financial covenant.

In management's opinion, we are not currently involved in any legal proceedings other than those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated.

Patent Litigation

On November 20, 2017, The Board of Regents, University of Texas System and TissueGen. Inc. (collectively, UT), served a lawsuit against us in the Western District of Texas. The complaint against the Company alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. UT primarily seeks a reasonable royalty. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. In April 2020, the United States Supreme Court denied the UT’s Petition for Certiorari. UT proceeded with its case against the Company in Delaware. In January 2023, a jury trial was held on the issue of whether the one UT patent still asserted in the case was valid and whether it was infringed by the Company. On January 31, 2023, a jury concluded that UT’s patent was valid and willfully infringed by the Company, and awarded UT $42 million in damages. Following the trial, UT has filed a motion seeking prejudgment interest and enhanced damages. The Company has filed a motion seeking judgment as a matter of law in its favor or alternatively a new trial.

Product Liability Litigation

Multiple product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us, predominantly in the United States, Canada, the United Kingdom, Scotland, Ireland, and Australia. Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. We have entered into individual and master settlement agreements in principle or are in the final stages of entering agreements with certain plaintiffs' counsel, to resolve the majority of these cases and claims. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. In addition, in April 2021 the Company's Board of Directors received a shareholder demand under section 220 of the Delaware General Corporation Law, for inspection of books and records related to mesh settlements. The Company has notified our insurer and retained counsel to respond to the demand.

We have established a product liability accrual for remaining claims asserted against us associated with our transvaginal surgical mesh products and the costs of defense thereof. We continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims, which we continue to vigorously contest. The final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.


103

Governmental Investigations and Qui Tam Matters

On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a “technical note,” announced that it was launching a formal administrative proceeding against Boston Scientific’s Brazilian subsidiary, Boston Scientific do Brasil Ltda. (BSB), as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. Under applicable guidance, BSB could be fined a percentage of BSB’s 2016 gross revenues. In August 2021, the investigating commissioner issued a preliminary recommendation of liability against all of the involved companies, and also recommended that CADE impose fines and penalties. However, on October 25, 2021, the CADE Attorney General's office recommended dismissal of the charges and allegations against BSB and the individual BSB employees who were still individual defendants. Subsequently, on March 30, 2022, the Federal Prosecutor’s office issued a non-binding recommendation that is contrary to the Attorney General’s recommendation. The full Commission is considering both of these recommendations but has not yet issued its decision. We continue to deny the allegations, intend to defend ourselves vigorously and will appeal any decision of liability by the full Commission to the Brazilian courts. During such an appeal, the decision would have no force and effect, and the Court would consider the case without being bound by CADE’s decision.

In March 2022, the Company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam. The Company has received related subpoenas for documents from the Office of the U.S. Attorney for the District of Massachusetts and the Securities and Exchange Commission. The Company is cooperating with government agencies while investigating these allegations.

On April 5, 2023, the Company received a subpoena from the U.S. Department of Justice (DOJ) that seeks documents and information relating to its ambulatory electrocardiography monitoring (AECG) business. The Company is cooperating with the DOJ in responding to this subpoena.

On December 18, 2023, the Company received a Civil Investigative Demand from the DOJ that relates to the provision of peripheral intervention services through office-based labs. The Company is cooperating with the DOJ in responding to the subpoena.

Other Proceedings

On December 4, 2020, Enrique Jevons, individually and on behalf of all others similarly situated, filed a class action complaint against the Company, Michael F. Mahoney and Daniel J. Brennan, stemming from the recall and retirement of the LOTUS Edge™ Aortic Valve System (LOTUS System) in United States District Court for the Eastern District of New York. On December 14, 2020, the parties agreed to transfer the case to the United States District Court for the District of Massachusetts. On December 16, 2020, Mariano Errichiello, individually and on behalf of all others similarly situated, filed a second, materially similar class action complaint against the Company, Michael F. Mahoney, Joseph M. Fitzgerald, and Daniel J. Brennan in the United States District Court for the District of Massachusetts. Subsequently, on March 30, 2021, the Court consolidated the two actions, and appointed Union Asset Management Holding AG as the lead plaintiff. The plaintiffs filed an Amended Complaint in June 2021 that seeks unspecified compensatory damages in favor of the alleged class as well as unspecified equitable relief. The Company filed a Motion to Dismiss in July 2021, which, in December 2022, the Court granted in part and denied in part. On October 23, 2023, the Company reached an agreement in principle with the lead plaintiff to settle the case. The settlement in principle is subject to approval of the Court. The Court granted the motion for preliminary approval of the proposed settlement on December 27, 2023, and scheduled a final approval hearing for April 23, 2024.

On December 15, 2020, the Securities and Exchange Commission’s Boston Regional Office (Boston SEC) notified the Company that it was conducting an investigation related to the Company’s decision to retire the LOTUS System and issued a voluntary request for documents and information related to that decision. On February 10, 2021, the Boston SEC issued a second voluntary request for additional documents and information. The Company cooperated fully with the requests, and on January 3, 2022, the SEC informed us that it was concluding its investigation and that it did not intend to recommend an enforcement action.

On February 8, 2021, the Company received a letter from The Vladimir Gusinsky Revocable Trust, a shareholder, demanding that the Company’s Board of Directors conduct an investigation into actions by the Company’s directors and executive officers regarding statements made about the effectiveness and commercial viability of the LOTUS System. The Trust subsequently
104

agreed to stay its demand, pending the outcome of any dispositive motion against the Amended Complaint in the class action complaint described above. The Company received letters on behalf of the Union Excavators Local 731 Pension Fund, Diane Nachbaur, and Frank Tripson, three stockholders of the Company, on July 26, 2021, July 29, 2021, and February 13, 2023, respectively, each demanding access to certain books and records of the Company, pursuant to Section 220 of the Delaware General Corporation Law, regarding the business, operations, effectiveness and commercial viability of the LOTUS system, and related items. On April 7, 2023, Diane Nachbaur filed a shareholder derivative complaint in the United States District Court for the District of Massachusetts against the Company, Michael F. Mahoney, Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, David Roux, John E. Sununu, Ellen M. Zane, Joseph M. Fitzgerald, Daniel J. Brennan, Shawn McCarthy, Ian Meredith, Kevin Ballinger, and Susan Vissers Lisa. On May 8, 2023, the Court stayed the case until the conclusion of the consolidated class action case. On October 18, 2023, Frank Tripson filed a shareholder derivative complaint in the Court of Chancery of the State of Delaware against the Company, Michael F. Mahoney, Daniel J. Brennan, Joseph M. Fitzgerald, Shawn McCarthy, Kevin Ballinger, Ian Meredith, Susan Vissers Lisa, Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, Stephen P. MacMillan, David Roux, John E. Sununu, and Ellen M. Zane. On December 15, 2023, the Court stayed that case until March 31, 2024.

Matters Concluded Since December 31, 2022

On October 28, 2015, the Company filed suit against Cook Group Limited and Cook Medical LLC (collectively, Cook) in the United States District Court for the District of Delaware (1:15-cv-00980) alleging infringement of certain Company patents regarding Cook’s Instinct™ Endoscopic Hemoclip. The Company was seeking lost profits, a reasonable royalty and a permanent injunction. The case was transferred to the District Court for the Southern District of Indiana. Cook filed Inter Partes Review (IPR) requests with the U.S. Patent and Trademark Office (USPTO) against four then-asserted patents, which resulted in the court staying the case until 2020. All IPRs concluded and confirmed the validity of certain claims of each challenged patent. In February 2023, the District Court issued summary judgment rulings dismissing certain claims and defenses. Trial on the remaining two asserted patents took place in May and June 2023 and the jury found that the Company’s patents were both valid and infringed and awarded the Company $158 million as lost profits. On August 4, 2023, the parties entered into a settlement to resolve all claims, and the case was dismissed on August 22, 2023.

NOTE J – STOCKHOLDERS' EQUITY

Preferred Stock

We are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders.

On May 27, 2020, we completed an offering of 10,062,500 shares of 5.50% Mandatory Convertible Preferred Stock, Series A (MCPS) at a price to the public and liquidation preference of $100 per share. The net proceeds from the MCPS offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses.

On June 1, 2023 (the Mandatory Conversion Date), all outstanding shares of MCPS automatically converted into shares of common stock. The conversion rate for each share of MCPS was 2.3834 shares of common stock. No action by the holders of the MCPS was required in connection with the mandatory conversion. Cash was paid in lieu of fractional shares in accordance with the terms of the MCPS. An aggregate of approximately 24 million shares of common stock, including shares of common stock issued to holders of MCPS that elected to convert prior to the Mandatory Conversion Date, were issued upon conversion of the MCPS. Following the mandatory conversion of the MCPS, there were no outstanding shares of MCPS.

Prior to the Mandatory Conversion Date during 2023, the Audit Committee of our Board of Directors (the Committee), pursuant to authority delegated to such committee by our Board of Directors, declared, and we paid, cash dividends of $28 million, or $1.3750 per MCPS share to holders representing dividend periods through May 2023.

105

Common Stock

We are authorized to issue 2.000 billion shares of common stock, $0.01 par value per share. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by our Board of Directors, and to share ratably in our assets legally available for distribution to our stockholders in the event of liquidation. Holders of common stock have no preemptive, subscription, redemption, or conversion rights. The holders of common stock do not have cumulative voting rights. The holders of a majority of the shares of common stock can elect all of the directors and can control our management and affairs. Prior to the Mandatory Conversion Date, holders of common stock were junior to holders of MCPS in terms of liquidation preference.

On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. We did not repurchase any shares of our common stock during 2023 and had the full amount available under the authorization as of December 31, 2023.

There were approximately 263 million shares in treasury as of December 31, 2023 and 2022.

NOTE K – STOCK INCENTIVE AND PURCHASE PLANS

Employee and Director Stock Incentive Plans

In 2020, our Board of Directors and stockholders approved amendments to our 2011 Long-Term Incentive Plan effective October 1, 2020 (Amended and Restated 2011 LTIP), authorizing for issuance up to 171 million shares of our common stock. The Amended and Restated 2011 LTIP covers officers, directors, employees and consultants and provides for the grant of restricted or unrestricted common stock, restricted stock units (RSUs), options to acquire our common stock, stock appreciation rights, performance awards (market-based and performance-based RSUs) and other stock and non-stock awards. Shares reserved under our current and former stock incentive plans totaled approximately 145 million as of December 31, 2023. The Executive Compensation and Human Resources Committee (the Committee) of the Board of Directors, consisting of independent, non-employee directors may authorize the issuance of common stock and cash awards under the Amended and Restated 2011 LTIP in recognition of the achievement of long-term performance objectives established by the Committee.

Non-qualified options issued to employees are generally granted with an exercise price equal to the market price of our stock on the grant date, vest over a three or four-year service period and have a ten-year contractual life. In the case of qualified options, if the recipient owns more than ten percent of the voting power of all classes of stock, the option granted will be at an exercise price of 110 percent of the fair market value of our common stock on the date of grant and will expire over a period not to exceed five years. Non-vested stock awards, including restricted stock awards (RSAs) and RSUs issued to employees are generally granted with an exercise price of zero and typically vest in four equal annual installments. These awards represent our commitment to issue shares to recipients after the vesting period. Upon each vesting date, such awards are no longer subject to risk of forfeiture and we issue shares of our common stock to the recipient.

The following presents the impact of stock-based compensation on our consolidated statements of operations:
 Year Ended December 31,
(in millions, except per share data)202320222021
Cost of products sold$12 $12 $11 
Selling, general and administrative expenses179 167 147 
Research and development expenses42 41 36 
 233 220 194 
Income tax (benefit) expense(35)(32)(29)
 $198 $188 $165 
Net impact per common share - basic$0.14 $0.13 $0.12 
Net impact per common share - assuming dilution$0.14 $0.13 $0.12 

Stock Options

We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions:
106


 Year Ended December 31,
 202320222021
Options granted (in thousands)
2,934 3,287 3,822 
Weighted-average exercise price$47.43 $44.02 $37.69 
Weighted-average grant-date fair value$16.83 $13.64 $10.77 
Black-Scholes Assumptions   
Expected volatility26 %28 %29 %
Expected term (in years, weighted)
6.36.15.9
Risk-free interest rate3.62%-4.75%1.42%-3.87%0.66%-1.20%

Expected Volatility

We use our historical volatility and implied volatility as a basis to estimate expected volatility in our valuation of stock options.

Expected Term

We estimate the expected term of options using historical exercise and forfeiture data. We believe that this historical data provides the best estimate of the expected term of new option grants.

Risk-Free Interest Rate

We use yield rates on U.S. Treasury securities for a period approximating the expected term of the award to estimate the risk-free interest rate in our grant-date fair value assessment.

Expected Dividend Yield

We have not historically paid cash dividends on our common stock and currently we do not intend to pay cash dividends on our common stock. Therefore, we have assumed an expected dividend yield of zero in our grant-date fair value assessment.

107

Information related to stock options under stock incentive plans are as follows:
Stock Options
(in thousands)
Weighted
Average
Exercise Price
Weighted Average
Remaining
Contractual Life
(in years)
Aggregate
Intrinsic
Value
(in millions)
Outstanding as of December 31, 202023,122 $24 
Granted3,822 38 
Exercised(4,796)13 
Cancelled/forfeited(699)26 
Outstanding as of December 31, 202121,448 $29 
Granted3,287 44 
Exercised(2,745)17 
Cancelled/forfeited(502)34 
Outstanding as of December 31, 202221,489 $32 
Granted2,934 47 
Exercised(3,325)25 
Cancelled/forfeited(249)44 
Outstanding as of December 31, 202320,850 $36 5.8462 
Exercisable as of December 31, 202313,532 31 4.5359 
Expected to vest as of December 31, 20237,052 44 8.199 
Total vested and expected to vest as of December 31, 202320,584 $36 5.8$458 
The total intrinsic value of stock options exercised was $89 million in 2023, $72 million in 2022 and $137 million in 2021.

Non-Vested Stock

We value RSAs and RSUs based on the closing trading value of our shares on the date of grant. Information related to non-vested stock awards is as follows:
Non-Vested
Stock Award Units
(in thousands)
Weighted Average
Grant-Date
Fair Value
Balance as of December 31, 20209,987 $34 
Granted4,240 39 
Vested(1)
(3,823)31 
Forfeited(658)36 
Balance as of December 31, 20219,745 $37 
Granted3,854 45 
Vested(1)
(3,482)36 
Forfeited(680)44 
Balance as of December 31, 20229,438 $41 
Granted3,958 49 
Vested(1)
(3,624)39 
Forfeited(485)44 
Balance as of December 31, 20239,287 $45 
(1) The number of shares vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.

The total vesting date fair value of shares that vested was approximately $171 million in 2023, $150 million in 2022 and $148 million in 2021.

108

Market-based RSU Awards

During 2023, 2022 and 2021 we granted market-based RSU awards to certain members of our senior management team. The number of shares ultimately issued to the recipient is based on the total stockholder return (TSR) of our common stock as compared to the TSR of the common stock of the other companies in the S&P 500 Health Care Index over a three-year period. The number of RSUs ultimately granted under this program range from 0 percent to 200 percent of the target number awarded to the participant as determined by achievement of the TSR criteria of the program. In addition, in general, award recipients must remain employed by us throughout the three-year period to attain the full amount of the market-based RSUs that satisfied the market performance criteria.

We determined the fair value of the market-based RSU awards to be approximately $13 million for 2023, $12 million for 2022 and $11 million for 2021. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions:
 202320222021
AwardsAwardsAwards
Stock price on date of grant$47.28 $44.19 $37.50 
Measurement period (in years)
2.92.92.9
Risk-free rate4.31 %1.71 %0.20 %
We recognize the expense on these awards in our consolidated statements of operations on a straight-line basis over the three-year measurement period.

Organic Net Sales Growth and Free Cash Flow Performance-based RSU Awards

During 2023, we granted organic net sales growth (ONSG) performance-based RSU awards to certain members of our senior management team. The attainment of these performance-based RSUs is based on our organic net sales growth over a three-year performance period beginning January 1, 2023 and ending December 31, 2025 against a target set by the Committee. The number of RSUs ultimately granted under this program range from 0 percent to 200 percent of the target number of performance-based RSUs awarded to the participant as determined by achievement of the performance criteria of the program.

During 2022 and 2021, we granted free-cash flow performance-based RSU awards to certain members of our senior management team. The attainment of these performance-based RSUs is based on our adjusted free cash flow (AFCF) measured against our goal set by the Committee, based on our internal annual financial plan performance for AFCF. AFCF was measured over a one-year performance period beginning January 1st of each year and ending December 31st. The number of RSUs ultimately granted under this program range from 0 percent to 150 percent of the target number of performance-based RSUs awarded to the participant as determined by achievement of the performance criteria of the program. In addition, in general, award recipients must remain employed by us throughout a three-year service period (inclusive of the one-year performance period) to attain the full amount of the performance-based RSUs that satisfied the performance criteria.

The following table presents our assumptions used in determining the fair value of our ONSG and AFCF awards currently expected to vest as of December 31, 2023:
2023 ONSG2022 AFCF2021 AFCF
Fair value, net of forfeitures to date (in millions)
$20 $7 $12 
Achievement of target payout(1)
200 %88 %131 %
Stock price used in determining fair value$47.28 $46.27 $42.48 
(1) Company's estimate of target payout as of December 31, 2023.

We recognize the expense on these awards in our consolidated statements of operations over the vesting period which is three years after the date of grant.

109

Expense Attribution

We recognize compensation expense for our stock incentive plan using a straight-line method over the substantive vesting period. Most of our stock awards provide for immediate vesting upon death or disability of the participant. In addition, our stock grants to employees provide for accelerated vesting of our stock-based awards, other than performance-based and market-based awards, upon retirement, if the stock award has been held for at least one year by the recipient. In accordance with the terms of our stock grants, for employees who will become retirement eligible prior to the vest date we expense stock-based awards, other than performance-based and market-based awards, over the greater of one year or the period between grant date and retirement-eligibility. The performance-based and market-based awards discussed above do not contain provisions that would accelerate the full vesting of the awards upon retirement-eligibility.

We recognize stock-based compensation expense for the value of the portion of awards that are ultimately expected to vest. FASB ASC Topic 718, Compensation – Stock Compensation allows forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock-based award. We have applied, based on an analysis of our historical forfeitures, a weighted-average annual forfeiture rate of approximately five percent to all unvested stock-based awards as of December 31, 2023, which represents the portion that we expect will be forfeited each year over the vesting period. We re-evaluate this analysis annually or more frequently if there are significant changes in circumstances and adjust the forfeiture rate as necessary. Ultimately, we will only recognize expense for those shares that vest.

Unrecognized Compensation Cost

We expect to recognize the following future expense for awards outstanding as of December 31, 2023:
 Unrecognized
 Compensation Cost
(in millions) (1)
Weighted Average Remaining
Vesting Period
(in years)
Stock options$40  
Non-vested stock awards203  
 $243 1.7
(1) Amounts presented represent compensation cost, net of estimated forfeitures.

Employee Stock Purchase Plan

In May 2022, our stockholders approved an additional 10 million shares that may be issued under our global employee stock purchase plan. Our global employee stock purchase plan provides for the granting of options to purchase up to 60 million shares of our common stock to all eligible employees. Under the global employee stock purchase plan, we grant each eligible employee, at the beginning of each six-month offering period, an option to purchase shares of our common stock equal to not more than ten percent of the employee’s eligible compensation or the statutory limit under the U.S. Internal Revenue Code. Such options may be exercised only to the extent of accumulated payroll deductions at the end of the offering period, at a purchase price equal to 85 percent of the fair market value of our common stock at the beginning or end of each offering period, whichever is less. As of December 31, 2023, there were approximately 9 million shares available for future issuance under the employee stock purchase plan.

Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:
Year Ended December 31,
202320222021
Shares issued or to be issued (in thousands)
2,623 2,850 2,578 
Range of purchase prices$39.11 -$45.51 $31.68 -$32.31 $29.98 -$36.11 
Expense recognized (in millions)
$29 $28 $24 

We use the Black-Scholes option-pricing model to calculate the grant-date fair value of shares issued under the employee stock purchase plan. We recognize expense related to shares purchased through the employee stock purchase plan ratably over the offering period.
110

NOTE L – WEIGHTED AVERAGE SHARES OUTSTANDING

Year Ended December 31,
(in millions)202320222021
Weighted average shares outstanding - basic1,453.0 1,430.5 1,422.3 
Net effect of common stock equivalents10.6 9.2 11.5 
Weighted average shares outstanding - diluted1,463.5 1,439.7 1,433.8 

The following securities were excluded from the calculation of weighted average shares outstanding - diluted because their effect in the periods presented below would have been antidilutive:
Year Ended December 31,
(in millions)202320222021
Stock options outstanding(1)
063
MCPS(2)
102424
(1) Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.
(2) Represents common stock issuable upon the conversion of MCPS. Refer to Note J – Stockholders' Equity for additional information.

We base Net income (loss) per common share - diluted upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options, stock awards and, prior to the Mandatory Conversion Date, our MCPS, from the calculation if the effect would be anti-dilutive. The dilutive effect of MCPS is calculated using the if-converted method. The if-converted method assumes that these securities were converted to shares of common stock at the beginning of the reporting period to the extent that the effect is dilutive.

In 2023, 2022 and 2021, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of earnings per share (EPS). Accordingly, Net income (loss) was reduced by cumulative Preferred stock dividends, as presented in our consolidated statements of operations, for purposes of calculating Net income (loss) attributable to Boston Scientific common stockholders. On June 1, 2023, all outstanding shares of MCPS automatically converted into shares of common stock.

NOTE M – SEGMENT REPORTING

In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve, and, in particular, benefit our Cardiology customers and patients. Following the reorganization, we have aggregated our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. We have revised prior periods to conform to the current year presentation. In accordance with FASB ASC Topic 280, Segment Reporting, we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments.

We measure and evaluate our reportable segments based on their respective net sales, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all based on internally-derived standard currency exchange rates to exclude the impact of foreign currency, which may be updated from year to year. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and European Union (EU) Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from operating income of reportable segments, they are included in reported Income (loss) before income taxes within our consolidated statements of operations and are included in the reconciliation below. Refer to Note N – Revenue for net sales by reportable segment presented in accordance with GAAP.

111

A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying consolidated statements of operations is as follows (in millions, except percentages). Prior period amounts have been restated at constant currency to conform to the current year presentation.
 Year Ended December 31,
Net sales202320222021
MedSurg$5,320 $4,805 $4,389 
Cardiovascular8,630 7,599 6,721 
Total net sales of reportable segments 13,949 12,404 11,109 
Other(1)
— (60)12 
Impact of foreign currency fluctuations291 338 766 
$14,240 $12,682 $11,888 

Year Ended December 31,
Income (loss) before income taxes202320222021
MedSurg$1,796 $1,458 $1,368 
Cardiovascular2,235 1,748 1,572 
Total operating income of reportable segments 4,031 3,206 2,940 
Unallocated amounts:
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(293)96 67 
Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs
(567)(789)(1,070)
Amortization expense(828)(803)(741)
Other(1)
— (60)3 
Operating income (loss) 2,343 1,649 1,199 
Other income (expense), net(358)(508)(123)
Income (loss) before income taxes$1,985 $1,141 $1,076 
(1)    In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments

Operating income of reportable segments as a percentage of net sales of reportable segmentsYear Ended December 31,
202320222021
MedSurg33.8 %30.3 %31.2 %
Cardiovascular25.9 %23.0 %23.4 %

Year Ended December 31,
Depreciation expense202320222021
MedSurg$103 $88 $91 
Cardiovascular263 245 261 
Consolidated depreciation expense$367 $333 $352 

112

As of December 31,
Total assets20232022
MedSurg$2,888 $2,501 
Cardiovascular5,988 5,205 
Total assets of reportable segments8,876 7,706 
Goodwill14,387 12,920 
Other intangible assets, net6,003 5,902 
All other corporate assets5,869 5,941 
 $35,136 $32,469 

As of December 31,
Long-lived assets20232022
U.S.$1,300 $1,241 
Ireland598 478 
Costa Rica373 246 
Other countries587 481 
Property, plant and equipment, net2,859 2,446 
Goodwill14,387 12,920 
Other intangible assets, net6,003 5,902 
Operating lease right-of-use assets in Other long-term assets
439 386 
 $23,688 $21,653 
113

NOTE N – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our consolidated statements of operations. Our business structure is organized into five operating segments. The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.
Year Ended December 31,
202320222021
BusinessesU.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Endoscopy$1,511 $970 $2,482 $1,341 $880 $2,221 1,222 $919 $2,141 
Urology1,369 595 1,964 1,257 516 1,773 1,120 463 1,583 
Neuromodulation736 240 976 715 202 917 713 196 909 
MedSurg3,617 1,805 5,422 3,312 1,599 4,911 3,055 1,578 4,633 
Interventional Cardiology Therapies743 1,674 2,417 744 1,485 2,228 778 1,431 2,209 
Watchman1,155 119 1,274 915 103 1,019 729 100 829 
Cardiac Rhythm Management1,405 813 2,218 1,337 763 2,100 1,214 805 2,019 
Electrophysiology370 430 800 275 310 585 128 237 365 
Cardiology3,673 3,036 6,709 3,271 2,662 5,932 2,850 2,572 5,422 
Peripheral Interventions1,135 975 2,110 1,048 850 1,899 996 824 1,820 
Cardiovascular4,808 4,011 8,819 4,319 3,512 7,831 3,846 3,396 7,242 
Other1
— — — — — (60)10 4 13 
Total Net Sales$8,425 $5,816 $14,240 $7,632 $5,111 $12,682 $6,911 $4,978 $11,888 
(1)    In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based.

Refer to Note M – Segment Reporting for information on our reportable segments.

Year Ended December 31,
Geographic Regions202320222021
U.S.$8,425 $7,632 $6,901 
Europe, Middle East and Africa2,856 2,526 2,518 
Asia-Pacific2,400 2,116 2,070 
Latin America and Canada560 469 386 
Other1
— (60)13 
Total Net Sales$14,240 $12,682 $11,888 
Emerging Markets(2)
$2,310 $1,968 $1,656 
(2) Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. We have revised prior period amounts to conform to the current year's presentation.

Deferred Revenue

Contract liabilities are classified within Other current liabilities and Other long-term liabilities within our accompanying consolidated balance sheets. Our deferred revenue balance was $577 million as of December 31, 2023 and $509 million as of December 31, 2022. Our contract liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiology business, for which revenue is recognized over the average service period based on device and patient longevity. Our contract liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor system, also within our Cardiology business, for which revenue is recognized over the average service period based on
114

device longevity and usage. We recognized revenue of $213 million in 2023 that was included in the above contract liability balance as of December 31, 2022. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

We capitalize sales force commissions related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE™ Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE™ Remote Monitoring Service. These fulfillment costs are amortized over the average service period.

Refer to Note A – Significant Accounting Policies for additional information on our accounting policies relating to revenue recognition.

NOTE O – CHANGES IN OTHER COMPREHENSIVE INCOME

The following table provides the reclassifications out of Other comprehensive income, net of tax attributable to Boston Scientific common stockholders:
(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2022$(1)$269 $1 $269 
Other comprehensive income (loss) before reclassifications(87)63 (10)(34)
(Income) loss amounts reclassified from accumulated other comprehensive income(8)(178)1 (185)
Total other comprehensive income (loss)(95)(115)(9)(219)
Balance as of December 31, 2023$(96)$154 $(8)$49 
(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2021$93 $206 $(36)$263 
Other comprehensive income (loss) before reclassifications(86)214 36 163 
(Income) loss amounts reclassified from accumulated other comprehensive income(8)(150)1 (157)
Total other comprehensive income (loss)(94)63 37 6 
Balance as of December 31, 2022$(1)$269 $1 $269 

Refer to Note D – Hedging Activities and Fair Value Measurements for further detail on our net investment hedges recorded in Foreign currency translation adjustment and our cash flow hedges recorded in Net change in derivative financial instruments.

The gains and losses on defined benefit and pension items before reclassifications and gains and losses on defined benefit and pension items reclassified from Accumulated other comprehensive income (loss), net of tax were reduced by income tax impacts of approximately $5 million in 2023 and approximately $6 million in 2022.

NOTE P – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our consolidated financial statements. During 2023, we implemented the following standards, none of which had a material impact on our financial position or results of operations.

115

ASC Update No. 2022-01

ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. Update No. 2022-01 expands the current single-layer method to allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods. We adopted Update No. 2022-01 on a prospective basis.

ASC Update No. 2022-02

ASC Update No. 2022-02, Financial Instruments- Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, as well as amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13. We adopted Update No. 2022-02 on a prospective basis.

ASC Update No. 2022-04

ASC Update No. 2022-04, Liabilities— Supplier Finance Programs (Subtopic 405-50) enhances the transparency of supplier finance programs by requiring that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude. We adopted Update No. 2022-04 on a retrospective basis to each period in which a balance sheet is presented, except for the amendment on roll forward information, which we will apply prospectively beginning January 1, 2024.

Standards to be Implemented

In June 2022, the FASB issued ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. Update No. 2022-03 clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. We do not expect the adoption to have a material impact on our financial position or results of operations.

In November 2023, the FASB issued ASC Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. Update No. 2023-07 requires disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss in addition to disclosure of amounts for other segment items and a description of its composition. Update No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. We do not expect the adoption to have a material impact on our financial position or results of operations.

In December 2023, the FASB issued ASC Update No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Update No. 2023-09 aims to enhance the transparency and decision usefulness of income tax disclosures. Update No. 2023-09 modifies the rules on income tax disclosures to require entities to disclose (1) specific categories in the rate reconciliation, (2) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (3) income tax expense or benefit from continuing operations (separated by federal, state, and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state and local jurisdictions, among other changes. Update No. 2023-09 is effective for fiscal years beginning after December 15, 2024. We expect to adopt Update No. 2023-09 prospectively. We are currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and related disclosures.

No other new accounting pronouncements issued or effective in the period had or are expected to have a material impact on our consolidated financial statements.








116

NOTE Q – EMPLOYEE RETIREMENT PLANS

Defined Benefit Pension Plans

Domestic Retirement Plans

Following our 2006 acquisition of Guidant, we assumed the Guidant Supplemental Retirement Plan, a frozen, non-qualified defined benefit plan for certain former officers and employees of Guidant. The Guidant Supplemental Retirement Plan was partially funded through a Rabbi Trust that contains segregated company assets within restricted cash used to pay the benefit obligations related to the plan.

We also maintain an Executive Retirement Plan, a defined benefit plan covering executive officers and other key contributors. Participants may retire with benefits once retirement conditions have been satisfied.

U.K. Plan

As a result of our 2019 acquisition of BTG plc. (BTG), we assumed a benefit obligation related to a defined benefit pension plan sponsored by BTG for eligible United Kingdom employees. During the second quarter of 2022, we transferred the benefit obligation and associated assets of the pension plan to third party insurers, and as a result, were relieved from primary responsibility of the benefit obligation and the related plan assets. The transaction did not have a material impact on our financial position or results of operations.

Other International Retirement Plans

In addition, we maintain retirement plans covering certain international employees.

We use a December 31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the consolidated balance sheets, recognizing changes primarily through OCI. As of December 31, 2023 and 2022, the funded status of our plans were unfunded or underfunded in aggregate. The outstanding obligation is as follows:
 As of December 31, 2023
(in millions)
Accumulated Benefit Obligation (ABO)Projected
Benefit
Obligation (PBO)		Fair value of Plan AssetsUnfunded/Underfunded
PBO Recognized
Domestic Retirement Plans$54 $59 $— $59 
Other International Retirement Plans145 159 101 58 
 $199 $218 $101 $117 

 As of December 31, 2022
(in millions)
Accumulated Benefit Obligation (ABO)Projected
Benefit
Obligation (PBO)		Fair value of Plan AssetsUnfunded/Underfunded PBO Recognized
Domestic Retirement Plans$50 $55 $— $55 
Other International Retirement Plans140 152 101 51 
 $190 $207 $101 $105 

117

A reconciliation of the changes in the PBO for our retirement plans is as follows:
 Year Ended December 31,
(in millions)20232022
Beginning obligations$207 $502 
Service costs10 13 
Interest costs7 3 
Actuarial (gain) loss(4)(54)
Plan curtailments/settlements(0)(191)
Plan amendments and assumption changes6 (25)
Benefits paid(10)(6)
Impact of foreign currency fluctuations3 (37)
Ending obligation$218 $207 

The critical assumptions associated with our employee retirement plans for 2023 are as follows:
Weighted Average Discount RateWeighted Average Expected Return
Weighted Average Rate of Compensation Increase(1)
Domestic Retirement Plans4.89%n/a2.00%
Other International Retirement Plans2.85%2.66%3.00%
(1)    Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.

The critical assumptions associated with our employee retirement plans for 2022 are as follows:
Weighted Average Discount RateWeighted Average Expected Return
Weighted Average Rate of Compensation Increase(1)
Domestic Retirement Plans5.32%n/a2.00%
Other International Retirement Plans2.62%2.27%3.00%
(1) Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.

A reconciliation of the changes in the fair value of plan assets for our funded retirement plans is as follows:
 Year Ended December 31,
(in millions)20232022
Beginning fair value$101 $336 
Actual return on plan assets(1)(2)
Employer contributions11 16 
Participant contributions1 1 
Plan curtailments/settlements(0)(185)
Actuarial gain (loss)(0)(25)
Benefits paid(10)(9)
Impact of foreign currency fluctuations0 (32)
Ending fair value$101 $101 

For our defined benefit plans, we base our discount rate on the rates of return available on high-quality bonds with maturities approximating the expected period over which benefits will be paid. The rate of compensation increase is based on historical and expected rate increases. We base our rate of expected return on plan assets on historical experience, our investment guidelines and expectations for long-term rates of return. Our assets are invested in a variety of securities, primarily equity securities and government bonds. These securities are considered Level 1 and Level 2 investments.

118

Expected benefit payments are estimated based on the same assumptions used in determining our benefit obligation as of December 31, 2023. Actual benefit payments will depend on future employment and compensation, average years employed and average life spans, in addition to other factors. Changes in any of these factors could significantly impact these estimated future benefit payments. Benefit payments expected to be paid during the next ten years for our Domestic Retirement Plans and our Other International Retirement Plans are as follows:
(in millions)Post Retirement Benefits
2024$16 
202513 
202614 
202715 
202815 
2029 - 203373 

Defined Contribution Plan

We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $135 million in 2023, $123 million in 2022 and $118 million in 2021.
119

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer (CEO) and Executive Vice President and Chief Financial Officer (CFO), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2023 pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended. Disclosure controls and procedures are designed to ensure that material information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and ensure that such material information is accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure. Based on their evaluation, our CEO and CFO concluded that as of December 31, 2023, our disclosure controls and procedures were effective.
Management’s Annual Report on Internal Control over Financial Reporting
Management’s annual report on our internal control over financial reporting is included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K.
Report of Independent Registered Public Accounting Firm on Internal Control over Financial Reporting
The report of Ernst & Young LLP on our internal control over financial reporting is included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K.
Changes in Internal Control over Financial Reporting

During 2022, we began a multi-year implementation of a new global enterprise resource planning (ERP) system, which will replace our existing system. The implementation is expected to occur in phases over the next several years. The portion of the transition to the new ERP system which we have completed to date resulted in changes in our internal control over financial reporting during the year ended December 31, 2023. As future phases are implemented, we expect the changes to have a material impact on our internal controls over financial reporting and we will evaluate whether these process changes necessitate further changes in the design of and testing for effectiveness of internal controls over financial reporting.

ITEM 9B. OTHER INFORMATION

On November 6, 2023, John Bradley Sorenson, our Executive Vice President, Global Operations, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Sorenson’s plan covers the sale of 33,938 shares of our common stock to be acquired upon the exercise of stock options. Transactions under Mr. Sorenson’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Sorenson’s plan will terminate on the earlier of December 31, 2024 or the date all shares subject to the plan have been sold.

On November 17, 2023, Wendy Carruthers, our Executive Vice President, Human Resources, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Ms. Carruthers’ plan covers the sale of 76,113 shares of our common stock, including 46,893 shares to be acquired upon the exercise of stock options. Transactions under Ms. Carruthers’ plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Ms. Carruthers’ plan will terminate on the earlier of December 31, 2024 or the date all shares subject to the plan have been sold.

On November 22, 2023, Arthur Butcher, our Executive Vice President and Group President, MedSurg and Asia Pacific, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Butcher’s plan covers the sale of up to 77,687 shares of our common stock, including up to 54,514 shares to be acquired upon determination and/or vesting of performance share units and restricted share units, and 16,742 shares to be acquired upon the exercise of stock options. Transactions under Mr. Butcher’s plan are based upon pre-established dates and stock price thresholds and will only occur upon
120

the expiration of the applicable mandatory cooling-off period. Mr. Butcher’s plan will terminate on the earlier of January 31, 2025 or the date all shares subject to the plan have been sold.

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

Not applicable.
121

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
The information required by this Item is set forth in our Proxy Statement for the 2024 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2023 and is incorporated into this Annual Report on Form 10-K by reference.

ITEM 11. EXECUTIVE COMPENSATION
The information required by this Item is set forth in our Proxy Statement for the 2024 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2023 and is incorporated into this Annual Report on Form 10-K by reference.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
The information required by this Item is set forth in our Proxy Statement for the 2024 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2023 and is incorporated into this Annual Report on Form 10-K by reference.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE
The information required by this Item is set forth in our Proxy Statement for the 2024 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2023 and is incorporated into this Annual Report on Form 10-K by reference.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
Our independent registered public accounting firm is Ernst & Young LLP, New York, NY, (PCAOB ID 42).
The information required by this Item is set forth in our Proxy Statement for the 2024 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2023 and is incorporated into this Annual Report on Form 10-K by reference.

122

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
(a)(1) Financial Statements.
The response to this portion of Item 15 is set forth under Item 8.
(a)(2) Financial Statement Schedules.
The response to this portion of Item 15 (Schedule II) follows the signature page to this report. All other financial statement schedules are not required under the related instructions or are inapplicable and therefore have been omitted.
(a)(3) Exhibits (* documents filed or furnished with this report, # compensatory plans or arrangements)
  
EXHIBIT
NO.
 TITLE
 
2.1
   
3.1 
3.2
 
3.3
3.4
4.1 Specimen Certificate for shares of the Company's Common Stock (incorporated herein by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-1. File No. 33-46980).
 
4.2 
 
4.3 
 
4.4 
 
4.5 
123

 
4.6 
 
4.7 
 
4.8 
 
4.9 
 
4.10
4.11
4.12
4.13
4.14
4.15
4.16
4.17
4.18
124

4.19
4.20
4.21
4.22
4.23
4.24
10.1 
10.2
 
10.3 
 
10.4
10.5 
Transaction Agreement, dated as of January 8, 2006, as amended, between the Company and Abbott Laboratories (incorporated herein by reference to Exhibit 10.47, Exhibit 10.48, Exhibit 10.49 and Exhibit 10.50 to the Company's Annual Report on Form 10-K for year ended December 31, 2005, filed on March 1, 2006, and Exhibit 10.1 to the Company's Current Report on Form 8-K filed on April 7, 2006, File No. 1-11083).
 
10.6
 
10.7 
 
125

10.8 
 
10.9 
Form of Boston Scientific Corporation Excess Benefit Plan, as amended (incorporated herein by reference to Exhibits 10.1 and 10.4 to the Company's Current Reports on Form 8-K filed on July 5, 2005 and December 22, 2008, respectively, File No. 1-11083).#
 
10.10
10.11 
 
10.12
10.13 
 
10.14 
10.15 
 
10.16 
 
10.17 
 
10.18 
10.19 
10.20
10.21 
 
126

10.22 
 
10.23 
 
10.24 
 
10.25 
 
10.26 
 
10.27 
 
10.28
10.29
10.30*
10.31
10.32
10.33
10.34
10.35
127

10.36
10.37
10.38
10.39
10.40
10.41
10.42
10.43
10.44
10.45
10.46
10.47
128

10.48
10.49
10.50
10.51
10.52
10.53
10.54
10.55
10.56
10.57
10.58
10.59
10.60
10.61
129

10.62
10.63
10.64
10.65
10.66
10.67
10.68
10.69
10.70
10.71
10.72
10.73
130

10.74
10.75
10.76
10.77
10.78
10.79
10.80
10.81
10.82
10.83
10.84
10.85
10.86
131

10.87
10.88
10.89
10.90
10.91
10.92
10.93
10.94
21*
23*
31.1*
31.2*
32.1*
32.2*
97*
101.SCH*
Inline XBRL Taxonomy Extension Schema Document.
101.CAL*
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*
Inline XBRL Taxonomy Extension Definition Linkbase Document.
132

101.LAB*
Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101)

ITEM 16. FORM 10-K SUMMARY
None.
133

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
Dated: February 20, 2024Boston Scientific Corporation
 By: /s/ Daniel J. Brennan
     
    Daniel J. Brennan
    Executive Vice President and Chief Financial Officer
    (duly authorized officer and principal financial officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
     
Dated: February 20, 2024 By: /s/ Daniel J. Brennan
    Daniel J. Brennan
    Executive Vice President and Chief Financial Officer
    (Principal Financial Officer)
     
Dated: February 20, 2024 By: /s/ Michael F. Mahoney
     
    Michael F. Mahoney
    Director, Chairman of the Board,
President and Chief Executive Officer
    (Principal Executive Officer)
     
Dated: February 20, 2024 By:  /s/ Jonathan R. Monson
    Jonathan R. Monson
    Senior Vice President, Global Controller and Chief Accounting Officer
    (Principal Accounting Officer)
     
Dated: February 20, 2024 By: /s/ Nelda J. Connors
     
    Nelda J. Connors
    Director
     
134

     
Dated: February 20, 2024 By: /s/ Charles J. Dockendorff
     
    Charles J. Dockendorff
    Director
     
     
Dated: February 20, 2024 By: /s/ Yoshiaki Fujimori
     
    Yoshiaki Fujimori
    Director
     
     
Dated: February 20, 2024 By:  /s/ Edward J. Ludwig
     
    Edward J. Ludwig
    Director
     
     
Dated: February 20, 2024 By: /s/ Jessica L. Mega
     
    Jessica L. Mega
    Director
     
     
Dated: February 20, 2024 By: /s/ Susan E. Morano
     
    Susan E. Morano
    Director
     
     
Dated: February 20, 2024 By: /s/ David J. Roux
    David J. Roux
    Director
     
135

     
Dated: February 20, 2024 By: /s/ John E. Sununu
     
    John E. Sununu
    Director
     
     
Dated: February 20, 2024 By: /s/ David S. Wichmann
     
    David S. Wichmann
    Director
     

     
Dated: February 20, 2024 By: /s/ Ellen M. Zane
     
    Ellen M. Zane
    Director
     
136

Schedule II
VALUATION AND QUALIFYING ACCOUNTS
Description (in millions)
Balance at
 Beginning of Year
Credit loss exposure(1)
Write-offs(2)
Balance at
End of Year
Year Ended December 31, 2023:
Allowances for credit losses$109 50 (48)$110 
Year Ended December 31, 2022:
Allowances for credit losses$108 35 (35)$109 
Year Ended December 31, 2021:
Allowances for credit losses$105 28 (25)$108 

(1) We record credit loss reserves to Allowance for credit losses when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. Subsequent credit loss reserves are recorded when deemed uncollectible. Amounts shown within credit loss exposure above were established through selling, general and administrative expense.
(2) Represents actual write-offs of uncollectible accounts.


137
 EX-10.30 2 exhibit1030-amendandrestat.htm EX-10.30 Document
Exhibit 10.30

THE BOSTON SCIENTIFIC CORPORATION
EXECUTIVE RETIREMENT PLAN As Amended and Restated Effective June 1, 2022
Section 1—Nature and Purpose
Boston Scientific Corporation maintains the Boston Scientific Corporation Executive Retirement Plan, which is an unfunded, nonqualified deferred compensation plan for a select group of management and highly compensated employees. The Plan is intended to be construed and administered in accordance with the Section 409A Standards. The Plan's purpose is to provide a consistent formula and system for making supplemental retirement payments to eligible Participants upon their Retirement from Covered Positions (or other eligible classifications). This document reflects the terms of the Plan in effect as of June 1, 2022, and it replaces and supersedes any prior Plan document.
The Glossary in Section 15 defines the capitalized terms used in the Plan (or tells you where in this document to find a term's meaning). When you see a capitalized term, turn to the Glossary to find its meaning.
Section 2—Participants and Eligibility Classifications
You will be a Participant in the Plan only if you are a Regular Employee who satisfies all of the requirements of one of the following eligibility classifications:
•You are serving in a Covered Position, which is any position on the Executive Committee, immediately preceding your Retirement and have consecutively served in a Covered Position for the one-year period immediately prior to your Retirement; or
•You are serving in a Transitional Position immediately preceding your Retirement and have consecutively served in a Covered Position for the one-year period immediately prior to serving in the Transitional Position; or
•You are a Grandfathered Individual, which means that you satisfy all of the following conditions:
oYou have completed at least 10 continuous Years of Service prior to your Retirement date, and
oImmediately prior to your Retirement, you are serving in a Special Assignment, which is a Regular Position that you assume, at the express written request of the Chief Executive Officer or his or her designee, immediately following a period of at least five (5) consecutive Years of Service in a Covered Position (the “Five-Year Covered Position Period”), and
oThe Compensation Committee, in its sole discretion, expressly approves your inclusion in an eligibility classification under the Plan as a Grandfathered Individual in connection with your acceptance of the Special Assignment.
For purposes of determining whether you have served in a Covered Position for either of the required one-year periods specified in the first two classifications above (each a “One-Year Covered Position Period”), your consecutive service in two Covered Positions during the one-year period will be combined. Similarly, for purposes of determining whether you have served in a Covered Position for a Five-Year Covered Position Period, your consecutive service in two or more Covered Positions during the period will be combined.
Section 3—Retirement and Conditions for Receipt of Benefits
For purposes of the Plan, Retirement (or to Retire) means your Separation From Service with the Company and all of its Affiliates, other than a termination of your employment by BSC for Cause, after you have satisfied all of the following conditions:
•The sum of your age and number of your Years of Service exceeds 65;
    1

•You are at least age 55 and have completed at least five (5) continuous Years of Service; and
•You have been continuously employed by Boston Scientific during the 5-year period immediately preceding your Separation From Service. For this purpose, “Boston Scientific” does not include any business entity that was acquired by or otherwise became an Affiliate of the Company during that 5-year period.
Upon your Retirement, you will not be entitled to a benefit under this Plan unless all of the following conditions are satisfied:
•You qualify as a Participant under the terms of Section 2.
•You timely sign, and do not timely revoke, a Separation Agreement. The Separation Agreement will be a written agreement, in a form determined by the Company, that will contain, among other things, a release of employment claims against BSC and certain related entities and individuals, the restrictive covenants described in Section 12, and agreements by you not to use or disclose confidential information or make detrimental communications, to cooperate in litigation and other proceedings, and to return all BSC property.
•You comply with the restrictive covenants described in Section 12 and included in your Separation Agreement. You will be required to repay your Plan benefit if you breach these covenants. See Section 12 for details.
Section 4—Years of Service
For purposes of the Plan, except as otherwise provided in this Section 4, your Years of Service will be calculated from your date of hire with BSC through your last day worked in a Regular Position prior to your Retirement. Partially completed Years of Service will be pro-rated based on calendar days, and calculated to the second decimal point. If your date of hire originated at a predecessor or acquired company of BSC that has been accepted by BSC during your employment as part of any “bridge-of-service” or related policy, your service with the predecessor or acquired company will count as employment with BSC for purposes of calculating your total Years of Service (subject to the non-duplication provision in the last paragraph of Section 5).
Notwithstanding any other provision of the Plan, the following will not be included, and will be disregarded, in calculating your Years of Service for purposes of the Plan:
•service to BSC other than in a Regular Position (for example, service as an independent contractor or other non-employee capacity under a consulting or similar arrangement); and
•any vacation accrued, but not taken, at the time of Retirement.
If you are on long-term disability status immediately prior to your Retirement, your Years of Service will be calculated to your last day on regular BSC payroll under the terms of BSC’s short-term disability plan.
Section 5—Amount of Benefit
If you qualify as a Participant who Retires under the Plan and you satisfy the conditions specified in Section 3, you will be eligible to receive the following supplemental retirement benefit:
•If you have been serving as an Executive Committee member for the entire One-Year Covered Position Period, the gross amount of your benefit will be equal to 2.5 months of your base salary, multiplied by the number of your Years of Service, to a maximum benefit of 36 months of base salary.
•If you are a Grandfathered Individual serving in a Special Assignment immediately prior to your Retirement Date, the gross amount of your benefit will be equal to 2.5 months of
2


your base salary, multiplied by the number of your Years of Service, to a maximum benefit of 36 months of base salary
If you serve in a Transitional Position immediately prior to your Retirement, then for purposes of calculating your benefit, your base salary will be your base salary in effect immediately prior to your assumption of the Transitional Position.
If you are a Grandfathered Individual serving in a Special Assignment immediately prior to your Retirement, then for purposes of calculating your benefit, your base salary will be the greater of (1) your base salary in effect immediately prior to your Retirement, or (2) your base salary in effect immediately prior to your assumption of the Special Assignment.
Non-Duplication Provision: Benefits are not cumulative. For example, if you Retire more than once from BSC, in calculating the benefit due you upon each Retirement, only your Years of Service accumulated since your most recent prior Retirement will be considered.
Section 6—Form and Timing of Benefit Payment
If you are entitled to a supplemental retirement benefit under Section 5, your benefit will be paid to you in a single lump sum payment in the first payroll period after the last day of the 6-month period following your actual Retirement date. No annuity or other periodic or irregular partial payments will be made under the Plan. Payment will be made from the same payroll and in the same currency in which your base salary was paid immediately prior to your Retirement.
Section 7—Death-in-Service
If you die while employed by BSC, and you would have been a Participant under Section 2 if you had Retired on the date of your death, then a death benefit will be payable to your designated beneficiary(ies) as nominated under BSC’s group term life insurance plan, unless you have made a separate beneficiary designation for this Plan. In the absence of any beneficiary designation, the benefit will be paid to your estate. The gross amount of the death benefit payment will be equal to the gross amount of the supplemental retirement benefit that would have been payable to you under Section 5 had you Retired on the date of your death and satisfied all of the conditions specified in Section 3. Payment will be made in a lump sum in cash within 60 days following your death and will be paid in the same currency in which your base salary was last paid prior to your death.
Section 8—No Integration with Other Retirement Benefits
The benefits described in the Plan are not reduced, offset, or otherwise integrated with any other retirement benefits to which you may be entitled. This includes, but is not limited to, benefits payable under BSC’s 401(k) plan, or U.S. Social Security payments. Notwithstanding the foregoing, if you become eligible to receive a benefit under this Plan, you will not be eligible for any payments or benefits under any existing BSC severance plan or layoff notification plan (such as, by way of example and without limitation, severance pay, outplacement assistance, COBRA subsidies or other coverage continuation or assistance, and any other benefit providing transition assistance to separated employees).
Section 9—Plan Assets and Tax Status
The Plan is a non-qualified retirement plan for tax purposes. Accordingly, as a Participant you will not have any vested right in any benefits until such time as they are paid. The Plan is not externally funded or insured, and no individual Participant accounts are maintained. For financial accounting purposes, a book reserve is made for the projected liability of this Plan; however, all amounts are unsecured and unsegregated. As such, they are subject to the claims of BSC’s creditors in case of bankruptcy or other legal action.
Section 10—Loans and In-Service Withdrawals Prohibited
No loans or other advance withdrawals may be made with respect to of any portion of the benefits described in this Plan.
3


Section 11—Withholding of Tax
Notwithstanding anything to the contrary in this Plan, all payments required to be made by BSC under the Plan to you; your estate or beneficiaries; or the estate of any of your beneficiaries will be subject to the withholding of such amounts as BSC may reasonably determine that it is required to withhold pursuant to applicable federal, state or local law or regulation.
Section 12—Restrictive Covenants
As a condition of receiving benefits under the Plan, you must comply with the following restrictive covenants, which will be expressly included in your Separation Agreement:
a)During the 12-month period beginning as of your Retirement date (or such other period as is specified in your Employment Agreement), you cannot engage in solicitation of customers or employees of Boston Scientific, as defined in the Employment Agreement, unless the Chief Executive Officer or his or her designee gives prior written approval.  In the absence of an Employment Agreement defining these terms, the Separation Agreement shall set forth the definition of solicitation and of BSC customers and employees as set forth in Boston Scientific’s then current form of Employment Agreement for similar level employees.
b)During the 12-month period beginning as of your Retirement date (or such other period as is specified in your Employment Agreement), you cannot directly or indirectly, engage in unfair competition with Boston Scientific, as defined in the Employment Agreement unless the Chief Executive Officer or his or her designee gives prior written approval. In the absence of an Employment Agreement defining these terms, the Separation Agreement shall set forth the definition of unfair competition as set forth in Boston Scientific’s then current form of Employment Agreement for similar level employees.
c)In the event you breach any of the provisions of this Section 12, you must repay to the Company all of the amounts paid under this Plan, and you will also be liable for any damages that a court may determine, and you will be subject to injunctive relief and any other relief that a court may award as set forth in Boston Scientific’s then current form of Employment Agreement for similar level employees.
Section 13—Administration and Modification of the Plan
The Plan is administered by the Senior Human Resources Officer (the “Administrator”) at the Company's headquarters, 300 Boston Scientific Way, Marlborough, Massachusetts 01752.
The Company reserves the right, by action of the Board or its designee, to amend, modify, change or eliminate the Plan, upon notice to Participants prior to their Retirement, at the Board’s sole discretion.
Section 14—Claims Procedure
If you (or your beneficiary) believe that you are entitled to a Plan benefit that has not been provided or to a greater or different benefit than has been provided, or if you disagree with any other action taken by the Administrator, then you (or your beneficiary) or your authorized representative may file a claim by writing to the Administrator. The Administrator will notify you of its decision on your claim within 90 days after the Administrator receives the claim.
If special circumstances require an extension of the 90-day decision period, the Administrator may extend the period by up to an additional 90 days, by notifying you, in writing, of the extension, the reason for it, and the date by which the Administrator expects to render a decision on the claim. If the Administrator denies the claim, in whole or in part, the Administrator's written notice of its decision will include the following:
•the specific reason(s) for denying the claim;
•specific reference to the Plan provision(s) on which the denial is based;
4


•a description of any additional material or information that you may need to provide with respect to the claim, with an explanation of why the material or information is necessary; and
•an explanation of your right to appeal the claim denial under the Plan's review procedures and your right to bring a civil court action following any further denial of your claim on review.
If your claim is denied, in whole or in part, you may appeal to the Administrator for a full and fair review of the denial. For these purposes, you may consider your claim to have been denied if the Administrator does not respond to your claim within 90 days of having received it. The following rules apply to your right of appeal:
•You or your duly authorized representative must file a written request for review with the Administrator within 60 days after you receive the Administrator's written denial of your claim or within 150 days after the Administrator received your claim if you have not received a written response.
• Your written request for review must be signed by you or your authorized representative.
•Upon reasonable request and free of charge, you may review, or obtain copies of, records, documents, or other information in the Administrator's possession or control relevant to your claim.
•You may also submit issues, arguments, and other comments in writing to the Administrator, along with any documentary evidence in support of your claim.
• You may have representation throughout the appeal procedure.
In its review of your claim, the Administrator will take into account all comments, document, records, and other information you submit, regardless of whether the information was submitted or considered in the initial claim decision. The Administrator will give you its decision on your appeal, in writing, within 60 days after it receives your written request for review. If special circumstances require extension of the 60-day period, the Administrator may extend the period for an additional 60 days by notifying you, in writing, of the extension, the reason for it, and the date by which you nay expect a decision.
If the Administrator again denies your claim on appeal, in whole or in part, it will notify you, in writing, and the notice will include the following:
•the specific reason(s) for the denial;
•specific references to the Plan provision(s) on which the denial is based;
•a description of your right to receive, upon request and free of charge, reasonable access to, and copies of, all documents, records, and other information in the Administrator's possession or control relating to your claim;. and
•an explanation of your right to bring a civil court action under Section 502(a) of ERISA.
Section 15—Glossary
When used in this document, the following words and terms have the following meanings, unless the context clearly indicates a different meaning.
Administrator has the meaning given in Section 13.
Affiliate means any corporation, trade or business that is considered to be a single employer with the Company under Code sections 414(b), (c), (m), or (o), such as a wholly-owned (or at least 80%-owned) subsidiary of the Company.
5


Beneficiary means the person who, under the provisions of Section 7, may be entitled to receive a benefit under this Plan in the event you die while employed by BSC and satisfy the other applicable conditions imposed by the Plan.
Board means the Board of Directors of the Company.
Boston Scientific means the (1) Company and (2) its Affiliates other than any business entity that was acquired by, merged into, or otherwise became an Affiliate of the Company within the 5-year period immediately preceding your Separation From Service.
BSC means the Company and its Affiliates.
Cause means, with respect to you, (a) your conviction of, or your failure to contest prosecution for, a felony, or (b) your misconduct or dishonesty that is harmful to BSC's business or reputation.
Chief Executive Officer means either the Chief Executive Officer of the Company or the Chief Executive Officer and President of the Company or the Chairman, Chief Executive Officer and President of the Company.
Code means the Internal Revenue Code of 1986, as amended, and its interpretive regulations.
Company means Boston Scientific Corporation.
Compensation Committee means the Executive Compensation and Human Resources Committee of the Board.
Covered Position means any position on the Executive Committee.
Employment Agreement means the Boston Scientific Agreement Concerning Employment for U.S. Employees (ACE), or if you have not acknowledged the ACE, your Contract of Employment or other written employment contract or offer letter attachment governing and setting forth the terms and conditions of your employment with BSC.
ERISA means the Employee Retirement Income Security Act of 1974, as amended, and interpretive rules and regulations.
Executive Committee means the Executive Committee of the Company (or a successor to that committee).
Five-Year Covered Position Period is defined in Section 2.
Grandfathered Individual is defined in Section 2.
One-Year Covered Position Period is defined in Section 2.
Participant has the meaning given in Section 2.
Plan means the Boston Scientific Executive Retirement Plan, as set forth in this document and as amended from time to time.
Regular Employee means a common law employee of BSC who is hired for an indefinite term and serving in a Regular Position.
Regular Position means a position classified by the Company as a regular full-time or regular part time common law employee of BSC regularly scheduled to work at least 20 hours per week. A Regular Position does not include any position not classified as a common law employee (such as a consultant, independent contractor, or leased employee) or any position not regularly scheduled to work at least 20 hours per week.
Retirement/Retire is defined in Section 3.
6


Section 409A Standards means the applicable requirements and standards for nonqualified deferred compensation plans established by Code section 409A.
Senior Human Resources Officer means the Company’s highest-ranking human resources executive.
Separation Agreement is defined in Section 3.
Separation From Service means, with respect to you, your termination of employment (other than by reason of your death) with the Company and all Affiliates and other entities, if any, that would be treated as a single "service recipient" with the Company under the Section 409A Standards, including §1.409A-1(h)(3). Whether your Separation From Service has occurred will be determined in accordance with the Section 409A Standard, including §1.409A-(h). The Administrator may, but need not, elect in writing, subject to the applicable limitations under the Section 409A Standards, any of the special elective rules prescribed in §1.409A-(h) for purposes of determining whether a Separation From Service has occurred. Any such written election will be deemed to be part of the Plan.
Special Assignment is defined in Section 2.
Transitional Position means a Regular Position that satisfies all of the following conditions with respect to you:
•You serve as a member of the Executive Committee immediately prior to your service in the position;
•The Company, at its own initiative and in its sole discretion, and with the express approval of the Compensation Committee, asks you to serve in the position for the purpose of effecting an orderly transition of responsibilities to your successor; and
•You serve in the position for a limited period of not greater than 12 months.
Years of Service is defined in Section 4.
image_0a.jpg
7

 EX-21 3 exhibit21-listofsubsidiari.htm EX-21 Document

EXHIBIT 21
List of worldwide subsidiaries of Boston Scientific Corporation as of January 31, 2024

Structure of ownership and control:

Boston Scientific wholly owns or has a majority interest in all of the below mentioned entities.
Acotec Scientific Holdings Limited (Cayman Islands)
Acurate Industria e Comercio Ltda. (Brazil)
American Medical Systems Europe B.V. (The Netherlands)
Apollo Endosurgery Australia Pty Ltd (Australia)
Apollo Endosurgery Brasil Aparelhos Cirurgicos Ltda. (Brazil)
Apollo Endosurgery Canada Ltd. (Canada)
Apollo Endosurgery Costa Rica, S.R.L. (Costa Rica)
Apollo Endosurgery International, LLC (Delaware)
Apollo Endosurgery UK Ltd (England)
Apollo Endosurgery US, Inc. (Delaware)
Apollo Endosurgery, Inc. (Delaware)
Baylis Medical Company Inc. (Canada)
Baylis Medical USA Inc. (Delaware)
Biocompatibles UK Limited (England)
Biocompatibles, Inc. (Delaware)
Boston Scientific (Malaysia) Sdn. Bhd. (Malaysia)
Boston Scientific (South Africa) Proprietary Limited (South Africa)
Boston Scientific (Thailand) Ltd. (Thailand)
Boston Scientific AG (Switzerland)
Boston Scientific Argentina S.A. (Argentina)
Boston Scientific Asia Pacific Pte. Ltd. (Singapore)
Boston Scientific Benelux NV (Belgium)
Boston Scientific Cardiac Diagnostic Services, LLC (Delaware)
Boston Scientific Cardiac Diagnostic Technologies, Inc. (Delaware)
Boston Scientific Cardiac Diagnostics, Inc. (Delaware)
Boston Scientific Ceska republika s.r.o. (Czech Republic)
Boston Scientific Chile SpA (Chile)
Boston Scientific Clonmel Limited, in liquidation (Ireland)
Boston Scientific Colombia Limitada (Colombia)
Boston Scientific Comercial de Costa Rica BSCR, S.R.L. (Costa Rica)
Boston Scientific de Costa Rica S.R.L. (Costa Rica)
Boston Scientific de Mexico, S.A. de C.V. (Mexico)
Boston Scientific del Caribe, Inc. (Puerto Rico)
Boston Scientific do Brasil Ltda. (Brazil)
Boston Scientific Egypt LLC (Egypt)
Boston Scientific Far East B.V. (The Netherlands)
Boston Scientific Gesellschaft m.b.H. (Austria)
Boston Scientific Group plc (Ireland)
Boston Scientific Gulf for Trading (Saudi Arabia)
Boston Scientific Healthcare Technology (Shanghai) Co., Ltd. (China)
Boston Scientific Hellas S.A. (Greece)
Boston Scientific Hong Kong Limited (Hong Kong)
Boston Scientific Iberica, S.A. (Spain)
Boston Scientific India Private Limited (India)
Boston Scientific International B.V. (The Netherlands)
Boston Scientific International Distribution FZE (UAE)
Boston Scientific International Finance Limited (Ireland)
Boston Scientific International S.A. (France)
Boston Scientific International Sdn. Bhd. (Malaysia)


Boston Scientific Israel Ltd. (Israel)
Boston Scientific Japan K.K. (Japan)
Boston Scientific Korea Co., Ltd. (Korea)
Boston Scientific Korea Holding Co., Ltd. (Korea)
Boston Scientific Limited (England)
Boston Scientific Limited (Ireland)
Boston Scientific LLC (Russian Federation)
Boston Scientific Ltd./Boston Scientifique Ltee. (Canada)
Boston Scientific Medical Device Limited (Ireland)
Boston Scientific Medical Device (Malaysia) Sdn. Bhd. (Malaysia)
Boston Scientific Medical Technology (Shanghai) Co., Ltd. (China)
Boston Scientific Medizintechnik GmbH (Germany)
Boston Scientific Middle East FZ-LLC (UAE)
Boston Scientific Middle East SAL (Offshore) (Lebanon)
Boston Scientific Nederland B.V. (The Netherlands)
Boston Scientific Neuromodulation Corporation (Delaware)
Boston Scientific New Zealand Limited (New Zealand)
Boston Scientific Nordic AB (Sweden)
Boston Scientific Pakistan (Private) Limited (Pakistan)
Boston Scientific Peru S.A.C. (Peru)
Boston Scientific Philippines, Inc. (Philippines)
Boston Scientific Polska Sp. z o.o. (Poland)
Boston Scientific Portugal - Dispositivos Medicos, Lda (Portugal)
Boston Scientific Pty Ltd (Australia)
Boston Scientific Regional Headquarters (Saudi Arabia)
Boston Scientific Romania S.R.L. (Romania)
Boston Scientific S.A.S. (France)
Boston Scientific S.p.A. (Italy)
Boston Scientific Scimed, Inc. (Minnesota)
Boston Scientific Technology & Engineering Services Private Limited (India)
Boston Scientific TIP Gerecleri Limited Sirketi (Turkey)
Boston Scientific Vietnam Company Limited (Vietnam)
Bravo Bidco Limited (England)
BSC International Medical Trading (Shanghai) Co., Ltd. (China)
BSC Medical Device Technology (Shanghai) Co., Ltd. (China)
BTG IM Holdings Ltd. (Israel)
BTG International (Holdings) Limited (England)
BTG International Canada Inc. (Canada)
BTG International Limited (England)
BTG Limited (England)
BTG Management Services Limited (England)
Cardiac Pacemakers, Inc. (Minnesota)
CeloNova BioSciences Germany GmbH, in liquidation (Germany)
DeVoro Medical Inc. (Delaware)
eCardio Sequoia Blocker Corp. (Delaware)
Electron Acquisition Corporation (Delaware)
EndoChoice, Inc. (Delaware)
EP Technologies, Inc. (Delaware)
Farapulse, Inc. (Delaware)
Galil Medical Inc. (Delaware)
Galil Medical Ltd. (Israel)
Golden Woods Services, LLC (Texas)
Guidant Delaware Holding Corporation (Delaware)
Guidant Europe NV (Belgium)
Guidant Puerto Rico B.V. (The Netherlands)
Hong Kong Medtech Trading Limited, in liquidation (Hong Kong)
Laguna Holdco Ltd. (Israel)
Lpath Therapeutics Inc. (Delaware)


Lumenis (HK) Limited (Hong Kong)
Lumenis (Italy) S.r.l. (Italy)
Lumenis (UK) Limited (England)
Lumenis Holdings Inc. (Delaware)
Lumenis Inc. (Massachusetts)
Lumenis India Private Limited (India)
Lumenis Ltd. (Israel)
Lumenis Medical Laser Equipment Trading (Beijing) Co., Ltd. (China)
Notebook Merger Sub, Ltd. (Delaware)
NXT Merger Corp. (Delaware)
Obsidio, Inc. (Delaware)
Provensis Limited (England)
PT Boston Scientific Indonesia (Indonesia)
Relievant Medsystems, Inc. (Delaware)
RMI Acquisition Corp. (California)
Sadie Merger Sub, Inc. (Delaware)
SNS Merger Corp. (Delaware)
Special K Merger Corp. (Delaware)
Starhealth Distribuidora de Produtos para a Saude Ltda. (Brazil)
Stream Enterprises LLC (Delaware)
Symetis SA (Switzerland)
Target Therapeutics, Inc. (Delaware)
Zuma Investment Pty Ltd (Australia)
34 Biomedical Merger Corp. (Delaware)
9357-1867 Quebec Inc., d/b/a Cryterion Medical Enterprise Canada (Canada)

 EX-23 4 exhibit23-2023eyconsent.htm EX-23 Document

EXHIBIT 23

Consent of Independent Registered Public Accounting Firm


We consent to the incorporation by reference in the following Registration Statements:
 
(1)    Registration Statement (Form S-3 Nos. 333-262937, 333-76346, 333-61994, and 333-64991) of Boston Scientific Corporation,

(2)    Registration Statement (Form S-4 Nos. 333-131608 and 333-22581) of Boston Scientific Corporation,

(3)    Registration Statement (Form S-8 Nos. 333-25033, 333-25037, 333-36636, 333-61056, 333-61060, 333-76380, 333-98755, 333-111047, 333-131608, 333-133569, 333-134932, 333-151280, 333-174620, 333-174622, 333-188905, 333-196672, 333-241022, and 333-264754) of Boston Scientific Corporation;
 
of our reports dated February 20, 2024, with respect to the consolidated financial statements and schedule of Boston Scientific Corporation and the effectiveness of internal control over financial reporting of Boston Scientific Corporation included in this Annual Report (Form 10-K) of Boston Scientific Corporation for the year ended December 31, 2023.


Boston, Massachusetts 
February 20, 2024



 EX-31.1 5 exhibit311-ceo302202310xk.htm EX-31.1 Document

EXHIBIT 31.1
 
CERTIFICATIONS
 
I, Michael F. Mahoney, certify that:

1 I have reviewed this Annual Report on Form 10-K of Boston Scientific Corporation;
2 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3 Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4 The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)   
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    
 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5 The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)    
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)    
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: February 20, 2024 /s/ Michael F. Mahoney 
  Michael F. Mahoney 
  Chief Executive Officer 


 EX-31.2 6 exhibit312-cfo302202310xk.htm EX-31.2 Document

EXHIBIT 31.2
 
CERTIFICATIONS
 
I, Daniel J. Brennan, certify that:

1 I have reviewed this Annual Report on Form 10-K of Boston Scientific Corporation;
2 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3 Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4 The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)   
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    
 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5 The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)    
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)    
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: February 20, 2024 /s/ Daniel J. Brennan 
  Daniel J. Brennan 
  Executive Vice President and Chief Financial Officer 


 EX-32.1 7 exhibit321-ceo906202310xk.htm EX-32.1 Document

EXHIBIT 32.1
 
 
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C.
SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Boston Scientific Corporation (the “Company”) for the period ending December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Executive Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge:
 (1)   the Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
(2)   the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation.

   
By:/s/ Michael F. Mahoney
 Michael F. Mahoney 
 Chief Executive Officer 
   
 February 20, 2024 
 


 EX-32.2 8 exhibit322-cfo906202310xk.htm EX-32.2 Document

EXHIBIT 32.2
 
 
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C.
SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Boston Scientific Corporation (the “Company”) for the period ending December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Financial Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge:
 (1)   the Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
(2)   the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation.

   
By:/s/ Daniel J. Brennan
 Daniel J. Brennan 
 Executive Vice President and Chief Financial Officer 
   
 February 20, 2024 


 EX-97 9 exhibit97-bscdoddxfrankcla.htm EX-97 Document
Exhibit 97
BOSTON SCIENTIFIC CORPORATION
DODD-FRANK CLAWBACK POLICY
Purpose:The purpose of this policy is to comply with applicable provisions of The New York Stock Exchange Listed Company Manual, promulgated pursuant to the final rules adopted by the Securities and Exchange Commission enacting the clawback standards under Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act, with respect to the recoupment of incentive-based compensation.
Scope:This policy applies to Covered Individuals with respect to Incentive-Based Compensation, each as defined in the policy.
References:
•Securities Exchange Act Rule 10D-1
•NYSE Listed Company Manual, Section 303A.14, Erroneously Awarded Compensation
TerminologySee Section 4, Definitions
Date of Effectiveness:This policy has been approved by the Boston Scientific Board of Directors and is effective as of November 17, 2023.

The Board of Directors (the “Board”) of Boston Scientific Corporation (the “Company”) has adopted this Dodd-Frank Clawback Policy (this “Policy”) in accordance with the applicable provisions of The New York Stock Exchange Listed Company Manual (the “Clawback Rules”), promulgated pursuant to the final rules adopted by the Securities and Exchange Commission enacting the clawback standards under Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act. The Executive Compensation and Human Resources Committee (the “Committee”) of the Board is designated to administer this Policy. Unless otherwise defined in this Policy, capitalized terms shall have the meaning ascribed to such terms in Section 4.
1.Recovery of Erroneously Awarded Incentive Compensation. In the event the Company is required to prepare an Accounting Restatement, the Company shall recover reasonably promptly the amount of Erroneously Awarded Compensation Received by any current or former Executive Officer (“Covered Individuals”) during the Applicable Period, in accordance with the Clawback Rules and the provisions of this Policy.

2.Covered Compensation. This Policy applies to all Incentive-Based Compensation Received by a Covered Individual: (1) on or after the effective date of the Clawback Rules, (2) after such Covered Individual began service as an Executive Officer; (3) who served as an Executive Officer at any time during the applicable performance period for such Incentive-Based Compensation; (4) while the Company has a class of securities listed on a national securities exchange or a national securities association; and (5) during the Applicable Period.

3.Method of Recovery; Non-Recovery.

a.The Committee shall determine, in its sole discretion, the manner in which any Erroneously Awarded Compensation shall be recovered. Methods of recovery may include, but are not limited to: (1) seeking direct repayment from the Covered Individual; (2) reducing (subject to applicable law and the terms and conditions of the applicable plan, program or arrangement pursuant to which the incentive-based compensation was paid) the amount that would otherwise be payable to the Covered Individual under any compensation, bonus, incentive, equity or other benefit plan, agreement, policy or


arrangement maintained by the Company or any of its affiliates; (3) cancelling any award (whether cash- or equity-based) or portion thereof previously granted to the Covered Individual; or (4) any combination of the foregoing.

b.The Committee may determine to not recover Erroneously Awarded Compensation pursuant to this Policy in circumstances where non-enforcement is expressly permitted by the Clawback Rules, if the Committee determines that recovery would be impracticable and:

i.The direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered; provided, that, before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on expense of enforcement, the Company must make a reasonable attempt to recover such Erroneously Awarded Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the New York Stock Exchange (the “NYSE”);

ii.Recovery would violate applicable home country law where that law was adopted prior to November 28, 2022; provided, before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on violation of home country law, the Company must obtain an opinion of home country counsel, acceptable to the NYSE, that recovery would result in such a violation, and must provide such opinion to the NYSE; or

iii.Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to the Company’s employees, to fail to meet the requirements of Section 401(a)(13) and 411(a) of the Internal Revenue Code of 1986, as amended, and regulations thereunder.

4.Definitions. For purposes of this Policy:

a.“Accounting Restatement” means an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.

b.“Applicable Period” means the three (3) completed fiscal years immediately preceding the date that the Company is required to prepare an Accounting Restatement, which date is the earlier to occur of (a) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement. In addition to these last three (3) completed fiscal years, the Applicable Period also applies to any transition period (that results from a change in the Company’s fiscal year) within or immediately following those three (3) completed fiscal years. However, a transition period between the last day of the Company’s previous fiscal year end and the first day of its new fiscal year that comprises a period of nine (9) to twelve (12) months would be deemed a completed fiscal year.

c.“Executive Officer” means, as determined by the Committee and intended to be those designated as an “officer” of the Company as defined in 17 CFR 240.16a-1(f), the Company’s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division or function (such as sales, administration or finance), any other officer who performs a policy-making function, or any other person
2

who performs similar policy-making functions for the Company. An executive officer of the Company’s parent or subsidiary is deemed an executive officer of the Company if the executive officer performs such policy making functions for the Company. Identification of an Executive Officer for purposes of this Policy and Section 303A.14 of the New York Stock Exchange Listed Company Manual would include at a minimum executive officers identified pursuant to 17 CFR 229.401(b).

d.“Erroneously Awarded Compensation” means the amount of Incentive-Based Compensation Received by an Executive Officer that exceeds the amount of Incentive-Based Compensation that otherwise would have been Received had it been determined based on the restated amounts, which amount must be computed without regard to any taxes paid. For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement: (i) the amount of Erroneously Awarded Compensation must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received, and (ii) the Company must maintain documentation of the determination of that reasonable estimate and provide such documentation to the NYSE. The Committee shall make all final determinations regarding amounts of Erroneously Awarded Compensation.

e.“Financial Reporting Measure” means any measure that is determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measure that is derived wholly or in part from such measures. Stock price and total shareholder return are also Financial Reporting Measures. A Financial Reporting Measure need not be presented within the financial statements or included in a filing with the U.S. Securities and Exchange Commission.

f.“Incentive-Based Compensation” means any compensation that is granted, earned or vested based wholly or in part upon the attainment of any Financial Reporting Measure.

g.“Received” with respect to Incentive-Based Compensation means the fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period. For the avoidance of doubt, Incentive-Based Compensation that is subject to both a Financial Reporting Measure vesting condition and a service-based vesting condition shall be considered received when the relevant Financial Reporting Measure is achieved, even if the Incentive-Based Compensation continues to be subject to the service-based vesting condition.

5.No-Fault Basis. This Policy applies on a no-fault basis, and Covered Individuals will be subject to recovery under this Policy without regard to their personal culpability or responsibility for the accounting error leading to an Accounting Restatement.

6.Other Company Arrangements. This Policy shall be in addition to, and not in lieu of, any other clawback, recovery or recoupment policy maintained by the Company from time to time, as well as any clawback, recovery or recoupment provision in any of the Company’s plans, awards or individual agreements (including clawback, recovery and recoupment provisions in the Company’s equity award agreements) (collectively, “Other Company Arrangements”) and any other rights or remedies available to the Company, including termination of employment; provided, however, that there is no intention to, nor shall there be, any duplicative recoupment of the same compensation amount, as calculated and recovered pursuant to this Policy, under more than one policy, plan, award or agreement. In addition, no Other Company Arrangements shall serve to restrict the scope or the recoverability of Erroneously Awarded Compensation under this Policy or in any way limit recovery in compliance with the Clawback Rules.
3


7.No Indemnification or Insurance Reimbursement. Notwithstanding anything to the contrary set forth in any policy, arrangement, bylaws, charter, certificate of incorporation or plan of the Company or any individual agreement between a Covered Individual and the Company or any of its affiliates, no Covered Individual shall be entitled to indemnification from the Company or any of its affiliates for the amount that is or may be recovered by the Company pursuant to this Policy. In addition, the Company is prohibited from paying or reimbursing a Covered Individual for purchasing insurance to cover any such loss.

8.Administration; Interpretation. The Committee shall interpret and construe this Policy consistent with the Clawback Rules and any other applicable law, rule or regulation and shall make all determinations necessary, appropriate or advisable for the administration of this Policy. Any determinations made by the Committee shall be final, binding and conclusive on all affected individuals and need not be uniform with respect to each Covered Individual. Subject to any limitation under applicable law, the Committee may authorize and empower any officer or employee of the Company to take any and all actions necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee or with regard to determinations made under Section 3(b) of this Policy). Subject to compliance with the Committee’s Charter and any applicable law, rule or regulation, the Committee shall have the power, in its sole discretion, to retain or obtain advice from consultants, legal counsel, accountants or other advisors, as it deems appropriate, to assist with administration of this Policy, including but not limited to in determining amounts of Erroneously Awarded Compensation. To the extent this Policy conflicts or is inconsistent with the Clawback Rules, the Clawback Rules shall govern. In no event is this Policy intended to be broader than, or require recoupment in addition to, that required pursuant to the Clawback Rules.

9.Required Policy-Related Filings. The Company shall file all disclosures with respect to this Policy in accordance with the requirements of the federal securities laws, including disclosures required to be included in or as a part of U.S. Securities and Exchange Commission filings.

10.Amendment or Termination of this Policy. The Board reserves the right to amend this Policy at any time and for any reason, subject to applicable law and the Clawback Rules. The Board may terminate this Policy at any time.
4

BOSTON SCIENTIFIC CORPORATION
DODD-FRANK CLAWBACK POLICY

COVERED INDIVIDUAL ACKNOWLEDGMENT FORM
By signing below, the undersigned acknowledges and agrees that the undersigned has received and reviewed a copy of the Boston Scientific Corporation (the “Company”) Dodd-Frank Clawback Policy (the “Policy”).
By signing this acknowledgment, the undersigned hereby acknowledges and agrees (i) the undersigned is and will continue to be subject to the Policy and that the Policy will apply both during and after the undersigned’s service with the Company, and (ii) to abide by the terms of the Policy, including, without limitation, by returning any Erroneously Awarded Compensation (as defined in the Policy) to the Company to the extent required by, and in a manner consistent with, the Policy.

COVERED INDIVIDUAL

                    
Signature    

                    
Name

                    
Date



 EX-101.SCH 10 bsx-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Balance Sheet Paranthetical link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Acquisitions and Strategic Investments link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Hedging Activities and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Contractual Obligations and Commitments link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Supplemental Balance Sheet Information link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Stock Inventive and Purchase Plans link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Weighted Average Shares Outstanding link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Changes in Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - New Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Employee Retirement Plans (Notes) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Schedule II link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Acquisitions and Strategic Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Hedging Activities and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Contractual Obligations and Commitments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Supplemental Balance Sheet Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Stock Incentive and Purchase Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Weighted Average Shares Outstanding (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Changes in Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Employee Retirement Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Acquisitions and Strategic Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Acquisitions and Strategic Investments - Price Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Acquisitions and Strategic Investments - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Acquisitions and Strategic Investments - Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Acquisitions and Strategic Investments - Strategic Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Acquisitions and Strategic Investments - Level 3 (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Goodwill and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Hedging Activities and Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Contractual Obligations and Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Income Taxes (Details - Rate Table) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Income Taxes Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Income Taxes - Net Deferred Tax Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Stock Incentive and Purchase Plans (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Weighted Average Shares Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Segment Reporting - Income (loss) before income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Segment Reporting - Operating income of reportable segments as a percentage of net sales of reportable segments (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Segment Reporting - Depreciation expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Segment Reporting - Total Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Segment Reporting - Long-lived assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Changes in Other Comprehensive Income (AOCI Rollforward with Reclassification) (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Changes in Other Comprehensive Income - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Employee Retirement Plans (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Schedule II (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 bsx-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 bsx-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 bsx-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Accrued expenses Accrued liabilities, current Accrued Liabilities, Current Other long-term liabilities Other Noncurrent Liabilities [Member] Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Increase (decrease) in operating assets and liabilities, excluding purchase accounting: Increase (Decrease) in Operating Capital [Abstract] Preferred stock dividends Dividends, Preferred Stock, Stock Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax All Award Types Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Payments on short-term borrowings Repayments of Short-Term Debt Legal reserves Estimated Litigation Liability, Noncurrent Pension and Other Postretirement Plans, Policy [Policy Text Block] Pension and Other Postretirement Plans, Policy [Policy Text Block] Intangible asset impairment charges Impairment of Intangible Assets (Excluding Goodwill) Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges Watchman Watchman [Member] Watchman Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Deferred tax liabilities Deferred Income Tax Liabilities, Net Other current assets Prepaid Expenses and Other Current Assets [Member] Insider Trading Policies and Procedures [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Derivative assets Derivative Asset, Current Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] STOCKHOLDER'S EQUITY Equity [Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Accrued expenses Accrued Liabilities, Current [Abstract] Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans Proceeds from Stock Plans Other Other Accrued Liabilities, Noncurrent Ownership [Axis] Ownership [Axis] Other Current Assets [Abstract] Other Current Assets [Abstract] Other Current Assets Requirement, four quarters following material acquisition Requirement, four quarters following material acquisition [Member] Requirement, four quarters following qualified acquisition Restricted cash equivalents included in Other long-term assets Restricted cash equivalents Restricted Cash Equivalents, Noncurrent Current liabilities: Liabilities, Current [Abstract] Deferred Federal Income Tax Expense (Benefit) Deferred Federal Income Tax Expense (Benefit) Payment of contingent consideration Payment of contingent consideration Payment of contingent consideration Goodwill, Impaired, Accumulated Impairment Loss Goodwill, Impaired, Accumulated Impairment Loss Preferred stock, $0.01 par value - authorized 50,000,000 shares; 0 shares issued as of December 31, 2023 and 10,062,500 shares issued as of December 31, 2022 Preferred Stock, Value, Issued Dividends, Cash Dividends, Cash Actual, Covenant Actual, Covenant [Member] Actual Covenant. Subsequent Event Type [Domain] Subsequent Event Type [Domain] Proceeds from disposal of certain businesses and assets Proceeds from Divestiture of Businesses Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Deferred tax liabilities Deferred tax liabilities [Member] Deferred tax liabilities Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax Net income (loss) per common share — diluted Earnings Per Share, Diluted Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Four Amortization and Impairment of Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Treasury stock, at cost - 263,289,848 shares as of December 31, 2023 and 2022 Treasury Stock, Value Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Executive Retirement Plan Rate of Compensation Increase Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Requirement, as of March 31, 2021 Requirement, as of March 31, 2021 [Member] Requirement, as of March 31, 2021 Other income (expense): Other Nonoperating Income (Expense) [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] Trading Symbol Trading Symbol Letters of Credit Outstanding, Amount Letters of Credit Outstanding, Amount Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Indefinite Lived Intangible Assets Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Prepaid income taxes Prepaid Taxes Stockholders’ equity: Equity, Attributable to Parent [Abstract] Change in tax rates Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Contract with Customer, Liability Contract with Customer, Liability Deferred Tax Assets, Tax Deferred Expense Deferred Tax Assets, Tax Deferred Expense Other intangible assets Other Intangible Assets [Member] Defined Benefit Plan, Service Cost Defined Benefit Plan, Service Cost Derivative Liability, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO Euro denominated Euro Denominated Factoring Arrangements [Member] Euro Denominated Factoring Arrangements [Member] Executive Category: Executive Category [Axis] Schedule of Weighted Average Number of Shares Schedule of Weighted Average Number of Shares [Table Text Block] Global Urology and Pelvic Health Reporting Unit [Member] Global Urology and Pelvic Health Reporting Unit [Member] Global Urology and Pelvic Health Reporting Unit [Member] SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Deferred Tax Assets, Net of Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance transition tax payment remaining Transition Tax Payment Remaining Transition Tax Payment Remaining Property, plant and equipment, net Property, Plant and Equipment [Table Text Block] Statement, Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Other Intangible Assets (Textuals) [Abstract] Other Intangible Assets (Textuals) [Abstract] Other Intangible Assets (Textuals) [Abstract] Hedging Relationship [Domain] Hedging Relationship [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Disaggregation of Revenue [Abstract] Disaggregation of Revenue [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Reconciliation of Revenue from Segments to Consolidated Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Entity Small Business Entity Small Business Future Amortization Expense, Year Four Finite-Lived Intangible Asset, Expected Amortization, Year Four Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Relievant Medsystems Relievant Medsystems [Member] Relievant Medsystems Covenant [Axis] Covenant [Axis] Covenant. Legal and Product Liability Costs Legal Costs, Policy [Policy Text Block] Supplier Finance Program, Obligation Supplier Finance Program, Obligation Derivative, Notional Amount Derivative, Notional Amount Measurement Frequency [Axis] Measurement Frequency [Axis] Deferred Tax Assets, Operating Loss Carryforwards, Domestic Deferred Tax Assets, Operating Loss Carryforwards, Domestic Restricted cash and restricted cash equivalents included in Other current assets Restricted Cash and Cash Equivalents, Current Retirement Plan Type [Domain] Retirement Plan Type [Domain] Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three Lessee, Operating Lease, Liability, to be Paid, Rolling Year Three March 2028 Notes March 2028 Notes [Member] March 2028 Notes [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Depreciation Depreciation Retirement Benefits [Abstract] Retirement Benefits [Abstract] Contractual Obligation, Fiscal Year Maturity Contractual Obligation, Fiscal Year Maturity [Table Text Block] Schedule of Long-term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Research credit Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Changes to noncontrolling ownership interest Noncontrolling Interest, Period Increase (Decrease) Research and development expenses Research and Development Expense (Excluding Acquired in Process Cost) Schedule of Business Acquisitions, by Acquisition Schedule of Business Acquisitions, by Acquisition [Table Text Block] Other(1) Other, Reserves Other, Reserves Other Assets, Noncurrent [Abstract] Other Assets, Noncurrent [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Contingent Liability Exposure Contingent Liability Exposure Contingent Liability Exposure Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Domestic Plan Domestic Plan [Member] Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two Lessee, Operating Lease, Liability, to be Paid, Rolling Year Two Cash used to net share settle employee equity awards Payment to net share settle employee equity awards Payment to net share settle employee equity awards Research and Development Expense [Member] Research and Development Expense [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Restructuring Reserve Restructuring Reserve Contract with Customer, Liability [Abstract] Contract with Customer, Liability [Abstract] contingent consideration liability, probability of payment contingent consideration liability, probability of payment contingent consideration liability, probability of payment Award Type Award Type [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Hedging Designation [Axis] Hedging Designation [Axis] Property, plant and equipment Property, Plant and Equipment, Gross Goodwill and Other Intangible Assets Goodwill [Line Items] Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Payments for Royalties Payments for Royalties Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Defined Benefit Plan, Plan Assets, Contributions by Employer Defined Benefit Plan, Plan Assets, Contributions by Employer Indemnification asset Indemnification asset Indemnification asset PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Schedule of Components of Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Covenant [Domain] Covenant [Domain] Covenant. Operating Lease, Liability, Current Operating Lease, Liability, Current Schedule of Other Assets Schedule of Other Assets [Table Text Block] Non-cash impact of transferred royalty rights Non-cash impact of transferred royalty rights Non-cash impact of transferred royalty rights Stock Issued During Period, Shares, Employee Stock Purchase Plans Stock Issued During Period, Shares, Employee Stock Purchase Plans annualweightedaverageforfeiturerate annualweightedaverageforfeiturerate Annual Weighted Average Forfeiture Rate The weighted average of estimated forfeitures for grants based on historical trends Average interest rate of de-recognized receivables Receivable with Imputed Interest, Effective Yield (Interest Rate) Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option Employee Stock Ownership Plan (ESOP), Compensation Expense Employee Stock Ownership Plan (ESOP), Compensation Expense Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Axonics Axonics [Member] Axonics Debt Instrument, Fair Value Disclosure Debt Instrument, Fair Value Disclosure Schedule of Income before Income Tax, Domestic and Foreign Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Measurement period - market based awards Measurement period - market based award Measurement period - market based awards Income (Loss) from Continuing Operations before Income Taxes, Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Gross profit Gross Profit Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name pension benefit obligation, benefits paid pension benefit obligation, benefits paid pension benefit obligation, benefits paid Selling, general and administrative expenses Selling, General and Administrative Expense Accumulated other comprehensive income (loss), net of tax: Accumulated Other Comprehensive Income (Loss), Net of Tax Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Share-based Payment Arrangement, Option [Member] Employee Stock Option [Member] Investments in Publicly Traded and Privately-Held Entities Investment, Policy [Policy Text Block] Options expected to vest, weighted average exercise price Options expected to vest, weighted average exercise price Options expected to vest, weighted average exercise price Brazil CADE - # of individuals for alleged anti-competitive behavior Brazil CADE - # of individuals for alleged anti-competitive behavior Brazil CADE - # of individuals for alleged anti-competitive behavior Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Maximum High end of range [Member] Maximum [Member] Property, plant and equipment, net Property, Plant and Equipment, Net [Abstract] Document Type Document Type Technology Related and Customer Relationships Technology Related and Customer Relationships [Member] Technology Related and Customer Relationships Deferred tax assets Deferred tax assets [Member] Deferred tax assets Goodwill acquired Goodwill, Acquired During Period Tabular List, Table Tabular List [Table Text Block] EMEA [Member] EMEA [Member] Repurchase of common stock Treasury Stock, Value, Acquired, Cost Method Inventories Inventory, Policy [Policy Text Block] Consolidated Balance Sheet (Parenthetical) [Abstract] Consolidated Balance Sheet (Parenthetical) Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Restructuring charges remaining to be excluded from calculation of consolidated EBITDA Restructuring charges remaining to be excluded from calculation of consolidated EBITDA Restructuring charges remaining to be excluded from calculation of consolidated EBITDA. STOCK INCENTIVE AND PURCHASE PLANS Share-Based Payment Arrangement [Text Block] Current Federal Tax Expense (Benefit) Current Federal Tax Expense (Benefit) Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Allowance for credit losses Accounts Receivable, Allowance for Credit Loss, Current John Bradley Sorenson [Member] John Bradley Sorenson Deferred State and Local Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Accounts payable, accrued expenses and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Inventory, Raw Materials, Net of Reserves Inventory, Raw Materials, Net of Reserves Title of 12(b) Security Title of 12(b) Security Litigation Settlement, Amount Awarded from Other Party Litigation Settlement, Amount Awarded from Other Party Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) ACQUISITIONS AND STRATEGIC INVESTMENTS Business Combination Disclosure [Text Block] Indefinite-lived Intangible Assets (Excluding Goodwill) Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Subsidiary, Ownership Percentage, Noncontrolling Owner Subsidiary, Ownership Percentage, Noncontrolling Owner Operating Segments Operating Segments [Member] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Trade accounts receivable, net Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Deferred Tax Assets, Inventory Deferred Tax Assets, Inventory Range [Axis] Statistical Measurement [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Expense related to matching contributions Expense related to matching contributions Expense related to matching contributions Segment operating income as percentage of net sales Segment operating income as percentage of net sales Segment operating income as percentage of net sales Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Risk-Adjusted Discount Rates used in Purchase Price Allocation Discount Rate, Fair Value Input Discount Rate, Fair Value Input Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Goodwill Valuation Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five Lessee, Operating Lease, Liability, to be Paid, Rolling Year Five Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Financial Instruments Derivatives, Policy [Policy Text Block] Purchase Obligations, Future Minimum Payments, Due in Four Years Purchase Obligation, to be Paid, Year Four Defined Benefit Plan, Plan Assets, Payment for Settlement Defined Benefit Plan, Plan Assets, Payment for Settlement Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Purchase Obligations, Future Minimum Payments Due, Current Purchase Obligation, to be Paid, Year One Future Amortization Expense, Year One Finite-Lived Intangible Asset, Expected Amortization, Year One Operating Lease, Payments Operating Lease, Payments the Offering - early redemption of combined aggregate principal SN the Offering - early redemption of combined aggregate principal SN [Member] the Offering - early redemption of combined aggregate principal SN Defined Benefit Plan, Interest Cost Defined Benefit Plan, Interest Cost PEO PEO [Member] Income Tax Examination, Penalties and Interest Accrued Income Tax Examination, Penalties and Interest Accrued Concentrations of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Auditor Location Auditor Location Requirement, eighth quarter and thereafter following qualified acquisition Requirement, eighth quarter and thereafter following qualified acquisition [Member] Requirement, eighth quarter and thereafter following qualified acquisition Long-term Debt, Maturities, Repayments of Principal in Rolling Year Five Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Five Costa Rica COSTA RICA Preferred Stock, Dividends, Per Share, Cash Paid Preferred Stock, Dividends, Per Share, Cash Paid Other, net Other Operating Activities, Cash Flow Statement AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Deferred Tax Assets, Operating Loss Carryforwards, Foreign Deferred Tax Assets, Operating Loss Carryforwards, Foreign Common Stock, Par or Stated Value Per Share Common Stock, Par or Stated Value Per Share Common Stock, Par or Stated Value Per Share Legal reserves Estimated Litigation Liability, Current Cash provided by (used for) investing activities Net Cash Provided by (Used in) Investing Activities Deferred Tax Liabilities, Derivatives Deferred Tax Liabilities, Derivatives Equity Securities, FV-NI Equity Securities, FV-NI, Current Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Debt Instrument [Axis] Debt Instrument [Axis] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Conversion of mandatory convertible preferred stock to common stock Conversion of Stock, Shares Converted Credit Facility [Axis] Credit Facility [Axis] Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items] Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items] Current Income Tax Expense (Benefit) Current Income Tax Expense (Benefit) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Net decrease in commercial paper Proceeds from (Repayments of) Commercial Paper Common Stock, Capital Shares Reserved for Future Issuance Common Stock, Capital Shares Reserved for Future Issuance Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Impact of foreign currency fluctuations on net sales Impact of foreign currency fluctuations on net sales Impact of foreign currency fluctuations on net sales Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less) Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less) Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less) Amount of employees total compensation eligible for GESOP purchase Amount of employees total compensation eligible for GESOP purchase Amount of employees total compensation eligible for GESOP purchase Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Deferred Tax Assets, in Process Research and Development Deferred Tax Assets, in Process Research and Development Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Defined Benefit Plan, Expected Future Benefit Payment, Year Two Defined Benefit Plan, Expected Future Benefit Payment, Year Two Arthur Butcher Rule Trading Arrangement, Stock Options [Member] Arthur Butcher Rule Trading Arrangement, Stock Options Decrease in Unrecognized Tax Benefits is Reasonably Possible Decrease in Unrecognized Tax Benefits is Reasonably Possible Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Percent of finished goods at consignment Percent of finished goods at consignment Percent of finished goods at consignment Current State and Local Tax Expense (Benefit) Current State and Local Tax Expense (Benefit) Total current assets Assets, Current Preferred stock Preferred Stock [Member] Fair value of contingent consideration Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability Supplemental Information Supplemental Cash Flow Information [Abstract] Retirement Plan Name [Domain] Retirement Plan Name [Domain] Schedule of Deferred Compensation Arrangement with Individual, Postretirement Benefits [Table] Schedule of Deferred Compensation Arrangement with Individual, Postretirement Benefits [Table] Purchase Obligations, Future Minimum Payments Due Purchase Obligation Supplemental Balance Sheet Information Supplemental Balance Sheet Information [Abstract] Supplemental Balance Sheet Information. Licensing arrangements Licensing arrangements Licensing arrangements Requirement, seventh quarter following qualified acquisition Requirement, seventh quarter following qualified acquisition [Member] Requirement, seventh quarter following qualified acquisition Patents and Licenses Patents and Licenses [Member] Patents and Licenses GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] State income taxes, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Investments Investments Investments Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Future Amortization Expense, Year Five Finite-Lived Intangible Asset, Expected Amortization, Year Five Wendy Carruthers Rule Trading Arrangement, Stock Options [Member] Wendy Carruthers Rule Trading Arrangement, Stock Options Ireland IRELAND Cash provided by (used for) operating activities Net Cash Provided by (Used in) Operating Activities Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Schedule of Expected Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Contingent consideration Business Combination, Contingent Consideration, Liability, Current Class of Stock [Axis] Class of Stock [Axis] Entities [Table] Entities [Table] Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Unrecognized Compensation Cost - Non-vested stock awards Unrecognized Compensation Cost - Non-vested stock awards Unrecognized Compensation Cost - Non-vested stock awards Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Depreciation and amortization Depreciation, Depletion and Amortization Other Operating Income (Expense), Net Other Operating Income (Expense), Net Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] weighted average remaining vesting period weighted average remaining vesting period weighted average remaining vesting period Entity Information [Line Items] Entity Information [Line Items] Business Combination and Asset Acquisition [Abstract] Consolidation Items [Axis] Consolidation Items [Axis] Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Long-Lived Assets Long-Lived Assets Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Valuation Allowance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Forward Currency Contracts, Time to Maturity Forward Currency Contracts, Time to Maturity Forward Currency Contracts, Time to Maturity in Months Contract with Customer, Liability, Revenue Recognized Contract with Customer, Liability, Revenue Recognized country_US excluding Other Net Sales US excluding Other Net Sales [Member] US excluding Other Net Sales March 2049 Notes March 2049 Notes [Member] March 2049 Notes March 2039 Notes March 2039 Notes [Member] March 2039 Notes Foreign currency translation adjustment Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Net Change in Derivative Financial Instruments Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Long-term debt Long-term Debt and Capital Lease Obligations Long-Term Debt and Lease Obligation Measurement alternative investments(1, 2) Equity Securities without Readily Determinable Fair Value, Amount Retirement Plan Name [Axis] Retirement Plan Name [Axis] Property, Plant and Equipment by Type [Axis] Long-Lived Tangible Asset [Axis] Preferred Stock, Shares Issued Preferred Stock, Shares Issued Preferred Stock, Shares Issued Preferred Stock, Shares Issued Operating Income Unallocated to Segment Operating Income Unallocated to Segment Operating Income Unallocated to Segment Liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Emerging Markets [Member] Emerging Markets [Member] Emerging Markets [Member] Entity Emerging Growth Company Entity Emerging Growth Company Other intangible assets, net Intangible Assets, Net (Excluding Goodwill) Intangible Assets, Net (Excluding Goodwill) Other long-term assets Other Noncurrent Assets [Member] Deferred Tax Assets, Gross Deferred Tax Assets, Gross Purchase Obligations, Future Minimum Payments, Due in Five Years Purchase Obligation, to be Paid, Year Five Warranty Obligations Standard Product Warranty, Policy [Policy Text Block] Proceeds from settlements of hedge contracts Payments for (Proceeds from) Hedge, Investing Activities Amortizable intangible assets Amount Assigned (in millions) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Range of the target number of performance-based DSUs awarded Range of the target number of performance-based DSUs awarded Range of the target number of performance-based DSUs awarded Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Title Trading Arrangement, Individual Title Requirement, sixth quarter following qualified acquisition Requirement, sixth quarter following qualified acquisition [Member] Requirement, sixth quarter following qualified acquisition [Member] Common stock Common Stock [Member] Net change in defined benefit pensions and other items Defined benefit pensions and other items Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Individual: Individual [Axis] Net proceeds from issuance of preferred stock in connection with public offering Proceeds from Issuance of Convertible Preferred Stock Entity Address, Postal Zip Code Entity Address, Postal Zip Code Other countries Other countries [Member] Other countries [Member] Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Income Statement Location [Domain] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Income Statement Location [Domain] Revenues from contracts with customers, disaggregated - performance measurement Revenues from contracts with customers, disaggregated - performance measurement Revenues from contracts with customers, disaggregated - performance measurement Discount Rate Valuation Technique, Discounted Cash Flow [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] compensation expense, per share - diluted compensation expense, per share - diluted compensation expense, per share - diluted Total stockholders’ equity Total equity Equity, Including Portion Attributable to Noncontrolling Interest Investments [Abstract] Minimum Minimum [Member] Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Property, Plant and Equipment, Net Weighted-average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Cash Cash Other comprehensive income (loss) Changes in other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax compensation expense, per share - basic compensation expense, per share - basic compensation expense, per share - basic Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Audit Information [Abstract] Audit Information Defined Benefit Plan, Benefit Obligation Defined Benefit Plan, Benefit Obligation ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Defined Benefit Plan, Expected Future Benefit Payment, Year Three Defined Benefit Plan, Expected Future Benefit Payment, Year Three Foreign Currency Transaction Gain (Loss), before Tax Net gain (loss) from foreign currency transaction exposures Gain (Loss), Foreign Currency Transaction, before Tax Schedule of Derivative Instruments in Statement of Financial Position, Fair Value Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Income Taxes [Table] Income Taxes [Table] Income Taxes [Table] Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration] Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration] Cash provided by (used for) financing activities Net Cash Provided by (Used in) Financing Activities Deferred tax assets Deferred Income Tax Assets, Net Retirement Plan Type [Axis] Retirement Plan Type [Axis] Unrecognized Compensation Cost - Stock Options Unrecognized Compensation Cost - Stock Options Unrecognized Compensation Cost - Stock Options COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Proceeds from royalty rights Payments for (Proceeds from) Other Investing Activities December 2027 Notes December 2027 Notes [Member] December 2027 Notes Business Acquisition, Percentage of Voting Interests Acquired Business Acquisition, Percentage of Voting Interests Acquired Retained earnings (Accumulated deficit) Retained Earnings [Member] Federal benefit of uncertain tax positions Federal benefit of uncertain tax positions Federal benefit of uncertain tax positions Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Fair value of the organic net sales growth (ONSG) performance awards Fair value of the organic net sales growth (ONSG) performance awards Fair value of the organic net sales growth (ONSG) performance awards Net change in derivative financial instruments Derivative financial instruments Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Net income (loss) per common share — basic Earnings Per Share, Basic Accounting Policies [Abstract] Accounting Policies [Abstract] Schedule of Changes in Projected Benefit Obligations [Table Text Block] Schedule of Changes in Projected Benefit Obligations [Table Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Defined Benefit Plan, Plan Assets, Amount Defined Benefit Plan, Plan Assets, Amount Deferred Tax Assets Deferred Tax Assets, Net Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Yen denominated Yen Denominated Factoring Arrangements [Member] Yen denominated factoring arrangements. Defined Benefit Plan, Benefit Obligation, Benefits Paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Cash paid for income taxes, net Income Taxes Paid Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] NEW ACCOUNTING PRONOUNCEMENTS New Accounting Pronouncements, Policy [Text Block] New Accounting Pronouncements, Policy Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] June 2025 Notes June 2025 Notes [Member] June 2025 Notes Interest expense Interest Expense [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Technology-related Technology-Based Intangible Assets [Member] Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Summary of Income Tax Contingencies Summary of Income Tax Contingencies [Table Text Block] Entity Public Float Entity Public Float Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Derivative Instrument [Axis] Derivative Instrument [Axis] All Trading Arrangements All Trading Arrangements [Member] Loss (gain) on disposal of businesses and assets Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal All Adjustments to Compensation All Adjustments to Compensation [Member] Acotec Acotec [Member] Acotec Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] March 2031 Notes March 2031 Notes [Member] March 2031 Notes Compensation Amount Outstanding Recovery Compensation Amount Wendy Carruthers Rule Trading Arrangement, Common Stock [Member] Wendy Carruthers Rule Trading Arrangement, Common Stock Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution Reconciliation of Assets from Segment to Consolidated Reconciliation of Assets from Segment to Consolidated [Table Text Block] International retirement plans [Member] International retirement plans [Member] International retirement plans [Member] Credit loss expense Net (credits) charges to expenses Accounts Receivable, Credit Loss Expense (Reversal) Other long-term liabilities Other Liabilities, Noncurrent [Abstract] Derivative assets Derivative Asset Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Licensing arrangements Licensing arrangements, liability Licensing arrangements, liability Deferred Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Electrophysiology (EP) Electrophysiology (EP) [Member] Electrophysiology (EP) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Defined Benefit Plan, Accumulated Benefit Obligation Defined Benefit Plan, Accumulated Benefit Obligation Beginning balance Ending balance Accounts Receivable, Allowance for Credit Loss Deferred revenue Deferred Revenue Schedule of Intangible Assets and Goodwill Schedule of Intangible Assets and Goodwill [Table Text Block] Share Price Share Price Other Assets Other Assets Schedule Of Segment Reporting Information By Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution Proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block] Summary of term loan and revolving credit facility agreement compliance with debt covenants. Document Period End Date Document Period End Date Adoption Date Trading Arrangement Adoption Date Purchase Obligations, Future Minimum Payments, Due Thereafter Purchase Obligation, to be Paid, after Year Five Treasury Stock Treasury Stock, Common [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Accrual for legal matters that are probable and estimable Loss Contingency Accrual Income tax expense (benefit) Income Tax Expense (Benefit) Income Tax Expense (Benefit) Non-US [Member] Non-US [Member] Write-offs Utilization of allowances Accounts Receivable, Allowance for Credit Loss, Writeoff Designated as Hedging Instrument [Member] Designated as Hedging Instrument [Member] Global Endoscopy (Endo) Reporting Unit [Member] Global Endoscopy (Endo) Reporting Unit [Member] Global Endoscopy (Endo) Reporting Unit [Member] Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] (Income) loss amounts reclassified from accumulated other comprehensive income Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Deemed Consolidated EBITDA [Member] Deemed Consolidated EBITDA Deemed Consolidated EBITDA Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Voting power of all classes of stock Voting power of all classes of stock Voting power of all classes of stock Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Payments for acquisitions of businesses, net of cash acquired Payment for acquisition, net of cash acquired (2) Payments to Acquire Businesses, Net of Cash Acquired Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Non-deductible expenses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent Credit Facility [Domain] Credit Facility [Domain] Property, Plant and Equipment, Useful Life Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution Significant Accounting Policies Significant Accounting Policies [Table] Significant Accounting Policies [Table] Software Development Software Development [Member] Interest rate derivative contracts Interest Rate Contract [Member] Other long-term liabilities Other Noncurrent Liabilities [Table Text Block] REVENUE Revenue from Contract with Customer [Text Block] Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Tax Incentives in Puerto Rico Tax Incentives in Puerto Rico Tax Incentives in Puerto Rico Range of the target number of market-based DSUs awarded Range of the target number of market-based DSUs awarded Range of the target number of market-based DSUs awarded Additional paid-in capital Additional Paid in Capital, Common Stock Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Additional paid-in capital Additional Paid-in Capital [Member] Document Annual Report Document Annual Report Balance Sheet Location [Axis] Balance Sheet Location [Axis] Uncapped Contingent Considertation Uncapped Contingent Considertation Uncapped Contingent Considertation Cover [Abstract] Maturities of Lease Liabilities Maturities of Lease Liabilities [Table Text Block] Maturities of Lease Liabilities U.S. UNITED STATES UNITED STATES Fair Value, Measurements, Recurring [Member] Fair Value, Recurring [Member] Other Current Liabilities Other Current Liabilities [Table Text Block] Cash dividends paid on preferred stock Payments of Dividends Other long-term liabilities Other long-term liabilities Other Liabilities, Noncurrent Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, to be Paid Other, net Other Nonoperating Income (Expense) [Member] EMPLOYEE RETIREMENT PLANS Compensation and Employee Benefit Plans [Text Block] Cash flow hedge Cash Flow Hedging [Member] Operating expenses Operating Expenses SEGMENT REPORTING Segment Reporting Disclosure [Text Block] Arthur Butcher Rule Trading Arrangement, PSU and RSU [Member] Arthur Butcher Rule Trading Arrangement, PSU and RSU Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Stock Incentive and Ownership Plans [Abstract] Stock Incentive and Purchase Plans [Abstract] Stock Incentive and Purchase Plans [Abstract] Foreign currency denominated in debt Foreign currency denominated in debt [Member] Foreign currency denominated in debt Equity Component [Domain] Equity Component [Domain] Tax incentives in Malaysia Tax incentives in Malaysia Tax incentives in Malaysia Inventory, Work in Process, Net of Reserves Inventory, Work in Process, Net of Reserves Trade accounts receivable, net Trade accounts receivable, net Accounts and Financing Receivable, after Allowance for Credit Loss, Current Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Deferred Tax Liabilities, Other Deferred Tax Liabilities, Other Entity Current Reporting Status Entity Current Reporting Status Operating income (loss) Operating Income (Loss) Operating Income (Loss) November 2019 Aggregate Offering November 2019 Aggregate Offering [Member] November 2019 Aggregate Offering Deferred Tax Liabilities, Gross Deferred Tax Liabilities, Gross March 2025 Notes March 2025 Notes [Member] March 2025 Notes Segments [Axis] Segments [Axis] Segments [Axis] Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] March 2034 Notes March 2034 Notes [Member] March 2034 Notes Customer relationships Customer Relationships [Member] Net income (loss) attributable to noncontrolling interests Net income (loss) attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Pay vs Performance Disclosure [Line Items] Entity Voluntary Filers Entity Voluntary Filers Range [Domain] Statistical Measurement [Domain] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Licensing arrangements Accrued Royalties, Current Legal payments remaining to be excluded from calculation of consolidated EBITDA Legal payments remaining to be excluded from calculation of consolidated EBITDA Legal payments remaining to be excluded from calculation of consolidated EBITDA Preferred Stock, Liquidation Preference Per Share Preferred Stock, Liquidation Preference Per Share Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number the Offering - aggregate principal amount the Offering - aggregate principal amount [Member] the Offering - aggregate principal amount CONTRACTUAL OBLIGATIONS AND COMMITMENTS Debt Disclosure [Text Block] Other current liabilities Other Current Liabilities [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Research and Development Research and Development Expense, Policy [Policy Text Block] Operating Income (Loss) Allocated to Reportable Segments Operating Income (Loss) Allocated to Reportable Segments Operating Income (Loss) Allocated to Reportable Segments Revolving Credit Facility Revolving Credit Facility [Member] Effect of foreign exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Segment Reporting [Abstract] Segment Reporting [Abstract] Accounts payable Accounts Payable, Current Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Restatement Determination Date: Restatement Determination Date [Axis] Derivatives Not Designated as Hedging Instruments Derivatives Not Designated as Hedging Instruments [Table Text Block] Other income (expense), net Nonoperating Income (Expense) U.S. federal statutory income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Commitments and contingencies Commitments and Contingencies Goodwill and other intangible asset impairment charges Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Capital in progress Construction in Progress, Gross Financial Liability Licensing arrangement liabilities [Member] Licensing arrangement liabilities Deferred revenue Deferred Revenue, Current Schedule of Goodwill [Table] Schedule of Goodwill [Table] Geographical [Axis] Geographical [Axis] Geographical [Axis] INCOME TAXES Income Tax Disclosure [Text Block] Defined Benefit Plan, Expected Future Benefit Payment, Year Five Defined Benefit Plan, Expected Future Benefit Payment, Year Five Other Other Assets, Miscellaneous, Current Revenue Recognition Revenue [Policy Text Block] Preferred Stock, Par or Stated Value Per Share Preferred Stock, Par or Stated Value Per Share Business Acquisition [Line Items] Business Acquisition [Line Items] Inventory, Net [Abstract] Inventory, Net [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] MedSurg MedSurg [Member] MedSurg [Member] Payment of contingent consideration previously established in purchase accounting Payment for Contingent Consideration Liability, Financing Activities Derivative Liability, Fair Value, Gross Liability Derivative Liability, Subject to Master Netting Arrangement, before Offset PEO Total Compensation Amount PEO Total Compensation Amount Hedging Relationship [Axis] Hedging Relationship [Axis] Land Land Senior Note due 2027 [Member] Senior Note due 2027 [Member] Senior Note due 2027 [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Business Acquisition, Share Price Business Acquisition, Share Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Treasury Stock, Shares Treasury Stock, Common, Shares Defined Benefit Plan, Expected Future Benefit Payment, Year One Defined Benefit Plan, Expected Future Benefit Payment, Year One Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Unrecognized Compensation Cost Unrecognized Compensation Cost Unrecognized Compensation Cost Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Schedule of Other Current Assets Schedule of Other Current Assets [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Net Income (Loss) Net Income (Loss) Other Comprehensive Income (Loss), Tax Other Comprehensive Income (Loss), Tax Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Schedule of Notional Amounts of Outstanding Derivative Positions Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Translation of Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name LEASES Lessee, Operating Leases [Text Block] Total debt Debt and Lease Obligation Cardiovascular Cardiovascular [Member] Cardiovascular [Member] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Income (Loss) from Continuing Operations before Income Taxes, Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Cost of products sold Cost of Goods and Services Sold Cost of Goods and Services Sold Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position Weighted Average Amortization Period (in years) Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Forward currency contracts Foreign Exchange Contract [Member] Global Peripheral Interventions (PI) Reporting Unit [Member] Global Peripheral Interventions (PI) Reporting Unit [Member] Global Peripheral Interventions (PI) Reporting Unit [Member] Name Measure Name Patents Patents [Member] Segment operating income as percentage of net sales Segment operating income as percentage of net sales [Table Text Block] Segment operating income as percentage of net sales Name Forgone Recovery, Individual Name Goodwill Goodwill Goodwill, Beginning Balance Goodwill, Ending Balance Goodwill Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Buildings and improvements Buildings and Improvements, Gross Apollo Apollo [Member] Apollo Underlying Securities Award Underlying Securities Amount Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] CHANGES IN OTHER COMPREHENSIVE INCOME Comprehensive Income (Loss) Note [Text Block] Trade accounts receivable Increase (Decrease) in Accounts Receivable Tax Adjustments, Settlements, and Unusual Provisions Tax Adjustments, Settlements, and Unusual Provisions Selling, General and Administrative Expenses [Member] Selling, General and Administrative Expenses [Member] Goodwill (Roll Forward) Goodwill (Textuals) [Abstract] Goodwill (Textuals) [Abstract] Compensation-related Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent Operating lease liabilities Operating Lease, Liability, Noncurrent Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Three Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Interventional Cardiology Therapies Interventional Cardiology Therapies [Member] Interventional Cardiology Therapies Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis] Income Statement Location [Axis] Income Statement Location [Axis] Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Exclusion from EBITDA for Restructuring Charges Exclusion from EBITDA for Restructuring Charges Exclusion from EBITDA for Restructuring Charges Weighted Average Number Diluted Shares Outstanding Adjustment Weighted Average Number of Shares Outstanding, Diluted, Adjustment Share-based compensation, net of tax benefit Share-based compensation, net of tax benefit Share-based compensation, net of tax benefit Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax Payments on long-term borrowings and debt extinguishment costs Repayments of Senior Debt Arthur Butcher [Member] Arthur Butcher Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Inventory step-up amortization InventoryStepUpAmortization Inventory Step Up Amortization Lease, Cost Lease, Cost [Table Text Block] Inventories Increase (Decrease) in Inventories Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Derivative Instruments and Hedging Activities Disclosure [Abstract] Plan Name [Domain] Plan Name [Domain] Interest expense Interest Expense Interest Expense Debt extinguishment net charges Gain (Loss) on Extinguishment of Debt Gain (Loss) on Extinguishment of Debt Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Stockholders' Equity Note [Abstract] Trading Arrangement: Trading Arrangement [Axis] Accounting Estimates Use of Estimates, Policy [Policy Text Block] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Global Cardiology Reporting Unit Global Cardiology Reporting Unit [Member] Global Cardiology Reporting Unit [Member] Schedule of Share-based Compensation, Restricted Stock Units Award Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Auditor Firm ID Auditor Firm ID Amortization expense Amortization expense Amortization of Intangible Assets Entity Shell Company Entity Shell Company Fair value of noncontrolling interest Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Restatement Determination Date Restatement Determination Date Class of Stock Disclosures [Abstract] Class of Stock Disclosures [Abstract] Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Net Deferred Tax Liabilities and Prepaid on Intercompany Profit Net Deferred Tax Assets and Prepaid on Intercompany Profit Net Deferred Tax Assets and Prepaid on Intercompany Profit Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table Text Block] [Table Text Block] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table] Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies Subsequent Events Subsequent Events, Policy [Policy Text Block] Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block] Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block] Operating Lease, Cost Operating Lease, Cost Common Stock, Shares, Issued Balance (Shares) Balance (Shares) Common Stock, Shares, Issued Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Comprehensive income (loss) attributable to noncontrolling interests Other Comprehensive Income (Loss), before Tax, Portion Attributable to Noncontrolling Interest Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five Lessee, Operating Lease, Liability, to be Paid, after Rolling Year Five Assets, Fair Value Disclosure Assets, Fair Value Disclosure Long-term Debt Long-Term Debt Foreign Currency Translation Adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Lessee, Operating and Finance Leases, Option to Extend Lessee, Operating and Finance Leases, Option to Extend Lessee, Operating and Finance Leases, Option to Extend Net deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Net Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Comprehensive income attributable to Boston Scientific common stockholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent June 2030 Notes June 2030 Notes [Member] June 2030 Notes Schedule of Expected Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Options expected to vest, weighted average remaining contractual life Options expected to vest, weighted average remaining contractual life Options expected to vest, weighted average remaining contractual life Impact of stock-based compensation plans Stock Issued During Period, Shares, Period Increase (Decrease) Taxes payable Taxes Payable, Current Other International Plans Other International Plans [Member] Other International Plans Subsequent Event [Member] Subsequent Event [Member] Other current liabilities Other current liabilities Other Liabilities, Current Income Statement [Abstract] Income Statement [Abstract] Conversion of mandatory convertible preferred stock to common stock Conversion of Stock, Amount Converted October 2023 Notes October 2023 Notes [Member] October 2023 Notes [Member] Payments for royalty rights Payments for royalty rights Payments for royalty rights Stock Issued During Period, Shares, New Issues Stock Issued During Period, Shares, New Issues Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Goodwill, Gross Goodwill, Gross Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Global Neuromodulation (NM) Reporting Unit [Member] Global Neuromodulation (NM) Reporting Unit [Member] Global Neuromodulation (NM) Reporting Unit [Member] Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax Trade accounts receivable, net Accounts and Financing Receivable, after Allowance for Credit Loss, Current [Abstract] Foreign Currency Contracts, Liability, Fair Value Disclosure Derivative Liability Free Trade Zone Regime Tax Incentive Free Trade Zone Regime Tax Incentive Free Trade Zone Regime Tax Incentive Other Assets, Current Other Assets, Current Class of Stock [Line Items] Class of Stock [Line Items] Return to provision Effective Income Tax Rate Reconciliation, Return to provision Effective Income Tax Rate Reconciliation, Return to provision Equity method investments Equity Method Investments Inventories Inventories Inventory, Net Renminbi denominated Renminbi Denominated Factoring Arrangements [Member] Renminbi Denominated Factoring Arrangements Financial Instrument [Axis] Financial Instrument [Axis] Other assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Total Shareholder Return Amount Total Shareholder Return Amount Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Deferred Foreign Income Tax Expense (Benefit) Deferred Foreign Income Tax Expense (Benefit) Segment [Domain] Segments [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Retained earnings (Accumulated deficit) Retained Earnings (Accumulated Deficit) Current assets: Assets, Current [Abstract] Trade accounts receivable Accounts Receivable, before Allowance for Credit Loss, Current Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Qualified options exercise price Non-vested stock awards exercise price Non-vested stock awards exercise price Fair value of market based awards Fair value of market based awards Fair value of market based awards Baylis Medical Baylis Medical [Member] Baylis Medical Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Derivative Asset, Fair Value, Gross Asset Derivative Asset, Subject to Master Netting Arrangement, before Offset 2011 LTIP Plan [Member] 2011 LTIP Plan [Member] 2011 LTIP Plan [Member] Other, net Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Class of Stock [Domain] Class of Stock [Domain] Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Net income (loss) attributable to Boston Scientific common stockholders Net Income (Loss) Available to Common Stockholders, Basic Wendy Carruthers [Member] Wendy Carruthers Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Proceeds from (payments for) investments and acquisitions of certain technologies Proceeds from (payments for) investments and acquisitions of certain technologies Proceeds from (payments for) investments and acquisitions of certain technologies Executive retirement plan [Member] Executive retirement plan [Member] Executive retirement plan [Member] Litigation-related net charges (credits) Litigation Settlement, Expense Reported tax rate Effective Income Tax Rate Reconciliation, Percent Operating Lease, Liability Operating Lease, Liability Exercise price of the fair market value of our common stock on the date of grant Exercise price of the fair market value of our common stock on the date of grant Exercise price of the fair market value of our common stock on the date of grant Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value Requirement, fifth quarter following qualified acquisition Requirement, fifth quarter following qualified acquisition [Member] Requirement, fifth quarter following qualified acquisition [Member] Deferred and prepaid income taxes Cash flow impact of deferred income tax expense (benefit) Cash flow impact of deferred income tax expense (benefit) Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Accumulated other comprehensive income (loss), net of tax AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Market-based awards, valuation assumptions Market-based awards, valuation assumptions [Table Text Block] Market-based awards, valuation assumptions [Table Text Block] All Executive Categories All Executive Categories [Member] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Net Change in Defined Benefit Pensions and Other Items Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Plan Name [Axis] Plan Name [Axis] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Employee Service Share-based Compensation, Tax Benefit from Compensation Expense Share-Based Payment Arrangement, Expense, Tax Benefit Number of Reportable Segments Number of Reportable Segments Earnings Per Share [Abstract] Earnings Per Share [Abstract] November 2035 Notes November 2035 Notes [Member] November 2035 Notes [Member] Proceeds from long-term borrowings, net of debt issuance costs Proceeds from Issuance of Senior Long-Term Debt Common stock, $0.01 par value - authorized 2,000,000,000 shares; 1,729,000,224 shares issued as of December 31, 2023 and 1,696,633,993 shares issued as of December 31, 2022 Common Stock, Value, Issued Reclassification adjustment from AOCI, tax impact Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, Tax Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Senior Notes Senior Notes [Member] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Net currency exchange gain (loss) Net currency exchange gain (loss) Net currency exchange gain (loss) Other, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Other Other, Other Long-term Assets Other, Other Long-term Assets Statement [Table] Statement [Table] Contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Authorized Amount Tax rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Unrecognized Tax Benefits Unrecognized Tax Benefits PEO Name PEO Name Other Other Sundry Liabilities, Current APAC [Member] Asia Pacific [Member] Preferred Stock, Shares Authorized Preferred Stock, Shares Authorized Preferred Stock, Shares Authorized Supplemental Balance Sheet Information (Textuals) Supplemental Balance Sheet Information (Textuals) [Abstract] Supplemental Balance Sheet Information (Textuals) Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Building Building [Member] Schedule of Goodwill Schedule of Goodwill [Table Text Block] Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Foreign currency fluctuations and other changes Goodwill, Translation and Purchase Accounting Adjustments Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four Lessee, Operating Lease, Liability, to be Paid, Rolling Year Four Cardiac Rhythm Management Cardiac Rhythm Management [Member] Cardiac Rhythm Management Other Other Accrued Liabilities, Current Corporate, Non-Segment Corporate, Non-Segment [Member] Fair value of the Free Cash Flow (FCF) performance awards Fair value of the Free Cash Flow (FCF) performance awards Fair value of the Free Cash Flow (FCF) performance awards Litigation Settlement, Amount Awarded to Other Party Litigation Settlement, Amount Awarded to Other Party Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Loss (Gain) on Disposal of Businesses and Assets Gain (Loss) on Disposition of Business Equity, Attributable to Parent Beginning Stockholders' Equity Ending Stockholders' Equity Equity, Attributable to Parent Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Domestic taxes on foreign earnings Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return March 2028 Senior Notes March 2028 Senior Notes [Member] March 2028 Senior Notes Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Schedule of Defined Benefit Plans Disclosures [Table Text Block] Schedule of Defined Benefit Plans Disclosures [Table Text Block] Income (loss) before income taxes Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Long-term Debt, Maturities, Repayments of Principal in Rolling after Year Five Long-Term Debt, Maturities, Repayments of Principal in Rolling after Year Five Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased Fair Value Measurement Fair Value Measurement, Policy [Policy Text Block] Not Designated as Hedging Instrument [Member] Not Designated as Hedging Instrument [Member] Hedging Designation [Domain] Hedging Designation [Domain] Level 2 Fair Value, Inputs, Level 2 [Member] Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Net investment hedge Net Investment Hedging [Member] Requirement, as of December 31, 2021 and through remaining term of facility Requirement, as of December 31, 2021 and through remaining term of facility [Member] Requirement, as of December 31, 2021 and through remaining term of facility Impact of stock-based compensation plans Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture Derivative Instruments, Gain (Loss) Derivative Instruments, Gain (Loss) [Table Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Finite-Lived Intangible Assets, Useful Life Finite-Lived Intangible Asset, Useful Life target payout of organic net sales growth (ONSG) performance-based RSU target payout of organic net sales growth (ONSG) performance-based RSU target payout of organic net sales growth (ONSG) performance-based RSU Schedule of Changes in Fair Value of Plan Assets [Table Text Block] Schedule of Changes in Fair Value of Plan Assets [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Risk-Adjusted Discount Rates used in Purchase Price Allocation Weighted Average Weighted Average [Member] Income Taxes [Abstract] Income Taxes [Abstract] Income Taxes [Abstract] Accrued income taxes Accrued Income Taxes, Noncurrent City Area Code City Area Code Product and Service [Axis] Product and Service [Axis] WEIGHTED AVERAGE SHARES OUTSTANDING Earnings Per Share [Text Block] Target payout of Free Cash Flows (FCF) performance awards Target payout of Free Cash Flows (FCF) performance awards Target payout of Free Cash Flows (FCF) performance awards Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Equipment, Furniture, Fixtures Equipment, Furniture, Fixtures [Member] Equipment, Furniture, Fixtures Lessee, Operating Lease, Term of Contract Lessee, Operating Lease, Term of Contract Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block] Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block] Share-based Compensation, Stock Options, Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] One-time transaction tax post-1986 E&P - net payment One-time transaction tax post-1986 E&P - net payment One-time transaction tax post-1986 E&P - net payment Convertible Preferred Stock, Terms of Conversion Preferred Stock, Convertible, Terms Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Financial and Nonfinancial Liabilities, Fair Value Disclosure Liabilities, Fair Value Disclosure Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Net income (loss) Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Fair value of contingent consideration recorded in purchase accounting Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Schedule of Employee Service Share-based Compensation, Allocation of Recognized Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Reconciliation of Operating Profit (Loss) from Segments to Consolidated Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] TOTAL LIABILITIES AND EQUITY Liabilities and Equity Other long-term assets Other long-term assets (total) Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Ownership [Domain] Ownership [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Debt Instrument [Table] Schedule of Long-Term Debt Instruments [Table] Costs Associated with Exit Activities Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Current Foreign Tax Expense (Benefit) Current Foreign Tax Expense (Benefit) Uncertain tax positions Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions March 2026 Notes March 2026 Notes [Member] March 2026 Notes Executive Retirement Plan Discount Rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Arrangement Duration Trading Arrangement Duration IPR&D In Process Research and Development [Member] Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Purchase Obligations, Future Minimum Payments, Due in Two Years Purchase Obligation, to be Paid, Year Two Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Purchase Obligations, Future Minimum Payments, Due in Three Years Purchase Obligation, to be Paid, Year Three SUPPLEMENTAL BALANCE SHEET INFORMATION Supplemental Balance Sheet Disclosures [Text Block] Restructuring net charges (credits) Restructuring Charges Restructuring Charges Business Combinations [Abstract] Business Combinations [Abstract] Termination Date Trading Arrangement Termination Date Derivative Instruments in Hedges, Assets, at Fair Value Derivative Instruments in Hedges, Assets, at Fair Value Common Stock, Shares Authorized Common Stock, Shares Authorized Common Stock, Shares Authorized Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax March 2024 Notes March 2024 Notes [Member] March 2024 Notes Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Investment Investment Holdings, Schedule of Investments [Table Text Block] Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Award Timing Disclosures [Line Items] Litigation and Debt Exclusion from EBITDA Litigation and Debt Exclusion from EBITDA Exclusion of litigation payments and any debt Issued to fund tax deficiency payments Royalty expense Royalty Expense Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Total Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Net loss (gain) on investments and notes receivable Gain (Loss) on Investments Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Long-term Purchase Commitment Long-Term Purchase Commitment [Table Text Block] Change in Contract with Customer, Liability [Abstract] Change in Contract with Customer, Liability [Abstract] Income Taxes Income Tax, Policy [Policy Text Block] Current debt obligations Debt, Current Debt, Current Other current assets Prepaid Expense and Other Assets, Current Future Amortization Expense, Year Three Finite-Lived Intangible Asset, Expected Amortization, Year Three Latin America and Canada [Member] Latin America and Canada [Member] Latin America and Canada [Member] Finance Lease Obligation Capital Lease Obligations [Member] Insider Trading Arrangements [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Other Liabilities, Current [Abstract] Other Liabilities, Current [Abstract] Entity Registrant Name Entity Registrant Name Award Timing Method Award Timing Method [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Other assets Increase (Decrease) in Other Operating Assets Effect of foreign taxes Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Future Amortization Expense, Year Two Finite-Lived Intangible Asset, Expected Amortization, Year Two Indefinite-lived Intangibles and IPR&D In Process Research and Development, Policy [Policy Text Block] Schedule of Unrecognized Compensation Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Cost of products sold Cost of Sales [Member] Contingent consideration net expense (benefit) Contingent consideration net expense (benefit) Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Noncontrolling interests Equity, Attributable to Noncontrolling Interest Auditor Name Auditor Name Financial Asset Licensing arrangement assets [Member] Licensing arrangement assets Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Preferred Stock, Dividend Rate, Percentage Preferred Stock, Dividend Rate, Percentage Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price John Bradley Sorenson Rule Trading Arrangement, Common Stock [Member] John Bradley Sorenson Rule Trading Arrangement, Common Stock Entity Central Index Key Entity Central Index Key Transfer of Financial Assets Accounted for as Sales Transfer of Financial Assets Accounted for as Sales [Table Text Block] Maximum Leverage Ratio Maximum Leverage Ratio Maximum leverage ratio permitted by revolving credit facility agreement. Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Inventory, Finished Goods, Net of Reserves Inventory, Finished Goods, Net of Reserves Acquisition-related Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Payroll and related liabilities Employee-related Liabilities, Current Entity Listing, Par Value Per Share Entity Listing, Par Value Per Share Preferred stock dividends Dividends, Preferred Stock, Cash Proceeds from Royalties Received Proceeds from Royalties Received Revenue-based Payments and Milestones revenue-based payments [Member] revenue-based payments [Member] Name Trading Arrangement, Individual Name Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Supplemental Balance Sheet Information Related to Leases Supplemental Balance Sheet Information Related to Leases [Table Text Block] Supplemental Balance Sheet Information Related to Leases Net sales Revenue from Contract with Customer, Excluding Assessed Tax Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability Deferred Tax Assets, Goodwill and Intangible Assets Deferred Tax Assets, Goodwill and Intangible Assets Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Allowance for doubtful accounts SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Equipment, furniture and fixtures Equipment, furniture and fixtures Gross Equipment, furniture and fixtures Gross. Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Two Valuation of Business Combinations Business Combinations Policy [Policy Text Block] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Deferred Tax Liabilities, Net Deferred Tax Liabilities, Net Diluted Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Supplemental Cash Flow Information Related to Leases Supplemental Cash Flow Information Related to Leases [Table Text Block] Supplemental Cash Flow Information Related to Leases Money Market Funds, at Carrying Value Money Market Funds, at Carrying Value Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Rebates Accrued Rebates, Current Accrued Rebates, Current Operating expenses: Operating Expenses [Abstract] Income Taxes [Line Items] Income Taxes [Line Items] Income Taxes [Line Items] Purchases of property, plant and equipment and internal use software Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount March 2029 Notes March 2029 Notes [Member] March 2029 Notes Defined Benefit Plan, Expected Future Benefit Payment, Year Four Defined Benefit Plan, Expected Future Benefit Payment, Year Four TOTAL ASSETS Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Defined benefit plan, plan assets, actuarial gain loss Defined benefit plan, plan assets, actuarial gain loss Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] 5.50% MCPS, Series A 5.50% MCPS, Series A [Member] 5.50% MCPS, Series A Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract] Options expected to vest Options expected to vest Options expected to vest Non-PEO NEO Non-PEO NEO [Member] Derivative Instruments in Hedges, Liabilities, at Fair Value Derivative Instruments in Hedges, Liabilities, at Fair Value Other Other [Member] Other Deferred Tax Assets, Prepaid on Intercompany Profit Deferred Tax Assets, Prepaid on Intercompany Profit Deferred Tax Assets, Prepaid on Intercompany Profit Adjustment to Compensation: Adjustment to Compensation [Axis] Deferred Tax Assets, Operating Loss Carryforwards Deferred Tax Assets, Operating Loss Carryforwards Debt Instrument [Line Items] Debt Instrument [Line Items] Basic Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic Deferred Tax Assets, Property, Plant and Equipment Deferred Tax Assets, Property, Plant and Equipment Deferred Tax Liabilities, Property, Plant and Equipment Deferred Tax Liabilities, Property, Plant and Equipment January 2040 Notes January 2040 Notes [Member] January 2040 Notes [Member] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Licensing arrangements Licensing arrangements, asset Licensing arrangements, asset Noncontrolling interests Noncontrolling Interest [Member] EX-101.PRE 14 bsx-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 15 image_0a.jpg begin 644 image_0a.jpg MB5!.1PT*&@H -24A$4@ #+( "9" 8 "!^_): "7!(67, $SE M !,Y0%USO"5 'G4E$051XG.W! 0$ ""(/^O;DA 0 M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M '!A6^, 2BF[B$ 245.1*Y" "8((! end GRAPHIC 16 bsx-20231231_g1.jpg begin 644 bsx-20231231_g1.jpg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�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end XML 17 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2023
Jan. 31, 2024
Jun. 30, 2023
Entity Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2023    
Document Transition Report false    
Entity File Number 1-11083    
Entity Registrant Name BOSTON SCIENTIFIC CORPORATION    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 04-2695240    
Entity Address, Address Line One 300 Boston Scientific Way    
Entity Address, City or Town Marlborough    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 01752-1234    
City Area Code 508    
Local Phone Number 683-4000    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 79,000
Entity Listing, Par Value Per Share $ 0.01    
Entity Common Stock, Shares Outstanding   1,467,095,627  
Entity Central Index Key 0000885725    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Amendment Flag false    
Documents Incorporated by Reference
Documents Incorporated by Reference
Portions of the registrant’s definitive proxy statement to be filed within 120 days of December 31, 2023 with the Securities and Exchange Commission in connection with its 2024 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K.
    
Common stock      
Entity Information [Line Items]      
Title of 12(b) Security Common Stock, $0.01 par value    
Trading Symbol BSX    
Security Exchange Name NYSE    
Senior Note due 2027 [Member]      
Entity Information [Line Items]      
Title of 12(b) Security 0.625% Senior Notes due 2027    
Trading Symbol BSX27    
Security Exchange Name NYSE    

XML 18 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Audit Information
 12 Months Ended
Dec. 31, 2023
Audit Information [Abstract]  
Auditor Name Ernst & Young LLP
Auditor Firm ID 42
Auditor Location Boston, Massachusetts
XML 19 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]      
Net sales $ 14,240 $ 12,682 $ 11,888
Cost of products sold 4,345 3,956 3,711
Gross profit 9,896 8,727 8,177
Operating expenses:      
Selling, general and administrative expenses 5,190 4,520 4,359
Research and development expenses 1,414 1,323 1,204
Royalty expense 46 47 49
Amortization expense 828 803 741
Intangible asset impairment charges 58 132 370
Contingent consideration net expense (benefit) 58 35 (136)
Restructuring net charges (credits) 69 24 40
Litigation-related net charges (credits) (111) 173 430
Loss (Gain) on Disposal of Businesses and Assets 0 22 (78)
Operating expenses 7,553 7,078 6,978
Operating income (loss) 2,343 1,649 1,199
Other income (expense):      
Interest expense (265) (470) (341)
Other, net (93) (38) 218
Income (loss) before income taxes 1,985 1,141 1,076
Income tax expense (benefit) 393 443 36
Net income (loss) 1,592 698 1,041
Preferred stock dividends 23 55 55
Net income (loss) attributable to noncontrolling interests (1) 0 0
Net income (loss) attributable to Boston Scientific common stockholders $ 1,570 $ 642 $ 985
Net income (loss) per common share — basic $ 1.08 $ 0.45 $ 0.69
Net income (loss) per common share — diluted $ 1.07 $ 0.45 $ 0.69
Weighted-average shares outstanding      
Basic 1,453,000 1,430,500 1,422,300
Diluted 1,463,500 1,439,700 1,433,800
XML 20 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of Comprehensive Income [Abstract]      
Net income (loss) $ 1,592 $ 698 $ 1,041
Other comprehensive income (loss), net of tax:      
Foreign currency translation adjustment (105) (94) (125)
Net change in derivative financial instruments (115) 63 170
Net change in defined benefit pensions and other items (9) 37 11
Other comprehensive income (loss) (230) 6 56
Comprehensive income (loss) 1,362 704 1,096
Comprehensive income (loss) attributable to noncontrolling interests (11) 0 0
Comprehensive income attributable to Boston Scientific common stockholders $ 1,373 $ 704 $ 1,096
XML 21 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 865 $ 928
Trade accounts receivable, net 2,228 1,970
Inventories 2,484 1,867
Prepaid income taxes 315 264
Other current assets 621 731
Total current assets 6,514 5,760
Property, plant and equipment, net 2,859 2,446
Goodwill 14,387 12,920
Other intangible assets, net 6,003 5,902
Deferred tax assets 3,841 3,942
Other long-term assets 1,531 1,500
TOTAL ASSETS 35,136 32,469
Current liabilities:    
Current debt obligations 531 20
Accounts payable 942 862
Accrued expenses 2,646 2,160
Other current liabilities 814 761
Total current liabilities 4,933 3,803
Long-term debt 8,571 8,915
Deferred tax liabilities 134 144
Other long-term liabilities 1,967 2,035
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.01 par value - authorized 50,000,000 shares; 0 shares issued as of December 31, 2023 and 10,062,500 shares issued as of December 31, 2022 0 0
Common stock, $0.01 par value - authorized 2,000,000,000 shares; 1,729,000,224 shares issued as of December 31, 2023 and 1,696,633,993 shares issued as of December 31, 2022 17 17
Treasury stock, at cost - 263,289,848 shares as of December 31, 2023 and 2022 (2,251) (2,251)
Additional paid-in capital 20,647 20,289
Retained earnings (Accumulated deficit) 819 (750)
Accumulated other comprehensive income (loss), net of tax: 49 269
Equity, Attributable to Parent 19,282 17,573
Noncontrolling interests 248 0
Total stockholders’ equity 19,530 17,573
TOTAL LIABILITIES AND EQUITY $ 35,136 $ 32,469
XML 22 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheet Paranthetical - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Consolidated Balance Sheet (Parenthetical) [Abstract]    
Preferred Stock, Par or Stated Value Per Share $ 0.01 $ 0.01
Preferred Stock, Shares Authorized 50,000,000 50,000,000
Preferred Stock, Shares Issued 0 10,062,500
Common Stock, Par or Stated Value Per Share $ 0.01 $ 0.01
Common Stock, Shares Authorized 2,000,000,000 2,000,000,000
Common Stock, Shares, Issued 1,729,000,224 1,696,633,993
Treasury Stock, Shares 263,289,848 263,289,848
XML 23 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Millions
Total
Preferred stock
Common stock
Treasury Stock
Additional paid-in capital
Retained earnings (Accumulated deficit)
Accumulated other comprehensive income (loss), net of tax
Noncontrolling interests
Preferred Stock, Shares Issued at Dec. 31, 2020   10,062,500            
Balance (Shares) at Dec. 31, 2020     1,679,911,918          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Conversion of mandatory convertible preferred stock to common stock   0 0          
Impact of stock-based compensation plans     8,898,134          
Preferred Stock, Shares Issued at Dec. 31, 2021   10,062,500            
Balance (Shares) at Dec. 31, 2021 1,688,810,052   1,688,810,052          
Beginning Stockholders' Equity at Dec. 31, 2020   $ 0 $ 17 $ (2,251) $ 19,732 $ (2,378) $ 207 $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Conversion of mandatory convertible preferred stock to common stock $ 0 0 0          
Impact of stock-based compensation plans     0   254      
Repurchase of common stock       0        
Net income (loss) 1,041         1,041    
Preferred stock dividends           (55)    
Foreign currency translation adjustment (125)           (125)  
Derivative financial instruments 170           170  
Defined benefit pensions and other items 11           11  
Changes to noncontrolling ownership interest               0
Net income (loss) attributable to noncontrolling interests 0             0
Changes in other comprehensive income (loss) 56             0
Ending Stockholders' Equity at Dec. 31, 2021 16,622 $ 0 $ 17 (2,251) 19,986 (1,392) 263 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Total equity $ 16,622              
Conversion of mandatory convertible preferred stock to common stock   0 0          
Impact of stock-based compensation plans     7,823,941          
Preferred Stock, Shares Issued at Dec. 31, 2022 10,062,500 10,062,500            
Balance (Shares) at Dec. 31, 2022 1,696,633,993   1,696,633,993          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Conversion of mandatory convertible preferred stock to common stock   $ 0 $ 0   0      
Impact of stock-based compensation plans     0   303      
Repurchase of common stock       0        
Net income (loss) $ 698         698    
Preferred stock dividends           (55)    
Foreign currency translation adjustment (94)           (94)  
Derivative financial instruments 63           63  
Defined benefit pensions and other items 37           37  
Changes to noncontrolling ownership interest               0
Net income (loss) attributable to noncontrolling interests 0             0
Changes in other comprehensive income (loss) 6           6 0
Ending Stockholders' Equity at Dec. 31, 2022 17,573 $ 0 $ 17 (2,251) 20,289 (750) 269 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Total equity $ 17,573              
Conversion of mandatory convertible preferred stock to common stock   (10,062,500) 23,982,902          
Impact of stock-based compensation plans     8,383,329          
Preferred Stock, Shares Issued at Dec. 31, 2023 0 0            
Balance (Shares) at Dec. 31, 2023 1,729,000,224              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Conversion of mandatory convertible preferred stock to common stock   $ 0 $ 0   0      
Impact of stock-based compensation plans     0   359      
Repurchase of common stock       0        
Net income (loss) $ 1,592         1,592    
Preferred stock dividends           (23)    
Foreign currency translation adjustment (105)           (95)  
Derivative financial instruments (115)           (115)  
Defined benefit pensions and other items (9)           (9)  
Changes to noncontrolling ownership interest               259
Net income (loss) attributable to noncontrolling interests 1             (1)
Changes in other comprehensive income (loss) (230)           (219) (10)
Ending Stockholders' Equity at Dec. 31, 2023 19,282 $ 0 $ 17 $ (2,251) $ 20,647 $ 819 $ 49 $ 248
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Total equity $ 19,530              
XML 24 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of Cash Flows [Abstract]      
Net income (loss) $ 1,592,000,000 $ 698,000,000 $ 1,041,000,000
Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities      
Loss (gain) on disposal of businesses and assets 0 22,000,000 (78,000,000)
Depreciation and amortization 1,196,000,000 1,136,000,000 1,093,000,000
Deferred and prepaid income taxes (1,000,000) (63,000,000) (124,000,000)
Stock-based compensation expense 233,000,000 220,000,000 194,000,000
Goodwill and other intangible asset impairment charges 58,000,000 132,000,000 370,000,000
Net loss (gain) on investments and notes receivable 59,000,000 1,000,000 (250,000,000)
Contingent consideration net expense (benefit) 58,000,000 35,000,000 (136,000,000)
Inventory step-up amortization 6,000,000 32,000,000 34,000,000
Debt extinguishment net charges 0 194,000,000 0
Other, net 73,000,000 125,000,000 78,000,000
Increase (decrease) in operating assets and liabilities, excluding purchase accounting:      
Trade accounts receivable (238,000,000) (220,000,000) (279,000,000)
Inventories (660,000,000) (321,000,000) (346,000,000)
Other assets 10,000,000 (209,000,000) (134,000,000)
Accounts payable, accrued expenses and other liabilities 118,000,000 (255,000,000) 408,000,000
Cash provided by (used for) operating activities 2,503,000,000 1,526,000,000 1,870,000,000
Investing Activities      
Purchases of property, plant and equipment and internal use software (711,000,000) (588,000,000) (554,000,000)
Proceeds from sale of property, plant and equipment 4,000,000 12,000,000 14,000,000
Payments for acquisitions of businesses, net of cash acquired (1,811,000,000) (1,542,000,000) (2,258,000,000)
Proceeds from (payments for) investments and acquisitions of certain technologies (89,000,000) (24,000,000) 279,000,000
Proceeds from disposal of certain businesses and assets 0 5,000,000 826,000,000
Proceeds from royalty rights 30,000,000 70,000,000 82,000,000
Proceeds from settlements of hedge contracts 2,000,000 56,000,000 15,000,000
Cash provided by (used for) investing activities (2,574,000,000) (2,011,000,000) (1,597,000,000)
Financing Activities      
Payment of contingent consideration previously established in purchase accounting (39,000,000) (335,000,000) (15,000,000)
Payments for royalty rights (50,000,000) (75,000,000) (85,000,000)
Payments on short-term borrowings 0 (250,000,000) 0
Net decrease in commercial paper (4,000,000) (1,000,000) 0
Payments on long-term borrowings and debt extinguishment costs 0 (3,184,000,000) 0
Proceeds from long-term borrowings, net of debt issuance costs 0 3,270,000,000 0
Cash dividends paid on preferred stock (28,000,000) (55,000,000) (55,000,000)
Cash used to net share settle employee equity awards (56,000,000) (53,000,000) (50,000,000)
Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans 182,000,000 136,000,000 110,000,000
Cash provided by (used for) financing activities 5,000,000 (548,000,000) (95,000,000)
Effect of foreign exchange rates on cash (4,000,000) (9,000,000) (6,000,000)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents (70,000,000) (1,042,000,000) 173,000,000
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period 1,126,000,000 2,168,000,000 1,995,000,000
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period 1,055,000,000 1,126,000,000 2,168,000,000
Supplemental Information      
Cash paid for income taxes, net 512,000,000 662,000,000 302,000,000
Cash paid for interest 259,000,000 450,000,000 338,000,000
Fair value of contingent consideration recorded in purchase accounting 273,000,000 0 440,000,000
Non-cash impact of transferred royalty rights (30,000,000) (70,000,000) (82,000,000)
Cash and cash equivalents 865,000,000 928,000,000 1,925,000,000
Restricted cash and restricted cash equivalents included in Other current assets 130,000,000 149,000,000 188,000,000
Restricted cash equivalents included in Other long-term assets 60,000,000 48,000,000 55,000,000
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period $ 1,055,000,000 $ 1,126,000,000 $ 2,168,000,000
XML 25 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
Significant Accounting Policies
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES
NOTE A – SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

Our consolidated financial statements include the accounts of Boston Scientific Corporation's wholly owned subsidiaries and entities for which we have a controlling financial interest. All intercompany balances and transactions have been eliminated in consolidation.

When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE). For any VIEs, we perform an analysis to determine whether our variable interests give us a controlling financial interest. The analysis identifies the primary beneficiary of a VIE as the enterprise that has both 1) the power to direct activities of a VIE that most significantly impact the entity’s economic performance and 2) the obligation to absorb losses of the entity or the right to receive benefits from the entity. Based on our assessments under the applicable guidance, we did not have controlling financial interests in any VIEs and, therefore, did not consolidate any VIEs during 2023, 2022 or 2021.

Basis of Presentation

The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and with the instructions to Form 10-K and Regulation S-X.

Amounts reported in millions within this Annual Report on Form 10-K are computed based on the amounts in thousands. As a result, the sum of the components may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded numbers.

Subsequent Events

We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly.

Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note B – Acquisitions and Strategic Investments for further details.

Accounting Estimates

To prepare our consolidated financial statements in accordance with GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our consolidated financial statements and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to Critical Accounting Estimates included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for further discussion.

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents

Cash and Cash Equivalents

We record Cash and cash equivalents in our consolidated balance sheets at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider cash equivalents to be all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash.
Restricted Cash

Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in Other current assets within our consolidated balance sheets. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the customer payments collected by us for servicing previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee.

Restricted Cash Equivalents

Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in Other current assets within our consolidated balance sheets. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents included in Other long-term assets within our consolidated balance sheets are related to deferred compensation plans.

Concentrations of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including distributors, hospitals, health care agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral.

We record credit loss reserves to Allowance for credit losses when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach to determine the reserve to record at accounts receivable commencement for certain customers, applying country or region-specific factors. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account.

We write-off amounts determined to be uncollectible against this reserve. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in 2023, 2022 and 2021; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups are important to our business and represent a substantial portion of our net sales.

We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other countries. Further, the ongoing site-of-service trend of shifting procedure volumes in the U.S. toward non-hospital settings, particularly ambulatory surgery centers and office-based labs, continues. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions, as appropriate. We believe our Allowance for credit losses is adequate as of December 31, 2023; however, if significant changes were to occur in the payment practices of government customers, or if there is an increase in bankruptcies among our ambulatory surgery center or office-based customers, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts may increase.
 
Revenue Recognition

We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers:

•We have a contract with a customer that creates enforceable rights and obligations,
•Promised products or services are identified,
•The transaction price, or the amount we expect to receive, is determinable and
•We have transferred control of the promised items to the customer.

Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a component of Selling, general and administrative expenses when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.

Deferred Revenue

We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.

Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying consolidated balance sheets. Our contract liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. Our contract liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

Variable Consideration

We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.

We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.
Post-Implant Services

We provide non-contractual services to customers, where necessary, to ensure the safe and effective use of certain implanted devices. Because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to Selling, general and administrative expenses within our consolidated statements of operations. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost. Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.

Warranty Obligations

We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our CRM business, which include implantable defibrillator and pacemaker systems. These products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a liability equal to these estimated costs as Cost of products sold at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary.

Inventories

We state inventories at the lower of first-in, first-out cost or net realizable value. We utilize a standard costing system, capitalizing variances between estimated and actual production costs during periods of normal production, and amortize to Cost of products sold over inventory turns. We expense manufacturing variances during periods of abnormal production, or less than 75 percent of manufacturing capacity. We did not record any abnormal production variances during the years ended December 31, 2023, 2022 or 2021.

We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory.

Property, Plant and Equipment

We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of 40 years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a three to seven year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.

Valuation of Business Combinations

We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&D, on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through Selling, general and administrative expenses.

In cases where we acquire a company in which we previously held an equity stake, we attribute a portion of the purchase price to the previously-held equity interest, which is implied based on the total purchase consideration allocable to each of the shareholders, including Boston Scientific, according to priority of equity interests. We record a gain or loss in Other, net equal to the difference between the implied fair value of our prior ownership and the book value immediately prior to the acquisition.
Where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through Contingent consideration net expense (benefit) on our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.

Indefinite-lived Intangibles and IPR&D

Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which are foundational to our ongoing operations, as well as IPR&D intangible assets acquired in a business combination. Our IPR&D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&D intangible asset.

We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, Intangibles - Goodwill and Other (FASB ASC Topic 350). If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value.

We use the income approach to determine the fair values of our IPR&D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects’ stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See Note C – Goodwill and Other Intangible Assets for more information related to indefinite-lived intangibles, including IPR&D.

For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date.

Amortization and Impairment of Intangible Assets

We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, two to 20 years; amortizable technology-related and customer relationships, five to 25 years; other intangible assets, various. In addition, we classify internal use software as an intangible asset within our accompanying consolidated balance sheets and amortize over a one to 15 year useful life. Due to the operational nature of these assets, we record the amortization of our internal use software within Cost of products sold; Selling, general and administrative expenses and Research and development expenses, as appropriate within our accompanying consolidated statements of operations, and include in Amortization expense only that associated with intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents.

We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for
recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified.

We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See Note C – Goodwill and Other Intangible Assets for more information related to impairments of intangible assets.

For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent.

Goodwill Valuation

We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances, utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350, Intangibles - Goodwill and Other, in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.

We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2023 annual impairment assessment, we identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components into a single Rhythm Management reporting unit.

In performing annual impairment assessments, the qualitative approach is used for testing reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units are tested using the quantitative approach. When a quantitative test is performed, we typically use the income approach, specifically the Discounted Cash Flow method, to derive the fair value of each of our reporting units in preparing our goodwill impairment assessments. We historically selected this method as being the most meaningful in preparing our goodwill assessments because we believe the income approach most appropriately measures the fair value of our income producing assets. We make assumptions about the amount and timing of future expected cash flows, terminal value growth rates and appropriate discount rates. The amount and timing of future cash flows within our Discounted Cash Flow analysis is based on our most recent operational budgets, long range strategic plans and other estimates.

Investments in Publicly Traded and Privately-Held Entities

For publicly-held equity securities for which we do not have the ability to exercise significant influence, we measure at fair value with changes in fair value recognized currently in Other, net within our accompanying consolidated statements of operations. For privately-held equity securities for which we do not have the ability to exercise significant influence, we apply the measurement alternative approach and measure these investments at cost minus impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We account for investments in entities for which we have the ability to exercise significant influence under the equity method if we hold 50 percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with FASB ASC Topic 323, Investments - Equity Method and Joint Ventures. We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing consolidated financial statements. Lastly, we have notes receivable from certain companies that we account for in accordance with FASB ASC Topic 320, Investments - Debt and Equity Securities. Refer to Note B – Acquisitions and Strategic Investments for additional details on our investment balances.

Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an
investee’s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. For our investments for which we apply the measurement alternative, if the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. For our equity method investments, if we determine an impairment is other-than-temporary, we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value.

Net gains and losses and impairments associated with our investment portfolio are included within Other, net in our consolidated statements of operations.

Income Taxes

We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial condition and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We recognize interest and penalties related to income taxes as a component of income tax expense. As part of the Tax Cuts and Jobs Act (TCJA), we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and report it as part of continuing operations. See Note H – Income Taxes for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA.

Legal and Product Liability Costs

We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities and product liability litigation. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related charges (credits) in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our consolidated statements of operations. See Note I – Commitments and Contingencies for discussion of our individual material legal proceedings.

Costs Associated with Exit Activities

We record employee termination costs in accordance with FASB ASC Topic 712, Compensation - Nonretirement and Postemployment Benefits, if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with FASB ASC Topic 420, Exit or Disposal Cost Obligations (FASB ASC Topic 420). We record such costs into expense over the employee’s future service period, if any.
Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with FASB ASC Topic 420 and are included within Restructuring net charges (credits) in our consolidated statements of operations. We recorded Restructuring net charges (credits) of $69 million in 2023, $24 million in 2022 and $40 million in 2021. The restructuring reserve balance as of December 31, 2023 and 2022 was $41 million and $10 million, respectively. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities are included within Costs of products sold, Selling, general and administrative expenses and Research and development expenses within our consolidated statements of operations. Impairment of right of use lease assets and lease termination costs directly related to our active restructuring initiatives are expensed in accordance with FASB ASC Topic 842, Leases (FASB ASC Topic 842) and included within Costs of products sold or Selling, general and administrative expenses in our consolidated statements of operations.

Translation of Foreign Currency

We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate. We show the net effect of these translation adjustments within our consolidated financial statements as a component of Accumulated other comprehensive income (loss), net of tax. We translate revenues and expenses at the average exchange rates in effect during the year. For any significant foreign subsidiaries located in highly inflationary economies, we re-measure their financial statements as if the functional currency were the U.S. dollar.

Foreign currency transaction gains and losses are included within Other, net in our consolidated statements of operations, net of losses and gains from any related derivative financial instruments.

Financial Instruments

We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815, Derivatives and Hedging (FASB ASC Topic 815), and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our consolidated financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to Note D – Hedging Activities and Fair Value Measurements for more information on our hedging instruments.

Research and Development

We expense research and development (R&D) costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to Indefinite-lived Intangibles and IPR&D above for our policy regarding R&D projects acquired in connection with our business combinations and asset purchases.
XML 26 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions and Strategic Investments
 12 Months Ended
Dec. 31, 2023
Business Combinations [Abstract]  
ACQUISITIONS AND STRATEGIC INVESTMENTS
NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS

Our consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our consolidated financial statements. Further, transaction costs were immaterial to our consolidated financial statements and were expensed as incurred.

On January 8, 2024, we announced our entry into a definitive agreement to acquire 100 percent of Axonics, Inc. (Axonics), a publicly traded medical technology company primarily focused on the development and commercialization of devices to treat urinary and bowel dysfunction. The purchase price is $71.00 in cash per share, or approximately $3.670 billion. The transaction is expected to close in the first half of 2024, subject to customary closing conditions. The Axonics business will be integrated into our Urology division.
2023 Acquisitions

On February 20, 2023, we completed the acquisition of a majority stake investment in Acotec, a publicly traded Chinese manufacturer of drug-coated balloons and other products used in the treatment of vascular and other diseases. We consolidated this majority stake investment in Acotec based on the conclusion we control the entity, and recorded a noncontrolling interest for the portion we do not own. We acquired approximately 65 percent of the outstanding shares of Acotec, for an upfront cash payment of HK$20.00 per share, or $519 million at foreign currency exchange rates at closing. The Acotec portfolio complements our existing Peripheral Interventions portfolio.

On April 4, 2023, we completed our acquisition of 100 percent of the outstanding equity of Apollo Endosurgery, Inc. (Apollo), a public company which offers a portfolio of devices used during endoluminal procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity. The transaction consisted of an upfront cash payment of $636 million, net of cash acquired. The Apollo business is being integrated into our Endoscopy division.

On November 17, 2023, we completed our acquisition of 100 percent of the outstanding equity of Relievant Medsystems, Inc. (Relievant), a privately held medical technology company that developed and commercialized the Intracept® Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain. The transaction consisted of an upfront cash payment of $794 million, net of cash acquired, and additional sales-based milestones over the 3 years following the transaction close. These milestones, certain of which are uncapped, are estimated to have a fair value of $273 million. The Relievant business is being integrated into our Neuromodulation division.

Purchase Price Allocation

We accounted for these transactions as business combinations in accordance with FASB ASC Topic 805, Business Combinations (FASB ASC Topic 805). The preliminary purchase prices were comprised of the amounts presented below:

(in millions)
Acotec(1)
ApolloRelievant
Payment for acquisition, net of cash acquired (2)
$381 $636 $794 
Fair value of contingent consideration— — 273 
$381 $636 $1,067 
(1) Excludes approximately $140 million of cash on hand at the closing of the transaction
(2) Related to Acotec, represents our majority stake investment

We recorded the assets acquired, liabilities assumed and specific to Acotec, the noncontrolling interest, at their respective fair values as of the closing date of the transaction. The preliminary purchase price allocations were comprised of the components presented below, which represent the preliminary determination of the fair value of identifiable assets acquired and liabilities assumed, as well as goodwill. The final determination of the fair value of certain assets and liabilities will be completed within the measurement period in accordance with FASB ASC Topic 805:

(in millions)AcotecApolloRelievant
Goodwill$337 $378 $731 
Amortizable intangible assets334 248 325 
Other assets acquired93 50 24 
Liabilities assumed(48)(33)(15)
Net deferred tax liabilities(76)(5)1 
Fair value of noncontrolling interest(259)— — 
$381 $636 $1,067 
The fair value of Acotec's noncontrolling interest was based on the publicly traded market value of the remaining 35 percent of the outstanding shares we did not acquire as of the transaction date and is presented within Stockholders' equity within our accompanying consolidated balance sheets. Goodwill was primarily established for Acotec due to opportunities for collaboration in research and development, manufacturing and commercial strategies, and for Apollo and Relievant, due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies, none of which is deductible for tax purposes.

We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Acotec:
Amortizable intangible assets:
Technology-related$308 1114%
Customer relationships15 1114%
Other intangible assets11 1314%
$334 
Apollo:
Amortizable intangible assets:
Technology-related$222 1112%
Customer relationships26 1112%
$248 
Relievant
Amortizable intangible assets:
Technology-related$287 1212%
Customer relationships38 1212%
$325 

2022 Acquisition

On February 14, 2022, we completed our acquisition of Baylis Medical Company Inc. (Baylis Medical), a privately-held company which developed the radiofrequency (RF) NRG™ and VersaCross™ Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access, which expanded our electrophysiology and structural heart product portfolios. The transaction consisted of an upfront cash payment of $1.463 billion, net of cash acquired, subject to closing adjustments. We are integrating Baylis Medical into our Cardiology division.

Purchase Price Allocation

We accounted for the acquisition of Baylis Medical as a business combination in accordance with FASB ASC Topic 805. The final purchase price was comprised of the amount presented below:

(in millions)
Payment for acquisition, net of cash acquired$1,463 
$1,463 
We recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The final purchase price allocation was comprised of the following components:

(in millions)
Goodwill$988 
Amortizable intangible assets657 
Other assets acquired112 
Liabilities assumed(287)
Net deferred tax liabilities(7)
$1,463 

Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies, and was deductible for tax purposes.

We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
Technology-related622 1111%
Other intangible assets36 1111%
$657 

Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes and will carry forward from one product generation to the next. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives.

Contingent Consideration

Changes in the fair value of our contingent consideration liability during 2023 and 2022 associated with current and prior period acquisitions were as follows:
(in millions)
Balance as of December 31, 2021$486 
Contingent consideration net expense (benefit)35 
Contingent consideration payments(371)
Balance as of December 31, 2022$149 
Amount recorded related to current year acquisitions273 
Contingent consideration net expense (benefit)58 
Contingent consideration payments(76)
Balance as of December 31, 2023$404 
In 2023, payments were primarily related to our acquisition of Farapulse, Inc. (Farapulse) following the achievement of revenue milestones. In 2022, payments were primarily related to our acquisition of Farapulse and Preventice Solutions, Inc., following the achievement of revenue and/or regulatory milestones. The net expense of $58 million and $35 million recorded in 2023 and 2022, respectively, related primarily to an increase in expected revenue-based payments as a result of over-achievement of net sales performance, primarily related to our acquisition of Farapulse. In both periods, this increase was partially offset by a reduction in the contingent consideration liability for certain acquisitions for which we reduced the probability of achievement of associated regulatory and commercialization-based milestones upon which payment is conditioned.

The maximum amount for certain contingent consideration is not determinable as it is uncapped and based on a percent of certain sales. As of December 31, 2023, the fair value of such uncapped contingent consideration is estimated at $177 million. As of December 31, 2023, the maximum amount that we could be required to pay under our other contingent consideration arrangements (undiscounted) is approximately $398 million.

The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:
Contingent Consideration LiabilityFair Value as of December 31, 2023Valuation TechniqueUnobservable InputRange
Weighted Average(1)
Revenue-based Payments and Milestones$404 millionDiscounted Cash FlowDiscount Rate6 %-12%10%
Probability of Payment90%-100%98%
Projected Year of Payment2024-20272025
(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Projected contingent payment amounts related to our revenue-based payments and milestones are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of December 31, 2023.

Strategic Investments

The aggregate carrying amount of our strategic investments was comprised of the following:
As of December 31,
(in millions)20232022
Equity method investments$219 $188 
Measurement alternative investments(1, 2)
194 219 
$413 $407 
(1) Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying consolidated statements of operations.
(2) Includes publicly-held equity securities and convertible notes measured at fair value with changes in fair value recognized in Other, net within our consolidated statements of operations.

These investments are classified as Other long-term assets within our consolidated balance sheets, in accordance with GAAP and our accounting policies.
In 2023, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $261 million, which represents amortizable intangible assets, IPR&D, goodwill and deferred tax liabilities.
XML 27 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Other Intangible Assets
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS
NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:
 As of December 31, 2023As of December 31, 2022
(in millions)Gross Carrying AmountAccumulated
Amortization/
Write-offs		Gross Carrying AmountAccumulated
Amortization/
Write-offs
Technology-related$13,207 $(8,101)$12,397 $(7,378)
Patents480 (387)486 (394)
Other intangible assets2,130 (1,500)1,960 (1,400)
Amortizable intangible assets$15,817 $(9,988)$14,843 $(9,173)
Goodwill$24,287 $(9,900)$22,820 $(9,900)
IPR&D54 112 
Technology-related120 120 
Indefinite-lived intangible assets$174 $232 

The increase in our balance of goodwill and amortizable intangible assets is related primarily to our majority stake investment in Acotec completed in the first quarter of 2023 and our acquisitions of Apollo and Relievant completed during the second and fourth quarters of 2023, respectively.

Intangible asset impairment charges were $58 million in 2023, $132 million in 2022 and $370 million in 2021. The impairment charges recorded in 2023 were primarily associated with the cancellation of an IPR&D program due to the incremental time and cost to complete the program and bring the technology to market. The impairment charges recorded in 2022 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of Vertiflex, Inc., which is now part of our Neuromodulation business, resulting from lower revenue projections due to reimbursement challenges.

The following represents a rollforward of our goodwill balance by reportable segment:
(in millions)MedSurgCardiovascularTotal
Balance as of December 31, 2021$4,246 $7,741 $11,988 
Goodwill acquired— 1,030 1,030 
Foreign currency fluctuations and other changes(10)(88)(98)
Balance as of December 31, 2022$4,237 $8,684 $12,920 
Goodwill acquired1,110 337 1,447 
Foreign currency fluctuations and other changes— 20 20 
Balance as of December 31, 2023$5,347 $9,041 $14,387 
In the second quarter of 2023, we performed our annual goodwill impairment test utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350. The qualitative approach was used for testing reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units were tested using the quantitative approach. We determined that the fair value of each reporting unit exceeded its carrying value and concluded that goodwill was not impaired or at risk of impairment.
Refer to Note A – Significant Accounting Policies for further discussion of our goodwill and intangible asset impairment testing.
Estimated Amortization expense for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio, consisting of intangible assets acquired in a business combination or asset acquisition, as well as internally developed patents, as of December 31, 2023 is as follows:
Fiscal Year(in millions)
2024$828 
2025757 
2026737 
2027714 
2028690 

These estimates do not include amortization expense associated with future acquisitions that have been announced but not yet completed as of December 31, 2023.
XML 28 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
Hedging Activities and Fair Value Measurements
 12 Months Ended
Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS
NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS

Derivative Instruments and Hedging Activities

We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.

We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.

Currency Hedging Instruments
Risk Management Strategy
Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities; forecasted intercompany and third-party transactions; and net investments in certain subsidiaries. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates.

The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in euro, Chinese renminbi, Japanese yen, British pound sterling, Australian dollar, Swiss franc and South Korean won. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecasted. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.

Hedge Designations and Relationships

Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the Net change in derivative financial instruments component of Other comprehensive income (loss), net of tax (OCI) within our consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within Cost of products sold in our consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within Accumulated
other comprehensive income (loss), net of tax (AOCI) to earnings at that time. The cash flows related to the derivative instruments designated as cash flow hedges are reported as operating activities in our consolidated statements of cash flows.

We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Japanese yen and Taiwan dollar. For these derivative instruments, we elected to use the spot method to assess hedge effectiveness. We also elected to exclude the spot-forward difference, referred to as the excluded component, from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. As such, we defer recognition of foreign currency gains and losses within the Foreign currency translation adjustment (CTA) component of OCI, and we reclassify amortization of the excluded component from AOCI to current period earnings within Interest expense in our consolidated statements of operations.

We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro. As of December 31, 2023 and 2022, we designated as a net investment hedge our €900 million in aggregate principal amount of 0.625% senior notes issued in November 2019 and due in 2027 (2027 Notes). For these nonderivative instruments, we defer recognition of the foreign currency remeasurement gains and losses within the CTA component of OCI. We reclassify these gains and losses to current period earnings within Other, net in our consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary.

We also use forward currency contracts that are not part of designated hedging relationships as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within Other, net in our consolidated statements of operations.

Interest Rate Hedging Instruments
Risk Management Strategy

Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.

Hedge Designations and Relationships

We had no interest rate derivative instruments designated as cash flow hedges outstanding as of December 31, 2023 and December 31, 2022. In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within OCI until the underlying hedged transaction occurs.

We had no interest rate derivative instruments designated as fair value hedges outstanding as of December 31, 2023 and December 31, 2022. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in Interest expense, which generally offset.

The following table presents the contractual amounts of our hedging instruments outstanding:
(in millions)FASB ASC Topic 815 DesignationAs of December 31,
20232022
Forward currency contractsCash flow hedge$2,284 $2,725 
Forward currency contractsNet investment hedge333 365 
Foreign currency-denominated debt(1)
Net investment hedge997 997 
Forward currency contractsNon-designated3,282 4,235 
Total Notional Outstanding$6,896 $8,321 
(1) Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge.
The remaining time to maturity as of December 31, 2023 is within 36 months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature between one and two years. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.

The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying consolidated statements of operations. Refer to Note O – Changes in Other Comprehensive Income for the total amounts relating to derivative and nonderivative instruments presented within our consolidated statements of comprehensive income (loss).
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Year Ended December 31, 2023
Forward currency contracts
Cash flow hedges$81 $(18)$63 Cost of products sold$4,345 $(235)$53 $(182)
Net investment hedges(2)
32 (7)25 Interest expense265 (10)2 (8)
Foreign currency-denominated debt
Net investment hedges(3)
(34)8 (27)Other, net93 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense265 3 (1)2 
Year Ended December 31, 2022
Forward currency contracts
Cash flow hedges$276 $(62)$214 Cost of products sold$3,956 $(209)$47 $(162)
Net investment hedges(2)
41 (10)32 Interest expense470 (10)2 (8)
Foreign currency-denominated debt
Net investment hedges(3)
61 (14)47 Other, net38 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense470 16 (4)13 
Year Ended December 31, 2021
Forward currency contracts
Cash flow hedges$268 $(60)$208 Cost of products sold$3,711 $(54)$12 $(42)
Net investment hedges(2)
56 (13)43 Interest expense341 (13)3 (10)
Foreign currency-denominated debt
Net investment hedges(3)
82 (19)64 Other, net(218)— — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense341 5 (1)4 
(1) In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings.
(2) For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.
(3) For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.
As of December 31, 2023, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):
Designated Hedging InstrumentFASB ASC Topic 815 DesignationLocation on Consolidated Statements of OperationsAmount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Forward currency contractsCash flow hedgeCost of products sold$152 
Forward currency contractsNet investment hedgeInterest expense9 
Interest rate derivative contractsCash flow hedgeInterest expense(1)

Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
(in millions)Location on Consolidated Statements of OperationsYear Ended December 31,
202320222021
Net gain (loss) on currency hedge contractsOther, net$3 $(53)$(16)
Net gain (loss) on currency transaction exposuresOther, net(44)21 (12)
Net currency exchange gain (loss)$(41)$(31)$(27)
Fair Value Measurements

FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures (FASB ASC Topic 820), and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:
(in millions)
Location on Consolidated Balance Sheets(1)
As of December 31,
20232022
Derivative and Nonderivative Assets:   
Designated Hedging Instruments  
Forward currency contractsOther current assets$140 $196 
Forward currency contractsOther long-term assets107 149 
  246 345 
Non-Designated Hedging Instruments   
Forward currency contractsOther current assets20 36 
Total Derivative and Nonderivative Assets $266 $381 
Derivative and Nonderivative Liabilities:   
Designated Hedging Instruments  
Forward currency contractsOther current liabilities$15 $— 
Forward currency contractsOther long-term liabilities9 1 
Foreign currency-denominated debt(2)
Long-term debt988 952 
  1,012 953 
Non-Designated Hedging Instruments   
Forward currency contractsOther current liabilities38 52 
Total Derivative and Nonderivative Liabilities$1,050 $1,005 
(1) We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.
(2) Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.

Recurring Fair Value Measurements
On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
•Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
•Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
•Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
Assets and liabilities measured at fair value on a recurring basis consist of the following:
As of
 December 31, 2023December 31, 2022
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets        
Money market funds and time deposits$454 $— $— $454 $673 $— $— $673 
Publicly-held securities18 — — 18 2 — — 2 
Hedging instruments— 266 — 266 — 381 — 381 
Licensing arrangements— — 77 77 — — 127 127 
 $472 $266 $77 $816 $674 $381 $127 $1,182 
Liabilities        
Hedging instruments$— $1,050 $— $1,050 $— $1,005 $— $1,005 
Contingent consideration liability— — 404 404 — — 149 149 
Licensing arrangements— — 90 90 — — 159 159 
 $— $1,050 $494 $1,545 $— $1,005 $308 $1,313 

Our investments in money market funds and time deposits are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents within our accompanying consolidated balance sheets, in accordance with GAAP and our accounting policies. In addition to $454 million invested in money market funds and time deposits as of December 31, 2023 and $673 million as of December 31, 2022, we held $411 million in interest-bearing and non-interest-bearing bank accounts as of December 31, 2023 and $256 million as of December 31, 2022.

Our recurring fair value measurements using Level 3 inputs include those related to our contingent consideration liability. Refer to Note B – Acquisitions and Strategic Investments for a discussion of the changes in the fair value of our contingent consideration liability.

In addition, our recurring fair value measurements using Level 3 inputs related to our licensing arrangements, including the contractual right to receive future royalty payments related to the Zytiga™ Drug. We own the contractual right to receive 50 percent of the future Zytiga Drug royalty payments from the licensee and remit such payments to the inventors associated with the intellectual property. We recognized a financial asset and associated liability for our licensing arrangements at fair value in our consolidated balance sheets using the fair value option in accordance with FASB ASC Topic 825, Financial Instruments. We elected the fair value option to measure the financial asset and associated liability as it provides for consistency and comparability of these financial instruments with others. Royalty payments we receive reduce the fair value of the financial asset and are presented within Proceeds from royalty rights, and payments we remit to inventors reduce the fair value of the financial liability and are presented within Payments for royalty rights within our consolidated statements of cash flows. We sold our right to receive and retain the other 50 percent of the future royalty payments in 2019 for an upfront cash payment, which we accounted for as a secured borrowing in accordance with FASB ASC Topic 860, Transfers and Servicing (FASB ASC Topic 860). Although we sold these rights, we continue to recognize at fair value the future royalty payments as a financial asset and associated liability. Royalty payments associated with the rights we sold no longer impact our cash flows, and we present this activity as Non-cash impact of transferred royalty rights in the supplemental information to our consolidated statements of cash flows. We reduce the fair value of the financial asset and associated liability when such non-cash activity occurs.

We record the fair value of the financial asset and associated liability using a discounted cash flow approach considering the probability-weighted expected future cash flows to be generated by the royalty stream. The fair value of the financial liability also considers the related contractual provisions that govern our payment obligations. Significant increases or decreases in projected cash flows of the royalty stream and the related contractual provisions that govern our payment obligations, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement of the licensing arrangements' financial asset and liability as of December 31, 2023. However, increases or decreases in the financial asset would be offset by increases or decreases in the financial liability, other than for timing of receipt and remittance; as such our earnings are not subject to material gains and losses from the licensing arrangement.
The recurring Level 3 fair value measurements of our licensing arrangements recognized in our consolidated balance sheets as of December 31, 2023 include the following significant unobservable inputs:
Licensing ArrangementsFair Value as of December 31, 2023Valuation TechniqueUnobservable InputRange
Weighted Average(1)
Financial Asset$77 millionDiscounted Cash FlowDiscount Rate15%15%
Projected Year of Payment2024-20252024
Financial Liability$90 millionDiscounted Cash FlowDiscount Rate12%-15%13%
Projected Year of Payment2024-20262025
(1) Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Changes in the fair value of our licensing arrangements' financial asset were as follows:
(in millions)
Balance as of December 31, 2021$246 
Proceeds from royalty rights(141)
Fair value adjustment (expense) benefit22 
Balance as of December 31, 2022$127 
Proceeds from royalty rights(61)
Fair value adjustment (expense) benefit11 
Balance as of December 31, 2023$77 

Changes in the fair value of our licensing arrangements' financial liability were as follows:
(in millions)
Balance as of December 31, 2021$281 
Payments for royalty rights(145)
Fair value adjustment expense (benefit)23 
Balance as of December 31, 2022$159 
Payments for royalty rights(80)
Fair value adjustment expense (benefit)12 
Balance as of December 31, 2023$90 

Non-Recurring Fair Value Measurements

We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B – Acquisitions and Strategic Investments for a discussion of our strategic investments and Note C – Goodwill and Other Intangible Assets for a discussion of the fair values of our intangible assets including goodwill.

The fair value of our outstanding debt obligations, excluding finance leases, was $8.735 billion as of December 31, 2023 and $8.203 billion as of December 31, 2022. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to Note E – Contractual Obligations and Commitments for a discussion of our debt obligations.
XML 29 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
Contractual Obligations and Commitments
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
CONTRACTUAL OBLIGATIONS AND COMMITMENTS
NOTE E – CONTRACTUAL OBLIGATIONS AND COMMITMENTS

Borrowings and Credit Arrangements

We had total debt outstanding of $9.102 billion as of December 31, 2023 and $8.935 billion as of December 31, 2022, with current maturities of $531 million as of December 31, 2023 and $20 million as of December 31, 2022. The debt maturity schedule for our long-term debt obligations is presented below:
Issuance DateMaturity DateAs of December 31,
Coupon Rate(1)
(in millions, except interest rates)20232022
March 2024 NotesFebruary 2019March 2024— 504 3.450%
March 2025 Senior Notes(3)
March 2022March 20251,105 1,067 0.750%
June 2025 Senior NotesMay 2020June 2025500 500 1.900%
March 2026 Senior NotesFebruary 2019March 2026255 255 3.750%
December 2027 Senior Notes(3)
November 2019December 2027995 960 0.625%
March 2028 Senior Notes(3)
March 2022March 2028829 800 1.375%
March 2028 Senior NotesFebruary 2018March 2028344 344 4.000%
March 2029 Senior NotesFebruary 2019March 2029272 272 4.000%
June 2030 Senior NotesMay 2020June 20301,200 1,200 2.650%
March 2031 Senior Notes(3)
March 2022March 2031829 800 1.625%
March 2034 Senior Notes(3)
March 2022March 2034553 534 1.875%
November 2035 Senior Notes(2)
November 2005November 2035350 350 6.500%
March 2039 Senior NotesFebruary 2019March 2039450 450 4.550%
January 2040 Senior NotesDecember 2009January 2040300 300 7.375%
March 2049 Senior NotesFebruary 2019March 2049650 650 4.700%
Unamortized Debt Issuance Discount and Deferred Financing Costs2024 - 2049(65)(76)
Finance Lease ObligationVarious5 5 
Long-term debt $8,571 $8,915 
(1) Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.
(2) Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate of 6.25% if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher.
(3) These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of December 31, 2023 and 2022, respectively.

Contractual maturities of our long-term debt outstanding as of December 31, 2023 are as follows (in millions):

Fiscal Year
20251,605 
2026255 
2027995 
20281,173 
Thereafter4,604 

Revolving Credit Facility

On May 10, 2021, we entered into a $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks, initially scheduled to mature on May 10, 2026, with one-year extension options, subject to certain conditions. On March 1, 2023, we entered into an amendment of the 2021 Revolving Credit Facility credit agreement, which provided for an extension of the scheduled maturity date to May 10, 2027 and replaced the London Interbank Offered Rate (LIBOR) with the Secured Overnight Financing Rate (SOFR) as the Eurocurrency Rate for Dollars, including applicable credit spread adjustments and relevant SOFR benchmark provisions, among other things described under Financial Covenant below. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces
borrowing capacity under the 2021 Revolving Credit Facility. We had no amounts outstanding under the 2021 Revolving Credit Facility as of December 31, 2023 or December 31, 2022.

Financial Covenant

As of December 31, 2023, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility.
 Covenant Requirement
as of December 31, 2023		 Actual
as of December 31, 2023
Maximum permitted leverage ratio(1)
3.75 times 2.33 times
(1) Ratio of total debt to deemed consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), as defined by the 2021 Revolving Credit Facility credit agreement, as amended.

The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times for the remaining term. The agreement provides for higher leverage ratios, at our election, for the period following a qualified acquisition, for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. It steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have not elected to increase the maximum permitted leverage ratio for qualified acquisitions to date, due to our funding of these acquisitions using cash on hand or commercial paper.

The financial covenant requirement, as amended on March 1, 2023, provides for an exclusion from the calculation of consolidated EBITDA, as defined by the credit agreement, through maturity, of certain charges and expenses. The credit agreement amendment reset the starting date for purposes of calculating such permitted exclusions in each case from March 31, 2021 to December 31, 2022. Permitted exclusions include any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of December 31, 2023, we had $317 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreement, are excluded from the calculation of consolidated EBITDA, as defined by the agreement, provided that the sum of any excluded net cash litigation payments do not exceed $1.000 billion plus all accrued legal liabilities as of December 31, 2022. As of December 31, 2023, we had $1.484 billion of the litigation exclusion remaining.

Any inability to maintain compliance with this covenant could require us to seek to further renegotiate the terms of our credit arrangements or seek waivers from compliance with this covenant, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all 2021 Revolving Credit Facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our 2021 Revolving Credit Facility may negatively impact the credit ratings assigned to our commercial paper program, which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable.

Commercial Paper

Our commercial paper program is backed by the 2021 Revolving Credit Facility. We did not have any commercial paper outstanding as of December 31, 2023 and 2022.

Senior Notes

We had senior notes outstanding of $9.136 billion as of December 31, 2023 and $8.986 billion as of December 31, 2022. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (see Other Arrangements below).

In March 2022, American Medical Systems Europe B.V. (AMS Europe), an indirect, wholly owned subsidiary of Boston Scientific, completed a registered public offering (the Offering) of €3.000 billion in aggregate principal amount of euro-dominated senior notes comprised of €1.000 billion of 0.750% Senior Notes due 2025, €750 million of 1.375% Senior Notes due 2028, €750 million of 1.625% Senior Notes due 2031 and €500 million of 1.875% Senior Notes due 2034 (collectively, the Eurobonds). Boston Scientific has fully and unconditionally guaranteed all of AMS Europe's obligations under the Eurobonds, and no other subsidiary of Boston Scientific will guarantee these obligations. AMS Europe is a “finance subsidiary” as defined
in Rule 13-01(a)(4)(vi) of Regulation S-X. The financial condition, results of operations and cash flows of AMS Europe are consolidated in the financial statements of Boston Scientific. The Offering resulted in cash proceeds of $3.270 billion, net of investor discounts and issuance costs.

We used the net proceeds from the Offering to fund the tender offer and early redemption of combined aggregate principal amount of $3.275 billion of certain of our outstanding senior notes, as well as to pay accrued interest, tender premiums, fees and expenses. We recorded associated debt extinguishment net charges of $194 million during the first quarter of 2022 presented in Interest expense within our consolidated statements of operations.

Other Arrangements

We have accounts receivable factoring programs in certain European countries and with commercial banks in China and Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net in our accompanying consolidated balance sheets, are aggregated by contract denominated currency below (in millions):

As of December 31, 2023As of December 31, 2022
Factoring ArrangementsAmount
De-recognized		Weighted Average Interest RateAmount
De-recognized		Weighted Average Interest Rate
Euro denominated$206 5.1 %$161 2.4 %
Yen denominated214 0.6 %194 0.6 %
Renminbi denominated14 2.9 %13 3.1 %

Other Contractual Obligations and Commitments

We had outstanding letters of credit of $174 million as of December 31, 2023 and $135 million as of December 31, 2022, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of December 31, 2023 and December 31, 2022, we had not recognized a related liability for our outstanding letters of credit in our consolidated balance sheets.

As of December 31, 2023, future minimum purchase obligations, relating primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business, were (in millions):
Fiscal YearUnrecorded Purchase Obligations
2024$951 
2025283 
2026155 
202745 
202831 
Thereafter150 
 $1,615 

We have a supplier financing program offered primarily in the U.S. that enables our suppliers to opt to receive early payment at a nominal discount, while allowing us to lengthen our payment terms and optimize working capital. Our standard payment term in the U.S. is 90 days. All outstanding payables related to the supplier finance program are classified within Accounts Payable within our unaudited consolidated balance sheets and were $152 million as of December 31, 2023 and $129 million as of December 31, 2022.
XML 30 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases
 12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
LEASES
NOTE F – LEASES

We have operating and finance leases for real estate including corporate offices, land, warehouse space, and vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that we are reasonably certain to exercise (short-term leases). We recognize lease expense on a straight-line basis over the lease term for short-term leases that we do not record on our balance sheet. If there is a change in our assessment of the lease term and, as a result, the remaining lease term extends more than 12 months from the end of the previously determined lease term, or we subsequently become reasonably certain that we will exercise an option to purchase the underlying asset, the lease no longer meets the definition of a short-term lease and is accounted for as either an operating or finance lease and recognized on the balance sheet. In accordance with FASB ASC Topic 842, we account for the lease components and the non-lease components as a single lease component, with the exception of our warehouse leases. Our leases have remaining lease terms of less than 1 year to approximately 53 years, some of which may include options to extend the leases for up to 10 years. If we are reasonably certain we will exercise an option to extend the lease, the time period covered by the extension option is included in the lease term.

We determine whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.

Our operating lease right-of-use assets are presented within Other long-term assets and corresponding liabilities are presented within Other current liabilities and Other long-term liabilities on our consolidated balance sheets. Refer to Note E – Contractual Obligations and Commitments for information regarding our finance leases. As of December 31, 2023, we have entered into two leases for additional office, warehouse and lab space which have not yet commenced. These facilities are currently under construction. We do not control the building during construction and are thus not deemed to be the owner during construction. Total estimated undiscounted future lease payments are approximately $500 million, which includes a buyout option exercisable once construction is complete which we are reasonably certain to exercise with respect to one of the leases. These leases will commence at the end of 2024 and second half of 2025 with noncancellable lease terms ranging from 20 to 25 years.

The following table presents supplemental balance sheet information related to our operating leases:
As of December 31,
(in millions)20232022
Assets
Operating lease right-of-use assets in Other long-term assets
$439 $386 
Liabilities
Operating lease liabilities in Other current liabilities
76 61 
Operating lease liabilities in Other long-term liabilities
390 347 

The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:
As of December 31,
20232022
Weighted average remaining lease term9 years10 years
Weighted average discount rate4.5%3.3%
Our operating lease cost under FASB ASC Topic 842 was $96 million in 2023, $91 million in 2022 and $90 million in 2021.

The following table presents supplemental cash flow information related to our operating leases:
Year Ended December 31,
(in millions)20232022
Cash paid for amounts included in the measurement of operating lease liabilities
Operating cash flows from operating leases$93 $91 

Right-of-use assets obtained in exchange for operating lease obligations were $123 million and $43 million for the years ended December 31, 2023 and 2022, respectively.

The following table presents the maturities of our operating lease liabilities as of December 31, 2023 (in millions):
Fiscal year
Operating Leases (1)
2024$89 
202578 
202665 
202749 
202841 
Thereafter217 
Total future minimum operating lease payments539 
Less: imputed interest(74)
Present value of operating lease liabilities$466 
(1) Excludes expected lease payments for lease terms that have not yet commenced.
XML 31 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
Supplemental Balance Sheet Information
 12 Months Ended
Dec. 31, 2023
Supplemental Balance Sheet Information [Abstract]  
SUPPLEMENTAL BALANCE SHEET INFORMATION
NOTE G – SUPPLEMENTAL BALANCE SHEET INFORMATION

Components of selected captions in our accompanying consolidated balance sheets are as follows:
Trade accounts receivable, net
 As of December 31,
(in millions)20232022
Trade accounts receivable$2,338 $2,079 
Allowance for credit losses(110)(109)
 $2,228 $1,970 

The following is a rollforward of our Allowance for credit losses:
Year Ended December 31,
(in millions)202320222021
Beginning balance$109 $108 $105 
Credit loss expense50 35 28 
Write-offs(48)(35)(25)
Ending balance$110 $109 $108 
Inventories
 As of December 31,
(in millions)20232022
Finished goods$1,537 $1,171 
Work-in-process174 147 
Raw materials773 548 
 $2,484 $1,867 

Approximately 22 percent of our finished goods inventory as of December 31, 2023 and approximately 27 percent as of December 31, 2022 was at customer locations pursuant to consignment arrangements or held by sales representatives.

Other current assets
 As of December 31,
(in millions)20232022
Restricted cash and restricted cash equivalents$130 $149 
Derivative assets159 232 
Licensing arrangements47 60 
Other285 290 
 $621 $731 

Property, plant and equipment, net
 As of December 31,
(in millions)20232022
Land$140 $137 
Buildings and improvements1,843 1,695 
Equipment, furniture and fixtures3,503 3,297 
Capital in progress857 598 
 6,343 5,728 
Less: accumulated depreciation3,484 3,282 
 $2,859 $2,446 

Depreciation expense was $367 million in 2023, $333 million in 2022 and $352 million in 2021.

Other long-term assets
 As of December 31,
(in millions)20232022
Restricted cash equivalents$60 $48 
Operating lease right-of-use assets439 386 
Derivative assets107 149 
Investments413 407 
Licensing arrangements30 67 
Indemnification asset176 172 
Other306 271 
 $1,531 $1,500 
Accrued expenses
 As of December 31,
(in millions)20232022
Legal reserves$206 $231 
Payroll and related liabilities1,051 830 
Rebates389 352 
Contingent consideration304 74 
Other696 674 
 $2,646 $2,160 

Other current liabilities
 As of December 31,
(in millions)20232022
Deferred revenue$266 $220 
Licensing arrangements49 79 
Taxes payable220 232 
Other278 230 
 $814 $761 

Other long-term liabilities
 As of December 31,
(in millions)20232022
Accrued income taxes$470 $597 
Legal reserves172 212 
Contingent consideration100 75 
Licensing arrangements41 80 
Operating lease liabilities390 347 
Deferred revenue311 289 
Other484 434 
 $1,967 $2,035 
XML 32 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
INCOME TAXES
NOTE H – INCOME TAXES

Our Income (loss) before income taxes consisted of the following:
Year Ended December 31,
(in millions)202320222021
Domestic$(394)$(1,119)$(648)
Foreign2,379 2,260 1,724 
$1,985 $1,141 $1,076 
The related expense (benefit) for income taxes consisted of the following:
Year Ended December 31,
(in millions)202320222021
Current
Federal$189 $51 $18 
State15 19 33 
Foreign116 381 127 
320 451 178 
Deferred
Federal(82)(92)(256)
State(22)(32)(3)
Foreign176 117 117 
73 (7)(142)
$393 $443 $36 

The reconciliation of income taxes at the federal statutory rate to the actual expense (benefit) for income taxes is as follows:
Year Ended December 31,
202320222021
U.S. federal statutory income tax rate21.0 %21.0 %21.0 %
State income taxes, net of federal benefit0.7 %0.7 %2.5 %
Domestic taxes on foreign earnings6.9 %15.3 %6.8 %
Effect of foreign taxes(15.3)%(3.8)%(14.3)%
Acquisition-related2.2 %4.4 %(8.1)%
Research credit(2.9)%(4.5)%(3.0)%
Valuation allowance7.5 %(1.3)%0.8 %
Compensation-related0.5 %0.6 %(0.6)%
Non-deductible expenses0.4 %0.4 %0.4 %
Uncertain tax positions(0.5)%7.7 %1.2 %
Return to provision(0.1)%(2.1)%(5.7)%
Change in tax rates(0.6)%(0.2)%1.9 %
Other, net— %0.7 %0.4 %
19.8 %38.9 %3.3 %
Significant components of our deferred tax assets and liabilities are as follows:
 As of December 31,
 (in millions)
20232022
 Deferred Tax Assets:
 
Inventory costs and related reserves$30 $19 
Tax benefit of net operating losses and credits744 511 
Reserves and accruals305 304 
Restructuring-related charges14 6 
Litigation and product liability reserves88 103 
Investment write-down58 38 
Compensation related154 136 
Federal benefit of uncertain tax positions11 9 
Intangible assets3,394 3,668 
Capitalized R&D232 160 
Property, plant and equipment— 2 
 5,029 4,954 
Less: valuation allowance(1,220)(1,004)
 3,809 3,950 
 Deferred Tax Liabilities:
  
Property, plant and equipment24 — 
Unrealized gains and losses on derivative financial instruments66 117 
Other12 34 
102 151 
 Net Deferred Tax Assets
3,707 3,799 
Prepaid on intercompany profit315 264 
 Net Deferred Tax Assets and Prepaid on Intercompany Profit$4,022 $4,062 

Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit are included in the following locations within our accompanying consolidated balance sheets (in millions):
Location on Consolidated Balance SheetsAs of December 31,
Component20232022
Prepaid on intercompany profitPrepaid income taxes$315 $264 
Non-current deferred tax assetDeferred tax assets3,841 3,942 
Deferred Tax Assets and Prepaid on Intercompany Profit 4,157 4,206 
Non-current deferred tax liabilityDeferred tax liabilities134 144 
Deferred Tax Liabilities 134 144 
Net Deferred Tax Assets and Prepaid on Intercompany Profit$4,022 $4,062 

As of December 31, 2023 and 2022, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $540 million and $464 million, respectively. In addition, we had foreign tax net operating loss carryforwards and tax credits, the tax effect of which was $203 million as of December 31, 2023, and $47 million as of December 31, 2022. These tax attributes expire periodically beginning in 2024.

After consideration of all positive and negative evidence, we believe that it is more likely than not that a portion of our deferred tax assets will not be realized. As a result, we recorded a valuation allowance of $1.220 billion as of December 31, 2023, and $1.004 billion as of December 31, 2022. The increase in the valuation allowance as of December 31, 2023, compared to December 31, 2022, is primarily due to establishing valuation allowances on certain foreign deferred tax assets, mainly a capital loss carryforward in the UK. The income tax impact of the unrealized gain or loss component of other comprehensive income
and stockholders' equity was a benefit of $39 million in 2023, a charge of $56 million in 2022 and a charge of $81 million in 2021.

We obtain tax incentives through Free Trade Zone Regime offered in Costa Rica which allows 100 percent exemption from income tax in the first eight years of operations and 50 percent exemption in the following four years. This tax incentive resulted in income tax savings of $212 million in 2023, $162 million in 2022 and $149 million in 2021. The tax incentive for 100 percent exemption from income tax is expected to expire in 2027, with the 50 percent exemption to expire in 2031. The impact on Net income (loss) per common share - diluted was $0.15 for 2023, $0.11 for 2022 and $0.10 for 2021. We also benefit from tax incentives in Puerto Rico through a Grant of Industrial Tax Exemption (Grant) which applies a reduced tax rate to our taxable profits, resulting in income tax savings of $16 million in 2023, $21 million in 2022 and $27 million in 2021. This Grant expires in 2034, with an option to extend for an additional 15 years. The impact on Net income (loss) per common share - diluted was $0.01 in 2023 and $0.02 in the years 2022 and 2021. Additionally, we benefit from tax incentives in Malaysia which allow a full tax exemption on manufacturing of specific medical device products, which will expire in 2029, with an option to renew for an additional five-year term. This incentive has resulted in income tax savings of $20 million in 2023, $17 million in 2022 and $0 in 2021. The impact on Net income (loss) per common share - diluted was $0.01 in the years 2023 and 2022 and de minimis in 2021.

As of December 31, 2023, we had $467 million of gross unrecognized tax benefits, of which a net $395 million, if recognized, would affect our effective tax rate. As of December 31, 2022, we had $492 million of gross unrecognized tax benefits, of which a net $410 million, if recognized, would affect our effective tax rate. As of December 31, 2021, we had $255 million of gross unrecognized tax benefits, of which a net $177 million, if recognized, would affect our effective tax rate. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
 Year Ended December 31,
(in millions)202320222021
Beginning Balance$492 $255 $261 
Additions based on positions related to the current year65 88 8 
Additions based on positions related to prior years67 177 41 
Reductions for tax positions of prior years(114)(20)(36)
Settlements with taxing authorities(14)(1)(2)
Statute of limitation expirations(29)(8)(17)
Ending Balance$467 $492 $255 
We are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. We have concluded all U.S. federal income tax matters through 2018 and substantially all material state and local income tax matters through 2016. We have concluded substantially all foreign income tax matters through 2015.

In 2023, we received notification from the IRS that the examination of our 2017 and 2018 tax years was resolved. Due to the resolution of these tax years, we recorded a net tax benefit of $44 million to release the reserves related to these years. We paid tax of $16 million to the IRS reflecting the net balance of amounts due for the tax period including an increase to past transition tax installment payments for periods prior to 2023 and interest. The subsequent transition tax payments in 2024 and 2025 will be increased to reflect the final audit settlement.

We recognize interest and penalties related to income taxes as a component of income tax expense. We had $70 million accrued for gross interest and penalties as of December 31, 2023, $77 million as of December 31, 2022, and $43 million as of December 31, 2021. Net tax expense related to interest and penalties was immaterial in 2023, 2022 and 2021.

It is reasonably possible that within the next 12 months we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to $24 million.

For the year ended December 31, 2017, we were required under the TCJA to calculate a one-time transition tax based on our total post-1986 foreign subsidiaries' earnings and profits (E&P) that we previously deferred from U.S. income taxes. The amount of transition tax remains unchanged at approximately $937 million for both December 31, 2023 and 2022. We anticipate offsetting this liability against existing tax attributes, reducing the required payment to approximately $586 million, which will be remitted over an eight-year period. We have begun remitting the required installment payments, with a balance remaining of $264 million as of December 31, 2023. In addition, we have provided for U.S. state income taxes of $8 million on all U.S. dollar-denominated E&P accumulated through December 31, 2017, which constitutes the preponderance of our foreign
subsidiaries' accumulated E&P through December 31, 2017. We intend to indefinitely reinvest the unremitted foreign earnings of all other subsidiaries as of December 31, 2017, as well as all subsequent earnings generated by all of our foreign subsidiaries. Determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings and additional outside basis difference in these entities is not practicable.
We are subject to a territorial tax system under the TCJA, in which we are required to provide for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have established an accounting policy election to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense.
XML 33 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES
NOTE I – COMMITMENTS AND CONTINGENCIES

The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.

During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In addition, product liability, securities and commercial claims have been asserted against us and similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity.

In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) within our accompanying consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our accompanying consolidated statements of operations.

Our accrual for legal matters that are probable and estimable was $377 million as of December 31, 2023, and $443 million as of December 31, 2022, and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims related to our transvaginal surgical mesh products. A portion of this accrual is already funded through our qualified settlement fund, which is included in restricted cash and restricted cash equivalents in Other current assets of $130 million as of December 31, 2023, and $149 million as of December 31, 2022. Refer to Note A – Significant Accounting Policies and Note G – Supplemental Balance Sheet Information for additional information.
We recorded litigation-related net credits of $111 million in 2023, primarily related to the settlement of offensive patent litigation, and net charges of $173 million in 2022 and $430 million in 2021, primarily related to litigation associated with our transvaginal surgical mesh products, and other legal matters.

We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our financial covenant.

In management's opinion, we are not currently involved in any legal proceedings other than those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated.

Patent Litigation

On November 20, 2017, The Board of Regents, University of Texas System and TissueGen. Inc. (collectively, UT), served a lawsuit against us in the Western District of Texas. The complaint against the Company alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. UT primarily seeks a reasonable royalty. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. In April 2020, the United States Supreme Court denied the UT’s Petition for Certiorari. UT proceeded with its case against the Company in Delaware. In January 2023, a jury trial was held on the issue of whether the one UT patent still asserted in the case was valid and whether it was infringed by the Company. On January 31, 2023, a jury concluded that UT’s patent was valid and willfully infringed by the Company, and awarded UT $42 million in damages. Following the trial, UT has filed a motion seeking prejudgment interest and enhanced damages. The Company has filed a motion seeking judgment as a matter of law in its favor or alternatively a new trial.

Product Liability Litigation

Multiple product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us, predominantly in the United States, Canada, the United Kingdom, Scotland, Ireland, and Australia. Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. We have entered into individual and master settlement agreements in principle or are in the final stages of entering agreements with certain plaintiffs' counsel, to resolve the majority of these cases and claims. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. In addition, in April 2021 the Company's Board of Directors received a shareholder demand under section 220 of the Delaware General Corporation Law, for inspection of books and records related to mesh settlements. The Company has notified our insurer and retained counsel to respond to the demand.

We have established a product liability accrual for remaining claims asserted against us associated with our transvaginal surgical mesh products and the costs of defense thereof. We continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims, which we continue to vigorously contest. The final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.
Governmental Investigations and Qui Tam Matters

On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a “technical note,” announced that it was launching a formal administrative proceeding against Boston Scientific’s Brazilian subsidiary, Boston Scientific do Brasil Ltda. (BSB), as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. Under applicable guidance, BSB could be fined a percentage of BSB’s 2016 gross revenues. In August 2021, the investigating commissioner issued a preliminary recommendation of liability against all of the involved companies, and also recommended that CADE impose fines and penalties. However, on October 25, 2021, the CADE Attorney General's office recommended dismissal of the charges and allegations against BSB and the individual BSB employees who were still individual defendants. Subsequently, on March 30, 2022, the Federal Prosecutor’s office issued a non-binding recommendation that is contrary to the Attorney General’s recommendation. The full Commission is considering both of these recommendations but has not yet issued its decision. We continue to deny the allegations, intend to defend ourselves vigorously and will appeal any decision of liability by the full Commission to the Brazilian courts. During such an appeal, the decision would have no force and effect, and the Court would consider the case without being bound by CADE’s decision.

In March 2022, the Company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam. The Company has received related subpoenas for documents from the Office of the U.S. Attorney for the District of Massachusetts and the Securities and Exchange Commission. The Company is cooperating with government agencies while investigating these allegations.

On April 5, 2023, the Company received a subpoena from the U.S. Department of Justice (DOJ) that seeks documents and information relating to its ambulatory electrocardiography monitoring (AECG) business. The Company is cooperating with the DOJ in responding to this subpoena.

On December 18, 2023, the Company received a Civil Investigative Demand from the DOJ that relates to the provision of peripheral intervention services through office-based labs. The Company is cooperating with the DOJ in responding to the subpoena.

Other Proceedings

On December 4, 2020, Enrique Jevons, individually and on behalf of all others similarly situated, filed a class action complaint against the Company, Michael F. Mahoney and Daniel J. Brennan, stemming from the recall and retirement of the LOTUS Edge™ Aortic Valve System (LOTUS System) in United States District Court for the Eastern District of New York. On December 14, 2020, the parties agreed to transfer the case to the United States District Court for the District of Massachusetts. On December 16, 2020, Mariano Errichiello, individually and on behalf of all others similarly situated, filed a second, materially similar class action complaint against the Company, Michael F. Mahoney, Joseph M. Fitzgerald, and Daniel J. Brennan in the United States District Court for the District of Massachusetts. Subsequently, on March 30, 2021, the Court consolidated the two actions, and appointed Union Asset Management Holding AG as the lead plaintiff. The plaintiffs filed an Amended Complaint in June 2021 that seeks unspecified compensatory damages in favor of the alleged class as well as unspecified equitable relief. The Company filed a Motion to Dismiss in July 2021, which, in December 2022, the Court granted in part and denied in part. On October 23, 2023, the Company reached an agreement in principle with the lead plaintiff to settle the case. The settlement in principle is subject to approval of the Court. The Court granted the motion for preliminary approval of the proposed settlement on December 27, 2023, and scheduled a final approval hearing for April 23, 2024.

On December 15, 2020, the Securities and Exchange Commission’s Boston Regional Office (Boston SEC) notified the Company that it was conducting an investigation related to the Company’s decision to retire the LOTUS System and issued a voluntary request for documents and information related to that decision. On February 10, 2021, the Boston SEC issued a second voluntary request for additional documents and information. The Company cooperated fully with the requests, and on January 3, 2022, the SEC informed us that it was concluding its investigation and that it did not intend to recommend an enforcement action.

On February 8, 2021, the Company received a letter from The Vladimir Gusinsky Revocable Trust, a shareholder, demanding that the Company’s Board of Directors conduct an investigation into actions by the Company’s directors and executive officers regarding statements made about the effectiveness and commercial viability of the LOTUS System. The Trust subsequently
agreed to stay its demand, pending the outcome of any dispositive motion against the Amended Complaint in the class action complaint described above. The Company received letters on behalf of the Union Excavators Local 731 Pension Fund, Diane Nachbaur, and Frank Tripson, three stockholders of the Company, on July 26, 2021, July 29, 2021, and February 13, 2023, respectively, each demanding access to certain books and records of the Company, pursuant to Section 220 of the Delaware General Corporation Law, regarding the business, operations, effectiveness and commercial viability of the LOTUS system, and related items. On April 7, 2023, Diane Nachbaur filed a shareholder derivative complaint in the United States District Court for the District of Massachusetts against the Company, Michael F. Mahoney, Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, David Roux, John E. Sununu, Ellen M. Zane, Joseph M. Fitzgerald, Daniel J. Brennan, Shawn McCarthy, Ian Meredith, Kevin Ballinger, and Susan Vissers Lisa. On May 8, 2023, the Court stayed the case until the conclusion of the consolidated class action case. On October 18, 2023, Frank Tripson filed a shareholder derivative complaint in the Court of Chancery of the State of Delaware against the Company, Michael F. Mahoney, Daniel J. Brennan, Joseph M. Fitzgerald, Shawn McCarthy, Kevin Ballinger, Ian Meredith, Susan Vissers Lisa, Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, Stephen P. MacMillan, David Roux, John E. Sununu, and Ellen M. Zane. On December 15, 2023, the Court stayed that case until March 31, 2024.

Matters Concluded Since December 31, 2022

On October 28, 2015, the Company filed suit against Cook Group Limited and Cook Medical LLC (collectively, Cook) in the United States District Court for the District of Delaware (1:15-cv-00980) alleging infringement of certain Company patents regarding Cook’s Instinct™ Endoscopic Hemoclip. The Company was seeking lost profits, a reasonable royalty and a permanent injunction. The case was transferred to the District Court for the Southern District of Indiana. Cook filed Inter Partes Review (IPR) requests with the U.S. Patent and Trademark Office (USPTO) against four then-asserted patents, which resulted in the court staying the case until 2020. All IPRs concluded and confirmed the validity of certain claims of each challenged patent. In February 2023, the District Court issued summary judgment rulings dismissing certain claims and defenses. Trial on the remaining two asserted patents took place in May and June 2023 and the jury found that the Company’s patents were both valid and infringed and awarded the Company $158 million as lost profits. On August 4, 2023, the parties entered into a settlement to resolve all claims, and the case was dismissed on August 22, 2023.
XML 34 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stockholders' Equity
 12 Months Ended
Dec. 31, 2023
Stockholders' Equity Note [Abstract]  
STOCKHOLDER'S EQUITY
NOTE J – STOCKHOLDERS' EQUITY

Preferred Stock

We are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders.

On May 27, 2020, we completed an offering of 10,062,500 shares of 5.50% Mandatory Convertible Preferred Stock, Series A (MCPS) at a price to the public and liquidation preference of $100 per share. The net proceeds from the MCPS offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses.

On June 1, 2023 (the Mandatory Conversion Date), all outstanding shares of MCPS automatically converted into shares of common stock. The conversion rate for each share of MCPS was 2.3834 shares of common stock. No action by the holders of the MCPS was required in connection with the mandatory conversion. Cash was paid in lieu of fractional shares in accordance with the terms of the MCPS. An aggregate of approximately 24 million shares of common stock, including shares of common stock issued to holders of MCPS that elected to convert prior to the Mandatory Conversion Date, were issued upon conversion of the MCPS. Following the mandatory conversion of the MCPS, there were no outstanding shares of MCPS.

Prior to the Mandatory Conversion Date during 2023, the Audit Committee of our Board of Directors (the Committee), pursuant to authority delegated to such committee by our Board of Directors, declared, and we paid, cash dividends of $28 million, or $1.3750 per MCPS share to holders representing dividend periods through May 2023.
Common Stock

We are authorized to issue 2.000 billion shares of common stock, $0.01 par value per share. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by our Board of Directors, and to share ratably in our assets legally available for distribution to our stockholders in the event of liquidation. Holders of common stock have no preemptive, subscription, redemption, or conversion rights. The holders of common stock do not have cumulative voting rights. The holders of a majority of the shares of common stock can elect all of the directors and can control our management and affairs. Prior to the Mandatory Conversion Date, holders of common stock were junior to holders of MCPS in terms of liquidation preference.

On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. We did not repurchase any shares of our common stock during 2023 and had the full amount available under the authorization as of December 31, 2023.

There were approximately 263 million shares in treasury as of December 31, 2023 and 2022.
XML 35 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock Inventive and Purchase Plans
 12 Months Ended
Dec. 31, 2023
Stock Incentive and Purchase Plans [Abstract]  
STOCK INCENTIVE AND PURCHASE PLANS
NOTE K – STOCK INCENTIVE AND PURCHASE PLANS

Employee and Director Stock Incentive Plans

In 2020, our Board of Directors and stockholders approved amendments to our 2011 Long-Term Incentive Plan effective October 1, 2020 (Amended and Restated 2011 LTIP), authorizing for issuance up to 171 million shares of our common stock. The Amended and Restated 2011 LTIP covers officers, directors, employees and consultants and provides for the grant of restricted or unrestricted common stock, restricted stock units (RSUs), options to acquire our common stock, stock appreciation rights, performance awards (market-based and performance-based RSUs) and other stock and non-stock awards. Shares reserved under our current and former stock incentive plans totaled approximately 145 million as of December 31, 2023. The Executive Compensation and Human Resources Committee (the Committee) of the Board of Directors, consisting of independent, non-employee directors may authorize the issuance of common stock and cash awards under the Amended and Restated 2011 LTIP in recognition of the achievement of long-term performance objectives established by the Committee.

Non-qualified options issued to employees are generally granted with an exercise price equal to the market price of our stock on the grant date, vest over a three or four-year service period and have a ten-year contractual life. In the case of qualified options, if the recipient owns more than ten percent of the voting power of all classes of stock, the option granted will be at an exercise price of 110 percent of the fair market value of our common stock on the date of grant and will expire over a period not to exceed five years. Non-vested stock awards, including restricted stock awards (RSAs) and RSUs issued to employees are generally granted with an exercise price of zero and typically vest in four equal annual installments. These awards represent our commitment to issue shares to recipients after the vesting period. Upon each vesting date, such awards are no longer subject to risk of forfeiture and we issue shares of our common stock to the recipient.

The following presents the impact of stock-based compensation on our consolidated statements of operations:
 Year Ended December 31,
(in millions, except per share data)202320222021
Cost of products sold$12 $12 $11 
Selling, general and administrative expenses179 167 147 
Research and development expenses42 41 36 
 233 220 194 
Income tax (benefit) expense(35)(32)(29)
 $198 $188 $165 
Net impact per common share - basic$0.14 $0.13 $0.12 
Net impact per common share - assuming dilution$0.14 $0.13 $0.12 

Stock Options

We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions:
 Year Ended December 31,
 202320222021
Options granted (in thousands)
2,934 3,287 3,822 
Weighted-average exercise price$47.43 $44.02 $37.69 
Weighted-average grant-date fair value$16.83 $13.64 $10.77 
Black-Scholes Assumptions   
Expected volatility26 %28 %29 %
Expected term (in years, weighted)
6.36.15.9
Risk-free interest rate3.62%-4.75%1.42%-3.87%0.66%-1.20%

Expected Volatility

We use our historical volatility and implied volatility as a basis to estimate expected volatility in our valuation of stock options.

Expected Term

We estimate the expected term of options using historical exercise and forfeiture data. We believe that this historical data provides the best estimate of the expected term of new option grants.

Risk-Free Interest Rate

We use yield rates on U.S. Treasury securities for a period approximating the expected term of the award to estimate the risk-free interest rate in our grant-date fair value assessment.

Expected Dividend Yield

We have not historically paid cash dividends on our common stock and currently we do not intend to pay cash dividends on our common stock. Therefore, we have assumed an expected dividend yield of zero in our grant-date fair value assessment.
Information related to stock options under stock incentive plans are as follows:
Stock Options
(in thousands)
Weighted
Average
Exercise Price
Weighted Average
Remaining
Contractual Life
(in years)
Aggregate
Intrinsic
Value
(in millions)
Outstanding as of December 31, 202023,122 $24 
Granted3,822 38 
Exercised(4,796)13 
Cancelled/forfeited(699)26 
Outstanding as of December 31, 202121,448 $29 
Granted3,287 44 
Exercised(2,745)17 
Cancelled/forfeited(502)34 
Outstanding as of December 31, 202221,489 $32 
Granted2,934 47 
Exercised(3,325)25 
Cancelled/forfeited(249)44 
Outstanding as of December 31, 202320,850 $36 5.8462 
Exercisable as of December 31, 202313,532 31 4.5359 
Expected to vest as of December 31, 20237,052 44 8.199 
Total vested and expected to vest as of December 31, 202320,584 $36 5.8$458 
The total intrinsic value of stock options exercised was $89 million in 2023, $72 million in 2022 and $137 million in 2021.

Non-Vested Stock

We value RSAs and RSUs based on the closing trading value of our shares on the date of grant. Information related to non-vested stock awards is as follows:
Non-Vested
Stock Award Units
(in thousands)
Weighted Average
Grant-Date
Fair Value
Balance as of December 31, 20209,987 $34 
Granted4,240 39 
Vested(1)
(3,823)31 
Forfeited(658)36 
Balance as of December 31, 20219,745 $37 
Granted3,854 45 
Vested(1)
(3,482)36 
Forfeited(680)44 
Balance as of December 31, 20229,438 $41 
Granted3,958 49 
Vested(1)
(3,624)39 
Forfeited(485)44 
Balance as of December 31, 20239,287 $45 
(1) The number of shares vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.

The total vesting date fair value of shares that vested was approximately $171 million in 2023, $150 million in 2022 and $148 million in 2021.
Market-based RSU Awards

During 2023, 2022 and 2021 we granted market-based RSU awards to certain members of our senior management team. The number of shares ultimately issued to the recipient is based on the total stockholder return (TSR) of our common stock as compared to the TSR of the common stock of the other companies in the S&P 500 Health Care Index over a three-year period. The number of RSUs ultimately granted under this program range from 0 percent to 200 percent of the target number awarded to the participant as determined by achievement of the TSR criteria of the program. In addition, in general, award recipients must remain employed by us throughout the three-year period to attain the full amount of the market-based RSUs that satisfied the market performance criteria.

We determined the fair value of the market-based RSU awards to be approximately $13 million for 2023, $12 million for 2022 and $11 million for 2021. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions:
 202320222021
AwardsAwardsAwards
Stock price on date of grant$47.28 $44.19 $37.50 
Measurement period (in years)
2.92.92.9
Risk-free rate4.31 %1.71 %0.20 %
We recognize the expense on these awards in our consolidated statements of operations on a straight-line basis over the three-year measurement period.

Organic Net Sales Growth and Free Cash Flow Performance-based RSU Awards

During 2023, we granted organic net sales growth (ONSG) performance-based RSU awards to certain members of our senior management team. The attainment of these performance-based RSUs is based on our organic net sales growth over a three-year performance period beginning January 1, 2023 and ending December 31, 2025 against a target set by the Committee. The number of RSUs ultimately granted under this program range from 0 percent to 200 percent of the target number of performance-based RSUs awarded to the participant as determined by achievement of the performance criteria of the program.

During 2022 and 2021, we granted free-cash flow performance-based RSU awards to certain members of our senior management team. The attainment of these performance-based RSUs is based on our adjusted free cash flow (AFCF) measured against our goal set by the Committee, based on our internal annual financial plan performance for AFCF. AFCF was measured over a one-year performance period beginning January 1st of each year and ending December 31st. The number of RSUs ultimately granted under this program range from 0 percent to 150 percent of the target number of performance-based RSUs awarded to the participant as determined by achievement of the performance criteria of the program. In addition, in general, award recipients must remain employed by us throughout a three-year service period (inclusive of the one-year performance period) to attain the full amount of the performance-based RSUs that satisfied the performance criteria.

The following table presents our assumptions used in determining the fair value of our ONSG and AFCF awards currently expected to vest as of December 31, 2023:
2023 ONSG2022 AFCF2021 AFCF
Fair value, net of forfeitures to date (in millions)
$20 $7 $12 
Achievement of target payout(1)
200 %88 %131 %
Stock price used in determining fair value$47.28 $46.27 $42.48 
(1) Company's estimate of target payout as of December 31, 2023.

We recognize the expense on these awards in our consolidated statements of operations over the vesting period which is three years after the date of grant.
Expense Attribution

We recognize compensation expense for our stock incentive plan using a straight-line method over the substantive vesting period. Most of our stock awards provide for immediate vesting upon death or disability of the participant. In addition, our stock grants to employees provide for accelerated vesting of our stock-based awards, other than performance-based and market-based awards, upon retirement, if the stock award has been held for at least one year by the recipient. In accordance with the terms of our stock grants, for employees who will become retirement eligible prior to the vest date we expense stock-based awards, other than performance-based and market-based awards, over the greater of one year or the period between grant date and retirement-eligibility. The performance-based and market-based awards discussed above do not contain provisions that would accelerate the full vesting of the awards upon retirement-eligibility.

We recognize stock-based compensation expense for the value of the portion of awards that are ultimately expected to vest. FASB ASC Topic 718, Compensation – Stock Compensation allows forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock-based award. We have applied, based on an analysis of our historical forfeitures, a weighted-average annual forfeiture rate of approximately five percent to all unvested stock-based awards as of December 31, 2023, which represents the portion that we expect will be forfeited each year over the vesting period. We re-evaluate this analysis annually or more frequently if there are significant changes in circumstances and adjust the forfeiture rate as necessary. Ultimately, we will only recognize expense for those shares that vest.

Unrecognized Compensation Cost

We expect to recognize the following future expense for awards outstanding as of December 31, 2023:
 Unrecognized
 Compensation Cost
(in millions) (1)
Weighted Average Remaining
Vesting Period
(in years)
Stock options$40  
Non-vested stock awards203  
 $243 1.7
(1) Amounts presented represent compensation cost, net of estimated forfeitures.

Employee Stock Purchase Plan

In May 2022, our stockholders approved an additional 10 million shares that may be issued under our global employee stock purchase plan. Our global employee stock purchase plan provides for the granting of options to purchase up to 60 million shares of our common stock to all eligible employees. Under the global employee stock purchase plan, we grant each eligible employee, at the beginning of each six-month offering period, an option to purchase shares of our common stock equal to not more than ten percent of the employee’s eligible compensation or the statutory limit under the U.S. Internal Revenue Code. Such options may be exercised only to the extent of accumulated payroll deductions at the end of the offering period, at a purchase price equal to 85 percent of the fair market value of our common stock at the beginning or end of each offering period, whichever is less. As of December 31, 2023, there were approximately 9 million shares available for future issuance under the employee stock purchase plan.

Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:
Year Ended December 31,
202320222021
Shares issued or to be issued (in thousands)
2,623 2,850 2,578 
Range of purchase prices$39.11 -$45.51 $31.68 -$32.31 $29.98 -$36.11 
Expense recognized (in millions)
$29 $28 $24 

We use the Black-Scholes option-pricing model to calculate the grant-date fair value of shares issued under the employee stock purchase plan. We recognize expense related to shares purchased through the employee stock purchase plan ratably over the offering period.
XML 36 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
Weighted Average Shares Outstanding
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
WEIGHTED AVERAGE SHARES OUTSTANDING
NOTE L – WEIGHTED AVERAGE SHARES OUTSTANDING

Year Ended December 31,
(in millions)202320222021
Weighted average shares outstanding - basic1,453.0 1,430.5 1,422.3 
Net effect of common stock equivalents10.6 9.2 11.5 
Weighted average shares outstanding - diluted1,463.5 1,439.7 1,433.8 

The following securities were excluded from the calculation of weighted average shares outstanding - diluted because their effect in the periods presented below would have been antidilutive:
Year Ended December 31,
(in millions)202320222021
Stock options outstanding(1)
063
MCPS(2)
102424
(1) Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.
(2) Represents common stock issuable upon the conversion of MCPS. Refer to Note J – Stockholders' Equity for additional information.

We base Net income (loss) per common share - diluted upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options, stock awards and, prior to the Mandatory Conversion Date, our MCPS, from the calculation if the effect would be anti-dilutive. The dilutive effect of MCPS is calculated using the if-converted method. The if-converted method assumes that these securities were converted to shares of common stock at the beginning of the reporting period to the extent that the effect is dilutive.

In 2023, 2022 and 2021, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of earnings per share (EPS). Accordingly, Net income (loss) was reduced by cumulative Preferred stock dividends, as presented in our consolidated statements of operations, for purposes of calculating Net income (loss) attributable to Boston Scientific common stockholders. On June 1, 2023, all outstanding shares of MCPS automatically converted into shares of common stock.
XML 37 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Reporting
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
SEGMENT REPORTING
NOTE M – SEGMENT REPORTING

In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve, and, in particular, benefit our Cardiology customers and patients. Following the reorganization, we have aggregated our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. We have revised prior periods to conform to the current year presentation. In accordance with FASB ASC Topic 280, Segment Reporting, we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments.

We measure and evaluate our reportable segments based on their respective net sales, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all based on internally-derived standard currency exchange rates to exclude the impact of foreign currency, which may be updated from year to year. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and European Union (EU) Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from operating income of reportable segments, they are included in reported Income (loss) before income taxes within our consolidated statements of operations and are included in the reconciliation below. Refer to Note N – Revenue for net sales by reportable segment presented in accordance with GAAP.
A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying consolidated statements of operations is as follows (in millions, except percentages). Prior period amounts have been restated at constant currency to conform to the current year presentation.
 Year Ended December 31,
Net sales202320222021
MedSurg$5,320 $4,805 $4,389 
Cardiovascular8,630 7,599 6,721 
Total net sales of reportable segments 13,949 12,404 11,109 
Other(1)
— (60)12 
Impact of foreign currency fluctuations291 338 766 
$14,240 $12,682 $11,888 

Year Ended December 31,
Income (loss) before income taxes202320222021
MedSurg$1,796 $1,458 $1,368 
Cardiovascular2,235 1,748 1,572 
Total operating income of reportable segments 4,031 3,206 2,940 
Unallocated amounts:
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(293)96 67 
Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs
(567)(789)(1,070)
Amortization expense(828)(803)(741)
Other(1)
— (60)3 
Operating income (loss) 2,343 1,649 1,199 
Other income (expense), net(358)(508)(123)
Income (loss) before income taxes$1,985 $1,141 $1,076 
(1)    In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments

Operating income of reportable segments as a percentage of net sales of reportable segmentsYear Ended December 31,
202320222021
MedSurg33.8 %30.3 %31.2 %
Cardiovascular25.9 %23.0 %23.4 %

Year Ended December 31,
Depreciation expense202320222021
MedSurg$103 $88 $91 
Cardiovascular263 245 261 
Consolidated depreciation expense$367 $333 $352 
As of December 31,
Total assets20232022
MedSurg$2,888 $2,501 
Cardiovascular5,988 5,205 
Total assets of reportable segments8,876 7,706 
Goodwill14,387 12,920 
Other intangible assets, net6,003 5,902 
All other corporate assets5,869 5,941 
 $35,136 $32,469 

As of December 31,
Long-lived assets20232022
U.S.$1,300 $1,241 
Ireland598 478 
Costa Rica373 246 
Other countries587 481 
Property, plant and equipment, net2,859 2,446 
Goodwill14,387 12,920 
Other intangible assets, net6,003 5,902 
Operating lease right-of-use assets in Other long-term assets
439 386 
 $23,688 $21,653 
XML 38 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
REVENUE
NOTE N – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our consolidated statements of operations. Our business structure is organized into five operating segments. The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.
Year Ended December 31,
202320222021
BusinessesU.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Endoscopy$1,511 $970 $2,482 $1,341 $880 $2,221 1,222 $919 $2,141 
Urology1,369 595 1,964 1,257 516 1,773 1,120 463 1,583 
Neuromodulation736 240 976 715 202 917 713 196 909 
MedSurg3,617 1,805 5,422 3,312 1,599 4,911 3,055 1,578 4,633 
Interventional Cardiology Therapies743 1,674 2,417 744 1,485 2,228 778 1,431 2,209 
Watchman1,155 119 1,274 915 103 1,019 729 100 829 
Cardiac Rhythm Management1,405 813 2,218 1,337 763 2,100 1,214 805 2,019 
Electrophysiology370 430 800 275 310 585 128 237 365 
Cardiology3,673 3,036 6,709 3,271 2,662 5,932 2,850 2,572 5,422 
Peripheral Interventions1,135 975 2,110 1,048 850 1,899 996 824 1,820 
Cardiovascular4,808 4,011 8,819 4,319 3,512 7,831 3,846 3,396 7,242 
Other1
— — — — — (60)10 4 13 
Total Net Sales$8,425 $5,816 $14,240 $7,632 $5,111 $12,682 $6,911 $4,978 $11,888 
(1)    In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based.

Refer to Note M – Segment Reporting for information on our reportable segments.

Year Ended December 31,
Geographic Regions202320222021
U.S.$8,425 $7,632 $6,901 
Europe, Middle East and Africa2,856 2,526 2,518 
Asia-Pacific2,400 2,116 2,070 
Latin America and Canada560 469 386 
Other1
— (60)13 
Total Net Sales$14,240 $12,682 $11,888 
Emerging Markets(2)
$2,310 $1,968 $1,656 
(2) Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. We have revised prior period amounts to conform to the current year's presentation.

Deferred Revenue

Contract liabilities are classified within Other current liabilities and Other long-term liabilities within our accompanying consolidated balance sheets. Our deferred revenue balance was $577 million as of December 31, 2023 and $509 million as of December 31, 2022. Our contract liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiology business, for which revenue is recognized over the average service period based on device and patient longevity. Our contract liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor system, also within our Cardiology business, for which revenue is recognized over the average service period based on
device longevity and usage. We recognized revenue of $213 million in 2023 that was included in the above contract liability balance as of December 31, 2022. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

We capitalize sales force commissions related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE™ Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE™ Remote Monitoring Service. These fulfillment costs are amortized over the average service period.

Refer to Note A – Significant Accounting Policies for additional information on our accounting policies relating to revenue recognition.
XML 39 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
Changes in Other Comprehensive Income
 12 Months Ended
Dec. 31, 2023
Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract]  
CHANGES IN OTHER COMPREHENSIVE INCOME
NOTE O – CHANGES IN OTHER COMPREHENSIVE INCOME

The following table provides the reclassifications out of Other comprehensive income, net of tax attributable to Boston Scientific common stockholders:
(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2022$(1)$269 $1 $269 
Other comprehensive income (loss) before reclassifications(87)63 (10)(34)
(Income) loss amounts reclassified from accumulated other comprehensive income(8)(178)1 (185)
Total other comprehensive income (loss)(95)(115)(9)(219)
Balance as of December 31, 2023$(96)$154 $(8)$49 
(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2021$93 $206 $(36)$263 
Other comprehensive income (loss) before reclassifications(86)214 36 163 
(Income) loss amounts reclassified from accumulated other comprehensive income(8)(150)1 (157)
Total other comprehensive income (loss)(94)63 37 6 
Balance as of December 31, 2022$(1)$269 $1 $269 

Refer to Note D – Hedging Activities and Fair Value Measurements for further detail on our net investment hedges recorded in Foreign currency translation adjustment and our cash flow hedges recorded in Net change in derivative financial instruments.
The gains and losses on defined benefit and pension items before reclassifications and gains and losses on defined benefit and pension items reclassified from Accumulated other comprehensive income (loss), net of tax were reduced by income tax impacts of approximately $5 million in 2023 and approximately $6 million in 2022.
XML 40 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
New Accounting Pronouncements
 12 Months Ended
Dec. 31, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]  
NEW ACCOUNTING PRONOUNCEMENTS
NOTE P – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our consolidated financial statements. During 2023, we implemented the following standards, none of which had a material impact on our financial position or results of operations.
ASC Update No. 2022-01

ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. Update No. 2022-01 expands the current single-layer method to allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods. We adopted Update No. 2022-01 on a prospective basis.

ASC Update No. 2022-02

ASC Update No. 2022-02, Financial Instruments- Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, as well as amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13. We adopted Update No. 2022-02 on a prospective basis.

ASC Update No. 2022-04

ASC Update No. 2022-04, Liabilities— Supplier Finance Programs (Subtopic 405-50) enhances the transparency of supplier finance programs by requiring that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude. We adopted Update No. 2022-04 on a retrospective basis to each period in which a balance sheet is presented, except for the amendment on roll forward information, which we will apply prospectively beginning January 1, 2024.

Standards to be Implemented

In June 2022, the FASB issued ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. Update No. 2022-03 clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. We do not expect the adoption to have a material impact on our financial position or results of operations.

In November 2023, the FASB issued ASC Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. Update No. 2023-07 requires disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss in addition to disclosure of amounts for other segment items and a description of its composition. Update No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. We do not expect the adoption to have a material impact on our financial position or results of operations.

In December 2023, the FASB issued ASC Update No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Update No. 2023-09 aims to enhance the transparency and decision usefulness of income tax disclosures. Update No. 2023-09 modifies the rules on income tax disclosures to require entities to disclose (1) specific categories in the rate reconciliation, (2) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (3) income tax expense or benefit from continuing operations (separated by federal, state, and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state and local jurisdictions, among other changes. Update No. 2023-09 is effective for fiscal years beginning after December 15, 2024. We expect to adopt Update No. 2023-09 prospectively. We are currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and related disclosures.

No other new accounting pronouncements issued or effective in the period had or are expected to have a material impact on our consolidated financial statements.
XML 41 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
Employee Retirement Plans (Notes)
 12 Months Ended
Dec. 31, 2023
Retirement Benefits [Abstract]  
EMPLOYEE RETIREMENT PLANS
NOTE Q – EMPLOYEE RETIREMENT PLANS

Defined Benefit Pension Plans

Domestic Retirement Plans

Following our 2006 acquisition of Guidant, we assumed the Guidant Supplemental Retirement Plan, a frozen, non-qualified defined benefit plan for certain former officers and employees of Guidant. The Guidant Supplemental Retirement Plan was partially funded through a Rabbi Trust that contains segregated company assets within restricted cash used to pay the benefit obligations related to the plan.

We also maintain an Executive Retirement Plan, a defined benefit plan covering executive officers and other key contributors. Participants may retire with benefits once retirement conditions have been satisfied.

U.K. Plan

As a result of our 2019 acquisition of BTG plc. (BTG), we assumed a benefit obligation related to a defined benefit pension plan sponsored by BTG for eligible United Kingdom employees. During the second quarter of 2022, we transferred the benefit obligation and associated assets of the pension plan to third party insurers, and as a result, were relieved from primary responsibility of the benefit obligation and the related plan assets. The transaction did not have a material impact on our financial position or results of operations.

Other International Retirement Plans

In addition, we maintain retirement plans covering certain international employees.

We use a December 31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the consolidated balance sheets, recognizing changes primarily through OCI. As of December 31, 2023 and 2022, the funded status of our plans were unfunded or underfunded in aggregate. The outstanding obligation is as follows:
 As of December 31, 2023
(in millions)
Accumulated Benefit Obligation (ABO)Projected
Benefit
Obligation (PBO)		Fair value of Plan AssetsUnfunded/Underfunded
PBO Recognized
Domestic Retirement Plans$54 $59 $— $59 
Other International Retirement Plans145 159 101 58 
 $199 $218 $101 $117 

 As of December 31, 2022
(in millions)
Accumulated Benefit Obligation (ABO)Projected
Benefit
Obligation (PBO)		Fair value of Plan AssetsUnfunded/Underfunded PBO Recognized
Domestic Retirement Plans$50 $55 $— $55 
Other International Retirement Plans140 152 101 51 
 $190 $207 $101 $105 
A reconciliation of the changes in the PBO for our retirement plans is as follows:
 Year Ended December 31,
(in millions)20232022
Beginning obligations$207 $502 
Service costs10 13 
Interest costs7 3 
Actuarial (gain) loss(4)(54)
Plan curtailments/settlements(0)(191)
Plan amendments and assumption changes6 (25)
Benefits paid(10)(6)
Impact of foreign currency fluctuations3 (37)
Ending obligation$218 $207 

The critical assumptions associated with our employee retirement plans for 2023 are as follows:
Weighted Average Discount RateWeighted Average Expected Return
Weighted Average Rate of Compensation Increase(1)
Domestic Retirement Plans4.89%n/a2.00%
Other International Retirement Plans2.85%2.66%3.00%
(1)    Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.

The critical assumptions associated with our employee retirement plans for 2022 are as follows:
Weighted Average Discount RateWeighted Average Expected Return
Weighted Average Rate of Compensation Increase(1)
Domestic Retirement Plans5.32%n/a2.00%
Other International Retirement Plans2.62%2.27%3.00%
(1) Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.

A reconciliation of the changes in the fair value of plan assets for our funded retirement plans is as follows:
 Year Ended December 31,
(in millions)20232022
Beginning fair value$101 $336 
Actual return on plan assets(1)(2)
Employer contributions11 16 
Participant contributions1 1 
Plan curtailments/settlements(0)(185)
Actuarial gain (loss)(0)(25)
Benefits paid(10)(9)
Impact of foreign currency fluctuations0 (32)
Ending fair value$101 $101 

For our defined benefit plans, we base our discount rate on the rates of return available on high-quality bonds with maturities approximating the expected period over which benefits will be paid. The rate of compensation increase is based on historical and expected rate increases. We base our rate of expected return on plan assets on historical experience, our investment guidelines and expectations for long-term rates of return. Our assets are invested in a variety of securities, primarily equity securities and government bonds. These securities are considered Level 1 and Level 2 investments.
Expected benefit payments are estimated based on the same assumptions used in determining our benefit obligation as of December 31, 2023. Actual benefit payments will depend on future employment and compensation, average years employed and average life spans, in addition to other factors. Changes in any of these factors could significantly impact these estimated future benefit payments. Benefit payments expected to be paid during the next ten years for our Domestic Retirement Plans and our Other International Retirement Plans are as follows:
(in millions)Post Retirement Benefits
2024$16 
202513 
202614 
202715 
202815 
2029 - 203373 

Defined Contribution Plan

We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $135 million in 2023, $123 million in 2022 and $118 million in 2021.
XML 42 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule II
 12 Months Ended
Dec. 31, 2018
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure
Description (in millions)
Balance at
 Beginning of Year
Credit loss exposure(1)
Write-offs(2)
Balance at
End of Year
Year Ended December 31, 2023:
Allowances for credit losses$109 50 (48)$110 
Year Ended December 31, 2022:
Allowances for credit losses$108 35 (35)$109 
Year Ended December 31, 2021:
Allowances for credit losses$105 28 (25)$108 

(1) We record credit loss reserves to Allowance for credit losses when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. Subsequent credit loss reserves are recorded when deemed uncollectible. Amounts shown within credit loss exposure above were established through selling, general and administrative expense.
(2) Represents actual write-offs of uncollectible accounts.
XML 43 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
Insider Trading Arrangements
 3 Months Ended 12 Months Ended
Dec. 31, 2023
shares
Dec. 31, 2023
shares
John Bradley Sorenson [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement   On November 6, 2023, John Bradley Sorenson, our Executive Vice President, Global Operations, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Sorenson’s plan covers the sale of 33,938 shares of our common stock to be acquired upon the exercise of stock options. Transactions under Mr. Sorenson’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Sorenson’s plan will terminate on the earlier of December 31, 2024 or the date all shares subject to the plan have been sold.
Name John Bradley Sorenson  
Title Executive Vice President, Global Operations  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date November 6, 2023  
Arrangement Duration 421 days  
Wendy Carruthers [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement   On November 17, 2023, Wendy Carruthers, our Executive Vice President, Human Resources, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Ms. Carruthers’ plan covers the sale of 76,113 shares of our common stock, including 46,893 shares to be acquired upon the exercise of stock options. Transactions under Ms. Carruthers’ plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Ms. Carruthers’ plan will terminate on the earlier of December 31, 2024 or the date all shares subject to the plan have been sold.
Name Wendy Carruthers  
Title Executive Vice President, Human Resources  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date November 17, 2023  
Arrangement Duration 421 days  
Arthur Butcher [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement  
On November 22, 2023, Arthur Butcher, our Executive Vice President and Group President, MedSurg and Asia Pacific, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Butcher’s plan covers the sale of up to 77,687 shares of our common stock, including up to 54,514 shares to be acquired upon determination and/or vesting of performance share units and restricted share units, and 16,742 shares to be acquired upon the exercise of stock options. Transactions under Mr. Butcher’s plan are based upon pre-established dates and stock price thresholds and will only occur upon
the expiration of the applicable mandatory cooling-off period. Mr. Butcher’s plan will terminate on the earlier of January 31, 2025 or the date all shares subject to the plan have been sold.
Name Arthur Butcher  
Title Executive Vice President and Group President, MedSurg and Asia Pacific  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date November 22, 2023  
Arrangement Duration 436 days  
John Bradley Sorenson Rule Trading Arrangement, Common Stock [Member] | John Bradley Sorenson [Member]    
Trading Arrangements, by Individual    
Aggregate Available 33,938 33,938
Wendy Carruthers Rule Trading Arrangement, Common Stock [Member] | Wendy Carruthers [Member]    
Trading Arrangements, by Individual    
Aggregate Available 76,113 76,113
Wendy Carruthers Rule Trading Arrangement, Common Stock [Member] | Arthur Butcher [Member]    
Trading Arrangements, by Individual    
Aggregate Available 77,687 77,687
Wendy Carruthers Rule Trading Arrangement, Stock Options [Member] | Wendy Carruthers [Member]    
Trading Arrangements, by Individual    
Aggregate Available 46,893 46,893
Arthur Butcher Rule Trading Arrangement, PSU and RSU [Member] | Arthur Butcher [Member]    
Trading Arrangements, by Individual    
Aggregate Available 54,514 54,514
Arthur Butcher Rule Trading Arrangement, Stock Options [Member] | Arthur Butcher [Member]    
Trading Arrangements, by Individual    
Aggregate Available 16,742 16,742
XML 44 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
Significant Accounting Policies Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation

The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and with the instructions to Form 10-K and Regulation S-X.

Amounts reported in millions within this Annual Report on Form 10-K are computed based on the amounts in thousands. As a result, the sum of the components may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded numbers.
Subsequent Events
Subsequent Events

We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly.

Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note B – Acquisitions and Strategic Investments for further details.
Accounting Estimates
Accounting Estimates

To prepare our consolidated financial statements in accordance with GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our consolidated financial statements and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to Critical Accounting Estimates included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for further discussion.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents

Cash and Cash Equivalents

We record Cash and cash equivalents in our consolidated balance sheets at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider cash equivalents to be all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash.
Restricted Cash

Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in Other current assets within our consolidated balance sheets. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the customer payments collected by us for servicing previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee.

Restricted Cash Equivalents
Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in Other current assets within our consolidated balance sheets. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents included in Other long-term assets within our consolidated balance sheets are related to deferred compensation plans.
Concentrations of Credit Risk
Concentrations of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including distributors, hospitals, health care agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral.

We record credit loss reserves to Allowance for credit losses when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach to determine the reserve to record at accounts receivable commencement for certain customers, applying country or region-specific factors. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account.

We write-off amounts determined to be uncollectible against this reserve. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in 2023, 2022 and 2021; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups are important to our business and represent a substantial portion of our net sales.
We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other countries. Further, the ongoing site-of-service trend of shifting procedure volumes in the U.S. toward non-hospital settings, particularly ambulatory surgery centers and office-based labs, continues. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions, as appropriate. We believe our Allowance for credit losses is adequate as of December 31, 2023; however, if significant changes were to occur in the payment practices of government customers, or if there is an increase in bankruptcies among our ambulatory surgery center or office-based customers, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts may increase.
Revenue Recognition
Revenue Recognition

We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers:

•We have a contract with a customer that creates enforceable rights and obligations,
•Promised products or services are identified,
•The transaction price, or the amount we expect to receive, is determinable and
•We have transferred control of the promised items to the customer.

Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a component of Selling, general and administrative expenses when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.

Deferred Revenue

We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.

Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying consolidated balance sheets. Our contract liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. Our contract liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

Variable Consideration

We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.

We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.
Post-Implant Services

We provide non-contractual services to customers, where necessary, to ensure the safe and effective use of certain implanted devices. Because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to Selling, general and administrative expenses within our consolidated statements of operations. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost. Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.
Warranty Obligations
Warranty Obligations

We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our CRM business, which include implantable defibrillator and pacemaker systems. These products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a liability equal to these estimated costs as Cost of products sold at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary.
Inventories
Inventories

We state inventories at the lower of first-in, first-out cost or net realizable value. We utilize a standard costing system, capitalizing variances between estimated and actual production costs during periods of normal production, and amortize to Cost of products sold over inventory turns. We expense manufacturing variances during periods of abnormal production, or less than 75 percent of manufacturing capacity. We did not record any abnormal production variances during the years ended December 31, 2023, 2022 or 2021.
We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory.
Property, Plant and Equipment
Property, Plant and Equipment

We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of 40 years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a three to seven year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.
Valuation of Business Combinations
Valuation of Business Combinations

We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&D, on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through Selling, general and administrative expenses.

In cases where we acquire a company in which we previously held an equity stake, we attribute a portion of the purchase price to the previously-held equity interest, which is implied based on the total purchase consideration allocable to each of the shareholders, including Boston Scientific, according to priority of equity interests. We record a gain or loss in Other, net equal to the difference between the implied fair value of our prior ownership and the book value immediately prior to the acquisition.
Where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through Contingent consideration net expense (benefit) on our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.
Indefinite-lived Intangibles and IPR&D
Indefinite-lived Intangibles and IPR&D

Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which are foundational to our ongoing operations, as well as IPR&D intangible assets acquired in a business combination. Our IPR&D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&D intangible asset.

We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, Intangibles - Goodwill and Other (FASB ASC Topic 350). If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value.

We use the income approach to determine the fair values of our IPR&D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects’ stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See Note C – Goodwill and Other Intangible Assets for more information related to indefinite-lived intangibles, including IPR&D.
For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date.
Amortization and Impairment of Intangible Assets
Amortization and Impairment of Intangible Assets

We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, two to 20 years; amortizable technology-related and customer relationships, five to 25 years; other intangible assets, various. In addition, we classify internal use software as an intangible asset within our accompanying consolidated balance sheets and amortize over a one to 15 year useful life. Due to the operational nature of these assets, we record the amortization of our internal use software within Cost of products sold; Selling, general and administrative expenses and Research and development expenses, as appropriate within our accompanying consolidated statements of operations, and include in Amortization expense only that associated with intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents.

We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for
recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified.

We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See Note C – Goodwill and Other Intangible Assets for more information related to impairments of intangible assets.
For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent.
Goodwill Valuation
Goodwill Valuation

We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances, utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350, Intangibles - Goodwill and Other, in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.

We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2023 annual impairment assessment, we identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components into a single Rhythm Management reporting unit.

In performing annual impairment assessments, the qualitative approach is used for testing reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units are tested using the quantitative approach. When a quantitative test is performed, we typically use the income approach, specifically the Discounted Cash Flow method, to derive the fair value of each of our reporting units in preparing our goodwill impairment assessments. We historically selected this method as being the most meaningful in preparing our goodwill assessments because we believe the income approach most appropriately measures the fair value of our income producing assets. We make assumptions about the amount and timing of future expected cash flows, terminal value growth rates and appropriate discount rates. The amount and timing of future cash flows within our Discounted Cash Flow analysis is based on our most recent operational budgets, long range strategic plans and other estimates.
Investments in Publicly Traded and Privately-Held Entities
Investments in Publicly Traded and Privately-Held Entities

For publicly-held equity securities for which we do not have the ability to exercise significant influence, we measure at fair value with changes in fair value recognized currently in Other, net within our accompanying consolidated statements of operations. For privately-held equity securities for which we do not have the ability to exercise significant influence, we apply the measurement alternative approach and measure these investments at cost minus impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We account for investments in entities for which we have the ability to exercise significant influence under the equity method if we hold 50 percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with FASB ASC Topic 323, Investments - Equity Method and Joint Ventures. We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing consolidated financial statements. Lastly, we have notes receivable from certain companies that we account for in accordance with FASB ASC Topic 320, Investments - Debt and Equity Securities. Refer to Note B – Acquisitions and Strategic Investments for additional details on our investment balances.

Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an
investee’s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. For our investments for which we apply the measurement alternative, if the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. For our equity method investments, if we determine an impairment is other-than-temporary, we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value.
Net gains and losses and impairments associated with our investment portfolio are included within Other, net in our consolidated statements of operations.
Income Taxes
Income Taxes

We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial condition and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We recognize interest and penalties related to income taxes as a component of income tax expense. As part of the Tax Cuts and Jobs Act (TCJA), we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and report it as part of continuing operations. See Note H – Income Taxes for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA.
Legal and Product Liability Costs
Legal and Product Liability Costs

We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities and product liability litigation. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related charges (credits) in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our consolidated statements of operations. See Note I – Commitments and Contingencies for discussion of our individual material legal proceedings.
In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) within our accompanying consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our accompanying consolidated statements of operations.
Costs Associated with Exit Activities
Costs Associated with Exit Activities

We record employee termination costs in accordance with FASB ASC Topic 712, Compensation - Nonretirement and Postemployment Benefits, if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with FASB ASC Topic 420, Exit or Disposal Cost Obligations (FASB ASC Topic 420). We record such costs into expense over the employee’s future service period, if any.
Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with FASB ASC Topic 420 and are included within Restructuring net charges (credits) in our consolidated statements of operations. We recorded Restructuring net charges (credits) of $69 million in 2023, $24 million in 2022 and $40 million in 2021. The restructuring reserve balance as of December 31, 2023 and 2022 was $41 million and $10 million, respectively. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities are included within Costs of products sold, Selling, general and administrative expenses and Research and development expenses within our consolidated statements of operations. Impairment of right of use lease assets and lease termination costs directly related to our active restructuring initiatives are expensed in accordance with FASB ASC Topic 842, Leases (FASB ASC Topic 842) and included within Costs of products sold or Selling, general and administrative expenses in our consolidated statements of operations.
Translation of Foreign Currency
Translation of Foreign Currency

We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate. We show the net effect of these translation adjustments within our consolidated financial statements as a component of Accumulated other comprehensive income (loss), net of tax. We translate revenues and expenses at the average exchange rates in effect during the year. For any significant foreign subsidiaries located in highly inflationary economies, we re-measure their financial statements as if the functional currency were the U.S. dollar.
Foreign currency transaction gains and losses are included within Other, net in our consolidated statements of operations, net of losses and gains from any related derivative financial instruments.
Financial Instruments
Financial Instruments

We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815, Derivatives and Hedging (FASB ASC Topic 815), and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our consolidated financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to Note D – Hedging Activities and Fair Value Measurements for more information on our hedging instruments.
Research and Development
Research and Development

We expense research and development (R&D) costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to Indefinite-lived Intangibles and IPR&D above for our policy regarding R&D projects acquired in connection with our business combinations and asset purchases.
Fair Value Measurement FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures (FASB ASC Topic 820), and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means.
XML 45 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions and Strategic Investments (Tables)
 12 Months Ended
Dec. 31, 2023
Business Combinations [Abstract]  
Schedule of Business Acquisitions, by Acquisition
We accounted for these transactions as business combinations in accordance with FASB ASC Topic 805, Business Combinations (FASB ASC Topic 805). The preliminary purchase prices were comprised of the amounts presented below:

(in millions)
Acotec(1)
ApolloRelievant
Payment for acquisition, net of cash acquired (2)
$381 $636 $794 
Fair value of contingent consideration— — 273 
$381 $636 $1,067 
(1) Excludes approximately $140 million of cash on hand at the closing of the transaction
(2) Related to Acotec, represents our majority stake investment
We accounted for the acquisition of Baylis Medical as a business combination in accordance with FASB ASC Topic 805. The final purchase price was comprised of the amount presented below:

(in millions)
Payment for acquisition, net of cash acquired$1,463 
$1,463 
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed The preliminary purchase price allocations were comprised of the components presented below, which represent the preliminary determination of the fair value of identifiable assets acquired and liabilities assumed, as well as goodwill. The final determination of the fair value of certain assets and liabilities will be completed within the measurement period in accordance with FASB ASC Topic 805:
(in millions)AcotecApolloRelievant
Goodwill$337 $378 $731 
Amortizable intangible assets334 248 325 
Other assets acquired93 50 24 
Liabilities assumed(48)(33)(15)
Net deferred tax liabilities(76)(5)1 
Fair value of noncontrolling interest(259)— — 
$381 $636 $1,067 
We recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The final purchase price allocation was comprised of the following components:

(in millions)
Goodwill$988 
Amortizable intangible assets657 
Other assets acquired112 
Liabilities assumed(287)
Net deferred tax liabilities(7)
$1,463 
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination
We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Acotec:
Amortizable intangible assets:
Technology-related$308 1114%
Customer relationships15 1114%
Other intangible assets11 1314%
$334 
Apollo:
Amortizable intangible assets:
Technology-related$222 1112%
Customer relationships26 1112%
$248 
Relievant
Amortizable intangible assets:
Technology-related$287 1212%
Customer relationships38 1212%
$325 
We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
Technology-related622 1111%
Other intangible assets36 1111%
$657 
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
Changes in the fair value of our contingent consideration liability during 2023 and 2022 associated with current and prior period acquisitions were as follows:
(in millions)
Balance as of December 31, 2021$486 
Contingent consideration net expense (benefit)35 
Contingent consideration payments(371)
Balance as of December 31, 2022$149 
Amount recorded related to current year acquisitions273 
Contingent consideration net expense (benefit)58 
Contingent consideration payments(76)
Balance as of December 31, 2023$404 
Fair Value Measurement Inputs and Valuation Techniques
The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:
Contingent Consideration LiabilityFair Value as of December 31, 2023Valuation TechniqueUnobservable InputRange
Weighted Average(1)
Revenue-based Payments and Milestones$404 millionDiscounted Cash FlowDiscount Rate6 %-12%10%
Probability of Payment90%-100%98%
Projected Year of Payment2024-20272025
(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.
Investment
The aggregate carrying amount of our strategic investments was comprised of the following:
As of December 31,
(in millions)20232022
Equity method investments$219 $188 
Measurement alternative investments(1, 2)
194 219 
$413 $407 
(1) Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying consolidated statements of operations.
(2) Includes publicly-held equity securities and convertible notes measured at fair value with changes in fair value recognized in Other, net within our consolidated statements of operations.
XML 46 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets and Goodwill
The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:
 As of December 31, 2023As of December 31, 2022
(in millions)Gross Carrying AmountAccumulated
Amortization/
Write-offs		Gross Carrying AmountAccumulated
Amortization/
Write-offs
Technology-related$13,207 $(8,101)$12,397 $(7,378)
Patents480 (387)486 (394)
Other intangible assets2,130 (1,500)1,960 (1,400)
Amortizable intangible assets$15,817 $(9,988)$14,843 $(9,173)
Goodwill$24,287 $(9,900)$22,820 $(9,900)
IPR&D54 112 
Technology-related120 120 
Indefinite-lived intangible assets$174 $232 
Schedule of Goodwill
The following represents a rollforward of our goodwill balance by reportable segment:
(in millions)MedSurgCardiovascularTotal
Balance as of December 31, 2021$4,246 $7,741 $11,988 
Goodwill acquired— 1,030 1,030 
Foreign currency fluctuations and other changes(10)(88)(98)
Balance as of December 31, 2022$4,237 $8,684 $12,920 
Goodwill acquired1,110 337 1,447 
Foreign currency fluctuations and other changes— 20 20 
Balance as of December 31, 2023$5,347 $9,041 $14,387 
Schedule of Expected Amortization Expense
Estimated Amortization expense for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio, consisting of intangible assets acquired in a business combination or asset acquisition, as well as internally developed patents, as of December 31, 2023 is as follows:
Fiscal Year(in millions)
2024$828 
2025757 
2026737 
2027714 
2028690 
XML 47 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
Hedging Activities and Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Notional Amounts of Outstanding Derivative Positions
The following table presents the contractual amounts of our hedging instruments outstanding:
(in millions)FASB ASC Topic 815 DesignationAs of December 31,
20232022
Forward currency contractsCash flow hedge$2,284 $2,725 
Forward currency contractsNet investment hedge333 365 
Foreign currency-denominated debt(1)
Net investment hedge997 997 
Forward currency contractsNon-designated3,282 4,235 
Total Notional Outstanding$6,896 $8,321 
(1) Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge.
Derivative Instruments, Gain (Loss)
The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying consolidated statements of operations. Refer to Note O – Changes in Other Comprehensive Income for the total amounts relating to derivative and nonderivative instruments presented within our consolidated statements of comprehensive income (loss).
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Year Ended December 31, 2023
Forward currency contracts
Cash flow hedges$81 $(18)$63 Cost of products sold$4,345 $(235)$53 $(182)
Net investment hedges(2)
32 (7)25 Interest expense265 (10)2 (8)
Foreign currency-denominated debt
Net investment hedges(3)
(34)8 (27)Other, net93 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense265 3 (1)2 
Year Ended December 31, 2022
Forward currency contracts
Cash flow hedges$276 $(62)$214 Cost of products sold$3,956 $(209)$47 $(162)
Net investment hedges(2)
41 (10)32 Interest expense470 (10)2 (8)
Foreign currency-denominated debt
Net investment hedges(3)
61 (14)47 Other, net38 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense470 16 (4)13 
Year Ended December 31, 2021
Forward currency contracts
Cash flow hedges$268 $(60)$208 Cost of products sold$3,711 $(54)$12 $(42)
Net investment hedges(2)
56 (13)43 Interest expense341 (13)3 (10)
Foreign currency-denominated debt
Net investment hedges(3)
82 (19)64 Other, net(218)— — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense341 5 (1)4 
(1) In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings.
(2) For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.
(3) For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.
Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months
As of December 31, 2023, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):
Designated Hedging InstrumentFASB ASC Topic 815 DesignationLocation on Consolidated Statements of OperationsAmount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Forward currency contractsCash flow hedgeCost of products sold$152 
Forward currency contractsNet investment hedgeInterest expense9 
Interest rate derivative contractsCash flow hedgeInterest expense(1)
Derivatives Not Designated as Hedging Instruments
Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
(in millions)Location on Consolidated Statements of OperationsYear Ended December 31,
202320222021
Net gain (loss) on currency hedge contractsOther, net$3 $(53)$(16)
Net gain (loss) on currency transaction exposuresOther, net(44)21 (12)
Net currency exchange gain (loss)$(41)$(31)$(27)
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value The following are the balances of our derivative and nonderivative assets and liabilities:
(in millions)
Location on Consolidated Balance Sheets(1)
As of December 31,
20232022
Derivative and Nonderivative Assets:   
Designated Hedging Instruments  
Forward currency contractsOther current assets$140 $196 
Forward currency contractsOther long-term assets107 149 
  246 345 
Non-Designated Hedging Instruments   
Forward currency contractsOther current assets20 36 
Total Derivative and Nonderivative Assets $266 $381 
Derivative and Nonderivative Liabilities:   
Designated Hedging Instruments  
Forward currency contractsOther current liabilities$15 $— 
Forward currency contractsOther long-term liabilities9 1 
Foreign currency-denominated debt(2)
Long-term debt988 952 
  1,012 953 
Non-Designated Hedging Instruments   
Forward currency contractsOther current liabilities38 52 
Total Derivative and Nonderivative Liabilities$1,050 $1,005 
(1) We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.
(2) Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
Assets and liabilities measured at fair value on a recurring basis consist of the following:
As of
 December 31, 2023December 31, 2022
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets        
Money market funds and time deposits$454 $— $— $454 $673 $— $— $673 
Publicly-held securities18 — — 18 2 — — 2 
Hedging instruments— 266 — 266 — 381 — 381 
Licensing arrangements— — 77 77 — — 127 127 
 $472 $266 $77 $816 $674 $381 $127 $1,182 
Liabilities        
Hedging instruments$— $1,050 $— $1,050 $— $1,005 $— $1,005 
Contingent consideration liability— — 404 404 — — 149 149 
Licensing arrangements— — 90 90 — — 159 159 
 $— $1,050 $494 $1,545 $— $1,005 $308 $1,313 
The recurring Level 3 fair value measurements of our licensing arrangements recognized in our consolidated balance sheets as of December 31, 2023 include the following significant unobservable inputs:
Licensing ArrangementsFair Value as of December 31, 2023Valuation TechniqueUnobservable InputRange
Weighted Average(1)
Financial Asset$77 millionDiscounted Cash FlowDiscount Rate15%15%
Projected Year of Payment2024-20252024
Financial Liability$90 millionDiscounted Cash FlowDiscount Rate12%-15%13%
Projected Year of Payment2024-20262025
(1) Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Changes in the fair value of our licensing arrangements' financial asset were as follows:
(in millions)
Balance as of December 31, 2021$246 
Proceeds from royalty rights(141)
Fair value adjustment (expense) benefit22 
Balance as of December 31, 2022$127 
Proceeds from royalty rights(61)
Fair value adjustment (expense) benefit11 
Balance as of December 31, 2023$77 

Changes in the fair value of our licensing arrangements' financial liability were as follows:
(in millions)
Balance as of December 31, 2021$281 
Payments for royalty rights(145)
Fair value adjustment expense (benefit)23 
Balance as of December 31, 2022$159 
Payments for royalty rights(80)
Fair value adjustment expense (benefit)12 
Balance as of December 31, 2023$90 
XML 48 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
Contractual Obligations and Commitments (Tables)
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments The debt maturity schedule for our long-term debt obligations is presented below:
Issuance DateMaturity DateAs of December 31,
Coupon Rate(1)
(in millions, except interest rates)20232022
March 2024 NotesFebruary 2019March 2024— 504 3.450%
March 2025 Senior Notes(3)
March 2022March 20251,105 1,067 0.750%
June 2025 Senior NotesMay 2020June 2025500 500 1.900%
March 2026 Senior NotesFebruary 2019March 2026255 255 3.750%
December 2027 Senior Notes(3)
November 2019December 2027995 960 0.625%
March 2028 Senior Notes(3)
March 2022March 2028829 800 1.375%
March 2028 Senior NotesFebruary 2018March 2028344 344 4.000%
March 2029 Senior NotesFebruary 2019March 2029272 272 4.000%
June 2030 Senior NotesMay 2020June 20301,200 1,200 2.650%
March 2031 Senior Notes(3)
March 2022March 2031829 800 1.625%
March 2034 Senior Notes(3)
March 2022March 2034553 534 1.875%
November 2035 Senior Notes(2)
November 2005November 2035350 350 6.500%
March 2039 Senior NotesFebruary 2019March 2039450 450 4.550%
January 2040 Senior NotesDecember 2009January 2040300 300 7.375%
March 2049 Senior NotesFebruary 2019March 2049650 650 4.700%
Unamortized Debt Issuance Discount and Deferred Financing Costs2024 - 2049(65)(76)
Finance Lease ObligationVarious5 5 
Long-term debt $8,571 $8,915 
(1) Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.
(2) Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate of 6.25% if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher.
(3) These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of December 31, 2023 and 2022, respectively.
Contractual Obligation, Fiscal Year Maturity
Contractual maturities of our long-term debt outstanding as of December 31, 2023 are as follows (in millions):

Fiscal Year
20251,605 
2026255 
2027995 
20281,173 
Thereafter4,604 
Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants
As of December 31, 2023, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility.
 Covenant Requirement
as of December 31, 2023		 Actual
as of December 31, 2023
Maximum permitted leverage ratio(1)
3.75 times 2.33 times
(1) Ratio of total debt to deemed consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), as defined by the 2021 Revolving Credit Facility credit agreement, as amended.
Transfer of Financial Assets Accounted for as Sales Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net in our accompanying consolidated balance sheets, are aggregated by contract denominated currency below (in millions):
As of December 31, 2023As of December 31, 2022
Factoring ArrangementsAmount
De-recognized		Weighted Average Interest RateAmount
De-recognized		Weighted Average Interest Rate
Euro denominated$206 5.1 %$161 2.4 %
Yen denominated214 0.6 %194 0.6 %
Renminbi denominated14 2.9 %13 3.1 %
Long-term Purchase Commitment
As of December 31, 2023, future minimum purchase obligations, relating primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business, were (in millions):
Fiscal YearUnrecorded Purchase Obligations
2024$951 
2025283 
2026155 
202745 
202831 
Thereafter150 
 $1,615 
XML 49 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases (Tables)
 12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
Supplemental Balance Sheet Information Related to Leases
The following table presents supplemental balance sheet information related to our operating leases:
As of December 31,
(in millions)20232022
Assets
Operating lease right-of-use assets in Other long-term assets
$439 $386 
Liabilities
Operating lease liabilities in Other current liabilities
76 61 
Operating lease liabilities in Other long-term liabilities
390 347 
Lease, Cost
The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:
As of December 31,
20232022
Weighted average remaining lease term9 years10 years
Weighted average discount rate4.5%3.3%
Supplemental Cash Flow Information Related to Leases
The following table presents supplemental cash flow information related to our operating leases:
Year Ended December 31,
(in millions)20232022
Cash paid for amounts included in the measurement of operating lease liabilities
Operating cash flows from operating leases$93 $91 
Maturities of Lease Liabilities
The following table presents the maturities of our operating lease liabilities as of December 31, 2023 (in millions):
Fiscal year
Operating Leases (1)
2024$89 
202578 
202665 
202749 
202841 
Thereafter217 
Total future minimum operating lease payments539 
Less: imputed interest(74)
Present value of operating lease liabilities$466 
(1) Excludes expected lease payments for lease terms that have not yet commenced.
XML 50 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
Supplemental Balance Sheet Information (Tables)
 12 Months Ended
Dec. 31, 2023
Supplemental Balance Sheet Information [Abstract]  
Trade accounts receivable, net
Components of selected captions in our accompanying consolidated balance sheets are as follows:
Trade accounts receivable, net
 As of December 31,
(in millions)20232022
Trade accounts receivable$2,338 $2,079 
Allowance for credit losses(110)(109)
 $2,228 $1,970 

The following is a rollforward of our Allowance for credit losses:
Year Ended December 31,
(in millions)202320222021
Beginning balance$109 $108 $105 
Credit loss expense50 35 28 
Write-offs(48)(35)(25)
Ending balance$110 $109 $108 
Schedule of Inventory, Current
Inventories
 As of December 31,
(in millions)20232022
Finished goods$1,537 $1,171 
Work-in-process174 147 
Raw materials773 548 
 $2,484 $1,867 
Schedule of Other Current Assets
Other current assets
 As of December 31,
(in millions)20232022
Restricted cash and restricted cash equivalents$130 $149 
Derivative assets159 232 
Licensing arrangements47 60 
Other285 290 
 $621 $731 
Property, plant and equipment, net
Property, plant and equipment, net
 As of December 31,
(in millions)20232022
Land$140 $137 
Buildings and improvements1,843 1,695 
Equipment, furniture and fixtures3,503 3,297 
Capital in progress857 598 
 6,343 5,728 
Less: accumulated depreciation3,484 3,282 
 $2,859 $2,446 
Schedule of Other Assets
Other long-term assets
 As of December 31,
(in millions)20232022
Restricted cash equivalents$60 $48 
Operating lease right-of-use assets439 386 
Derivative assets107 149 
Investments413 407 
Licensing arrangements30 67 
Indemnification asset176 172 
Other306 271 
 $1,531 $1,500 
Schedule of Accrued Liabilities
Accrued expenses
 As of December 31,
(in millions)20232022
Legal reserves$206 $231 
Payroll and related liabilities1,051 830 
Rebates389 352 
Contingent consideration304 74 
Other696 674 
 $2,646 $2,160 
Other Current Liabilities
Other current liabilities
 As of December 31,
(in millions)20232022
Deferred revenue$266 $220 
Licensing arrangements49 79 
Taxes payable220 232 
Other278 230 
 $814 $761 
Other long-term liabilities
Other long-term liabilities
 As of December 31,
(in millions)20232022
Accrued income taxes$470 $597 
Legal reserves172 212 
Contingent consideration100 75 
Licensing arrangements41 80 
Operating lease liabilities390 347 
Deferred revenue311 289 
Other484 434 
 $1,967 $2,035 
XML 51 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of Income before Income Tax, Domestic and Foreign
Our Income (loss) before income taxes consisted of the following:
Year Ended December 31,
(in millions)202320222021
Domestic$(394)$(1,119)$(648)
Foreign2,379 2,260 1,724 
$1,985 $1,141 $1,076 
Schedule of Components of Income Tax Expense (Benefit)
The related expense (benefit) for income taxes consisted of the following:
Year Ended December 31,
(in millions)202320222021
Current
Federal$189 $51 $18 
State15 19 33 
Foreign116 381 127 
320 451 178 
Deferred
Federal(82)(92)(256)
State(22)(32)(3)
Foreign176 117 117 
73 (7)(142)
$393 $443 $36 
Schedule of Deferred Tax Assets and Liabilities
Significant components of our deferred tax assets and liabilities are as follows:
 As of December 31,
 (in millions)
20232022
 Deferred Tax Assets:
 
Inventory costs and related reserves$30 $19 
Tax benefit of net operating losses and credits744 511 
Reserves and accruals305 304 
Restructuring-related charges14 6 
Litigation and product liability reserves88 103 
Investment write-down58 38 
Compensation related154 136 
Federal benefit of uncertain tax positions11 9 
Intangible assets3,394 3,668 
Capitalized R&D232 160 
Property, plant and equipment— 2 
 5,029 4,954 
Less: valuation allowance(1,220)(1,004)
 3,809 3,950 
 Deferred Tax Liabilities:
  
Property, plant and equipment24 — 
Unrealized gains and losses on derivative financial instruments66 117 
Other12 34 
102 151 
 Net Deferred Tax Assets
3,707 3,799 
Prepaid on intercompany profit315 264 
 Net Deferred Tax Assets and Prepaid on Intercompany Profit$4,022 $4,062 

Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit are included in the following locations within our accompanying consolidated balance sheets (in millions):
Location on Consolidated Balance SheetsAs of December 31,
Component20232022
Prepaid on intercompany profitPrepaid income taxes$315 $264 
Non-current deferred tax assetDeferred tax assets3,841 3,942 
Deferred Tax Assets and Prepaid on Intercompany Profit 4,157 4,206 
Non-current deferred tax liabilityDeferred tax liabilities134 144 
Deferred Tax Liabilities 134 144 
Net Deferred Tax Assets and Prepaid on Intercompany Profit$4,022 $4,062 
Summary of Income Tax Contingencies A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
 Year Ended December 31,
(in millions)202320222021
Beginning Balance$492 $255 $261 
Additions based on positions related to the current year65 88 8 
Additions based on positions related to prior years67 177 41 
Reductions for tax positions of prior years(114)(20)(36)
Settlements with taxing authorities(14)(1)(2)
Statute of limitation expirations(29)(8)(17)
Ending Balance$467 $492 $255 
Tax rate
The reconciliation of income taxes at the federal statutory rate to the actual expense (benefit) for income taxes is as follows:
Year Ended December 31,
202320222021
U.S. federal statutory income tax rate21.0 %21.0 %21.0 %
State income taxes, net of federal benefit0.7 %0.7 %2.5 %
Domestic taxes on foreign earnings6.9 %15.3 %6.8 %
Effect of foreign taxes(15.3)%(3.8)%(14.3)%
Acquisition-related2.2 %4.4 %(8.1)%
Research credit(2.9)%(4.5)%(3.0)%
Valuation allowance7.5 %(1.3)%0.8 %
Compensation-related0.5 %0.6 %(0.6)%
Non-deductible expenses0.4 %0.4 %0.4 %
Uncertain tax positions(0.5)%7.7 %1.2 %
Return to provision(0.1)%(2.1)%(5.7)%
Change in tax rates(0.6)%(0.2)%1.9 %
Other, net— %0.7 %0.4 %
19.8 %38.9 %3.3 %
XML 52 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock Incentive and Purchase Plans (Tables)
 12 Months Ended
Dec. 31, 2023
Stock Incentive and Purchase Plans [Abstract]  
Schedule of Employee Service Share-based Compensation, Allocation of Recognized
The following presents the impact of stock-based compensation on our consolidated statements of operations:
 Year Ended December 31,
(in millions, except per share data)202320222021
Cost of products sold$12 $12 $11 
Selling, general and administrative expenses179 167 147 
Research and development expenses42 41 36 
 233 220 194 
Income tax (benefit) expense(35)(32)(29)
 $198 $188 $165 
Net impact per common share - basic$0.14 $0.13 $0.12 
Net impact per common share - assuming dilution$0.14 $0.13 $0.12 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions:
 Year Ended December 31,
 202320222021
Options granted (in thousands)
2,934 3,287 3,822 
Weighted-average exercise price$47.43 $44.02 $37.69 
Weighted-average grant-date fair value$16.83 $13.64 $10.77 
Black-Scholes Assumptions   
Expected volatility26 %28 %29 %
Expected term (in years, weighted)
6.36.15.9
Risk-free interest rate3.62%-4.75%1.42%-3.87%0.66%-1.20%
Schedule of Share-based Compensation, Restricted Stock Units Award Activity Information related to non-vested stock awards is as follows:
Non-Vested
Stock Award Units
(in thousands)
Weighted Average
Grant-Date
Fair Value
Balance as of December 31, 20209,987 $34 
Granted4,240 39 
Vested(1)
(3,823)31 
Forfeited(658)36 
Balance as of December 31, 20219,745 $37 
Granted3,854 45 
Vested(1)
(3,482)36 
Forfeited(680)44 
Balance as of December 31, 20229,438 $41 
Granted3,958 49 
Vested(1)
(3,624)39 
Forfeited(485)44 
Balance as of December 31, 20239,287 $45 
(1) The number of shares vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.
Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity
Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:
Year Ended December 31,
202320222021
Shares issued or to be issued (in thousands)
2,623 2,850 2,578 
Range of purchase prices$39.11 -$45.51 $31.68 -$32.31 $29.98 -$36.11 
Expense recognized (in millions)
$29 $28 $24 
Schedule of Unrecognized Compensation
We expect to recognize the following future expense for awards outstanding as of December 31, 2023:
 Unrecognized
 Compensation Cost
(in millions) (1)
Weighted Average Remaining
Vesting Period
(in years)
Stock options$40  
Non-vested stock awards203  
 $243 1.7
(1) Amounts presented represent compensation cost, net of estimated forfeitures.
Market-based awards, valuation assumptions
We determined the fair value of the market-based RSU awards to be approximately $13 million for 2023, $12 million for 2022 and $11 million for 2021. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions:
 202320222021
AwardsAwardsAwards
Stock price on date of grant$47.28 $44.19 $37.50 
Measurement period (in years)
2.92.92.9
Risk-free rate4.31 %1.71 %0.20 %
Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions
The following table presents our assumptions used in determining the fair value of our ONSG and AFCF awards currently expected to vest as of December 31, 2023:
2023 ONSG2022 AFCF2021 AFCF
Fair value, net of forfeitures to date (in millions)
$20 $7 $12 
Achievement of target payout(1)
200 %88 %131 %
Stock price used in determining fair value$47.28 $46.27 $42.48 
(1) Company's estimate of target payout as of December 31, 2023.
Share-based Compensation, Stock Options, Activity
Information related to stock options under stock incentive plans are as follows:
Stock Options
(in thousands)
Weighted
Average
Exercise Price
Weighted Average
Remaining
Contractual Life
(in years)
Aggregate
Intrinsic
Value
(in millions)
Outstanding as of December 31, 202023,122 $24 
Granted3,822 38 
Exercised(4,796)13 
Cancelled/forfeited(699)26 
Outstanding as of December 31, 202121,448 $29 
Granted3,287 44 
Exercised(2,745)17 
Cancelled/forfeited(502)34 
Outstanding as of December 31, 202221,489 $32 
Granted2,934 47 
Exercised(3,325)25 
Cancelled/forfeited(249)44 
Outstanding as of December 31, 202320,850 $36 5.8462 
Exercisable as of December 31, 202313,532 31 4.5359 
Expected to vest as of December 31, 20237,052 44 8.199 
Total vested and expected to vest as of December 31, 202320,584 $36 5.8$458 
XML 53 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
Weighted Average Shares Outstanding (Tables)
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Schedule of Weighted Average Number of Shares
Year Ended December 31,
(in millions)202320222021
Weighted average shares outstanding - basic1,453.0 1,430.5 1,422.3 
Net effect of common stock equivalents10.6 9.2 11.5 
Weighted average shares outstanding - diluted1,463.5 1,439.7 1,433.8 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following securities were excluded from the calculation of weighted average shares outstanding - diluted because their effect in the periods presented below would have been antidilutive:
Year Ended December 31,
(in millions)202320222021
Stock options outstanding(1)
063
MCPS(2)
102424
(1) Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.
(2) Represents common stock issuable upon the conversion of MCPS. Refer to Note J – Stockholders' Equity for additional information.
XML 54 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Reporting (Tables)
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Reconciliation of Revenue from Segments to Consolidated
A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying consolidated statements of operations is as follows (in millions, except percentages). Prior period amounts have been restated at constant currency to conform to the current year presentation.
 Year Ended December 31,
Net sales202320222021
MedSurg$5,320 $4,805 $4,389 
Cardiovascular8,630 7,599 6,721 
Total net sales of reportable segments 13,949 12,404 11,109 
Other(1)
— (60)12 
Impact of foreign currency fluctuations291 338 766 
$14,240 $12,682 $11,888 
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
Year Ended December 31,
Income (loss) before income taxes202320222021
MedSurg$1,796 $1,458 $1,368 
Cardiovascular2,235 1,748 1,572 
Total operating income of reportable segments 4,031 3,206 2,940 
Unallocated amounts:
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(293)96 67 
Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs
(567)(789)(1,070)
Amortization expense(828)(803)(741)
Other(1)
— (60)3 
Operating income (loss) 2,343 1,649 1,199 
Other income (expense), net(358)(508)(123)
Income (loss) before income taxes$1,985 $1,141 $1,076 
(1)    In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments
Segment operating income as percentage of net sales
Operating income of reportable segments as a percentage of net sales of reportable segmentsYear Ended December 31,
202320222021
MedSurg33.8 %30.3 %31.2 %
Cardiovascular25.9 %23.0 %23.4 %
Reconciliation of Assets from Segment to Consolidated
Year Ended December 31,
Depreciation expense202320222021
MedSurg$103 $88 $91 
Cardiovascular263 245 261 
Consolidated depreciation expense$367 $333 $352 
As of December 31,
Total assets20232022
MedSurg$2,888 $2,501 
Cardiovascular5,988 5,205 
Total assets of reportable segments8,876 7,706 
Goodwill14,387 12,920 
Other intangible assets, net6,003 5,902 
All other corporate assets5,869 5,941 
 $35,136 $32,469 
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas
As of December 31,
Long-lived assets20232022
U.S.$1,300 $1,241 
Ireland598 478 
Costa Rica373 246 
Other countries587 481 
Property, plant and equipment, net2,859 2,446 
Goodwill14,387 12,920 
Other intangible assets, net6,003 5,902 
Operating lease right-of-use assets in Other long-term assets
439 386 
 $23,688 $21,653 
XML 55 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue (Tables)
 12 Months Ended
Dec. 31, 2023
Disaggregation of Revenue [Abstract]  
Disaggregation of Revenue The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.
Year Ended December 31,
202320222021
BusinessesU.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Endoscopy$1,511 $970 $2,482 $1,341 $880 $2,221 1,222 $919 $2,141 
Urology1,369 595 1,964 1,257 516 1,773 1,120 463 1,583 
Neuromodulation736 240 976 715 202 917 713 196 909 
MedSurg3,617 1,805 5,422 3,312 1,599 4,911 3,055 1,578 4,633 
Interventional Cardiology Therapies743 1,674 2,417 744 1,485 2,228 778 1,431 2,209 
Watchman1,155 119 1,274 915 103 1,019 729 100 829 
Cardiac Rhythm Management1,405 813 2,218 1,337 763 2,100 1,214 805 2,019 
Electrophysiology370 430 800 275 310 585 128 237 365 
Cardiology3,673 3,036 6,709 3,271 2,662 5,932 2,850 2,572 5,422 
Peripheral Interventions1,135 975 2,110 1,048 850 1,899 996 824 1,820 
Cardiovascular4,808 4,011 8,819 4,319 3,512 7,831 3,846 3,396 7,242 
Other1
— — — — — (60)10 4 13 
Total Net Sales$8,425 $5,816 $14,240 $7,632 $5,111 $12,682 $6,911 $4,978 $11,888 
(1)    In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based.

Refer to Note M – Segment Reporting for information on our reportable segments.

Year Ended December 31,
Geographic Regions202320222021
U.S.$8,425 $7,632 $6,901 
Europe, Middle East and Africa2,856 2,526 2,518 
Asia-Pacific2,400 2,116 2,070 
Latin America and Canada560 469 386 
Other1
— (60)13 
Total Net Sales$14,240 $12,682 $11,888 
Emerging Markets(2)
$2,310 $1,968 $1,656 
(2) Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. We have revised prior period amounts to conform to the current year's presentation.

Deferred Revenue
XML 56 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
Changes in Other Comprehensive Income (Tables)
 12 Months Ended
Dec. 31, 2023
Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
The following table provides the reclassifications out of Other comprehensive income, net of tax attributable to Boston Scientific common stockholders:
(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2022$(1)$269 $1 $269 
Other comprehensive income (loss) before reclassifications(87)63 (10)(34)
(Income) loss amounts reclassified from accumulated other comprehensive income(8)(178)1 (185)
Total other comprehensive income (loss)(95)(115)(9)(219)
Balance as of December 31, 2023$(96)$154 $(8)$49 
(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2021$93 $206 $(36)$263 
Other comprehensive income (loss) before reclassifications(86)214 36 163 
(Income) loss amounts reclassified from accumulated other comprehensive income(8)(150)1 (157)
Total other comprehensive income (loss)(94)63 37 6 
Balance as of December 31, 2022$(1)$269 $1 $269 
XML 57 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
Employee Retirement Plans (Tables)
 12 Months Ended
Dec. 31, 2023
Retirement Benefits [Abstract]  
Pension and Other Postretirement Plans, Policy [Policy Text Block]
We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $135 million in 2023, $123 million in 2022 and $118 million in 2021.
Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block] The outstanding obligation is as follows:
 As of December 31, 2023
(in millions)
Accumulated Benefit Obligation (ABO)Projected
Benefit
Obligation (PBO)		Fair value of Plan AssetsUnfunded/Underfunded
PBO Recognized
Domestic Retirement Plans$54 $59 $— $59 
Other International Retirement Plans145 159 101 58 
 $199 $218 $101 $117 

 As of December 31, 2022
(in millions)
Accumulated Benefit Obligation (ABO)Projected
Benefit
Obligation (PBO)		Fair value of Plan AssetsUnfunded/Underfunded PBO Recognized
Domestic Retirement Plans$50 $55 $— $55 
Other International Retirement Plans140 152 101 51 
 $190 $207 $101 $105 
Schedule of Changes in Projected Benefit Obligations [Table Text Block]
A reconciliation of the changes in the PBO for our retirement plans is as follows:
 Year Ended December 31,
(in millions)20232022
Beginning obligations$207 $502 
Service costs10 13 
Interest costs7 3 
Actuarial (gain) loss(4)(54)
Plan curtailments/settlements(0)(191)
Plan amendments and assumption changes6 (25)
Benefits paid(10)(6)
Impact of foreign currency fluctuations3 (37)
Ending obligation$218 $207 
Schedule of Defined Benefit Plans Disclosures [Table Text Block]
The critical assumptions associated with our employee retirement plans for 2023 are as follows:
Weighted Average Discount RateWeighted Average Expected Return
Weighted Average Rate of Compensation Increase(1)
Domestic Retirement Plans4.89%n/a2.00%
Other International Retirement Plans2.85%2.66%3.00%
(1)    Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.

The critical assumptions associated with our employee retirement plans for 2022 are as follows:
Weighted Average Discount RateWeighted Average Expected Return
Weighted Average Rate of Compensation Increase(1)
Domestic Retirement Plans5.32%n/a2.00%
Other International Retirement Plans2.62%2.27%3.00%
(1) Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.
Schedule of Changes in Fair Value of Plan Assets [Table Text Block]
A reconciliation of the changes in the fair value of plan assets for our funded retirement plans is as follows:
 Year Ended December 31,
(in millions)20232022
Beginning fair value$101 $336 
Actual return on plan assets(1)(2)
Employer contributions11 16 
Participant contributions1 1 
Plan curtailments/settlements(0)(185)
Actuarial gain (loss)(0)(25)
Benefits paid(10)(9)
Impact of foreign currency fluctuations0 (32)
Ending fair value$101 $101 
Schedule of Expected Benefit Payments Benefit payments expected to be paid during the next ten years for our Domestic Retirement Plans and our Other International Retirement Plans are as follows:
(in millions)Post Retirement Benefits
2024$16 
202513 
202614 
202715 
202815 
2029 - 203373 
XML 58 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
Significant Accounting Policies Significant Accounting Policies (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Significant Accounting Policies [Line Items]      
Restructuring Charges $ 69 $ 24 $ 40
Restructuring Reserve $ 41 $ 10  
Building      
Significant Accounting Policies [Line Items]      
Property, Plant and Equipment, Useful Life 40 years    
Minimum | Patents and Licenses      
Significant Accounting Policies [Line Items]      
Finite-Lived Intangible Assets, Useful Life 2 years    
Minimum | Technology Related and Customer Relationships      
Significant Accounting Policies [Line Items]      
Finite-Lived Intangible Assets, Useful Life 5 years    
Minimum | Software Development      
Significant Accounting Policies [Line Items]      
Finite-Lived Intangible Assets, Useful Life 1 year    
Minimum | Equipment, Furniture, Fixtures      
Significant Accounting Policies [Line Items]      
Property, Plant and Equipment, Useful Life 3 years    
Maximum | Patents and Licenses      
Significant Accounting Policies [Line Items]      
Finite-Lived Intangible Assets, Useful Life 20 years    
Maximum | Technology Related and Customer Relationships      
Significant Accounting Policies [Line Items]      
Finite-Lived Intangible Assets, Useful Life 25 years    
Maximum | Software Development      
Significant Accounting Policies [Line Items]      
Finite-Lived Intangible Assets, Useful Life 15 years    
Maximum | Equipment, Furniture, Fixtures      
Significant Accounting Policies [Line Items]      
Property, Plant and Equipment, Useful Life 7 years    
XML 59 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions and Strategic Investments - Narrative (Details)
$ / shares in Units, $ in Millions
 12 Months Ended
Jan. 08, 2024
USD ($)
$ / shares
Nov. 17, 2023
USD ($)
Apr. 04, 2023
USD ($)
Feb. 20, 2023
USD ($)
Feb. 20, 2023
HKD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Business Acquisition [Line Items]                
Payment for acquisition, net of cash acquired (2)           $ 1,811 $ 1,542 $ 2,258
Contingent consideration net expense (benefit)           58 $ 35 $ (136)
Contingent Liability Exposure           398    
Uncapped Contingent Considertation           177    
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity           261    
Acotec                
Business Acquisition [Line Items]                
Subsidiary, Ownership Percentage, Noncontrolling Owner       35.00% 35.00%      
Axonics | Subsequent Event [Member]                
Business Acquisition [Line Items]                
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value $ 3,670              
Business Acquisition, Percentage of Voting Interests Acquired 100.00%              
Business Acquisition, Share Price | $ / shares $ 71.00              
Acotec                
Business Acquisition [Line Items]                
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value       $ 519 $ 20.00      
Business Acquisition, Percentage of Voting Interests Acquired       65.00% 65.00%      
Payment for acquisition, net of cash acquired (2)           381    
Apollo                
Business Acquisition [Line Items]                
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value     $ 636          
Business Acquisition, Percentage of Voting Interests Acquired     100.00%          
Payment for acquisition, net of cash acquired (2)           636    
Relievant Medsystems                
Business Acquisition [Line Items]                
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value   $ 794            
Business Acquisition, Percentage of Voting Interests Acquired   100.00%            
Payment for acquisition, net of cash acquired (2)           794    
Uncapped Contingent Considertation   $ 273            
Baylis Medical                
Business Acquisition [Line Items]                
Payment for acquisition, net of cash acquired (2)           $ 1,463    
XML 60 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions and Strategic Investments - Price Allocation (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Feb. 20, 2023
Business Acquisition [Line Items]        
Payment for acquisition, net of cash acquired (2) $ 1,811 $ 1,542 $ 2,258  
Fair value of contingent consideration 404 149 486  
Cash 411 256    
Goodwill 14,387 $ 12,920 $ 11,988  
Acotec        
Business Acquisition [Line Items]        
Payment for acquisition, net of cash acquired (2) 381      
Fair value of contingent consideration 0      
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net 381      
Cash       $ 140
Goodwill 337      
Amortizable intangible assets 334      
Other assets acquired 93      
Liabilities assumed (48)      
Net deferred tax liabilities (76)      
Fair value of noncontrolling interest (259)      
Apollo        
Business Acquisition [Line Items]        
Payment for acquisition, net of cash acquired (2) 636      
Fair value of contingent consideration 0      
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net 636      
Goodwill 378      
Amortizable intangible assets 248      
Other assets acquired 50      
Liabilities assumed (33)      
Net deferred tax liabilities (5)      
Fair value of noncontrolling interest 0      
Relievant Medsystems        
Business Acquisition [Line Items]        
Payment for acquisition, net of cash acquired (2) 794      
Fair value of contingent consideration 273      
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net 1,067      
Goodwill 731      
Amortizable intangible assets 325      
Other assets acquired 24      
Liabilities assumed (15)      
Net deferred tax liabilities 1      
Fair value of noncontrolling interest 0      
Baylis Medical        
Business Acquisition [Line Items]        
Payment for acquisition, net of cash acquired (2) 1,463      
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net 1,463      
Goodwill 988      
Amortizable intangible assets 657      
Other assets acquired 112      
Liabilities assumed (287)      
Net deferred tax liabilities $ (7)      
XML 61 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions and Strategic Investments - Intangible Assets (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2023
USD ($)
Acotec  
Business Acquisition [Line Items]  
Amount Assigned (in millions) $ 334
Acotec | Technology-related  
Business Acquisition [Line Items]  
Amount Assigned (in millions) $ 308
Weighted Average Amortization Period (in years) 11 years
Acotec | Technology-related | Risk-Adjusted Discount Rates used in Purchase Price Allocation  
Business Acquisition [Line Items]  
Risk-Adjusted Discount Rates used in Purchase Price Allocation 14.00%
Acotec | Customer relationships  
Business Acquisition [Line Items]  
Amount Assigned (in millions) $ 15
Weighted Average Amortization Period (in years) 11 years
Acotec | Customer relationships | Risk-Adjusted Discount Rates used in Purchase Price Allocation  
Business Acquisition [Line Items]  
Risk-Adjusted Discount Rates used in Purchase Price Allocation 14.00%
Acotec | Other intangible assets  
Business Acquisition [Line Items]  
Amount Assigned (in millions) $ 11
Weighted Average Amortization Period (in years) 13 years
Acotec | Other intangible assets | Risk-Adjusted Discount Rates used in Purchase Price Allocation  
Business Acquisition [Line Items]  
Risk-Adjusted Discount Rates used in Purchase Price Allocation 14.00%
Apollo  
Business Acquisition [Line Items]  
Amount Assigned (in millions) $ 248
Apollo | Technology-related  
Business Acquisition [Line Items]  
Amount Assigned (in millions) $ 222
Weighted Average Amortization Period (in years) 11 years
Apollo | Technology-related | Risk-Adjusted Discount Rates used in Purchase Price Allocation  
Business Acquisition [Line Items]  
Risk-Adjusted Discount Rates used in Purchase Price Allocation 12.00%
Apollo | Customer relationships  
Business Acquisition [Line Items]  
Amount Assigned (in millions) $ 26
Weighted Average Amortization Period (in years) 11 years
Apollo | Customer relationships | Risk-Adjusted Discount Rates used in Purchase Price Allocation  
Business Acquisition [Line Items]  
Risk-Adjusted Discount Rates used in Purchase Price Allocation 12.00%
Relievant Medsystems  
Business Acquisition [Line Items]  
Amount Assigned (in millions) $ 325
Relievant Medsystems | Technology-related  
Business Acquisition [Line Items]  
Amount Assigned (in millions) $ 287
Weighted Average Amortization Period (in years) 12 years
Relievant Medsystems | Technology-related | Risk-Adjusted Discount Rates used in Purchase Price Allocation  
Business Acquisition [Line Items]  
Risk-Adjusted Discount Rates used in Purchase Price Allocation 12.00%
Relievant Medsystems | Customer relationships  
Business Acquisition [Line Items]  
Amount Assigned (in millions) $ 38
Weighted Average Amortization Period (in years) 12 years
Relievant Medsystems | Customer relationships | Risk-Adjusted Discount Rates used in Purchase Price Allocation  
Business Acquisition [Line Items]  
Risk-Adjusted Discount Rates used in Purchase Price Allocation 12.00%
Baylis Medical  
Business Acquisition [Line Items]  
Amount Assigned (in millions) $ 657
Baylis Medical | Technology-related  
Business Acquisition [Line Items]  
Amount Assigned (in millions) $ 622
Weighted Average Amortization Period (in years) 11 years
Baylis Medical | Technology-related | Risk-Adjusted Discount Rates used in Purchase Price Allocation  
Business Acquisition [Line Items]  
Risk-Adjusted Discount Rates used in Purchase Price Allocation 11.00%
Baylis Medical | Other intangible assets  
Business Acquisition [Line Items]  
Amount Assigned (in millions) $ 36
Weighted Average Amortization Period (in years) 11 years
Baylis Medical | Other intangible assets | Risk-Adjusted Discount Rates used in Purchase Price Allocation  
Business Acquisition [Line Items]  
Risk-Adjusted Discount Rates used in Purchase Price Allocation 11.00%
XML 62 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions and Strategic Investments - Contingent Consideration (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Business Combinations [Abstract]      
Business Combination, Contingent Consideration, Liability $ 149 $ 486  
Contingent consideration net expense (benefit) 58 35 $ (136)
Payment of contingent consideration (76) (371)  
Fair value of contingent consideration recorded in purchase accounting 273 0 440
Business Combination, Contingent Consideration, Liability $ 404 $ 149 $ 486
XML 63 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions and Strategic Investments - Strategic Investments (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Investments [Abstract]    
Equity method investments $ 219 $ 188
Measurement alternative investments(1, 2) 194 219
Investments $ 413 $ 407
XML 64 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions and Strategic Investments - Level 3 (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Business Acquisition [Line Items]      
Fair value of contingent consideration $ 404 $ 149 $ 486
Revenue-based Payments and Milestones | Discount Rate      
Business Acquisition [Line Items]      
Fair value of contingent consideration $ 404    
Revenue-based Payments and Milestones | Discount Rate | Minimum      
Business Acquisition [Line Items]      
contingent consideration liability, probability of payment 90.00%    
Risk-Adjusted Discount Rates used in Purchase Price Allocation 6.00%    
Revenue-based Payments and Milestones | Discount Rate | Maximum      
Business Acquisition [Line Items]      
contingent consideration liability, probability of payment 100.00%    
Risk-Adjusted Discount Rates used in Purchase Price Allocation 12.00%    
Revenue-based Payments and Milestones | Discount Rate | Weighted Average      
Business Acquisition [Line Items]      
contingent consideration liability, probability of payment 98.00%    
Risk-Adjusted Discount Rates used in Purchase Price Allocation 10.00%    
XML 65 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Other Intangible Assets (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Goodwill and Other Intangible Assets      
Finite-Lived Intangible Assets, Gross $ 15,817 $ 14,843  
Finite-Lived Intangible Assets, Accumulated Amortization (9,988) (9,173)  
Goodwill, Gross 24,287 22,820  
Goodwill, Impaired, Accumulated Impairment Loss (9,900) (9,900)  
Indefinite-lived Intangible Assets (Excluding Goodwill) 174 232  
Intangible asset impairment charges 58 132 $ 370
Goodwill (Roll Forward)      
Goodwill, Beginning Balance 12,920 11,988  
Foreign currency fluctuations and other changes 20 (98)  
Goodwill acquired 1,447 1,030  
Goodwill, Ending Balance 14,387 12,920 11,988
Other Intangible Assets (Textuals) [Abstract]      
Future Amortization Expense, Year One 828    
Future Amortization Expense, Year Two 757    
Future Amortization Expense, Year Three 737    
Future Amortization Expense, Year Four 714    
Future Amortization Expense, Year Five 690    
MedSurg      
Goodwill (Roll Forward)      
Goodwill, Beginning Balance 4,237 4,246  
Foreign currency fluctuations and other changes 0 (10)  
Goodwill acquired 1,110 0  
Goodwill, Ending Balance 5,347 4,237 4,246
Cardiovascular      
Goodwill (Roll Forward)      
Goodwill, Beginning Balance 8,684 7,741  
Foreign currency fluctuations and other changes 20 (88)  
Goodwill acquired 337 1,030  
Goodwill, Ending Balance 9,041 8,684 $ 7,741
IPR&D      
Goodwill and Other Intangible Assets      
Indefinite-lived Intangible Assets (Excluding Goodwill) 54 112  
Technology-related      
Goodwill and Other Intangible Assets      
Indefinite-lived Intangible Assets (Excluding Goodwill) 120 120  
Technology-related      
Goodwill and Other Intangible Assets      
Finite-Lived Intangible Assets, Gross 13,207 12,397  
Finite-Lived Intangible Assets, Accumulated Amortization (8,101) (7,378)  
Patents      
Goodwill and Other Intangible Assets      
Finite-Lived Intangible Assets, Gross 480 486  
Finite-Lived Intangible Assets, Accumulated Amortization (387) (394)  
Other intangible assets      
Goodwill and Other Intangible Assets      
Finite-Lived Intangible Assets, Gross 2,130 1,960  
Finite-Lived Intangible Assets, Accumulated Amortization $ (1,500) $ (1,400)  
XML 66 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
Hedging Activities and Fair Value Measurements (Details)
€ in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2023
USD ($)
units
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2021
EUR (€)
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative, Notional Amount $ 6,896 $ 8,321    
Cost of Goods and Services Sold 4,345 3,956 $ 3,711  
Interest Expense 265 470 341  
Other Operating Income (Expense), Net 93 38 (218)  
Derivative Asset, Fair Value, Gross Asset 266 381    
Derivative Liability, Fair Value, Gross Liability 1,050 1,005    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Derivative assets 107 149    
Licensing arrangements $ 30 67    
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Noncurrent      
Fair value of contingent consideration $ 404 149 486  
Licensing arrangements 41 80    
Cash 411 256    
Debt Instrument, Fair Value Disclosure 8,735 8,203    
November 2019 Aggregate Offering        
Derivative Instruments, Gain (Loss) [Line Items]        
Long-term Debt | €       € 900
December 2027 Notes        
Derivative Instruments, Gain (Loss) [Line Items]        
Long-term Debt $ 995 960    
Debt Instrument, Interest Rate, Stated Percentage 0.625%      
Financial Asset        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Risk-Adjusted Discount Rates used in Purchase Price Allocation 15.00%      
Level 3        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Licensing arrangements $ 77      
Licensing arrangements 90      
Fair Value, Measurements, Recurring [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Money Market Funds, at Carrying Value 454 673    
Equity Securities, FV-NI 18 2    
Derivative assets 266 381    
Licensing arrangements 77 127    
Assets, Fair Value Disclosure 816 1,182    
Foreign Currency Contracts, Liability, Fair Value Disclosure 1,050 1,005    
Fair value of contingent consideration 404 149    
Licensing arrangements 90 159    
Financial and Nonfinancial Liabilities, Fair Value Disclosure 1,545 1,313    
Fair Value, Measurements, Recurring [Member] | Level 1        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Money Market Funds, at Carrying Value 454 673    
Equity Securities, FV-NI 18 2    
Derivative assets 0 0    
Licensing arrangements 0 0    
Assets, Fair Value Disclosure 472 674    
Foreign Currency Contracts, Liability, Fair Value Disclosure 0 0    
Fair value of contingent consideration 0 0    
Licensing arrangements 0 0    
Financial and Nonfinancial Liabilities, Fair Value Disclosure 0 0    
Fair Value, Measurements, Recurring [Member] | Level 2        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Money Market Funds, at Carrying Value 0 0    
Equity Securities, FV-NI 0 0    
Derivative assets 266 381    
Licensing arrangements 0 0    
Assets, Fair Value Disclosure 266 381    
Foreign Currency Contracts, Liability, Fair Value Disclosure 1,050 1,005    
Fair value of contingent consideration 0 0    
Licensing arrangements 0 0    
Financial and Nonfinancial Liabilities, Fair Value Disclosure 1,050 1,005    
Fair Value, Measurements, Recurring [Member] | Level 3        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Money Market Funds, at Carrying Value 0 0    
Equity Securities, FV-NI 0 0    
Derivative assets 0 0    
Licensing arrangements 77 127    
Assets, Fair Value Disclosure 77 127    
Foreign Currency Contracts, Liability, Fair Value Disclosure 0 0    
Fair value of contingent consideration 404 149    
Licensing arrangements 90 159    
Financial and Nonfinancial Liabilities, Fair Value Disclosure 494 308    
Fair Value, Measurements, Recurring [Member] | Level 3 | Financial Asset        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Licensing arrangements 77 127 246  
Proceeds from Royalties Received (61) (141)    
Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option 11 22    
Fair Value, Measurements, Recurring [Member] | Level 3 | Financial Liability        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Licensing arrangements 90 159 281  
Payments for Royalties (80) (145)    
Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option 12 23    
Designated as Hedging Instrument [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative Instruments in Hedges, Assets, at Fair Value 246 345    
Derivative Instruments in Hedges, Liabilities, at Fair Value 1,012 953    
Designated as Hedging Instrument [Member] | Other long-term liabilities        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative Instruments in Hedges, Liabilities, at Fair Value $ 988 952    
Designated as Hedging Instrument [Member] | Forward currency contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Forward Currency Contracts, Time to Maturity | units 36      
Designated as Hedging Instrument [Member] | Forward currency contracts | Other long-term assets        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative Instruments in Hedges, Assets, at Fair Value $ 107 149    
Designated as Hedging Instrument [Member] | Forward currency contracts | Other current liabilities        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative Instruments in Hedges, Liabilities, at Fair Value 15 0    
Designated as Hedging Instrument [Member] | Forward currency contracts | Other long-term liabilities        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative Instruments in Hedges, Liabilities, at Fair Value 9 1    
Designated as Hedging Instrument [Member] | Forward currency contracts | Other current assets        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative Instruments in Hedges, Assets, at Fair Value 140 196    
Not Designated as Hedging Instrument [Member] | Other, net        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments 3 (53) (16)  
Foreign Currency Transaction Gain (Loss), before Tax (44) 21 (12)  
Net gain (loss) from foreign currency transaction exposures 44 (21) 12  
Net currency exchange gain (loss) (41) (31) (27)  
Not Designated as Hedging Instrument [Member] | Forward currency contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative, Notional Amount 3,282 4,235    
Not Designated as Hedging Instrument [Member] | Forward currency contracts | Other current liabilities        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value 38 52    
Not Designated as Hedging Instrument [Member] | Forward currency contracts | Other current assets        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value $ 20 36    
Weighted Average | Financial Asset        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Risk-Adjusted Discount Rates used in Purchase Price Allocation 15.00%      
Weighted Average | Financial Liability        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Risk-Adjusted Discount Rates used in Purchase Price Allocation 13.00%      
Minimum | Financial Liability        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Risk-Adjusted Discount Rates used in Purchase Price Allocation 12.00%      
Maximum | Financial Liability        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Risk-Adjusted Discount Rates used in Purchase Price Allocation 15.00%      
Cash flow hedge | Forward currency contracts | Cost of products sold        
Derivative Instruments, Gain (Loss) [Line Items]        
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months $ 152      
Cash flow hedge | Interest rate derivative contracts | Interest expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net (1)      
Cash flow hedge | Designated as Hedging Instrument [Member] | Forward currency contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative, Notional Amount 2,284 2,725    
Cash flow hedge | Designated as Hedging Instrument [Member] | Forward currency contracts | Cost of products sold        
Derivative Instruments, Gain (Loss) [Line Items]        
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 81 276 268  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax (18) (62) (60)  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 63 214 208  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax (235) (209) (54)  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax 53 47 12  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax (182) (162) (42)  
Cash flow hedge | Designated as Hedging Instrument [Member] | Interest rate derivative contracts | Interest expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 0 0 0  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax 0 0 0  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 0 0 0  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 3 16 5  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax (1) (4) (1)  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 2 13 4  
Net investment hedge | Forward currency contracts | Interest expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net 9      
Net investment hedge | Designated as Hedging Instrument [Member] | Forward currency contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative, Notional Amount 333 365    
Net investment hedge | Designated as Hedging Instrument [Member] | Forward currency contracts | Interest expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax 32 41 56  
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax (7) (10) (13)  
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax 25 32 43  
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax (10) (10) (13)  
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax 2 2 3  
Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax (8) (8) (10)  
Net investment hedge | Designated as Hedging Instrument [Member] | Foreign currency denominated in debt        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative, Notional Amount 997 997    
Net investment hedge | Designated as Hedging Instrument [Member] | Foreign currency denominated in debt | Interest expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax (34) 61 82  
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax 8 (14) (19)  
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax (27) 47 64  
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax 0 0 0  
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax 0 0 0  
Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax $ 0 $ 0 $ 0  
XML 67 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
Contractual Obligations and Commitments (Details)
€ in Millions, $ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2022
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2023
EUR (€)
Dec. 31, 2023
Dec. 31, 2023
Rate
May 10, 2021
USD ($)
Debt Instrument [Line Items]                  
Total debt     $ 8,935   $ 9,102        
Debt, Current     20   531        
Long-term Debt and Capital Lease Obligations     8,915   8,571        
Deemed Consolidated EBITDA [Member]   $ 1,000              
Exclusion from EBITDA for Restructuring Charges         500        
Restructuring charges remaining to be excluded from calculation of consolidated EBITDA         317        
Litigation and Debt Exclusion from EBITDA         1,000        
Letters of Credit Outstanding, Amount     135   174        
Legal payments remaining to be excluded from calculation of consolidated EBITDA         1,484        
Purchase Obligations, Future Minimum Payments Due, Current         951        
Purchase Obligations, Future Minimum Payments, Due in Two Years         283        
Purchase Obligations, Future Minimum Payments, Due in Three Years         155        
Purchase Obligations, Future Minimum Payments, Due in Four Years         45        
Purchase Obligations, Future Minimum Payments, Due in Five Years         31        
Purchase Obligations, Future Minimum Payments, Due Thereafter         150        
Purchase Obligations, Future Minimum Payments Due         1,615        
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two         1,605        
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three         255        
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four         995        
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Five         1,173        
Long-term Debt, Maturities, Repayments of Principal in Rolling after Year Five         4,604        
Proceeds from long-term borrowings, net of debt issuance costs   0 3,270 $ 0          
Gain (Loss) on Extinguishment of Debt $ 194 $ 0 (194) $ 0          
Supplier Finance Program, Obligation     $ 129   152        
Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]   Accounts Payable, Current Accounts Payable, Current            
Actual, Covenant                  
Debt Instrument [Line Items]                  
Maximum Leverage Ratio             2.33    
Requirement, as of March 31, 2021                  
Debt Instrument [Line Items]                  
Maximum Leverage Ratio             3.75    
Requirement, as of December 31, 2021 and through remaining term of facility                  
Debt Instrument [Line Items]                  
Maximum Leverage Ratio             3.75    
Requirement, four quarters following material acquisition                  
Debt Instrument [Line Items]                  
Maximum Leverage Ratio             4.75    
Requirement, fifth quarter following qualified acquisition                  
Debt Instrument [Line Items]                  
Maximum Leverage Ratio             4.50    
Requirement, sixth quarter following qualified acquisition                  
Debt Instrument [Line Items]                  
Maximum Leverage Ratio             4.25    
Requirement, seventh quarter following qualified acquisition                  
Debt Instrument [Line Items]                  
Maximum Leverage Ratio             4.00    
Requirement, eighth quarter and thereafter following qualified acquisition                  
Debt Instrument [Line Items]                  
Maximum Leverage Ratio             3.75    
Revolving Credit Facility                  
Debt Instrument [Line Items]                  
Line of Credit Facility, Maximum Borrowing Capacity                 $ 2,750
October 2023 Notes                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage             (3.45%)    
Long-term Debt     $ 504   0        
March 2024 Notes                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage             (0.75%)    
Long-term Debt     1,067   1,105        
June 2025 Notes                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage             (1.90%)    
Long-term Debt     500   500        
March 2026 Notes                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage             (3.75%)    
Long-term Debt     255   255        
December 2027 Notes                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage             (0.625%)    
Long-term Debt     960   995        
March 2028 Notes                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage             (4.00%)    
Long-term Debt     344   344        
March 2029 Notes                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage             (4.00%)    
Long-term Debt     272   272        
June 2030 Notes                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage             (2.65%)    
Long-term Debt     1,200   1,200        
November 2035 Notes                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage             (6.50%)    
Long-term Debt     350   350        
March 2039 Notes                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage             (4.55%)    
Long-term Debt     450   450        
January 2040 Notes                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage             (7.375%)    
Long-term Debt     300   300        
March 2049 Notes                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage             (4.70%)    
Long-term Debt     650   650        
Finance Lease Obligation                  
Debt Instrument [Line Items]                  
Long-term Debt     5   5        
Senior Notes                  
Debt Instrument [Line Items]                  
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net     76   65        
Long-term Debt     8,986   9,136        
March 2028 Senior Notes                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage             (1.375%) (1.375%)  
Long-term Debt     800   829 € 750      
March 2031 Notes                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage             (1.625%) (1.625%)  
Long-term Debt     800   829 750      
March 2034 Notes                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage             (1.875%) (1.875%)  
Long-term Debt     534   553 500      
the Offering - aggregate principal amount                  
Debt Instrument [Line Items]                  
Long-term Debt | €           3,000      
March 2025 Notes                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage | Rate               (0.75%)  
Long-term Debt | €           € 1,000      
the Offering - early redemption of combined aggregate principal SN                  
Debt Instrument [Line Items]                  
Long-term Debt         3,275        
Euro denominated                  
Debt Instrument [Line Items]                  
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized     $ 161   206        
Average interest rate of de-recognized receivables   5.10% 2.40%            
Yen denominated                  
Debt Instrument [Line Items]                  
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized     $ 194   214        
Average interest rate of de-recognized receivables   0.60% 0.60%            
Renminbi denominated                  
Debt Instrument [Line Items]                  
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized     $ 13   $ 14        
Average interest rate of de-recognized receivables   2.90% 3.10%            
XML 68 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Operating Leased Assets [Line Items]      
Lessee, Operating Lease, Liability, to be Paid $ 539    
Operating lease right-of-use assets $ 439 $ 386  
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other current liabilities Other current liabilities  
Operating Lease, Liability, Current $ 76 $ 61  
Operating lease liabilities $ 390 $ 347  
Operating Lease, Weighted Average Remaining Lease Term 9 years 10 years  
Operating Lease, Weighted Average Discount Rate, Percent 4.50% 3.30%  
Operating Lease, Cost $ 96 $ 91 $ 90
Operating Lease, Payments 93 91  
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 123 $ 43  
Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months 89    
Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two 78    
Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three 65    
Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four 49    
Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five 41    
Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five 217    
Lessee, Operating Lease, Liability, Undiscounted Excess Amount (74)    
Operating Lease, Liability 466    
Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount $ 500    
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other Assets, Noncurrent Other Assets, Noncurrent  
Minimum      
Operating Leased Assets [Line Items]      
Lessee, Operating Lease, Term of Contract 1 year    
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract 20 years    
Maximum      
Operating Leased Assets [Line Items]      
Lessee, Operating Lease, Term of Contract 53 years    
Lessee, Operating and Finance Leases, Option to Extend 10 years    
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract 25 years    
XML 69 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
Supplemental Balance Sheet Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Trade accounts receivable, net      
Trade accounts receivable $ 2,338 $ 2,079  
Allowance for credit losses (110) (109)  
Trade accounts receivable, net 2,228 1,970  
Allowance for doubtful accounts      
Beginning balance 109 108 $ 105
Credit loss expense 50 35 28
Write-offs (48) (35) (25)
Ending balance 110 109 108
Inventory, Net [Abstract]      
Inventory, Finished Goods, Net of Reserves 1,537 1,171  
Inventory, Work in Process, Net of Reserves 174 147  
Inventory, Raw Materials, Net of Reserves 773 548  
Inventories 2,484 1,867  
Other Current Assets [Abstract]      
Restricted cash and restricted cash equivalents included in Other current assets 130 149 188
Derivative assets 159 232  
Licensing arrangements 47 60  
Other 285 290  
Other Assets, Current $ 621 $ 731  
Supplemental Balance Sheet Information (Textuals)      
Percent of finished goods at consignment 22.00% 27.00%  
Depreciation $ 367 $ 333 352
Property, plant and equipment, net      
Land 140 137  
Buildings and improvements 1,843 1,695  
Equipment, furniture and fixtures 3,503 3,297  
Capital in progress 857 598  
Property, plant and equipment 6,343 5,728  
Less: accumulated depreciation 3,484 3,282  
Property, plant and equipment, net 2,859 2,446  
Other Assets, Noncurrent [Abstract]      
Restricted cash equivalents 60 48 $ 55
Operating lease right-of-use assets 439 386  
Derivative assets 107 149  
Investments 413 407  
Licensing arrangements 30 67  
Indemnification asset 176 172  
Other 306 271  
Other long-term assets (total) 1,531 1,500  
Accrued expenses      
Legal reserves 206 231  
Payroll and related liabilities 1,051 830  
Rebates 389 352  
Contingent consideration 304 74  
Other 696 674  
Accrued liabilities, current 2,646 2,160  
Other Liabilities, Current [Abstract]      
Deferred revenue 266 220  
Licensing arrangements 49 79  
Taxes payable 220 232  
Other 278 230  
Other current liabilities 814 761  
Other long-term liabilities      
Accrued income taxes 470 597  
Legal reserves 172 212  
Contingent consideration 100 75  
Licensing arrangements 41 80  
Operating lease liabilities $ 390 $ 347  
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other long-term liabilities Other long-term liabilities  
Deferred revenue $ 311 $ 289  
Other 484 434  
Other long-term liabilities $ 1,967 $ 2,035  
XML 70 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes (Details - Rate Table)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Taxes [Abstract]      
U.S. federal statutory income tax rate 21.00% 21.00% 21.00%
State income taxes, net of federal benefit 0.70% 0.70% 2.50%
Domestic taxes on foreign earnings 6.90% 15.30% 6.80%
Effect of foreign taxes (15.30%) (3.80%) (14.30%)
Acquisition-related 2.20% 4.40% (8.10%)
Research credit (2.90%) (4.50%) (3.00%)
Valuation allowance 7.50% (1.30%) 0.80%
Compensation-related 0.50% 0.60% (0.60%)
Non-deductible expenses 0.40% 0.40% 0.40%
Uncertain tax positions (0.50%) 7.70% 1.20%
Return to provision (0.10%) (2.10%) (5.70%)
Change in tax rates (0.60%) (0.20%) 1.90%
Other, net 0.00% 0.70% 0.40%
Reported tax rate 19.80% 38.90% 3.30%
XML 71 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes Income Taxes (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Taxes [Abstract]        
Income (Loss) from Continuing Operations before Income Taxes, Domestic $ (394) $ (1,119) $ (648)  
Income (Loss) from Continuing Operations before Income Taxes, Foreign 2,379 2,260 1,724  
Income (loss) before income taxes 1,985 1,141 1,076  
Current Federal Tax Expense (Benefit) 189 51 18  
Current State and Local Tax Expense (Benefit) 15 19 33  
Current Foreign Tax Expense (Benefit) 116 381 127  
Current Income Tax Expense (Benefit) 320 451 178  
Deferred Federal Income Tax Expense (Benefit) (82) (92) (256)  
Deferred State and Local Income Tax Expense (Benefit) (22) (32) (3)  
Deferred Foreign Income Tax Expense (Benefit) 176 117 117  
Deferred Income Tax Expense (Benefit) 73 (7) (142)  
Income Tax Expense (Benefit) 393 443 36  
Deferred Tax Assets, Inventory 30 19    
Deferred Tax Assets, Operating Loss Carryforwards 744 511    
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals 305 304    
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges 14 6    
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies 88 103    
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses 58 38    
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost 154 136    
Federal benefit of uncertain tax positions 11 9    
Deferred Tax Assets, Goodwill and Intangible Assets 3,394 3,668    
Deferred Tax Assets, in Process Research and Development 232 160    
Deferred Tax Assets, Property, Plant and Equipment 0 2    
Deferred Tax Assets, Tax Deferred Expense 5,029 4,954    
Deferred Tax Assets, Valuation Allowance (1,220) (1,004)    
Deferred Tax Assets, Net of Valuation Allowance 3,809 3,950    
Deferred Tax Liabilities, Property, Plant and Equipment 24 0    
Deferred Tax Liabilities, Derivatives 66 117    
Deferred Tax Liabilities, Other 12 34    
Deferred Tax Liabilities, Gross 102 151    
Deferred Tax Assets, Gross 3,707 3,799    
Deferred Tax Assets, Prepaid on Intercompany Profit 315 264    
Net Deferred Tax Liabilities and Prepaid on Intercompany Profit 4,022 4,062    
Deferred Tax Assets, Operating Loss Carryforwards, Domestic 540 464    
Deferred Tax Assets, Operating Loss Carryforwards, Foreign 203 47    
Other Comprehensive Income (Loss), Tax (39) (56) 81  
Free Trade Zone Regime Tax Incentive 212 162 149  
Tax Incentives in Puerto Rico 16 21 27  
Unrecognized Tax Benefits that Would Impact Effective Tax Rate 395 410 177  
Unrecognized Tax Benefits 467 492 255 $ 261
Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions 65 88 8  
Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions 67 177 41  
Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions (114) (20) (36)  
Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities (14) (1) (2)  
Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations (29) (8) (17)  
Tax Adjustments, Settlements, and Unusual Provisions 44 16    
Income Tax Examination, Penalties and Interest Accrued 70 $ 77 $ 43  
Decrease in Unrecognized Tax Benefits is Reasonably Possible 24      
Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability 937      
One-time transaction tax post-1986 E&P - net payment $ 586      
Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution $ 0.15 $ 0.11 $ 0.10  
Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution $ 0.01 $ 0.02 $ 0.02  
transition tax payment remaining $ 264      
Tax incentives in Malaysia $ 20 $ 17 $ 0  
Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution $ 0.01      
Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense $ 8      
XML 72 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Net Deferred Tax Assets (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Income Taxes [Line Items]    
Deferred Tax Assets $ 4,157 $ 4,206
Deferred Tax Liabilities, Net 134 144
Net Deferred Tax Liabilities and Prepaid on Intercompany Profit 4,022 4,062
Other current assets    
Income Taxes [Line Items]    
Deferred Tax Assets 315 264
Deferred tax assets    
Income Taxes [Line Items]    
Deferred Tax Assets 3,841 3,942
Deferred tax liabilities    
Income Taxes [Line Items]    
Deferred Tax Liabilities, Net $ 134 $ 144
XML 73 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies (Details)
$ in Millions
 12 Months Ended
Jan. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Unit
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Commitments and Contingencies Disclosure [Abstract]        
Accrual for legal matters that are probable and estimable   $ 377 $ 443  
Restricted cash and restricted cash equivalents included in Other current assets   130 149 $ 188
Litigation-related net charges (credits)   $ (111) $ 173 $ 430
Litigation Settlement, Amount Awarded to Other Party $ 42      
Brazil CADE - # of individuals for alleged anti-competitive behavior | Unit   29    
Litigation Settlement, Amount Awarded from Other Party   $ 158    
XML 74 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stockholders' Equity (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Jun. 01, 2023
May 27, 2020
Dec. 31, 2023
Dec. 31, 2022
Dec. 14, 2020
Class of Stock [Line Items]          
Preferred Stock, Shares Authorized     50,000,000 50,000,000  
Preferred Stock, Shares Issued     0 10,062,500  
Common Stock, Shares Authorized     2,000,000,000 2,000,000,000  
Common Stock, Par or Stated Value Per Share     $ 0.01 $ 0.01  
Stock Issued During Period, Shares, New Issues 24,000,000        
Stock Repurchase Program, Authorized Amount         $ 1,000
Dividends, Cash     $ 28    
Treasury Stock, Shares     263,289,848 263,289,848  
5.50% MCPS, Series A          
Class of Stock [Line Items]          
Preferred Stock, Shares Issued   10,062,500      
Preferred Stock, Dividend Rate, Percentage   5.50%      
Preferred Stock, Liquidation Preference Per Share   $ 100      
Net proceeds from issuance of preferred stock in connection with public offering   $ 975      
Preferred Stock, Dividends, Per Share, Cash Paid     $ 1.3750    
5.50% MCPS, Series A | Minimum          
Class of Stock [Line Items]          
Convertible Preferred Stock, Terms of Conversion     2.3834    
XML 75 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock Incentive and Purchase Plans (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Feb. 17, 2021
Dec. 31, 2020
Oct. 01, 2020
Feb. 18, 2020
Feb. 21, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Fair value of market based awards $ 13 $ 12 $ 11          
Share Price $ 47.28 $ 46.27 $ 42.48 $ 47.28     $ 44.19 $ 37.50
Unrecognized Compensation Cost - Stock Options $ 40              
Stock Issued During Period, Shares, Employee Stock Purchase Plans 2,623,000 2,850,000 2,578,000          
Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased $ 39.11 $ 31.68            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 9,287,000 9,438,000 9,745,000   9,987,000      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $ 45 $ 41 $ 37   $ 34      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3,958,000 3,854,000 4,240,000          
Measurement period - market based awards 2 years 10 months 24 days 2 years 10 months 24 days 2 years 10 months 24 days          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 4.31% 1.71% 0.20%          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value $ 49 $ 45 $ 39          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (3,624,000) (3,482,000) (3,823,000)          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value $ 39 $ 36 $ 31          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (485,000) (680,000) (658,000)          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Date Fair Value $ 44 $ 44 $ 36          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 20,850,000 21,489,000 21,448,000   23,122,000      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 2,934,000 3,287,000 3,822,000          
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price $ 47.43 $ 44.02 $ 37.69          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (3,325,000) (2,745,000) (4,796,000)          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price $ 25 $ 17 $ 13          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period (249,000) (502,000) (699,000)          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price $ 44 $ 34 $ 26          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $ 462              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 5 years 9 months 18 days              
Stock-based compensation expense $ 233 $ 220 $ 194          
Common Stock, Shares Authorized 2,000,000,000 2,000,000,000            
Common Stock, Capital Shares Reserved for Future Issuance 145,000,000              
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense $ (35) $ (32) (29)          
Share-based compensation, net of tax benefit $ 198 $ 188 $ 165          
compensation expense, per share - basic $ 0.14 $ 0.13 $ 0.12          
compensation expense, per share - diluted 0.14 0.13 0.12          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 16.83 $ 13.64 $ 10.77          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 26.00% 28.00% 29.00%          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term 6 years 3 months 18 days 6 years 1 month 6 days 5 years 10 months 24 days          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value $ 89 $ 72 $ 137          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $ 36 $ 32 $ 29   $ 24      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number 13,532,000              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $ 31              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term 4 years 6 months              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $ 359              
Options expected to vest 7,052,000              
Options expected to vest, weighted average exercise price $ 44              
Options expected to vest, weighted average remaining contractual life 8 years 1 month 6 days              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value $ 99              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number 20,584,000              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $ 36              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term 5 years 9 months 18 days              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $ 458              
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Total Fair Value $ 171 $ 150 $ 148          
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 60,000,000              
Amount of employees total compensation eligible for GESOP purchase 10.00%              
Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less) 85.00%              
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant 9,000,000              
Unrecognized Compensation Cost - Non-vested stock awards $ 203              
Unrecognized Compensation Cost $ 243              
weighted average remaining vesting period 1 year 8 months 12 days              
annualweightedaverageforfeiturerate 5.00%              
Voting power of all classes of stock 10.00%              
Exercise price of the fair market value of our common stock on the date of grant 110.00%              
Qualified options exercise price $ 0              
Fair value of the Free Cash Flow (FCF) performance awards   $ 7 $ 12          
target payout of organic net sales growth (ONSG) performance-based RSU 200.00%              
Target payout of Free Cash Flows (FCF) performance awards   88.00% 131.00%          
Employee Stock Ownership Plan (ESOP), Compensation Expense $ 29 $ 28 $ 24          
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 10,000,000              
Fair value of the organic net sales growth (ONSG) performance awards $ 20              
Minimum                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Range of the target number of performance-based DSUs awarded 0.00% 0.00%            
Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased     $ 29.98          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3.62% 1.42% 0.66%          
Range of the target number of market-based DSUs awarded 0.00%              
High end of range [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Range of the target number of performance-based DSUs awarded 200.00% 150.00%            
Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased $ 45.51 $ 32.31 $ 36.11          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 4.75% 3.87% 1.20%          
Range of the target number of market-based DSUs awarded 200.00%              
2011 LTIP Plan [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Common Stock, Shares Authorized           171,000,000    
Cost of products sold                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Stock-based compensation expense $ 12 $ 12 $ 11          
Selling, General and Administrative Expenses [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Stock-based compensation expense 179 167 147          
Research and Development Expense [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Stock-based compensation expense $ 42 $ 41 $ 36          
XML 76 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
Weighted Average Shares Outstanding (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Weighted Average Number of Shares Outstanding, Basic 1,453,000 1,430,500 1,422,300
Weighted Average Number Diluted Shares Outstanding Adjustment 10,600 9,200 11,500
Weighted Average Number of Shares Outstanding, Diluted 1,463,500 1,439,700 1,433,800
Share-based Payment Arrangement, Option [Member]      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 0 6,000 3,000
5.50% MCPS, Series A      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 10,000 24,000 24,000
XML 77 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Reporting (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2023
USD ($)
reportablesegments
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Segment Reporting Information [Line Items]      
Number of Reportable Segments | reportablesegments 2    
Impact of foreign currency fluctuations on net sales $ 291 $ 338 $ 766
Net sales 14,240 12,682 11,888
Other      
Segment Reporting Information [Line Items]      
Revenues from contracts with customers, disaggregated - performance measurement 0 (60) 12
Net sales 0 (60) 13
Operating Segments      
Segment Reporting Information [Line Items]      
Revenues from contracts with customers, disaggregated - performance measurement 13,949 12,404 11,109
Operating Segments | MedSurg      
Segment Reporting Information [Line Items]      
Revenues from contracts with customers, disaggregated - performance measurement 5,320 4,805 4,389
Net sales 5,422 4,911 4,633
Operating Segments | Cardiovascular      
Segment Reporting Information [Line Items]      
Revenues from contracts with customers, disaggregated - performance measurement 8,630 7,599 6,721
Net sales $ 8,819 $ 7,831 $ 7,242
XML 78 R62.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Reporting - Income (loss) before income taxes (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Segment Reporting Information [Line Items]      
Operating Income Unallocated to Segment $ (567) $ (789) $ (1,070)
Amortization expense (828) (803) (741)
Other(1) 0 (60) 3
Operating Income (Loss) 2,343 1,649 1,199
Other income (expense), net (358) (508) (123)
Income (loss) before income taxes 1,985 1,141 1,076
Operating Segments      
Segment Reporting Information [Line Items]      
Operating Income (Loss) Allocated to Reportable Segments 4,031 3,206 2,940
Operating Segments | MedSurg      
Segment Reporting Information [Line Items]      
Operating Income (Loss) Allocated to Reportable Segments 1,796 1,458 1,368
Operating Segments | Cardiovascular      
Segment Reporting Information [Line Items]      
Operating Income (Loss) Allocated to Reportable Segments 2,235 1,748 1,572
Corporate, Non-Segment      
Segment Reporting Information [Line Items]      
Operating Income Unallocated to Segment $ (293) $ 96 $ 67
XML 79 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Reporting - Operating income of reportable segments as a percentage of net sales of reportable segments (Details) - Operating Segments
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
MedSurg      
Segment Reporting Information [Line Items]      
Segment operating income as percentage of net sales 33.80% 30.30% 31.20%
Cardiovascular      
Segment Reporting Information [Line Items]      
Segment operating income as percentage of net sales 25.90% 23.00% 23.40%
XML 80 R64.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Reporting - Depreciation expense (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Segment Reporting Information [Line Items]      
Depreciation $ 367 $ 333 $ 352
Operating Segments      
Segment Reporting Information [Line Items]      
Depreciation 367 333 352
MedSurg | Operating Segments      
Segment Reporting Information [Line Items]      
Depreciation 103 88 91
Cardiovascular | Operating Segments      
Segment Reporting Information [Line Items]      
Depreciation $ 263 $ 245 $ 261
XML 81 R65.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Reporting - Total Assets (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Segment Reporting Information [Line Items]      
Other Assets $ 35,136 $ 32,469  
Goodwill 14,387 12,920 $ 11,988
Intangible Assets, Net (Excluding Goodwill) 6,003 5,902  
MedSurg      
Segment Reporting Information [Line Items]      
Goodwill 5,347 4,237 4,246
Cardiovascular      
Segment Reporting Information [Line Items]      
Goodwill 9,041 8,684 $ 7,741
Operating Segments      
Segment Reporting Information [Line Items]      
Other Assets 8,876 7,706  
Operating Segments | MedSurg      
Segment Reporting Information [Line Items]      
Other Assets 2,888 2,501  
Operating Segments | Cardiovascular      
Segment Reporting Information [Line Items]      
Other Assets 5,988 5,205  
Corporate, Non-Segment      
Segment Reporting Information [Line Items]      
Other Assets $ 5,869 $ 5,941  
XML 82 R66.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Reporting - Long-lived assets (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]      
Long-Lived Assets $ 23,688 $ 21,653  
Property, Plant and Equipment, Net 2,859 2,446  
Goodwill 14,387 12,920 $ 11,988
Intangible Assets, Net (Excluding Goodwill) 6,003 5,902  
Operating lease right-of-use assets 439 386  
U.S.      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Long-Lived Assets 1,300 1,241  
Ireland      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Long-Lived Assets 598 478  
Costa Rica      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Long-Lived Assets 373 246  
Other countries      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Long-Lived Assets $ 587 $ 481  
XML 83 R67.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]      
Net sales $ 14,240 $ 12,682 $ 11,888
Contract with Customer, Liability [Abstract]      
Contract with Customer, Liability 577 509  
Change in Contract with Customer, Liability [Abstract]      
Contract with Customer, Liability, Revenue Recognized 213    
UNITED STATES      
Disaggregation of Revenue [Line Items]      
Net sales 8,425 7,632 6,911
Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 5,816 5,111 4,978
EMEA [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 2,856 2,526 2,518
APAC [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 2,400 2,116 2,070
Latin America and Canada [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 560 469 386
Emerging Markets [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 2,310 1,968 1,656
country_US excluding Other Net Sales      
Disaggregation of Revenue [Line Items]      
Net sales 8,425 7,632 6,901
Global Endoscopy (Endo) Reporting Unit [Member] | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 2,482 2,221 2,141
Global Endoscopy (Endo) Reporting Unit [Member] | UNITED STATES | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 1,511 1,341 1,222
Global Endoscopy (Endo) Reporting Unit [Member] | Non-US [Member] | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 970 880 919
Global Urology and Pelvic Health Reporting Unit [Member] | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 1,964 1,773 1,583
Global Urology and Pelvic Health Reporting Unit [Member] | UNITED STATES | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 1,369 1,257 1,120
Global Urology and Pelvic Health Reporting Unit [Member] | Non-US [Member] | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 595 516 463
Global Neuromodulation (NM) Reporting Unit [Member] | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 976 917 909
Global Neuromodulation (NM) Reporting Unit [Member] | UNITED STATES | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 736 715 713
Global Neuromodulation (NM) Reporting Unit [Member] | Non-US [Member] | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 240 202 196
Global Peripheral Interventions (PI) Reporting Unit [Member] | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 2,110 1,899 1,820
Global Peripheral Interventions (PI) Reporting Unit [Member] | UNITED STATES | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 1,135 1,048 996
Global Peripheral Interventions (PI) Reporting Unit [Member] | Non-US [Member] | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 975 850 824
Interventional Cardiology Therapies | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 2,417 2,228 2,209
Interventional Cardiology Therapies | UNITED STATES | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 743 744 778
Interventional Cardiology Therapies | Non-US [Member] | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 1,674 1,485 1,431
Cardiac Rhythm Management | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 2,218 2,100 2,019
Cardiac Rhythm Management | UNITED STATES | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 1,405 1,337 1,214
Cardiac Rhythm Management | Non-US [Member] | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 813 763 805
Electrophysiology (EP) | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 800 585 365
Electrophysiology (EP) | UNITED STATES | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 370 275 128
Electrophysiology (EP) | Non-US [Member] | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 430 310 237
Watchman | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 1,274 1,019 829
Watchman | UNITED STATES | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 1,155 915 729
Watchman | Non-US [Member] | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 119 103 100
Global Cardiology Reporting Unit | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 6,709 5,932 5,422
Global Cardiology Reporting Unit | UNITED STATES | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 3,673 3,271 2,850
Global Cardiology Reporting Unit | Non-US [Member] | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 3,036 2,662 2,572
Other      
Disaggregation of Revenue [Line Items]      
Net sales 0 (60) 13
Other | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Net sales 0 0 10
Other | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 0 0 4
MedSurg | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 5,422 4,911 4,633
MedSurg | UNITED STATES | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 3,617 3,312 3,055
MedSurg | Non-US [Member] | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 1,805 1,599 1,578
Cardiovascular | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 8,819 7,831 7,242
Cardiovascular | UNITED STATES | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 4,808 4,319 3,846
Cardiovascular | Non-US [Member] | Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales $ 4,011 $ 3,512 $ 3,396
XML 84 R68.htm IDEA: XBRL DOCUMENT v3.24.0.1
Changes in Other Comprehensive Income (AOCI Rollforward with Reclassification) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward]      
Beginning Stockholders' Equity $ 17,573 $ 16,622  
Other comprehensive income (loss) (230) 6 $ 56
Ending Stockholders' Equity 19,282 17,573 16,622
Accumulated other comprehensive income (loss), net of tax      
AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward]      
Beginning Stockholders' Equity 269 263 207
Other comprehensive income (loss) before reclassifications (34) 163  
(Income) loss amounts reclassified from accumulated other comprehensive income (185) (157)  
Other comprehensive income (loss) (219) 6  
Ending Stockholders' Equity 49 269 263
Foreign Currency Translation Adjustments      
AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward]      
Beginning Stockholders' Equity (1) 93  
Other comprehensive income (loss) before reclassifications (87) (86)  
(Income) loss amounts reclassified from accumulated other comprehensive income (8) (8)  
Other comprehensive income (loss) (95) (94)  
Ending Stockholders' Equity (96) (1) 93
Net Change in Derivative Financial Instruments      
AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward]      
Beginning Stockholders' Equity 269 206  
Other comprehensive income (loss) before reclassifications 63 214  
(Income) loss amounts reclassified from accumulated other comprehensive income (178) (150)  
Other comprehensive income (loss) (115) 63  
Ending Stockholders' Equity 154 269 206
Net Change in Defined Benefit Pensions and Other Items      
AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward]      
Beginning Stockholders' Equity 1 (36)  
Other comprehensive income (loss) before reclassifications (10) 36  
(Income) loss amounts reclassified from accumulated other comprehensive income 1 1  
Other comprehensive income (loss) 9 (37)  
Ending Stockholders' Equity $ (8) $ 1 $ (36)
XML 85 R69.htm IDEA: XBRL DOCUMENT v3.24.0.1
Changes in Other Comprehensive Income - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract]    
Reclassification adjustment from AOCI, tax impact $ 5 $ 6
XML 86 R70.htm IDEA: XBRL DOCUMENT v3.24.0.1
Employee Retirement Plans (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Accumulated Benefit Obligation $ 199 $ 190  
Defined Benefit Plan, Benefit Obligation 218 207 $ 502
Defined Benefit Plan, Plan Assets, Amount 101 101 336
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position 117 105  
Defined Benefit Plan, Service Cost 10 13  
Defined Benefit Plan, Interest Cost 7 3  
Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment 6 (25)  
pension benefit obligation, benefits paid (10) (6)  
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) 3 (37)  
Defined Benefit Plan, Plan Assets, Payment for Settlement 0 (185)  
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) (1) (2)  
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) (4) (54)  
Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO 0 191  
Defined Benefit Plan, Plan Assets, Contributions by Employer 11 16  
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant 1 1  
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) 0 (25)  
Defined Benefit Plan, Benefit Obligation, Benefits Paid (10) (9)  
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) 0 (32)  
Expense related to matching contributions 135 $ 123 $ 118
Defined Benefit Plan, Expected Future Benefit Payment, Year One 16    
Defined Benefit Plan, Expected Future Benefit Payment, Year Two 13    
Defined Benefit Plan, Expected Future Benefit Payment, Year Three 14    
Defined Benefit Plan, Expected Future Benefit Payment, Year Four 15    
Defined Benefit Plan, Expected Future Benefit Payment, Year Five 15    
Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years $ 73    
Domestic Plan      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Executive Retirement Plan Discount Rate 4.89% 5.32%  
Executive Retirement Plan Rate of Compensation Increase 2.00% 2.00%  
Other International Plans      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return 2.66% 2.27%  
Executive Retirement Plan Discount Rate 2.85% 2.62%  
Executive Retirement Plan Rate of Compensation Increase 3.00% 3.00%  
Executive retirement plan [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Accumulated Benefit Obligation $ 54 $ 50  
Defined Benefit Plan, Benefit Obligation 59 55  
Defined Benefit Plan, Plan Assets, Amount 0 0  
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position 59 55  
International retirement plans [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Accumulated Benefit Obligation 145 140  
Defined Benefit Plan, Benefit Obligation 159 152  
Defined Benefit Plan, Plan Assets, Amount 101 101  
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position $ 58 $ 51  
XML 87 R71.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule II (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]      
Beginning balance $ 109 $ 108 $ 105
Net (credits) charges to expenses 50 35 28
Utilization of allowances (48) (35) (25)
Ending balance $ 110 $ 109 $ 108
EXCEL 89 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

"5%A&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M " #G@E18X XML 90 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 91 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 93 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 494 622 1 false 132 0 false 10 false false R1.htm 0000001 - Document - Cover Sheet http://www.bostonscientific.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.bostonscientific.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - Consolidated Statements of Operations Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations Consolidated Statements of Operations Statements 3 false false R4.htm 0000004 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss Consolidated Statements of Comprehensive Income (Loss) Statements 4 false false R5.htm 0000005 - Statement - Consolidated Balance Sheets Sheet http://www.bostonscientific.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 5 false false R6.htm 0000006 - Statement - Consolidated Balance Sheet Paranthetical Sheet http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical Consolidated Balance Sheet Paranthetical Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 7 false false R8.htm 0000008 - Statement - Consolidated Statements of Cash Flows Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 0000009 - Disclosure - Significant Accounting Policies Sheet http://www.bostonscientific.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Acquisitions and Strategic Investments Sheet http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestments Acquisitions and Strategic Investments Notes 10 false false R11.htm 0000011 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 11 false false R12.htm 0000012 - Disclosure - Hedging Activities and Fair Value Measurements Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements Hedging Activities and Fair Value Measurements Notes 12 false false R13.htm 0000013 - Disclosure - Contractual Obligations and Commitments Sheet http://www.bostonscientific.com/role/ContractualObligationsandCommitments Contractual Obligations and Commitments Notes 13 false false R14.htm 0000014 - Disclosure - Leases Sheet http://www.bostonscientific.com/role/Leases Leases Notes 14 false false R15.htm 0000015 - Disclosure - Supplemental Balance Sheet Information Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation Supplemental Balance Sheet Information Notes 15 false false R16.htm 0000016 - Disclosure - Income Taxes Sheet http://www.bostonscientific.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 0000017 - Disclosure - Commitments and Contingencies Sheet http://www.bostonscientific.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 17 false false R18.htm 0000018 - Disclosure - Stockholders' Equity Sheet http://www.bostonscientific.com/role/StockholdersEquity Stockholders' Equity Notes 18 false false R19.htm 0000019 - Disclosure - Stock Inventive and Purchase Plans Sheet http://www.bostonscientific.com/role/StockInventiveandPurchasePlans Stock Inventive and Purchase Plans Notes 19 false false R20.htm 0000020 - Disclosure - Weighted Average Shares Outstanding Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding Weighted Average Shares Outstanding Notes 20 false false R21.htm 0000021 - Disclosure - Segment Reporting Sheet http://www.bostonscientific.com/role/SegmentReporting Segment Reporting Notes 21 false false R22.htm 0000022 - Disclosure - Revenue Sheet http://www.bostonscientific.com/role/Revenue Revenue Notes 22 false false R23.htm 0000023 - Disclosure - Changes in Other Comprehensive Income Sheet http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome Changes in Other Comprehensive Income Notes 23 false false R24.htm 0000024 - Disclosure - New Accounting Pronouncements Sheet http://www.bostonscientific.com/role/NewAccountingPronouncements New Accounting Pronouncements Notes 24 false false R25.htm 0000025 - Disclosure - Employee Retirement Plans (Notes) Notes http://www.bostonscientific.com/role/EmployeeRetirementPlansNotes Employee Retirement Plans (Notes) Notes 25 false false R26.htm 0000026 - Disclosure - Schedule II Sheet http://www.bostonscientific.com/role/ScheduleII Schedule II Notes 26 false false R27.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 27 false false R28.htm 9954471 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Policies) Sheet http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies Significant Accounting Policies Significant Accounting Policies (Policies) Policies http://www.bostonscientific.com/role/SignificantAccountingPolicies 28 false false R29.htm 9954472 - Disclosure - Acquisitions and Strategic Investments (Tables) Sheet http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables Acquisitions and Strategic Investments (Tables) Tables http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestments 29 false false R30.htm 9954473 - Disclosure - Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables) Sheet http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables) Tables 30 false false R31.htm 9954474 - Disclosure - Hedging Activities and Fair Value Measurements (Tables) Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables Hedging Activities and Fair Value Measurements (Tables) Tables http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements 31 false false R32.htm 9954475 - Disclosure - Contractual Obligations and Commitments (Tables) Sheet http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables Contractual Obligations and Commitments (Tables) Tables http://www.bostonscientific.com/role/ContractualObligationsandCommitments 32 false false R33.htm 9954476 - Disclosure - Leases (Tables) Sheet http://www.bostonscientific.com/role/LeasesTables Leases (Tables) Tables http://www.bostonscientific.com/role/Leases 33 false false R34.htm 9954477 - Disclosure - Supplemental Balance Sheet Information (Tables) Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables Supplemental Balance Sheet Information (Tables) Tables http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation 34 false false R35.htm 9954478 - Disclosure - Income Taxes (Tables) Sheet http://www.bostonscientific.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.bostonscientific.com/role/IncomeTaxes 35 false false R36.htm 9954479 - Disclosure - Stock Incentive and Purchase Plans (Tables) Sheet http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables Stock Incentive and Purchase Plans (Tables) Tables 36 false false R37.htm 9954480 - Disclosure - Weighted Average Shares Outstanding (Tables) Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables Weighted Average Shares Outstanding (Tables) Tables http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding 37 false false R38.htm 9954481 - Disclosure - Segment Reporting (Tables) Sheet http://www.bostonscientific.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.bostonscientific.com/role/SegmentReporting 38 false false R39.htm 9954482 - Disclosure - Revenue (Tables) Sheet http://www.bostonscientific.com/role/RevenueTables Revenue (Tables) Tables http://www.bostonscientific.com/role/Revenue 39 false false R40.htm 9954483 - Disclosure - Changes in Other Comprehensive Income (Tables) Sheet http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables Changes in Other Comprehensive Income (Tables) Tables http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome 40 false false R41.htm 9954484 - Disclosure - Employee Retirement Plans (Tables) Sheet http://www.bostonscientific.com/role/EmployeeRetirementPlansTables Employee Retirement Plans (Tables) Tables http://www.bostonscientific.com/role/EmployeeRetirementPlansNotes 41 false false R42.htm 9954485 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Details) Sheet http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails Significant Accounting Policies Significant Accounting Policies (Details) Details http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies 42 false false R43.htm 9954486 - Disclosure - Acquisitions and Strategic Investments - Narrative (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails Acquisitions and Strategic Investments - Narrative (Details) Details 43 false false R44.htm 9954487 - Disclosure - Acquisitions and Strategic Investments - Price Allocation (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails Acquisitions and Strategic Investments - Price Allocation (Details) Details 44 false false R45.htm 9954488 - Disclosure - Acquisitions and Strategic Investments - Intangible Assets (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails Acquisitions and Strategic Investments - Intangible Assets (Details) Details 45 false false R46.htm 9954489 - Disclosure - Acquisitions and Strategic Investments - Contingent Consideration (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsContingentConsiderationDetails Acquisitions and Strategic Investments - Contingent Consideration (Details) Details 46 false false R47.htm 9954490 - Disclosure - Acquisitions and Strategic Investments - Strategic Investments (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsStrategicInvestmentsDetails Acquisitions and Strategic Investments - Strategic Investments (Details) Details 47 false false R48.htm 9954491 - Disclosure - Acquisitions and Strategic Investments - Level 3 (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsLevel3Details Acquisitions and Strategic Investments - Level 3 (Details) Details 48 false false R49.htm 9954492 - Disclosure - Goodwill and Other Intangible Assets (Details) Sheet http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails Goodwill and Other Intangible Assets (Details) Details http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables 49 false false R50.htm 9954493 - Disclosure - Hedging Activities and Fair Value Measurements (Details) Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails Hedging Activities and Fair Value Measurements (Details) Details http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables 50 false false R51.htm 9954494 - Disclosure - Contractual Obligations and Commitments (Details) Sheet http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails Contractual Obligations and Commitments (Details) Details http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables 51 false false R52.htm 9954495 - Disclosure - Leases (Details) Sheet http://www.bostonscientific.com/role/LeasesDetails Leases (Details) Details http://www.bostonscientific.com/role/LeasesTables 52 false false R53.htm 9954496 - Disclosure - Supplemental Balance Sheet Information (Details) Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails Supplemental Balance Sheet Information (Details) Details http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables 53 false false R54.htm 9954497 - Disclosure - Income Taxes (Details - Rate Table) Sheet http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable Income Taxes (Details - Rate Table) Details http://www.bostonscientific.com/role/IncomeTaxesTables 54 false false R55.htm 9954498 - Disclosure - Income Taxes Income Taxes (Details) Sheet http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails Income Taxes Income Taxes (Details) Details 55 false false R56.htm 9954499 - Disclosure - Income Taxes - Net Deferred Tax Assets (Details) Sheet http://www.bostonscientific.com/role/IncomeTaxesNetDeferredTaxAssetsDetails Income Taxes - Net Deferred Tax Assets (Details) Details 56 false false R57.htm 9954500 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.bostonscientific.com/role/CommitmentsandContingencies 57 false false R58.htm 9954501 - Disclosure - Stockholders' Equity (Details) Sheet http://www.bostonscientific.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.bostonscientific.com/role/StockholdersEquity 58 false false R59.htm 9954502 - Disclosure - Stock Incentive and Purchase Plans (Details) Sheet http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails Stock Incentive and Purchase Plans (Details) Details http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables 59 false false R60.htm 9954503 - Disclosure - Weighted Average Shares Outstanding (Details) Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails Weighted Average Shares Outstanding (Details) Details http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables 60 false false R61.htm 9954504 - Disclosure - Segment Reporting (Details) Sheet http://www.bostonscientific.com/role/SegmentReportingDetails Segment Reporting (Details) Details http://www.bostonscientific.com/role/SegmentReportingTables 61 false false R62.htm 9954505 - Disclosure - Segment Reporting - Income (loss) before income taxes (Details) Sheet http://www.bostonscientific.com/role/SegmentReportingIncomelossbeforeincometaxesDetails Segment Reporting - Income (loss) before income taxes (Details) Details 62 false false R63.htm 9954506 - Disclosure - Segment Reporting - Operating income of reportable segments as a percentage of net sales of reportable segments (Details) Sheet http://www.bostonscientific.com/role/SegmentReportingOperatingincomeofreportablesegmentsasapercentageofnetsalesofreportablesegmentsDetails Segment Reporting - Operating income of reportable segments as a percentage of net sales of reportable segments (Details) Details 63 false false R64.htm 9954507 - Disclosure - Segment Reporting - Depreciation expense (Details) Sheet http://www.bostonscientific.com/role/SegmentReportingDepreciationexpenseDetails Segment Reporting - Depreciation expense (Details) Details 64 false false R65.htm 9954508 - Disclosure - Segment Reporting - Total Assets (Details) Sheet http://www.bostonscientific.com/role/SegmentReportingTotalAssetsDetails Segment Reporting - Total Assets (Details) Details 65 false false R66.htm 9954509 - Disclosure - Segment Reporting - Long-lived assets (Details) Sheet http://www.bostonscientific.com/role/SegmentReportingLonglivedassetsDetails Segment Reporting - Long-lived assets (Details) Details 66 false false R67.htm 9954510 - Disclosure - Revenue (Details) Sheet http://www.bostonscientific.com/role/RevenueDetails Revenue (Details) Details http://www.bostonscientific.com/role/RevenueTables 67 false false R68.htm 9954511 - Disclosure - Changes in Other Comprehensive Income (AOCI Rollforward with Reclassification) (Details) Sheet http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails Changes in Other Comprehensive Income (AOCI Rollforward with Reclassification) (Details) Details http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables 68 false false R69.htm 9954512 - Disclosure - Changes in Other Comprehensive Income - Narrative (Details) Sheet http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeNarrativeDetails Changes in Other Comprehensive Income - Narrative (Details) Details 69 false false R70.htm 9954513 - Disclosure - Employee Retirement Plans (Details) Sheet http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails Employee Retirement Plans (Details) Details http://www.bostonscientific.com/role/EmployeeRetirementPlansTables 70 false false R71.htm 9954514 - Disclosure - Schedule II (Details) Sheet http://www.bostonscientific.com/role/ScheduleIIDetails Schedule II (Details) Details http://www.bostonscientific.com/role/ScheduleII 71 false false All Reports Book All Reports bsx-20231231.htm bsx-20231231.xsd bsx-20231231_cal.xml bsx-20231231_def.xml bsx-20231231_lab.xml bsx-20231231_pre.xml bsx-20231231_g1.jpg http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 96 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bsx-20231231.htm": { "nsprefix": "bsx", "nsuri": "http://www.bostonscientific.com/20231231", "dts": { "inline": { "local": [ "bsx-20231231.htm" ] }, "schema": { "local": [ "bsx-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "bsx-20231231_cal.xml" ] }, "definitionLink": { "local": [ "bsx-20231231_def.xml" ] }, "labelLink": { "local": [ "bsx-20231231_lab.xml" ] }, "presentationLink": { "local": [ "bsx-20231231_pre.xml" ] } }, "keyStandard": 530, "keyCustom": 92, "axisStandard": 32, "axisCustom": 1, "memberStandard": 54, "memberCustom": 74, "hidden": { "total": 21, "http://xbrl.sec.gov/dei/2023": 4, "http://fasb.org/us-gaap/2023": 14, "http://xbrl.sec.gov/ecd/2023": 3 }, "contextCount": 494, "entityCount": 1, "segmentCount": 132, "elementCount": 994, "unitCount": 10, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1726, "http://xbrl.sec.gov/dei/2023": 42, "http://xbrl.sec.gov/ecd/2023": 24, "http://fasb.org/srt/2023": 2 }, "report": { "R1": { "role": "http://www.bostonscientific.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.bostonscientific.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "longName": "0000003 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GrossProfit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "unique": true } }, "R4": { "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "longName": "0000004 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "unique": true } }, "R5": { "role": "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "longName": "0000005 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:PrepaidTaxes", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "unique": true } }, "R6": { "role": "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "longName": "0000006 - Statement - Consolidated Balance Sheet Paranthetical", "shortName": "Consolidated Balance Sheet Paranthetical", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity", "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity", "shortName": "Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "longName": "0000008 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "unique": true } }, "R9": { "role": "http://www.bostonscientific.com/role/SignificantAccountingPolicies", "longName": "0000009 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestments", "longName": "0000010 - Disclosure - Acquisitions and Strategic Investments", "shortName": "Acquisitions and Strategic Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets", "longName": "0000011 - Disclosure - Goodwill and Other Intangible Assets", "shortName": "Goodwill and Other Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements", "longName": "0000012 - Disclosure - Hedging Activities and Fair Value Measurements", "shortName": "Hedging Activities and Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.bostonscientific.com/role/ContractualObligationsandCommitments", "longName": "0000013 - Disclosure - Contractual Obligations and Commitments", "shortName": "Contractual Obligations and Commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.bostonscientific.com/role/Leases", "longName": "0000014 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation", "longName": "0000015 - Disclosure - Supplemental Balance Sheet Information", "shortName": "Supplemental Balance Sheet Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.bostonscientific.com/role/IncomeTaxes", "longName": "0000016 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.bostonscientific.com/role/CommitmentsandContingencies", "longName": "0000017 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.bostonscientific.com/role/StockholdersEquity", "longName": "0000018 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.bostonscientific.com/role/StockInventiveandPurchasePlans", "longName": "0000019 - Disclosure - Stock Inventive and Purchase Plans", "shortName": "Stock Inventive and Purchase Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding", "longName": "0000020 - Disclosure - Weighted Average Shares Outstanding", "shortName": "Weighted Average Shares Outstanding", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.bostonscientific.com/role/SegmentReporting", "longName": "0000021 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.bostonscientific.com/role/Revenue", "longName": "0000022 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome", "longName": "0000023 - Disclosure - Changes in Other Comprehensive Income", "shortName": "Changes in Other Comprehensive Income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.bostonscientific.com/role/NewAccountingPronouncements", "longName": "0000024 - Disclosure - New Accounting Pronouncements", "shortName": "New Accounting Pronouncements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "bsx:NewAccountingPronouncementsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bsx:NewAccountingPronouncementsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.bostonscientific.com/role/EmployeeRetirementPlansNotes", "longName": "0000025 - Disclosure - Employee Retirement Plans (Notes)", "shortName": "Employee Retirement Plans (Notes)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.bostonscientific.com/role/ScheduleII", "longName": "0000026 - Disclosure - Schedule II", "shortName": "Schedule II", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-494", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-494", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R27": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-482", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-482", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables", "longName": "9954472 - Disclosure - Acquisitions and Strategic Investments (Tables)", "shortName": "Acquisitions and Strategic Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables", "longName": "9954473 - Disclosure - Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables)", "shortName": "Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables", "longName": "9954474 - Disclosure - Hedging Activities and Fair Value Measurements (Tables)", "shortName": "Hedging Activities and Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables", "longName": "9954475 - Disclosure - Contractual Obligations and Commitments (Tables)", "shortName": "Contractual Obligations and Commitments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.bostonscientific.com/role/LeasesTables", "longName": "9954476 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "bsx:SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bsx:SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables", "longName": "9954477 - Disclosure - Supplemental Balance Sheet Information (Tables)", "shortName": "Supplemental Balance Sheet Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.bostonscientific.com/role/IncomeTaxesTables", "longName": "9954478 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables", "longName": "9954479 - Disclosure - Stock Incentive and Purchase Plans (Tables)", "shortName": "Stock Incentive and Purchase Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables", "longName": "9954480 - Disclosure - Weighted Average Shares Outstanding (Tables)", "shortName": "Weighted Average Shares Outstanding (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.bostonscientific.com/role/SegmentReportingTables", "longName": "9954481 - Disclosure - Segment Reporting (Tables)", "shortName": "Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.bostonscientific.com/role/RevenueTables", "longName": "9954482 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables", "longName": "9954483 - Disclosure - Changes in Other Comprehensive Income (Tables)", "shortName": "Changes in Other Comprehensive Income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables", "longName": "9954484 - Disclosure - Employee Retirement Plans (Tables)", "shortName": "Employee Retirement Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementPlansPolicy", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementPlansPolicy", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails", "longName": "9954485 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Details)", "shortName": "Significant Accounting Policies Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "unique": true } }, "R43": { "role": "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails", "longName": "9954486 - Disclosure - Acquisitions and Strategic Investments - Narrative (Details)", "shortName": "Acquisitions and Strategic Investments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "bsx:ContingentLiabilityExposure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "unique": true } }, "R44": { "role": "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails", "longName": "9954487 - Disclosure - Acquisitions and Strategic Investments - Price Allocation (Details)", "shortName": "Acquisitions and Strategic Investments - Price Allocation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-81", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "unique": true } }, "R45": { "role": "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails", "longName": "9954488 - Disclosure - Acquisitions and Strategic Investments - Intangible Assets (Details)", "shortName": "Acquisitions and Strategic Investments - Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-81", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-85", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "unique": true } }, "R46": { "role": "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsContingentConsiderationDetails", "longName": "9954489 - Disclosure - Acquisitions and Strategic Investments - Contingent Consideration (Details)", "shortName": "Acquisitions and Strategic Investments - Contingent Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bsx:PaymentOfContingentConsideration", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "unique": true } }, "R47": { "role": "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsStrategicInvestmentsDetails", "longName": "9954490 - Disclosure - Acquisitions and Strategic Investments - Strategic Investments (Details)", "shortName": "Acquisitions and Strategic Investments - Strategic Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsLevel3Details", "longName": "9954491 - Disclosure - Acquisitions and Strategic Investments - Level 3 (Details)", "shortName": "Acquisitions and Strategic Investments - Level 3 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-114", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "unique": true } }, "R49": { "role": "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "longName": "9954492 - Disclosure - Goodwill and Other Intangible Assets (Details)", "shortName": "Goodwill and Other Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "longName": "9954493 - Disclosure - Hedging Activities and Fair Value Measurements (Details)", "shortName": "Hedging Activities and Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "longName": "9954494 - Disclosure - Contractual Obligations and Commitments (Details)", "shortName": "Contractual Obligations and Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:DebtAndCapitalLeaseObligations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:DebtAndCapitalLeaseObligations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.bostonscientific.com/role/LeasesDetails", "longName": "9954495 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "bsx:MaturitiesOfLeaseLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "bsx:MaturitiesOfLeaseLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails", "longName": "9954496 - Disclosure - Supplemental Balance Sheet Information (Details)", "shortName": "Supplemental Balance Sheet Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable", "longName": "9954497 - Disclosure - Income Taxes (Details - Rate Table)", "shortName": "Income Taxes (Details - Rate Table)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails", "longName": "9954498 - Disclosure - Income Taxes Income Taxes (Details)", "shortName": "Income Taxes Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.bostonscientific.com/role/IncomeTaxesNetDeferredTaxAssetsDetails", "longName": "9954499 - Disclosure - Income Taxes - Net Deferred Tax Assets (Details)", "shortName": "Income Taxes - Net Deferred Tax Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "longName": "9954500 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.bostonscientific.com/role/StockholdersEquityDetails", "longName": "9954501 - Disclosure - Stockholders' Equity (Details)", "shortName": "Stockholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-281", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "unique": true } }, "R59": { "role": "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails", "longName": "9954502 - Disclosure - Stock Incentive and Purchase Plans (Details)", "shortName": "Stock Incentive and Purchase Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "bsx:Fairvalueofmarketbasedawards", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "bsx:MarketBasedAwardsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bsx:Fairvalueofmarketbasedawards", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "bsx:MarketBasedAwardsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails", "longName": "9954503 - Disclosure - Weighted Average Shares Outstanding (Details)", "shortName": "Weighted Average Shares Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "unique": true } }, "R61": { "role": "http://www.bostonscientific.com/role/SegmentReportingDetails", "longName": "9954504 - Disclosure - Segment Reporting (Details)", "shortName": "Segment Reporting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "reportablesegments", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "reportablesegments", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.bostonscientific.com/role/SegmentReportingIncomelossbeforeincometaxesDetails", "longName": "9954505 - Disclosure - Segment Reporting - Income (loss) before income taxes (Details)", "shortName": "Segment Reporting - Income (loss) before income taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "bsx:OperatingIncomeUnallocatedToSegment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bsx:OperatingIncomeUnallocatedToSegment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.bostonscientific.com/role/SegmentReportingOperatingincomeofreportablesegmentsasapercentageofnetsalesofreportablesegmentsDetails", "longName": "9954506 - Disclosure - Segment Reporting - Operating income of reportable segments as a percentage of net sales of reportable segments (Details)", "shortName": "Segment Reporting - Operating income of reportable segments as a percentage of net sales of reportable segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-308", "name": "bsx:Segmentoperatingincomeaspercentageofnetsales", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "bsx:SegmentoperatingincomeaspercentageofnetsalesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-308", "name": "bsx:Segmentoperatingincomeaspercentageofnetsales", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "bsx:SegmentoperatingincomeaspercentageofnetsalesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.bostonscientific.com/role/SegmentReportingDepreciationexpenseDetails", "longName": "9954507 - Disclosure - Segment Reporting - Depreciation expense (Details)", "shortName": "Segment Reporting - Depreciation expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-314", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "unique": true } }, "R65": { "role": "http://www.bostonscientific.com/role/SegmentReportingTotalAssetsDetails", "longName": "9954508 - Disclosure - Segment Reporting - Total Assets (Details)", "shortName": "Segment Reporting - Total Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:OtherAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:OtherAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.bostonscientific.com/role/SegmentReportingLonglivedassetsDetails", "longName": "9954509 - Disclosure - Segment Reporting - Long-lived assets (Details)", "shortName": "Segment Reporting - Long-lived assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:NoncurrentAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:NoncurrentAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.bostonscientific.com/role/RevenueDetails", "longName": "9954510 - Disclosure - Revenue (Details)", "shortName": "Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "unique": true } }, "R68": { "role": "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails", "longName": "9954511 - Disclosure - Changes in Other Comprehensive Income (AOCI Rollforward with Reclassification) (Details)", "shortName": "Changes in Other Comprehensive Income (AOCI Rollforward with Reclassification) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-49", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "unique": true } }, "R69": { "role": "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeNarrativeDetails", "longName": "9954512 - Disclosure - Changes in Other Comprehensive Income - Narrative (Details)", "shortName": "Changes in Other Comprehensive Income - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "longName": "9954513 - Disclosure - Employee Retirement Plans (Details)", "shortName": "Employee Retirement Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.bostonscientific.com/role/ScheduleIIDetails", "longName": "9954514 - Disclosure - Schedule II (Details)", "shortName": "Schedule II (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20231231.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "bsx_A2011LtipPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "A2011LtipPlanMember", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2011 LTIP Plan [Member]", "label": "2011 LTIP Plan [Member]", "documentation": "2011 LTIP Plan [Member]" } } }, "auth_ref": [] }, "bsx_A550MCPSSeriesAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "A550MCPSSeriesAMember", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails", "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.50% MCPS, Series A", "label": "5.50% MCPS, Series A [Member]", "documentation": "5.50% MCPS, Series A" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesAndLoansReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade accounts receivable, net", "totalLabel": "Trade accounts receivable, net", "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable." } } }, "auth_ref": [ "r431", "r1071" ] }, "us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesAndLoansReceivableNetCurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade accounts receivable, net", "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r45", "r1107" ] }, "us-gaap_AccountsReceivableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableGrossCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts receivable", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r319", "r431", "r432", "r1058" ] }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesNoncurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued income taxes", "label": "Accrued Income Taxes, Noncurrent", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent." } } }, "auth_ref": [ "r175", "r253" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "totalLabel": "Accrued liabilities, current", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r48" ] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "bsx_AccruedRebatesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "AccruedRebatesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rebates", "label": "Accrued Rebates, Current", "documentation": "Accrued Rebates, Current" } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing arrangements", "label": "Accrued Royalties, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r48", "r1061" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Change in Defined Benefit Pensions and Other Items", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r8", "r25", "r60", "r1228", "r1229", "r1230" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r97", "r309", "r879" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Change in Derivative Financial Instruments", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r333", "r342", "r343", "r761", "r1066", "r1228" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r341", "r342", "r800", "r802", "r803", "r804", "r805", "r806" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss), net of tax:", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r59", "r60", "r190", "r320", "r874", "r914", "r915" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r341", "r342", "r800", "r802", "r803", "r804", "r805", "r806" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss), net of tax", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r5", "r25", "r60", "r774", "r777", "r821", "r910", "r911", "r1228", "r1229", "r1230", "r1244", "r1245", "r1246" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation Adjustments", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r7", "r25", "r60", "r342", "r343", "r802", "r803", "r804", "r805", "r806", "r1228" ] }, "bsx_AcotecMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "AcotecMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acotec", "label": "Acotec [Member]", "documentation": "Acotec" } } }, "auth_ref": [] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Amortization Period (in years)", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r211" ] }, "bsx_ActualCovenantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "ActualCovenantMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actual, Covenant", "label": "Actual, Covenant [Member]", "documentation": "Actual Covenant." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r1161" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r180" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r711", "r712", "r713", "r929", "r1244", "r1245", "r1246", "r1383", "r1411" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r1167" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r1167" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r1167" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r1167" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1131", "r1143", "r1153", "r1179" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r1134", "r1146", "r1156", "r1182" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r1167" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r1174" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r1138", "r1147", "r1157", "r1174", "r1183", "r1187", "r1195" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r1193" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ScheduleIIDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r321", "r433", "r470", "r473", "r476", "r1401" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Allowance for credit losses", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r321", "r433", "r470" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ScheduleIIDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Write-offs", "negatedTerseLabel": "Utilization of allowances", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance." } } }, "auth_ref": [ "r475" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/SegmentReportingIncomelossbeforeincometaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense", "negatedTerseLabel": "Amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r17", "r90", "r95" ] }, "bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "AmountOfEmployeesTotalCompensationEligibleForGesopPurchase", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of employees total compensation eligible for GESOP purchase", "label": "Amount of employees total compensation eligible for GESOP purchase", "documentation": "Amount of employees total compensation eligible for GESOP purchase" } } }, "auth_ref": [] }, "bsx_Annualweightedaverageforfeiturerate": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "Annualweightedaverageforfeiturerate", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "annualweightedaverageforfeiturerate", "label": "annualweightedaverageforfeiturerate", "documentation": "Annual Weighted Average Forfeiture Rate The weighted average of estimated forfeitures for grants based on historical trends" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r390" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r76" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r76" ] }, "bsx_ApolloMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "ApolloMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Apollo", "label": "Apollo [Member]", "documentation": "Apollo" } } }, "auth_ref": [] }, "bsx_ArthurButcherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "ArthurButcherMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arthur Butcher [Member]", "documentation": "Arthur Butcher" } } }, "auth_ref": [] }, "bsx_ArthurButcherRuleTradingArrangementPSUAndRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "ArthurButcherRuleTradingArrangementPSUAndRSUMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arthur Butcher Rule Trading Arrangement, PSU and RSU [Member]", "documentation": "Arthur Butcher Rule Trading Arrangement, PSU and RSU" } } }, "auth_ref": [] }, "bsx_ArthurButcherRuleTradingArrangementStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "ArthurButcherRuleTradingArrangementStockOptionsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arthur Butcher Rule Trading Arrangement, Stock Options [Member]", "documentation": "Arthur Butcher Rule Trading Arrangement, Stock Options" } } }, "auth_ref": [] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AsiaPacificMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "APAC [Member]", "label": "Asia Pacific [Member]", "documentation": "Region of Asia Pacific." } } }, "auth_ref": [ "r1413", "r1414", "r1415", "r1416" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r251", "r313", "r360", "r401", "r416", "r422", "r467", "r528", "r529", "r531", "r532", "r533", "r535", "r537", "r539", "r540", "r757", "r763", "r793", "r867", "r973", "r1107", "r1120", "r1278", "r1279", "r1392" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r304", "r325", "r360", "r467", "r528", "r529", "r531", "r532", "r533", "r535", "r537", "r539", "r540", "r757", "r763", "r793", "r1107", "r1278", "r1279", "r1392" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets, Fair Value Disclosure", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r163" ] }, "bsx_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.bostonscientific.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r1125", "r1126", "r1139" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.bostonscientific.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r1125", "r1126", "r1139" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.bostonscientific.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r1125", "r1126", "r1139" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r1190" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r1191" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r1186" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r1186" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r1186" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r1186" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r1186" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r1186" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r1189" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r1188" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r1187" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r1187" ] }, "bsx_AxonicsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "AxonicsMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Axonics", "label": "Axonics [Member]", "documentation": "Axonics" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/IncomeTaxesNetDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/IncomeTaxesNetDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r149", "r155" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "bsx_BaylisMedicalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "BaylisMedicalMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Baylis Medical", "label": "Baylis Medical [Member]", "documentation": "Baylis Medical" } } }, "auth_ref": [] }, "bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior": { "xbrltype": "integerItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Brazil CADE - # of individuals for alleged anti-competitive behavior", "label": "Brazil CADE - # of individuals for alleged anti-competitive behavior", "documentation": "Brazil CADE - # of individuals for alleged anti-competitive behavior" } } }, "auth_ref": [] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingMember", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Building", "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r215" ] }, "us-gaap_BuildingsAndImprovementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingsAndImprovementsGross", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings and improvements", "label": "Buildings and Improvements, Gross", "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [ "r215" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r752", "r1094", "r1097" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r130", "r132", "r752", "r1094", "r1097" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsLevel3Details", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r752" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Percentage of Voting Interests Acquired", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r131" ] }, "us-gaap_BusinessAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionSharePrice", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Share Price", "label": "Business Acquisition, Share Price", "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Fair value of noncontrolling interest", "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value", "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date." } } }, "auth_ref": [ "r135" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 }, "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsContingentConsiderationDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration net expense (benefit)", "verboseLabel": "Contingent consideration net expense (benefit)", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r755", "r1234" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsContingentConsiderationDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsLevel3Details", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of contingent consideration", "periodStartLabel": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Business Combination, Contingent Consideration, Liability", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r2", "r137", "r754" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r137" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r137" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestments" ], "lang": { "en-us": { "role": { "verboseLabel": "ACQUISITIONS AND STRATEGIC INVESTMENTS", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r244", "r753" ] }, "bsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNet", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net deferred tax liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Net", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Net" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Amortizable intangible assets", "terseLabel": "Amount Assigned (in millions)", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r133", "r134" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Liabilities assumed", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": [ "r134" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r134" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r134" ] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages." } } }, "auth_ref": [ "r33" ] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Business Combinations [Abstract]", "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation of Business Combinations", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r129" ] }, "country_CR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "CR", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingLonglivedassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Costa Rica", "label": "COSTA RICA" } } }, "auth_ref": [] }, "us-gaap_CapitalLeaseObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalLeaseObligationsMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease Obligation", "label": "Capital Lease Obligations [Member]", "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time." } } }, "auth_ref": [ "r262" ] }, "bsx_CardiacRhythmManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "CardiacRhythmManagementMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cardiac Rhythm Management", "label": "Cardiac Rhythm Management [Member]", "documentation": "Cardiac Rhythm Management" } } }, "auth_ref": [] }, "bsx_CardiovascularMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "CardiovascularMember", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDepreciationexpenseDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SegmentReportingIncomelossbeforeincometaxesDetails", "http://www.bostonscientific.com/role/SegmentReportingOperatingincomeofreportablesegmentsasapercentageofnetsalesofreportablesegmentsDetails", "http://www.bostonscientific.com/role/SegmentReportingTotalAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cardiovascular", "label": "Cardiovascular [Member]", "documentation": "Cardiovascular [Member]" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r265", "r871", "r940", "r968", "r1107", "r1120", "r1221" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 3.0 }, "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r69", "r307", "r1056" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r70", "r249" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period", "periodEndLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period", "totalLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r69", "r204", "r356" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease)\u00a0in cash, cash equivalents, restricted cash and restricted cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r4", "r204" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flow hedge", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r146" ] }, "bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "CashFlowImpactOfDeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred and prepaid income taxes", "label": "Cash flow impact of deferred income tax expense (benefit)", "documentation": "Cash flow impact of deferred income tax expense (benefit)" } } }, "auth_ref": [] }, "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInContractWithCustomerLiabilityAbstract", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Contract with Customer, Liability [Abstract]", "label": "Change in Contract with Customer, Liability [Abstract]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r1165" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDisclosuresAbstract", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock Disclosures [Abstract]", "label": "Class of Stock Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails", "http://www.bostonscientific.com/role/Cover", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r279", "r316", "r317", "r318", "r360", "r383", "r384", "r387", "r389", "r395", "r396", "r467", "r528", "r531", "r532", "r533", "r539", "r540", "r571", "r572", "r575", "r578", "r585", "r793", "r921", "r922", "r923", "r924", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r941", "r960", "r982", "r1002", "r1030", "r1031", "r1032", "r1033", "r1034", "r1203", "r1238", "r1247" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r316", "r317", "r318", "r395", "r571", "r572", "r573", "r575", "r578", "r583", "r585", "r921", "r922", "r923", "r924", "r1082", "r1203", "r1238" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r1166" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r1166" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r53", "r170", "r870", "r959" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "verboseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r218", "r520", "r521", "r1040", "r1273" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r54" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r1110", "r1111", "r1112", "r1114", "r1115", "r1116", "r1117", "r1244", "r1245", "r1383", "r1403", "r1411" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, Par or Stated Value Per Share", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r179" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, Shares Authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r179", "r960" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Common Stock, Shares, Issued", "periodStartLabel": "Balance (Shares)", "periodEndLabel": "Balance (Shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r179" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, $0.01 par value - authorized 2,000,000,000 shares; 1,729,000,224 shares issued as of December\u00a031, 2023 and 1,696,633,993 shares issued as of December\u00a031, 2022", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r179", "r873", "r1107" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r1171" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r1170" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r1172" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r1169" ] }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansNotes" ], "lang": { "en-us": { "role": { "terseLabel": "EMPLOYEE RETIREMENT PLANS", "label": "Compensation and Employee Benefit Plans [Text Block]", "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": [ "r224", "r227", "r228", "r232" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "bsx_CompensationExpensePerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "CompensationExpensePerShareBasic", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "compensation expense, per share - basic", "label": "compensation expense, per share - basic", "documentation": "compensation expense, per share - basic" } } }, "auth_ref": [] }, "bsx_CompensationExpensePerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "CompensationExpensePerShareDiluted", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "compensation expense, per share - diluted", "label": "compensation expense, per share - diluted", "documentation": "compensation expense, per share - diluted" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income attributable to Boston Scientific common stockholders", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r61", "r337", "r339", "r347", "r861", "r888" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r142", "r247", "r337", "r339", "r346", "r860", "r887" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "CHANGES IN OTHER COMPREHENSIVE INCOME", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r189", "r345", "r859", "r885" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentrations of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r172", "r270" ] }, "bsx_ConsolidatedBalanceSheetParentheticalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "ConsolidatedBalanceSheetParentheticalAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Balance Sheet (Parenthetical) [Abstract]", "documentation": "Consolidated Balance Sheet (Parenthetical)" } } }, "auth_ref": [] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDepreciationexpenseDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SegmentReportingIncomelossbeforeincometaxesDetails", "http://www.bostonscientific.com/role/SegmentReportingOperatingincomeofreportablesegmentsasapercentageofnetsalesofreportablesegmentsDetails", "http://www.bostonscientific.com/role/SegmentReportingTotalAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r364", "r403", "r414", "r415", "r416", "r417", "r418", "r420", "r424", "r528", "r529", "r530", "r531", "r533", "r534", "r536", "r538", "r539", "r1218", "r1219", "r1278", "r1279" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDepreciationexpenseDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SegmentReportingIncomelossbeforeincometaxesDetails", "http://www.bostonscientific.com/role/SegmentReportingOperatingincomeofreportablesegmentsasapercentageofnetsalesofreportablesegmentsDetails", "http://www.bostonscientific.com/role/SegmentReportingTotalAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r364", "r403", "r414", "r415", "r416", "r417", "r418", "r420", "r424", "r528", "r529", "r530", "r531", "r533", "r534", "r536", "r538", "r539", "r1218", "r1219", "r1278", "r1279" ] }, "us-gaap_ConstructionInProgressGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressGross", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital in progress", "label": "Construction in Progress, Gross", "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [ "r215" ] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationByTypeAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration by Type [Axis]", "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "bsx_ContingentConsiderationLiabilityProbabilityOfPayment": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "ContingentConsiderationLiabilityProbabilityOfPayment", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "contingent consideration liability, probability of payment", "label": "contingent consideration liability, probability of payment", "documentation": "contingent consideration liability, probability of payment" } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationTypeDomain", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Type [Domain]", "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "bsx_ContingentLiabilityExposure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "ContingentLiabilityExposure", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Liability Exposure", "label": "Contingent Liability Exposure", "documentation": "Contingent Liability Exposure" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Liability", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r587", "r588", "r599" ] }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityAbstract", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Liability [Abstract]", "label": "Contract with Customer, Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Liability, Revenue Recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r600" ] }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual Obligation, Fiscal Year Maturity", "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." } } }, "auth_ref": [ "r1242" ] }, "us-gaap_ConversionOfStockAmountConverted1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockAmountConverted1", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Conversion of mandatory convertible preferred stock to common stock", "label": "Conversion of Stock, Amount Converted", "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r72", "r73", "r74" ] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of mandatory convertible preferred stock to common stock", "label": "Conversion of Stock, Shares Converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r72", "r73", "r74" ] }, "us-gaap_ConvertiblePreferredStockTermsOfConversion": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockTermsOfConversion", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Preferred Stock, Terms of Conversion", "label": "Preferred Stock, Convertible, Terms", "documentation": "Description of conversion terms for preferred stock." } } }, "auth_ref": [ "r43", "r106", "r109", "r178", "r221", "r222" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingIncomelossbeforeincometaxesDetails", "http://www.bostonscientific.com/role/SegmentReportingTotalAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate, Non-Segment", "label": "Corporate, Non-Segment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r35", "r415", "r416", "r417", "r418", "r424", "r1250" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of products sold", "verboseLabel": "Cost of Goods and Services Sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r196", "r855" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of products sold", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Costs Associated with Exit Activities", "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]", "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation." } } }, "auth_ref": [ "r98", "r216", "r217" ] }, "bsx_CovenantAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "CovenantAxis", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Covenant [Axis]", "label": "Covenant [Axis]", "documentation": "Covenant." } } }, "auth_ref": [] }, "bsx_CovenantDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "CovenantDomain", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Covenant [Domain]", "label": "Covenant [Domain]", "documentation": "Covenant." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current Federal Tax Expense (Benefit)", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1210", "r1241", "r1379" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current Foreign Tax Expense (Benefit)", "label": "Current Foreign Tax Expense (Benefit)", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1210", "r1241" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current Income Tax Expense (Benefit)", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r243", "r738", "r744", "r1241" ] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current State and Local Tax Expense (Benefit)", "label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1210", "r1241", "r1379" ] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r136" ] }, "us-gaap_DebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtAndCapitalLeaseObligations", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total debt", "label": "Debt and Lease Obligation", "documentation": "Amount of short-term and long-term debt and lease obligation." } } }, "auth_ref": [ "r258" ] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Current debt obligations", "terseLabel": "Debt, Current", "label": "Debt, Current", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [ "r315" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitments" ], "lang": { "en-us": { "role": { "verboseLabel": "CONTRACTUAL OBLIGATIONS AND COMMITMENTS", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r219", "r358", "r541", "r547", "r548", "r549", "r550", "r551", "r552", "r557", "r564", "r565", "r567" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r42", "r173", "r174", "r252", "r255", "r364", "r542", "r543", "r544", "r545", "r546", "r548", "r553", "r554", "r555", "r556", "r558", "r559", "r560", "r561", "r562", "r563", "r809", "r1077", "r1078", "r1079", "r1080", "r1081", "r1239" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Fair Value Disclosure", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r555", "r792", "r1078", "r1079" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "negatedTerseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r50", "r543" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r364", "r542", "r543", "r544", "r545", "r546", "r548", "r553", "r554", "r555", "r556", "r558", "r559", "r560", "r561", "r562", "r563", "r566", "r809", "r1077", "r1078", "r1079", "r1080", "r1081", "r1239" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r51", "r364", "r542", "r543", "r544", "r545", "r546", "r548", "r553", "r554", "r555", "r556", "r558", "r559", "r560", "r561", "r562", "r563", "r809", "r1077", "r1078", "r1079", "r1080", "r1081", "r1239" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r51", "r106", "r109", "r166", "r167", "r169", "r171", "r221", "r222", "r364", "r542", "r543", "r544", "r545", "r546", "r548", "r553", "r554", "r555", "r556", "r558", "r559", "r560", "r561", "r562", "r563", "r566", "r809", "r1077", "r1078", "r1079", "r1080", "r1081", "r1239" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r168", "r553", "r568", "r1078", "r1079" ] }, "bsx_December2027NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "December2027NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "December 2027 Notes", "label": "December 2027 Notes [Member]", "documentation": "December 2027 Notes" } } }, "auth_ref": [] }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit." } } }, "auth_ref": [ "r127" ] }, "bsx_DeemedConsolidatedEBITDA": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "DeemedConsolidatedEBITDA", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deemed Consolidated EBITDA [Member]", "label": "Deemed Consolidated EBITDA", "documentation": "Deemed Consolidated EBITDA" } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]", "label": "Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Federal Income Tax Expense (Benefit)", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1241", "r1378", "r1379" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Foreign Income Tax Expense (Benefit)", "label": "Deferred Foreign Income Tax Expense (Benefit)", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r243", "r1241", "r1378" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r719", "r720" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred Income Tax Expense (Benefit)", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r17", "r243", "r276", "r743", "r744", "r1241" ] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Liabilities, Gross", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r176", "r177", "r254", "r732" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r719", "r720", "r868" ] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenue", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Deferred Revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r1226" ] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Deferred Revenue, Current", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r1225" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred State and Local Income Tax Expense (Benefit)", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1241", "r1378", "r1379" ] }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets, Goodwill and Intangible Assets", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets, Gross", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r733" ] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets, in Process Research and Development", "label": "Deferred Tax Assets, in Process Research and Development", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination." } } }, "auth_ref": [ "r128", "r1377" ] }, "us-gaap_DeferredTaxAssetsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInventory", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets, Inventory", "label": "Deferred Tax Assets, Inventory", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory." } } }, "auth_ref": [ "r128", "r1377" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesNetDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r1376" ] }, "bsx_DeferredTaxAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "DeferredTaxAssetsMember", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesNetDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred tax assets [Member]", "documentation": "Deferred tax assets" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets, Net of Valuation Allowance", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1376" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r128", "r1377" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards." } } }, "auth_ref": [ "r128", "r1377" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards." } } }, "auth_ref": [ "r128", "r1377" ] }, "bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "DeferredTaxAssetsPrepaidonIntercompanyProfit", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets, Prepaid on Intercompany Profit", "label": "Deferred Tax Assets, Prepaid on Intercompany Profit", "documentation": "Deferred Tax Assets, Prepaid on Intercompany Profit" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets, Property, Plant and Equipment", "label": "Deferred Tax Assets, Property, Plant and Equipment", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpense", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets, Tax Deferred Expense", "label": "Deferred Tax Assets, Tax Deferred Expense", "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances." } } }, "auth_ref": [ "r128", "r1377" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r128", "r1377" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals." } } }, "auth_ref": [ "r128", "r1377" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities." } } }, "auth_ref": [ "r128", "r1377" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses." } } }, "auth_ref": [ "r128", "r1377" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from restructuring reserve." } } }, "auth_ref": [ "r128", "r1377" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred Tax Assets, Valuation Allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r734" ] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilities", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesNetDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Liabilities, Net", "label": "Deferred Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r126", "r1376" ] }, "us-gaap_DeferredTaxLiabilitiesDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesDerivatives", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Liabilities, Derivatives", "label": "Deferred Tax Liabilities, Derivatives", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from derivatives." } } }, "auth_ref": [ "r128", "r1377" ] }, "bsx_DeferredTaxLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "DeferredTaxLiabilitiesMember", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesNetDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities", "label": "Deferred tax liabilities [Member]", "documentation": "Deferred tax liabilities" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Liabilities, Other", "label": "Deferred Tax Liabilities, Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": [ "r128", "r1377" ] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Liabilities, Property, Plant and Equipment", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r128", "r1377" ] }, "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Accumulated Benefit Obligation", "label": "Defined Benefit Plan, Accumulated Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level." } } }, "auth_ref": [ "r633" ] }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses." } } }, "auth_ref": [ "r616", "r1092" ] }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanActuarialGainLoss", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan." } } }, "auth_ref": [ "r609" ] }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position", "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans." } } }, "auth_ref": [ "r112", "r113" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Retirement Plan Discount Rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan." } } }, "auth_ref": [ "r646" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Retirement Plan Rate of Compensation Increase", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan." } } }, "auth_ref": [ "r647" ] }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanBenefitObligation", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Benefit Obligation", "label": "Defined Benefit Plan, Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r604" ] }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": [ "r611", "r663" ] }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets." } } }, "auth_ref": [ "r618", "r627", "r661", "r1090", "r1091", "r1092", "r1093" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year." } } }, "auth_ref": [ "r634" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year." } } }, "auth_ref": [ "r634" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year." } } }, "auth_ref": [ "r634" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year." } } }, "auth_ref": [ "r634" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year." } } }, "auth_ref": [ "r634" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year." } } }, "auth_ref": [ "r634" ] }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Amount", "label": "Defined Benefit Plan, Plan Assets, Amount", "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee." } } }, "auth_ref": [ "r615", "r626", "r627", "r628", "r1090", "r1091", "r1092" ] }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan." } } }, "auth_ref": [ "r610" ] }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Interest Cost", "label": "Defined Benefit Plan, Interest Cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": [ "r603", "r607", "r638", "r655", "r1092", "r1093" ] }, "us-gaap_DefinedBenefitPlanPlanAmendments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPlanAmendments", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment", "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan." } } }, "auth_ref": [ "r612" ] }, "bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "DefinedBenefitPlanPlanAssetsActuarialGainLoss", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "label": "Defined benefit plan, plan assets, actuarial gain loss", "documentation": "Defined benefit plan, plan assets, actuarial gain loss" } } }, "auth_ref": [] }, "bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return", "label": "Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return", "documentation": "Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets." } } }, "auth_ref": [ "r619" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan." } } }, "auth_ref": [ "r617" ] }, "bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO", "documentation": "Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Service Cost", "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r605", "r637", "r654", "r1092", "r1093" ] }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanSettlementsPlanAssets", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract." } } }, "auth_ref": [ "r623" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDepreciationexpenseDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r17", "r96" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r17", "r406" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssets", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative assets", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r327", "r328", "r792", "r942", "r943", "r944", "r945", "r946", "r948", "r949", "r950", "r951", "r952", "r966", "r967", "r1019", "r1022", "r1023", "r1024", "r1025", "r1026", "r1065", "r1112", "r1407" ] }, "us-gaap_DerivativeAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative assets", "label": "Derivative Asset, Current", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r327" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r950", "r952", "r965", "r966", "r967", "r969", "r970", "r971", "r972", "r974", "r975", "r976", "r977", "r989", "r990", "r991", "r992", "r995", "r996", "r997", "r998", "r1019", "r1020", "r1023", "r1025", "r1110", "r1112" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset, Fair Value, Gross Asset", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r39", "r152", "r188", "r326", "r1065" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability, Fair Value, Gross Liability", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r39", "r152", "r188", "r326", "r1065" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r150", "r153", "r156", "r158", "r950", "r952", "r965", "r966", "r967", "r969", "r970", "r971", "r972", "r974", "r975", "r976", "r977", "r989", "r990", "r991", "r992", "r995", "r996", "r997", "r998", "r1019", "r1020", "r1023", "r1025", "r1065", "r1110", "r1112" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r27", "r150", "r156" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r27", "r150", "r156", "r158", "r160", "r161", "r771" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r771" ] }, "bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months", "label": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]", "documentation": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments in Hedges, Assets, at Fair Value", "label": "Derivative Instruments in Hedges, Assets, at Fair Value", "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments in Hedges, Liabilities, at Fair Value", "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value", "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value", "label": "Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value", "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as an asset." } } }, "auth_ref": [ "r154" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value", "label": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value", "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability." } } }, "auth_ref": [ "r154" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r327", "r328", "r792", "r942", "r943", "r944", "r945", "r948", "r949", "r950", "r951", "r952", "r974", "r976", "r977", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1065", "r1407" ] }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative liability." } } }, "auth_ref": [ "r765" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Notional Amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1381", "r1382" ] }, "bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "label": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "documentation": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net" } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r27", "r143", "r144", "r148", "r159", "r363" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument [Member]", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r27" ] }, "us-gaap_DisaggregationOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueAbstract", "presentation": [ "http://www.bostonscientific.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Abstract]", "label": "Disaggregation of Revenue [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r598", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r598", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1282" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.bostonscientific.com/role/StockInventiveandPurchasePlans" ], "lang": { "en-us": { "role": { "terseLabel": "STOCK INCENTIVE AND PURCHASE PLANS", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r677", "r680", "r708", "r709", "r710", "r1101" ] }, "bsx_DiscountRateFairValueInput": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "DiscountRateFairValueInput", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsLevel3Details", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-Adjusted Discount Rates used in Purchase Price Allocation", "label": "Discount Rate, Fair Value Input", "documentation": "Discount Rate, Fair Value Input" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss (gain) on disposal of businesses and assets", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations." } } }, "auth_ref": [ "r505", "r1235", "r1270" ] }, "us-gaap_DividendsCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsCash", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends, Cash", "label": "Dividends, Cash", "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred." } } }, "auth_ref": [ "r13", "r223" ] }, "us-gaap_DividendsPreferredStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPreferredStockCash", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Preferred stock dividends", "label": "Dividends, Preferred Stock, Cash", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r13", "r223" ] }, "us-gaap_DividendsPreferredStockStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPreferredStockStock", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock dividends", "label": "Dividends, Preferred Stock, Stock", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock." } } }, "auth_ref": [ "r13", "r223" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r1125", "r1126", "r1139" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r1125", "r1126", "r1139", "r1175" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r1160" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r1123" ] }, "us-gaap_DomesticPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticPlanMember", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic Plan", "label": "Domestic Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r1343", "r1344", "r1345" ] }, "us-gaap_EMEAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EMEAMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EMEA [Member]", "label": "EMEA [Member]", "documentation": "Regions of Europe, Middle East and Africa." } } }, "auth_ref": [ "r1413", "r1414", "r1415", "r1416" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Net income (loss) per common share \u2014 basic", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r348", "r371", "r372", "r373", "r374", "r375", "r380", "r383", "r387", "r388", "r389", "r393", "r782", "r783", "r862", "r889", "r1069" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Net income (loss) per common share \u2014 diluted", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r348", "r371", "r372", "r373", "r374", "r375", "r383", "r387", "r388", "r389", "r393", "r782", "r783", "r862", "r889", "r1069" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding" ], "lang": { "en-us": { "role": { "verboseLabel": "WEIGHTED AVERAGE SHARES OUTSTANDING", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r379", "r390", "r391", "r392" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign exchange rates on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r799" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Reported tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r722" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "lang": { "en-us": { "role": { "verboseLabel": "U.S. federal statutory income tax rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r362", "r722", "r746" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation allowance", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r1374", "r1380" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Change in tax rates", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates." } } }, "auth_ref": [ "r746", "r1374" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign taxes", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": [ "r1374", "r1380" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition-related", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r1374", "r1380" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Non-deductible expenses", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses." } } }, "auth_ref": [ "r1374", "r1380" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r1374", "r1380" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic taxes on foreign earnings", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings." } } }, "auth_ref": [ "r1374", "r1380" ] }, "bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvision", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Return to provision", "label": "Effective Income Tax Rate Reconciliation, Return to provision", "documentation": "Effective Income Tax Rate Reconciliation, Return to provision" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation-related", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r1205", "r1374" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "State income taxes, net of federal benefit", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r1374", "r1380" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Research credit", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r1374", "r1380" ] }, "bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Uncertain tax positions", "label": "Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions", "documentation": "Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions" } } }, "auth_ref": [] }, "bsx_ElectrophysiologyEPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "ElectrophysiologyEPMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Electrophysiology (EP)", "label": "Electrophysiology (EP) [Member]", "documentation": "Electrophysiology (EP)" } } }, "auth_ref": [] }, "bsx_EmergingMarketsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "EmergingMarketsMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Emerging Markets [Member]", "label": "Emerging Markets [Member]", "documentation": "Emerging Markets [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payroll and related liabilities", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r48" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Employee Service Share-based Compensation, Tax Benefit from Compensation Expense", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": [ "r707" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Option [Member]", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Ownership Plan (ESOP), Compensation Expense", "label": "Employee Stock Ownership Plan (ESOP), Compensation Expense", "documentation": "The amount of plan compensation cost recognized during the period." } } }, "auth_ref": [ "r125" ] }, "us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased", "label": "Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased", "documentation": "Weighted average purchase price of capital shares purchased through an employee stock ownership plan." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitiesTable", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1122" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1122" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1122" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationLineItems", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1200" ] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingParValuePerShare", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Listing, Par Value Per Share", "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1122" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1122" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1122" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1122" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r1201" ] }, "bsx_EquipmentFurnitureAndFixturesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "EquipmentFurnitureAndFixturesGross", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment, furniture and fixtures", "label": "Equipment, furniture and fixtures Gross", "documentation": "Equipment, furniture and fixtures Gross." } } }, "auth_ref": [] }, "bsx_EquipmentFurnitureFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "EquipmentFurnitureFixturesMember", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment, Furniture, Fixtures", "label": "Equipment, Furniture, Fixtures [Member]", "documentation": "Equipment, Furniture, Fixtures" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r26", "r300", "r341", "r342", "r343", "r366", "r367", "r368", "r370", "r376", "r378", "r394", "r468", "r469", "r586", "r711", "r712", "r713", "r739", "r740", "r773", "r774", "r775", "r776", "r777", "r778", "r781", "r800", "r802", "r803", "r804", "r805", "r806", "r821", "r910", "r911", "r912", "r929", "r1002" ] }, "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity", "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity", "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee." } } }, "auth_ref": [ "r466" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsStrategicInvestmentsDetails": { "parentTag": "us-gaap_Investments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r411", "r465", "r1222", "r1255" ] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities, FV-NI", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r314", "r791", "r1059" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsStrategicInvestmentsDetails": { "parentTag": "us-gaap_Investments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement alternative investments(1, 2)", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r464" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r1168" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r1131", "r1143", "r1153", "r1179" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r1128", "r1140", "r1150", "r1176" ] }, "bsx_EuroDenominatedFactoringArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "EuroDenominatedFactoringArrangementsMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Euro denominated", "label": "Euro Denominated Factoring Arrangements [Member]", "documentation": "Euro Denominated Factoring Arrangements [Member]" } } }, "auth_ref": [] }, "bsx_ExclusionFromEbitdaForRestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "ExclusionFromEbitdaForRestructuringCharges", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Exclusion from EBITDA for Restructuring Charges", "label": "Exclusion from EBITDA for Restructuring Charges", "documentation": "Exclusion from EBITDA for Restructuring Charges" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r1174" ] }, "bsx_ExecutiveRetirementPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "ExecutiveRetirementPlanMember", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Executive retirement plan [Member]", "label": "Executive retirement plan [Member]", "documentation": "Executive retirement plan [Member]" } } }, "auth_ref": [] }, "bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price of the fair market value of our common stock on the date of grant", "label": "Exercise price of the fair market value of our common stock on the date of grant", "documentation": "Exercise price of the fair market value of our common stock on the date of grant" } } }, "auth_ref": [] }, "bsx_ExpenseRelatedToMatchingContributions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "ExpenseRelatedToMatchingContributions", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense related to matching contributions", "label": "Expense related to matching contributions", "documentation": "Expense related to matching contributions" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r785", "r786", "r789" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r785", "r786", "r789" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r29" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r555", "r627", "r628", "r629", "r630", "r631", "r632", "r786", "r826", "r827", "r828", "r1078", "r1079", "r1090", "r1091", "r1092" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r785", "r786", "r787", "r788", "r790" ] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements" ], "lang": { "en-us": { "role": { "verboseLabel": "HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r784" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r555", "r627", "r632", "r786", "r826", "r1090", "r1091", "r1092" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r555", "r627", "r632", "r786", "r827", "r1078", "r1079", "r1090", "r1091", "r1092" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r555", "r627", "r628", "r629", "r630", "r631", "r632", "r786", "r828", "r1078", "r1079", "r1090", "r1091", "r1092" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r30", "r165" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsContingentConsiderationDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of contingent consideration recorded in purchase accounting", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases", "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r164" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r555", "r627", "r628", "r629", "r630", "r631", "r632", "r826", "r827", "r828", "r1078", "r1079", "r1090", "r1091", "r1092" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Recurring [Member]", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r784", "r790" ] }, "bsx_FairValueOfFreeCashFlowFcfPerformanceAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "FairValueOfFreeCashFlowFcfPerformanceAwards", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of the Free Cash Flow (FCF) performance awards", "label": "Fair value of the Free Cash Flow (FCF) performance awards", "documentation": "Fair value of the Free Cash Flow (FCF) performance awards" } } }, "auth_ref": [] }, "bsx_FairValueOfTheOrganicNetSalesGrowthONSGPerformanceAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "FairValueOfTheOrganicNetSalesGrowthONSGPerformanceAwards", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of the organic net sales growth (ONSG) performance awards", "label": "Fair value of the organic net sales growth (ONSG) performance awards", "documentation": "Fair value of the organic net sales growth (ONSG) performance awards" } } }, "auth_ref": [] }, "bsx_Fairvalueofmarketbasedawards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "Fairvalueofmarketbasedawards", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of market based awards", "label": "Fair value of market based awards", "documentation": "Fair value of market based awards" } } }, "auth_ref": [] }, "bsx_FederalBenefitOfUncertainTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "FederalBenefitOfUncertainTaxPositions", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal benefit of uncertain tax positions", "label": "Federal benefit of uncertain tax positions", "documentation": "Federal benefit of uncertain tax positions" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r471", "r472", "r477", "r478", "r479", "r480", "r481", "r482", "r566", "r583", "r779", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r886", "r1073", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1251", "r1252", "r1253", "r1254" ] }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Useful Life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Finite-Lived Intangible Assets, Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r311", "r502" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future Amortization Expense, Year One", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r213" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future Amortization Expense, Year Five", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r213" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future Amortization Expense, Year Four", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r213" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future Amortization Expense, Year Three", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r213" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future Amortization Expense, Year Two", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r213" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r499", "r501", "r502", "r504", "r856", "r857" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Gross", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r212", "r857" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r91", "r94" ] }, "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months", "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months", "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months." } } }, "auth_ref": [ "r162" ] }, "bsx_ForeignCurrencyDenominatedInDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "ForeignCurrencyDenominatedInDebtMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency denominated in debt", "label": "Foreign currency denominated in debt [Member]", "documentation": "Foreign currency denominated in debt" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Net gain (loss) from foreign currency transaction exposures", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r795", "r796", "r797", "r798", "r999" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Translation of Foreign Currency", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r794" ] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeContractMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward currency contracts", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r1065", "r1090", "r1105" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r1135", "r1147", "r1157", "r1183" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r1135", "r1147", "r1157", "r1183" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r1135", "r1147", "r1157", "r1183" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r1135", "r1147", "r1157", "r1183" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r1135", "r1147", "r1157", "r1183" ] }, "bsx_ForwardCurrencyContractsTimetoMaturity": { "xbrltype": "integerItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "ForwardCurrencyContractsTimetoMaturity", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward Currency Contracts, Time to Maturity", "label": "Forward Currency Contracts, Time to Maturity", "documentation": "Forward Currency Contracts, Time to Maturity in Months" } } }, "auth_ref": [] }, "bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions", "label": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table Text Block]", "documentation": "[Table Text Block] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]" } } }, "auth_ref": [] }, "bsx_FreeTradeZoneRegimeTaxIncentive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "FreeTradeZoneRegimeTaxIncentive", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Free Trade Zone Regime Tax Incentive", "label": "Free Trade Zone Regime Tax Incentive", "documentation": "Free Trade Zone Regime Tax Incentive" } } }, "auth_ref": [] }, "bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution": { "xbrltype": "perShareItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution", "label": "Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution", "documentation": "Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution" } } }, "auth_ref": [] }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments." } } }, "auth_ref": [ "r150", "r157" ] }, "us-gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnInvestments", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net loss (gain) on investments and notes receivable", "label": "Gain (Loss) on Investments", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": [ "r199", "r1202" ] }, "us-gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss (Gain) on Disposal of Businesses and Assets", "label": "Gain (Loss) on Disposition of Business", "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant." } } }, "auth_ref": [ "r762", "r1235" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Debt extinguishment net charges", "terseLabel": "Gain (Loss) on Extinguishment of Debt", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r17", "r101", "r102" ] }, "bsx_GlobalCardiologyReportingUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "GlobalCardiologyReportingUnitMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Global Cardiology Reporting Unit", "label": "Global Cardiology Reporting Unit [Member]", "documentation": "Global Cardiology Reporting Unit [Member]" } } }, "auth_ref": [] }, "bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less)", "label": "Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less)", "documentation": "Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less)" } } }, "auth_ref": [] }, "bsx_GlobalEndoscopyEndoReportingUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "GlobalEndoscopyEndoReportingUnitMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Global Endoscopy (Endo) Reporting Unit [Member]", "label": "Global Endoscopy (Endo) Reporting Unit [Member]", "documentation": "Global Endoscopy (Endo) Reporting Unit [Member]" } } }, "auth_ref": [] }, "bsx_GlobalNeuromodulationNmReportingUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "GlobalNeuromodulationNmReportingUnitMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Global Neuromodulation (NM) Reporting Unit [Member]", "label": "Global Neuromodulation (NM) Reporting Unit [Member]", "documentation": "Global Neuromodulation (NM) Reporting Unit [Member]" } } }, "auth_ref": [] }, "bsx_GlobalPeripheralInterventionsPiReportingUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "GlobalPeripheralInterventionsPiReportingUnitMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Global Peripheral Interventions (PI) Reporting Unit [Member]", "label": "Global Peripheral Interventions (PI) Reporting Unit [Member]", "documentation": "Global Peripheral Interventions (PI) Reporting Unit [Member]" } } }, "auth_ref": [] }, "bsx_GlobalUrologyandPelvicHealthReportingUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "GlobalUrologyandPelvicHealthReportingUnitMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Global Urology and Pelvic Health Reporting Unit [Member]", "label": "Global Urology and Pelvic Health Reporting Unit [Member]", "documentation": "Global Urology and Pelvic Health Reporting Unit [Member]" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/SegmentReportingLonglivedassetsDetails", "http://www.bostonscientific.com/role/SegmentReportingTotalAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Goodwill", "terseLabel": "Goodwill", "periodStartLabel": "Goodwill, Beginning Balance", "periodEndLabel": "Goodwill, Ending Balance", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r310", "r487", "r858", "r1075", "r1107", "r1259", "r1266" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill acquired", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r490", "r1075" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets" ], "lang": { "en-us": { "role": { "verboseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r210" ] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill Valuation", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r486", "r498", "r1075" ] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization and Impairment of Intangible Assets", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined." } } }, "auth_ref": [ "r20" ] }, "us-gaap_GoodwillGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillGross", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, Gross", "label": "Goodwill, Gross", "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r489", "r496", "r1075" ] }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Goodwill, Impaired, Accumulated Impairment Loss", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r489", "r496", "r1075" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillLineItems", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Other Intangible Assets", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r1075" ] }, "bsx_GoodwillTextualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "GoodwillTextualsAbstract", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill (Roll Forward)", "label": "Goodwill (Textuals) [Abstract]", "documentation": "Goodwill (Textuals) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency fluctuations and other changes", "label": "Goodwill, Translation and Purchase Accounting Adjustments", "documentation": "Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r1", "r1258" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r195", "r360", "r401", "r415", "r421", "r424", "r467", "r528", "r529", "r531", "r532", "r533", "r535", "r537", "r539", "r540", "r793", "r1070", "r1278" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r27", "r771" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r27" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r27" ] }, "country_IE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "IE", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingLonglivedassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ireland", "label": "IRELAND" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r1125", "r1126", "r1139" ] }, "bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "ImpactOfForeignCurrencyFluctuationsOnNetSales", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of foreign currency fluctuations on net sales", "label": "Impact of foreign currency fluctuations on net sales", "documentation": "Impact of foreign currency fluctuations on net sales" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset impairment charges", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value." } } }, "auth_ref": [ "r17", "r34" ] }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and other intangible asset impairment charges", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value." } } }, "auth_ref": [ "r1235", "r1269" ] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPR&D", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InProcessResearchAndDevelopmentPolicy", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangibles and IPR&D", "label": "In Process Research and Development, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r361", "r745" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails", "http://www.bostonscientific.com/role/SegmentReportingIncomelossbeforeincometaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) before income taxes", "terseLabel": "Income (loss) before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r192", "r259", "r401", "r415", "r421", "r424", "r863", "r881", "r1070" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r361", "r745" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]", "verboseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r506", "r514", "r985" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "verboseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r514", "r985" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "verboseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r362", "r715", "r723", "r730", "r736", "r741", "r747", "r750", "r751", "r926" ] }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Examination, Penalties and Interest Accrued", "label": "Income Tax Examination, Penalties and Interest Accrued", "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations." } } }, "auth_ref": [ "r1375" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense (benefit)", "verboseLabel": "Income Tax Expense (Benefit)", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r264", "r277", "r377", "r378", "r409", "r721", "r742", "r891" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r340", "r717", "r718", "r730", "r731", "r735", "r737", "r920" ] }, "bsx_IncomeTaxesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "IncomeTaxesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Taxes [Abstract]", "label": "Income Taxes [Abstract]", "documentation": "Income Taxes [Abstract]" } } }, "auth_ref": [] }, "bsx_IncomeTaxesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "IncomeTaxesLineItems", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesNetDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes [Line Items]", "label": "Income Taxes [Line Items]", "documentation": "Income Taxes [Line Items]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes, net", "label": "Income Taxes Paid", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r68", "r71" ] }, "bsx_IncomeTaxesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "IncomeTaxesTable", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesNetDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes [Table]", "label": "Income Taxes [Table]", "documentation": "Income Taxes [Table]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable, accrued expenses and other liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r16" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Trade accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r16" ] }, "us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option", "label": "Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option", "documentation": "Amount of increase (decrease) in fair value adjustment on other assets (liabilities) carried at fair value under the fair value option on the statement of cash flows of Federal Home Loan Banks (FHLBanks)." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r16" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in operating assets and liabilities, excluding purchase accounting:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r16" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r500", "r503" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r214" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite Lived Intangible Assets Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r92", "r214" ] }, "bsx_IndemnificationAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "IndemnificationAsset", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indemnification asset", "label": "Indemnification asset", "documentation": "Indemnification asset" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r1138", "r1147", "r1157", "r1174", "r1183", "r1187", "r1195" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r1193" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r1127", "r1199" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r1127", "r1199" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r1127", "r1199" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SegmentReportingLonglivedassetsDetails", "http://www.bostonscientific.com/role/SegmentReportingTotalAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other intangible assets, net", "terseLabel": "Intangible Assets, Net (Excluding Goodwill)", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r89", "r93" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "terseLabel": "Interest Expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r168", "r261", "r344", "r405", "r808", "r986", "r1118", "r1410" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r38" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r351", "r354", "r355" ] }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months." } } }, "auth_ref": [ "r162" ] }, "us-gaap_InterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateContractMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate derivative contracts", "label": "Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate." } } }, "auth_ref": [ "r1053", "r1065", "r1090" ] }, "bsx_InternationalRetirementPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "InternationalRetirementPlansMember", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International retirement plans [Member]", "label": "International retirement plans [Member]", "documentation": "International retirement plans [Member]" } } }, "auth_ref": [] }, "bsx_InterventionalCardiologyTherapiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "InterventionalCardiologyTherapiesMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interventional Cardiology Therapies", "label": "Interventional Cardiology Therapies [Member]", "documentation": "Interventional Cardiology Therapies" } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, Finished Goods, Net of Reserves", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r209", "r1062" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "totalLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r323", "r1057", "r1107" ] }, "us-gaap_InventoryNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNetAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, Net [Abstract]", "label": "Inventory, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r267", "r306", "r322", "r483", "r484", "r485", "r854", "r1067" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, Raw Materials, Net of Reserves", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r209", "r1064" ] }, "bsx_InventoryStepUpAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "InventoryStepUpAmortization", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory step-up amortization", "label": "InventoryStepUpAmortization", "documentation": "Inventory Step Up Amortization" } } }, "auth_ref": [] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, Work in Process, Net of Reserves", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r209", "r1063" ] }, "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Investment", "label": "Investment Holdings, Schedule of Investments [Table Text Block]", "documentation": "Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments." } } }, "auth_ref": [ "r1404", "r1405", "r1406", "r1407", "r1408", "r1409" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in Publicly Traded and Privately-Held Entities", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r890", "r916", "r917", "r918", "r919", "r1010", "r1011" ] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Investments", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 7.0 }, "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsStrategicInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Investments", "terseLabel": "Investments", "label": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": [ "r865" ] }, "us-gaap_InvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Investments [Abstract]" } } }, "auth_ref": [] }, "bsx_January2040NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "January2040NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "January 2040 Notes", "label": "January 2040 Notes [Member]", "documentation": "January 2040 Notes [Member]" } } }, "auth_ref": [] }, "bsx_JohnBradleySorensonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "JohnBradleySorensonMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "John Bradley Sorenson [Member]", "documentation": "John Bradley Sorenson" } } }, "auth_ref": [] }, "bsx_JohnBradleySorensonRuleTradingArrangementCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "JohnBradleySorensonRuleTradingArrangementCommonStockMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "John Bradley Sorenson Rule Trading Arrangement, Common Stock [Member]", "documentation": "John Bradley Sorenson Rule Trading Arrangement, Common Stock" } } }, "auth_ref": [] }, "bsx_June2025NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "June2025NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "June 2025 Notes", "label": "June 2025 Notes [Member]", "documentation": "June 2025 Notes" } } }, "auth_ref": [] }, "bsx_June2030NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "June2030NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "June 2030 Notes", "label": "June 2030 Notes [Member]", "documentation": "June 2030 Notes" } } }, "auth_ref": [] }, "us-gaap_Land": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Land", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land", "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale." } } }, "auth_ref": [ "r1223" ] }, "bsx_LatinAmericaandCanadaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "LatinAmericaandCanadaMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Latin America and Canada [Member]", "label": "Latin America and Canada [Member]", "documentation": "Latin America and Canada [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, Cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1390" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LegalCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LegalCostsPolicyTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Legal and Product Liability Costs", "label": "Legal Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights." } } }, "auth_ref": [ "r527" ] }, "bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal payments remaining to be excluded from calculation of consolidated EBITDA", "label": "Legal payments remaining to be excluded from calculation of consolidated EBITDA", "documentation": "Legal payments remaining to be excluded from calculation of consolidated EBITDA" } } }, "auth_ref": [] }, "bsx_LesseeOperatingAndFinanceLeasesOptionToExtend": { "xbrltype": "durationItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "LesseeOperatingAndFinanceLeasesOptionToExtend", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating and Finance Leases, Option to Extend", "label": "Lessee, Operating and Finance Leases, Option to Extend", "documentation": "Lessee, Operating and Finance Leases, Option to Extend" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1389" ] }, "bsx_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount", "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount", "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, to be Paid", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r820" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five", "label": "Lessee, Operating Lease, Liability, to be Paid, after Rolling Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r1391" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five", "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r1391" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four", "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r1391" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three", "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r1391" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two", "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r1391" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months", "label": "Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r1391" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r820" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Term of Contract", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1388" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.bostonscientific.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r810" ] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of Credit Outstanding, Amount", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r184", "r257", "r877", "r1107", "r1240", "r1256", "r1385" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r49", "r305", "r360", "r467", "r528", "r529", "r531", "r532", "r533", "r535", "r537", "r539", "r540", "r758", "r763", "r764", "r793", "r1107", "r1278", "r1392", "r1393" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r163" ] }, "bsx_LicensingArrangementAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "LicensingArrangementAssetsMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Asset", "label": "Licensing arrangement assets [Member]", "documentation": "Licensing arrangement assets" } } }, "auth_ref": [] }, "bsx_LicensingArrangementLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "LicensingArrangementLiabilitiesMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Liability", "label": "Licensing arrangement liabilities [Member]", "documentation": "Licensing arrangement liabilities" } } }, "auth_ref": [] }, "bsx_LicensingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "LicensingArrangements", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing arrangements", "label": "Licensing arrangements", "documentation": "Licensing arrangements" } } }, "auth_ref": [] }, "bsx_LicensingArrangementsAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "LicensingArrangementsAsset", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing arrangements", "label": "Licensing arrangements, asset", "documentation": "Licensing arrangements, asset" } } }, "auth_ref": [] }, "bsx_LicensingArrangementsLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "LicensingArrangementsLiability", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing arrangements", "label": "Licensing arrangements, liability", "documentation": "Licensing arrangements, liability" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r46" ] }, "bsx_LitigationAndDebtExclusionFromEbitda": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "LitigationAndDebtExclusionFromEbitda", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation and Debt Exclusion from EBITDA", "label": "Litigation and Debt Exclusion from EBITDA", "documentation": "Exclusion of litigation payments and any debt Issued to fund tax deficiency payments" } } }, "auth_ref": [] }, "us-gaap_LitigationReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationReserveCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal reserves", "label": "Estimated Litigation Liability, Current", "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position." } } }, "auth_ref": [ "r53", "r1274" ] }, "us-gaap_LitigationReserveNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationReserveNoncurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal reserves", "label": "Estimated Litigation Liability, Noncurrent", "documentation": "Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r53", "r1274" ] }, "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementAmountAwardedFromOtherParty", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Settlement, Amount Awarded from Other Party", "label": "Litigation Settlement, Amount Awarded from Other Party", "documentation": "Amount awarded from other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Settlement, Amount Awarded to Other Party", "label": "Litigation Settlement, Amount Awarded to Other Party", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementExpense", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation-related net charges (credits)", "label": "Litigation Settlement, Expense", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r42", "r255", "r554", "r569", "r1078", "r1079", "r1400" ] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term debt", "terseLabel": "Long-term Debt and Capital Lease Obligations", "label": "Long-Term Debt and Lease Obligation", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } }, "auth_ref": [ "r42", "r869" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Rolling after Year Five", "label": "Long-Term Debt, Maturities, Repayments of Principal in Rolling after Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [ "r1243" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Five", "label": "Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [ "r1243" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four", "label": "Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [ "r1243" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three", "label": "Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [ "r1243" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two", "label": "Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [ "r1243" ] }, "us-gaap_LongTermPurchaseCommitmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Purchase Commitment", "label": "Long-Term Purchase Commitment [Table Text Block]", "documentation": "Tabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r51" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r51", "r100" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrual for legal matters that are probable and estimable", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r522", "r1204" ] }, "bsx_March2024NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "March2024NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2024 Notes", "label": "March 2024 Notes [Member]", "documentation": "March 2024 Notes" } } }, "auth_ref": [] }, "bsx_March2025NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "March2025NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2025 Notes", "label": "March 2025 Notes [Member]", "documentation": "March 2025 Notes" } } }, "auth_ref": [] }, "bsx_March2026NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "March2026NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2026 Notes", "label": "March 2026 Notes [Member]", "documentation": "March 2026 Notes" } } }, "auth_ref": [] }, "bsx_March2028NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "March2028NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2028 Notes", "label": "March 2028 Notes [Member]", "documentation": "March 2028 Notes [Member]" } } }, "auth_ref": [] }, "bsx_March2028SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "March2028SeniorNotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2028 Senior Notes", "label": "March 2028 Senior Notes [Member]", "documentation": "March 2028 Senior Notes" } } }, "auth_ref": [] }, "bsx_March2029NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "March2029NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2029 Notes", "label": "March 2029 Notes [Member]", "documentation": "March 2029 Notes" } } }, "auth_ref": [] }, "bsx_March2031NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "March2031NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2031 Notes", "label": "March 2031 Notes [Member]", "documentation": "March 2031 Notes" } } }, "auth_ref": [] }, "bsx_March2034NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "March2034NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2034 Notes", "label": "March 2034 Notes [Member]", "documentation": "March 2034 Notes" } } }, "auth_ref": [] }, "bsx_March2039NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "March2039NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2039 Notes", "label": "March 2039 Notes [Member]", "documentation": "March 2039 Notes" } } }, "auth_ref": [] }, "bsx_March2049NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "March2049NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2049 Notes", "label": "March 2049 Notes [Member]", "documentation": "March 2049 Notes" } } }, "auth_ref": [] }, "bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "MarketBasedAwardsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Market-based awards, valuation assumptions", "label": "Market-based awards, valuation assumptions [Table Text Block]", "documentation": "Market-based awards, valuation assumptions [Table Text Block]" } } }, "auth_ref": [] }, "bsx_MaturitiesOfLeaseLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "MaturitiesOfLeaseLiabilitiesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities of Lease Liabilities", "label": "Maturities of Lease Liabilities [Table Text Block]", "documentation": "Maturities of Lease Liabilities" } } }, "auth_ref": [] }, "bsx_MaximumLeverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "MaximumLeverageRatio", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum Leverage Ratio", "label": "Maximum Leverage Ratio", "documentation": "Maximum leverage ratio permitted by revolving credit facility agreement." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsLevel3Details", "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/LeasesDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails", "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "verboseLabel": "High end of range [Member]", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r523", "r524", "r525", "r526", "r670", "r853", "r909", "r951", "r952", "r1007", "r1012", "r1016", "r1017", "r1027", "r1050", "r1051", "r1072", "r1082", "r1100", "r1109", "r1280", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r1166" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r1166" ] }, "bsx_Measurementperiodmarketbasedaward": { "xbrltype": "durationItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "Measurementperiodmarketbasedaward", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement period - market based awards", "label": "Measurement period - market based award", "documentation": "Measurement period - market based awards" } } }, "auth_ref": [] }, "bsx_MedsurgMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "MedsurgMember", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDepreciationexpenseDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SegmentReportingIncomelossbeforeincometaxesDetails", "http://www.bostonscientific.com/role/SegmentReportingOperatingincomeofreportablesegmentsasapercentageofnetsalesofreportablesegmentsDetails", "http://www.bostonscientific.com/role/SegmentReportingTotalAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MedSurg", "label": "MedSurg [Member]", "documentation": "MedSurg [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsLevel3Details", "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/LeasesDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails", "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r523", "r524", "r525", "r526", "r670", "r853", "r909", "r951", "r952", "r1007", "r1012", "r1016", "r1017", "r1027", "r1050", "r1051", "r1072", "r1082", "r1100", "r1109", "r1280", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r58", "r256", "r360", "r467", "r528", "r531", "r532", "r533", "r539", "r540", "r793", "r876", "r962" ] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestPeriodIncreaseDecrease", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Changes to noncontrolling ownership interest", "label": "Noncontrolling Interest, Period Increase (Decrease)", "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period." } } }, "auth_ref": [ "r139" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r1186" ] }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money Market Funds, at Carrying Value", "label": "Money Market Funds, at Carrying Value", "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInValuationAllowancesAndReservesRollForward", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Allowance for doubtful accounts", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r1194" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r1167" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Cash provided by (used for) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r353" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Cash provided by (used for) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r353" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Cash provided by (used for) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r204", "r205", "r206" ] }, "bsx_NetCurrencyExchangeGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "NetCurrencyExchangeGainLoss", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net currency exchange gain (loss)", "label": "Net currency exchange gain (loss)", "documentation": "Net currency exchange gain (loss)" } } }, "auth_ref": [] }, "bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails", "http://www.bostonscientific.com/role/IncomeTaxesNetDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Deferred Tax Liabilities and Prepaid on Intercompany Profit", "label": "Net Deferred Tax Assets and Prepaid on Intercompany Profit", "documentation": "Net Deferred Tax Assets and Prepaid on Intercompany Profit" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r193", "r206", "r260", "r303", "r335", "r338", "r343", "r360", "r369", "r371", "r372", "r373", "r374", "r377", "r378", "r385", "r401", "r415", "r421", "r424", "r467", "r528", "r529", "r531", "r532", "r533", "r535", "r537", "r539", "r540", "r783", "r793", "r884", "r981", "r1000", "r1001", "r1070", "r1118", "r1278" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net income (loss) attributable to noncontrolling interests", "terseLabel": "Net income (loss) attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r141", "r248", "r335", "r338", "r377", "r378", "r883", "r1230" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) attributable to Boston Scientific common stockholders", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r350", "r371", "r372", "r373", "r374", "r380", "r381", "r386", "r389", "r401", "r415", "r421", "r424", "r1070" ] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net investment hedge", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r147" ] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]", "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]" } } }, "auth_ref": [] }, "bsx_NewAccountingPronouncementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "NewAccountingPronouncementsPolicyTextBlock", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncements" ], "lang": { "en-us": { "role": { "terseLabel": "NEW ACCOUNTING PRONOUNCEMENTS", "label": "New Accounting Pronouncements, Policy [Text Block]", "documentation": "New Accounting Pronouncements, Policy" } } }, "auth_ref": [] }, "bsx_NonCashImpactOfTransferredRoyaltyRights": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "NonCashImpactOfTransferredRoyaltyRights", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash impact of transferred royalty rights", "label": "Non-cash impact of transferred royalty rights", "documentation": "Non-cash impact of transferred royalty rights" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r1166" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r1135", "r1147", "r1157", "r1174", "r1183" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r1164" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r1163" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r1174" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1194" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1194" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-US [Member]", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1413", "r1414", "r1415", "r1416" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r138", "r586", "r1244", "r1245", "r1246", "r1411" ] }, "us-gaap_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncurrentAssets", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingLonglivedassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Assets", "label": "Long-Lived Assets", "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets." } } }, "auth_ref": [ "r429" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NondesignatedMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Not Designated as Hedging Instrument [Member]", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r27" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingIncomelossbeforeincometaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r200" ] }, "bsx_Nonvestedstockawardsexerciseprice": { "xbrltype": "perShareItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "Nonvestedstockawardsexerciseprice", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Qualified options exercise price", "label": "Non-vested stock awards exercise price", "documentation": "Non-vested stock awards exercise price" } } }, "auth_ref": [] }, "bsx_November2019AggregateOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "November2019AggregateOfferingMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "November 2019 Aggregate Offering", "label": "November 2019 Aggregate Offering [Member]", "documentation": "November 2019 Aggregate Offering" } } }, "auth_ref": [] }, "bsx_November2035NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "November2035NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "November 2035 Notes", "label": "November 2035 Notes [Member]", "documentation": "November 2035 Notes [Member]" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Reportable Segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r1249" ] }, "bsx_October2023NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "October2023NotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "October 2023 Notes", "label": "October 2023 Notes [Member]", "documentation": "October 2023 Notes [Member]" } } }, "auth_ref": [] }, "bsx_Onetimetransactiontaxpost1986EPnetpayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "Onetimetransactiontaxpost1986EPnetpayment", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "One-time transaction tax post-1986 E&P - net payment", "label": "One-time transaction tax post-1986 E&P - net payment", "documentation": "One-time transaction tax post-1986 E&P - net payment" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/SegmentReportingIncomelossbeforeincometaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income (loss)", "terseLabel": "Operating Income (Loss)", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r401", "r415", "r421", "r424", "r1070" ] }, "bsx_OperatingIncomeLossAllocatedToReportableSegments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "OperatingIncomeLossAllocatedToReportableSegments", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingIncomelossbeforeincometaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Income (Loss) Allocated to Reportable Segments", "label": "Operating Income (Loss) Allocated to Reportable Segments", "documentation": "Operating Income (Loss) Allocated to Reportable Segments" } } }, "auth_ref": [] }, "bsx_OperatingIncomeUnallocatedToSegment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "OperatingIncomeUnallocatedToSegment", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingIncomelossbeforeincometaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Income Unallocated to Segment", "label": "Operating Income Unallocated to Segment", "documentation": "Operating Income Unallocated to Segment" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r815", "r1106" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r812" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Current", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r812" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r813" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r812" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": [ "r813" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Payments", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r814", "r816" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails", "http://www.bostonscientific.com/role/SegmentReportingLonglivedassetsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r811" ] }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": [ "r813" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r819", "r1106" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r818", "r1106" ] }, "us-gaap_OperatingLeasedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasedAssetsLineItems", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leased Assets [Line Items]", "label": "Operating Leased Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDepreciationexpenseDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SegmentReportingIncomelossbeforeincometaxesDetails", "http://www.bostonscientific.com/role/SegmentReportingOperatingincomeofreportablesegmentsasapercentageofnetsalesofreportablesegmentsDetails", "http://www.bostonscientific.com/role/SegmentReportingTotalAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r414", "r415", "r416", "r417", "r418", "r424" ] }, "bsx_OptionsExpectedToVest": { "xbrltype": "sharesItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "OptionsExpectedToVest", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options expected to vest", "label": "Options expected to vest", "documentation": "Options expected to vest" } } }, "auth_ref": [] }, "bsx_OptionsExpectedToVestWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "OptionsExpectedToVestWeightedAverageExercisePrice", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options expected to vest, weighted average exercise price", "label": "Options expected to vest, weighted average exercise price", "documentation": "Options expected to vest, weighted average exercise price" } } }, "auth_ref": [] }, "bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife": { "xbrltype": "durationItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "OptionsExpectedToVestWeightedAverageRemainingContractualLife", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options expected to vest, weighted average remaining contractual life", "label": "Options expected to vest, weighted average remaining contractual life", "documentation": "Options expected to vest, weighted average remaining contractual life" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r48" ] }, "us-gaap_OtherAccruedLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Noncurrent", "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r52" ] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssets", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTotalAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "label": "Other Assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r250", "r312", "r866", "r1120" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other Assets, Current", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r324", "r1107" ] }, "us-gaap_OtherAssetsMiscellaneousCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMiscellaneousCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Assets, Miscellaneous, Current", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other long-term assets", "totalLabel": "Other long-term assets (total)", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r312" ] }, "us-gaap_OtherAssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets, Noncurrent [Abstract]", "label": "Other Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before reclassifications", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r41", "r60", "r342", "r800", "r803", "r806", "r1228" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests", "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Noncontrolling Interest", "documentation": "Amount before tax of other comprehensive income (loss) attributable to noncontrolling interests." } } }, "auth_ref": [ "r14", "r24", "r247" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Net change in derivative financial instruments", "verboseLabel": "Derivative financial instruments", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r329", "r331" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r329", "r331" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r329", "r331", "r766", "r767", "r772" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r332" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r331", "r334" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r274", "r331", "r334" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax", "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r332" ] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax", "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r330", "r331", "r768", "r772" ] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax", "documentation": "Amount, before adjustments, of tax expense (benefit) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r330", "r331", "r768", "r772" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency translation adjustment", "terseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r6" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r769" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r770" ] }, "bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax", "documentation": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss)", "terseLabel": "Changes in other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r26", "r41", "r336", "r339", "r345", "r800", "r801", "r806", "r859", "r885", "r1228", "r1229" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract", "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of tax:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Net change in defined benefit pensions and other items", "negatedTerseLabel": "Defined benefit pensions and other items", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": [ "r9", "r190" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification adjustment from AOCI, tax impact", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, Tax", "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan." } } }, "auth_ref": [ "r10" ] }, "us-gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Comprehensive Income (Loss), Tax", "label": "Other Comprehensive Income (Loss), Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": [ "r10", "r341", "r345", "r721", "r748", "r749", "r800", "r804", "r806", "r859", "r885" ] }, "bsx_OtherCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "OtherCountriesMember", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingLonglivedassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other countries", "label": "Other countries [Member]", "documentation": "Other countries [Member]" } } }, "auth_ref": [] }, "bsx_OtherCurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "OtherCurrentAssetsAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Assets [Abstract]", "label": "Other Current Assets [Abstract]", "documentation": "Other Current Assets" } } }, "auth_ref": [] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentLiabilitiesMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Liabilities", "label": "Other Current Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [] }, "bsx_OtherIntangibleAssetsTextualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "OtherIntangibleAssetsTextualsAbstract", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Intangible Assets (Textuals) [Abstract]", "label": "Other Intangible Assets (Textuals) [Abstract]", "documentation": "Other Intangible Assets (Textuals) [Abstract]" } } }, "auth_ref": [] }, "bsx_OtherInternationalPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "OtherInternationalPlansMember", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other International Plans", "label": "Other International Plans [Member]", "documentation": "Other International Plans" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "totalLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r48", "r1107" ] }, "us-gaap_OtherLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Liabilities, Current [Abstract]", "label": "Other Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other long-term liabilities", "totalLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r52" ] }, "us-gaap_OtherLiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrentAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "bsx_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "OtherMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other [Member]", "documentation": "Other" } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentAssetsMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Other long-term liabilities", "label": "Other Noncurrent Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Other, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r201" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Other income (expense):", "label": "Other Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Other Nonoperating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)." } } }, "auth_ref": [] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Operating Income (Expense), Net", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "bsx_OtherOtherLongTermAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "OtherOtherLongTermAssets", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other, Other Long-term Assets", "documentation": "Other, Other Long-term Assets" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r1166" ] }, "bsx_OtherReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "OtherReserves", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingIncomelossbeforeincometaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other(1)", "label": "Other, Reserves", "documentation": "Other, Reserves" } } }, "auth_ref": [] }, "us-gaap_OtherSundryLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherSundryLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Sundry Liabilities, Current", "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date." } } }, "auth_ref": [ "r48", "r99" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1133", "r1145", "r1155", "r1181" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r1136", "r1148", "r1158", "r1184" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r1136", "r1148", "r1158", "r1184" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]", "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]", "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "bsx_PatentsAndLicensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "PatentsAndLicensesMember", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents and Licenses", "label": "Patents and Licenses [Member]", "documentation": "Patents and Licenses" } } }, "auth_ref": [] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PatentsMember", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents", "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r246" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r1162" ] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment of contingent consideration previously established in purchase accounting", "label": "Payment for Contingent Consideration Liability, Financing Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r12" ] }, "bsx_PaymentOfContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "PaymentOfContingentConsideration", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of contingent consideration", "label": "Payment of contingent consideration", "documentation": "Payment of contingent consideration" } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromHedgeInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromHedgeInvestingActivities", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Proceeds from settlements of hedge contracts", "label": "Payments for (Proceeds from) Hedge, Investing Activities", "documentation": "The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation." } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Proceeds from royalty rights", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r1206", "r1231" ] }, "us-gaap_PaymentsForRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRoyalties", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for Royalties", "label": "Payments for Royalties", "documentation": "The amount of cash paid for royalties during the current period." } } }, "auth_ref": [ "r15" ] }, "bsx_PaymentsForRoyaltyRights": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "PaymentsForRoyaltyRights", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for royalty rights", "label": "Payments for royalty rights", "documentation": "Payments for royalty rights" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash dividends paid on preferred stock", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r65" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments for acquisitions of businesses, net of cash acquired", "terseLabel": "Payment for acquisition, net of cash acquired (2)", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r63" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property, plant and equipment and internal use software", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r203" ] }, "bsx_Paymenttonetsharesettleemployeeequityawards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "Paymenttonetsharesettleemployeeequityawards", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash used to net share settle employee equity awards", "label": "Payment to net share settle employee equity awards", "documentation": "Payment to net share settle employee equity awards" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r1165" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r1165" ] }, "us-gaap_PensionAndOtherPostretirementPlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementPlansPolicy", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and Other Postretirement Plans, Policy [Policy Text Block]", "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived." } } }, "auth_ref": [ "r19", "r21", "r22", "r28", "r118" ] }, "bsx_Pensionbenefitobligationbenefitspaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "Pensionbenefitobligationbenefitspaid", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "pension benefit obligation, benefits paid", "label": "pension benefit obligation, benefits paid", "documentation": "pension benefit obligation, benefits paid" } } }, "auth_ref": [] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r1164" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r1174" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r1167" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r1163" ] }, "bsx_PercentOfFinishedGoodsAtConsignment": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "PercentOfFinishedGoodsAtConsignment", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percent of finished goods at consignment", "label": "Percent of finished goods at consignment", "documentation": "Percent of finished goods at consignment" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371" ] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendRatePercentage", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Dividend Rate, Percentage", "label": "Preferred Stock, Dividend Rate, Percentage", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": [ "r572", "r1008", "r1013", "r1015", "r1028" ] }, "us-gaap_PreferredStockDividendsPerShareCashPaid": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendsPerShareCashPaid", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Dividends, Per Share, Cash Paid", "label": "Preferred Stock, Dividends, Per Share, Cash Paid", "documentation": "Aggregate dividends paid during the period for each share of preferred stock outstanding." } } }, "auth_ref": [] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockLiquidationPreference", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Liquidation Preference Per Share", "label": "Preferred Stock, Liquidation Preference Per Share", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } } }, "auth_ref": [ "r106", "r107", "r178", "r1238", "r1281" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r1110", "r1111", "r1114", "r1115", "r1116", "r1117", "r1403", "r1411" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Par or Stated Value Per Share", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r178", "r571" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, Shares Authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r178", "r960" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Shares Issued", "periodStartLabel": "Preferred Stock, Shares Issued", "periodEndLabel": "Preferred Stock, Shares Issued", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r178", "r571" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, $0.01 par value - authorized 50,000,000 shares; 0 shares issued as of December\u00a031, 2023 and 10,062,500 shares issued as of December\u00a031, 2022", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r178", "r872", "r1107" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1227" ] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/IncomeTaxesNetDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidTaxes", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid income taxes", "label": "Prepaid Taxes", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1060", "r1074", "r1257" ] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from disposal of certain businesses and assets", "label": "Proceeds from Divestiture of Businesses", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r62" ] }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from issuance of preferred stock in connection with public offering", "label": "Proceeds from Issuance of Convertible Preferred Stock", "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from long-term borrowings, net of debt issuance costs", "label": "Proceeds from Issuance of Senior Long-Term Debt", "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer)." } } }, "auth_ref": [ "r64" ] }, "bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Proceeds from (payments for) investments and acquisitions of certain technologies", "label": "Proceeds from (payments for) investments and acquisitions of certain technologies", "documentation": "Proceeds from (payments for) investments and acquisitions of certain technologies" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromRepaymentsOfCommercialPaper": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentsOfCommercialPaper", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net decrease in commercial paper", "label": "Proceeds from (Repayments of) Commercial Paper", "documentation": "The net cash inflow or cash outflow from issuing (borrowing) and repaying commercial paper." } } }, "auth_ref": [ "r1232", "r1233", "r1236" ] }, "us-gaap_ProceedsFromRoyaltiesReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRoyaltiesReceived", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Proceeds from Royalties Received", "label": "Proceeds from Royalties Received", "documentation": "Cash received for royalties during the current period." } } }, "auth_ref": [ "r67" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of property, plant and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r202" ] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockPlans", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans", "label": "Proceeds from Stock Plans", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": [ "r11" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r426", "r855", "r903", "r904", "r905", "r906", "r907", "r908", "r1054", "r1083", "r1108", "r1209", "r1275", "r1276", "r1282", "r1402" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r426", "r855", "r903", "r904", "r905", "r906", "r907", "r908", "r1054", "r1083", "r1108", "r1209", "r1275", "r1276", "r1282", "r1402" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 }, "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "terseLabel": "Net income (loss)", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r303", "r335", "r338", "r352", "r360", "r369", "r377", "r378", "r401", "r415", "r421", "r424", "r467", "r528", "r529", "r531", "r532", "r533", "r535", "r537", "r539", "r540", "r756", "r759", "r760", "r783", "r793", "r863", "r882", "r928", "r981", "r1000", "r1001", "r1070", "r1103", "r1104", "r1119", "r1230", "r1278" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment by Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r18" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Property, plant and equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r215", "r308", "r880" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SegmentReportingLonglivedassetsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "terseLabel": "Property, Plant and Equipment, Net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r18", "r864", "r880", "r1107" ] }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNetAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r18", "r271", "r275", "r878" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r18" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r215" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Useful Life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ScheduleIIDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Credit loss expense", "terseLabel": "Net (credits) charges to expenses", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r349", "r474" ] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligation", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Purchase Obligations, Future Minimum Payments Due", "label": "Purchase Obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueAfterFifthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueAfterFifthYear", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": { "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Obligations, Future Minimum Payments, Due Thereafter", "label": "Purchase Obligation, to be Paid, after Year Five", "documentation": "Amount of purchase arrangement to be paid after fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInFifthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueInFifthYear", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": { "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Obligations, Future Minimum Payments, Due in Five Years", "label": "Purchase Obligation, to be Paid, Year Five", "documentation": "Amount of purchase arrangement to be paid in fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInFourthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueInFourthYear", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": { "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Obligations, Future Minimum Payments, Due in Four Years", "label": "Purchase Obligation, to be Paid, Year Four", "documentation": "Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": { "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Obligations, Future Minimum Payments Due, Current", "label": "Purchase Obligation, to be Paid, Year One", "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInSecondYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueInSecondYear", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": { "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Obligations, Future Minimum Payments, Due in Two Years", "label": "Purchase Obligation, to be Paid, Year Two", "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInThirdYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueInThirdYear", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": { "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Obligations, Future Minimum Payments, Due in Three Years", "label": "Purchase Obligation, to be Paid, Year Three", "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r1162" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r1162" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsLevel3Details", "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/LeasesDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails", "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r523", "r524", "r525", "r526", "r625", "r670", "r703", "r704", "r705", "r829", "r853", "r909", "r951", "r952", "r1007", "r1012", "r1016", "r1017", "r1027", "r1050", "r1051", "r1072", "r1082", "r1100", "r1109", "r1112", "r1271", "r1280", "r1395", "r1396", "r1397", "r1398", "r1399" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsLevel3Details", "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/LeasesDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails", "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r523", "r524", "r525", "r526", "r625", "r670", "r703", "r704", "r705", "r829", "r853", "r909", "r951", "r952", "r1007", "r1012", "r1016", "r1017", "r1027", "r1050", "r1051", "r1072", "r1082", "r1100", "r1109", "r1112", "r1271", "r1280", "r1395", "r1396", "r1397", "r1398", "r1399" ] }, "bsx_RangeofthetargetnumberofmarketbasedDSUsawarded": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "RangeofthetargetnumberofmarketbasedDSUsawarded", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range of the target number of market-based DSUs awarded", "label": "Range of the target number of market-based DSUs awarded", "documentation": "Range of the target number of market-based DSUs awarded" } } }, "auth_ref": [] }, "bsx_RangeofthetargetnumberofperformancebasedDSUsawarded": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "RangeofthetargetnumberofperformancebasedDSUsawarded", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range of the target number of performance-based DSUs awarded", "label": "Range of the target number of performance-based DSUs awarded", "documentation": "Range of the target number of performance-based DSUs awarded" } } }, "auth_ref": [] }, "us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivableWithImputedInterestEffectiveYieldInterestRate", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Average interest rate of de-recognized receivables", "label": "Receivable with Imputed Interest, Effective Yield (Interest Rate)", "documentation": "Yield on the receivable, on which interest has been imputed, as calculated from its issuance value or purchase price. The calculated effective interest rate considers factors such as the issued face value or price paid for the receivable, the time period between payments, and the time until maturity [full receipt] of the receivable." } } }, "auth_ref": [ "r167", "r809" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Income) loss amounts reclassified from accumulated other comprehensive income", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r41", "r60", "r342", "r800", "r805", "r806", "r1228" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI attributable to Boston Scientific common stockholders, Net of Tax [Roll Forward]", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Assets from Segment to Consolidated", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets." } } }, "auth_ref": [ "r85", "r86" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r84", "r86" ] }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Revenue from Segments to Consolidated", "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": [ "r83", "r86" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r1128", "r1140", "r1150", "r1176" ] }, "bsx_RelievantMedsystemsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "RelievantMedsystemsMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Relievant Medsystems", "label": "Relievant Medsystems [Member]", "documentation": "Relievant Medsystems" } } }, "auth_ref": [] }, "bsx_RenminbiDenominatedFactoringArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "RenminbiDenominatedFactoringArrangementsMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Renminbi denominated", "label": "Renminbi Denominated Factoring Arrangements [Member]", "documentation": "Renminbi Denominated Factoring Arrangements" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfSeniorDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfSeniorDebt", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments on long-term borrowings and debt extinguishment costs", "label": "Repayments of Senior Debt", "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period." } } }, "auth_ref": [ "r66" ] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on short-term borrowings", "label": "Repayments of Short-Term Debt", "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r66" ] }, "bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requirement, as of December 31, 2021 and through remaining term of facility", "label": "Requirement, as of December 31, 2021 and through remaining term of facility [Member]", "documentation": "Requirement, as of December 31, 2021 and through remaining term of facility" } } }, "auth_ref": [] }, "bsx_RequirementAsOfMarch312021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "RequirementAsOfMarch312021Member", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requirement, as of March 31, 2021", "label": "Requirement, as of March 31, 2021 [Member]", "documentation": "Requirement, as of March 31, 2021" } } }, "auth_ref": [] }, "bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requirement, eighth quarter and thereafter following qualified acquisition", "label": "Requirement, eighth quarter and thereafter following qualified acquisition [Member]", "documentation": "Requirement, eighth quarter and thereafter following qualified acquisition" } } }, "auth_ref": [] }, "bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "RequirementFourQuartersFollowingMaterialAcquisitionMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requirement, four quarters following material acquisition", "label": "Requirement, four quarters following material acquisition [Member]", "documentation": "Requirement, four quarters following qualified acquisition" } } }, "auth_ref": [] }, "bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "RequirementSeventhQuarterFollowingQualifiedAcquisitionMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requirement, seventh quarter following qualified acquisition", "label": "Requirement, seventh quarter following qualified acquisition [Member]", "documentation": "Requirement, seventh quarter following qualified acquisition" } } }, "auth_ref": [] }, "bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "RequirementSixthQuarterFollowingQualifiedAcquisitionMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requirement, sixth quarter following qualified acquisition", "label": "Requirement, sixth quarter following qualified acquisition [Member]", "documentation": "Requirement, sixth quarter following qualified acquisition [Member]" } } }, "auth_ref": [] }, "bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "RequirementfifthquarterfollowingqualifiedacquisitionMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requirement, fifth quarter following qualified acquisition", "label": "Requirement, fifth quarter following qualified acquisition [Member]", "documentation": "Requirement, fifth quarter following qualified acquisition [Member]" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept." } } }, "auth_ref": [ "r1372" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expense [Member]", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r714" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r1129", "r1141", "r1151", "r1177" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r1130", "r1142", "r1152", "r1178" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r1137", "r1149", "r1159", "r1185" ] }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash and restricted cash equivalents included in Other current assets", "label": "Restricted Cash and Cash Equivalents, Current", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r69", "r307", "r356" ] }, "us-gaap_RestrictedCashEquivalentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashEquivalentsNoncurrent", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash equivalents included in Other long-term assets", "verboseLabel": "Restricted cash equivalents", "label": "Restricted Cash Equivalents, Noncurrent", "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r266", "r1038", "r1039", "r1224", "r1237" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Restructuring net charges (credits)", "terseLabel": "Restructuring Charges", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r17", "r516", "r518", "r1272" ] }, "bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA", "label": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA", "documentation": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r513", "r517" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Retained earnings (Accumulated deficit)", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r181", "r223", "r875", "r913", "r915", "r925", "r961", "r1107" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings (Accumulated deficit)", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r300", "r366", "r367", "r368", "r370", "r376", "r378", "r468", "r469", "r711", "r712", "r713", "r739", "r740", "r773", "r775", "r776", "r778", "r781", "r910", "r912", "r929", "r1411" ] }, "us-gaap_RetirementPlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanNameAxis", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Name [Axis]", "label": "Retirement Plan Name [Axis]", "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r1100", "r1207", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342" ] }, "us-gaap_RetirementPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanNameDomain", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Name [Domain]", "label": "Retirement Plan Name [Domain]", "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r1100", "r1207", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342" ] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTypeAxis", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Axis]", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r602", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r664", "r665", "r666", "r676", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099" ] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTypeDomain", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Domain]", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r602", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r664", "r665", "r666", "r676", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099" ] }, "bsx_RevenueBasedPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "RevenueBasedPaymentsMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue-based Payments and Milestones", "label": "revenue-based payments [Member]", "documentation": "revenue-based payments [Member]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r402", "r403", "r414", "r419", "r420", "r426", "r428", "r430", "r597", "r598", "r855" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.bostonscientific.com/role/Revenue" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUE", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r278", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r601" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r983", "r1052", "r1068" ] }, "bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues from contracts with customers, disaggregated - performance measurement", "label": "Revenues from contracts with customers, disaggregated - performance measurement", "documentation": "Revenues from contracts with customers, disaggregated - performance measurement" } } }, "auth_ref": [] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingLonglivedassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r817", "r1106" ] }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyExpense", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty expense", "label": "Royalty Expense", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": [ "r197" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1194" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1194" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade accounts receivable, net", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block]", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r1092", "r1331", "r1332" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r60", "r1386", "r1387" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r76" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r76" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsLevel3Details", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r130", "r132", "r752" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } }, "auth_ref": [ "r130", "r132" ] }, "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]", "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements." } } }, "auth_ref": [ "r230" ] }, "us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Projected Benefit Obligations [Table Text Block]", "label": "Schedule of Changes in Projected Benefit Obligations [Table Text Block]", "documentation": "Tabular disclosure of the change in the benefit obligation of pension plans and/or other employee benefit plans from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits." } } }, "auth_ref": [ "r229" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r238" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r51", "r106", "r109", "r166", "r167", "r169", "r171", "r221", "r222", "r1078", "r1080", "r1243" ] }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Compensation Arrangement with Individual, Postretirement Benefits [Table]", "label": "Schedule of Deferred Compensation Arrangement with Individual, Postretirement Benefits [Table]", "documentation": "Schedule, table or text reflecting pension and other postretirement benefit arrangements with individual employees, which are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability." } } }, "auth_ref": [ "r225", "r226" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Tax Assets and Liabilities", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r237" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]", "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]", "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans." } } }, "auth_ref": [ "r19", "r114", "r115", "r116", "r117" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss)", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r150", "r156", "r771" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r151" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Tax rate", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r236" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r123" ] }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Expected Benefit Payments", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter." } } }, "auth_ref": [ "r231" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r785", "r786" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": [ "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r1075" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r1075", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r1241" ] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets and Goodwill", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": [ "r88" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory, Current", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r44", "r185", "r186", "r187" ] }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Notional Amounts of Outstanding Derivative Positions", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions." } } }, "auth_ref": [ "r145" ] }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOperatingLeasedAssetsTable", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Leased Assets [Table]", "label": "Schedule of Operating Leased Assets [Table]", "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherAssetsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Assets", "label": "Schedule of Other Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Current Assets", "label": "Schedule of Other Current Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives Not Designated as Hedging Instruments", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument." } } }, "auth_ref": [ "r157", "r1208" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r245" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r87", "r194" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingLonglivedassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r87", "r191" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDepreciationexpenseDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SegmentReportingIncomelossbeforeincometaxesDetails", "http://www.bostonscientific.com/role/SegmentReportingOperatingincomeofreportablesegmentsasapercentageofnetsalesofreportablesegmentsDetails", "http://www.bostonscientific.com/role/SegmentReportingTotalAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Segment Reporting Information By Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r80", "r81", "r82", "r88" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r678", "r679", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706" ] }, "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity", "label": "Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]", "documentation": "Tabular disclosure of employee stock purchase plan activity." } } }, "auth_ref": [ "r122" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r121" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation, Stock Options, Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r31", "r32", "r121" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r234" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r103", "r104", "r105", "r106", "r107", "r108", "r109", "r221", "r222", "r223", "r316", "r317", "r318", "r395", "r571", "r572", "r573", "r575", "r578", "r583", "r585", "r921", "r922", "r923", "r924", "r1082", "r1203", "r1238" ] }, "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Unrecognized Compensation", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]", "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r235" ] }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ScheduleII" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "documentation": "The entire disclosure for valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r280", "r365" ] }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Weighted Average Number of Shares", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }, "auth_ref": [ "r75" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Expected Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r94" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1121" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r1124" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDepreciationexpenseDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SegmentReportingIncomelossbeforeincometaxesDetails", "http://www.bostonscientific.com/role/SegmentReportingOperatingincomeofreportablesegmentsasapercentageofnetsalesofreportablesegmentsDetails", "http://www.bostonscientific.com/role/SegmentReportingTotalAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r398", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r424", "r430", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r515", "r519", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r1075", "r1209", "r1402" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingLonglivedassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r428", "r429", "r944", "r947", "r949", "r1009", "r1014", "r1018", "r1029", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1055", "r1084", "r1112", "r1282", "r1402" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SegmentReporting" ], "lang": { "en-us": { "role": { "verboseLabel": "SEGMENT REPORTING", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r397", "r398", "r399", "r400", "r401", "r413", "r418", "r422", "r423", "r424", "r425", "r426", "r427", "r430" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDepreciationexpenseDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SegmentReportingIncomelossbeforeincometaxesDetails", "http://www.bostonscientific.com/role/SegmentReportingOperatingincomeofreportablesegmentsasapercentageofnetsalesofreportablesegmentsDetails", "http://www.bostonscientific.com/role/SegmentReportingTotalAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "bsx_Segmentoperatingincomeaspercentageofnetsales": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "Segmentoperatingincomeaspercentageofnetsales", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingOperatingincomeofreportablesegmentsasapercentageofnetsalesofreportablesegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment operating income as percentage of net sales", "label": "Segment operating income as percentage of net sales", "documentation": "Segment operating income as percentage of net sales" } } }, "auth_ref": [] }, "bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "SegmentoperatingincomeaspercentageofnetsalesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Segment operating income as percentage of net sales", "label": "Segment operating income as percentage of net sales [Table Text Block]", "documentation": "Segment operating income as percentage of net sales" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r198" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, General and Administrative Expenses [Member]", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "bsx_SeniorNotedue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "SeniorNotedue2027Member", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Note due 2027 [Member]", "label": "Senior Note due 2027 [Member]", "documentation": "Senior Note due 2027 [Member]" } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r697" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r697" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r695" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r695" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r692", "r693" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r692", "r693" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r696" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Total Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r699" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r696" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r703" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r705" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r678", "r679", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r1102" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r120" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r686" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r686" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r699" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r1352" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r1352" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r688" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r698" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r120" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r684", "r685" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r684", "r685" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r700" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r700" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r700" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r689" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r688" ] }, "bsx_ShareBasedCompensationNetOfTaxBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "ShareBasedCompensationNetOfTaxBenefit", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, net of tax benefit", "label": "Share-based compensation, net of tax benefit", "documentation": "Share-based compensation, net of tax benefit" } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Price", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r702" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r120" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r120" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r233" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r700" ] }, "bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "bsx_SignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "SignificantAccountingPoliciesLineItems", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies [Line Items]", "label": "Significant Accounting Policies [Line Items]", "documentation": "Significant Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "bsx_SignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "SignificantAccountingPoliciesTable", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies", "label": "Significant Accounting Policies [Table]", "documentation": "Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r207", "r357" ] }, "us-gaap_SoftwareDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SoftwareDevelopmentMember", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Software Development", "label": "Software Development [Member]", "documentation": "Internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "us-gaap_StandardProductWarrantyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StandardProductWarrantyPolicy", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Warranty Obligations", "label": "Standard Product Warranty, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability." } } }, "auth_ref": [ "r1277" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDepreciationexpenseDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SegmentReportingIncomelossbeforeincometaxesDetails", "http://www.bostonscientific.com/role/SegmentReportingOperatingincomeofreportablesegmentsasapercentageofnetsalesofreportablesegmentsDetails", "http://www.bostonscientific.com/role/SegmentReportingTotalAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Segments [Axis]", "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r302", "r398", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r424", "r430", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r507", "r515", "r519", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r1075", "r1209", "r1402" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsPriceAllocationDetails", "http://www.bostonscientific.com/role/Cover", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r279", "r316", "r317", "r318", "r360", "r383", "r384", "r387", "r389", "r395", "r396", "r467", "r528", "r531", "r532", "r533", "r539", "r540", "r571", "r572", "r575", "r578", "r585", "r793", "r921", "r922", "r923", "r924", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r941", "r960", "r982", "r1002", "r1030", "r1031", "r1032", "r1033", "r1034", "r1203", "r1238", "r1247" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement, Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r26", "r56", "r300", "r341", "r342", "r343", "r366", "r367", "r368", "r370", "r376", "r378", "r394", "r468", "r469", "r586", "r711", "r712", "r713", "r739", "r740", "r773", "r774", "r775", "r776", "r777", "r778", "r781", "r800", "r802", "r803", "r804", "r805", "r806", "r821", "r910", "r911", "r912", "r929", "r1002" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingLonglivedassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "verboseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r281", "r290", "r428", "r429", "r944", "r947", "r949", "r1009", "r1014", "r1018", "r1029", "r1037", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1055", "r1084", "r1112", "r1282", "r1402" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r366", "r367", "r368", "r394", "r855", "r916", "r941", "r953", "r954", "r955", "r956", "r957", "r958", "r960", "r963", "r964", "r965", "r966", "r967", "r969", "r970", "r971", "r972", "r974", "r975", "r976", "r977", "r978", "r980", "r983", "r984", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r1002", "r1113" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r366", "r367", "r368", "r394", "r855", "r916", "r941", "r953", "r954", "r955", "r956", "r957", "r958", "r960", "r963", "r964", "r965", "r966", "r967", "r969", "r970", "r971", "r972", "r974", "r975", "r976", "r977", "r978", "r980", "r983", "r984", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r1002", "r1113" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r1132", "r1144", "r1154", "r1180" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of stock-based compensation plans", "label": "Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r119", "r124" ] }, "bsx_StockIncentiveAndPurchasePlansAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "StockIncentiveAndPurchasePlansAbstract", "lang": { "en-us": { "role": { "terseLabel": "Stock Incentive and Ownership Plans [Abstract]", "label": "Stock Incentive and Purchase Plans [Abstract]", "documentation": "Stock Incentive and Purchase Plans [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r26", "r178", "r179", "r223" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock Issued During Period, Shares, New Issues", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r26", "r178", "r179", "r223", "r921", "r1002", "r1031" ] }, "us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesPeriodIncreaseDecrease", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of stock-based compensation plans", "label": "Stock Issued During Period, Shares, Period Increase (Decrease)", "documentation": "The increase (decrease) during the period in the number of shares issued." } } }, "auth_ref": [ "r26", "r1411", "r1412" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r26", "r178", "r179", "r223", "r689" ] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Repurchase Program, Authorized Amount", "label": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeAOCIRollforwardwithReclassificationDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Equity, Attributable to Parent", "periodStartLabel": "Beginning Stockholders' Equity", "periodEndLabel": "Ending Stockholders' Equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r179", "r182", "r183", "r208", "r962", "r979", "r1003", "r1004", "r1107", "r1120", "r1240", "r1256", "r1385", "r1411" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "terseLabel": "Total equity", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r138", "r139", "r140", "r300", "r301", "r342", "r366", "r367", "r368", "r370", "r376", "r468", "r469", "r586", "r711", "r712", "r713", "r739", "r740", "r773", "r774", "r775", "r776", "r777", "r778", "r781", "r800", "r802", "r806", "r821", "r911", "r912", "r927", "r962", "r979", "r1003", "r1004", "r1035", "r1119", "r1240", "r1256", "r1385", "r1411" ] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDER'S EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r220", "r359", "r570", "r572", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r584", "r586", "r780", "r1005", "r1006", "r1036" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Member]", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r807", "r822" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r807", "r822" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r807", "r822" ] }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsPolicyPolicyTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for reporting subsequent events." } } }, "auth_ref": [] }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Income Tax Contingencies", "label": "Summary of Income Tax Contingencies [Table Text Block]", "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r23", "r241", "r242" ] }, "bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants", "label": "Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block]", "documentation": "Summary of term loan and revolving credit facility agreement compliance with debt covenants." } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation" ], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL BALANCE SHEET INFORMATION", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r1220" ] }, "bsx_SupplementalBalanceSheetInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "SupplementalBalanceSheetInformationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Balance Sheet Information", "label": "Supplemental Balance Sheet Information [Abstract]", "documentation": "Supplemental Balance Sheet Information." } } }, "auth_ref": [] }, "bsx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Balance Sheet Information Related to Leases", "label": "Supplemental Balance Sheet Information Related to Leases [Table Text Block]", "documentation": "Supplemental Balance Sheet Information Related to Leases" } } }, "auth_ref": [] }, "bsx_SupplementalBalanceSheetInformationTextualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "SupplementalBalanceSheetInformationTextualsAbstract", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Supplemental Balance Sheet Information (Textuals)", "label": "Supplemental Balance Sheet Information (Textuals) [Abstract]", "documentation": "Supplemental Balance Sheet Information (Textuals)" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Supplemental Information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "bsx_SupplementalCashFlowInformationRelatedToLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "SupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Information Related to Leases", "label": "Supplemental Cash Flow Information Related to Leases [Table Text Block]", "documentation": "Supplemental Cash Flow Information Related to Leases" } } }, "auth_ref": [] }, "us-gaap_SupplierFinanceProgramObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplierFinanceProgramObligation", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Finance Program, Obligation", "label": "Supplier Finance Program, Obligation", "documentation": "Amount of obligation for supplier finance program." } } }, "auth_ref": [ "r508", "r509", "r510", "r511", "r512", "r1076" ] }, "us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]", "label": "Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes obligation for supplier finance program." } } }, "auth_ref": [ "r509" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r1173" ] }, "bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "TargetPayoutOfFreeCashFlowsFcfPerformanceAwards", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Target payout of Free Cash Flows (FCF) performance awards", "label": "Target payout of Free Cash Flows (FCF) performance awards", "documentation": "Target payout of Free Cash Flows (FCF) performance awards" } } }, "auth_ref": [] }, "bsx_TargetPayoutOfOrganicNetSalesGrowthONSGPerformanceBasedRSU": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "TargetPayoutOfOrganicNetSalesGrowthONSGPerformanceBasedRSU", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "target payout of organic net sales growth (ONSG) performance-based RSU", "label": "target payout of organic net sales growth (ONSG) performance-based RSU", "documentation": "target payout of organic net sales growth (ONSG) performance-based RSU" } } }, "auth_ref": [] }, "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Adjustments, Settlements, and Unusual Provisions", "label": "Tax Adjustments, Settlements, and Unusual Provisions", "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement." } } }, "auth_ref": [ "r239", "r240" ] }, "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability", "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability", "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act." } } }, "auth_ref": [ "r1373" ] }, "bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense", "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense", "documentation": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense" } } }, "auth_ref": [] }, "bsx_TaxIncentivesInMalaysia": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "TaxIncentivesInMalaysia", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax incentives in Malaysia", "label": "Tax incentives in Malaysia", "documentation": "Tax incentives in Malaysia" } } }, "auth_ref": [] }, "bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution": { "xbrltype": "perShareItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution", "label": "Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution", "documentation": "Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution" } } }, "auth_ref": [] }, "bsx_TaxIncentivesInPuertoRico": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "TaxIncentivesInPuertoRico", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Incentives in Puerto Rico", "label": "Tax Incentives in Puerto Rico", "documentation": "Tax Incentives in Puerto Rico" } } }, "auth_ref": [] }, "bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution": { "xbrltype": "perShareItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution", "label": "Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution", "documentation": "Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution" } } }, "auth_ref": [] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes payable", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r47" ] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technology-related", "label": "Technology-Based Intangible Assets [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": [ "r40" ] }, "bsx_TechnologyRelatedAndCustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "TechnologyRelatedAndCustomerRelationshipsMember", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technology Related and Customer Relationships", "label": "Technology Related and Customer Relationships [Member]", "documentation": "Technology Related and Customer Relationships" } } }, "auth_ref": [] }, "bsx_TheOfferingAggregatePrincipalAmountMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "TheOfferingAggregatePrincipalAmountMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "the Offering - aggregate principal amount", "label": "the Offering - aggregate principal amount [Member]", "documentation": "the Offering - aggregate principal amount" } } }, "auth_ref": [] }, "bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "the Offering - early redemption of combined aggregate principal SN", "label": "the Offering - early redemption of combined aggregate principal SN [Member]", "documentation": "the Offering - early redemption of combined aggregate principal SN" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r1165" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r1172" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r1193" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r1195" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized", "label": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized", "documentation": "Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition." } } }, "auth_ref": [ "r37" ] }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer of Financial Assets Accounted for as Sales", "label": "Transfer of Financial Assets Accounted for as Sales [Table Text Block]", "documentation": "Tabular disclosure of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction." } } }, "auth_ref": [ "r36" ] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r566", "r583", "r779", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r886", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1251", "r1252", "r1253", "r1254" ] }, "bsx_TransitionTaxPaymentRemaining": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "TransitionTaxPaymentRemaining", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "transition tax payment remaining", "label": "Transition Tax Payment Remaining", "documentation": "Transition Tax Payment Remaining" } } }, "auth_ref": [] }, "us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax", "label": "Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax", "documentation": "Amount, after tax, of reclassification from accumulated other comprehensive income (AOCI) of gain (loss) from increase (decrease) in fair value of net investment hedge." } } }, "auth_ref": [ "r263", "r770" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r1196" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r1197" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r1195" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r1195" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r1198" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r1196" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r110" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock, Shares", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r110" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock, at cost - 263,289,848 shares as of December\u00a031, 2023 and 2022", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r55", "r110", "r111" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r26", "r110", "r223" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingLonglivedassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S.", "verboseLabel": "UNITED STATES", "label": "UNITED STATES" } } }, "auth_ref": [] }, "bsx_USExcludingOtherNetSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "USExcludingOtherNetSalesMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "country_US excluding Other Net Sales", "label": "US excluding Other Net Sales [Member]", "documentation": "US excluding Other Net Sales" } } }, "auth_ref": [] }, "bsx_UncappedContingentConsidertation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "UncappedContingentConsidertation", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Uncapped Contingent Considertation", "label": "Uncapped Contingent Considertation", "documentation": "Uncapped Contingent Considertation" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r1192" ] }, "bsx_UnrecognizedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "UnrecognizedCompensationCost", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized Compensation Cost", "label": "Unrecognized Compensation Cost", "documentation": "Unrecognized Compensation Cost" } } }, "auth_ref": [] }, "bsx_UnrecognizedCompensationCostNonVestedStockAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "UnrecognizedCompensationCostNonVestedStockAwards", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized Compensation Cost - Non-vested stock awards", "label": "Unrecognized Compensation Cost - Non-vested stock awards", "documentation": "Unrecognized Compensation Cost - Non-vested stock awards" } } }, "auth_ref": [] }, "bsx_UnrecognizedCompensationCostStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "UnrecognizedCompensationCostStockOptions", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized Compensation Cost - Stock Options", "label": "Unrecognized Compensation Cost - Stock Options", "documentation": "Unrecognized Compensation Cost - Stock Options" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized Tax Benefits", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r716", "r724" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r725" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities." } } }, "auth_ref": [ "r727" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r726" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r725" ] }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "crdr": "debit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations." } } }, "auth_ref": [ "r728" ] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r729" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r77", "r78", "r79", "r268", "r269", "r272", "r273" ] }, "srt_ValuationAndQualifyingAccountsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ValuationAndQualifyingAccountsAbstract", "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueAxis", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Axis]", "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": [ "r29" ] }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDiscountedCashFlowMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Discount Rate", "label": "Valuation Technique, Discounted Cash Flow [Member]", "documentation": "Valuation technique calculating present value of future cash flows." } } }, "auth_ref": [ "r1384" ] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDomain", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Domain]", "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": [ "r29" ] }, "bsx_VotingPowerOfAllClassesOfStock": { "xbrltype": "percentItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "VotingPowerOfAllClassesOfStock", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Voting power of all classes of stock", "label": "Voting power of all classes of stock", "documentation": "Voting power of all classes of stock" } } }, "auth_ref": [] }, "bsx_WatchmanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "WatchmanMember", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Watchman", "label": "Watchman [Member]", "documentation": "Watchman" } } }, "auth_ref": [] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "WeightedAverageMember", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsIntangibleAssetsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsLevel3Details", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-Adjusted Discount Rates used in Purchase Price Allocation", "verboseLabel": "Weighted Average", "label": "Weighted Average [Member]", "documentation": "Average of a range of values, calculated with consideration of proportional relevance." } } }, "auth_ref": [ "r1050", "r1051", "r1394", "r1396", "r1399" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Number Diluted Shares Outstanding Adjustment", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r1248" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r382", "r389" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic", "terseLabel": "Weighted Average Number of Shares Outstanding, Basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r380", "r389" ] }, "bsx_WeightedAverageRemainingVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "WeightedAverageRemainingVestingPeriod", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "weighted average remaining vesting period", "label": "weighted average remaining vesting period", "documentation": "weighted average remaining vesting period" } } }, "auth_ref": [] }, "bsx_WendyCarruthersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "WendyCarruthersMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Wendy Carruthers [Member]", "documentation": "Wendy Carruthers" } } }, "auth_ref": [] }, "bsx_WendyCarruthersRuleTradingArrangementCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "WendyCarruthersRuleTradingArrangementCommonStockMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Wendy Carruthers Rule Trading Arrangement, Common Stock [Member]", "documentation": "Wendy Carruthers Rule Trading Arrangement, Common Stock" } } }, "auth_ref": [] }, "bsx_WendyCarruthersRuleTradingArrangementStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "WendyCarruthersRuleTradingArrangementStockOptionsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Wendy Carruthers Rule Trading Arrangement, Stock Options [Member]", "documentation": "Wendy Carruthers Rule Trading Arrangement, Stock Options" } } }, "auth_ref": [] }, "bsx_YenDenominatedFactoringArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20231231", "localname": "YenDenominatedFactoringArrangementsMember", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Yen denominated", "label": "Yen Denominated Factoring Arrangements [Member]", "documentation": "Yen denominated factoring arrangements." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-16" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "b", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i),(j),(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i-k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481097/715-30-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "60", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "80", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(1)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29,30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 5.P.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-10" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "70", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "30", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480513/718-10-30-3" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "30", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480843/718-30-35-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "40", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480870/815-30-50-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//220/tableOfContent" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r200": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r201": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r202": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r203": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r204": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r205": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r206": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r207": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r208": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r209": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r210": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r211": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r212": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r213": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r214": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r215": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r216": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r217": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r218": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r219": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r220": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r221": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r222": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r223": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r224": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//710/tableOfContent" }, "r225": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-9" }, "r226": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1" }, "r227": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//712/tableOfContent" }, "r228": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r229": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(a)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r230": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(b)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r231": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(f)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r232": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r233": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r234": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r235": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(i)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r236": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r237": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r238": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r239": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482620/740-10-25-10" }, "r240": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482620/740-10-25-8" }, "r241": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r242": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r243": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r244": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r245": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r246": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r247": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r248": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r249": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r250": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r251": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r252": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r253": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r254": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r255": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r256": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r257": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r258": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.13,16)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r259": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r260": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r261": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r262": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481161/840-30-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "09", "Publisher": "SEC" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "2", "Publisher": "SEC" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "4", "Publisher": "SEC" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iii)(C)", "Publisher": "SEC" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(dd)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-20/tableOfContent" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-4" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-4" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-11" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-3" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r943": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r944": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r945": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r946": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12" }, "r947": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r948": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r949": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r950": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r951": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r952": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r953": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r954": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r955": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r956": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r957": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r958": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r959": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r960": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r961": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r962": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r963": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r964": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r965": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r966": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r967": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r968": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r969": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r970": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r971": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r972": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r973": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r974": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r975": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r976": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r977": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r978": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r979": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r980": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r981": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r982": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r983": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r984": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r985": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r986": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r987": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r988": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r989": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r990": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r991": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r992": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r993": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r994": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r995": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r996": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r997": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r998": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r999": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1000": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1001": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1002": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1003": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1004": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1005": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r1006": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r1007": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1008": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1009": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1010": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12" }, "r1011": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r1012": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1013": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1014": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1015": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1016": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1017": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1018": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1019": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r1020": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r1021": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r1022": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r1023": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r1024": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r1025": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r1026": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r1027": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1028": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1029": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1030": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r1031": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r1032": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r1033": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r1034": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r1035": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r1036": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r1037": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r1038": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4" }, "r1039": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2" }, "r1040": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r1041": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1042": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1043": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1044": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1045": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1046": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1047": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1048": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1049": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1050": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r1051": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r1052": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r1053": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r1054": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r1055": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r1056": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r1057": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r1058": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r1059": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r1060": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r1061": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r1062": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1063": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1064": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1065": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r1066": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r1067": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r1068": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r1069": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r1070": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r1071": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r1072": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r1073": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r1074": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r1075": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r1076": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477128/405-50-55-5" }, "r1077": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r1078": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r1079": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r1080": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r1081": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r1082": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r1083": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1084": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1085": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1086": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1087": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1088": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1089": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1090": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1091": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1092": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r1093": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18" }, "r1094": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r1095": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r1096": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r1097": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r1098": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r1099": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r1100": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r1101": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1102": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1103": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r1104": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r1105": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r1106": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r1107": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r1108": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r1109": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r1110": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r1111": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1112": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r1113": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r1114": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1115": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1116": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1117": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1118": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r1119": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r1120": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r1121": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1122": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1123": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r1124": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1125": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r1126": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r1127": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r1128": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r1129": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r1130": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1131": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1132": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1133": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1134": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1135": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r1136": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r1137": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r1138": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r1139": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r1140": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r1141": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r1142": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1143": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1144": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1145": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1146": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1147": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1148": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1149": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1150": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1151": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1152": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1153": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1154": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1155": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1156": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1157": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1158": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1159": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1160": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1161": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1162": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1163": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1164": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1165": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1166": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1167": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1168": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1169": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1170": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1171": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1172": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1173": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1174": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1175": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r1176": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1177": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1178": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1179": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1180": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1181": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1182": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1183": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1184": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1185": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1186": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1187": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1188": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1189": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1190": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1191": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1192": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1193": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1194": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1195": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1196": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1197": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1198": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1199": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1200": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1201": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r1202": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r1203": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r1204": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2" }, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CC" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r1210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(ii)", "Publisher": "SEC" }, "r1219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iii)", "Publisher": "SEC" }, "r1220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//210/tableOfContent" }, "r1221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r1229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r1230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r1231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r1232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r1233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r1234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r1235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r1236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-9" }, "r1237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r1238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(S-X 210.12-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r1244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r1245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r1249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r1257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r1258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1267": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r1268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r1269": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r1270": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r1271": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r1272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r1273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r1274": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r1275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r1276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r1277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r1278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r1281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r1282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r1283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1295": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1306": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1308": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1309": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1310": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1311": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1312": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1314": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1322": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r1331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r1332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r1333": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1335": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1339": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1342": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8" }, "r1343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1" }, "r1344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r1345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9" }, "r1346": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1358": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1360": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1361": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1362": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1363": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1364": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1365": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1366": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1367": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1368": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1369": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1370": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1371": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1372": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r1373": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r1374": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r1375": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r1376": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r1377": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r1378": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r1379": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r1380": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r1381": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r1382": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r1383": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1384": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r1385": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1386": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r1387": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r1388": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r1389": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r1390": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r1391": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r1392": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1393": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1394": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1395": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1396": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1397": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1398": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1399": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1400": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1401": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1402": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r1405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1408": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1409": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1410": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1411": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1412": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1413": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1414": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1415": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1416": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 97 0000885725-24-000017-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000885725-24-000017-xbrl.zip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end XML 98 bsx-20231231_htm.xml IDEA: XBRL DOCUMENT 0000885725 2023-01-01 2023-12-31 0000885725 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000885725 bsx:SeniorNotedue2027Member 2023-01-01 2023-12-31 0000885725 2023-06-30 0000885725 2024-01-31 0000885725 2022-01-01 2022-12-31 0000885725 2021-01-01 2021-12-31 0000885725 2023-12-31 0000885725 2022-12-31 0000885725 us-gaap:PreferredStockMember 2022-12-31 0000885725 us-gaap:PreferredStockMember 2021-12-31 0000885725 us-gaap:PreferredStockMember 2020-12-31 0000885725 us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0000885725 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0000885725 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0000885725 us-gaap:PreferredStockMember 2023-12-31 0000885725 us-gaap:CommonStockMember 2022-12-31 0000885725 us-gaap:CommonStockMember 2021-12-31 0000885725 us-gaap:CommonStockMember 2020-12-31 0000885725 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000885725 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000885725 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000885725 2021-12-31 0000885725 us-gaap:CommonStockMember 2023-12-31 0000885725 us-gaap:TreasuryStockCommonMember 2022-12-31 0000885725 us-gaap:TreasuryStockCommonMember 2021-12-31 0000885725 us-gaap:TreasuryStockCommonMember 2020-12-31 0000885725 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0000885725 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0000885725 us-gaap:TreasuryStockCommonMember 2021-01-01 2021-12-31 0000885725 us-gaap:TreasuryStockCommonMember 2023-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000885725 us-gaap:RetainedEarningsMember 2022-12-31 0000885725 us-gaap:RetainedEarningsMember 2021-12-31 0000885725 us-gaap:RetainedEarningsMember 2020-12-31 0000885725 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000885725 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000885725 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000885725 us-gaap:RetainedEarningsMember 2023-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000885725 us-gaap:NoncontrollingInterestMember 2022-12-31 0000885725 us-gaap:NoncontrollingInterestMember 2021-12-31 0000885725 us-gaap:NoncontrollingInterestMember 2020-12-31 0000885725 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0000885725 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0000885725 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0000885725 us-gaap:NoncontrollingInterestMember 2023-12-31 0000885725 2020-12-31 0000885725 us-gaap:BuildingMember 2023-12-31 0000885725 srt:MinimumMember bsx:EquipmentFurnitureFixturesMember 2023-12-31 0000885725 srt:MaximumMember bsx:EquipmentFurnitureFixturesMember 2023-12-31 0000885725 srt:MinimumMember bsx:PatentsAndLicensesMember 2023-12-31 0000885725 srt:MaximumMember bsx:PatentsAndLicensesMember 2023-12-31 0000885725 srt:MinimumMember bsx:TechnologyRelatedAndCustomerRelationshipsMember 2023-12-31 0000885725 srt:MaximumMember bsx:TechnologyRelatedAndCustomerRelationshipsMember 2023-12-31 0000885725 srt:MinimumMember us-gaap:SoftwareDevelopmentMember 2023-12-31 0000885725 srt:MaximumMember us-gaap:SoftwareDevelopmentMember 2023-12-31 0000885725 bsx:AxonicsMember us-gaap:SubsequentEventMember 2024-01-08 0000885725 bsx:AxonicsMember us-gaap:SubsequentEventMember 2024-01-08 2024-01-08 0000885725 bsx:AcotecMember 2023-02-20 0000885725 bsx:AcotecMember 2023-02-20 2023-02-20 0000885725 bsx:ApolloMember 2023-04-04 0000885725 bsx:ApolloMember 2023-04-04 2023-04-04 0000885725 bsx:RelievantMedsystemsMember 2023-11-17 0000885725 bsx:RelievantMedsystemsMember 2023-11-17 2023-11-17 0000885725 bsx:AcotecMember 2023-01-01 2023-12-31 0000885725 bsx:ApolloMember 2023-01-01 2023-12-31 0000885725 bsx:RelievantMedsystemsMember 2023-01-01 2023-12-31 0000885725 bsx:AcotecMember 2023-12-31 0000885725 bsx:ApolloMember 2023-12-31 0000885725 bsx:RelievantMedsystemsMember 2023-12-31 0000885725 bsx:AcotecMember 2023-02-20 0000885725 bsx:AcotecMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0000885725 bsx:AcotecMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-01-01 2023-12-31 0000885725 srt:WeightedAverageMember bsx:AcotecMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-01-01 2023-12-31 0000885725 bsx:AcotecMember us-gaap:CustomerRelationshipsMember 2023-12-31 0000885725 bsx:AcotecMember us-gaap:CustomerRelationshipsMember 2023-01-01 2023-12-31 0000885725 srt:WeightedAverageMember bsx:AcotecMember us-gaap:CustomerRelationshipsMember 2023-01-01 2023-12-31 0000885725 bsx:AcotecMember us-gaap:OtherIntangibleAssetsMember 2023-12-31 0000885725 bsx:AcotecMember us-gaap:OtherIntangibleAssetsMember 2023-01-01 2023-12-31 0000885725 srt:WeightedAverageMember bsx:AcotecMember us-gaap:OtherIntangibleAssetsMember 2023-01-01 2023-12-31 0000885725 bsx:ApolloMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0000885725 bsx:ApolloMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-01-01 2023-12-31 0000885725 srt:WeightedAverageMember bsx:ApolloMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-01-01 2023-12-31 0000885725 bsx:ApolloMember us-gaap:CustomerRelationshipsMember 2023-12-31 0000885725 bsx:ApolloMember us-gaap:CustomerRelationshipsMember 2023-01-01 2023-12-31 0000885725 srt:WeightedAverageMember bsx:ApolloMember us-gaap:CustomerRelationshipsMember 2023-01-01 2023-12-31 0000885725 bsx:RelievantMedsystemsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0000885725 bsx:RelievantMedsystemsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-01-01 2023-12-31 0000885725 srt:WeightedAverageMember bsx:RelievantMedsystemsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-01-01 2023-12-31 0000885725 bsx:RelievantMedsystemsMember us-gaap:CustomerRelationshipsMember 2023-12-31 0000885725 bsx:RelievantMedsystemsMember us-gaap:CustomerRelationshipsMember 2023-01-01 2023-12-31 0000885725 srt:WeightedAverageMember bsx:RelievantMedsystemsMember us-gaap:CustomerRelationshipsMember 2023-01-01 2023-12-31 0000885725 bsx:BaylisMedicalMember 2023-01-01 2023-12-31 0000885725 bsx:BaylisMedicalMember 2023-12-31 0000885725 bsx:BaylisMedicalMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0000885725 bsx:BaylisMedicalMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-01-01 2023-12-31 0000885725 srt:WeightedAverageMember bsx:BaylisMedicalMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-01-01 2023-12-31 0000885725 bsx:BaylisMedicalMember us-gaap:OtherIntangibleAssetsMember 2023-12-31 0000885725 bsx:BaylisMedicalMember us-gaap:OtherIntangibleAssetsMember 2023-01-01 2023-12-31 0000885725 srt:WeightedAverageMember bsx:BaylisMedicalMember us-gaap:OtherIntangibleAssetsMember 2023-01-01 2023-12-31 0000885725 bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-12-31 0000885725 srt:MinimumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-01-01 2023-12-31 0000885725 srt:MaximumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-01-01 2023-12-31 0000885725 srt:WeightedAverageMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-01-01 2023-12-31 0000885725 srt:MinimumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-12-31 0000885725 srt:MaximumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-12-31 0000885725 srt:WeightedAverageMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0000885725 us-gaap:PatentsMember 2023-12-31 0000885725 us-gaap:PatentsMember 2022-12-31 0000885725 us-gaap:OtherIntangibleAssetsMember 2023-12-31 0000885725 us-gaap:OtherIntangibleAssetsMember 2022-12-31 0000885725 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0000885725 us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0000885725 bsx:MedsurgMember 2021-12-31 0000885725 bsx:CardiovascularMember 2021-12-31 0000885725 bsx:MedsurgMember 2022-01-01 2022-12-31 0000885725 bsx:CardiovascularMember 2022-01-01 2022-12-31 0000885725 bsx:MedsurgMember 2022-12-31 0000885725 bsx:CardiovascularMember 2022-12-31 0000885725 bsx:MedsurgMember 2023-01-01 2023-12-31 0000885725 bsx:CardiovascularMember 2023-01-01 2023-12-31 0000885725 bsx:MedsurgMember 2023-12-31 0000885725 bsx:CardiovascularMember 2023-12-31 0000885725 bsx:November2019AggregateOfferingMember 2021-12-31 0000885725 bsx:December2027NotesMember 2023-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 bsx:ForeignCurrencyDenominatedInDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000885725 bsx:ForeignCurrencyDenominatedInDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-01-01 2023-12-31 0000885725 bsx:ForeignCurrencyDenominatedInDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-01-01 2023-12-31 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-01-01 2023-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2022-01-01 2022-12-31 0000885725 bsx:ForeignCurrencyDenominatedInDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2022-01-01 2022-12-31 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2022-01-01 2022-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2021-01-01 2021-12-31 0000885725 bsx:ForeignCurrencyDenominatedInDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2021-01-01 2021-12-31 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2021-01-01 2021-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2023-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:InterestExpenseMember 2023-12-31 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2023-12-31 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-01 2023-12-31 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-12-31 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-01-01 2021-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000885725 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000885725 us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-12-31 0000885725 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000885725 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000885725 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000885725 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000885725 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000885725 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000885725 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000885725 bsx:LicensingArrangementAssetsMember 2023-01-01 2023-12-31 0000885725 srt:WeightedAverageMember bsx:LicensingArrangementAssetsMember 2023-01-01 2023-12-31 0000885725 srt:MinimumMember bsx:LicensingArrangementLiabilitiesMember 2023-01-01 2023-12-31 0000885725 srt:MaximumMember bsx:LicensingArrangementLiabilitiesMember 2023-01-01 2023-12-31 0000885725 srt:WeightedAverageMember bsx:LicensingArrangementLiabilitiesMember 2023-01-01 2023-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bsx:LicensingArrangementAssetsMember 2021-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bsx:LicensingArrangementAssetsMember 2022-01-01 2022-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bsx:LicensingArrangementAssetsMember 2022-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bsx:LicensingArrangementAssetsMember 2023-01-01 2023-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bsx:LicensingArrangementAssetsMember 2023-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bsx:LicensingArrangementLiabilitiesMember 2021-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bsx:LicensingArrangementLiabilitiesMember 2022-01-01 2022-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bsx:LicensingArrangementLiabilitiesMember 2022-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bsx:LicensingArrangementLiabilitiesMember 2023-01-01 2023-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bsx:LicensingArrangementLiabilitiesMember 2023-12-31 0000885725 bsx:October2023NotesMember 2023-12-31 0000885725 bsx:October2023NotesMember 2022-12-31 0000885725 bsx:March2024NotesMember 2023-12-31 0000885725 bsx:March2024NotesMember 2022-12-31 0000885725 bsx:June2025NotesMember 2023-12-31 0000885725 bsx:June2025NotesMember 2022-12-31 0000885725 bsx:March2026NotesMember 2023-12-31 0000885725 bsx:March2026NotesMember 2022-12-31 0000885725 bsx:December2027NotesMember 2022-12-31 0000885725 bsx:March2028SeniorNotesMember 2023-12-31 0000885725 bsx:March2028SeniorNotesMember 2022-12-31 0000885725 bsx:March2028NotesMember 2023-12-31 0000885725 bsx:March2028NotesMember 2022-12-31 0000885725 bsx:March2029NotesMember 2023-12-31 0000885725 bsx:March2029NotesMember 2022-12-31 0000885725 bsx:June2030NotesMember 2023-12-31 0000885725 bsx:June2030NotesMember 2022-12-31 0000885725 bsx:March2031NotesMember 2023-12-31 0000885725 bsx:March2031NotesMember 2022-12-31 0000885725 bsx:March2034NotesMember 2023-12-31 0000885725 bsx:March2034NotesMember 2022-12-31 0000885725 bsx:November2035NotesMember 2023-12-31 0000885725 bsx:November2035NotesMember 2022-12-31 0000885725 bsx:March2039NotesMember 2023-12-31 0000885725 bsx:March2039NotesMember 2022-12-31 0000885725 bsx:January2040NotesMember 2023-12-31 0000885725 bsx:January2040NotesMember 2022-12-31 0000885725 bsx:March2049NotesMember 2023-12-31 0000885725 bsx:March2049NotesMember 2022-12-31 0000885725 us-gaap:SeniorNotesMember 2023-12-31 0000885725 us-gaap:SeniorNotesMember 2022-12-31 0000885725 us-gaap:CapitalLeaseObligationsMember 2023-12-31 0000885725 us-gaap:CapitalLeaseObligationsMember 2022-12-31 0000885725 us-gaap:RevolvingCreditFacilityMember 2021-05-10 0000885725 bsx:RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember 2023-12-31 0000885725 bsx:ActualCovenantMember 2023-12-31 0000885725 bsx:RequirementAsOfMarch312021Member 2023-12-31 0000885725 bsx:RequirementFourQuartersFollowingMaterialAcquisitionMember 2023-12-31 0000885725 bsx:RequirementfifthquarterfollowingqualifiedacquisitionMember 2023-12-31 0000885725 bsx:RequirementSixthQuarterFollowingQualifiedAcquisitionMember 2023-12-31 0000885725 bsx:RequirementSeventhQuarterFollowingQualifiedAcquisitionMember 2023-12-31 0000885725 bsx:RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember 2023-12-31 0000885725 bsx:TheOfferingAggregatePrincipalAmountMember 2023-12-31 0000885725 bsx:March2025NotesMember 2023-12-31 0000885725 bsx:TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember 2023-12-31 0000885725 2022-01-01 2022-03-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2023-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2023-01-01 2023-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2022-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2022-01-01 2022-12-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2023-12-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2023-01-01 2023-12-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2022-12-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2022-01-01 2022-12-31 0000885725 bsx:RenminbiDenominatedFactoringArrangementsMember 2023-12-31 0000885725 bsx:RenminbiDenominatedFactoringArrangementsMember 2023-01-01 2023-12-31 0000885725 bsx:RenminbiDenominatedFactoringArrangementsMember 2022-12-31 0000885725 bsx:RenminbiDenominatedFactoringArrangementsMember 2022-01-01 2022-12-31 0000885725 srt:MinimumMember 2023-12-31 0000885725 srt:MaximumMember 2023-12-31 0000885725 srt:MaximumMember 2023-01-01 2023-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2023-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2022-12-31 0000885725 bsx:DeferredTaxAssetsMember 2023-12-31 0000885725 bsx:DeferredTaxAssetsMember 2022-12-31 0000885725 bsx:DeferredTaxLiabilitiesMember 2023-12-31 0000885725 bsx:DeferredTaxLiabilitiesMember 2022-12-31 0000885725 2023-01-31 2023-01-31 0000885725 bsx:A550MCPSSeriesAMember 2020-05-27 0000885725 bsx:A550MCPSSeriesAMember 2020-05-27 2020-05-27 0000885725 srt:MinimumMember bsx:A550MCPSSeriesAMember 2023-01-01 2023-12-31 0000885725 2023-06-01 2023-06-01 0000885725 bsx:A550MCPSSeriesAMember 2023-01-01 2023-12-31 0000885725 2020-12-14 0000885725 bsx:A2011LtipPlanMember 2020-10-01 0000885725 us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0000885725 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0000885725 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0000885725 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0000885725 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0000885725 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0000885725 srt:MinimumMember 2023-01-01 2023-12-31 0000885725 srt:MinimumMember 2022-01-01 2022-12-31 0000885725 srt:MaximumMember 2022-01-01 2022-12-31 0000885725 srt:MinimumMember 2021-01-01 2021-12-31 0000885725 srt:MaximumMember 2021-01-01 2021-12-31 0000885725 2021-02-17 0000885725 2020-02-18 0000885725 2019-02-21 0000885725 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0000885725 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000885725 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000885725 bsx:A550MCPSSeriesAMember 2023-01-01 2023-12-31 0000885725 bsx:A550MCPSSeriesAMember 2022-01-01 2022-12-31 0000885725 bsx:A550MCPSSeriesAMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:MedsurgMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:MedsurgMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:MedsurgMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:CardiovascularMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:CardiovascularMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:CardiovascularMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember 2021-01-01 2021-12-31 0000885725 bsx:OtherMember 2023-01-01 2023-12-31 0000885725 bsx:OtherMember 2022-01-01 2022-12-31 0000885725 bsx:OtherMember 2021-01-01 2021-12-31 0000885725 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-12-31 0000885725 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-12-31 0000885725 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:MedsurgMember 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:MedsurgMember 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:CardiovascularMember 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:CardiovascularMember 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember 2022-12-31 0000885725 us-gaap:CorporateNonSegmentMember 2023-12-31 0000885725 us-gaap:CorporateNonSegmentMember 2022-12-31 0000885725 country:US 2023-12-31 0000885725 country:US 2022-12-31 0000885725 country:IE 2023-12-31 0000885725 country:IE 2022-12-31 0000885725 country:CR 2023-12-31 0000885725 country:CR 2022-12-31 0000885725 bsx:OtherCountriesMember 2023-12-31 0000885725 bsx:OtherCountriesMember 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalEndoscopyEndoReportingUnitMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalEndoscopyEndoReportingUnitMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalEndoscopyEndoReportingUnitMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalNeuromodulationNmReportingUnitMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalNeuromodulationNmReportingUnitMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalNeuromodulationNmReportingUnitMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember country:US bsx:MedsurgMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bsx:MedsurgMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember country:US bsx:MedsurgMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bsx:MedsurgMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember country:US bsx:MedsurgMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bsx:MedsurgMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:InterventionalCardiologyTherapiesMember country:US 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:InterventionalCardiologyTherapiesMember us-gaap:NonUsMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:InterventionalCardiologyTherapiesMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:InterventionalCardiologyTherapiesMember country:US 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:InterventionalCardiologyTherapiesMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:InterventionalCardiologyTherapiesMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:InterventionalCardiologyTherapiesMember country:US 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:InterventionalCardiologyTherapiesMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:InterventionalCardiologyTherapiesMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:WatchmanMember country:US 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:WatchmanMember us-gaap:NonUsMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:WatchmanMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:WatchmanMember country:US 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:WatchmanMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:WatchmanMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:WatchmanMember country:US 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:WatchmanMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:WatchmanMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:CardiacRhythmManagementMember country:US 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:CardiacRhythmManagementMember us-gaap:NonUsMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:CardiacRhythmManagementMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:CardiacRhythmManagementMember country:US 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:CardiacRhythmManagementMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:CardiacRhythmManagementMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:CardiacRhythmManagementMember country:US 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:CardiacRhythmManagementMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:CardiacRhythmManagementMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:ElectrophysiologyEPMember country:US 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:ElectrophysiologyEPMember us-gaap:NonUsMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:ElectrophysiologyEPMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:ElectrophysiologyEPMember country:US 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:ElectrophysiologyEPMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:ElectrophysiologyEPMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:ElectrophysiologyEPMember country:US 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:ElectrophysiologyEPMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:ElectrophysiologyEPMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalCardiologyReportingUnitMember country:US 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalCardiologyReportingUnitMember us-gaap:NonUsMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalCardiologyReportingUnitMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalCardiologyReportingUnitMember country:US 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalCardiologyReportingUnitMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalCardiologyReportingUnitMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalCardiologyReportingUnitMember country:US 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalCardiologyReportingUnitMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalCardiologyReportingUnitMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember country:US bsx:CardiovascularMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bsx:CardiovascularMember 2023-01-01 2023-12-31 0000885725 us-gaap:OperatingSegmentsMember country:US bsx:CardiovascularMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bsx:CardiovascularMember 2022-01-01 2022-12-31 0000885725 us-gaap:OperatingSegmentsMember country:US bsx:CardiovascularMember 2021-01-01 2021-12-31 0000885725 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bsx:CardiovascularMember 2021-01-01 2021-12-31 0000885725 bsx:OtherMember country:US 2023-01-01 2023-12-31 0000885725 bsx:OtherMember us-gaap:NonUsMember 2023-01-01 2023-12-31 0000885725 bsx:OtherMember country:US 2022-01-01 2022-12-31 0000885725 bsx:OtherMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 bsx:OtherMember country:US 2021-01-01 2021-12-31 0000885725 bsx:OtherMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 country:US 2023-01-01 2023-12-31 0000885725 us-gaap:NonUsMember 2023-01-01 2023-12-31 0000885725 country:US 2022-01-01 2022-12-31 0000885725 us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 country:US 2021-01-01 2021-12-31 0000885725 us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 bsx:USExcludingOtherNetSalesMember 2023-01-01 2023-12-31 0000885725 bsx:USExcludingOtherNetSalesMember 2022-01-01 2022-12-31 0000885725 bsx:USExcludingOtherNetSalesMember 2021-01-01 2021-12-31 0000885725 us-gaap:EMEAMember 2023-01-01 2023-12-31 0000885725 us-gaap:EMEAMember 2022-01-01 2022-12-31 0000885725 us-gaap:EMEAMember 2021-01-01 2021-12-31 0000885725 srt:AsiaPacificMember 2023-01-01 2023-12-31 0000885725 srt:AsiaPacificMember 2022-01-01 2022-12-31 0000885725 srt:AsiaPacificMember 2021-01-01 2021-12-31 0000885725 bsx:LatinAmericaandCanadaMember 2023-01-01 2023-12-31 0000885725 bsx:LatinAmericaandCanadaMember 2022-01-01 2022-12-31 0000885725 bsx:LatinAmericaandCanadaMember 2021-01-01 2021-12-31 0000885725 bsx:EmergingMarketsMember 2023-01-01 2023-12-31 0000885725 bsx:EmergingMarketsMember 2022-01-01 2022-12-31 0000885725 bsx:EmergingMarketsMember 2021-01-01 2021-12-31 0000885725 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000885725 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000885725 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000885725 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-12-31 0000885725 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-12-31 0000885725 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-12-31 0000885725 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000885725 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000885725 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0000885725 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000885725 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000885725 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000885725 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-12-31 0000885725 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-12-31 0000885725 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-12-31 0000885725 bsx:ExecutiveRetirementPlanMember 2023-12-31 0000885725 bsx:InternationalRetirementPlansMember 2023-12-31 0000885725 bsx:ExecutiveRetirementPlanMember 2022-12-31 0000885725 bsx:InternationalRetirementPlansMember 2022-12-31 0000885725 us-gaap:DomesticPlanMember 2023-12-31 0000885725 bsx:OtherInternationalPlansMember 2023-12-31 0000885725 us-gaap:DomesticPlanMember 2022-12-31 0000885725 bsx:OtherInternationalPlansMember 2022-12-31 0000885725 bsx:JohnBradleySorensonMember 2023-01-01 2023-12-31 0000885725 bsx:JohnBradleySorensonMember 2023-10-01 2023-12-31 0000885725 bsx:JohnBradleySorensonMember bsx:JohnBradleySorensonRuleTradingArrangementCommonStockMember 2023-12-31 0000885725 bsx:WendyCarruthersMember 2023-01-01 2023-12-31 0000885725 bsx:WendyCarruthersMember 2023-10-01 2023-12-31 0000885725 bsx:WendyCarruthersMember bsx:WendyCarruthersRuleTradingArrangementCommonStockMember 2023-12-31 0000885725 bsx:WendyCarruthersMember bsx:WendyCarruthersRuleTradingArrangementStockOptionsMember 2023-12-31 0000885725 bsx:ArthurButcherMember 2023-01-01 2023-12-31 0000885725 bsx:ArthurButcherMember 2023-10-01 2023-12-31 0000885725 bsx:ArthurButcherMember bsx:WendyCarruthersRuleTradingArrangementCommonStockMember 2023-12-31 0000885725 bsx:ArthurButcherMember bsx:ArthurButcherRuleTradingArrangementPSUAndRSUMember 2023-12-31 0000885725 bsx:ArthurButcherMember bsx:ArthurButcherRuleTradingArrangementStockOptionsMember 2023-12-31 0000885725 2018-01-01 2018-12-31 iso4217:USD iso4217:USD shares shares pure iso4217:HKD iso4217:EUR bsx:units utr:Rate bsx:Unit bsx:reportablesegments 0000885725 2023 FY false P3Y P7Y P2Y P5Y P1Y http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#AccountsPayableCurrent http://fasb.org/us-gaap/2023#AccountsPayableCurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent P421D P436D P421D 10-K true 2023-12-31 --12-31 false 1-11083 BOSTON SCIENTIFIC CORPORATION DE 04-2695240 300 Boston Scientific Way Marlborough MA 01752-1234 508 683-4000 Common Stock, $0.01 par value BSX NYSE 0.625% Senior Notes due 2027 BSX27 NYSE Yes No Yes Yes Large Accelerated Filer false false true false false 79000000000 0.01 1467095627 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Documents Incorporated by Reference</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant’s definitive proxy statement to be filed within 120 days of December 31, 2023 with the Securities and Exchange Commission in connection with its 2024 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K.</span></div> Ernst & Young LLP Boston, Massachusetts 14240000000 12682000000 11888000000 4345000000 3956000000 3711000000 9896000000 8727000000 8177000000 5190000000 4520000000 4359000000 1414000000 1323000000 1204000000 46000000 47000000 49000000 828000000 803000000 741000000 58000000 132000000 370000000 58000000 35000000 -136000000 69000000 24000000 40000000 -111000000 173000000 430000000 0 -22000000 78000000 7553000000 7078000000 6978000000 2343000000 1649000000 1199000000 265000000 470000000 341000000 -93000000 -38000000 218000000 1985000000 1141000000 1076000000 393000000 443000000 36000000 1592000000 698000000 1041000000 23000000 55000000 55000000 1000000 0 0 1570000000 642000000 985000000 1.08 0.45 0.69 1.07 0.45 0.69 1453000000 1430500000 1422300000 1463500000 1439700000 1433800000 1592000000 698000000 1041000000 -105000000 -94000000 -125000000 -115000000 63000000 170000000 9000000 -37000000 -11000000 -230000000 6000000 56000000 1362000000 704000000 1096000000 -11000000 0 0 1373000000 704000000 1096000000 865000000 928000000 2228000000 1970000000 2484000000 1867000000 315000000 264000000 621000000 731000000 6514000000 5760000000 2859000000 2446000000 14387000000 12920000000 6003000000 5902000000 3841000000 3942000000 1531000000 1500000000 35136000000 32469000000 531000000 20000000 942000000 862000000 2646000000 2160000000 814000000 761000000 4933000000 3803000000 8571000000 8915000000 134000000 144000000 1967000000 2035000000 0.01 0.01 50000000 50000000 0 10062500 0 0 0.01 0.01 2000000000 2000000000 1729000224 1696633993 17000000 17000000 263289848 263289848 2251000000 2251000000 20647000000 20289000000 819000000 -750000000 49000000 269000000 19282000000 17573000000 248000000 0 19530000000 17573000000 35136000000 32469000000 10062500 10062500 10062500 -10062500 0 0 0 10062500 10062500 1696633993 1688810052 1679911918 8383329 7823941 8898134 23982902 0 0 1729000224 1696633993 1688810052 0 0 0 0 0 0 0 0 0 17000000 17000000 17000000 0 0 0 0 0 0 17000000 17000000 17000000 -2251000000 -2251000000 -2251000000 0 0 0 -2251000000 -2251000000 -2251000000 20289000000 19986000000 19732000000 0 0 0 359000000 303000000 254000000 20647000000 20289000000 19986000000 -750000000 -1392000000 -2378000000 1592000000 698000000 1041000000 1000000 0 0 23000000 55000000 55000000 819000000 -750000000 -1392000000 269000000 263000000 207000000 -95000000 -94000000 -125000000 -115000000 63000000 170000000 9000000 -37000000 -11000000 49000000 269000000 263000000 19282000000 17573000000 16622000000 0 0 0 259000000 0 0 -1000000 0 0 -10000000 0 0 248000000 0 0 19530000000 17573000000 16622000000 1592000000 698000000 1041000000 0 -22000000 78000000 1196000000 1136000000 1093000000 -1000000 -63000000 -124000000 233000000 220000000 194000000 58000000 132000000 370000000 -59000000 -1000000 250000000 58000000 35000000 -136000000 6000000 32000000 34000000 0 -194000000 0 73000000 125000000 78000000 238000000 220000000 279000000 660000000 321000000 346000000 -10000000 209000000 134000000 118000000 -255000000 408000000 2503000000 1526000000 1870000000 711000000 588000000 554000000 4000000 12000000 14000000 1811000000 1542000000 2258000000 89000000 24000000 -279000000 0 5000000 826000000 -30000000 -70000000 -82000000 -2000000 -56000000 -15000000 -2574000000 -2011000000 -1597000000 39000000 335000000 15000000 50000000 75000000 85000000 0 250000000 0 -4000000 -1000000 0 0 3184000000 0 0 3270000000 0 28000000 55000000 55000000 56000000 53000000 50000000 182000000 136000000 110000000 5000000 -548000000 -95000000 -4000000 -9000000 -6000000 -70000000 -1042000000 173000000 1126000000 2168000000 1995000000 1055000000 1126000000 2168000000 512000000 662000000 302000000 259000000 450000000 338000000 273000000 0 440000000 -30000000 -70000000 -82000000 865000000 928000000 1925000000 130000000 149000000 188000000 60000000 48000000 55000000 1055000000 1126000000 2168000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE A – SIGNIFICANT ACCOUNTING POLICIES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the accounts of Boston Scientific Corporation's wholly owned subsidiaries and entities for which we have a controlling financial interest. All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For any VIEs, we perform an analysis to determine whether our variable interests give us a controlling financial interest. The analysis identifies the primary beneficiary of a VIE as the enterprise that has both 1) the power to direct activities of a VIE that most significantly impact the entity’s economic performance and 2) the obligation to absorb losses of the entity or the right to receive benefits from the entity. Based on our assessments under the applicable guidance, we did not have controlling financial interests in any VIEs and, therefore, did not consolidate any VIEs during 2023, 2022 or 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and with the instructions to Form 10-K and Regulation S-X.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported in millions within this Annual Report on Form 10-K are computed based on the amounts in thousands. As a result, the sum of the components may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded numbers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Events</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B – Acquisitions and Strategic Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further details.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To prepare our consolidated financial statements in accordance with GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our consolidated financial statements and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Accounting Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for further discussion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider cash equivalents to be all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated balance sheets. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the customer payments collected by us for servicing previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our consolidated balance sheets. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our consolidated balance sheets are related to deferred compensation plans. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including distributors, hospitals, health care agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record credit loss reserves to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when we establish Trade accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach to determine the reserve to record at accounts receivable commencement for certain customers, applying country or region-specific factors. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We write-off amounts determined to be uncollectible against this reserve. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in 2023, 2022 and 2021; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups are important to our business and represent a substantial portion of our net sales. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other countries. Further, the ongoing site-of-service trend of shifting procedure volumes in the U.S. toward non-hospital settings, particularly ambulatory surgery centers and office-based labs, continues. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions, as appropriate. We believe our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is adequate as of December 31, 2023; however, if significant changes were to occur in the payment practices of government customers, or if there is an increase in bankruptcies among our ambulatory surgery center or office-based customers, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts may increase. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a contract with a customer that creates enforceable rights and obligations,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Promised products or services are identified,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The transaction price, or the amount we expect to receive, is determinable and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have transferred control of the promised items to the customer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our accompanying consolidated balance sheets. Our contract liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. Our contract liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Implant Services</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide non-contractual services to customers, where necessary, to ensure the safe and effective use of certain implanted devices. Because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost. Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warranty Obligations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our CRM business, which include implantable defibrillator and pacemaker systems. These products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a liability equal to these estimated costs as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state inventories at the lower of first-in, first-out cost or net realizable value. We utilize a standard costing system, capitalizing variances between estimated and actual production costs during periods of normal production, and amortize to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over inventory turns. We expense manufacturing variances during periods of abnormal production, or less than 75 percent of manufacturing capacity. We did not record any abnormal production variances during the years ended December 31, 2023, 2022 or 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of 40 years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a <span style="-sec-ix-hidden:f-483">three</span> to <span style="-sec-ix-hidden:f-484">seven</span> year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Business Combinations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&amp;D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&amp;D, on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases where we acquire a company in which we previously held an equity stake, we attribute a portion of the purchase price to the previously-held equity interest, which is implied based on the total purchase consideration allocable to each of the shareholders, including Boston Scientific, according to priority of equity interests. We record a gain or loss in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equal to the difference between the implied fair value of our prior ownership and the book value immediately prior to the acquisition.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration net expense (benefit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-lived Intangibles and IPR&amp;D </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which are foundational to our ongoing operations, as well as IPR&amp;D intangible assets acquired in a business combination. Our IPR&amp;D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&amp;D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&amp;D intangible asset. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(FASB ASC Topic 350)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the income approach to determine the fair values of our IPR&amp;D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects’ stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C – Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information related to indefinite-lived intangibles, including IPR&amp;D.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization and Impairment of Intangible Assets </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, <span style="-sec-ix-hidden:f-488">two</span> to 20 years; amortizable technology-related and customer relationships, <span style="-sec-ix-hidden:f-490">five</span> to 25 years; other intangible assets, various. In addition, we classify internal use software as an intangible asset within our accompanying consolidated balance sheets and amortize over a <span style="-sec-ix-hidden:f-492">one</span> to 15 year useful life. Due to the operational nature of these assets, we record the amortization of our internal use software within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold; Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as appropriate within our accompanying consolidated statements of operations, and include in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> only that associated with intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C – Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information related to impairments of intangible assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill Valuation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances, utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2023 annual impairment assessment, we identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components into a single Rhythm Management reporting unit. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing annual impairment assessments, the qualitative approach is used for testing reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units are tested using the quantitative approach. When a quantitative test is performed, we typically use the income approach, specifically the Discounted Cash Flow method, to derive the fair value of each of our reporting units in preparing our goodwill impairment assessments. We historically selected this method as being the most meaningful in preparing our goodwill assessments because we believe the income approach most appropriately measures the fair value of our income producing assets. We make assumptions about the amount and timing of future expected cash flows, terminal value growth rates and appropriate discount rates. The amount and timing of future cash flows within our Discounted Cash Flow analysis is based on our most recent operational budgets, long range strategic plans and other estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Publicly Traded and Privately-Held Entities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For publicly-held equity securities for which we do not have the ability to exercise significant influence, we measure at fair value with changes in fair value recognized currently in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying consolidated statements of operations. For privately-held equity securities for which we do not have the ability to exercise significant influence, we apply the measurement alternative approach and measure these investments at cost minus impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We account for investments in entities for which we have the ability to exercise significant influence under the equity method if we hold 50 percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with FASB ASC Topic 323, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Method and Joint Ventures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing consolidated financial statements. Lastly, we have notes receivable from certain companies that we account for in accordance with FASB ASC Topic 320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Investments - Debt and Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B – Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details on our investment balances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investee’s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. For our investments for which we apply the measurement alternative, if the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. For our equity method investments, if we determine an impairment is other-than-temporary, we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains and losses and impairments associated with our investment portfolio are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our consolidated statements of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial condition and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We recognize interest and penalties related to income taxes as a component of income tax expense. As part of the Tax Cuts and Jobs Act (TCJA), we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and report it as part of continuing operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note H – Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal and Product Liability Costs </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities and product liability litigation. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation-related charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I – Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for discussion of our individual material legal proceedings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs Associated with Exit Activities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record employee termination costs in accordance with FASB ASC Topic 712</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Nonretirement and Postemployment Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FASB ASC Topic 420, Exit or Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (FASB ASC Topic 420). We record such costs into expense over the employee’s future service period, if any. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with FASB ASC Topic 420 and are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring net charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring net charges (credits) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$69 million in 2023, $24 million in 2022 and $40 million in 2021. The restructuring reserve balance as of December 31, 2023 and 2022 was $41 million and $10 million, respectively. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of products sold, Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our consolidated statements of operations. Impairment of right of use lease assets and lease termination costs directly related to our active restructuring initiatives are expensed in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (FASB ASC Topic 842) and included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Translation of Foreign Currency</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate. We show the net effect of these translation adjustments within our consolidated financial statements as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss), net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We translate revenues and expenses at the average exchange rates in effect during the year. For any significant foreign subsidiaries located in highly inflationary economies, we re-measure their financial statements as if the functional currency were the U.S. dollar. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency transaction gains and losses are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our consolidated statements of operations, net of losses and gains from any related derivative financial instruments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Derivatives and Hedging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(FASB ASC Topic 815), and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our consolidated financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note D – Hedging Activities and Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information on our hedging instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development (R&amp;D) costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Indefinite-lived Intangibles and IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for our policy regarding R&amp;D projects acquired in connection with our business combinations and asset purchases.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and with the instructions to Form 10-K and Regulation S-X.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported in millions within this Annual Report on Form 10-K are computed based on the amounts in thousands. As a result, the sum of the components may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded numbers.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Events</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B – Acquisitions and Strategic Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further details.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To prepare our consolidated financial statements in accordance with GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our consolidated financial statements and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Accounting Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for further discussion.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider cash equivalents to be all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated balance sheets. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the customer payments collected by us for servicing previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash Equivalents</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our consolidated balance sheets. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets </span>within our consolidated balance sheets are related to deferred compensation plans. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including distributors, hospitals, health care agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record credit loss reserves to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when we establish Trade accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach to determine the reserve to record at accounts receivable commencement for certain customers, applying country or region-specific factors. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We write-off amounts determined to be uncollectible against this reserve. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in 2023, 2022 and 2021; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups are important to our business and represent a substantial portion of our net sales. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other countries. Further, the ongoing site-of-service trend of shifting procedure volumes in the U.S. toward non-hospital settings, particularly ambulatory surgery centers and office-based labs, continues. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions, as appropriate. We believe our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span> is adequate as of December 31, 2023; however, if significant changes were to occur in the payment practices of government customers, or if there is an increase in bankruptcies among our ambulatory surgery center or office-based customers, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts may increase. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a contract with a customer that creates enforceable rights and obligations,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Promised products or services are identified,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The transaction price, or the amount we expect to receive, is determinable and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have transferred control of the promised items to the customer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our accompanying consolidated balance sheets. Our contract liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. Our contract liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Implant Services</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide non-contractual services to customers, where necessary, to ensure the safe and effective use of certain implanted devices. Because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost. Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warranty Obligations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our CRM business, which include implantable defibrillator and pacemaker systems. These products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a liability equal to these estimated costs as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state inventories at the lower of first-in, first-out cost or net realizable value. We utilize a standard costing system, capitalizing variances between estimated and actual production costs during periods of normal production, and amortize to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over inventory turns. We expense manufacturing variances during periods of abnormal production, or less than 75 percent of manufacturing capacity. We did not record any abnormal production variances during the years ended December 31, 2023, 2022 or 2021.</span></div>We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of 40 years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a <span style="-sec-ix-hidden:f-483">three</span> to <span style="-sec-ix-hidden:f-484">seven</span> year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.</span></div> P40Y <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Business Combinations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&amp;D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&amp;D, on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases where we acquire a company in which we previously held an equity stake, we attribute a portion of the purchase price to the previously-held equity interest, which is implied based on the total purchase consideration allocable to each of the shareholders, including Boston Scientific, according to priority of equity interests. We record a gain or loss in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equal to the difference between the implied fair value of our prior ownership and the book value immediately prior to the acquisition.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration net expense (benefit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-lived Intangibles and IPR&amp;D </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which are foundational to our ongoing operations, as well as IPR&amp;D intangible assets acquired in a business combination. Our IPR&amp;D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&amp;D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&amp;D intangible asset. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(FASB ASC Topic 350)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the income approach to determine the fair values of our IPR&amp;D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects’ stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C – Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information related to indefinite-lived intangibles, including IPR&amp;D.</span></div>For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization and Impairment of Intangible Assets </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, <span style="-sec-ix-hidden:f-488">two</span> to 20 years; amortizable technology-related and customer relationships, <span style="-sec-ix-hidden:f-490">five</span> to 25 years; other intangible assets, various. In addition, we classify internal use software as an intangible asset within our accompanying consolidated balance sheets and amortize over a <span style="-sec-ix-hidden:f-492">one</span> to 15 year useful life. Due to the operational nature of these assets, we record the amortization of our internal use software within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold; Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as appropriate within our accompanying consolidated statements of operations, and include in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> only that associated with intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C – Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information related to impairments of intangible assets.</span></div>For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent. P20Y P25Y P15Y <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill Valuation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances, utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2023 annual impairment assessment, we identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components into a single Rhythm Management reporting unit. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing annual impairment assessments, the qualitative approach is used for testing reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units are tested using the quantitative approach. When a quantitative test is performed, we typically use the income approach, specifically the Discounted Cash Flow method, to derive the fair value of each of our reporting units in preparing our goodwill impairment assessments. We historically selected this method as being the most meaningful in preparing our goodwill assessments because we believe the income approach most appropriately measures the fair value of our income producing assets. We make assumptions about the amount and timing of future expected cash flows, terminal value growth rates and appropriate discount rates. The amount and timing of future cash flows within our Discounted Cash Flow analysis is based on our most recent operational budgets, long range strategic plans and other estimates.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Publicly Traded and Privately-Held Entities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For publicly-held equity securities for which we do not have the ability to exercise significant influence, we measure at fair value with changes in fair value recognized currently in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying consolidated statements of operations. For privately-held equity securities for which we do not have the ability to exercise significant influence, we apply the measurement alternative approach and measure these investments at cost minus impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We account for investments in entities for which we have the ability to exercise significant influence under the equity method if we hold 50 percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with FASB ASC Topic 323, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Method and Joint Ventures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing consolidated financial statements. Lastly, we have notes receivable from certain companies that we account for in accordance with FASB ASC Topic 320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Investments - Debt and Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B – Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details on our investment balances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investee’s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. For our investments for which we apply the measurement alternative, if the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. For our equity method investments, if we determine an impairment is other-than-temporary, we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains and losses and impairments associated with our investment portfolio are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span>in our consolidated statements of operations. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial condition and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We recognize interest and penalties related to income taxes as a component of income tax expense. As part of the Tax Cuts and Jobs Act (TCJA), we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and report it as part of continuing operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note H – Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal and Product Liability Costs </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities and product liability litigation. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation-related charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I – Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for discussion of our individual material legal proceedings.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with FASB ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation-related net charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses </span>within our accompanying consolidated statements of operations. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs Associated with Exit Activities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record employee termination costs in accordance with FASB ASC Topic 712</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Nonretirement and Postemployment Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FASB ASC Topic 420, Exit or Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (FASB ASC Topic 420). We record such costs into expense over the employee’s future service period, if any. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with FASB ASC Topic 420 and are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring net charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring net charges (credits) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$69 million in 2023, $24 million in 2022 and $40 million in 2021. The restructuring reserve balance as of December 31, 2023 and 2022 was $41 million and $10 million, respectively. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of products sold, Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our consolidated statements of operations. Impairment of right of use lease assets and lease termination costs directly related to our active restructuring initiatives are expensed in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (FASB ASC Topic 842) and included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span> in our consolidated statements of operations. 69000000 24000000 40000000 41000000 10000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Translation of Foreign Currency</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate. We show the net effect of these translation adjustments within our consolidated financial statements as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss), net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We translate revenues and expenses at the average exchange rates in effect during the year. For any significant foreign subsidiaries located in highly inflationary economies, we re-measure their financial statements as if the functional currency were the U.S. dollar. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency transaction gains and losses are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span>in our consolidated statements of operations, net of losses and gains from any related derivative financial instruments. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Derivatives and Hedging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(FASB ASC Topic 815), and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our consolidated financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note D – Hedging Activities and Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information on our hedging instruments.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development (R&amp;D) costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Indefinite-lived Intangibles and IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for our policy regarding R&amp;D projects acquired in connection with our business combinations and asset purchases.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our consolidated financial statements. Further, transaction costs were immaterial to our consolidated financial statements and were expensed as incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2024, we announced our entry into a definitive agreement to acquire 100 percent of Axonics, Inc. (Axonics), a publicly traded medical technology company primarily focused on the development and commercialization of devices to treat urinary and bowel dysfunction.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price is $71.00 in cash per share, or approximately $3.670 billion. The transaction is expected to close in the first half of 2024, subject to customary closing conditions. The Axonics business will be integrated into our Urology division.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 Acquisitions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2023, we completed the acquisition of a majority stake investment in Acotec, a publicly traded Chinese manufacturer of drug-coated balloons and other products used in the treatment of vascular and other diseases. We consolidated this majority stake investment in Acotec based on the conclusion we control the entity, and recorded a noncontrolling interest for the portion we do not own. We acquired approximately 65 percent of the outstanding shares of Acotec, for an upfront cash payment of HK$20.00 per share, or $519 million at foreign currency exchange rates at closing. The Acotec portfolio complements our existing Peripheral Interventions portfolio.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 4, 2023, we completed our acquisition of 100 percent of the outstanding equity of Apollo Endosurgery, Inc. (Apollo), a public company which offers a portfolio of devices used during endoluminal procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity. The transaction consisted of an upfront cash payment of $636 million, net of cash acquired. The Apollo business is being integrated into our Endoscopy division.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2023, we completed our acquisition of 100 percent of the outstanding equity of Relievant Medsystems, Inc. (Relievant), a privately held medical technology company that developed and commercialized the Intracept® Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain. The transaction consisted of an upfront cash payment of $794 million, net of cash acquired, and additional sales-based milestones over the 3 years following the transaction close. These milestones, certain of which are uncapped, are estimated to have a fair value of $273 million. The Relievant business is being integrated into our Neuromodulation division. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We accounted for these transactions as business combinations in accordance with FASB ASC Topic 805</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">, Business Combinations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(FASB ASC Topic 805). The preliminary purchase prices were comprised of the amounts presented below: </span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.082%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acotec</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Apollo</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Relievant</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for acquisition, net of cash acquired </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">636</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,067</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Excludes approximately $140 million of cash on hand at the closing of the transaction</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Related to Acotec, represents our majority stake investment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recorded the assets acquired, liabilities assumed and specific to Acotec, the noncontrolling interest, at their respective fair values as of the closing date of the transaction. The preliminary purchase price allocations were comprised of the components presented below, which represent the preliminary determination of the fair value of identifiable assets acquired and liabilities assumed, as well as goodwill. The final determination of the fair value of certain assets and liabilities will be completed within the measurement period in accordance with FASB ASC Topic 805: </span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acotec</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Apollo</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Relievant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">636</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,067</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Acotec's noncontrolling interest was based on the publicly traded market value of the remaining 35 percent of the outstanding shares we did not acquire as of the transaction date and is presented within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Stockholders' equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying consolidated balance sheets. Goodwill was primarily established for Acotec due to opportunities for collaboration in research and development, manufacturing and commercial strategies, and for Apollo and Relievant, due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies, none of which is deductible for tax purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated a portion of the purchase price to the specific intangible asset categories as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Assigned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Adjusted Discount <br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Acotec:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">334</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Apollo:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">248</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Relievant</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">325</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Acquisition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2022, we completed our acquisition of Baylis Medical Company Inc. (Baylis Medical), a privately-held company which developed the radiofrequency (RF) NRG™ and VersaCross™ Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access, which expanded our electrophysiology and structural heart product portfolios. The transaction consisted of an upfront cash payment of $1.463 billion, net of cash acquired, subject to closing adjustments. We are integrating Baylis Medical into our Cardiology division.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the acquisition of Baylis Medical as a business combination in accordance with FASB ASC Topic 805. The final purchase price was comprised of the amount presented below: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for acquisition, net of cash acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,463</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The final purchase price allocation was comprised of the following components:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.789%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,463</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies, and was deductible for tax purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated a portion of the purchase price to the specific intangible asset categories as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Assigned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Adjusted Discount <br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">657</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes and will carry forward from one product generation to the next. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contingent Consideration</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our contingent consideration liability during 2023 and 2022 associated with current and prior period acquisitions were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">486</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration net expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount recorded related to current year acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration net expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">404</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, payments were primarily related to our acquisition of Farapulse, Inc. (Farapulse) following the achievement of revenue milestones. In 2022, payments were primarily related to our acquisition of Farapulse and Preventice Solutions, Inc., following the achievement of revenue and/or regulatory milestones. The net expense of $58 million and $35 million recorded in 2023 and 2022, respectively, related primarily to an increase in expected revenue-based payments as a result of over-achievement of net sales performance, primarily related to our acquisition of Farapulse. In both periods, this increase was partially offset by a reduction in the contingent consideration liability for certain acquisitions for which we reduced the probability of achievement of associated regulatory and commercialization-based milestones upon which payment is conditioned. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum amount for certain contingent consideration is not determinable as it is uncapped and based on a percent of certain sales. As of December 31, 2023, the fair value of such uncapped contingent consideration is estimated at $177 million. As of December 31, 2023, the maximum amount that we could be required to pay under our other contingent consideration arrangements (undiscounted) is approximately $398 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:19.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue-based Payments and Milestones</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$404 million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projected contingent payment amounts related to our revenue-based payments and milestones are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Strategic Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate carrying amount of our strategic investments was comprised of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement alternative investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1, 2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">413</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">407</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our accompanying consolidated statements of operations.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes publicly-held equity securities and convertible notes measured at fair value with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These investments are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated balance sheets, in accordance with GAAP and our accounting policies.</span></div>In 2023, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $261 million, which represents amortizable intangible assets, IPR&amp;D, goodwill and deferred tax liabilities. 1 71.00 3670000000 0.65 20.00 519000000 1 636000000 1 794000000 273000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We accounted for these transactions as business combinations in accordance with FASB ASC Topic 805</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">, Business Combinations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(FASB ASC Topic 805). The preliminary purchase prices were comprised of the amounts presented below: </span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.082%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acotec</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Apollo</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Relievant</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for acquisition, net of cash acquired </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">636</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,067</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Excludes approximately $140 million of cash on hand at the closing of the transaction</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Related to Acotec, represents our majority stake investment</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the acquisition of Baylis Medical as a business combination in accordance with FASB ASC Topic 805. The final purchase price was comprised of the amount presented below: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for acquisition, net of cash acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,463</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 381000000 636000000 794000000 0 0 273000000 381000000 636000000 1067000000 140000000 The preliminary purchase price allocations were comprised of the components presented below, which represent the preliminary determination of the fair value of identifiable assets acquired and liabilities assumed, as well as goodwill. The final determination of the fair value of certain assets and liabilities will be completed within the measurement period in accordance with FASB ASC Topic 805: <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acotec</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Apollo</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Relievant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">636</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,067</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The final purchase price allocation was comprised of the following components:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.789%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,463</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div> 337000000 378000000 731000000 334000000 248000000 325000000 93000000 50000000 24000000 48000000 33000000 15000000 -76000000 -5000000 1000000 259000000 0 0 381000000 636000000 1067000000 0.35 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated a portion of the purchase price to the specific intangible asset categories as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Assigned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Adjusted Discount <br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Acotec:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">334</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Apollo:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">248</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Relievant</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">325</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated a portion of the purchase price to the specific intangible asset categories as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Assigned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Adjusted Discount <br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">657</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 308000000 P11Y 0.14 15000000 P11Y 0.14 11000000 P13Y 0.14 334000000 222000000 P11Y 0.12 26000000 P11Y 0.12 248000000 287000000 P12Y 0.12 38000000 P12Y 0.12 325000000 1463000000 1463000000 1463000000 1463000000 988000000 657000000 112000000 287000000 -7000000 1463000000 622000000 P11Y 0.11 36000000 P11Y 0.11 657000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our contingent consideration liability during 2023 and 2022 associated with current and prior period acquisitions were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">486</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration net expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount recorded related to current year acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration net expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">404</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 486000000 35000000 371000000 149000000 273000000 58000000 76000000 404000000 58000000 35000000 177000000 398000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:19.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue-based Payments and Milestones</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$404 million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div> 404000000 0.06 0.12 0.10 0.90 1 0.98 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate carrying amount of our strategic investments was comprised of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement alternative investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1, 2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">413</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">407</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our accompanying consolidated statements of operations.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes publicly-held equity securities and convertible notes measured at fair value with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our consolidated statements of operations.</span></div> 219000000 188000000 194000000 219000000 413000000 407000000 261000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:29.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization/<br/>Write-offs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization/<br/>Write-offs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,207 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,101)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,378)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(387)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,817</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,988)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,843</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,173)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">174</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The increase in our balance of goodwill and amortizable intangible assets is related primarily to our majority stake investment in Acotec completed in the first quarter of 2023 and our acquisitions of Apollo and Relievant completed during the second and fourth quarters of 2023, respectively.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible asset impairment charges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $58 million in 2023, $132 million in 2022 and $370 million in 2021. The impairment charges recorded in 2023 were primarily associated with the cancellation of an IPR&amp;D program due to the incremental time and cost to complete the program and bring the technology to market. The impairment charges recorded in 2022 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of Vertiflex, Inc., which is now part of our Neuromodulation business, resulting from lower revenue projections due to reimbursement challenges. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a rollforward of our goodwill balance by reportable segment:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:51.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,741</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,988</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency fluctuations and other changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,684</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,920</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,447 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency fluctuations and other changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,347</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,041</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2023, we performed our annual goodwill impairment test utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350. The qualitative approach was used for testing reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units were tested using the quantitative approach. We determined that the fair value of each reporting unit exceeded its carrying value and concluded that goodwill was not impaired or at risk of impairment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note A – Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further discussion of our goodwill and intangible asset impairment testing.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio, consisting of intangible assets acquired in a business combination or asset acquisition, as well as internally developed patents, as of December 31, 2023 is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These estimates do not include amortization expense associated with future acquisitions that have been announced but not yet completed as of December 31, 2023.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:29.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization/<br/>Write-offs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization/<br/>Write-offs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,207 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,101)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,378)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(387)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,817</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,988)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,843</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,173)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">174</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div> 13207000000 8101000000 12397000000 7378000000 480000000 387000000 486000000 394000000 2130000000 1500000000 1960000000 1400000000 15817000000 9988000000 14843000000 9173000000 24287000000 9900000000 22820000000 9900000000 54000000 112000000 120000000 120000000 174000000 232000000 58000000 132000000 370000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a rollforward of our goodwill balance by reportable segment:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:51.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,741</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,988</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency fluctuations and other changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,684</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,920</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,447 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency fluctuations and other changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,347</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,041</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4246000000 7741000000 11988000000 0 1030000000 1030000000 -10000000 -88000000 -98000000 4237000000 8684000000 12920000000 1110000000 337000000 1447000000 0 20000000 20000000 5347000000 9041000000 14387000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio, consisting of intangible assets acquired in a business combination or asset acquisition, as well as internally developed patents, as of December 31, 2023 is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 828000000 757000000 737000000 714000000 690000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Currency Hedging Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Management Strategy</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities; forecasted intercompany and third-party transactions; and net investments in certain subsidiaries. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in euro, Chinese renminbi, Japanese yen, British pound sterling, Australian dollar, Swiss franc and South Korean won. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecasted. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hedge Designations and Relationships</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net change in derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income (loss), net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (OCI) within our consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other comprehensive income (loss), net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (AOCI) to earnings at that time. The cash flows related to the derivative instruments designated as cash flow hedges are reported as operating activities in our consolidated statements of cash flows.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Japanese yen and Taiwan dollar. For these derivative instruments, we elected to use the spot method to assess hedge effectiveness. We also elected to exclude the spot-forward difference, referred to as the excluded component, from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. As such, we defer recognition of foreign currency gains and losses within the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Foreign currency translation adjustment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(CTA) component of OCI, and we reclassify amortization of the excluded component from AOCI to current period earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro. As of December 31, 2023 and 2022, we designated as a net investment hedge our €900 million in aggregate principal amount of 0.625% senior notes issued in November 2019 and due in 2027 (2027 Notes). For these nonderivative instruments, we defer recognition of the foreign currency remeasurement gains and losses within the CTA component of OCI. We reclassify these gains and losses to current period earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also use forward currency contracts that are not part of designated hedging relationships as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Rate Hedging Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Management Strategy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hedge Designations and Relationships</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no interest rate derivative instruments designated as cash flow hedges outstanding as of December 31, 2023 and December 31, 2022. In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within OCI until the underlying hedged transaction occurs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no interest rate derivative instruments designated as fair value hedges outstanding as of December 31, 2023 and December 31, 2022. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which generally offset. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the contractual amounts of our hedging instruments outstanding:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.196%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.497%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Notional Outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,896</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,321</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining time to maturity as of December 31, 2023 is within 36 months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature between one and two years. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying consolidated statements of operations. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note O – Changes in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the total amounts relating to derivative and nonderivative instruments presented within our consolidated statements of comprehensive income (loss).</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Reclassified from AOCI into Earnings</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pre-Tax Gain (Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (Loss) Net of Tax</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of Amount Reclassified and Total Amount of Line Item</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pre-Tax (Gain) Loss</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax (Benefit) Expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Gain) Loss Net of Tax</span></td></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to earnings as a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:30.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Designated Hedging Instrument</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.035%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency transaction exposures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net currency exchange gain (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(41)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB ASC Topic 820), and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.559%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.497%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Balance Sheets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recurring Fair Value Measurements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis consist of the following:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:31.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Publicly-held securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">816</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">674</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-864">Hedging instruments</span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">494</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,545</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">308</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,313</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in money market funds and time deposits are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying consolidated balance sheets, in accordance with GAAP and our accounting policies. In addition to $454 million invested in money market funds and time deposits as of December 31, 2023 and $673 million as of December 31, 2022, we held $411 million in interest-bearing and non-interest-bearing bank accounts as of December 31, 2023 and $256 million as of December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our recurring fair value measurements using Level 3 inputs include those related to our contingent consideration liability. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B – Acquisitions and Strategic Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a discussion of the changes in the fair value of our contingent consideration liability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our recurring fair value measurements using Level 3 inputs related to our licensing arrangements, including the contractual right to receive future royalty payments related to the Zytiga™ Drug. We own the contractual right to receive 50 percent of the future Zytiga Drug royalty payments from the licensee and remit such payments to the inventors associated with the intellectual property. We recognized a financial asset and associated liability for our licensing arrangements at fair value in our consolidated balance sheets using the fair value option in accordance with FASB ASC Topic 825, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the fair value option to measure the financial asset and associated liability as it provides for consistency and comparability of these financial instruments with others. Royalty payments we receive reduce the fair value of the financial asset and are presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceeds from royalty rights,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and payments we remit to inventors reduce the fair value of the financial liability and are presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payments for royalty rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of cash flows. We sold our right to receive and retain the other 50 percent of the future royalty payments in 2019 for an upfront cash payment, which we accounted for as a secured borrowing in accordance with FASB ASC Topic 860, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transfers and Servicing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(FASB ASC Topic 860). Although we sold these rights, we continue to recognize at fair value the future royalty payments as a financial asset and associated liability. Royalty payments associated with the rights we sold no longer impact our cash flows, and we present this activity as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-cash impact of transferred royalty rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the supplemental information to our consolidated statements of cash flows. We reduce the fair value of the financial asset and associated liability when such non-cash activity occurs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record the fair value of the financial asset and associated liability using a discounted cash flow approach considering the probability-weighted expected future cash flows to be generated by the royalty stream. The fair value of the financial liability also considers the related contractual provisions that govern our payment obligations. Significant increases or decreases in projected cash flows of the royalty stream and the related contractual provisions that govern our payment obligations, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement of the licensing arrangements' financial asset and liability as of December 31, 2023. However, increases or decreases in the financial asset would be offset by increases or decreases in the financial liability, other than for timing of receipt and remittance; as such our earnings are not subject to material gains and losses from the licensing arrangement. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our licensing arrangements recognized in our consolidated balance sheets as of December 31, 2023 include the following significant unobservable inputs:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:19.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Licensing Arrangements</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Asset</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$77 million</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liability</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$90 million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#bfe4ff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial asset were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from royalty rights</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment (expense) benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial liability were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for royalty rights</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B – Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of our strategic investments and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C – Goodwill and Other Intangible Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a discussion of the fair values of our intangible assets including goodwill.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our outstanding debt obligations, excluding finance leases, was $8.735 billion as of December 31, 2023 and $8.203 billion as of December 31, 2022. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note E – Contractual Obligations and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of our debt obligations.</span></div> 900000000 0.00625 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the contractual amounts of our hedging instruments outstanding:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.196%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.497%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Notional Outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,896</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,321</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge.</span></div> 2284000000 2725000000 333000000 365000000 997000000 997000000 3282000000 4235000000 6896000000 8321000000 900000000 36 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying consolidated statements of operations. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note O – Changes in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the total amounts relating to derivative and nonderivative instruments presented within our consolidated statements of comprehensive income (loss).</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Reclassified from AOCI into Earnings</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pre-Tax Gain (Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (Loss) Net of Tax</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of Amount Reclassified and Total Amount of Line Item</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pre-Tax (Gain) Loss</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax (Benefit) Expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Gain) Loss Net of Tax</span></td></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to earnings as a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.</span></div> -81000000 18000000 -63000000 4345000000 235000000 53000000 -182000000 32000000 -7000000 25000000 265000000 -10000000 2000000 8000000 -34000000 8000000 -27000000 93000000 0 0 0 0 0 0 265000000 -3000000 -1000000 2000000 -276000000 62000000 -214000000 3956000000 209000000 47000000 -162000000 41000000 -10000000 32000000 470000000 -10000000 2000000 8000000 61000000 -14000000 47000000 38000000 0 0 0 0 0 0 470000000 -16000000 -4000000 13000000 -268000000 60000000 -208000000 3711000000 54000000 12000000 -42000000 56000000 -13000000 43000000 341000000 -13000000 3000000 10000000 82000000 -19000000 64000000 -218000000 0 0 0 0 0 0 341000000 -5000000 -1000000 4000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:30.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Designated Hedging Instrument</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 152000000 9000000 -1000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.035%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency transaction exposures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net currency exchange gain (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(41)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3000000 -53000000 -16000000 -44000000 21000000 -12000000 -41000000 -31000000 -27000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures (</span>FASB ASC Topic 820), and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.559%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.497%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Balance Sheets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.</span></div> 140000000 196000000 107000000 149000000 246000000 345000000 20000000 36000000 266000000 381000000 15000000 0 9000000 1000000 988000000 952000000 1012000000 953000000 38000000 52000000 1050000000 1005000000 900000000 <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis consist of the following:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:31.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Publicly-held securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">816</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">674</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-864">Hedging instruments</span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">494</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,545</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">308</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,313</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our licensing arrangements recognized in our consolidated balance sheets as of December 31, 2023 include the following significant unobservable inputs:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:19.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Licensing Arrangements</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Asset</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$77 million</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liability</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$90 million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#bfe4ff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial asset were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from royalty rights</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment (expense) benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial liability were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for royalty rights</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 454000000 0 0 454000000 673000000 0 0 673000000 18000000 0 0 18000000 2000000 0 0 2000000 0 266000000 0 266000000 0 381000000 0 381000000 0 0 77000000 77000000 0 0 127000000 127000000 472000000 266000000 77000000 816000000 674000000 381000000 127000000 1182000000 0 1050000000 0 1050000000 0 1005000000 0 1005000000 0 0 404000000 404000000 0 0 149000000 149000000 0 0 90000000 90000000 0 0 159000000 159000000 0 1050000000 494000000 1545000000 0 1005000000 308000000 1313000000 454000000 673000000 411000000 256000000 77000000 0.15 0.15 90000000 0.12 0.15 0.13 246000000 141000000 22000000 127000000 61000000 11000000 77000000 281000000 145000000 23000000 159000000 80000000 12000000 90000000 8735000000 8203000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE E – CONTRACTUAL OBLIGATIONS AND COMMITMENTS </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Borrowings and Credit Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total debt outstanding of $9.102 billion as of December 31, 2023 and $8.935 billion as of December 31, 2022, with current maturities of $531 million as of December 31, 2023 and $20 million as of December 31, 2022. The debt maturity schedule for our long-term debt obligations is presented below: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.847%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Coupon Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except interest rates)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.450%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.900%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.750%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.625%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.375%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.650%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.625%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.875%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2005</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.500%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.550%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2009</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.375%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.700%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized Debt Issuance Discount and Deferred Financing Costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 - 2049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance Lease Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,571</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate of 6.25% if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of December 31, 2023 and 2022, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of our long-term debt outstanding as of December 31, 2023 are as follows (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in millions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,604 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revolving Credit Facility </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2021, we entered into a $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks, initially scheduled to mature on May 10, 2026, with one-year extension options, subject to certain conditions. On March 1, 2023, we entered into an amendment of the 2021 Revolving Credit Facility credit agreement, which provided for an extension of the scheduled maturity date to May 10, 2027 and replaced the London Interbank Offered Rate (LIBOR) with the Secured Overnight Financing Rate (SOFR) as the Eurocurrency Rate for Dollars, including applicable credit spread adjustments and relevant SOFR benchmark provisions, among other things described under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Covenant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">borrowing capacity under the 2021 Revolving Credit Facility. We had no amounts outstanding under the 2021 Revolving Credit Facility as of December 31, 2023 or December 31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Covenant</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Covenant Requirement<br/>as of December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Actual<br/>as of December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maximum permitted leverage ratio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75 times</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33 times</span></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Ratio of total debt to deemed consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), as defined by the 2021 Revolving Credit Facility credit agreement, as amended.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times for the remaining term. The agreement provides for higher leverage ratios, at our election, for the period following a qualified acquisition, for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. It steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have not elected to increase the maximum permitted leverage ratio for qualified acquisitions to date, due to our funding of these acquisitions using cash on hand or commercial paper.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial covenant requirement, as amended on March 1, 2023, provides for an exclusion from the calculation of consolidated EBITDA, as defined by the credit agreement, through maturity, of certain charges and expenses. The credit agreement amendment reset the starting date for purposes of calculating such permitted exclusions in each case from March 31, 2021 to December 31, 2022. Permitted exclusions include any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of December 31, 2023, we had $317 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreement, are excluded from the calculation of consolidated EBITDA, as defined by the agreement, provided that the sum of any excluded net cash litigation payments do not exceed $1.000 billion plus all accrued legal liabilities as of December 31, 2022. As of December 31, 2023, we had $1.484 billion of the litigation exclusion remaining.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to maintain compliance with this covenant could require us to seek to further renegotiate the terms of our credit arrangements or seek waivers from compliance with this covenant, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all 2021 Revolving Credit Facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our 2021 Revolving Credit Facility may negatively impact the credit ratings assigned to our commercial paper program, which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable</span><span style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Paper </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial paper program is backed by the 2021 Revolving Credit Facility. We did not have any commercial paper outstanding as of December 31, 2023 and 2022.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had senior notes outstanding of $9.136 billion as of December 31, 2023 and $8.986 billion as of December 31, 2022. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Other Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, American Medical Systems Europe B.V. (AMS Europe), an indirect, wholly owned subsidiary of Boston Scientific, completed a registered public offering (the Offering) of €3.000 billion in aggregate principal amount of euro-dominated senior notes comprised of €1.000 billion of 0.750% Senior Notes due 2025, €750 million of 1.375% Senior Notes due 2028, €750 million of 1.625% Senior Notes due 2031 and €500 million of 1.875% Senior Notes due 2034 (collectively, the Eurobonds). Boston Scientific has fully and unconditionally guaranteed all of AMS Europe's obligations under the Eurobonds, and no other subsidiary of Boston Scientific will guarantee these obligations. AMS Europe is a “finance subsidiary” as defined </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Rule 13-01(a)(4)(vi) of Regulation S-X. The financial condition, results of operations and cash flows of AMS Europe are consolidated in the financial statements of Boston Scientific. The Offering resulted in cash proceeds of $3.270 billion, net of investor discounts and issuance costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the net proceeds from the Offering to fund the tender offer and early redemption of combined aggregate principal amount of $3.275 billion of certain of our outstanding senior notes, as well as to pay accrued interest, tender premiums, fees and expenses. We recorded associated debt extinguishment net charges of $194 million during the first quarter of 2022 presented in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Arrangements </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accounts receivable factoring programs in certain European countries and with commercial banks in China and Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our accompanying consolidated balance sheets, are aggregated by contract denominated currency below (in millions): </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Factoring Arrangements</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Interest Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro denominated</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen denominated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renminbi denominated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Contractual Obligations and Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had outstanding letters of credit of $174 million as of December 31, 2023 and $135 million as of December 31, 2022, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of December 31, 2023 and December 31, 2022, we had not recognized a related liability for our outstanding letters of credit in our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, future minimum purchase obligations, relating primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business, were (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:76.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecorded Purchase Obligations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">951 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,615</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a supplier financing program offered primarily in the U.S. that enables our suppliers to opt to receive early payment at a nominal discount, while allowing us to lengthen our payment terms and optimize working capital. Our standard payment term in the U.S. is 90 days. All outstanding payables related to the supplier finance program are classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1039"><span style="-sec-ix-hidden:f-1040">Accounts Payable</span></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our unaudited consolidated balance sheets and were $152 million as of December 31, 2023 and $129 million as of December 31, 2022.</span></div> 9102000000 8935000000 531000000 20000000 The debt maturity schedule for our long-term debt obligations is presented below: <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.847%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Coupon Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except interest rates)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.450%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.900%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.750%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.625%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.375%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.650%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.625%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.875%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2005</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.500%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.550%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2009</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.375%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.700%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized Debt Issuance Discount and Deferred Financing Costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 - 2049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance Lease Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,571</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate of 6.25% if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of December 31, 2023 and 2022, respectively.</span></div> 0 504000000 0.03450 1105000000 1067000000 0.00750 500000000 500000000 0.01900 255000000 255000000 0.03750 995000000 960000000 0.00625 829000000 800000000 0.01375 344000000 344000000 0.04000 272000000 272000000 0.04000 1200000000 1200000000 0.02650 829000000 800000000 0.01625 553000000 534000000 0.01875 350000000 350000000 0.06500 450000000 450000000 0.04550 300000000 300000000 0.07375 650000000 650000000 0.04700 65000000 76000000 5000000 5000000 8571000000 8915000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of our long-term debt outstanding as of December 31, 2023 are as follows (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in millions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,604 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1605000000 255000000 995000000 1173000000 4604000000 2750000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Covenant Requirement<br/>as of December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Actual<br/>as of December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maximum permitted leverage ratio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75 times</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33 times</span></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Ratio of total debt to deemed consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), as defined by the 2021 Revolving Credit Facility credit agreement, as amended.</span></div> 3.75 2.33 3.75 1000000000 4.75 4.50 4.25 4.00 3.75 500000000 317000000 1000000000 1484000000 9136000000 8986000000 3000000000 1000000000 0.00750 750000000 0.01375 750000000 0.01625 500000000 0.01875 3270000000 3275000000 194000000 Amounts de-recognized for accounts and notes receivable, which are excluded from <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our accompanying consolidated balance sheets, are aggregated by contract denominated currency below (in millions): </span><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Factoring Arrangements</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Interest Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro denominated</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen denominated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renminbi denominated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 206000000 0.051 161000000 0.024 214000000 0.006 194000000 0.006 14000000 0.029 13000000 0.031 174000000 135000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, future minimum purchase obligations, relating primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business, were (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:76.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecorded Purchase Obligations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">951 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,615</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 951000000 283000000 155000000 45000000 31000000 150000000 1615000000 152000000 129000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE F – LEASES </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operating and finance leases for real estate including corporate offices, land, warehouse space, and vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that we are reasonably certain to exercise (short-term leases). We recognize lease expense on a straight-line basis over the lease term for short-term leases that we do not record on our balance sheet. If there is a change in our assessment of the lease term and, as a result, the remaining lease term extends more than 12 months from the end of the previously determined lease term, or we subsequently become reasonably certain that we will exercise an option to purchase the underlying asset, the lease no longer meets the definition of a short-term lease and is accounted for as either an operating or finance lease and recognized on the balance sheet. In accordance with FASB ASC Topic 842, we account for the lease components and the non-lease components as a single lease component, with the exception of our warehouse leases. Our leases have remaining lease terms of less than 1 year to approximately 53 years, some of which may include options to extend the leases for up to 10 years. If we are reasonably certain we will exercise an option to extend the lease, the time period covered by the extension option is included in the lease term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating lease right-of-use assets are presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and corresponding liabilities are presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note E – Contractual Obligations and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information regarding our finance leases. As of December 31, 2023, we have entered into two leases for additional office, warehouse and lab space which have not yet commenced. These facilities are currently under construction. We do not control the building during construction and are thus not deemed to be the owner during construction. Total estimated undiscounted future lease payments are approximately $500 million, which includes a buyout option exercisable once construction is complete which we are reasonably certain to exercise with respect to one of the leases. These leases will commence at the end of 2024 and second half of 2025 with noncancellable lease terms ranging from 20 to 25 years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table presents supplemental balance sheet information related to our operating leases:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="-sec-ix-hidden:f-1051"><span style="-sec-ix-hidden:f-1052"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term assets</span></span></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1056">76</span> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1057">61</span> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating lease cost under FASB ASC Topic 842 was $96 million in 2023, $91 million in 2022 and $90 million in 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information related to our operating leases:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for operating lease obligations were $123 million and $43 million for the years ended December 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the maturities of our operating lease liabilities as of December 31, 2023 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:76.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total future minimum operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">539</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">466</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> Excludes expected lease payments for lease terms that have not yet commenced.</span></div> P1Y P53Y P10Y 500000000 P20Y P25Y <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table presents supplemental balance sheet information related to our operating leases:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="-sec-ix-hidden:f-1051"><span style="-sec-ix-hidden:f-1052"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term assets</span></span></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1056">76</span> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1057">61</span> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 439000000 386000000 76000000 61000000 390000000 347000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3%</span></td></tr></table></div> P9Y P10Y 0.045 0.033 96000000 91000000 90000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information related to our operating leases:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 93000000 91000000 123000000 43000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the maturities of our operating lease liabilities as of December 31, 2023 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:76.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total future minimum operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">539</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">466</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> Excludes expected lease payments for lease terms that have not yet commenced.</span></div> 89000000 78000000 65000000 49000000 41000000 217000000 539000000 74000000 466000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE G – SUPPLEMENTAL BALANCE SHEET INFORMATION </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of selected captions in our accompanying consolidated balance sheets are as follows:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trade accounts receivable, net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,338 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,228</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,970</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inventories</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,867</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 22 percent of our finished goods inventory as of December 31, 2023 and approximately 27 percent as of December 31, 2022 was at customer locations pursuant to consignment arrangements or held by sales representatives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other current assets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">621</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">731</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property, plant and equipment, net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,843 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,728 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,859</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,446</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $367 million in 2023, $333 million in 2022 and $352 million in 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other long-term assets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnification asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,531</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accrued expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,646</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,160</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other current liabilities</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">814</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other long-term liabilities</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1194">390</span> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1197">347</span> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,967</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of selected captions in our accompanying consolidated balance sheets are as follows:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trade accounts receivable, net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,338 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,228</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,970</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2338000000 2079000000 110000000 109000000 2228000000 1970000000 109000000 108000000 105000000 50000000 35000000 28000000 48000000 35000000 25000000 110000000 109000000 108000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inventories</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,867</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1537000000 1171000000 174000000 147000000 773000000 548000000 2484000000 1867000000 0.22 0.27 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other current assets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">621</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">731</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 130000000 149000000 159000000 232000000 47000000 60000000 285000000 290000000 621000000 731000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property, plant and equipment, net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,843 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,728 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,859</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,446</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 140000000 137000000 1843000000 1695000000 3503000000 3297000000 857000000 598000000 6343000000 5728000000 3484000000 3282000000 2859000000 2446000000 367000000 333000000 352000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other long-term assets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnification asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,531</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 60000000 48000000 439000000 386000000 107000000 149000000 413000000 407000000 30000000 67000000 176000000 172000000 306000000 271000000 1531000000 1500000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accrued expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,646</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,160</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 206000000 231000000 1051000000 830000000 389000000 352000000 304000000 74000000 696000000 674000000 2646000000 2160000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other current liabilities</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">814</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 266000000 220000000 49000000 79000000 220000000 232000000 278000000 230000000 814000000 761000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other long-term liabilities</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1194">390</span> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1197">347</span> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,967</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 470000000 597000000 172000000 212000000 100000000 75000000 41000000 80000000 390000000 347000000 311000000 289000000 484000000 434000000 1967000000 2035000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE H – INCOME TAXES </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income (loss) before income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:58.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,119)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(648)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,985</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The related expense (benefit) for income taxes consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:58.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">393</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">443</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes at the federal statutory rate to the actual expense (benefit) for income taxes is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic taxes on foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:70.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.729%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.732%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory costs and related reserves</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit of net operating losses and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring-related charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and product liability reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment write-down</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal benefit of uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,029 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,954 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,004)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,809 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains and losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Deferred Tax Assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,707 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid on intercompany profit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> Net Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,062</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit are included in the following locations within our accompanying consolidated balance sheets (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:50.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Balance Sheets</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Component</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid on intercompany profit</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,841 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,157 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,062</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $540 million and $464 million, respectively. In addition, we had foreign tax net operating loss carryforwards and tax credits, the tax effect of which was $203 million as of December 31, 2023, and $47 million as of December 31, 2022. These tax attributes expire periodically beginning in 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After consideration of all positive and negative evidence, we believe that it is more likely than not that a portion of our deferred tax assets will not be realized. As a result, we recorded a valuation allowance of $1.220 billion as of December 31, 2023, and $1.004 billion as of December 31, 2022. The increase in the valuation allowance as of December 31, 2023, compared to December 31, 2022, is primarily due to establishing valuation allowances on certain foreign deferred tax assets, mainly a capital loss carryforward in the UK. The income tax impact of the unrealized gain or loss component of other comprehensive income </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and stockholders' equity was a benefit of $39 million in 2023, a charge of $56 million in 2022 and a charge of $81 million in 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain tax incentives through Free Trade Zone Regime offered in Costa Rica which allows 100 percent exemption from income tax in the first eight years of operations and 50 percent exemption in the following four years. This tax incentive resulted in income tax savings of $212 million in 2023, $162 million in 2022 and $149 million in 2021. The tax incentive for 100 percent exemption from income tax is expected to expire in 2027, with the 50 percent exemption to expire in 2031. The impact on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) per common share - diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $0.15 for 2023, $0.11 for 2022 and $0.10 for 2021. We also benefit from tax incentives in Puerto Rico through a Grant of Industrial Tax Exemption (Grant) which applies a reduced tax rate to our taxable profits, resulting in income tax savings of $16 million in 2023, $21 million in 2022 and $27 million in 2021. This Grant expires in 2034, with an option to extend for an additional 15 years. The impact on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) per common share - diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $0.01 in 2023 and $0.02 in the years 2022 and 2021. Additionally, we benefit from tax incentives in Malaysia which allow a full tax exemption on manufacturing of specific medical device products, which will expire in 2029, with an option to renew for an additional five-year term. This incentive has resulted in income tax savings of $20 million in 2023, $17 million in 2022 and $0 in 2021. The impact on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) per common share - diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $0.01 in the years 2023 and 2022 and de minimis in 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had $467 million of gross unrecognized tax benefits, of which a net $395 million, if recognized, would affect our effective tax rate. As of December 31, 2022, we had $492 million of gross unrecognized tax benefits, of which a net $410 million, if recognized, would affect our effective tax rate. As of December 31, 2021, we had $255 million of gross unrecognized tax benefits, of which a net $177 million, if recognized, would affect our effective tax rate. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:58.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements with taxing authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statute of limitation expirations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending Balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">467</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. We have concluded all U.S. federal income tax matters through 2018 and substantially all material state and local income tax matters through 2016. We have concluded substantially all foreign income tax matters through 2015.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2023, we received notification from the IRS that the examination of our 2017 and 2018 tax years was resolved. Due to the resolution of these tax years, we recorded a net tax benefit of $44 million to release the reserves related to these years. We paid tax of $16 million to the IRS reflecting the net balance of amounts due for the tax period including an increase to past transition tax installment payments for periods prior to 2023 and interest. The subsequent transition tax payments in 2024 and 2025 will be increased to reflect the final audit settlement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties related to income taxes as a component of income tax expense. We had $70 million accrued for gross interest and penalties as of December 31, 2023, $77 million as of December 31, 2022, and $43 million as of December 31, 2021. Net tax expense related to interest and penalties was immaterial in 2023, 2022 and 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that within the next 12 months we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to $24 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2017, we were required under the TCJA to calculate a one-time transition tax based on our total post-1986 foreign subsidiaries' earnings and profits (E&amp;P) that we previously deferred from U.S. income taxes. The amount of transition tax remains unchanged at approximately $937 million for both December 31, 2023 and 2022. We anticipate offsetting this liability against existing tax attributes, reducing the required payment to approximately $586 million, which will be remitted over an eight-year period. We have begun remitting the required installment payments, with a balance remaining of $264 million as of December 31, 2023. In addition, we have provided for U.S. state income taxes of $8 million on all U.S. dollar-denominated E&amp;P accumulated through December 31, 2017, which constitutes the preponderance of our foreign </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsidiaries' accumulated E&amp;P through December 31, 2017. We intend to indefinitely reinvest the unremitted foreign earnings of all other subsidiaries as of December 31, 2017, as well as all subsequent earnings generated by all of our foreign subsidiaries. Determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings and additional outside basis difference in these entities is not practicable.</span></div>We are subject to a territorial tax system under the TCJA, in which we are required to provide for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have established an accounting policy election to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income (loss) before income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:58.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,119)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(648)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,985</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -394000000 -1119000000 -648000000 2379000000 2260000000 1724000000 1985000000 1141000000 1076000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The related expense (benefit) for income taxes consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:58.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">393</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">443</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 189000000 51000000 18000000 15000000 19000000 33000000 116000000 381000000 127000000 320000000 451000000 178000000 -82000000 -92000000 -256000000 -22000000 -32000000 -3000000 176000000 117000000 117000000 73000000 -7000000 -142000000 393000000 443000000 36000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes at the federal statutory rate to the actual expense (benefit) for income taxes is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic taxes on foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div> 0.210 0.210 0.210 0.007 0.007 0.025 0.069 0.153 0.068 -0.153 -0.038 -0.143 0.022 0.044 -0.081 0.029 0.045 0.030 0.075 -0.013 0.008 0.005 0.006 -0.006 0.004 0.004 0.004 -0.005 0.077 0.012 -0.001 -0.021 -0.057 -0.006 -0.002 0.019 0 0.007 0.004 0.198 0.389 0.033 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:70.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.729%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.732%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory costs and related reserves</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit of net operating losses and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring-related charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and product liability reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment write-down</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal benefit of uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,029 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,954 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,004)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,809 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains and losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Deferred Tax Assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,707 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid on intercompany profit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> Net Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,062</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit are included in the following locations within our accompanying consolidated balance sheets (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:50.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Balance Sheets</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Component</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid on intercompany profit</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,841 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,157 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,062</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 30000000 19000000 744000000 511000000 305000000 304000000 14000000 6000000 88000000 103000000 58000000 38000000 154000000 136000000 11000000 9000000 3394000000 3668000000 232000000 160000000 0 2000000 5029000000 4954000000 1220000000 1004000000 3809000000 3950000000 24000000 0 66000000 117000000 12000000 34000000 102000000 151000000 3707000000 3799000000 315000000 264000000 4022000000 4062000000 315000000 264000000 3841000000 3942000000 4157000000 4206000000 134000000 144000000 134000000 144000000 4022000000 4062000000 540000000 464000000 203000000 47000000 1220000000 1004000000.000 39000000 56000000 -81000000 212000000 162000000 149000000 0.15 0.11 0.10 16000000 21000000 27000000 0.01 0.02 0.02 20000000 17000000 0 0.01 467000000 395000000 492000000 410000000 255000000 177000000 A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:58.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements with taxing authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statute of limitation expirations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending Balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">467</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 492000000 255000000 261000000 65000000 88000000 8000000 67000000 177000000 41000000 114000000 20000000 36000000 14000000 1000000 2000000 29000000 8000000 17000000 467000000 492000000 255000000 44000000 16000000 70000000 77000000 43000000 24000000 937000000 586000000 264000000 8000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE I – COMMITMENTS AND CONTINGENCIES </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, product liability, securities and commercial claims have been asserted against us and similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with FASB ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation-related net charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our accompanying consolidated statements of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accrual for legal matters that are probable and estimable was $377 million as of December 31, 2023, and $443 million as of December 31, 2022, and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims related to our transvaginal surgical mesh products. A portion of this accrual is already funded through our qualified settlement fund, which is included in restricted cash and restricted cash equivalents in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $130 million as of December 31, 2023, and $149 million as of December 31, 2022. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note A – Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note G – Supplemental Balance Sheet Information </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded litigation-related net credits of $111 million in 2023, primarily related to the settlement of offensive patent litigation, and net charges of $173 million in 2022 and $430 million in 2021, primarily related to litigation associated with our transvaginal surgical mesh products, and other legal matters. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our financial covenant. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management's opinion, we are not currently involved in any legal proceedings other than those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2017, The Board of Regents, University of Texas System and TissueGen. Inc. (collectively, UT), served a lawsuit against us in the Western District of Texas. The complaint against the Company alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. UT primarily seeks a reasonable royalty. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. In April 2020, the United States Supreme Court denied the UT’s Petition for Certiorari. UT proceeded with its case against the Company in Delaware. In January 2023, a jury trial was held on the issue of whether the one UT patent still asserted in the case was valid and whether it was infringed by the Company. On January 31, 2023, a jury concluded that UT’s patent was valid and willfully infringed by the Company, and awarded UT $42 million in damages. Following the trial, UT has filed a motion seeking prejudgment interest and enhanced damages. The Company has filed a motion seeking judgment as a matter of law in its favor or alternatively a new trial.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us, predominantly in the United States, Canada, the United Kingdom, Scotland, Ireland, and Australia. Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. We have entered into individual and master settlement agreements in principle or are in the final stages of entering agreements with certain plaintiffs' counsel, to resolve the majority of these cases and claims. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. In addition, in April 2021 the Company's Board of Directors received a shareholder demand under section 220 of the Delaware General Corporation Law, for inspection of books and records related to mesh settlements. The Company has notified our insurer and retained counsel to respond to the demand. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a product liability accrual for remaining claims asserted against us associated with our transvaginal surgical mesh products and the costs of defense thereof. We continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims, which we continue to vigorously contest. The final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Investigations and Qui Tam Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a “technical note,” announced that it was launching a formal administrative proceeding against Boston Scientific’s Brazilian subsidiary, Boston Scientific do Brasil Ltda. (BSB), as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. Under applicable guidance, BSB could be fined a percentage of BSB’s 2016 gross revenues. In August 2021, the investigating commissioner issued a preliminary recommendation of liability against all of the involved companies, and also recommended that CADE impose fines and penalties. However, on October 25, 2021, the CADE Attorney General's office recommended dismissal of the charges and allegations against BSB and the individual BSB employees who were still individual defendants. Subsequently, on March 30, 2022, the Federal Prosecutor’s office issued a non-binding recommendation that is contrary to the Attorney General’s recommendation. The full Commission is considering both of these recommendations but has not yet issued its decision. We continue to deny the allegations, intend to defend ourselves vigorously and will appeal any decision of liability by the full Commission to the Brazilian courts. During such an appeal, the decision would have no force and effect, and the Court would consider the case without being bound by CADE’s decision.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam. The Company has received related subpoenas for documents from the Office of the U.S. Attorney for the District of Massachusetts and the Securities and Exchange Commission. The Company is cooperating with government agencies while investigating these allegations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2023, the Company received a subpoena from the U.S. Department of Justice (DOJ) that seeks documents and information relating to its ambulatory electrocardiography monitoring (AECG) business. The Company is cooperating with the DOJ in responding to this subpoena.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2023, the Company received a Civil Investigative Demand from the DOJ that relates to the provision of peripheral intervention services through office-based labs. The Company is cooperating with the DOJ in responding to the subpoena.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 4, 2020, Enrique Jevons, individually and on behalf of all others similarly situated, filed a class action complaint against the Company, Michael F. Mahoney and Daniel J. Brennan, stemming from the recall and retirement of the LOTUS Edge™ Aortic Valve System (LOTUS System) in United States District Court for the Eastern District of New York. On December 14, 2020, the parties agreed to transfer the case to the United States District Court for the District of Massachusetts. On December 16, 2020, Mariano Errichiello, individually and on behalf of all others similarly situated, filed a second, materially similar class action complaint against the Company, Michael F. Mahoney, Joseph M. Fitzgerald, and Daniel J. Brennan in the United States District Court for the District of Massachusetts. Subsequently, on March 30, 2021, the Court consolidated the two actions, and appointed Union Asset Management Holding AG as the lead plaintiff. The plaintiffs filed an Amended Complaint in June 2021 that seeks unspecified compensatory damages in favor of the alleged class as well as unspecified equitable relief. The Company filed a Motion to Dismiss in July 2021, which, in December 2022, the Court granted in part and denied in part. On October 23, 2023, the Company reached an agreement in principle with the lead plaintiff to settle the case. The settlement in principle is subject to approval of the Court.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Court granted the motion for preliminary approval of the proposed settlement on December 27, 2023, and scheduled a final approval hearing for April 23, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2020, the Securities and Exchange Commission’s Boston Regional Office (Boston SEC) notified the Company that it was conducting an investigation related to the Company’s decision to retire the LOTUS System and issued a voluntary request for documents and information related to that decision. On February 10, 2021, the Boston SEC issued a second voluntary request for additional documents and information. The Company cooperated fully with the requests, and on January 3, 2022, the SEC informed us that it was concluding its investigation and that it did not intend to recommend an enforcement action. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the Company received a letter from The Vladimir Gusinsky Revocable Trust, a shareholder, demanding that the Company’s Board of Directors conduct an investigation into actions by the Company’s directors and executive officers regarding statements made about the effectiveness and commercial viability of the LOTUS System. The Trust subsequently </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreed to stay its demand, pending the outcome of any dispositive motion against the Amended Complaint in the class action complaint described above. The Company received letters on behalf of the Union Excavators Local 731 Pension Fund, Diane Nachbaur, and Frank Tripson, three stockholders of the Company, on July 26, 2021, July 29, 2021, and February 13, 2023, respectively, each demanding access to certain books and records of the Company, pursuant to Section 220 of the Delaware General Corporation Law, regarding the business, operations, effectiveness and commercial viability of the LOTUS system, and related items. On April 7, 2023, Diane Nachbaur filed a shareholder derivative complaint in the United States District Court for the District of Massachusetts against the Company, Michael F. Mahoney, Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, David Roux, John E. Sununu, Ellen M. Zane, Joseph M. Fitzgerald, Daniel J. Brennan, Shawn McCarthy, Ian Meredith, Kevin Ballinger, and Susan Vissers Lisa. On May 8, 2023, the Court stayed the case until the conclusion of the consolidated class action case. On October 18, 2023, Frank Tripson filed a shareholder derivative complaint in the Court of Chancery of the State of Delaware against the Company, Michael F. Mahoney, Daniel J. Brennan, Joseph M. Fitzgerald, Shawn McCarthy, Kevin Ballinger, Ian Meredith, Susan Vissers Lisa, Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, Stephen P. MacMillan, David Roux, John E. Sununu, and Ellen M. Zane. On December 15, 2023, the Court stayed that case until March 31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matters Concluded Since December 31, 2022</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2015, the Company filed suit against Cook Group Limited and Cook Medical LLC (collectively, Cook) in the United States District Court for the District of Delaware (1:15-cv-00980) alleging infringement of certain Company patents regarding Cook’s Instinct™ Endoscopic Hemoclip. The Company was seeking lost profits, a reasonable royalty and a permanent injunction. The case was transferred to the District Court for the Southern District of Indiana. Cook filed Inter Partes Review (IPR) requests with the U.S. Patent and Trademark Office (USPTO) against four then-asserted patents, which resulted in the court staying the case until 2020. All IPRs concluded and confirmed the validity of certain claims of each challenged patent. In February 2023, the District Court issued summary judgment rulings dismissing certain claims and defenses. Trial on the remaining two asserted patents took place in May and June 2023 and the jury found that the Company’s patents were both valid and infringed and awarded the Company $158 million as lost profits. On August 4, 2023, the parties entered into a settlement to resolve all claims, and the case was dismissed on August 22, 2023.</span></div> 377000000 443000000 130000000 149000000 -111000000 173000000 430000000 42000000 29 158000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE J – STOCKHOLDERS' EQUITY </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2020, we completed an offering of 10,062,500 shares of 5.50% Mandatory Convertible Preferred Stock, Series A (MCPS) at a price to the public and liquidation preference of $100 per share. The net proceeds from the MCPS offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2023 (the Mandatory Conversion Date), all outstanding shares of MCPS automatically converted into shares of common stock. The conversion rate for each share of MCPS was 2.3834 shares of common stock. No action by the holders of the MCPS was required in connection with the mandatory conversion. Cash was paid in lieu of fractional shares in accordance with the terms of the MCPS. An aggregate of approximately 24 million shares of common stock, including shares of common stock issued to holders of MCPS that elected to convert prior to the Mandatory Conversion Date, were issued upon conversion of the MCPS. Following the mandatory conversion of the MCPS, there were no outstanding shares of MCPS.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Mandatory Conversion Date during 2023, the Audit Committee of our Board of Directors (the Committee), pursuant to authority delegated to such committee by our Board of Directors, declared, and we paid, cash dividends of $28 million, or $1.3750 per MCPS share to holders representing dividend periods through May 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized to issue 2.000 billion shares of common stock, $0.01 par value per share. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by our Board of Directors, and to share ratably in our assets legally available for distribution to our stockholders in the event of liquidation. Holders of common stock have no preemptive, subscription, redemption, or conversion rights. The holders of common stock do not have cumulative voting rights. The holders of a majority of the shares of common stock can elect all of the directors and can control our management and affairs. Prior to the Mandatory Conversion Date, holders of common stock were junior to holders of MCPS in terms of liquidation preference. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. We did not repurchase any shares of our common stock during 2023 and had the full amount available under the authorization as of December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were approximately 263 million shares in treasury as of December 31, 2023 and 2022.</span></div> 50000000 10062500 0.0550 100 975000000 2.3834 24000000 28000000 1.3750 2000000000 0.01 1000000000 263000000 263000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE K – STOCK INCENTIVE AND PURCHASE PLANS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee and Director Stock Incentive Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, our Board of Directors and stockholders approved amendments to our 2011 Long-Term Incentive Plan effective October 1, 2020 (Amended and Restated 2011 LTIP), authorizing for issuance up to 171 million shares of our common stock. The Amended and Restated 2011 LTIP covers officers, directors, employees and consultants and provides for the grant of restricted or unrestricted common stock, restricted stock units (RSUs), options to acquire our common stock, stock appreciation rights, performance awards (market-based and performance-based RSUs) and other stock and non-stock awards. Shares reserved under our current and former stock incentive plans totaled approximately 145 million as of December 31, 2023. The Executive Compensation and Human Resources Committee (the Committee) of the Board of Directors, consisting of independent, non-employee directors may authorize the issuance of common stock and cash awards under the Amended and Restated 2011 LTIP in recognition of the achievement of long-term performance objectives established by the Committee. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-qualified options issued to employees are generally granted with an exercise price equal to the market price of our stock on the grant date, vest over a three or four-year service period and have a ten-year contractual life. In the case of qualified options, if the recipient owns more than ten percent of the voting power of all classes of stock, the option granted will be at an exercise price of 110 percent of the fair market value of our common stock on the date of grant and will expire over a period not to exceed five years. Non-vested stock awards, including restricted stock awards (RSAs) and RSUs issued to employees are generally granted with an exercise price of zero and typically vest in four equal annual installments. These awards represent our commitment to issue shares to recipients after the vesting period. Upon each vesting date, such awards are no longer subject to risk of forfeiture and we issue shares of our common stock to the recipient.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the impact of stock-based compensation on our consolidated statements of operations:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">188</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">165</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net impact per common share - basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net impact per common share - assuming dilution</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,934 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,822 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.02 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.69 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Black-Scholes Assumptions</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years, weighted)</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.62%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.42%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.66%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expected Volatility</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our historical volatility and implied volatility as a basis to estimate expected volatility in our valuation of stock options.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expected Term</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the expected term of options using historical exercise and forfeiture data. We believe that this historical data provides the best estimate of the expected term of new option grants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risk-Free Interest Rate</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use yield rates on U.S. Treasury securities for a period approximating the expected term of the award to estimate the risk-free interest rate in our grant-date fair value assessment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expected Dividend Yield</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not historically paid cash dividends on our common stock and currently we do not intend to pay cash dividends on our common stock. Therefore, we have assumed an expected dividend yield of zero in our grant-date fair value assessment.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to stock options under stock incentive plans are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,122</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,822 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,448</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(502)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,489</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,934 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,850</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">462</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,532 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total vested and expected to vest as of December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,584</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">458</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised was $89 million in 2023, $72 million in 2022 and $137 million in 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Vested Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value RSAs and RSUs based on the closing trading value of our shares on the date of grant. Information related to non-vested stock awards is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Vested</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Award Units</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant-Date <br/>Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,987</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,240 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,823)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(658)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,745</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,854 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(680)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,438</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,958 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,624)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(485)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total vesting date fair value of shares that vested was approximately $171 million in 2023, $150 million in 2022 and $148 million in 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market-based RSU Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, 2022 and 2021 we granted market-based RSU awards to certain members of our senior management team. The number of shares ultimately issued to the recipient is based on the total stockholder return (TSR) of our common stock as compared to the TSR of the common stock of the other companies in the S&amp;P 500 Health Care Index over a three-year period. The number of RSUs ultimately granted under this program range from 0 percent to 200 percent of the target number awarded to the participant as determined by achievement of the TSR criteria of the program. In addition, in general, award recipients must remain employed by us throughout the three-year period to attain the full amount of the market-based RSUs that satisfied the market performance criteria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the fair value of the market-based RSU awards to be approximately $13 million for 2023, $12 million for 2022 and $11 million for 2021. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price on date of grant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> (in years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the expense on these awards in our consolidated statements of operations on a straight-line basis over the three-year measurement period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organic Net Sales Growth and Free Cash Flow Performance-based RSU Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, we granted organic net sales growth (ONSG) performance-based RSU awards to certain members of our senior management team. The attainment of these performance-based RSUs is based on our organic net sales growth over a three-year performance period beginning January 1, 2023 and ending December 31, 2025 against a target set by the Committee. The number of RSUs ultimately granted under this program range from 0 percent to 200 percent of the target number of performance-based RSUs awarded to the participant as determined by achievement of the performance criteria of the program.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, we granted free-cash flow performance-based RSU awards to certain members of our senior management team. The attainment of these performance-based RSUs is based on our adjusted free cash flow (AFCF) measured against our goal set by the Committee, based on our internal annual financial plan performance for AFCF. AFCF was measured over a one-year performance period beginning January 1st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of each year and ending December 31st. The number of RSUs ultimately granted under this program range from 0 percent to 150 percent of the target number of performance-based RSUs awarded to the participant as determined by achievement of the performance criteria of the program. In addition, in general, award recipients must remain employed by us throughout a three-year service period (inclusive of the one-year performance period) to attain the full amount of the performance-based RSUs that satisfied the performance criteria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our assumptions used in determining the fair value of our ONSG and AFCF awards currently expected to vest as of December 31, 2023:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 ONSG</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 AFCF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 AFCF</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, net of forfeitures to date </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Achievement of target payout</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price used in determining fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Company's estimate of target payout as of December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the expense on these awards in our consolidated statements of operations over the vesting period which is three years after the date of grant.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expense Attribution</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation expense for our stock incentive plan using a straight-line method over the substantive vesting period. Most of our stock awards provide for immediate vesting upon death or disability of the participant. In addition, our stock grants to employees provide for accelerated vesting of our stock-based awards, other than performance-based and market-based awards, upon retirement, if the stock award has been held for at least one year by the recipient. In accordance with the terms of our stock grants, for employees who will become retirement eligible prior to the vest date we expense stock-based awards, other than performance-based and market-based awards, over the greater of one year or the period between grant date and retirement-eligibility. The performance-based and market-based awards discussed above do not contain provisions that would accelerate the full vesting of the awards upon retirement-eligibility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize stock-based compensation expense for the value of the portion of awards that are ultimately expected to vest. FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation – Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allows forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock-based award. We have applied, based on an analysis of our historical forfeitures, a weighted-average annual forfeiture rate of approximately five percent to all unvested stock-based awards as of December 31, 2023, which represents the portion that we expect will be forfeited each year over the vesting period. We re-evaluate this analysis annually or more frequently if there are significant changes in circumstances and adjust the forfeiture rate as necessary. Ultimately, we will only recognize expense for those shares that vest.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Compensation Cost</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to recognize the following future expense for awards outstanding as of December 31, 2023:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compensation Cost</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock awards</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.7</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts presented represent compensation cost, net of estimated forfeitures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, our stockholders approved an additional 10 million shares that may be issued under our global employee stock purchase plan. Our global employee stock purchase plan provides for the granting of options to purchase up to 60 million shares of our common stock to all eligible employees. Under the global employee stock purchase plan, we grant each eligible employee, at the beginning of each six-month offering period, an option to purchase shares of our common stock equal to not more than ten percent of the employee’s eligible compensation or the statutory limit under the U.S. Internal Revenue Code. Such options may be exercised only to the extent of accumulated payroll deductions at the end of the offering period, at a purchase price equal to 85 percent of the fair market value of our common stock at the beginning or end of each offering period, whichever is less. As of December 31, 2023, there were approximately 9 million shares available for future issuance under the employee stock purchase plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:51.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.532%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued or to be issued </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Range of purchase prices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expense recognized </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We use the Black-Scholes option-pricing model to calculate the grant-date fair value of shares issued under the employee stock purchase plan. We recognize expense related to shares purchased through the employee stock purchase plan ratably over the offering period.</span></div> 171000000 145000000 0.10 1.10 0 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the impact of stock-based compensation on our consolidated statements of operations:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">188</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">165</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net impact per common share - basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net impact per common share - assuming dilution</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 12000000 12000000 11000000 179000000 167000000 147000000 42000000 41000000 36000000 233000000 220000000 194000000 35000000 32000000 29000000 198000000 188000000 165000000 0.14 0.13 0.12 0.14 0.13 0.12 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,934 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,822 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.02 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.69 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Black-Scholes Assumptions</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years, weighted)</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.62%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.42%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.66%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td></tr></table></div> 2934000 3287000 3822000 47.43 44.02 37.69 16.83 13.64 10.77 0.26 0.28 0.29 P6Y3M18D P6Y1M6D P5Y10M24D 0.0362 0.0475 0.0142 0.0387 0.0066 0.0120 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to stock options under stock incentive plans are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,122</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,822 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,448</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(502)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,489</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,934 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,850</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">462</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,532 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total vested and expected to vest as of December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,584</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">458</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 23122000 24 3822000 38 4796000 13 699000 26 21448000 29 3287000 44 2745000 17 502000 34 21489000 32 2934000 47 3325000 25 249000 44 20850000 36 P5Y9M18D 462000000 13532000 31 P4Y6M 359000000 7052000 44 P8Y1M6D 99000000 20584000 36 P5Y9M18D 458000000 89000000 72000000 137000000 Information related to non-vested stock awards is as follows:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Vested</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Award Units</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant-Date <br/>Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,987</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,240 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,823)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(658)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,745</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,854 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(680)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,438</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,958 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,624)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(485)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.</span></div> 9987000 34 4240000 39 3823000 31 658000 36 9745000 37 3854000 45 3482000 36 680000 44 9438000 41 3958000 49 3624000 39 485000 44 9287000 45 171000000 150000000 148000000 0 2 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the fair value of the market-based RSU awards to be approximately $13 million for 2023, $12 million for 2022 and $11 million for 2021. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price on date of grant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> (in years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 13000000 12000000 11000000 47.28 44.19 37.50 P2Y10M24D P2Y10M24D P2Y10M24D 0.0431 0.0171 0.0020 0 2 0 1.50 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our assumptions used in determining the fair value of our ONSG and AFCF awards currently expected to vest as of December 31, 2023:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 ONSG</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 AFCF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 AFCF</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, net of forfeitures to date </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Achievement of target payout</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price used in determining fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Company's estimate of target payout as of December 31, 2023.</span></div> 20000000 7000000 12000000 2 0.88 1.31 47.28 46.27 42.48 0.05 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to recognize the following future expense for awards outstanding as of December 31, 2023:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compensation Cost</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock awards</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.7</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts presented represent compensation cost, net of estimated forfeitures.</span></div> 40000000 203000000 243000000 P1Y8M12D 10000000 60000000 0.10 0.85 9000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:51.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.532%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued or to be issued </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Range of purchase prices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expense recognized </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2623000 2850000 2578000 39.11 45.51 31.68 32.31 29.98 36.11 29000000 28000000 24000000 <div style="margin-top:20pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE L – WEIGHTED AVERAGE SHARES OUTSTANDING</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,453.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net effect of common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,463.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,439.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,433.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following securities were excluded from the calculation of weighted average shares outstanding - diluted because their effect in the periods presented below would have been antidilutive:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MCPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents common stock issuable upon the conversion of MCPS. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note J – Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) per common share - diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options, stock awards and, prior to the Mandatory Conversion Date, our MCPS, from the calculation if the effect would be anti-dilutive. The dilutive effect of MCPS is calculated using the if-converted method. The if-converted method assumes that these securities were converted to shares of common stock at the beginning of the reporting period to the extent that the effect is dilutive. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, 2022 and 2021, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of earnings per share (EPS). Accordingly, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was reduced by cumulative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred stock dividends</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as presented in our consolidated statements of operations, for purposes of calculating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) attributable to Boston Scientific common stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On June 1, 2023, all outstanding shares of MCPS automatically converted into shares of common stock.</span></div> <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,453.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net effect of common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,463.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,439.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,433.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1453000000 1430500000 1422300000 10600000 9200000 11500000 1463500000 1439700000 1433800000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following securities were excluded from the calculation of weighted average shares outstanding - diluted because their effect in the periods presented below would have been antidilutive:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MCPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents common stock issuable upon the conversion of MCPS. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note J – Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information.</span></div> 0 6000000 3000000 10000000 24000000 24000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE M – SEGMENT REPORTING </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve, and, in particular, benefit our Cardiology customers and patients. Following the reorganization, we have aggregated our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. We have revised prior periods to conform to the current year presentation. In accordance with FASB ASC Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Segment Reporting, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure and evaluate our reportable segments based on their respective net sales, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all based on internally-derived standard currency exchange rates to exclude the impact of foreign currency, which may be updated from year to year. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and European Union (EU) Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from operating income of reportable segments, they are included in reported </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income (loss) before income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations and are included in the reconciliation below. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note N – Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for net sales by reportable segment presented in accordance with GAAP.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying consolidated statements of operations is as follows (in millions, except percentages). Prior period amounts have been restated at constant currency to conform to the current year presentation.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,805 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,630 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales of reportable segments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,949 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,404 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,109 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,240</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,796 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,458 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating income of reportable segments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,031 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated amounts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(828)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(741)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss) </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,985</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income of reportable segments as a percentage of net sales of reportable segments</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">367</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,888 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,876 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,706 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other corporate assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,941 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,136</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,469</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-lived assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,859 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,446 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,688</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,653</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 2 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying consolidated statements of operations is as follows (in millions, except percentages). Prior period amounts have been restated at constant currency to conform to the current year presentation.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,805 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,630 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales of reportable segments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,949 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,404 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,109 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,240</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5320000000 4805000000 4389000000 8630000000 7599000000 6721000000 13949000000 12404000000 11109000000 0 -60000000 12000000 291000000 338000000 766000000 14240000000 12682000000 11888000000 <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,796 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,458 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating income of reportable segments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,031 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated amounts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(828)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(741)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss) </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,985</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments</span></div> 1796000000 1458000000 1368000000 2235000000 1748000000 1572000000 4031000000 3206000000 2940000000 -293000000 96000000 67000000 -567000000 -789000000 -1070000000 828000000 803000000 741000000 0 -60000000 3000000 2343000000 1649000000 1199000000 -358000000 -508000000 -123000000 1985000000 1141000000 1076000000 <div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income of reportable segments as a percentage of net sales of reportable segments</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.338 0.303 0.312 0.259 0.230 0.234 <div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">367</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,888 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,876 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,706 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other corporate assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,941 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,136</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,469</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 103000000 88000000 91000000 263000000 245000000 261000000 367000000 333000000 352000000 2888000000 2501000000 5988000000 5205000000 8876000000 7706000000 14387000000 12920000000 6003000000 5902000000 5869000000 5941000000 35136000000 32469000000 <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-lived assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,859 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,446 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,688</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,653</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 1300000000 1241000000 598000000 478000000 373000000 246000000 587000000 481000000 2859000000 2446000000 14387000000 12920000000 6003000000 5902000000 439000000 386000000 23688000000 21653000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE N – REVENUE</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our consolidated statements of operations. Our business structure is organized into five operating segments. The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Businesses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endoscopy</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,511 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,482 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,341 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,141 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Urology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,617</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,805</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,422</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,312</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,911</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,055</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,578</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Interventional Cardiology Therapies</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,674 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,417 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Watchman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cardiac Rhythm Management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,673 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,036 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,709 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,662 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,422 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peripheral Interventions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,808</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,011</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,819</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,512</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,831</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,846</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,396</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,425</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,816</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,240</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,632</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,911</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">    In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note M – Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information on our reportable segments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geographic Regions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,425 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,632 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,901 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,856 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America and Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,240</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. We have revised prior period amounts to conform to the current year's presentation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Deferred Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying consolidated balance sheets. Our deferred revenue balance was $577 million as of December 31, 2023 and $509 million as of December 31, 2022. Our contract liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiology business, for which revenue is recognized over the average service period based on device and patient longevity. Our contract liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor system, also within our Cardiology business, for which revenue is recognized over the average service period based on </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">device longevity and usage. We recognized revenue of $213 million in 2023 that was included in the above contract liability balance as of December 31, 2022. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize sales force commissions related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE™ Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE™ Remote Monitoring Service. These fulfillment costs are amortized over the average service period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note A – Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on our accounting policies relating to revenue recognition.</span></div> The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated. <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Businesses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endoscopy</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,511 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,482 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,341 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,141 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Urology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,617</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,805</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,422</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,312</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,911</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,055</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,578</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Interventional Cardiology Therapies</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,674 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,417 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Watchman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cardiac Rhythm Management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,673 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,036 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,709 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,662 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,422 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peripheral Interventions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,808</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,011</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,819</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,512</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,831</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,846</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,396</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,425</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,816</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,240</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,632</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,911</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">    In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note M – Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information on our reportable segments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geographic Regions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,425 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,632 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,901 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,856 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America and Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,240</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. We have revised prior period amounts to conform to the current year's presentation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Deferred Revenue</span></div> 1511000000 970000000 2482000000 1341000000 880000000 2221000000 1222000000 919000000 2141000000 1369000000 595000000 1964000000 1257000000 516000000 1773000000 1120000000 463000000 1583000000 736000000 240000000 976000000 715000000 202000000 917000000 713000000 196000000 909000000 3617000000 1805000000 5422000000 3312000000 1599000000 4911000000 3055000000 1578000000 4633000000 743000000 1674000000 2417000000 744000000 1485000000 2228000000 778000000 1431000000 2209000000 1155000000 119000000 1274000000 915000000 103000000 1019000000 729000000 100000000 829000000 1405000000 813000000 2218000000 1337000000 763000000 2100000000 1214000000 805000000 2019000000 370000000 430000000 800000000 275000000 310000000 585000000 128000000 237000000 365000000 3673000000 3036000000 6709000000 3271000000 2662000000 5932000000 2850000000 2572000000 5422000000 1135000000 975000000 2110000000 1048000000 850000000 1899000000 996000000 824000000 1820000000 4808000000 4011000000 8819000000 4319000000 3512000000 7831000000 3846000000 3396000000 7242000000 0 0 0 0 0 -60000000 10000000 4000000 13000000 8425000000 5816000000 14240000000 7632000000 5111000000 12682000000 6911000000 4978000000 11888000000 8425000000 7632000000 6901000000 2856000000 2526000000 2518000000 2400000000 2116000000 2070000000 560000000 469000000 386000000 0 -60000000 13000000 14240000000 12682000000 11888000000 2310000000 1968000000 1656000000 577000000 509000000 213000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE O – CHANGES IN OTHER COMPREHENSIVE INCOME </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the reclassifications out of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income, net of tax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attributable to Boston Scientific common stockholders:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(96)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note D – Hedging Activities and Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further detail on our net investment hedges recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our cash flow hedges recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net change in derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gains and losses on defined benefit and pension items before reclassifications and gains and losses on defined benefit and pension items reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss), net of tax</span> were reduced by income tax impacts of approximately $5 million in 2023 and approximately $6 million in 2022. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the reclassifications out of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income, net of tax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attributable to Boston Scientific common stockholders:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(96)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -1000000 269000000 1000000 269000000 -87000000 63000000 -10000000 -34000000 8000000 178000000 -1000000 185000000 -95000000 -115000000 9000000 -219000000 -96000000 154000000 -8000000 49000000 93000000 206000000 -36000000 263000000 -86000000 214000000 36000000 163000000 8000000 150000000 -1000000 157000000 -94000000 63000000 -37000000 6000000 -1000000 269000000 1000000 269000000 5000000 6000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE P – NEW ACCOUNTING PRONOUNCEMENTS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our consolidated financial statements. During 2023, we implemented the following standards, none of which had a material impact on our financial position or results of operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Update No. 2022-01</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Update No. 2022-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-01 expands the current single-layer method to allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods. We adopted Update No. 2022-01 on a prospective basis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Update No. 2022-02</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Update No. 2022-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments- Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13. We adopted Update No. 2022-02 on a prospective basis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Update No. 2022-04</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Update No. 2022-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liabilities— Supplier Finance Programs (Subtopic 405-50) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enhances the transparency of supplier finance programs by requiring that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude. We adopted Update No. 2022-04 on a retrospective basis to each period in which a balance sheet is presented, except for the amendment on roll forward information, which we will apply prospectively beginning January 1, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Standards to be Implemented</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the FASB issued ASC Update No. 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-03 clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. We do not expect the adoption to have a material impact on our financial position or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASC Update No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Update No. 2023-07 requires disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss in addition to disclosure of amounts for other segment items and a description of its composition. Update No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. We do not expect the adoption to have a material impact on our financial position or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2023, the FASB issued ASC Update No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Update No. 2023-09 aims to enhance the transparency and decision usefulness of income tax disclosures. Update No. 2023-09 modifies the rules on income tax disclosures to require entities to disclose (1) specific categories in the rate reconciliation, (2) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (3) income tax expense or benefit from continuing operations (separated by federal, state, and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state and local jurisdictions, among other changes. Update No. 2023-09 is effective for fiscal years beginning after December 15, 2024. We expect to adopt Update No. 2023-09 prospectively. We are currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and related disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncements issued or effective in the period had or are expected to have a material impact on our consolidated financial statements.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE Q – EMPLOYEE RETIREMENT PLANS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Benefit Pension Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Domestic Retirement Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following our 2006 acquisition of Guidant, we assumed the Guidant Supplemental Retirement Plan, a frozen, non-qualified defined benefit plan for certain former officers and employees of Guidant. The Guidant Supplemental Retirement Plan was partially funded through a Rabbi Trust that contains segregated company assets within restricted cash used to pay the benefit obligations related to the plan. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also maintain an Executive Retirement Plan, a defined benefit plan covering executive officers and other key contributors. Participants may retire with benefits once retirement conditions have been satisfied. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.K. Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our 2019 acquisition of BTG plc. (BTG), we assumed a benefit obligation related to a defined benefit pension plan sponsored by BTG for eligible United Kingdom employees. During the second quarter of 2022, we transferred the benefit obligation and associated assets of the pension plan to third party insurers, and as a result, were relieved from primary responsibility of the benefit obligation and the related plan assets. The transaction did not have a material impact on our financial position or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other International Retirement Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we maintain retirement plans covering certain international employees. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a December 31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the consolidated balance sheets, recognizing changes primarily through OCI. As of December 31, 2023 and 2022, the funded status of our plans were unfunded or underfunded in aggregate. The outstanding obligation is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:44.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">in millions)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligation (ABO)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected<br/>Benefit<br/>Obligation (PBO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of Plan Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unfunded/Underfunded<br/>PBO Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">117</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:44.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">in millions)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligation (ABO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected<br/>Benefit<br/>Obligation (PBO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of Plan Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unfunded/Underfunded PBO Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">190</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the changes in the PBO for our retirement plans is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments/settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendments and assumption changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending obligation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical assumptions associated with our employee retirement plans for 2023 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.295%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Expected Return</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Rate of Compensation Increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00%</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical assumptions associated with our employee retirement plans for 2022 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.008%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Expected Return</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Rate of Compensation Increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.32%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.62%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.27%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00%</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the changes in the fair value of plan assets for our funded retirement plans is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments/settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our defined benefit plans, we base our discount rate on the rates of return available on high-quality bonds with maturities approximating the expected period over which benefits will be paid. The rate of compensation increase is based on historical and expected rate increases. We base our rate of expected return on plan assets on historical experience, our investment guidelines and expectations for long-term rates of return. Our assets are invested in a variety of securities, primarily equity securities and government bonds. These securities are considered Level 1 and Level 2 investments. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected benefit payments are estimated based on the same assumptions used in determining our benefit obligation as of December 31, 2023. Actual benefit payments will depend on future employment and compensation, average years employed and average life spans, in addition to other factors. Changes in any of these factors could significantly impact these estimated future benefit payments. Benefit payments expected to be paid during the next ten years for our Domestic Retirement Plans and our Other International Retirement Plans are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Post Retirement Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 - 2033</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $135 million in 2023, $123 million in 2022 and $118 million in 2021.</span></div> The outstanding obligation is as follows:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:44.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">in millions)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligation (ABO)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected<br/>Benefit<br/>Obligation (PBO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of Plan Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unfunded/Underfunded<br/>PBO Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">117</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:44.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">in millions)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligation (ABO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected<br/>Benefit<br/>Obligation (PBO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of Plan Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unfunded/Underfunded PBO Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">190</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 54000000 59000000 0 59000000 145000000 159000000 101000000 58000000 199000000 218000000 101000000 117000000 50000000 55000000 0 55000000 140000000 152000000 101000000 51000000 190000000 207000000 101000000 105000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the changes in the PBO for our retirement plans is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments/settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendments and assumption changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending obligation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 207000000 502000000 10000000 13000000 7000000 3000000 -4000000 -54000000 0 191000000 6000000 -25000000 10000000 6000000 3000000 -37000000 218000000 207000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical assumptions associated with our employee retirement plans for 2023 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.295%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Expected Return</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Rate of Compensation Increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00%</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical assumptions associated with our employee retirement plans for 2022 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.008%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Expected Return</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Rate of Compensation Increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.32%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.62%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.27%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00%</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.</span></div> 0.0489 0.0200 0.0285 0.0266 0.0300 0.0532 0.0200 0.0262 0.0227 0.0300 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the changes in the fair value of plan assets for our funded retirement plans is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments/settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 101000000 336000000 -1000000 -2000000 11000000 16000000 1000000 1000000 0 185000000 0 -25000000 10000000 9000000 0 -32000000 101000000 101000000 Benefit payments expected to be paid during the next ten years for our Domestic Retirement Plans and our Other International Retirement Plans are as follows:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Post Retirement Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 - 2033</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 16000000 13000000 14000000 15000000 15000000 73000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $135 million in 2023, $123 million in 2022 and $118 million in 2021.</span></div> 135000000 123000000 118000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 6, 2023, John Bradley Sorenson, our Executive Vice President, Global Operations, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Sorenson’s plan covers the sale of 33,938 shares of our common stock to be acquired upon the exercise of stock options. Transactions under Mr. Sorenson’s plan are based upon pre-established dates and stock price thresholds and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span>will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Sorenson’s plan will terminate on the earlier of December 31, 2024 or the date all shares subject to the plan have been sold. November 6, 2023 John Bradley Sorenson Executive Vice President, Global Operations true 33938 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 17, 2023, Wendy Carruthers, our Executive Vice President, Human Resources, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Ms. Carruthers’ plan covers the sale of 76,113 shares of our common stock, including 46,893 shares to be acquired upon the exercise of stock options. Transactions under Ms. Carruthers’ plan are based upon pre-established dates and stock price thresholds and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span>will only occur upon the expiration of the applicable mandatory cooling-off period. Ms. Carruthers’ plan will terminate on the earlier of December 31, 2024 or the date all shares subject to the plan have been sold. November 17, 2023 Wendy Carruthers Executive Vice President, Human Resources true 76113 46893 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 22, 2023, Arthur Butcher, our Executive Vice President and Group President, MedSurg and Asia Pacific, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Butcher’s plan covers the sale of up to 77,687 shares of our common stock, including up to 54,514 shares to be acquired upon determination and/or vesting of performance share units and restricted share units, and 16,742 shares to be acquired upon the exercise of stock options. Transactions under Mr. Butcher’s plan are based upon pre-established dates and stock price thresholds and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">will only occur upon </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the expiration of the applicable mandatory cooling-off period. Mr. Butcher’s plan will terminate on the earlier of January 31, 2025 or the date all shares subject to the plan have been sold.</span></div> November 22, 2023 Arthur Butcher Executive Vice President and Group President, MedSurg and Asia Pacific true 77687 54514 16742 42 <div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.851%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at<br/> Beginning of Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Credit loss exposure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Write-offs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at<br/>End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for credit losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for credit losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for credit losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> We record credit loss reserves to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. Subsequent credit loss reserves are recorded when deemed uncollectible. Amounts shown within credit loss exposure above were established through selling, general and administrative expense. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Represents actual write-offs of uncollectible accounts.</span></div> 109000000 50000000 48000000 110000000 108000000 35000000 35000000 109000000 105000000 28000000 25000000 108000000